<SEC-DOCUMENT>0001367644-25-000202.txt : 20251030
<SEC-HEADER>0001367644-25-000202.hdr.sgml : 20251030
<ACCEPTANCE-DATETIME>20251029173845
ACCESSION NUMBER:		0001367644-25-000202
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251030
DATE AS OF CHANGE:		20251029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		251431253

	BUSINESS ADDRESS:	
		STREET 1:		300 PROFESSIONAL DR
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		300 PROFESSIONAL DR
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ebs-20250930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0b2479a1-7a21-4fa0-a33e-3a3a5f4f1cad,g:c7797084-9f00-4c6d-b9c9-e4498d399b6e,d:b415b040063d4dd9ba8a71e128a463b6-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ebs="http://emergentbiosolutions.com/20250930" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ebs-20250930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-27">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1070">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1071">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1074">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1075">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1078">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1079">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-467" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1251">445</ix:nonNumeric><ix:nonNumeric contextRef="c-469" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1252">292</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ebs-20250930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="category"><xbrli:measure>ebs:category</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>ebs:product</xbrli:measure></xbrli:unit><xbrli:unit id="category2"><xbrli:measure>ebs:Category</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ebs:segment</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>ebs:employee</xbrli:measure></xbrli:unit><xbrli:unit id="positions"><xbrli:measure>ebs:positions</xbrli:measure></xbrli:unit><xbrli:unit id="term"><xbrli:measure>ebs:Term</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="increment"><xbrli:measure>ebs:increment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:MarylandWarehouseSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-31</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-20</xbrli:startDate><xbrli:endDate>2024-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreBayviewFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-19</xbrli:startDate><xbrli:endDate>2025-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreBayviewFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:SeriesIWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:SeriesIIWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ebs:ValuationTechniqueBlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ebs:ValuationTechniqueBlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ebs:ValuationTechniqueBlackScholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolverLoanDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-30</xbrli:startDate><xbrli:endDate>2024-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ebs:VariableRateComponentAxis">ebs:UntilTheSecondAnniversaryOfTheClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-30</xbrli:startDate><xbrli:endDate>2024-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ebs:VariableRateComponentAxis">ebs:AfterTheSecondAnniversaryOfTheClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-30</xbrli:startDate><xbrli:endDate>2024-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-30</xbrli:startDate><xbrli:endDate>2024-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-30</xbrli:startDate><xbrli:endDate>2024-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansUntilSeptember302025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansUntilSeptember302025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansAfterSeptember302025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansAfterSeptember302025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:LongTermIncentiveAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:LongTermIncentiveAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:OtherEquityAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:SubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-17</xbrli:startDate><xbrli:endDate>2024-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:SubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JanssenPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-06</xbrli:startDate><xbrli:endDate>2025-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-18</xbrli:startDate><xbrli:endDate>2025-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-31</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:DonaldDeGolyerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:DonaldDeGolyerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:SujataTyagiDayalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:SujataTyagiDayalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-118 f-119 f-120 f-121" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/></ix:resources></ix:header></div><div id="ib415b040063d4dd9ba8a71e128a463b6_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:0.1%"/><td style="width:2.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2025</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:0.1%"/><td style="width:2.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from    to        </span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33137</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><img src="ebs-20250930_g1.jpg" alt="emergent logo gray + carmine  r.jpg" style="height:20px;margin-bottom:5pt;vertical-align:text-bottom;width:150px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">EMERGENT BIOSOLUTIONS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">14-1902018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">300 Professional Drive</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Gaithersburg,</ix:nonNumeric>  </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MD</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">20879</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address and zip code of Principal Executive Offices)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">240</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">631-3200</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant's Telephone Number, Including Area Code)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.963%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">EBS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#9746; <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9744; No</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#9746; <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9744; No</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:41.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">October&#160;22, 2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the registrant had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">52,519,964</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock outstanding.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.410%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_10">Part I. Financial Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_13">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_16">Condensed Consolidated Balance Sheets&#8212;</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_16">September 30, 2025</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_16"> and December 31, 202</a>4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_16">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">Condensed Consolidated Statements of Operations&#8212;Three and </a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">Nine</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19"> Months Ended </a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">September</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_19">6</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_22">Condensed Consolidated Statements of Comprehensive Income (Loss)&#8212;</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">Three and </a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">Nine</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19"> Months Ended </a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">September</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_22">7</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_25">Condensed Consolidated Statements of Cash Flows&#8212;</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_25">Nine</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_25"> Months Ended </a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_25">September</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_25"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_25">8</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_28">Condensed Consolidated Statements of Changes in Stockholders' Equity&#8212;</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">Three and </a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">Nine</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19"> Months Ended </a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19">September</a><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_19"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_28">9</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_31">11</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_97">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_97">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_97">35</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_115">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_115">62</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_118">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_118">62</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_121">Part II. Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_124">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_124">62</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_127">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_127">63</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_130">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_130">65</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_133">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_133">65</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_136">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_136">65</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_139">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_139">66</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_145">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_145">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_145">66</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib415b040063d4dd9ba8a71e128a463b6_151">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib415b040063d4dd9ba8a71e128a463b6_151">67</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> PART I. FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the documents we incorporate by reference include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of Emergent BioSolutions Inc. or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;future,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;position,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements are based on our current intentions, beliefs, assumptions and expectations regarding future events based on information that is currently available. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any such forward-looking statement speaks only as of the date on which such statement is made and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others:</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the availability of U.S. government (&#8220;USG&#8221;) funding for contracts related to procurement of our medical countermeasures (&#8220;MCM&#8221;) products, including CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Anthrax Vaccine Adsorbed (AVA), Adjuvanted), previously known as AV7909, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Smallpox (Vaccinia) Vaccine, Live), CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous, Human (VIGIV)), BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (ansuvimab-zykl) and/or TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">among others, as well as contracts related to development of medical countermeasures; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to meet our commitments to quality and compliance in all of our manufacturing operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to negotiate additional USG procurement or follow-on contracts for our MCM products that have expired or will be expiring;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the commercial availability and impact of a generic and competitive marketplace on future sales of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCL) Nasal Spray and over-the-counter NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to perform under our contracts with the USG, including the tim</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ing of and specifications relating to deliveries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to negotiate new or further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing related to our bioservices and under existing Bioservices contracts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to collect reimbursement for raw materials and payment of service fees from our Bioservices customers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the results of pending government investigations and their potential impact on our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to satisfy the conditions of our litigation settlement agreements, and the potential impact of such agreements, including the funds to resolve related litigation, on our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to comply with the operating and financial covenants required by (i) our term loan facility under a credit agreement, dated August 30, 2024, among the Company, the lenders from time to time party thereto and OHA Agency LLC, as administrative agent, (ii) our revolving credit facility under a credit agreement, dated September 30, 2024, among the Company, certain subsidiary borrowers, the lenders from time to time party thereto and Wells Fargo, National Association, as Agent, and (iii) our 3.875% Senior Unsecured Notes due 2028 (the &#8220;Senior Unsecured Notes&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to maintain adequate internal control over financial reporting and to prepare accurate financial statements in a timely manner;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to invest in our business operations as a result of our current indebtedness;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the impact of our share and debt repurchase programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to United States Food and Drug Administration (&#8220;FDA&#8221;) marketing authorization, and corresponding procurement by government entities outside the United States;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to realize the expected benefits of the sale of our travel health business to Bavarian Nordic, the sale of our Drug Product facility in Baltimore-Camden to Bora Pharmaceuticals Injectables Inc., a subsidiary of Bora Pharmaceuticals Co., Ltd. (&#8220;Bora&#8221;), the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Reactive Skin Decontamination Lotion) to BTG International Inc., a subsidiary of SERB Pharmaceuticals (collectively, &#8220;SERB&#8221;) and the sale of our Baltimore-Bayview drug substance manufacturing facility to Syngene International (&#8220;Syngene&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to realize the expected benefits from divestitures and restructuring activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the success of our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to attract and retain qualified personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to adequately secure and protect our intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to realize the full benefits from our divestitures and sales of assets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the impact of cybersecurity incidents, including the risks from the unauthorized access, interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the accuracy of our estimates regarding future revenues, expenses, capital requirements and need for additional financing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing sets forth many, but not all, of the factors that could cause actual results to differ materially from our expectations in any forward-looking statement. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements. When evaluating our forward-looking statements, you should consider this cautionary statement along with the sections entitled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; in this Quarterly Report on Form 10-Q, as well as the risks identified in our other reports filed with the SEC. New factors may emerge from time to time, and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Emergent BioSolutions Inc. and its consolidated subsidiaries.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADE NAMES</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emergent</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, BaciThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, Trobigard</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners, including KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is a registered trademark of Hikma Pharmaceuticals USA Inc.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_13"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div><span><br/></span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_16"></div><div><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.764%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-30">245.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-31">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-32">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-33">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-34">149.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-35">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-36">356.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-37">311.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-38">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-39">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="f-40">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="f-41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="f-42">786.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="f-43">598.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-44">209.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-45">270.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-46">452.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-47">501.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-48">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-49">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-50">1,461.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-51">1,389.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-52">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-53">60.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-54">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-55">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-56">36.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-57">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-58">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-59">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="f-60">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="f-61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-62">136.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-63">162.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-64">663.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-65">663.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-66">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-67">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-68">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-69">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-70">878.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-71">906.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-72"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-73">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-75">15.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-79">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-82"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-83">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-85">200.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-86">60.6</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-87">59.9</ix:nonFraction> shares issued; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-88">52.7</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-89">54.3</ix:nonFraction> shares outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-90">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-91">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-92">7.9</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-93">5.6</ix:nonFraction> common shares, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="f-94">243.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="f-95">227.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-96">938.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-97">928.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-98">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-99">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-100">105.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-101">212.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-102">582.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-103">482.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-104">1,461.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-105">1,389.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_19"></div><hr style="page-break-after:always"/><div style="background-color:#ffffff"><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Product and services sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-106">222.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-107">283.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-108">561.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-109">824.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-110">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-111">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-112">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-113">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-114">231.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-115">293.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-116">594.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-117">848.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product and services sales, net </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-118">85.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-119">122.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-120">241.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-121">563.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-122">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-123">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-124">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-125">61.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-126">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-127">76.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-128">135.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-129">247.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-130">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-131">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-132">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-133">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-137">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="f-138">154.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="f-139">229.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="f-140">466.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="f-141">948.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-142">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-143">64.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-144">128.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-145">99.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-146">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-147">8.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-148">44.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-149">56.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-151">64.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-152">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-153">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-154">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-155">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-156">62.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-157">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-158">18.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-159">77.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-160">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-161">16.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-162">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-163">142.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-164">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-165">115.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-166">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-167">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-168">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-169">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-170">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-171">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-172">107.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-173">159.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-174">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-175">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-176">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-177">3.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-178">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-179">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-180">1.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-181">3.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-182">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-183">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-184">53.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-185">52.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-186">56.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-187">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-188">56.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-189">52.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Exclusive of intangible asset amortization</span></div></ix:footnote></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_22"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-190">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-191">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-192">107.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-193">159.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-194">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-195">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-196">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-197">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-198">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-199">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-200">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-201">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive income (loss), net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-202">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-203">113.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-204">104.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-205">160.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_25"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"/><td style="width:64.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-206">107.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-207">159.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-208">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-209">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-210">72.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-211">82.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent obligations, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="f-212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-213">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-214">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-215">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-216">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-217">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss (gain) on sale of business and assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ebs:GainLossOnDispositionOfBusinessIncludingTransactionCosts" scale="6" id="f-218">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="ebs:GainLossOnDispositionOfBusinessIncludingTransactionCosts" scale="6" id="f-219">32.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="f-220">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" id="f-221">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-223">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="f-224">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="f-225">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-226">8.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-227">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-228">26.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-229">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-230">44.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-231">35.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-232">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-233">146.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-234">19.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-235">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-236">27.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-237">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term incentive plan accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual" scale="6" id="f-238">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual" scale="6" id="f-239">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-240">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-241">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes receivable and payable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="f-242">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="f-243">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-244">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-245">18.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-246">92.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-247">138.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-248">9.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-249">21.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sale of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-250">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-251">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments from prior asset divestiture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="ebs:PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" scale="6" id="f-252">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="ebs:PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sale of business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="f-254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="f-255">110.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of convertible note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="6" id="f-256">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="6" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-258">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-259">96.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the issuance of debt, net of lender fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="6" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="f-261">219.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds allocated to warrants issued in conjunction with debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="6" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-263">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds allocated to common stock issued in conjunction with debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" format="ixt:fixed-zero" scale="6" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="ebs:ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" scale="6" id="f-265">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments on term loan facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" format="ixt:fixed-zero" scale="6" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="f-267">198.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="f-269">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments on revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="f-271">284.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="f-273">14.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-274">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ebs:PaymentsForRepurchaseOfDebt" scale="6" id="f-276">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="ebs:PaymentsForRepurchaseOfDebt" format="ixt:fixed-zero" scale="6" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-278">15.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from share-based compensation activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:fixed-zero" scale="6" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-281">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Taxes paid for share-based compensation activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-282">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-283">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in financing activities:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-284">22.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-285">190.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-286">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-288">143.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-289">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-290">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-291">111.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-292">249.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-293">156.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-294">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-295">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for income taxes, net of refunds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-296">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-297">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment unpaid at period end</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-298">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-299">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment of debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-300">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-301">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="6" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockIssued1" scale="6" id="f-303">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Excise tax liability accrued for common stock repurchases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTaxPayable" scale="6" id="f-304">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTaxPayable" format="ixt:fixed-zero" scale="6" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of cash and cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-306">245.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-307">149.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-308">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-309">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-310">249.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-311">156.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_28"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:9pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.299%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-312"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-313"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-314"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-315"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-316"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-317"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-318"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-319">0.001</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Par Value </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Common Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Treasury Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-320">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-321">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-322">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-323">227.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-324">928.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-325">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-326">212.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-327">482.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-328">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-329">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-330">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-331">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-332">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-333">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-334">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-335">60.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-336">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-337">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-338">227.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-339">930.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-340">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-341">144.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-342">552.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-343">12.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-344">12.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-345">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-346">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-347">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-348">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-349">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-350">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-351">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-352">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-353">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-354">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-355">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-356">234.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-357">935.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-358">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-359">156.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-360">536.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-361">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-362">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-363">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-364">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-365">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-366">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-367">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-368">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-369">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-370">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-371">60.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-372">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-373">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-374">243.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-375">938.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-376">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-377">105.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-378">582.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.666%"/><td style="width:0.1%"/></tr><tr style="height:32pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-379"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-380"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-381"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-382"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-383"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-384"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-385"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-386">0.001</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Par Value </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Common Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Treasury Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Deficit</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-387">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-388">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-389">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-390">227.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-391">904.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-392">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-393">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-394">649.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-395">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-396">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-397">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-398">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-399">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-400">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-401">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-402">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-403">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-69" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-404">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-405">227.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-406">909.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-407">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-408">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-409">663.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-410">283.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-411">283.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-412">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-413">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-414">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-415">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-416">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-417">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-418">227.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-419">915.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-420">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-421">295.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-422">386.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-423">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-424">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-425">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-426">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-427">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-428">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-429">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-430">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-431">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-432">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-433">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-434">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-87" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-435">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-436">227.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-437">924.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-438">7.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-439">181.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-440">508.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EMERGENT BIOSOLUTIONS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, dollar and share amounts in tables in millions, except per share data)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_34"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-441" continuedAt="f-441-1" escape="true">Nature of the business and organization</ix:nonNumeric></span></div><ix:continuation id="f-441-1" continuedAt="f-441-2"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (&#8220;PHTs&#8221;). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (&#8220;CDMO&#8221;) services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following <ix:nonFraction unitRef="category" contextRef="c-1" decimals="INF" name="ebs:NumberOfCategoriesOfPublicHealthThreats" format="ixt-sec:numwordsen" scale="0" id="f-442">four</ix:nonFraction> PHT categories: chemical, biological, radiological, nuclear and explosives (&#8220;CBRNE&#8221;); emerging infectious diseases (&#8220;EID&#8221;); emerging health crises; and acute, emergency and community care. As of September 30, 2025, the Company has a portfolio of <ix:nonFraction unitRef="product" contextRef="c-1" decimals="INF" name="ebs:NumberOfRevenueGeneratingProducts" scale="0" id="f-443">11</ix:nonFraction> products consisting of vaccines, therapeutics, and drug-device combination products, including KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray for which the Company obtained certain exclusive commercial rights for product sales and marketing in the United States and Canada. The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following <ix:nonFraction unitRef="category2" contextRef="c-1" decimals="INF" name="ebs:NumberOfProductAndServiceCategories" format="ixt-sec:numwordsen" id="f-444">four</ix:nonFraction> product and service categories: Anthrax - Medical Countermeasures (&#8220;MCM&#8221;) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (&#8220;Bioservices&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the business with a focus on <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-445">three</ix:nonFraction> operating segments: (1) a Commercial Products segment consisting of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray and </span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">KL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray, described below; (2) a MCM Products segment consisting of our Anthrax - MCM, Smallpox - MCM and Other Products, described below and (3) a Services segment consisting of our Bioservices offerings. Commercial Products and MCM Products are our <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-446">two</ix:nonFraction> reportable segments (see Note 17, &#8220;Segment information&#8221; for more information on our reportable segments).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Naloxone Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray is an intranasal formulation of naloxone approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) (including in over-the-counter (&#8220;OTC&#8221;) form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(naloxone HCl) Nasal Spray. On January 14, 2025, the Company announced an agreement with Hikma Pharmaceuticals Inc. (&#8220;Hikma&#8221;) in which the Company obtained exclusive commercial rights for product sales and marketing in the United States and Canada to Hikma&#8217;s KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an 8 mg naloxone agent. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MCM Products Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers for their use; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-441-2" continuedAt="f-441-3"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics (&#8220;Ridgeback&#8221;), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trobigard Revocation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 2, 2024, the Belgium Federal Agency for Medicines and Health Products acknowledged and confirmed Emergent&#8217;s request to revoke the Market Authorization for the Trobigard Auto-Injector.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of RSDL</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2024, the Company entered into the Stock and Asset Purchase Agreement (the &#8220;RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Agreement&#8221;) with SERB Pharmaceuticals, through its wholly owned subsidiary BTG International Inc. (collectively, &#8220;SERB&#8221;), pursuant to which, among other things, the Company sold its worldwide rights to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB (the &#8220;RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction&#8221;). See Note 4, &#8220;Divestitures&#8221; for more information on the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment:</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-441-3">As of the first quarter of 2025, the Company&#8217;s Services operating segment no longer met the quantitative thresholds of a reportable segment and did not meet the aggregation criteria set forth in Accounting Standards Codification (&#8220;ASC&#8221;) 280, Segment Reporting, and as such is categorized within &#8220;All other revenues&#8221; along with &#8220;Contracts and Grants&#8221; within Note 17 &#8220;Segment information&#8221;. See Note 17, &#8220;Segment information&#8221; for more information about the Company&#8217;s reportable segments.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-447" continuedAt="f-447-1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-447-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-448" escape="true"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC on March 3, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2025. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-449" escape="true"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement&#8217;s specified effective date. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company does not expect a material impact from this new guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a public business entity to disclose additional information about specific expense categories in the notes to financial statements on an annual and interim basis. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. A public entity should apply the amendments either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-450" continuedAt="f-450-1" escape="true">Assets and liabilities held for sale</ix:nonNumeric></span></div><ix:continuation id="f-450-1" continuedAt="f-450-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2025, the Company classified the assets and related liabilities associated with warehouse space in Maryland as held for sale. In the accompanying Condensed Consolidated Balance Sheet as of September 30, 2025, the assets and liabilities that are expected to be conveyed are classified as held for sale and are measured at the lower of (i) the carrying value of the disposal group and (ii) the fair value of the disposal group, less estimated costs to sell. An orderly liquidation value was applied to estimate the fair value of the assets held for sale, representing Level 3 non-recurring fair value measurement. Effective with the designation of the assets as held for sale on March 10, 2025, the Company suspended recording depreciation of property, plant and equipment and right-of-use assets while these assets are classified as held for sale. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. The Company recognized a loss on assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-451">12.2</ix:nonFraction>&#160;million during the nine months ended September 30, 2025 in &#8220;Gain (loss) on sale of business and assets held for sale&#8221; within non-operating activities on the Condensed Consolidated Statements of Operations.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-452" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheet as of September 30, 2025 consist of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:76.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets held for sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" scale="6" id="f-453">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="f-454">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="6" id="f-455">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" scale="6" id="f-456">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="f-457">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities held for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="6" id="f-458">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" scale="6" id="f-459">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="f-460">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_43"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:continuation id="f-450-2" continuedAt="f-450-3">Divestitures</ix:continuation></span></div><ix:continuation id="f-450-3" continuedAt="f-450-4"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Travel Health Business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic (&#8220;Bavarian Nordic&#8221;), the Company completed the previously announced sale of the Company&#8217;s travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, Bavarian Nordic paid a cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-461">270.2</ix:nonFraction>&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic was required to pay milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-462">80.0</ix:nonFraction>&#160;million, which the Company records within &#8220;Other, net&#8221; in the Condensed Consolidated Statement of Operations, upon satisfaction of the following milestones:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On July 18, 2024, Bavarian Nordic announced that the European Medicines Agency had validated the marketing authorization application for CHIKV VLP, which triggered a development milestone payment receivable in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" format="ixt:num-dot-decimal" scale="6" id="f-463">10.0</ix:nonFraction>&#160;million. The Company received this milestone payment in the fourth quarter of 2024.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On August 13, 2024, Bavarian Nordic announced that the FDA has accepted and granted Priority Review for the Biologics License Application for CHIKV VLP, which triggered a milestone payment receivable in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" format="ixt:num-dot-decimal" scale="6" id="f-464">20.0</ix:nonFraction>&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company received this milestone payment in the fourth quarter of 2024.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On February 14, 2025, Bavarian Nordic announced that the FDA approved CHIKV VLP under the Priority Review, which triggered a milestone payment in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-465">30.0</ix:nonFraction>&#160;million which was recorded in &#8220;Other, net&#8221; during the nine months ended September 30, 2025. The Company received this milestone payment during the first quarter of 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-450-4"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On February 28, 2025, Bavarian Nordic announced that the European Commission approved CHIKV VLP, which triggered a milestone payment receivable in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-466">20.0</ix:nonFraction>&#160;million which was recorded in &#8220;Other, net&#8221; during the nine months ended September 30, 2025. The Company received this milestone payment in the second quarter of 2025. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase and Sale Agreement, the Company may receive up to $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-467">30.0</ix:nonFraction>&#160;million of earn-out payments from Bavarian Nordic based on aggregate net sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in calendar year 2026.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of RSDL</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2024, the Company, through its wholly owned subsidiary Emergent BioSolutions Canada Inc., entered into the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Agreement with SERB pursuant to which, among other things, the Company sold its worldwide rights to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB. The RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction also included the sale to SERB of all the outstanding capital stock of Emergent Protective Products USA Inc. (&#8220;EPPU&#8221;), a wholly owned subsidiary of the Company, which leases a manufacturing facility in Hattiesburg, Mississippi, as well as certain assets related to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including intellectual property rights, contract rights, inventory and marketing authorizations. In addition, the employees of EPPU joined SERB in connection with the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, SERB paid a cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-468">75.0</ix:nonFraction>&#160;million, exclusive of customary closing adjustments related to inventory. In addition, SERB will owe the Company a $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-469">5.0</ix:nonFraction>&#160;million payment upon achievement of a milestone relating to sourcing of a certain component of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decontamination lotion. In connection with the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transaction, the Company recognized a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-470">60.8</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-471">4.1</ix:nonFraction>&#160;million, recorded within &#8220;Gain (loss) on sale of business&#8221; on the Consolidated Statements of Operations during the year ended December 31, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and SERB entered into a transition services agreement (the &#8220;SERB TSA&#8221;) to ensure the orderly transition of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decontamination lotion and the related assets to SERB, and a supply agreement (the &#8220;SERB Supply Agreement&#8221;) pursuant to which SERB has a suite reservation at the Company&#8217;s Winnipeg facility where the Company will perform Bioservices activities to manufacture and supply bulk lotion to SERB. The Company and SERB also entered into a reverse supply agreement (together with the SERB TSA and the SERB Supply Agreement, the &#8220;SERB Agreements&#8221;) pursuant to which SERB supplies to the Company finished RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the purposes of the Company&#8217;s performance of certain transitional distribution services under customer contracts that have not yet transferred to SERB. Under the SERB Agreements, the Company will retain a portion of net sales received upon delivery of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the delayed transfer customers. Income from performing services under the SERB TSA is recorded within &#8220;Product and services sales, net&#8221; on the Condensed Consolidated Statements of Operations and was $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-472">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-473">1.7</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2025, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Baltimore-Camden Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2024, pursuant to the Asset Purchase Agreement, the Company completed the sale of its Drug Product facility in Baltimore-Camden to an affiliate of Bora. The Baltimore-Camden facility, which was part of the Company&#8217;s Services operating segment, had clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. At closing, Bora paid a cash purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-474">35.0</ix:nonFraction>&#160;million, which included customary closing adjustments to date for working capital and transaction expenses of the business at closing. As a result of the divestiture, the Company recognized a pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-475">36.5</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-476">3.8</ix:nonFraction>&#160;million, during the year ended December 31, 2024 recorded within &#8220;Gain (loss) on sale of business and assets held for sale&#8221; on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture, the Company entered into a Transition Services Agreement (the &#8220;Bora TSA&#8221;) with Bora to help support its ongoing operations. Under the Bora TSA, the Company is providing certain transition services to Bora, including information technology, finance and enterprise resource planning, human resources, employee benefits and other limited services. Income from performing services under the Bora TSA is recorded within &#8220;Other, net&#8221; on the Condensed Consolidated Statements of Operations and was <ix:nonFraction unitRef="usd" contextRef="c-106" decimals="INF" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-477">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-478">0.4</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2025, respectively.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Baltimore-Bayview Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2025, the Company completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International (&#8220;Syngene&#8221;). At closing, Syngene paid a cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-479">36.5</ix:nonFraction>&#160;million. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the divestiture, the Company recognized a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-480">7.9</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-481">1.2</ix:nonFraction>&#160;million, during the nine months ended September 30, 2025 recorded within &#8220;Other, net&#8221; on the Condensed Consolidated Statements of Operations. The Company determined that the disposal of the Baltimore-Bayview facility does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on the Company&#8217;s operations and financial results.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="f-482" continuedAt="f-482-1" escape="true">Impairment and restructuring charges</ix:nonNumeric></span></div><ix:continuation id="f-482-1" continuedAt="f-482-2"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. There were <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-483"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-484">no</ix:nonFraction></ix:nonFraction> impairment charges recorded on long-lived assets during the three and nine months ended September 30, 2025.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Impairment of long-lived assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the preparation of the Company&#8217;s financial statements for the three months ended June&#160;30, 2024, due to the decision to close the Company&#8217;s Baltimore-Bayview Drug Substance manufacturing facility and the Rockville, Maryland Drug Product facility, the Company determined there were sufficient indicators of impairment for the Bayview and Rockville asset groups within the Bioservices reporting unit. As a result, the Company performed recoverability tests on those asset groups and concluded that the Bayview and Rockville asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values. The Company allocated and recognized a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-485">27.2</ix:nonFraction> million during the second quarter of 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" id="f-486" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the total impairment charge by asset class for the nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.428%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-487">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-488">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-489">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-490">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total impairment of long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-491">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Charges</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">January 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;January 2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately <ix:nonFraction unitRef="employee" contextRef="c-114" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-492">125</ix:nonFraction> employees. The charges related to the January 2023 Plan consisted primarily of charges related to employee transition, severance payments and employee benefits. The cumulative amount of restructuring charge related to the January 2023 Plan since inception was $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="6" id="f-493">9.3</ix:nonFraction>&#160;million. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#8217;s classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately <ix:nonFraction unitRef="employee" contextRef="c-116" decimals="-2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-494">400</ix:nonFraction> employees. The charges related to the August 2023 Plan consisted primarily of employee transition, severance payment and employee benefit charges. The cumulative amount of restructuring charge related to the August 2023 Plan since inception is $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="6" id="f-495">19.4</ix:nonFraction>&#160;million. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#8217;s classification policy for each category of operating expense.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-482-2" continuedAt="f-482-3"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">May 2024 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company initiated the May 2024 Plan. These strategic actions led to a reduction of the Company&#8217;s workforce by approximately <ix:nonFraction unitRef="employee" contextRef="c-118" decimals="-2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-496">300</ix:nonFraction> employees across all areas of the Company and the elimination of approximately <ix:nonFraction unitRef="positions" contextRef="c-118" decimals="INF" name="ebs:RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" scale="0" id="f-497">85</ix:nonFraction> positions that were vacant, as well as the closure of the Company&#8217;s Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. Decisions regarding the elimination of positions and the closure of manufacturing facilities were subject to local law and consultation requirements in certain countries, as well as the Company&#8217;s business needs. The cumulative amount of restructuring charge related to the May 2024 Plan since inception is $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="6" id="f-498">18.5</ix:nonFraction>&#160;million. All activities related to the May 2024 Plan were substantially completed during the third quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2024 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company initiated the August 2024 Plan at the Company&#8217;s Lansing facility, which reduced the Company&#8217;s workforce by approximately <ix:nonFraction unitRef="employee" contextRef="c-120" decimals="-1" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-499">70</ix:nonFraction> employees, as well as eliminated several open positions. The Company also implemented non-labor optimization efforts, such as reducing the Company&#8217;s external and vendor spend. The cumulative amount of restructuring charges related to the August 2024 Plan since inception is $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="6" id="f-500">2.5</ix:nonFraction>&#160;million. All activities related to the August 2024 Plan were substantially completed during the fourth quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#8217;s classification policy for each category of operating expense.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-501" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by reportable segment as well as amounts included within non-reportable segments, unallocated corporate selling, general and administrative (&#8220;SG&amp;A&#8221;) expense and research and development (&#8220;R&amp;D&#8221;) expense:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment restructuring costs:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-502">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-503">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-504">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-505">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other segments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-507">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-509">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs included in Cost of product and services sales, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-510">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-511">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-512">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-513">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate restructuring costs: </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-514">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-515">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-516">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-517">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-519">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-520">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-521">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-522">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-523">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-524">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-525">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by function:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"> Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee transition</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-527">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-529">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Severance payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-531">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-532">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-533">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-534">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-535">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-536">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-537">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-538">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-539">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-540">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-541">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All financial impacts of the January 2023 Plan were reflected in the Company&#8217;s consolidated financial statements by the second quarter of 2024. As a result, there was <ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-542"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="INF" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-543">no</ix:nonFraction></ix:nonFraction> activity related to the January 2023 Plan for the three and nine months ended September 30, 2025. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-544" continuedAt="f-544-1" escape="true">The following table provides the components of and changes in the Company&#8217;s restructuring accrual for the January 2023 Plan during the three and nine months ended September 30, 2024:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-482-3" continuedAt="f-482-4"><ix:continuation id="f-544-1" continuedAt="f-544-2"><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-546">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-548">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-550">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-552">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-554">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-556">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-558">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-560">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All financial impacts of the August 2023 Plan were reflected in the Company&#8217;s consolidated financial statements by the fourth quarter of 2024. As a result, there was <ix:nonFraction unitRef="usd" contextRef="c-180" decimals="INF" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-569"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="INF" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-570">no</ix:nonFraction></ix:nonFraction> activity related to the August 2023 Plan for three and nine months ended September 30, 2025. <ix:continuation id="f-544-2" continuedAt="f-544-3">The following table provides the components of and changes in the Company&#8217;s restructuring accrual for the August 2023 Plan during the three and nine months ended September 30, 2024:</ix:continuation></span></div><ix:continuation id="f-544-3" continuedAt="f-544-4"><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-572">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-573">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-574">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-576">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-578">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-580">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-582">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-584">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-585">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-586">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-588">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-590">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-592">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-593">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-594">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-596">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-598">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-600">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-602">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-604">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-606">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the components of and changes in the Company&#8217;s restructuring accrual for the May 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-608">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-609">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-610">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-613">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-614">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-616">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-617">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-618">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-620">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-622">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-624">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-626">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-628">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-630">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-632">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-634">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-637">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-638">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-640">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-641">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-642">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-544-4"><ix:continuation id="f-482-4"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-655">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-656">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-657">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-658">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-659">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-662">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-664">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-665">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-666">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-668">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-669">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-670">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-672">6.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-673">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-674">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-676">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-677">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-678">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the components of and changes in the Company&#8217;s restructuring accrual for the August 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-680">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-681">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-682">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-684">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-685">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-686">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-688">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-689">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-690">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-692">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-694">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-696">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-698">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-700">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-702">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-723">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-724">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-725">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-726">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-727">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-730">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-732">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-733">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-734">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_49"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-735" continuedAt="f-735-1" escape="true">Inventories, net </ix:nonNumeric></span></div><ix:continuation id="f-735-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-736" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="f-737">126.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="f-738">95.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-739">115.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-740">86.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-741">114.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-742">129.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-743">356.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-744">311.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is stated at the lower of cost or net realizable value</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-745" continuedAt="f-745-1" escape="true">Property, plant and equipment, net</ix:nonNumeric></span></div><ix:continuation id="f-745-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-746" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024 </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-747">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-748">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-749">159.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-750">196.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-751">252.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-752">368.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-753">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-754">67.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-755">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-756">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-757">500.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-758">667.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-759">290.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-760">397.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-761">209.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-762">270.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> During 2024, the Company recorded non-cash impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-763">27.2</ix:nonFraction> million related to certain Bioservices long-lived assets. See Note 5, &#8220;Impairment and restructuring charges&#8221; for more details regarding the impairment charge.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December&#160;31, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">construction-in-progress primarily included costs incurred to advance the Company&#8217;s MCM Products capabilities. Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization.</span></div></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_55"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-764" continuedAt="f-764-1" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="f-764-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s finite-lived intangible assets consist of products acquired via business combinations or asset acquisitions. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-765" continuedAt="f-765-1" escape="true">The following table summarizes the Company&#8217;s finite-lived intangible assets:</ix:nonNumeric></span></div><ix:continuation id="f-765-1"><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.601%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-315" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-766">13.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-767">855.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-768">402.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-769">452.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-770">855.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-771">353.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-772">501.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-773">855.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-774">402.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-775">452.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-776">855.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-777">353.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-778">501.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="f-779" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company&#8217;s finite-lived intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-780">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-781">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-782">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-783">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_58"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-784" continuedAt="f-784-1" escape="true">Fair value measurements</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-785" escape="true"><ix:continuation id="f-784-1" continuedAt="f-784-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.071%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-786">105.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-787">105.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-790">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-791">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-794">105.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-795">105.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-798">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-799">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-800">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" scale="6" id="f-802">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" scale="6" id="f-805">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" scale="6" id="f-806">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" scale="6" id="f-809">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-810">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-813">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-814">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-817">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-784-2"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Warrant liability</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s Credit Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto (the &#8220;Term Loan Agreement&#8221;), the Company issued to the lenders warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-331" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="f-818">1.0</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-331" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-819">9.8802</ix:nonFraction> per share (the &#8220;Series I Warrants&#8221;) and warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-332" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="f-820">1.5</ix:nonFraction>&#160;million shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-332" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-821">15.7185</ix:nonFraction> per share (the &#8220;Series II Warrants&#8221; and, together with the Series I Warrants, the &#8220;Warrants&#8221;). The Warrants are currently exercisable and will expire on August 30, 2029. Because the Warrants could be cash settled based on events that are outside the control of the Company, it precludes the Warrants from applying the equity contract scope exception, and so are classified as a liability. As a result, the fair value of the Warrants will be remeasured each period with the gain or loss on the warrant liability included in &#8220;Other, net&#8221; on the Condensed Consolidated Statement of Operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December&#160;31, 2024, t</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the warrant liability was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" scale="6" id="f-822">14.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-823">16.2</ix:nonFraction>&#160;million, respectively, and was included within &#8220;Other Liabilities&#8221; on the Condensed Consolidated Balance Sheets, as determined using the Black-Scholes method. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to calculate the fair value of the Warrants at each reporting period. Assumptions used in the Black-Scholes option pricing model take into account the agreement terms as well as the quoted price of the Company&#8217;s common stock in an active market. The volatility is based on the average historical volatility of the common stock. The expected life is based on the remaining contractual term of the Warrants, and the risk free interest rate is based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the Warrants&#8217; expected life. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-824" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company&#8217;s Level 3 warrant liability: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-825">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-826">9.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-827">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-828">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-829">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-830">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-831">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-832" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurement for the Company's warrant liability used the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrant Liability</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Range</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024 Warrants</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes Method</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="term" contextRef="c-340" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-833">3.9</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-341" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-834">3.7</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-342" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-835">103</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2024, t</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="c-343" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-836"><ix:nonFraction unitRef="number" contextRef="c-344" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-837">3.875</ix:nonFraction></ix:nonFraction>% Senior Unsecured Notes due 2028 (the &#8220;Senior Unsecured Notes&#8221;) was $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-838">368.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-839">369.1</ix:nonFraction>&#160;million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, &#8220;Debt&#8221;, for more information regarding the Company&#8217;s repurchase of a portion of the Senior Unsecured Notes during the third quarter of 2025).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-840" continuedAt="f-840-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-840-1" continuedAt="f-840-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-841" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the components of the Company&#8217;s debt:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2029</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-842">250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-843">250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-344" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-844"><ix:nonFraction unitRef="number" contextRef="c-343" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-845">3.875</ix:nonFraction></ix:nonFraction>% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-846">443.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-847">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-848">693.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-849">700.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="f-850">30.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="f-851">36.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-852">663.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-853">663.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-854">35.0</ix:nonFraction>&#160;million of unamortized debt issuance costs recorded in connection with the execution of the Term Loan Agreement within a contra account to directly offset the Term Loan balance.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs associated with the Company&#8217;s Revolving Loans, as described in further detail below, were recorded as an asset within &#8220;Other long-term assets&#8221; on the Company&#8217;s Condensed Consolidated Balance Sheets. As of September 30, 2025, the Company has $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="f-855">3.0</ix:nonFraction>&#160;million in debt issuance costs associated with the Revolving Loans. If the Company draws on the capacity available under the Revolving Loans, the debt issuance costs would be reclassified to a contra account to directly offset the Revolving Loans balance.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="c-349" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-856">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-857">450.0</ix:nonFraction>&#160;million aggregate principal amount of its Senior Unsecured Notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Interest on the Senior Unsecured Notes is payable on February 15 and August 15 of each year until maturity, beginning on February 15, 2021. The Senior Unsecured Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of August 15, 2023, the Company may redeem all or a portion of the Senior Unsecured Notes at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="c-350" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-858">100</ix:nonFraction>% of the principal amount of the Senior Unsecured Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest as set forth in the related indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the Senior Unsecured Notes at a purchase price of <ix:nonFraction unitRef="number" contextRef="c-351" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-859">101</ix:nonFraction>% of the principal amount of such notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the indenture governing the Senior Unsecured Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">restricted payments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;7, 2025, the Board of Directors authorized the Company to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="f-860">30.0</ix:nonFraction> million in aggregate principal amount of the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior Unsecured Notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company may seek to opportunistically use this authority to repurchase its Senior Unsecured Notes in open market purchases, privately negotiated transactions or otherwise. Any such repurchases will depend upon prevailing market conditions, our liquidity requirements, contractual restrictions, applicable securities law and other factors. During the three and nine months ended September 30, 2025, the Company repurchased $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="6" id="f-861">6.9</ix:nonFraction> million principal amount of its outstanding Senior Unsecured Notes. The Company paid $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="ebs:PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" format="ixt:num-dot-decimal" scale="6" id="f-862"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="ebs:PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" format="ixt:num-dot-decimal" scale="6" id="f-863">5.8</ix:nonFraction></ix:nonFraction>&#160;million in cash, including fees and accrued interest, in connection with the repurchases and recognized a gain on extinguishment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-864"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-865">1.1</ix:nonFraction></ix:nonFraction>&#160;million, which was included in &#8220;Other, net&#8221; on the Consolidated Statement of Operations. As of September 30, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="ebs:DebtInstrumentRepurchaseAmountRemaining" format="ixt:num-dot-decimal" scale="6" id="f-866">23.1</ix:nonFraction>&#160;million available to repurchase additional Senior Unsecured Notes. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Term Loan Agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2024, the Company entered into the Term Loan Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto. The Term Loan Agreement provides for a term loan (the &#8220;Term Loan&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-867">250.0</ix:nonFraction>&#160;million, which was drawn in full on the date of entry into the Term Loan Agreement (the &#8220;Closing Date&#8221;). The Term Loan was issued with an original issue discount of <ix:nonFraction unitRef="number" contextRef="c-355" decimals="INF" name="ebs:DebtInstrumentOriginalIssueDiscountPercentage" scale="-2" id="f-868">3.00</ix:nonFraction>%.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan will accrue interest at the Company&#8217;s option at (i) the Base Rate (as defined in the Term Loan Agreement) (subject to a floor of <ix:nonFraction unitRef="number" contextRef="c-356" decimals="INF" name="ebs:DebtInstrumentVariableInterestRateFloor" scale="-2" id="f-869">1.00</ix:nonFraction>%) plus <ix:nonFraction unitRef="number" contextRef="c-356" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-870">7.25</ix:nonFraction>% per annum, referred to as &#8220;Term Base Rate Loans&#8221; or (ii) Adjusted Term SOFR (as defined in the Term Loan Agreement) (subject to a floor of <ix:nonFraction unitRef="number" contextRef="c-357" decimals="INF" name="ebs:DebtInstrumentVariableInterestRateFloor" scale="-2" id="f-871">2.00</ix:nonFraction>% until the second anniversary of the Closing Date, and thereafter, <ix:nonFraction unitRef="number" contextRef="c-358" decimals="INF" name="ebs:DebtInstrumentVariableInterestRateFloor" scale="-2" id="f-872">3.00</ix:nonFraction>%) plus <ix:nonFraction unitRef="number" contextRef="c-359" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-873">8.25</ix:nonFraction>% per annum, referred to as &#8220;Term SOFR Loans&#8221;). A default interest rate of an additional <ix:nonFraction unitRef="number" contextRef="c-360" decimals="INF" name="ebs:DebtInstrumentAdditionalDefaultInterestRate" scale="-2" id="f-874">2.00</ix:nonFraction>% per annum would apply on all outstanding obligations that are not paid when due. If any defaulted obligations are Term SOFR Loans, then such loans would, at the end of the applicable interest period, automatically be converted to Term Base Rate Loans that would continue to be subject to the default interest rate.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-840-2" continuedAt="f-840-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan will mature on the first to occur (such date, the &#8220;Term Loan Maturity Date&#8221;) of (i) August 30, 2029, (ii) the date of acceleration of the Term Loan upon the occurrence and during the continuance of an event of default and (iii) solely to the extent the aggregate principal amount of Senior Unsecured Notes outstanding exceeds $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="INF" name="ebs:DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" scale="6" id="f-875">25.0</ix:nonFraction> million, May 15, 2028, which is three months prior to the August 15, 2028 maturity date of the Senior Unsecured Notes. The Term Loan Agreement contains certain customary default and cross-default provisions, representations and warranties and affirmative and negative covenants, including (a) restrictions on prepayments and repurchases of indebtedness, including the Senior Unsecured Notes, subject to further customary permitted debt payments, (b) a minimum liquidity requirement of $<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="INF" name="ebs:DebtInstrumentCovenantLiquidityRequirementMinimum" format="ixt:num-dot-decimal" scale="6" id="f-876">75.0</ix:nonFraction>&#160;million commencing on September 30, 2024 and tested every two weeks, and (c) a consolidated gross leverage ratio tested every fiscal quarter commencing with the fiscal quarter ending December 31, 2025, initially at <ix:nonFraction unitRef="number" contextRef="c-355" decimals="INF" name="ebs:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="f-877">5.10</ix:nonFraction>:1.00 with step-downs as set forth in the Term Loan Agreement. As of September 30, 2025, the Company was in compliance with all covenants under the Term Loan Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All indebtedness outstanding under the Term Loan Agreement is guaranteed by certain of the Company&#8217;s direct and indirect subsidiaries, other than certain subsidiaries that are not material, are excluded pursuant to the terms of the Term Loan Agreement, or will become guarantors on a post-closing basis (the Company and the guarantors, collectively, the &#8220;Credit Parties&#8221;). The indebtedness under the Term Loan Agreement is secured by a first-priority security interest in and lien on substantially all assets of the Company and the other Credit Parties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay the Term Loan, in whole or in part, subject to (i) through and including the first anniversary of the Closing Date, a make-whole premium plus <ix:nonFraction unitRef="number" contextRef="c-355" decimals="INF" name="ebs:DebtInstrumentBasisSpreadOnMakeWholePremium" scale="-2" id="f-878">4.00</ix:nonFraction>% of the aggregate principal amount of the Term Loan subject to prepayment and (ii) after the first anniversary of the Closing Date, a <ix:nonFraction unitRef="number" contextRef="c-355" decimals="INF" name="ebs:DebtInstrumentPrepaymentPremium" scale="-2" id="f-879">4.00</ix:nonFraction>% prepayment premium, which percentage shall be reduced by <ix:nonFraction unitRef="number" contextRef="c-355" decimals="INF" sign="-" name="ebs:DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" scale="-2" id="f-880">0.25</ix:nonFraction>% as set forth on a schedule attached to the Term Loan Agreement. The Term Loan Agreement requires mandatory prepayments of the Term Loan in an amount equal to (a) <ix:nonFraction unitRef="number" contextRef="c-360" decimals="INF" name="ebs:DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" scale="-2" id="f-881">100</ix:nonFraction>% of the aggregate net cash proceeds from the incurrence of certain indebtedness by the Term Loan Credit Parties and (b) (subject to certain reinvestment rights) <ix:nonFraction unitRef="number" contextRef="c-360" decimals="INF" name="ebs:DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" scale="-2" id="f-882">100</ix:nonFraction>% of the aggregate net cash proceeds from (1) subject to certain specified exceptions, dispositions of property by the Credit Parties (provided that with respect to any dispositions occurring on or after the Closing Date, prepayment will not be required unless the net cash proceeds exceed $<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="INF" name="ebs:DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" scale="6" id="f-883">10.0</ix:nonFraction> million in the aggregate per fiscal year or $<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="INF" name="ebs:DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" scale="6" id="f-884">5.0</ix:nonFraction> million on a per-transaction basis) and (2) insurance proceeds received by any Credit Party or their subsidiaries resulting from theft, loss, physical destruction or damage of property.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, the Company used a portion of the proceeds of the Term Loan to repay all amounts outstanding and terminate commitments under the senior term loan facility under its Amended and Restated Credit Agreement, dated October 15, 2028, by and among the Company, the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the Administrative Agent (the &#8220;Prior Credit Agreement&#8221;), plus accrued interest and fees. The Company previously repaid all amounts outstanding under the revolving credit facility under the Prior Credit Agreement.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revolving Loan Agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2024, the Company entered into a credit agreement for asset-based revolving loans (the &#8220;Revolving Credit Agreement&#8221;) with certain subsidiary borrowers (together with the Company, the &#8220;Borrowers&#8221;), the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as agent (the &#8220;Agent&#8221;). The Credit Agreement provides for commitments with respect to the revolving loans (the &#8220;Revolving Loans&#8221;) of up to the lesser of (x) $<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-885">100.0</ix:nonFraction> million, which may be increased (but not above $<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="INF" name="ebs:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" scale="6" id="f-886">125.0</ix:nonFraction> million, or the &#8220;Maximum Revolver Amount&#8221;) or decreased (but not below $<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="INF" name="ebs:LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" scale="6" id="f-887">50.0</ix:nonFraction> million) by the Borrowers in accordance with the terms of the Revolving Credit Agreement and (y) the Borrowing Base (as defined in the Revolving Credit Agreement). Once reduced, the facility may not be increased. Up to $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-888">5.0</ix:nonFraction> million of capacity under the Revolving Loans may be used for swing loans and up to $<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-889">10.0</ix:nonFraction> million may be used for the issuance of letters of credit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Loans accrue interest at the Base Rate (as defined in the Revolving Credit Agreement) plus a margin of <ix:nonFraction unitRef="number" contextRef="c-365" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-890">1.25</ix:nonFraction>% (such loans, &#8220;Revolving Base Rate Loans&#8221;) or, at the Company&#8217;s election, at a rate equal to Adjusted Term SOFR (as defined in the Revolving Credit Agreement and subject to a floor of <ix:nonFraction unitRef="number" contextRef="c-366" decimals="INF" name="ebs:DebtInstrumentVariableInterestRateFloor" scale="-2" id="f-891">0.00</ix:nonFraction>%) plus a margin of <ix:nonFraction unitRef="number" contextRef="c-366" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-892">2.25</ix:nonFraction>% (such loans, &#8220;Revolving SOFR Loans&#8221;), in each case until September 30, 2025. After September 30, 2025, the applicable margin may be reduced to <ix:nonFraction unitRef="number" contextRef="c-367" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-893">0.75</ix:nonFraction>% in the case of Revolving Base Rate Loans, or <ix:nonFraction unitRef="number" contextRef="c-368" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-894">1.75</ix:nonFraction>% in the case of Revolving SOFR Loans, provided the Borrowers&#8217; total leverage ratio is less than <ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF" name="ebs:DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" scale="0" id="f-895">4.00</ix:nonFraction> to 1.00 for the most recently completed fiscal quarter and an event of default is not continuing. A default interest rate of an additional <ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-896">2.00</ix:nonFraction>% per annum would apply on all outstanding obligations that are not paid when due.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Loans will mature on the first to occur of (i) September 30, 2029; (ii) to the extent there remain outstanding any portion of the term loans extended under the Term Loan Agreement, the date that is <ix:nonNumeric contextRef="c-369" name="ebs:DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" format="ixt-sec:durday" id="f-897">90</ix:nonNumeric> days prior to the maturity date under the Term Loan Agreement; and (iii) to the extent any of the Senior Unsecured Notes remain outstanding, May 17, 2028, which is <ix:nonNumeric contextRef="c-369" name="ebs:DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" format="ixt-sec:durday" id="f-898">90</ix:nonNumeric> days prior to the August 15, 2028 maturity date of the Senior Unsecured Notes. The Revolving Credit Agreement contains certain customary default and cross-default provisions (including with respect to defaults under the Term Loan Agreement), representations and warranties and affirmative and negative covenants, including (a) restrictions on prepayments and repurchases of indebtedness, including the Senior Unsecured Notes, (b) restrictions on dispositions of material intellectual property, (c) a minimum liquidity </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-840-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">requirement of $<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="INF" name="ebs:DebtInstrumentCovenantLiquidityRequirementMinimum" format="ixt:num-dot-decimal" scale="6" id="f-899">50.0</ix:nonFraction>&#160;million through the day prior to the first date following September 30, 2025 on which the Company&#8217;s total leverage ratio measured as of the preceding 12-month period is less than <ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF" name="ebs:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="f-900">5.25</ix:nonFraction> to 1.00 (the &#8220;Covenant Conversion Date&#8221;) and (d) from the Covenant Conversion Date, a fixed charge coverage ratio requirement of at least <ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF" name="ebs:DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" scale="0" id="f-901">1.00</ix:nonFraction> to 1.00. As of September 30, 2025, the Company was in compliance with all covenants under the Revolving Credit Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All indebtedness outstanding under the Revolving Credit Agreement is guaranteed by certain of the Borrowers&#8217; material direct and indirect subsidiaries, subject to customary exclusions. The indebtedness under the Credit Agreement is secured by a first-priority security interest in and lien on the ABL Priority Collateral and a second-priority security interest and lien on the Term Loan Priority Collateral (in each case as defined in the Revolving Credit Agreement).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Borrowers may elect to prepay any Revolving Loans, in whole or in part, without premium or penalty. If at any time outstanding Revolving Loans and letters of credit exceed the lesser of (i) the Borrowing Base, as adjusted for reserves established by the Agent, and (ii) the Maximum Revolver Amount, the Borrowers will be required to prepay outstanding obligations in the amount of such excess. The Agent may establish, increase or decrease reserves at its discretion.</span></div></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_67"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-902" continuedAt="f-902-1" escape="true">Share-based compensation and stockholders' equity</ix:nonNumeric></span></div><ix:continuation id="f-902-1" continuedAt="f-902-2"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share-based compensation expense relates to stock options, performance stock options, restricted stock units, performance stock units and liability classified long-term incentive awards. During the nine months ended September 30, 2025, the Company granted stock options to purchase <ix:nonFraction unitRef="shares" contextRef="c-370" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-903">1.6</ix:nonFraction>&#160;million shares of common stock, <ix:nonFraction unitRef="shares" contextRef="c-371" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-904">2.7</ix:nonFraction>&#160;million restricted stock units and <ix:nonFraction unitRef="shares" contextRef="c-372" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-905">0.3</ix:nonFraction>&#160;million performance stock units. The grants were made under the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan and the Emergent BioSolutions Inc. Inducement Plan. The performance stock units settle in stock at the end of a <ix:nonNumeric contextRef="c-372" name="ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" format="ixt-sec:durwordsen" id="f-906">one-year</ix:nonNumeric> performance period based on the Company's results compared to the performance criteria. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, the Company granted an $<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" name="ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="f-907">8.0</ix:nonFraction>&#160;million long-term incentive award, subject to market conditions, with the option to settle in any combination of cash or shares, which is accounted for as a liability classified award. The Company&#8217;s performance stock options and the long-term incentive award are valued using Monte Carlo valuation models, and each have a performance period of <ix:nonNumeric contextRef="c-374" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-908"><ix:nonNumeric contextRef="c-375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-909">five years</ix:nonNumeric></ix:nonNumeric> to vest based on the Company&#8217;s stock price performance. The long-term incentive award is revalued at each reporting period until the award is earned or expires. The Company&#8217;s other equity awards typically vest over <ix:nonFraction unitRef="increment" contextRef="c-376" decimals="INF" name="ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" format="ixt-sec:numwordsen" id="f-910">three</ix:nonFraction> equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the <ix:nonNumeric contextRef="c-372" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-911">three-year</ix:nonNumeric> performance period based on the Company's results compared to the performance criteria. During the nine months ended September 30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="f-912">0.4</ix:nonFraction>&#160;million stock options, <ix:nonFraction unitRef="shares" contextRef="c-371" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="6" id="f-913">0.3</ix:nonFraction>&#160;million of restricted stock units and an <ix:nonFraction unitRef="shares" contextRef="c-372" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="f-914">immaterial</ix:nonFraction> number of performance stock units were forfeited prior to the completion of the applicable vesting requirements or expiration. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-915" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products and services sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-916">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-917">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-918">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-919">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research &amp; development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-920">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-921">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-922">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-923">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-924">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-925">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-926">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-927">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-928">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-929">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-930">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-931">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2025 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2025, the Company announced that its Board of Directors had authorized the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-932">50.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock (the &#8220;2025 Share Repurchase Program&#8221;) on or before March 27, 2026. Repurchases under the 2025 Share Repurchase Program may be made from time to time on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the Company&#8217;s management based on its evaluation of market conditions and other factors, including the market price of the Company&#8217;s common shares, macroeconomic environment and other investment opportunities, consistent with the Company&#8217;s insider trading policy. The 2025 Share Repurchase Program may be suspended or discontinued at any time. The Inflation Reduction Act of 2022, which was enacted on August 16, 2022, imposed a nondeductible 1% </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-902-2"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">excise tax on the net value of certain stock repurchases made after December 31, 2022. Excise tax accrued during the three and nine months ended September 30, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTaxPayable" scale="6" id="f-933">0.2</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2025, the Company utilized $<ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-934">8.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-935">15.8</ix:nonFraction>&#160;million to repurchase <ix:nonFraction unitRef="shares" contextRef="c-390" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-936">1.1</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="c-391" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-937">2.3</ix:nonFraction>&#160;million shares, respectively, at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-390" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-938">7.87</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-391" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-939">7.00</ix:nonFraction> per share, excluding commissions and excise taxes, respectively. As of September 30, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-940">34.2</ix:nonFraction>&#160;million available to repurchase shares under the 2025 Share Repurchase Program.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Issuance of Common Stock</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Term Loan Agreement, the Company entered into a Subscription Agreement, dated as of August 30, 2024 (the &#8220;Subscription Agreement&#8221;) with the lenders under the Term Loan Agreement, under which on September 17, 2024, the Company issued to the lenders <ix:nonFraction unitRef="shares" contextRef="c-393" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-941">1.1</ix:nonFraction>&#160;million shares of common stock with an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-942">10.0</ix:nonFraction>&#160;million, at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-394" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-943">8.98</ix:nonFraction>, which was based on the volume weighted average price per share of common stock for the 30 consecutive trading days ending on, but excluding, the tenth business day of the Term Loan Agreement. At inception, the Subscription Agreement represented a forward sale of the Company&#8217;s common stock (the &#8220;Forward&#8221;). The Forward was initially classified and recorded as a liability and was remeasured to its fair value, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-944">1.6</ix:nonFraction>&#160;million gain on settlement on September&#160;17, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Warrant Issuance</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Term Loan Agreement, the Company issued to the lenders Series I Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-331" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="f-945">1.0</ix:nonFraction>&#160;million shares of common stock and Series II Warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-332" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="f-946">1.5</ix:nonFraction>&#160;million shares of common stock. The Warrants are currently exercisable and will expire on August 30, 2029. Because the Warrants could be cash settled based on events that are outside the control of the Company, it precludes the Warrants from applying the equity contract scope exception, and so are classified as a liability. As of September 30, 2025, the fair value of the Warrants was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ebs:WarrantLiabilitiesFairValueDisclosure" scale="6" id="f-947">14.4</ix:nonFraction> million. See Note 9, &#8220;Fair value measurements,&#8221; for more information on the accounting treatment and valuation of the Warrants. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-948" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, the Company had the following Warrants outstanding to acquire shares of its common stock:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrants Outstanding</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Range of Exercise<br/>&#160;Price per Share</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued related to the Term Loan Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-395" decimals="-5" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="6" id="f-949">2.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-396" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-950">9.88</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-397" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-951">15.72</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">August 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="6" id="f-952">2.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2025, no Warrants expired or were exercised.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-953" continuedAt="f-953-1" escape="true">Earnings (loss) per common share</ix:nonNumeric></span></div><ix:continuation id="f-953-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per common share is calculated using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per common share adjusts basic earnings (loss) per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units and performance stock units, as well as shares issuable upon exercises of the Warrants. Diluted earnings (loss) per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plans and pursuant to exercises of the Warrants that were excluded from diluted earnings (loss) per common share because their effect would have been antidilutive.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-954" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings (loss) per common share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-955">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-956">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-957">107.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-958">159.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-959">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-960">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-961">53.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-962">52.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities - equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-963">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-964">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-965">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-967">56.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-968">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-969">56.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-970">52.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (loss) per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-971">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-972">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-973">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-974">3.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (loss) per common share - diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-975">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-976">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-977">1.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-978">3.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-979">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-980">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-981">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-982">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_76"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-983" continuedAt="f-983-1" escape="true">Revenue recognition</ix:nonNumeric></span></div><ix:continuation id="f-983-1" continuedAt="f-983-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates the majority of its revenues through product sales to customers. The Company also generates revenues through its Bioservices offerings and suite reservations for and to third parties and Contracts and grants revenue. The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with (a) customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Nasal Naloxone Products are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-984" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration include allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> may also be sold on consignment through third-party online retailers where revenues are recognized at the point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as SG&amp;A expenses and Cost of Commercial Product sales, respectively, in the Condensed Consolidated Statement of Operations. Revenues from OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including inventory levels within the distribution channel, product shelf life and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-983-2" continuedAt="f-983-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-985" continuedAt="f-985-1" escape="true">The Company's revenues disaggregated by major sources for the three and nine months ended September 30, 2025 and 2024 were as follows: </ix:nonNumeric></span></div><ix:continuation id="f-985-1"><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-986">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-987">74.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-988">74.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-990">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-991">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-992">123.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-993">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-994">142.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-995">161.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-996">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-997">174.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-998">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-999">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1000">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1001">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1002">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1003">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1004">133.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1005">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1006">231.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1007">171.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1008">122.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1009">293.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; includes Services and Contracts and grants revenue.</span></div></td></tr><tr style="height:5pt"><td colspan="36" style="padding:0 1pt"><div style="margin-bottom:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1010">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1011">185.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1012">187.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1013">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1014">333.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1015">333.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1016">235.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1017">121.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1018">357.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1019">319.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1020">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1021">393.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1022">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1023">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1024">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1025">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1026">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1027">122.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1028">269.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1029">324.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1030">594.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1031">343.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1032">505.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1033">848.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; includes Services and Contracts and grants revenue.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; for the nine months ended September 30, 2024 includes $<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1034">50.0</ix:nonFraction> million attributable to the confidential arbitration settlement (the &#8220;Settlement Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) related to the 2022 termination of the manufacturing services agreement with Janssen (the &#8220;Janssen Agreement&#8221;).  The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, &#8220;Litigation&#8221; for additional information related to the accounting treatment and settlement of the arbitration with Janssen.</span></div></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, the Company has future contract value on unsatisfied performance obligations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-1035">322.5</ix:nonFraction>&#160;million associated with all arrangements entered into by the Company. The Company expects to recognize $<ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-1036">259.2</ix:nonFraction>&#160;million of unsatisfied performance obligations within the next <ix:nonNumeric contextRef="c-443" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="f-1037">24</ix:nonNumeric> months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associated with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and that the Company does not currently have a contractual right to bill, to be contract assets. As of September 30, 2025 and December&#160;31, 2024, the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="6" id="f-1038">2.3</ix:nonFraction> million an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="6" id="f-1039">9.7</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of contract assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within &#8220;Accounts receivable, net&#8221; on the Condensed Consolidated Balance Sheets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Condensed Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. <ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-1040" continuedAt="f-1040-1" escape="true">The following table presents the roll forward of the contract liability balances:</ix:nonNumeric></span></div><ix:continuation id="f-1040-1"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1041">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-1042">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.6pt;font-weight:400;line-height:120%">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-1043">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-983-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December&#160;31, 2024, the current portion of contract liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1044">6.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1045">4.8</ix:nonFraction>&#160;million, respectively, and was included in &#8220;Other current liabilities&#8221; on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable and allowance for expected credit losses</span></div><ix:nonNumeric contextRef="c-1" name="ebs:ScheduleOfAccountsReceivableNetTableTextBlock" id="f-1046" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Billed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="f-1047">131.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="f-1048">135.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-1049">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-1050">19.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-1051">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-1052">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1053">149.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-1054">154.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate.</span></div></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_82"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1055" continuedAt="f-1055-1" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="f-1055-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, R&amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1056" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.154%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-1057">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-1058">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-1059">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-1060">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1061">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1062">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1063">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1064">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1065">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1066">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1067">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1068">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of &#8220;Cost of product and services sales, net&#8221;, &#8220;R&amp;D&#8221; expense and &#8220;SG&amp;A&#8221; expense on the Company's Condensed Consolidated Statements of Operations.</span></div><ix:nonNumeric contextRef="c-1" name="ebs:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-1069" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1070"><span style="-sec-ix-hidden:f-1071">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-1072">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-1073">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1074"><span style="-sec-ix-hidden:f-1075">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1076">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1077">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1078"><span style="-sec-ix-hidden:f-1079">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1080">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1081">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1082">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1083">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1084">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1085">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1086">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1087">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_85"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1088" continuedAt="f-1088-1" escape="true">Income taxes </ix:nonNumeric></span></div><ix:continuation id="f-1088-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated effective annual tax rate as of September 30, 2025 and 2024 for the years ended December&#160;31, 2025 and 2024, excluding the impact of discrete adjustments, was <ix:nonFraction unitRef="number" contextRef="c-444" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1089">22</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-314" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1090">20</ix:nonFraction>%, respectively. The effective tax rate for the nine months ended September 30, 2025 and 2024 was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1091">20</ix:nonFraction>% and (<ix:nonFraction unitRef="number" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1092">38</ix:nonFraction>)%, respectively. The increase in the estimated effective annual tax rate and the effective quarterly tax rate is primarily due to an increase in estimated profit combined with a change in jurisdictional mix of income and losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted into law in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. These impacts did not have a material effect on the tax rate for the three and nine months ended September 30, 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1093" continuedAt="f-1093-1" escape="true">Litigation </ix:nonNumeric></span></div><ix:continuation id="f-1093-1" continuedAt="f-1093-2"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Exchange Act. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth, and Stephen M. Weiss, respectively. The complaints alleged, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The lead plaintiffs in the consolidated matter (the "Lead Plaintiffs") are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. An order granting the Lead Plaintiffs&#8217; motion for class certification and appointment of class representatives was entered on June 18, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2024, the Company and the Lead Plaintiffs entered into an agreement in principle to settle the claims against the Company and each of the Company&#8217;s current and former officers and directors. On October 4, 2024, the Court granted preliminary approval of the proposed settlement, ordered notice to the settlement class and scheduled a fairness hearing for February 27, 2025. On February 6, 2025, the Lead Plaintiffs filed a Motion for Final Approval of Class Action Settlement, Certification of the Settlement Class and Approval of Plan of Allocation and Motion for Award of Attorneys' Fees, Reimbursement of Expenses and Compensatory Awards for Lead Plaintiffs. Under the settlement, the claims against the Company and its officers and directors were dismissed with prejudice and released in exchange for a payment from the Company of $<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="f-1094">40.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="ebs:LossContingencyDamagesPaidValueFromInsuranceProceeds" format="ixt:num-dot-decimal" scale="6" id="f-1095">30.0</ix:nonFraction>&#160;million of which was paid from insurance proceeds, and had previously been funded in the fourth quarter of 2024. The Company recorded the settlement and insurance recoverable amounts as pre-tax operating expense and income, respectively, within &#8220;Selling, general and administrative&#8221; expenses on the Consolidated Statement of Operations for the year ended December&#160;31, 2024. At the scheduled fairness hearing on February 27, 2025, the Court granted final approval of the settlement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints sought the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-DLB. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022, the Court approved the parties' joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund, respectively, in the Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints sought the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed a motion to dismiss the complaint. On March 29, 2022, an order was granted staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds, respectively, in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-1093-2" continuedAt="f-1093-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#8217; motion to dismiss, and on November 2, 2023, the Court approved the parties' joint stipulation to extend the stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, plaintiffs Lincolnshire and Pooja Sayal filed a motion in the United States District Court for the District of Maryland seeking preliminary approval of a stipulation of settlement with regard to the above referenced derivative matters (&#8220;Proposed Settlement&#8221;). </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Proposed Settlement intends to resolve all matters among and between the following parties: (i) Lincolnshire and Pooja Sayal, plaintiffs in the stockholder derivative action captioned In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-DLB, pending in the U.S. District Court for the District of Maryland; (ii) North Collier Fire Control and Rescue District Firefighter Pension Plan, Chang Kyum Kim and Mark Nevins, plaintiffs in the stockholder derivative action captioned In re Emergent BioSolutions Inc. Derivative Litigation, Case No. 2021-0974-MTZ, pending in the Delaware Court of Chancery; (iii) Zachary Elton, Jeffery Reynolds and Eric White, plaintiffs in the stockholder derivative action captioned Elton v. Kramer, et al, Case No. C-15-CV-21-000496, pending in the Circuit Court of Maryland for Montgomery County; (iv) Richard J. Levine and Christopher Seaver, plaintiffs in the stockholder derivative action captioned In Re Emergent BioSolutions Inc. Demand Refused Stockholder Derivative Litigation, Master File No. 8:23-cv-02969-DLB, pending in the U.S. District Court for the District of Maryland; (v) Christopher Andrews, plaintiff in the stockholder derivative action captioned Andrews v. Kramer, C.A. No. 2024-0925-MTZ, pending in the Delaware Court of Chancery; (vi) individual defendants Robert G. Kramer Sr., Fuad El-Hibri, Richard S. Lindahl, Ronald B. Richard, Zsolt Harsanyi, Louis W. Sullivan, George A. Joulwan, Jerome M. Hauer, Kathryn C. Zoon, Marvin White, Syed T. Husain, Seamus Mulligan, Adam Havey, Sean Kirk, Atul Saran and Sue Bailey and (vii) the Company, as nominal defendant (collectively with the individual defendants, the &#8220;Defendants&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement provided that no later than <ix:nonNumeric contextRef="c-446" name="ebs:LossContingencySettlementPeriod" format="ixt-sec:durday" id="f-1096">20</ix:nonNumeric> business days following the satisfaction of all conditions precedent set forth in the Proposed Settlement, Defendants must cause their insurers to pay to the Company a settlement amount of $<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="f-1097">15.0</ix:nonFraction>&#160;million, less a court-approved fee and expense amount (the &#8220;Settlement Amount&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, no later than <ix:nonNumeric contextRef="c-446" name="ebs:LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" format="ixt-sec:durday" id="f-1098">60</ix:nonNumeric> days following the satisfaction of all conditions precedent set forth in the Proposed Settlement, the Company must effectuate a series of corporate governance reforms and maintain such reforms for a period of not less than <ix:nonNumeric contextRef="c-446" name="ebs:LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" format="ixt-sec:durwordsen" id="f-1099">four years</ix:nonNumeric>, subject to the terms and conditions set forth in the Proposed Settlement. On May 9, 2025, the United States District Court for the District of Maryland (the &#8220;Court&#8221;) issued an order granting preliminary approval of the Proposed Settlement. The Proposed Settlement included no admission of fault, liability or wrongdoing by any of the Defendants. On August 6, 2025, the Court granted final approval of the Proposed Settlement without modification.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the Settlement Amount in September 2025. Accordingly, during the three and nine months ended September 30, 2025, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="us-gaap:LitigationSettlementGain" format="ixt:num-dot-decimal" scale="6" id="f-1100"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:LitigationSettlementGain" format="ixt:num-dot-decimal" scale="6" id="f-1101">10.5</ix:nonFraction></ix:nonFraction>&#160;million with respect to the Settlement Amount as a reduction of &#8220;Selling, general and administrative&#8221; expenses on the Condensed Consolidated Statement of Operations.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government investigations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions described above under &#8220;Securities and shareholder litigation,&#8221; the Company received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC (as discussed further below) and the Maryland Attorney General&#8217;s Office. The Company produced documents in response and will continue to cooperate with these government inquiries should further requests be made.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, the Company also received inquiries and subpoenas from the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries and the Select Subcommittee released its final report related to the coronavirus crisis on December 9, 2022. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Also in the second quarter of 2021, the Company also received subpoenas from the SEC related to certain disclosures regarding the incidents described above under the heading &#8220;Securities and shareholder litigation.&#8221; The Company has been cooperating with the SEC&#8217;s investigation. During the first quarter of 2025, the Company determined that a loss resulting from the investigation was probable and that the amount of loss could be reasonably estimated. As a result, the Company recorded an accrual within &#8220;Selling, general and administrative&#8221; expenses on the Consolidated Statement of Operations for the year ended December&#160;31, 2024 of $<ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="f-1102"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1103">1.5</ix:nonFraction></ix:nonFraction>&#160;million, and the related liability was included in &#8220;Other current liabilities&#8221; on the Company&#8217;s Consolidated Balance Sheet as of December&#160;31, 2024. On April 7, 2025, the Company consented to the SEC&#8217;s entry of an administrative order under which the Company agreed to cease and desist from committing or causing a violation of Section 17(a)(2) of the Securities Act of 1933 and to pay a fine of $<ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-1104">1.5</ix:nonFraction>&#160;million. The Company paid the fine on April 18, 2025 and <ix:nonFraction unitRef="usd" contextRef="c-452" decimals="INF" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt-sec:numwordsen" id="f-1105">no</ix:nonFraction> liability balance remains on the Company&#8217;s Consolidated Balance Sheet as of September 30, 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-1093-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, the Company received an additional inquiry from the New York Attorney General&#8217;s Office related to certain past trading activity by the Company&#8217;s former Chief Executive Officer. The Company has produced documents and is cooperating with the New York Attorney General&#8217;s office on this matter.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, the Company met with representatives of the Department of Justice regarding the Company&#8217;s 2017 and 2019 contracts with the Department of State to provide medical countermeasures for exposure to nerve toxins. The Company has provided documents and is continuing discussions with the Department of Justice on this matter. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2022 Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the parties exchanged notices alleging material breaches of the Janssen Agreement, with each asserting the other had failed to meet key contractual obligations. Janssen subsequently initiated arbitration proceedings, and the Company responded with counterclaims. On July 3, 2024, the Company and Janssen entered into the Settlement Agreement to resolve all claims among the parties arising from the Janssen Agreement and the activities referenced above. Pursuant to the terms of the Settlement Agreement, Janssen paid the Company $<ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:ProceedsFromLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-1106">50.0</ix:nonFraction>&#160;million on July 31, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2022, because the arbitration process with Janssen was expected to extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from &#8220;Inventories, net&#8221; and from &#8220;Prepaid expenses and other current assets&#8221; to &#8220;Other assets&#8221;, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1107">152.7</ix:nonFraction>&#160;million in long-term assets related to the Janssen Agreement on the Condensed Consolidated Balance Sheet as of December 31, 2022. The long-term asset balance within &#8220;Other Assets&#8221; prior to announcing the Settlement Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1108">158.7</ix:nonFraction>&#160;million. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1109"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1110">50.0</ix:nonFraction></ix:nonFraction>&#160;million in &#8220;Product and services sales, net&#8221; and &#8220;Cost product and services sales, net&#8221; on the Condensed Consolidated Statement of Operations during the second quarter of 2024 to reflect the settlement receivable as a change in the transaction price for the Janssen Agreement. Additionally, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-1111">110.2</ix:nonFraction>&#160;million in the second quarter of 2024 within &#8220;Cost product and services sales, net&#8221; on the Condensed Consolidated Statement of Operations to write down the remaining inventory to its net realizable value and for estimated disposal costs. The receivable for the settlement amount was collected during the third quarter of 2024 and there was <ix:nonFraction unitRef="usd" contextRef="c-458" decimals="INF" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1112">no</ix:nonFraction> long-term asset balance remaining within &#8220;Other Assets&#8221; related to the Janssen Agreement as of December&#160;31, 2024.</span></div></ix:continuation><div id="ib415b040063d4dd9ba8a71e128a463b6_91"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1113" continuedAt="f-1113-1" escape="true">Segment information</ix:nonNumeric></span></div><ix:continuation id="f-1113-1" continuedAt="f-1113-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, using the guidance provided in ASC 280, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 280&#8221;), along with the adoption of ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company reevaluated its reportable and operating segments. Based on updates to the Company&#8217;s internal operating and reporting structure and quantitative tests outlined in ASC 280, the Company manages its business with a focus on <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1114">two</ix:nonFraction> reportable segments; the Commercial Products segment, which includes Naloxone products and the MCM Products segment, which includes the Anthrax - MCM products, Smallpox - MCM products and Other Products. The Company&#8217;s Services operating segment no longer meets the quantitative threshold for determining reportable segments and is now included within &#8220;All other revenues&#8221; along with the Company&#8217;s Contracts and grants business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is its President and Chief Executive Officer. The CODM evaluates the performance of the Company's reportable segments based on segment adjusted gross margin. The Company defines segment adjusted gross margin as sales less cost of sales excluding restructuring costs, changes in fair value of financial instruments, settlement charges, net and inventory step-up provision for each reportable segment. The Company does not allocate amortization of intangible assets, research and development expenses, selling, general and administrative costs, interest and other income (expense) or taxes to each reportable segment in the operating results that are regularly reviewed by the CODM. The CODM uses these reported measures to assess segment performance, allocate resources and monitor budget and guidance versus actual results. These metrics are used by the CODM to make key operating decisions, such as decisions about allocating capital and other resources to each segment. The accounting policies for segment reporting are the same as those described in Note 2, "Summary of significant accounting policies" in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2024. Intersegment revenue, cost of sales, and profit are eliminated in the segment measures regularly reviewed by the CODM as these activities are eliminated in consolidation and thus are not included in management&#8217;s evaluation of performance for each segment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by segment, as the Company's operating assets are shared or commingled. Therefore, the Company&#8217;s CODM does not regularly review any asset information by segment and, accordingly, the Company does not report asset information by segment. The measure of segment assets is reported on the Condensed Consolidated Balance Sheet as "Total assets".</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="f-1113-2" continuedAt="f-1113-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-1115" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment information provided to the CODM, along with a reconciliation of segment adjusted gross margin to income before income taxes as reported in the Condensed Consolidated Statement of Operation for the three and nine months ended September 30, 2025 and 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1116">74.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1117">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1118">187.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1119">333.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1120">142.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1121">174.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1122">357.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1123">393.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of revenue:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1124">217.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1125">269.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1126">545.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1127">726.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1128">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1129">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1130">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1131">122.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1132">231.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1133">293.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1134">594.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1135">848.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales reportable segments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1136">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1137">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1138">103.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1139">152.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1140">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1141">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1142">113.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1143">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total of reportable segments</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1144">80.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1145">95.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1146">216.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1147">290.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1148">32.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1149">48.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1150">84.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1151">181.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1152">104.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1153">126.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1154">244.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1155">255.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total of reportable segments</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1156">136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1157">174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1158">328.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="f-1159">436.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation to income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues less other costs of revenue </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-1160">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-1161">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-1162">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-1163">141.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1164">16.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1165">16.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1166">48.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1167">48.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1168">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1169">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" sign="-" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1170">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1171">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory step-up provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="ebs:InventoryStepUp" format="ixt:fixed-zero" scale="6" id="f-1172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="ebs:InventoryStepUp" scale="6" id="f-1173">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="ebs:InventoryStepUp" scale="6" id="f-1174">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="ebs:InventoryStepUp" scale="6" id="f-1175">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="f-1176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="f-1177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="f-1178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1179">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-1180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-1181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="f-1182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="f-1183">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1184">13.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1185">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1186">41.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1187">61.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1188">38.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1189">76.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1190">135.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1191">247.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-1192">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-1193">8.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-1194">44.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-1195">56.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-1196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-1197">64.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-1198">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-1199">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1200">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1201">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1202">62.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1203">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1204">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1205">142.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1206">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1207">115.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; and &#8220;All other revenues less other cost of revenue&#8221; includes Services and Contracts and grants revenue, and Services and Contracts and grants revenue less Cost of services, respectively.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Excludes $<ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-1208">&#8212;</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1209">0.2</ix:nonFraction> million of restructuring costs for the three and nine months ended September 30, 2025, respectively.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> For 2025, excludes $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="ebs:InventoryStepUp" scale="6" id="f-1210">1.8</ix:nonFraction> million of inventory step-up provision for the nine months ended September 30, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1211">0.2</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" sign="-" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1212">0.8</ix:nonFraction>) million of restructuring costs for the three and nine months ended September 30, 2025, respectively. For 2024, excludes $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1213">0.6</ix:nonFraction> million of changes in fair value of financial instruments for the nine months ended September 30, 2024; it also excludes $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1214">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="ebs:RestructuringChargesAdjusted" scale="6" id="f-1215">7.5</ix:nonFraction> million of restructuring costs, and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="ebs:InventoryStepUp" scale="6" id="f-1216"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="ebs:InventoryStepUp" scale="6" id="f-1217">1.2</ix:nonFraction></ix:nonFraction> million of inventory step up for each of the three and nine months ended September 30, 2024.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1218" escape="true"><ix:continuation id="f-1113-3"><div style="margin-bottom:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each reportable segment:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"/><td style="width:42.275%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation from reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1219">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1220">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1221">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1222">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Items not included in depreciation from reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other segment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1223">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1224">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1225">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1226">7.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1227">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1228">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1229">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1230">10.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total depreciation</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1231">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1232">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1233">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1234">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 (the &#8220;2024 Form 10-K&#8221;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q includes information with respect to our plans and strategy for our business and financing, as well as forward-looking statements that involve risks and uncertainties. You should carefully review the sections entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this Quarterly Report on Form 10-Q for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_100"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS OVERVIEW</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (&#8220;PHTs&#8221;). The Company&#8217;s solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services (&#8220;CDMO&#8221;) portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently focused on the following four PHT categories: chemical, biological, radiological, nuclear and explosives (&#8220;CBRNE&#8221;); emerging infectious diseases (&#8220;EID&#8221;); emerging health crises; and acute, emergency and community care. We have a portfolio of 11 products, 10 of which are owned by the Company, that contribute a substantial portion of our revenue and are sold to government and commercial customers. Additionally, we have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates. Finally, we have a fully integrated portfolio of CDMO services which cover development services, drug substance manufacturing and drug product manufacturing and packaging.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (&#8220;MCM&#8221;) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (&#8220;Bioservices&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the business with a focus on three operating segments: (1) a Commercial Products segment consisting of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray and KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, (2) a MCM Products segment consisting of Anthrax - MCM, Smallpox - MCM and Other Products and (3) a Services segment consisting of our Bioservices offerings. Commercial Products and MCM Products are our two reportable segments (see Note 17, &#8220;Segment information&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Form 10-Q for more information on our reportable segments). </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products Segment:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our Commercial product revenue comes from the following products:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Naloxone Products</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) (including in over-the-counter (&#8220;OTC&#8221;) form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(naloxone HCl) Nasal Spray. On January 14, 2025, the Company announced an agreement with Hikma Pharmaceuticals Inc. (&#8220;Hikma&#8221;) in which the Company obtained exclusive commercial rights for product sales and marketing in the United States and Canada to Hikma&#8217;s KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an 8 mg naloxone agent.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MCM Products Segment:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our MCM product revenue comes from the following products and procured product candidates:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers for their use; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trobigard Revocation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 2, 2024, the Belgium Federal Agency for Medicines and Health Products (&#8220;FAMHP&#8221;) acknowledged and confirmed Emergent&#8217;s request to revoke the Market Authorization for the Trobigard Auto-Injector.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2024, the Company entered into the Stock and Asset Purchase Agreement (the &#8220;RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Agreement&#8221;) with SERB Pharmaceuticals, through its wholly owned subsidiary BTG International Inc. (collectively, &#8220;SERB&#8221;), pursuant to which, among other things, the Company sold its worldwide rights to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to SERB (the &#8220;RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction&#8221;). See Note 4, &#8220;Divestitures&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Form 10-Q for more information on the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2025, the Company&#8217;s Services operating segment no longer met the quantitative thresholds of a reportable segment and did not meet the aggregation criteria set forth in Accounting Standards Codification 280, Segment Reporting, and as such is categorized within &#8220;All other revenues&#8221; along with &#8220;Contracts and Grants&#8221;. See Note 17, &#8220;Segment information&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Form 10-Q for more information about the Company&#8217;s reportable segments. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other Strategic Activities</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">May 2024 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company initiated the May 2024 Plan. These strategic actions led to a reduction of the Company&#8217;s workforce by approximately 300 employees across all areas of the Company and the elimination of approximately 85 positions that were vacant, as well as the closure of the Company&#8217;s Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. Decisions regarding the elimination of positions and the closure of manufacturing facilities were subject to local law and consultation requirements in certain countries, as well as the Company&#8217;s business needs. The cumulative amount of restructuring charge related to the May 2024 Plan since inception is $18.5&#160;million. All activities related to the May 2024 Plan were substantially completed during the third quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Development milestone payments for CHIKV VLP</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;18, 2024, Bavarian Nordic announced that the European Medicines Agency had validated the marketing authorization application for CHIKV VLP, which was submitted in June 2024. This approval triggered a milestone payment receivable under the Purchase and Sale Agreement to the Company in the amount of $10.0&#160;million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2024, Bavarian Nordic announced that the FDA has accepted and granted priority review for the Biologics License Application for CHIKV VLP, which triggered a milestone payment receivable under the Purchase and Sale Agreement to the Company in the amount of $20.0&#160;million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> On February&#160;14, 2025, Bavarian Nordic announced that the FDA approved CHIKV VLP under the Priority Review, which triggered a development milestone payment receivable under the Purchase and Sale Agreement to the Company in the amount of $30.0&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;28, 2025, Bavarian Nordic announced that the European Commission approved CHIKV VLP, which triggered a development milestone payment receivable under the Purchase and Sale Agreement to the Company in the amount of $20.0&#160;million. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2024 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company initiated an organizational restructuring plan (the &#8220;August 2024 Plan&#8221;) at the Company&#8217;s Lansing facility, which reduced the Company&#8217;s workforce by approximately 70 employees, as well eliminated several open positions. The Company also implemented non-labor optimization efforts, such as reducing the Company&#8217;s external and vendor spend. The cumulative amount of restructuring charges related to the August 2024 Plan since inception is $2.5&#160;million. All activities related to the August 2024 Plan are expected to be substantially completed during the fourth quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Exclusive commercial rights to KLOXXADO</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> distribution in U.S. and Canada</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2025, the Company announced an agreement with Hikma in which the Company obtained exclusive commercial rights for product sales and marketing in the United States and Canada to Hikma&#8217;s KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an 8 mg naloxone agent. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2024, the Company and the lead plaintiffs in stockholder litigation against the Company entered into an agreement in principle to settle the claims against the Company and each of the Company&#8217;s current and former officers and directors. On October 4, 2024, the Court granted preliminary approval of the proposed settlement, ordered notice to the settlement class and scheduled a fairness hearing for February 27, 2025. On February 27, 2025, the court granted final approval of a settlement between the Company and the lead plaintiffs. Under the settlement, the claims against the Company and its officers and directors were dismissed with prejudice and released in exchange for a payment from the Company of $40.0&#160;million, $30.0&#160;million of which was paid from insurance proceeds, and was funded in the fourth quarter of 2024. The Company recorded the settlement and insurance recoverable amounts as pre-tax operating expense and income, respectively, within &#8220;Selling, general and administrative&#8221; expenses on the Consolidated Statement of Operations for the year ended December 31, 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Baltimore-Bayview Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;19, 2025, the Company completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International (&#8220;Syngene&#8221;). At closing, Syngene paid a cash purchase price of approximately $36.5&#160;million, which is subject to customary post-closing adjustments. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility. In addition, Emergent retains the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene. See Note 4, &#8220;Divestitures&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Form 10-Q for further discussion.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2025 Settlement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, plaintiffs Lincolnshire and Pooja Sayal filed a motion in the United States District Court for the District of Maryland seeking preliminary approval of a stipulation of settlement with regard to the putative shareholder derivative lawsuits filed in 2021 and 2022 (&#8220;Proposed Settlement&#8221;). The Proposed Settlement provided that Defendants must cause their insurers to pay to the Company a settlement amount of $15.0&#160;million, less a court-approved fee and expense amount (the &#8220;Settlement Amount&#8221;). On May 9, 2025, the United States District Court for the District of Maryland (the &#8220;Court&#8221;) issued an order granting preliminary approval of the Proposed Settlement.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2025, the Court granted final approval of the Proposed Settlement without modification. The Company received the Settlement Amount in September 2025. Accordingly, during the three and nine months ended September 30, 2025, the Company recorded $10.5&#160;million with respect to the Settlement Amount as a reduction of &#8220;Selling, general and administrative&#8221; expenses on the Condensed Consolidated Statement of Operations.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2025 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2025, the Company announced that its Board of Directors had authorized the repurchase of up to $50.0&#160;million of the Company&#8217;s common stock (the &#8220;2025 Share Repurchase Program&#8221;) on or before March&#160;27, 2026. During the three and nine months ended September 30, 2025, the Company utilized $8.9&#160;million and $15.8&#160;million to repurchase 1.1&#160;million and 2.3&#160;million shares, respectively, at an average price of $7.87 and $7.00 per share, excluding commissions and excise taxes, respectively. As of September 30, 2025, the Company had $34.2&#160;million available to repurchase shares under the 2025 Share Repurchase Program.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Unsecured Note Repurchases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board has authorized the Company to use up to $30.0&#160;million to repurchase Senior Unsecured Notes in open market purchases, privately negotiated transactions or otherwise. During the three and nine months ended September 30, 2025, there was $6.9 million in principal repurchases of the Company&#8217;s Senior Unsecured Notes for $5.8&#160;million in cash, including fees, and the Company recognized a gain on extinguishment of approximately $1.1&#160;million. As of September 30, 2025, the Company had $23.1&#160;million available to repurchase additional Senior Unsecured Notes.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_103"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We generate Commercial Product revenues through the sale of Naloxone products, primarily NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray, which is sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies, as well as KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray, which is currently being integrated into our distribution network, NARCANDirect</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. We generate MCM Product revenues from the sale of our marketed products and procured product candidates. The U.S. government (&#8220;USG&#8221;) is the largest purchaser of our Government - MCM products and primarily purchases our products for the Strategic National Stockpile, a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies. The USG primarily purchases our products under long-term, firm fixed-price procurement contracts, generally with annual options.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenue from our Services segment through our Bioservices portfolio, which is based on our established development and manufacturing infrastructure, technology platforms and expertise. Our services include a fully integrated molecule-to-market Bioservices business offering across development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">services, drug substance and drug product for small to large pharmaceutical and biotechnology industry and government agencies/non-governmental organizations. From time to time, clients require suite reservations at our various manufacturing sites, which may be considered leases depending on the facts and circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have received contracts and grant funding from the USG and other non-governmental organizations to perform R&amp;D activities, particularly related to programs addressing certain CBRNE threats and EIDs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, operating results and profitability vary quarterly based on the timing of production and deliveries, the timing of manufacturing services performed and the nature of our business, which involves providing large scale bundles of products and services as needs arise. We expect continued variability in our quarterly financial results.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cost of Product Sales and Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and MCM Products</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The primary expenses that we incur to deliver our Naloxone and MCM products consist of fixed and variable costs. We determine the cost of product sales for products sold during a reporting period based on the average manufacturing cost per unit in the period those units were manufactured. Fixed manufacturing costs include facilities, utilities and amortization of intangible assets. Variable manufacturing costs primarily consist of costs for materials and personnel-related expenses for direct and indirect manufacturing support staff, contract manufacturing operations, sales-based royalties, shipping and logistics. In addition to the fixed and variable manufacturing costs described above, the cost of product sales depends on utilization of available manufacturing capacity. For our commercial sales, other associated expenses include sales-based royalties, shipping, and logistics.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Services</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The primary expenses that we incur to deliver our Bioservices offerings consist of fixed and variable costs, including personnel, equipment, and facilities costs. Our manufacturing process includes the production of bulk material and performing drug product work for containment and distribution of biological products. For drug product customers, we receive work in process inventory to be prepared for distribution. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research and Development ("R&amp;D") Expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expense R&amp;D costs as incurred. Our R&amp;D expenses consist primarily of:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">personnel-related expenses;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of our clinical trials and obtaining and evaluating data from our clinical trials and non-clinical studies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs associated with technology transfer and scale up activities throughout the development stage, including internally and through third-party contract manufacturers;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of Bioservices for our clinical trial material; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of materials intended for use and used in clinical trials and R&amp;D.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, we seek funding for development activities from external sources and third parties, such as governments and non-governmental organizations, or through collaborative partnerships. We expect our R&amp;D spending will be dependent upon such factors as the results from our clinical trials, the availability of reimbursement of R&amp;D spending, the number of product candidates under development, the size, structure and duration of any clinical programs that we may initiate, the costs associated with manufacturing and development of our product candidates on a large-scale basis for later stage clinical trials, and our ability to use or rely on data generated by government agencies.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of personnel-related costs and professional fees in support of our executives, sales and marketing, business development, government affairs, finance, accounting, information technology, legal, human resource functions and other corporate functions. Other costs include facility costs not otherwise included in cost of product sales and Bioservices or R&amp;D expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in income taxes is accounted for using a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize in our financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws, rulings, policies, or related legal and regulatory interpretations occur frequently and may have significant favorable or adverse impacts on our effective tax rate. In 2021, the Organization for Economic Cooperation and Development released model rules for a 15% global minimum tax applied to cross-border profits of certain large multinational corporations, known as Pillar Two. Pillar Two has now been enacted by approximately 36 countries, including Ireland. This minimum tax is treated as a period cost beginning in 2024 and its impact is included on the Company's financial results of operations for the current period. The Company is monitoring legislative developments, as well as additional guidance from countries that have enacted legislation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the assumptions and estimates related to the provision for income taxes are critical to the Company&#8217;s results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted into law in the United States. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. These impacts did not have a material effect on the tax rate for the three and nine months ended September 30, 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_106"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and exp</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">enses. Actual results may differ from these estimates. There have been no significant changes to our critical accounting policies and estimates contained in &#8220;Critical Accounting Policies and Estimates&#8221; in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, in Part II, Item 7, of the 2024 Form 10-K, as filed with the SEC.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please see Note 2, &#8220;Summary of significant accounting policies&#8221;, in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Quarterly Report on Form 10-Q. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="21" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="21" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except %)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Product sales, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Naloxone</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">187.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(146.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Commercial Product sales, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">187.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(146.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MCM Product sales, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">106.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(45.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">83.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">132.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(49.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">230.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">200.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total MCM Product sales, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(31.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">357.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">393.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(35.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(73.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">231.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">293.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(62.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">594.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(254.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product and services sales, net</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">241.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">563.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(322.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(37.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">247.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(112.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">229.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(74.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">466.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">948.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(481.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">128.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(99.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">227.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(44.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(56.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(64.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(25.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(18.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(96.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(84.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(115.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">248.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(63.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(159.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">266.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; includes Services and Contracts and grants revenue</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Exclusive of intangible asset amortization</span></div></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-22.5pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025 Compared with Three Months Ended September&#160;30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and gross margin</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">231.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">293.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Product and services sales, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">222.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">283.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of product and services sales, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">144.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as product and services sales, net less cost of product and services sales, net and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by products and services sales, net.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues decreased $62.7 million, or 21%, to $231.1 million for the three months ended September 30, 2025. The decrease was due to decreases in MCM Products revenue of $31.7 million, Commercial Products revenue of $20.4 million, Services revenue of $9.7 million, and Contracts and grants revenue of $0.9 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization was consistent at $16.3 million for the three months ended September 30, 2025 and 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin decreased $25.1 million to $119.8 million for the three months ended September 30, 2025. Gross margin percentage increased 3 percentage points to 54% for the three months ended September 30, 2025. The decrease in gross margin was due to decreases in MCM Products gross margin and Commercial Products gross margin of $15.8 million each, partially offset by an increase in Services gross margin of $6.5 million. Gross margin and gross margin percentage exclude Contracts and grants revenues because the related costs are R&amp;D expenses. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See "Reportable Segment Results" for an expanded discussion of revenues and gross margin.</span></div><div style="margin-bottom:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unallocated corporate operating expenses</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Expenses</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased $0.3&#160;million, or 2%, to $13.5&#160;million for the three months ended September 30, 2025. The decrease was primarily due to decreases in overhead and severance related costs, partially offset by an increase in unfunded R&amp;D project spend and  in development work related to Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SG&amp;A Expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses decreased $37.7&#160;million, or 49%, to $38.9&#160;million for the three months ended September 30, 2025. The decrease was primarily due to the absence of a one-time expense of $10.0&#160;million recognized in the prior year period and the receipt of a one-time reimbursement of $10.5&#160;million in the current year period related to settlements of our securities and shareholder litigation matters. These non-recurring items were coupled with decreases in compensation and other employee related expenses as a result of the restructuring initiatives that began during the first quarter of 2023, and lower marketing, professional services and legal expenses. SG&amp;A expenses as a percentage of total revenues decreased 9 percentage points to 17% for the three months ended September 30, 2025. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets was consistent due to no impairment recognized during the three months ended September 30, 2025 and 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $6.9&#160;million, or 83%, to $15.2&#160;million for the three months ended September 30, 2025. The increase was primarily due to an increase in amortization of debt service costs and higher interest expense related to our Credit Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto (the &#8220;Term Loan Agreement&#8221;), partially offset by lower interest costs related to our prior syndicated borrowings.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale decreased $64.3&#160;million, or 100%, due to no sale of business or held for sale activity occurring during the three months ended September 30, 2025. The gain in the prior year was related to the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to SERB, partially offset by a reduction to the loss on the sale of the Company&#8217;s drug product facility in Baltimore-Camden to Bora, which was attributable to a net working capital adjustment payable to the Company.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net went from $21.9&#160;million in income to $3.7&#160;million in expense for the three months ended September 30, 2025. The change of $25.6&#160;million, or 117%, is primarily related to one-time income associated with development milestone achievements related to CHIK VLP in the prior year period and a loss on remeasurement of the Warrant liability in the current year period, partially offset by a decrease in property, plant and equipment disposals and an increase in interest income.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax provision</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision decreased $21.2&#160;million, or 77%, to $6.4&#160;million for the three months ended September 30, 2025. The decrease was primarily due to a change in jurisdictional mix of income and losses, and a decrease of profitability in the third quarter of 2025 relative to 2024.</span></div><div style="margin-bottom:9pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025 Compared with Nine Months Ended September 30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and gross margin</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">594.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Product and services sales, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">561.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">824.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of product and services sales, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">241.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">563.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">271.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">212.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as product and services sales, net less cost of product and services sales, net and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by products and services sales, net.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues decreased $254.7 million, or 30%, to $594.2 million for the nine months ended September 30, 2025. The decrease was due to lower Commercial Products revenue of $146.1 million, Services revenue of $81.3 million and MCM Products revenue of $35.5 million, partially offset by an increase in Contracts and grants revenue of $8.2 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization was consistent at $48.8 million for the nine months ended September 30, 2025 and 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased $59.1 million to $271.3 million for the nine months ended September 30, 2025. Gross margin percentage increased 22 percentage points to 48% for the nine months ended September 30, 2025. The increase in gross margin was due to a $158.3 million improvement in Services gross margin driven by the accounting for the Settlement Agreement with Janssen in the prior year period, partially offset by a decrease of $96.9 million in Commercial Products gross margin and a decrease of $2.3 million in MCM Products gross margin. Gross margin and gross margin percentage exclude Contracts and grants revenues because the related costs are R&amp;D expenses. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See "Reportable Segment Results" for an expanded discussion of revenues and gross margin.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unallocated corporate operating expenses</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Expenses</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased $20.5&#160;million, or 33%, to $41.1&#160;million for the nine months ended September 30, 2025. The decrease was primarily due to write-offs related to program terminations in the second quarter of 2024 and decreases in overhead and severance related costs in the current year. This decrease was partially offset by an increase in costs associated with the development work related to Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SG&amp;A Expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses decreased $112.2&#160;million, or 45%, to $135.0&#160;million for the nine months ended September 30, 2025. The decrease was primarily due to declines in compensation and other employee related costs as a result of the restructuring initiatives that began during the first quarter of 2023 as well as lower professional services and legal fees related to general corporate initiatives in the prior year. The decline in SG&amp;A was also due to the absence of a one-time expense of $10.0&#160;million recognized in the prior year period and the receipt of a one-time reimbursement of $10.5&#160;million in the current year period related to settlements of our securities and shareholder litigation matters as well as decreases in marketing spend. SG&amp;A expenses as a percentage of total revenues decreased 6 percentage points to 23% for the nine months ended September 30, 2025. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets decreased $27.2&#160;million, or 100%, due to no impairment recognized during the nine months ended September 30, 2025. The $27.2&#160;million non-cash impairment charge in the second quarter of 2024 was related to our Bayview and Rockville asset groups within the Bioservices reporting unit.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $11.6&#160;million, or 21%, to $44.6&#160;million for the nine months ended September 30, 2025. The decrease was primarily due to lower interest costs related to our prior syndicated borrowings, partially offset by higher interest expense related to our Term Loan Agreement and an increase in amortization of debt service costs.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale decreased $36.5&#160;million, or 150%, to a $12.2&#160;million loss for the nine months ended September 30, 2025. The loss on assets held for sale in the current period is related to warehouse space in Maryland and the gain on sale of business in the prior period is related to the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB, partially offset by a loss the sale of the Company&#8217;s drug product facility in Baltimore-Camden to Bora.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net increased from $15.8&#160;million in income to $62.3&#160;million in income for the nine months ended September 30, 2025. The change of $46.5&#160;million is primarily attributable to the $20.0 million of incremental income from milestone payments received in 2025 versus 2024 related to the sale of our travel health business to Bavarian Nordic, combined with a favorable shift from prior-year asset sale losses to asset sale gains in the current year related to our Bayview facility, as well as favorable impacts from warrant valuations, interest income and foreign currency revaluations. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax provision</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision decreased $17.7&#160;million, or 40%, to $26.3&#160;million for the nine months ended September 30, 2025. The decrease was primarily due to a change in jurisdictional mix of income and losses, reflecting a lower profitability in Ireland in the third quarter of 2025 relative to 2024.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REPORTABLE SEGMENT RESULTS</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL PRODUCT SEGMENT</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.488%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">187.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">152.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">152.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Add back:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">181.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin %</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as revenues less cost of sales and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by revenues.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Segment adjusted gross margin, which is a non-GAAP financial measure, for our Commercial Product segment is calculated as gross margin plus intangible asset amortization and restructuring costs. Segment adjusted gross margin percentage, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin percentage for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025 Compared with Three Months Ended September&#160;30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Naloxone</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Naloxone sales </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">decreased </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$20.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or 21%, to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$74.9 million for the three months ended September 30, 2025. The decrease was primarily driven by lower sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Canadian sales of branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, driven primarily by unfavorable pricing changes and unit volumes, partially offset by an increase in KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Commercial Product sales decreased $4.6&#160;million, or 10%, to $42.6&#160;million for the three months ended September 30, 2025. The decrease was primarily due to lower sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and lower Canadian sales of branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by an increase in KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products gross margin decreased $15.8&#160;million, or 41%, to $22.9&#160;million for the three months ended September 30, 2025. Commercial Products gross margin percentage decreased 10 percentage points to 31% for the three months ended September 30, 2025. The decrease was largely due to lower sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and lower branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales, as well as an unfavorable price and volume mix, partially offset by an increase in KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $9.4&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025 Compared with Nine Months Ended September 30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Naloxone</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Naloxone sales decreased $146.1 million, or 44%, to $187.7 million for the nine months ended September 30, 2025. The decrease was primarily driven by lower sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and lower Canadian sales of branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, primarily driven by unfavorable pricing changes and unit volumes, partially offset by an increase in KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Commercial Product sales decreased $49.2&#160;million, or 32%, to $103.5&#160;million for the nine months ended September 30, 2025. The decrease was primarily due to lower sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and lower Canadian sales of branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by an increase in KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products gross margin decreased $96.9&#160;million, or 63%, to $55.9&#160;million for the nine months ended September 30, 2025. Commercial Products gross margin percentage decreased 16 percentage points to 30% for the nine months ended September 30, 2025. The decrease was largely due to lower sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and lower branded NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales, as well as an unfavorable price and volume mix, partially offset by an increase in KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $28.3&#160;million and restructuring costs of $0.2&#160;million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MCM PRODUCTS SEGMENT</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.017%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">357.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">393.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">147.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">97.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">222.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">225.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin %</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Add back:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory step-up provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">244.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">255.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin %</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as revenues less cost of sales and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by revenues.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Segment adjusted gross margin, which is a non-GAAP financial measure, for our MCM Products segment is calculated as gross margin plus intangible asset amortization, restructuring costs, inventory step-up provision and changes in fair value of financial instruments. Segment adjusted gross margin percentage, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin percentage for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025 Compared with Three Months Ended September&#160;30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthrax MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM sales decreased $10.0 million, or 88%, to $1.4 million for the three months ended September 30, 2025. The decrease primarily reflects the impact of timing of USG sales of BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as well as timing of international sales of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the prior year period. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Smallpox MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM sales decreased $49.1&#160;million, or 37%, to $83.6 million for the three months ended September 30, 2025. The decrease was primarily due to lower USG ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (VIGIV)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales due to timing, partially offset by an increase in international CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (VIGIV), ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales. Fluctuations in revenues from Smallpox MCM result from the timing of the exercise of annual purchase options in the existing procurement contracts, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Products sales increased $27.4&#160;million, or 91%, to $57.5 million for the three months ended September 30, 2025. The increase was primarily due to higher USG BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales due to timing, partially offset by a decrease in international sales orders.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of MCM Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of MCM product sales decreased $15.9&#160;million, or 29%, to $38.1&#160;million for the three months ended September 30, 2025. The decrease was primarily due to lower production costs of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (VIGIV)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> reflecting reduced volumes, combined with favorable manufacturing variances due to lower shut-down and severance costs, partially offset by an increase in costs related to higher BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales volume.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product gross margin decreased $15.8&#160;million, or 14%, to $97.5&#160;million for the three months ended September 30, 2025. MCM Product gross margin percentage increased 3 percentage points to 68% for the three months ended September 30, 2025. The increase in gross margin percentage was primarily due to a favorable sales mix which was weighted more heavily towards higher margin products and a decrease in shutdown and severance related costs compared with the third quarter of 2024. MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $6.9&#160;million and restructuring costs of $0.2 million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025 Compared with Nine Months Ended September 30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthrax MCM </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM sales decreased $45.1&#160;million, or 43%, to $60.9&#160;million for the nine months ended September 30, 2025. The decrease reflects the impact of the timing of USG sales of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by increases due to timing of Canadian sales of Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and an increase of BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">international sales. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Smallpox MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM sales increased $29.8&#160;million, or 15%, to $230.6&#160;million for the nine months ended September 30, 2025. The increase was primarily due to higher ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">international sales due to foreign demand, coupled with increases in USG TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales due to timing and CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (VIGIV)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">international orders, partially offset by lower ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> USG sales due to timing. Fluctuations in revenues from Smallpox MCM result from the timing of the exercise of annual purchase options in the existing procurement contracts, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Products sales decreased $20.2&#160;million, or 23%, to $66.0&#160;million for the nine months ended September 30, 2025. The decrease was primarily due to no RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> product sales in the current year period due to the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB in the third quarter of 2024 and a decrease in BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> foreign sales, partially offset by higher USG BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales due to timing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of MCM Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of MCM product sales decreased $33.2&#160;million, or 23%, to $114.1&#160;million for the nine months ended September 30, 2025. The decrease was primarily due to lower production costs of CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">reflecting reduced volumes, as well as no RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> related costs in 2025 due to the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB in the third quarter of 2024, combined with favorable manufacturing variances mostly due to lower shut-down and severance costs and lower Raxibacumab inventory reserves. These decreases were partially offset by higher costs for Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (VIGIV) sales due to higher unit volume.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product gross margin decreased $2.3&#160;million, or 1%, to $222.9&#160;million for the nine months ended September 30, 2025. MCM Product gross margin percentage increased 5 percentage points to 62% for the nine months ended September 30, 2025. The increase in gross margin percentage was primarily due to a favorable sales mix which was weighted more heavily towards higher margin products and a decrease in shutdown and severance costs compared with the prior year period. MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $20.5&#160;million, inventory step-up provision of $1.8&#160;million and restructuring costs of $(1.0)&#160;million. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ALL OTHER REVENUE</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025 Compared with Three Months Ended September&#160;30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services revenues decreased $9.7&#160;million, or 68%, to $4.6&#160;million for the three months ended September 30, 2025. The decrease was primarily attributable to a decrease in revenue from the Company&#8217;s Camden facility in the current year period, which was sold to Bora in the third quarter of 2024, partially offset by an increase in production at the Company's Winnipeg facility.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts and Grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenue decreased $0.9&#160;million, or 9%, to $9.1&#160;million for the three months ended September 30, 2025. The decrease was due to declines in overall funded R&amp;D projects, partially offset by an increase in development work in connection with Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025 Compared with Nine Months Ended September 30, 2024</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services revenues decreased $81.3&#160;million, or 83%, to $16.2&#160;million for the nine months ended September 30, 2025. The decrease was primarily attributable to the one time $50.0&#160;million arbitration settlement with Janssen related to the Settlement Agreement, coupled with a decrease in revenue from the Company&#8217;s Camden facility in the current year period, which was sold to Bora in the third quarter of 2024, partially offset by an increase in production at the Company's Winnipeg facility.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts and Grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenue increased $8.2&#160;million, or 33%, to $32.8&#160;million for the nine months ended September 30, 2025. The increase was due to development work in connection with Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by a decrease in overall funded R&amp;D projects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-22.5pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2024 Compared with Three Months Ended September&#160;30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and gross margin</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">293.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">270.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Product and services sales, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">283.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">264.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of product and services sales, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">176.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">144.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin %</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as product and services sales, net less cost of product and services sales, net and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by revenues.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues increased $23.3 million, or 9%, to $293.8 million for the three months ended September&#160;30, 2024. The increase was due to an increase in MCM Products revenue of $66.5 million and an increase in Services revenue of $0.1 million, partially offset by a decrease in Commercial Products revenue of $46.8 million.</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization was consistent with the prior year period at $16.3&#160;million for the three months ended September 30, 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased $74.0 million, or 104%, to $144.9 million for the three months ended September&#160;30, 2024. Gross margin percentage increased 24 percentage points to 51% for the three months ended September&#160;30, 2024. The increase in gross margin was due to increases in Services gross margin of $23.0 million and MCM Products gross margin of $85.0 million, partially offset by a decrease in Commercial Products gross margin of $34.0 million. Gross margin and gross margin percentage exclude Contracts and grants revenues because the related costs are R&amp;D expenses. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See "Reportable Segment Results" for an expanded discussion of revenues and gross margin.</span></div><div style="margin-bottom:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unallocated corporate operating expenses</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Expenses</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased $1.5&#160;million, or 10%, to $13.8&#160;million for the three months ended September&#160;30, 2024. The decrease was driven by a reduction in spend for certain funded and unfunded projects, excluding Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease was partially offset by an increase in funded R&amp;D related to Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SG&amp;A Expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses decreased $9.4&#160;million, or 11%, to $76.6&#160;million for the three months ended September&#160;30, 2024. The decrease was primarily due to lower employee related expenses and compensation as a result of restructuring initiatives during 2023 and 2024, coupled with a decrease in legal services fees for disputes and other corporate initiatives. The decrease was partially offset by the settlement charge related to the stockholder litigation matter, net of expected insurance proceeds. SG&amp;A expenses as a percentage of total revenues decreased 6 percentage points to 26% for the three months ended September&#160;30, 2024. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment decreased $218.2&#160;million, or 100%, for the three months ended September 30, 2024. The decrease was due to a $218.2&#160;million impairment charge to goodwill in the MCM Products segment in the third quarter of 2023, which reduced the goodwill balance of the reporting unit and segment to zero as of September 30, 2024 and 2023. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $11.4&#160;million, or 58%, to $8.3&#160;million for the three months ended September&#160;30, 2024. The decrease was primarily due to lower amortization of debt service costs coupled with lower interest costs related to our syndicated borrowings, partially offset by higher interest expense related to the termination of our interest rate swap hedging agreements and interest related to our Term Loan Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale was a gain of $64.3&#160;million for the three months ended September&#160;30, 2024, compared with a loss of $0.7&#160;million for the three months ended September&#160;30, 2023. The gain on sale of business in the current year is related to the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB coupled with a reduction to the loss on the sale of the Company&#8217;s drug product facility in Baltimore-Camden to Bora, which is attributable to a net working capital adjustment payable to the Company.  The loss on sale of business in the prior year is attributable to a net working capital adjustment, payable to Bavarian Nordic, related to the sale of our travel health business to Bavarian Nordic during the second quarter of 2023. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net was $21.9&#160;million in income for the three months ended September&#160;30, 2024 compared with $3.4&#160;million in expense for the three months ended September&#160;30, 2023. The change of $25.3&#160;million was primarily attributable to income associated with development milestone achievements related to CHIK VLP, partially offset by a loss on the sale of a building at our Canton facility.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax provision</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision increased $30.1&#160;million, to $27.6&#160;million for the three months ended September&#160;30, 2024. The increase was primarily due to an increase in taxable income in the Company&#8217;s profitable jurisdictions.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024 Compared with Nine Months Ended September 30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and gross margin</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">772.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Product and services sales, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">824.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">753.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of product and services sales, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">563.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">520.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">212.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">183.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin %</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as product and services sales, net less cost of product and services sales, net and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by revenues.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues increased $76.2 million, or 10%, to $848.9 million for the nine months ended September 30, 2024. The increase was due increases in Services revenue of $39.8 million and MCM Products revenue of $83.8 million, partially offset by a decrease Commercial Products revenue of $52.4 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization decreased $0.6 million, or 1%, to $48.8 million for the nine months ended September 30, 2024. The decrease was due to a decrease in amortization expense resulting from the intangibles sold with our travel health business to Bavarian Nordic, partially offset by an increase in amortization expense for the intangible asset related to Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased $28.8 million, or 16%, to $212.2 million for the nine months ended September 30, 2024. Gross margin percentage increased 2 percentage points to 26% for the nine months ended September 30, 2024. The increase in gross margin was due to an increase in MCM Products gross margin of $144.6 million, partially offset by decreases in Services gross margin of $71.8 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">million and Commercial Products gross margin of $44.0 million. Gross margin and gross margin percentage exclude Contracts and grants revenues because the related costs are R&amp;D expenses. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See "Reportable Segment Results" for an expanded discussion of revenues and gross margin.</span></div><div style="margin-bottom:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unallocated corporate operating expenses</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Expenses</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased $20.4 million, or 25%, to $61.6 million for the nine months ended September 30, 2024. The decrease was primarily due to the sale of our development program for CHIKV VLP to Bavarian Nordic in the second quarter of 2023 and lower overhead costs driven by headcount reductions. The decrease was also driven by the wind-down of funded projects, excluding Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease was partially offset by write-offs related to program terminations during the period and increases in the allocation of R&amp;D overhead costs and funded R&amp;D related to Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SG&amp;A Expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses decreased $31.5 million, or 11%, to $247.2 million for the nine months ended September 30, 2024. The decrease was primarily due to lower employee related expenses and compensation as a result of restructuring initiatives during 2023 and 2024, lower professional services fees related to corporate initiatives, including organizational transformation consulting fees, and lower legal fees due to the wind-down of various legal matters. This decrease was partially offset by the settlement charge related to the stockholder litigation matter, net of expected insurance proceeds. SG&amp;A expenses as a percentage of total revenues decreased 7 percentage points to 29% for the nine months ended September 30, 2024. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment decreased $218.2&#160;million, or 100%, for the nine months ended September 30, 2024. The decrease was due to the $218.2&#160;million impairment charge to goodwill in the MCM Products segment in the third quarter of 2023, which reduced the goodwill balance of the reporting unit and segment to zero as of September 30, 2024 and 2023.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets decreased $279.5 million, or 91%, to $27.2 million for the nine months ended September 30, 2024. The decrease was due to a $27.2 million non-cash impairment charge in the second quarter of 2024 related to our Bayview and Rockville asset groups within the Bioservices reporting unit, compared with a $306.7 million non-cash impairment charge recorded in the second quarter of 2023 related to our Camden, Bayview and Rockville asset groups within the Bioservices reporting unit.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $10.0 million, or 15%, to $56.2 million for the nine months ended September 30, 2024. The decrease was primarily due to a decrease in interest expense related to our syndicated borrowings and a decrease in amortization of debt service costs, partially offset by higher interest expense related to the termination of our interest rate swap hedging agreements and interest related to our Term Loan Agreement.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale decreased $49.9 million, or 67%, to $24.3 million for the nine months ended September 30, 2024 The gain on sale of business in the current year is related to the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB, partially offset by a loss the sale of the Company&#8217;s drug product facility in Baltimore-Camden to Bora. The gain on sale of business in the prior year is attributable to the sale of our travel health business to Bavarian Nordic during the second quarter of 2023. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net was $15.8 million in income for the for the nine months ended September 30, 2024 compared to $2.1 million in expense for the nine months ended September 30, 2023. The change of $17.9 million was primarily due to income associated with development milestone achievements related to CHIK VLP, partially offset by a loss on the sale of a building at our Canton facility, lower interest income, due to lower balances in our money market accounts, and a write-off of an equity method investment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax provision</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision increased $9.7 million, or 28%, to $44.0 million for the nine months ended September 30, 2024. The increase largely due to the jurisdictional mix of income and losses. The effective tax rate was (38)% for the nine months ended September 30, 2024 as compared with (5)% in 2023. The effective annual tax rate increased largely due the jurisdictional mix of income and losses and the prior year impairment loss.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REPORTABLE SEGMENT RESULTS</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL PRODUCT SEGMENT</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended      September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">386.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">152.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">160.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">152.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">196.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin %</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Add back:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">181.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">226.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin %</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as revenues less cost of sales and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by revenues.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Segment adjusted gross margin, which is a non-GAAP financial measure, for our Commercial Product segment is calculated as gross margin plus intangible asset amortization. Segment adjusted gross margin percentage, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin percentage for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2024 Compared with Three Months Ended September&#160;30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Naloxone</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales decreased $46.8&#160;million, or 33%, to $95.3&#160;million for the three months ended September&#160;30, 2024. The decrease was primarily driven by the discontinuation of prescription NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> due to the launch of over-the-counter (&#8220;OTC&#8221;) NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Commercial Product sales decreased $12.8&#160;million, or 21%, to $47.2&#160;million for the three months ended September&#160;30, 2024. The decrease was primarily due to lower prescription NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unit volume, partially offset by higher OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> unit volume.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products gross margin decreased $34.0&#160;million, or 47%, to $38.7&#160;million for the three months ended September&#160;30, 2024. Commercial Products gross margin percentage decreased 10 percentage point to 41% for the three months ended September&#160;30, 2024. The decrease was largely due to an unfavorable price and volume mix in 2024 for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> products. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $9.4&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024 Compared with Nine Months Ended September 30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Naloxone</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales decreased $42.6&#160;million, or 11%, to $333.8&#160;million for the nine months ended September 30, 2024. The decrease was primarily driven by the discontinuation of prescription NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">due to the launch of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Commercial Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Commercial Products sales decreased $9.8&#160;million, or 100%, to no sales for the nine months ended September 30, 2024. During the second quarter of 2023, we sold Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to Bavarian Nordic as part of our travel health business.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Commercial Product sales decreased $7.5&#160;million, or 5%, to $152.7&#160;million for the nine months ended September 30, 2024. The decrease was primarily due to no current period costs related to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which were sold to Bavarian Nordic as part of our travel health business, and lower prescription NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unit</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">volume, partially offset by the higher OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">unit volume.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products gross margin decreased $44.9&#160;million, or 22%, to $152.8&#160;million for the nine months ended September 30, 2024. Commercial Products gross margin percentage decreased 5 percentage point to 46% for the nine months ended September 30, 2024. The decrease was largely due to an unfavorable price and volume mix in 2024 for NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> products, partially offset by the sale of the products associated with our travel health business to Bavarian Nordic. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $28.3&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MCM PRODUCTS SEGMENT</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">393.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">309.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">147.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">208.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">225.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Add back:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory step-up provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">255.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as revenues less cost of sales and intangible asset amortization. Gross margin percentage is calculated as gross margin divided by revenues.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Segment adjusted gross margin, which is a non-GAAP financial measure, for our MCM Products segment is calculated as gross margin plus intangible asset amortization, restructuring costs, inventory step-up provision and changes in fair value of financial instruments. Segment adjusted gross margin percentage, which is a non-GAAP financial measure, is calculated as segment adjusted gross margin divided by revenues. The Company&#8217;s management utilizes segment adjusted gross margin and segment adjusted gross margin percentage for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2024 Compared with Three Months Ended September&#160;30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthrax MCM </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM sales decreased $21.5&#160;million, or 65%, to $11.4&#160;million for the three months ended September&#160;30, 2024. The decrease reflects the impact of timing of sales related to CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by an increase in BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales, due to timing. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and the Company&#8217;s delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Smallpox MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM sales increased $108.0&#160;million to $132.7&#160;million for the three months ended September&#160;30, 2024. The increase was primarily due to timing of USG purchases of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and VIGIV. Fluctuations in revenues from Smallpox MCM result from the timing of the exercise of annual purchase options in the existing procurement contracts, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Products sales decreased $20.0&#160;million, or 40%, to $30.1&#160;million for the three months ended September&#160;30, 2024. The decrease was due to lower product sales of BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, due to timing of deliveries, and lower product sales of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which was sold to SERB during the third quarter of 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of MCM Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of MCM product sales decreased $18.5&#160;million, or 26%, to $54.0&#160;million for the three months ended September&#160;30, 2024. The decrease was primarily due to lower sales of BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, coupled with lower allocations to Cost of MCM Product sales at our Bayview facility. This decrease was partially offset by higher sales of BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product gross margin increased $85.0&#160;million to $113.3&#160;million for the three months ended September&#160;30, 2024. MCM Product gross margin percentage increased 39 percentage points to 65% for the three months ended September&#160;30, 2024. MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $6.9&#160;million, non-cash items related to restructuring costs of $4.9&#160;million and inventory step-up provision of $1.2 million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024 Compared with Nine Months Ended September 30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthrax MCM </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM sales increased $30.0&#160;million, or 39%, to $106.0&#160;million for the nine months ended September 30, 2024. The increase was due to the impact of timing of sales related to CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by a decrease in Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> sales, due to timing. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and the Company&#8217;s delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Smallpox MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM sales increased $45.0&#160;million, or 29%, to $200.8&#160;million for the nine months ended September 30, 2024. The increase was due to higher VIGIV sales, primarily related to USG, and higher ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sales to non-U.S. customers, partially offset by lower USG purchases of ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, due to timing. Fluctuations in revenues result from the timing of the exercise of annual purchase options in existing procurement contracts, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other Products sales increased $8.8&#160;million, or 11%, to $86.2&#160;million for the nine months ended September 30, 2024. The increase was primarily due to higher BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> product sales to USG and non-U.S. customers, partially offset by lower sales of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which was sold to SERB during the third quarter of 2024.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of MCM Product Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of MCM product sales decreased $61.1&#160;million, or 29%, to $147.3&#160;million for the nine months ended September 30, 2024. The decrease was primarily due to lower allocations to Cost of MCM Product sales at our Bayview facility, lower shutdown costs, and a reduction in Trobigard</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-related costs due to the Belgium FAMHP&#8217;s approval of the Trobigard</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> revocation, partially offset by higher BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and VIGIV sales.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product gross margin increased $144.6&#160;million, or 179%, to $225.2&#160;million for the nine months ended September 30, 2024. MCM Product gross margin percentage increased 31 percentage points to 57% for the nine months ended September 30, 2024. In addition to the MCM Product revenue and Cost of MCM Products items as discussed above, the increase was largely due to overall higher sales volumes with a favorable product mix weighted more heavily to higher margin products coupled with a realization of previously adjusted inventory values. MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $20.5&#160;million, non-cash items related to changes in the fair value of financial instruments of $0.6&#160;million, restructuring costs of $7.5&#160;million and inventory step-up provision of $1.2 million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ALL OTHER REVENUES</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September&#160;30, 2024 Compared with Three Months Ended September&#160;30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services revenues increased $0.1&#160;million, or 1%, to $14.3&#160;million for the three months ended September&#160;30, 2024. The increase was primarily attributable to an increase in production at the Company&#8217;s Camden facility, prior to the sale of the facility to Bora, partially offset by lower production at the Company&#8217;s Canton and Winnipeg facilities. The increase was further offset by Bioservices lease revenues which decreased $0.6&#160;million related to the completion of a lease for a Bioservices customer at our Canton facility, partially offset by new lease revenue associated with SERB at our Winnipeg facility.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts and Grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenue increased $3.5 million, or 54%, to $10.0&#160;million for the three months ended September&#160;30, 2024. The increase was primarily due to timing of funding as well as an increase related to work under the Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">program.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024 Compared with Nine Months Ended September 30, 2023</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services revenues increased $39.8&#160;million, or 69%, to $97.5&#160;million for the nine months ended September 30, 2024. The increase was primarily attributable to the $50.0&#160;million arbitration settlement with Janssen related to the Settlement Agreement, coupled with increased production at our Camden facility. The increase was partially offset by reduced production activities at the Company's Canton and Winnipeg facilities and the completion of a lease for a Bioservices customer at our Canton facility.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts and Grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenue increased $5.0&#160;million, or 26%, to $24.6&#160;million for the nine months ended September 30, 2024. The increase was related to work under the Ebanga</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">program, partially offset by the wind-down of our other funded development initiatives.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_112"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">245.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">249.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt, net of unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total borrowings</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Working capital:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">786.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">598.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">162.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">650.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">436.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Principal Sources of Capital Resources</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operating and capital expenditures through existing cash and cash equivalents, cash from operations, development contracts and grant funding and borrowings under various credit agreements, including our Term Loan Agreement and other lines of credit we have established from time to time. We also occasionally obtain financing from the sale of our common stock upon exercise of stock options. As of September&#160;30, 2025, we had unrestricted cash and cash equivalents of $245.5&#160;million and available borrowing capacity of up to $100.0&#160;million under the Revolving Credit Agreement. As of September 30, 2025, the Company believes that its sources of liquidity, including debt and cash flows from operating activities, are adequate to fund its operations for at least the next twelve months from the issuance of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2025 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2025, the Company announced that its Board of Directors had authorized the repurchase of up to $50.0&#160;million of the Company&#8217;s common stock (the &#8220;2025 Share Repurchase Program&#8221;) on or before March&#160;27, 2026. Repurchases under the 2025 Share Repurchase Program may be made from time to time on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the Company&#8217;s management based on its evaluation of market conditions and other factors, including the market price of the Company&#8217;s common shares, macroeconomic environment and other investment opportunities, consistent with the Company&#8217;s insider trading policy. The 2025 Share Repurchase Program may be suspended or discontinued at any time. The Inflation Reduction Act of 2022, which was enacted on August 16, 2022, imposed a nondeductible 1% excise tax on the net value of certain stock repurchases made after December 31, 2022. Excise tax accrued during the three and nine months ended September 30, 2025 was $0.2 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2025, the Company utilized $8.9&#160;million and $15.8&#160;million to repurchase 1.1&#160;million and 2.3&#160;million shares, respectively, at an average price of $7.87 and $7.00 per share, excluding commissions and excise taxes, respectively. As of September 30, 2025, the Company had $34.2&#160;million available to repurchase shares under the 2025 Share Repurchase Program.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Unsecured Note Repurchase</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;7, 2025, the Board of Directors authorized the Company to repurchase up to $30.0 million aggregate principal amount of the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior Unsecured Notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company may seek to opportunistically use this authority to repurchase its Senior Unsecured Notes in open market purchases, privately negotiated transactions or otherwise. Any such repurchases will depend upon prevailing market conditions, our liquidity requirements, contractual restrictions, applicable securities law and other factors. During the three and nine months ended September 30, 2025, we repurchased $6.9 million aggregate principal amount of the Company&#8217;s Senior Unsecured Notes for $5.8&#160;million in cash, including fees, and recognized a gain on extinguishment of approximately $1.1&#160;million. As of September 30, 2025, we had $23.1&#160;million available to repurchase additional Senior Unsecured Notes.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the nine months ended September 30, 2025 and 2024:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">92.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">96.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(22.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(190.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the nine months ended September 30, 2025 decreased $45.7&#160;million as compared with the nine months ended September 30, 2024. The decrease in net cash provided by operating activities was primarily driven by unfavorable changes in working capital, including significantly lower sources of cash contributions from prepaids and other assets, accounts receivable and inventories. Higher cash payments related to our accrued expenses, compensation and income taxes also contributed to the decrease. These working capital changes, combined with less favorable non-cash adjustments, offset the higher net income in 2025.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the nine months ended September 30, 2025 decreased $23.3&#160;million as compared with the nine months ended September 30, 2024. The decrease in net cash provided by investing activities was primarily attributable to the significant cash inflows in 2024 related to the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transaction and the sale of the Baltimore-Camden facility, partially offset in 2025 by the $50.0&#160;million in aggregate milestone payments received in connection with the sale of the Company&#8217;s travel health business to Bavarian Nordic, proceeds from the sale of property, plant and equipment, including the sale of our Baltimore-Bayview facility to Syngene, and a reduction in capital expenditures compared to the prior year. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the nine months ended September 30, 2025 decreased $167.8&#160;million as compared with the nine months ended September 30, 2024. The decrease in net cash used in financing activities was primarily driven by significant financing outflows in 2024, including principal repayments on the Company&#8217;s former revolving and term loan facilities and associated debt issuance costs. The reduction in cash outflows was partially offset by 2024 inflows related to the issuance of a new term loan, warrants, and common stock issued in connection with the debt restructuring. Additionally, 2025 financing outflows included repurchases under the Company&#8217;s 2025 Share Repurchase Program and Senior Unsecured Note repurchases, which partially offset the year-over-year decrease.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company has $693.1&#160;million of fixed and variable rate debt with varying maturities. See Note 10, &#8220;Debt&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Form 10-Q for further discussion.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Uncertainties and Trends Affecting Funding Requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to fund our short-term and long-term anticipated operating expenses, capital expenditures, debt service requirements, any potential debt repurchases and any future repurchase of our common stock from the following sources:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">existing cash and cash equivalents;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">net proceeds from the sale of our products and Bioservices;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">development contracts and grant funding; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">proceeds from potential asset sales; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our Term Loan Agreement and Revolving Loans.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous risks and uncertainties associated with product sales and with the development and commercialization of our product candidates. We may seek additional external financing to provide additional financial flexibility. Our future capital requirements will depend on many factors, including (but not limited to):</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the level, timing and cost of product and services sales;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans, collaboration and licensing arrangements, cost reductions, assets sales or a combination of these options. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Unsecured Notes, our Term Loan Agreement and our Revolving Credit Agreement, which could limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities, buying back shares or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions, including market volatility and adverse impacts on financial markets, may make it more difficult to obtain financing on attractive terms, or at all. Any new debt funding, if available, may be on terms less favorable to us than our Senior Unsecured Notes, our Term Loan Agreement or our Revolving Credit Agreement. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Unused Credit Capacity</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Available room under the Revolving Loans as of September&#160;30, 2025 and December&#160;31, 2024 was:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:63.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total Capacity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unused Capacity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_115"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET&#160;RISK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional risks arising from our operations, see the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, under the heading &#8220;Item 1A. Risk Factors&#8221; in addition to updates contained in &#8220;Item&#160;1A. Risk Factors&#8221; of this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Market risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have interest rate and foreign currency market risk. Because of the short-term maturities of our cash and cash equivalents, we believe that an increase in market rates would likely not have a significant impact on the realized value of our investments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have debt with a mix of fixed and variable rates of interest and we are satisfied with the current fix-float mix of the Company's debt portfolio. Floating rate debt carries interest based generally on the eurocurrency rate, as defined in the Prior Credit Agreement, as amended from time to time, plus an applicable margin. Increases in interest rates could result in an increase in interest payments for our floating rate debt. See&#160;Note 10, "Debt" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Form 10-Q. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may use derivative instruments to manage our interest rate risk and market risk exposure.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed our exposure to changes in interest rates by analyzing the sensitivity to our operating results assuming various changes in market interest rates. A hypothetical increase of one percentage point in the eurocurrency rate as of September 30, 2025 would increase our interest expense by approximately $2.5 million annually.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency exchange rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to foreign currency exchange rate fluctuations worldwide and primarily with respect to the Euro, Canadian dollar, Swiss franc and British pound. We manage our foreign currency exchange rate risk primarily by either entering into foreign currency hedging transactions or incurring operating expenses in the local currency in the countries in which we operate, to the extent practical. We currently do not hedge all of our foreign currency exchange exposure and the movement of foreign currency exchange rates could have an adverse or positive impact on our results of operations.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_118"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2025, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_121"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_124"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, &#8220;Litigation&#8221; in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, of this Form 10-Q. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_127"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the year ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 contains disclosure regarding the risks and uncertainties related to the Company&#8217;s business under the heading Item 1A. Risk Factors. There have been no material changes to the Company&#8217;s risk factors as presented in the Company&#8217;s 2024 Form 10-K, except as described below:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestitures and sales of assets could negatively impact our business, and retained liabilities from businesses or assets that we have sold could adversely affect our financial results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of our multi-year strategic plan to stabilize, turnaround and transform the Company, we have completed several divestitures and sales of assets. These divestitures and asset sales pose risks and challenges that could negatively impact our business, including retained liabilities related to divested businesses and sold assets, obligations to indemnify buyers against contingent liabilities and potential disputes with buyers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If post-completion liabilities and obligations related to divestitures and asset sales are substantial and exceed our expectations, our financial position, results of operations and cash flows could be negatively impacted. Any divestiture or asset sale may result in a dilutive impact to our future earnings if we are unable to offset the dilutive impact from the loss of revenue and profits associated with the divestiture or sold asset, as well as significant write-offs, including those related to goodwill and other intangible assets, which could have a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not realize the expected benefits of the sale of our travel health business to Bavarian Nordic, the sale of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> to SERB, the sale of our drug product facility in Baltimore-Camden to Bora, and the sale of our Baltimore-Bayview drug substance manufacturing facility to Syngene.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement, we completed the previously announced sale to Bavarian Nordic of our travel health business, including rights to Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, as well as our development-stage chikungunya vaccine candidate CHIKV VLP, our manufacturing site in Bern, Switzerland and certain of our development facilities in San Diego, California for a cash purchase price of $270.2&#160;million, subject to certain customary adjustments. In addition, we may receive milestone payments of up to $80.0&#160;million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and sales-based milestone payments of up to $30.0&#160;million based on aggregate net sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in calendar year 2026.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 20, 2024, Cangene bioPharma LLC (&#8220;Cangene&#8221;), a subsidiary of the Company (together with Cangene, the &#8220;Seller&#8221;), entered into an Asset Purchase Agreement with Bora, under which the Seller sold its drug product facility in Baltimore-Camden for a cash purchase price of approximately $35.0&#160;million. The transaction closed on August 20, 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2024, we entered into the Stock and Asset Purchase Agreement with SERB Pharmaceuticals, through its wholly owned subsidiary BTG International Inc. (collectively, &#8220;SERB&#8221;), pursuant to which, among other things, we sold our worldwide rights to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to SERB (the &#8220;RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction&#8221;) for a cash purchase price of $75.0&#160;million, exclusive of customary closing adjustments related to inventory. In addition, SERB will pay us a $5.0&#160;million payment upon achievement of a milestone relating to sourcing of a certain component of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decontamination lotion. The Transaction also included the sale to SERB of all the outstanding capital stock of Emergent Protective Products USA Inc. (&#8220;EPPU&#8221;), a wholly owned subsidiary of the Company, which leases a manufacturing facility in Hattiesburg, Mississippi, as well as certain assets related to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including intellectual property rights, contract rights, inventory and marketing authorizations. In addition, the employees of EPPU joined SERB in connection with the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2025, we sold our Baltimore-Bayview Drug Substance manufacturing facility to Syngene International (&#8220;Syngene&#8221;) for a cash purchase price of approximately $36.5&#160;million. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility. We retained rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to realize in full the expected benefits of these transactions, including as to whether any milestone payments will be received. If we are unable to or do not realize the expected strategic, economic, or other benefits of these transactions, it could adversely affect our business and financial position.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We cannot guarantee that our 2025 Share Repurchase Program will be utilized in full, or at all, or that our 2025 Share Repurchase Program will enhance long-term stockholder value. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors authorized the 2025 Share Repurchase Program for up to $50.0&#160;million of the Company&#8217;s common stock through March 27, 2026, and through September 30, 2025 we have repurchased approximately $15.8 million under the Share Repurchase Program. Any share repurchases will depend upon, among other factors, market conditions, the market price of the Company&#8217;s common shares, macroeconomic environment and other investment opportunities. The existence of the 2025 Share Repurchase Program could cause our stock price, in certain cases, to be higher or lower than it otherwise would be and could potentially reduce the market liquidity or have other unintended consequences for our stock. We can provide no assurance that we will repurchase shares of our common stock at favorable prices, if at all. Although the 2025 Share Repurchase Program is intended to enhance long-term stockholder value, we can provide no assurance it will do so. The 2025 Share Repurchase Program does not obligate the Company to acquire any particular amount of common stock and it may be suspended or discontinued, or the amount to be spent by the Company to repurchase shares could be reduced, at any time at the Company&#8217;s discretion. Any decision to reduce or discontinue repurchasing shares of our common stock pursuant to our 2025 Share Repurchase Program could cause the market price for our common stock to decline and may negatively impact our reputation and investor confidence in us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent sales of unregistered securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Use of proceeds</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of equity securities</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2025 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2025, the Company announced that its Board of Directors authorized the repurchase of up to $50.0&#160;million of the Company&#8217;s common stock (the &#8220;2025 Share Repurchase Program&#8221;) on or before March&#160;27, 2026. Repurchases under the 2025 Share Repurchase Program may be made from time to time on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the Company&#8217;s management based on its evaluation of market conditions and other factors, including the market price of the company&#8217;s common shares, macroeconomic environment and other investment opportunities, consistent with the Company&#8217;s insider trading policy. The 2025 Share Repurchase Program may be suspended or discontinued at any time. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information regarding shares of our common stock that we repurchased during the three months ended September 30, 2025 under the 2025 Share Repurchase Program:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.543%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Periods</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Average Price Paid Per Share </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">July 1, 2025 - July 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">428,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">428,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41,146,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">August 1, 2025 - August 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">339,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">339,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,190,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">September 1, 2025 - September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">364,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">364,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34,229,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,132,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,132,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Exclusive of commissions and nondeductible 1% excise tax, which excise was imposed pursuant to the Inflation Reduction Act of 2022 enacted into law on August 16, 2022. </span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Dollar amounts presented are inclusive of commissions and nondeductible 1% excise tax.</span></div></td></tr></table></div><div id="ib415b040063d4dd9ba8a71e128a463b6_133"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_136"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_139"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><ix:nonNumeric contextRef="c-13" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1235" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2025, directors and officers (as defined in Exchange Act Rule 16a-1(f)) of the Company <ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1236">adopted</ix:nonNumeric> written plans for the sale of the Company&#8217;s common stock intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (&#8220;Rule 10b5-1 trading arrangements&#8221;) as set forth in the table below.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Action</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Adoption date</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Rule 10b5-1 Trading Plan Provides for Purchase/Sale </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total Shares of Common Stock to be Sold</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-467" name="ecd:TrdArrIndName" id="f-1237">Donald DeGolyer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-467" name="ecd:TrdArrIndTitle" id="f-1238">Director</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-467" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1239">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-467" name="ecd:TrdArrAdoptionDate" id="f-1240">August 11, 2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-468" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1241">51,081</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-467" name="ecd:TrdArrExpirationDate" id="f-1242">October 30, 2026</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-469" name="ecd:TrdArrIndName" id="f-1243">Sujata Tyagi Dayal</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-469" name="ecd:TrdArrIndTitle" id="f-1244">Director</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-469" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1245">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-469" name="ecd:TrdArrAdoptionDate" id="f-1246">August 8, 2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-470" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1247">22,313</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-469" name="ecd:TrdArrExpirationDate" id="f-1248">May 27, 2026</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Sales may begin on the 91</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> day following the adoption of the Rule 10b5-1 trading arrangement.</span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Subject to early termination in accordance with the terms of the Rule 10b5-1 trading arrangement.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The above-named director is currently and is expected to remain in compliance with share ownership guidelines following the sale of any common shares pursuant to her Rule <ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1249"><ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1250">10b5-1 trading arrangement</ix:nonNumeric></ix:nonNumeric>.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_145"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto.</span></div><div id="ib415b040063d4dd9ba8a71e128a463b6_148"></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"/><td style="width:8.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.363%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/cyfendusmod.htm">Modification No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/cyfendusmod.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/cyfendusmod.htm">, effective A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/cyfendusmod.htm">ugust 29</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/cyfendusmod.htm">, 2025, to the BARDA AV7909 Contract</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed September 5, 2025.</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.2 #</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="redactedmod13-acam2000.htm">Modification No. 13, effective December 17, 2024, to the ACAM2000 Contract.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.3 #</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="feacam_75a50119c00071xmo.htm">Modification No. 14, effective September 9, 2025, to the ACAM2000 Contract.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.1 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a311-papacert093025.htm">Certification of the Chief Executive Officer, pursuant to Exchange Act rule 13a-14(a)</a></span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.2 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a312-lindahlcert093025.htm">Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.1 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a321-papacert093025.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.2 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a322-lindahlcert093025.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information related to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statement of Changes in Stockholders' Equity; and (vi) the related Notes to the Condensed Consolidated Financial Statements.</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.<br/></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="ib415b040063d4dd9ba8a71e128a463b6_151"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.222%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/JOSEPH C. PAPA</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Joseph C. Papa</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">President. Chief Executive Officer and Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: October 29, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/RICHARD S. LINDAHL</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Richard S. Lindahl</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer and Treasurer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: October 29, 2025</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>redactedmod13-acam2000.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>redactedmod13-acam2000</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- redactedmod13-acam2000001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="redactedmod13-acam2000001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- redactedmod13-acam2000002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="redactedmod13-acam2000002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- redactedmod13-acam2000003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="redactedmod13-acam2000003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>feacam_75a50119c00071xmo.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>feacam_75a50119c00071xmo</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- feacam_75a50119c00071xmo001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="feacam_75a50119c00071xmo001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535;&#61535; &#61480;&#61560;&#61481; &#61560; &#61495;&#61493;&#61505;&#61493;&#61488;&#61489;&#61489;&#61497;&#61507;&#61488;&#61488;&#61488;&#61495;&#61489; &#61539;&#61551;&#61552;&#61545;&#61541;&#61555; &#61551;&#61542; &#61556;&#61544;&#61541; &#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61499; &#61480;&#61538;&#61481; &#61506;&#61561; &#61537;&#61539;&#61547;&#61550;&#61551;&#61559;&#61548;&#61541;&#61540;&#61543;&#61545;&#61550;&#61543; &#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556; &#61551;&#61542; &#61556;&#61544;&#61545;&#61555; &#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556; &#61551;&#61550; &#61541;&#61537;&#61539;&#61544; &#61539;&#61551;&#61552;&#61561; &#61551;&#61542; &#61556;&#61544;&#61541; &#61551;&#61542;&#61542;&#61541;&#61554; &#61555;&#61557;&#61538;&#61549;&#61545;&#61556;&#61556;&#61541;&#61540; &#61499; &#61551;&#61554; &#61480;&#61539;&#61481; &#61506;&#61561; &#61555;&#61541;&#61552;&#61537;&#61554;&#61537;&#61556;&#61541; &#61548;&#61541;&#61556;&#61556;&#61541;&#61554; &#61551;&#61554; &#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539; &#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550; &#61559;&#61544;&#61545;&#61539;&#61544; &#61545;&#61550;&#61539;&#61548;&#61557;&#61540;&#61541;&#61555; &#61537; &#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541; &#61556;&#61551; &#61556;&#61544;&#61541; &#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550; &#61537;&#61550;&#61540; &#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556; &#61550;&#61557;&#61549;&#61538;&#61541;&#61554;&#61555;&#61486; &#61510;&#61505;&#61513;&#61516;&#61525;&#61522;&#61509; &#61519;&#61510; &#61529;&#61519;&#61525;&#61522; &#61505;&#61507;&#61515;&#61518;&#61519;&#61527;&#61516;&#61509;&#61508;&#61511;&#61509;&#61517;&#61509;&#61518;&#61524; &#61524;&#61519; &#61506;&#61509; &#61522;&#61509;&#61507;&#61509;&#61513;&#61526;&#61509;&#61508; &#61505;&#61524; &#61524;&#61512;&#61509; &#61520;&#61516;&#61505;&#61507;&#61509; &#61508;&#61509;&#61523;&#61513;&#61511;&#61518;&#61505;&#61524;&#61509;&#61508; &#61510;&#61519;&#61522; &#61524;&#61512;&#61509; &#61522;&#61509;&#61507;&#61509;&#61513;&#61520;&#61524; &#61519;&#61510; &#61519;&#61510;&#61510;&#61509;&#61522;&#61523; &#61520;&#61522;&#61513;&#61519;&#61522; &#61524;&#61519; &#61524;&#61512;&#61509; &#61512;&#61519;&#61525;&#61522; &#61505;&#61518;&#61508; &#61508;&#61505;&#61524;&#61509; &#61523;&#61520;&#61509;&#61507;&#61513;&#61510;&#61513;&#61509;&#61508; &#61517;&#61505;&#61529; &#61522;&#61509;&#61523;&#61525;&#61516;&#61524; &#61513;&#61518; &#61522;&#61509;&#61514;&#61509;&#61507;&#61524;&#61513;&#61519;&#61518; &#61519;&#61510; &#61529;&#61519;&#61525;&#61522; &#61519;&#61510;&#61510;&#61509;&#61522;&#61486; &#61513;&#61542; &#61538;&#61561; &#61558;&#61545;&#61554;&#61556;&#61557;&#61541; &#61551;&#61542; &#61556;&#61544;&#61545;&#61555; &#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556; &#61561;&#61551;&#61557; &#61540;&#61541;&#61555;&#61545;&#61554;&#61541; &#61556;&#61551; &#61539;&#61544;&#61537;&#61550;&#61543;&#61541; &#61537;&#61550; &#61551;&#61542;&#61542;&#61541;&#61554; &#61537;&#61548;&#61554;&#61541;&#61537;&#61540;&#61561; &#61555;&#61557;&#61538;&#61549;&#61545;&#61556;&#61556;&#61541;&#61540; &#61484; &#61555;&#61557;&#61539;&#61544; &#61539;&#61544;&#61537;&#61550;&#61543;&#61541; &#61549;&#61537;&#61561; &#61538;&#61541; &#61549;&#61537;&#61540;&#61541; &#61538;&#61561; &#61548;&#61541;&#61556;&#61556;&#61541;&#61554; &#61551;&#61554; &#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539; &#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550;&#61484; &#61552;&#61554;&#61551;&#61558;&#61545;&#61540;&#61541;&#61540; &#61541;&#61537;&#61539;&#61544; &#61548;&#61541;&#61556;&#61556;&#61541;&#61554; &#61551;&#61554; &#61541;&#61548;&#61541;&#61539;&#61556;&#61554;&#61551;&#61550;&#61545;&#61539; &#61539;&#61551;&#61549;&#61549;&#61557;&#61550;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550; &#61549;&#61537;&#61547;&#61541;&#61555; &#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541; &#61556;&#61551; &#61556;&#61544;&#61541; &#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550; &#61537;&#61550;&#61540; &#61556;&#61544;&#61545;&#61555; &#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556;&#61484; &#61537;&#61550;&#61540; &#61545;&#61555; &#61554;&#61541;&#61539;&#61541;&#61545;&#61558;&#61541;&#61540; &#61552;&#61554;&#61545;&#61551;&#61554; &#61556;&#61551; &#61556;&#61544;&#61541; &#61551;&#61552;&#61541;&#61550;&#61545;&#61550;&#61543; &#61544;&#61551;&#61557;&#61554; &#61537;&#61550;&#61540; &#61540;&#61537;&#61556;&#61541; &#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540;&#61486; &#61490;&#61488;&#61490;&#61493;&#61486;&#61521;&#61497;&#61497;&#61523;&#61518;&#61519;&#61516;&#61486;&#61490;&#61494;&#61488;&#61496;&#61496; &#61511;&#61505;&#61513;&#61524;&#61512;&#61509;&#61522;&#61523;&#61506;&#61525;&#61522;&#61511; &#61517;&#61508; &#61490;&#61488;&#61496;&#61495;&#61497;&#61491;&#61492;&#61489;&#61497; &#61489;&#61491;&#61494;&#61493;&#61496;&#61494;&#61497; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524; &#61520;&#61522;&#61519;&#61508;&#61525;&#61507;&#61524; &#61508;&#61509;&#61526;&#61509;&#61516;&#61519;&#61520;&#61517;&#61509;&#61518;&#61524; &#61511;&#61505;&#61513;&#61524;&#61512;&#61509;&#61522;&#61523;&#61506;&#61525;&#61522;&#61511; &#61513;&#61518;&#61507;&#61486; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61524;&#61516;&#61505;&#61518;&#61524;&#61505;&#61484; &#61511;&#61505; &#61491;&#61488;&#61491;&#61492;&#61489; &#61490;&#61497;&#61492;&#61493; &#61510;&#61516;&#61519;&#61527;&#61509;&#61522;&#61523; &#61522;&#61519;&#61505;&#61508; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61525;&#61523; &#61508;&#61509;&#61520;&#61524; &#61519;&#61510; &#61512;&#61509;&#61505;&#61516;&#61524;&#61512; &#61478; &#61512;&#61525;&#61517;&#61505;&#61518; &#61523;&#61509;&#61522;&#61526;&#61513;&#61507;&#61509;&#61523; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61524;&#61516;&#61505;&#61518;&#61524;&#61505;&#61484; &#61511;&#61505; &#61491;&#61488;&#61491;&#61492;&#61489; &#61490;&#61497;&#61492;&#61493; &#61510;&#61516;&#61519;&#61527;&#61509;&#61522;&#61523; &#61522;&#61519;&#61505;&#61508; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61523;&#61520;&#61522;&#61487;&#61523;&#61518;&#61523; &#61505;&#61523;&#61520;&#61491;&#61492;&#61490;&#61492;&#61492;&#61489;&#61488;&#61497;&#61487;&#61491;&#61488;&#61487;&#61490;&#61488;&#61490;&#61493;&#61520;&#61488;&#61488;&#61488;&#61489;&#61492; &#61491;&#61489; &#61489;&#61491;&#61486; &#61524;&#61512;&#61513;&#61523; &#61513;&#61524;&#61509;&#61517; &#61519;&#61518;&#61516;&#61529; &#61505;&#61520;&#61520;&#61516;&#61513;&#61509;&#61523; &#61524;&#61519; &#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518; &#61519;&#61510; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61523;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522;&#61523;&#61486; &#61513;&#61524; &#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61509;&#61523; &#61524;&#61512;&#61509; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522; &#61518;&#61519;&#61486; &#61505;&#61523; &#61508;&#61509;&#61523;&#61507;&#61522;&#61513;&#61506;&#61509;&#61508; &#61513;&#61518; &#61513;&#61524;&#61509;&#61517; &#61489;&#61492;&#61486; &#61489;&#61490;&#61486; &#61505;&#61507;&#61507;&#61519;&#61525;&#61518;&#61524;&#61513;&#61518;&#61511; &#61505;&#61518;&#61508; &#61505;&#61520;&#61520;&#61522;&#61519;&#61520;&#61522;&#61513;&#61505;&#61524;&#61513;&#61519;&#61518; &#61508;&#61505;&#61524;&#61505; &#61480;&#61513;&#61542; &#61554;&#61541;&#61553;&#61557;&#61545;&#61554;&#61541;&#61540;&#61481; &#61545;&#61555; &#61550;&#61551;&#61556; &#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61541;&#61540;&#61486;&#61545;&#61555; &#61541;&#61560;&#61556;&#61541;&#61550;&#61540;&#61541;&#61540;&#61484; &#61513;&#61556;&#61541;&#61549;&#61555; &#61496; &#61537;&#61550;&#61540; &#61489;&#61493;&#61484; &#61537;&#61550;&#61540; &#61554;&#61541;&#61556;&#61557;&#61554;&#61550;&#61545;&#61550;&#61543; &#61519;&#61542;&#61542;&#61541;&#61554;&#61555; &#61549;&#61557;&#61555;&#61556; &#61537;&#61539;&#61547;&#61550;&#61551;&#61559;&#61548;&#61541;&#61540;&#61543;&#61541; &#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556; &#61551;&#61542; &#61556;&#61544;&#61545;&#61555; &#61537;&#61549;&#61541;&#61550;&#61540;&#61549;&#61541;&#61550;&#61556; &#61552;&#61554;&#61545;&#61551;&#61554; &#61556;&#61551; &#61556;&#61544;&#61541; &#61544;&#61551;&#61557;&#61554; &#61537;&#61550;&#61540; &#61540;&#61537;&#61556;&#61541; &#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540; &#61545;&#61550; &#61556;&#61544;&#61541; &#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550; &#61551;&#61554; &#61537;&#61555; &#61537;&#61549;&#61541;&#61550;&#61540;&#61541;&#61540; &#61484; &#61538;&#61561; &#61551;&#61550;&#61541; &#61551;&#61542; &#61556;&#61544;&#61541; &#61542;&#61551;&#61548;&#61548;&#61551;&#61559;&#61545;&#61550;&#61543; &#61549;&#61541;&#61556;&#61544;&#61551;&#61540;&#61555;&#61498; &#61480;&#61537;&#61481; &#61506;&#61561; &#61539;&#61551;&#61549;&#61552;&#61548;&#61541;&#61556;&#61545;&#61550;&#61543; &#61524;&#61544;&#61541; &#61537;&#61538;&#61551;&#61558;&#61541; &#61550;&#61557;&#61549;&#61538;&#61541;&#61554;&#61541;&#61540; &#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550; &#61545;&#61555; &#61537;&#61549;&#61541;&#61550;&#61540;&#61541;&#61540; &#61537;&#61555; &#61555;&#61541;&#61556; &#61542;&#61551;&#61554;&#61556;&#61544; &#61545;&#61550; &#61513;&#61556;&#61541;&#61549; &#61489;&#61492;&#61486; &#61524;&#61544;&#61541; &#61544;&#61551;&#61557;&#61554; &#61537;&#61550;&#61540; &#61540;&#61537;&#61556;&#61541; &#61555;&#61552;&#61541;&#61539;&#61545;&#61542;&#61545;&#61541;&#61540; &#61542;&#61551;&#61554; &#61554;&#61541;&#61539;&#61541;&#61545;&#61552;&#61556; &#61551;&#61542; &#61519;&#61542;&#61542;&#61541;&#61554;&#61555; &#61489;&#61489;&#61486; &#61524;&#61512;&#61513;&#61523; &#61513;&#61524;&#61509;&#61517; &#61519;&#61518;&#61516;&#61529; &#61505;&#61520;&#61520;&#61516;&#61513;&#61509;&#61523; &#61524;&#61519; &#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61523; &#61519;&#61510; &#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61523; &#61510;&#61505;&#61507;&#61513;&#61516;&#61513;&#61524;&#61529; &#61507;&#61519;&#61508;&#61509;&#61507;&#61519;&#61508;&#61509; &#61489;&#61488;&#61506;&#61486; &#61508;&#61505;&#61524;&#61509;&#61508; &#61480;&#61523;&#61509;&#61509; &#61513;&#61524;&#61509;&#61517; &#61489;&#61491;&#61481; &#61489;&#61488;&#61505;&#61486; &#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518; &#61519;&#61510; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522; &#61518;&#61519;&#61486; &#61497;&#61506;&#61486; &#61508;&#61505;&#61524;&#61509;&#61508; &#61480;&#61523;&#61509;&#61509; &#61513;&#61524;&#61509;&#61517; &#61489;&#61489;&#61481; &#61497;&#61505;&#61486; &#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524; &#61519;&#61510; &#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518; &#61518;&#61519;&#61486; &#61507;&#61519;&#61508;&#61509; &#61496;&#61486; &#61518;&#61505;&#61517;&#61509; &#61505;&#61518;&#61508; &#61505;&#61508;&#61508;&#61522;&#61509;&#61523;&#61523; &#61519;&#61510; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61519;&#61522; &#61480;&#61518;&#61551;&#61486;&#61484; &#61555;&#61556;&#61554;&#61541;&#61541;&#61556;&#61484; &#61539;&#61551;&#61557;&#61550;&#61556;&#61561;&#61484; &#61523;&#61556;&#61537;&#61556;&#61541; &#61537;&#61550;&#61540; &#61530;&#61513;&#61520; &#61507;&#61551;&#61540;&#61541;&#61481; &#61495;&#61486; &#61505;&#61508;&#61517;&#61513;&#61518;&#61513;&#61523;&#61524;&#61509;&#61522;&#61509;&#61508; &#61506;&#61529; &#61480;&#61513;&#61542; &#61551;&#61556;&#61544;&#61541;&#61554; &#61556;&#61544;&#61537;&#61550; &#61513;&#61556;&#61541;&#61549; &#61494;&#61481;&#61507;&#61519;&#61508;&#61509;&#61494;&#61486; &#61513;&#61523;&#61523;&#61525;&#61509;&#61508; &#61506;&#61529; &#61520;&#61505;&#61511;&#61509; &#61519;&#61510; &#61520;&#61505;&#61511;&#61509;&#61523; &#61492;&#61486; &#61522;&#61509;&#61521;&#61525;&#61513;&#61523;&#61513;&#61524;&#61513;&#61519;&#61518;&#61487;&#61520;&#61525;&#61522;&#61507;&#61512;&#61505;&#61523;&#61509; &#61522;&#61509;&#61521;&#61486; &#61518;&#61519;&#61486;&#61491;&#61486; &#61509;&#61510;&#61510;&#61509;&#61507;&#61524;&#61513;&#61526;&#61509; &#61508;&#61505;&#61524;&#61509;&#61490;&#61486; &#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518; &#61518;&#61519;&#61486; &#61493;&#61486; &#61520;&#61522;&#61519;&#61514;&#61509;&#61507;&#61524; &#61518;&#61519;&#61486; &#61480;&#61513;&#61542; &#61537;&#61552;&#61552;&#61548;&#61545;&#61539;&#61537;&#61538;&#61548;&#61541;&#61481; &#61489;&#61486; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524; &#61513;&#61508; &#61507;&#61519;&#61508;&#61509; &#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524; &#61519;&#61510; &#61523;&#61519;&#61516;&#61513;&#61507;&#61513;&#61524;&#61505;&#61524;&#61513;&#61519;&#61518;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518; &#61519;&#61510; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524; &#61488;&#61496;&#61487;&#61491;&#61488;&#61487;&#61490;&#61488;&#61489;&#61497; &#61505;&#61556;&#61556;&#61550;&#61498; &#61523;&#61524;&#61509;&#61526;&#61509; &#61522;&#61505;&#61517;&#61506;&#61519; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524; &#61520;&#61522;&#61519;&#61508;&#61525;&#61507;&#61524; &#61508;&#61509;&#61526;&#61509;&#61516;&#61519;&#61520;&#61517;&#61509;&#61518;&#61524; &#61511;&#61505;&#61513;&#61524;&#61512;&#61509; &#61491;&#61488;&#61488; &#61520;&#61522;&#61519;&#61510;&#61509;&#61523;&#61523;&#61513;&#61519;&#61518;&#61505;&#61516; &#61508;&#61522; &#61518;&#61541;&#61556; &#61513;&#61550;&#61539;&#61554;&#61541;&#61537;&#61555;&#61541;&#61498; &#61476;&#61493;&#61494;&#61484;&#61488;&#61488;&#61488;&#61484;&#61488;&#61488;&#61488;&#61486;&#61488;&#61488; &#61507;&#61512;&#61509;&#61507;&#61515; &#61519;&#61518;&#61509; &#61505;&#61486; &#61524;&#61512;&#61513;&#61523; &#61507;&#61512;&#61505;&#61518;&#61511;&#61509; &#61519;&#61522;&#61508;&#61509;&#61522; &#61513;&#61523; &#61513;&#61523;&#61523;&#61525;&#61509;&#61508; &#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524; &#61524;&#61519;&#61498; &#61480;&#61523;&#61552;&#61541;&#61539;&#61545;&#61542;&#61561; &#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61556;&#61561;&#61481; &#61524;&#61512;&#61509; &#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61523; &#61523;&#61509;&#61524; &#61510;&#61519;&#61522;&#61524;&#61512; &#61513;&#61518; &#61513;&#61524;&#61509;&#61517; &#61489;&#61492; &#61505;&#61522;&#61509; &#61517;&#61505;&#61508;&#61509; &#61513;&#61518; &#61524;&#61512;&#61509; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524; &#61506;&#61486; &#61524;&#61512;&#61509; &#61505;&#61506;&#61519;&#61526;&#61509; &#61518;&#61525;&#61517;&#61506;&#61509;&#61522;&#61509;&#61508; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61487;&#61519;&#61522;&#61508;&#61509;&#61522; &#61513;&#61523; &#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61509;&#61508; &#61524;&#61519; &#61522;&#61509;&#61510;&#61516;&#61509;&#61507;&#61524; &#61524;&#61512;&#61509; &#61505;&#61508;&#61517;&#61513;&#61518;&#61513;&#61523;&#61524;&#61522;&#61505;&#61524;&#61513;&#61526;&#61509; &#61507;&#61512;&#61505;&#61518;&#61511;&#61509;&#61523; &#61480;&#61555;&#61557;&#61539;&#61544; &#61537;&#61555; &#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61555; &#61545;&#61550; &#61552;&#61537;&#61561;&#61545;&#61550;&#61543; &#61551;&#61542;&#61542;&#61545;&#61539;&#61541;&#61484; &#61507;&#61486; &#61524;&#61512;&#61513;&#61523; &#61523;&#61525;&#61520;&#61520;&#61516;&#61509;&#61517;&#61509;&#61518;&#61524;&#61505;&#61516; &#61505;&#61511;&#61522;&#61509;&#61509;&#61517;&#61509;&#61518;&#61524; &#61513;&#61523; &#61509;&#61518;&#61524;&#61509;&#61522;&#61509;&#61508; &#61513;&#61518;&#61524;&#61519; &#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524; &#61524;&#61519; &#61505;&#61525;&#61524;&#61512;&#61519;&#61522;&#61513;&#61524;&#61529; &#61519;&#61510;&#61498; &#61508;&#61486; &#61519;&#61524;&#61512;&#61509;&#61522; &#61480;&#61523;&#61552;&#61541;&#61539;&#61545;&#61542;&#61561; &#61556;&#61561;&#61552;&#61541; &#61551;&#61542; &#61549;&#61551;&#61540;&#61545;&#61542;&#61545;&#61539;&#61537;&#61556;&#61545;&#61551;&#61550; &#61537;&#61550;&#61540; &#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61556;&#61561;&#61481; &#61537;&#61552;&#61552;&#61554;&#61551;&#61552;&#61554;&#61545;&#61537;&#61556;&#61545;&#61551;&#61550; &#61540;&#61537;&#61556;&#61537;&#61484; &#61541;&#61556;&#61539;&#61486;&#61481; &#61523;&#61509;&#61524; &#61510;&#61519;&#61522;&#61524;&#61512; &#61513;&#61518; &#61513;&#61524;&#61509;&#61517; &#61489;&#61492;&#61484; &#61520;&#61525;&#61522;&#61523;&#61525;&#61505;&#61518;&#61524; &#61524;&#61519; &#61524;&#61512;&#61509; &#61505;&#61525;&#61524;&#61512;&#61519;&#61522;&#61513;&#61524;&#61529; &#61519;&#61510; &#61510;&#61505;&#61522; &#61492;&#61491;&#61486;&#61489;&#61488;&#61491;&#61480;&#61538;&#61481;&#61486; &#61509;&#61486; &#61513;&#61517;&#61520;&#61519;&#61522;&#61524;&#61505;&#61518;&#61524;&#61498; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61551;&#61554; &#61545;&#61555; &#61550;&#61551;&#61556; &#61545;&#61555; &#61554;&#61541;&#61553;&#61557;&#61545;&#61554;&#61541;&#61540; &#61556;&#61551; &#61555;&#61545;&#61543;&#61550; &#61556;&#61544;&#61545;&#61555; &#61540;&#61551;&#61539;&#61557;&#61549;&#61541;&#61550;&#61556; &#61537;&#61550;&#61540; &#61554;&#61541;&#61556;&#61557;&#61554;&#61550; &#61539;&#61551;&#61552;&#61545;&#61541;&#61555; &#61556;&#61551; &#61556;&#61544;&#61541; &#61545;&#61555;&#61555;&#61557;&#61545;&#61550;&#61543; &#61551;&#61542;&#61542;&#61545;&#61539;&#61541;&#61486; &#61519;&#61522;&#61508;&#61509;&#61522; &#61518;&#61519;&#61486; &#61513;&#61518; &#61513;&#61524;&#61509;&#61517; &#61489;&#61488;&#61505;&#61486; &#61510;&#61505;&#61522; &#61493;&#61490;&#61486;&#61490;&#61489;&#61495;&#61485;&#61497; &#61519;&#61552;&#61556;&#61545;&#61551;&#61550; &#61556;&#61551; &#61509;&#61560;&#61556;&#61541;&#61550;&#61540; &#61556;&#61544;&#61541; &#61524;&#61541;&#61554;&#61549; &#61551;&#61542; &#61556;&#61544;&#61541; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556; &#61480;&#61517;&#61537;&#61554;&#61539;&#61544; &#61490;&#61488;&#61488;&#61488;&#61481; &#61560; &#61489;&#61492;&#61486; &#61508;&#61509;&#61523;&#61507;&#61522;&#61513;&#61520;&#61524;&#61513;&#61519;&#61518; &#61519;&#61510; &#61505;&#61517;&#61509;&#61518;&#61508;&#61517;&#61509;&#61518;&#61524;&#61487;&#61517;&#61519;&#61508;&#61513;&#61510;&#61513;&#61507;&#61505;&#61524;&#61513;&#61519;&#61518; &#61480;&#61519;&#61554;&#61543;&#61537;&#61550;&#61545;&#61562;&#61541;&#61540; &#61538;&#61561; &#61525;&#61507;&#61510; &#61555;&#61541;&#61539;&#61556;&#61545;&#61551;&#61550; &#61544;&#61541;&#61537;&#61540;&#61545;&#61550;&#61543;&#61555;&#61484; &#61545;&#61550;&#61539;&#61548;&#61557;&#61540;&#61545;&#61550;&#61543; &#61555;&#61551;&#61548;&#61545;&#61539;&#61545;&#61556;&#61537;&#61556;&#61545;&#61551;&#61550;&#61487;&#61539;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556; &#61555;&#61557;&#61538;&#61546;&#61541;&#61539;&#61556; &#61549;&#61537;&#61556;&#61556;&#61541;&#61554; &#61559;&#61544;&#61541;&#61554;&#61541; &#61542;&#61541;&#61537;&#61555;&#61545;&#61538;&#61548;&#61541;&#61486;&#61481; &#61528; &#61489; &#61524;&#61537;&#61560; &#61513;&#61508; &#61518;&#61557;&#61549;&#61538;&#61541;&#61554;&#61498; &#61525;&#61509;&#61513;&#61498; &#61507;&#61518;&#61520;&#61526;&#61507;&#61522;&#61496;&#61508;&#61515;&#61495;&#61517;&#61496; &#61520;&#61551;&#61545;&#61550;&#61556;&#61555; &#61551;&#61542; &#61507;&#61551;&#61550;&#61556;&#61537;&#61539;&#61556;&#61498; &#61507;&#61519;&#61522;&#61498; &#61506;&#61554;&#61557;&#61539;&#61541; &#61516;&#61541;&#61541;&#61484; &#61484; &#61506;&#61554;&#61557;&#61539;&#61541;&#61486;&#61516;&#61541;&#61541;&#61504;&#61544;&#61544;&#61555;&#61486;&#61543;&#61551;&#61558; &#61507;&#61519;&#61498; &#61515;&#61545;&#61549;&#61538;&#61541;&#61554;&#61548;&#61561; &#61511;&#61551;&#61548;&#61540;&#61541;&#61550;&#61484; &#61547;&#61545;&#61549;&#61538;&#61541;&#61554;&#61548;&#61561;&#61486;&#61543;&#61551;&#61548;&#61540;&#61541;&#61550;&#61489;&#61504;&#61544;&#61544;&#61555;&#61486;&#61543;&#61551;&#61558;&#61484; &#61507;&#61523;&#61498; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556; &#61507;&#61551;&#61550;&#61555;&#61557;&#61548;&#61556;&#61537;&#61550;&#61556;&#61484; &#61516;&#61545;&#61550;&#61540;&#61537; &#61527;&#61545;&#61548;&#61548;&#61545;&#61537;&#61549;&#61555;&#61484; &#61516;&#61545;&#61550;&#61540;&#61537;&#61486;&#61527;&#61545;&#61548;&#61548;&#61545;&#61537;&#61549;&#61555;&#61504;&#61544;&#61544;&#61555;&#61486;&#61543;&#61551;&#61558;&#61484; &#61509;&#61517;&#61509;&#61522;&#61511;&#61509;&#61518;&#61524;&#61498; &#61505;&#61548;&#61541;&#61560;&#61537;&#61550;&#61540;&#61541;&#61554; &#61515;&#61551;&#61550;&#61541;&#61558;&#61484; &#61508;&#61545;&#61554;&#61541;&#61539;&#61556;&#61551;&#61554; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537;&#61539;&#61556;&#61555; &#61517;&#61507;&#61517; &#61519;&#61552;&#61541;&#61554;&#61537;&#61556;&#61545;&#61551;&#61550;&#61555;&#61484; &#61499; &#61547;&#61551;&#61550;&#61541;&#61558;&#61537;&#61504;&#61541;&#61538;&#61555;&#61545;&#61486;&#61539;&#61551;&#61549; &#61519;&#61524;&#61505;&#61498; &#61518; &#61505;&#61552;&#61552;&#61554;&#61486; &#61529;&#61554;&#61486;&#61498; &#61490;&#61488;&#61490;&#61493; &#61507;&#61505;&#61518;&#61498; &#61521;&#61497;&#61497;&#61523;&#61518;&#61519;&#61516; &#61519;&#61538;&#61546;&#61541;&#61539;&#61556; &#61507;&#61548;&#61537;&#61555;&#61555;&#61498; &#61490;&#61494;&#61488;&#61496;&#61496; &#61507;&#61551;&#61550;&#61556;&#61545;&#61550;&#61557;&#61541;&#61540; &#61486;&#61486;&#61486; &#61489;&#61494;&#61505;&#61486; &#61518;&#61505;&#61517;&#61509; &#61505;&#61518;&#61508; &#61524;&#61513;&#61524;&#61516;&#61509; &#61519;&#61510; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61513;&#61518;&#61511; &#61519;&#61510;&#61510;&#61513;&#61507;&#61509;&#61522; &#61480;&#61524;&#61561;&#61552;&#61541; &#61551;&#61554; &#61552;&#61554;&#61545;&#61550;&#61556;&#61481;&#61489;&#61493;&#61505;&#61486; &#61518;&#61505;&#61517;&#61509; &#61505;&#61518;&#61508; &#61524;&#61513;&#61524;&#61516;&#61509; &#61519;&#61510; &#61523;&#61513;&#61511;&#61518;&#61509;&#61522; &#61480;&#61524;&#61561;&#61552;&#61541; &#61551;&#61554; &#61552;&#61554;&#61545;&#61550;&#61556;&#61481; &#61489;&#61493;&#61507;&#61486; &#61508;&#61505;&#61524;&#61509; &#61523;&#61513;&#61511;&#61518;&#61509;&#61508; &#61489;&#61494;&#61506;&#61486; &#61525;&#61518;&#61513;&#61524;&#61509;&#61508; &#61523;&#61524;&#61505;&#61524;&#61509;&#61523; &#61519;&#61510; &#61505;&#61517;&#61509;&#61522;&#61513;&#61507;&#61505;&#61489;&#61493;&#61506;&#61486; &#61507;&#61519;&#61518;&#61524;&#61522;&#61505;&#61507;&#61524;&#61519;&#61522;&#61487;&#61519;&#61510;&#61510;&#61509;&#61522;&#61519;&#61522; &#61489;&#61494;&#61507;&#61486; &#61508;&#61505;&#61524;&#61509; &#61523;&#61513;&#61511;&#61518;&#61509;&#61508; &#61480;&#61523;&#61545;&#61543;&#61550;&#61537;&#61556;&#61557;&#61554;&#61541; &#61551;&#61542; &#61552;&#61541;&#61554;&#61555;&#61551;&#61550; &#61537;&#61557;&#61556;&#61544;&#61551;&#61554;&#61545;&#61562;&#61541;&#61540; &#61556;&#61551; &#61555;&#61545;&#61543;&#61550;&#61481; &#61480;&#61523;&#61545;&#61543;&#61550;&#61537;&#61556;&#61557;&#61554;&#61541; &#61551;&#61542; &#61507;&#61551;&#61550;&#61556;&#61554;&#61537; &#61556;&#61545;&#61550;&#61543; &#61519;&#61542;&#61542;&#61545;&#61539;&#61541;&#61554;&#61481; &#61515;&#61513;&#61517;&#61506;&#61509;&#61522;&#61516;&#61529; &#61516;&#61486; &#61511;&#61519;&#61516;&#61508;&#61509;&#61518; &#61523;&#61524;&#61505;&#61518;&#61508;&#61505;&#61522;&#61508; &#61510;&#61519;&#61522;&#61517; &#61491;&#61488; &#61480;&#61522;&#61509;&#61526;&#61486; &#61489;&#61489;&#61487;&#61490;&#61488;&#61489;&#61494;&#61481; &#61520;&#61554;&#61541;&#61555;&#61539;&#61554;&#61545;&#61538;&#61541;&#61540; &#61538;&#61561; &#61511;&#61523;&#61505; &#61510;&#61505;&#61522; &#61480;&#61492;&#61496; &#61507;&#61510;&#61522;&#61481; &#61493;&#61491;&#61486;&#61490;&#61492;&#61491; &#61520;&#61554;&#61541;&#61558;&#61545;&#61551;&#61557;&#61555; &#61541;&#61540;&#61545;&#61556;&#61545;&#61551;&#61550; &#61557;&#61550;&#61557;&#61555;&#61537;&#61538;&#61548;&#61541; &#61509;&#61560;&#61539;&#61541;&#61552;&#61556; &#61537;&#61555; &#61552;&#61554;&#61551;&#61558;&#61545;&#61540;&#61541;&#61540; &#61544;&#61541;&#61554;&#61541;&#61545;&#61550;&#61484; &#61537;&#61548;&#61548; &#61556;&#61541;&#61554;&#61549;&#61555; &#61537;&#61550;&#61540; &#61539;&#61551;&#61550;&#61540;&#61545;&#61556;&#61545;&#61551;&#61550;&#61555; &#61551;&#61542; &#61556;&#61544;&#61541; &#61540;&#61551;&#61539;&#61557;&#61549;&#61541;&#61550;&#61556; &#61554;&#61541;&#61542;&#61541;&#61554;&#61541;&#61550;&#61539;&#61541;&#61540; &#61545;&#61550; &#61513;&#61556;&#61541;&#61549; &#61497; &#61505; &#61551;&#61554; &#61489;&#61488;&#61505;&#61484; &#61537;&#61555; &#61544;&#61541;&#61554;&#61541;&#61556;&#61551;&#61542;&#61551;&#61554;&#61541; &#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61540;&#61484; &#61554;&#61541;&#61549;&#61537;&#61545;&#61550;&#61555; &#61557;&#61550;&#61539;&#61544;&#61537;&#61550;&#61543;&#61541;&#61540; &#61537;&#61550;&#61540; &#61545;&#61550; &#61542;&#61557;&#61548;&#61548; &#61542;&#61551;&#61554;&#61539;&#61541; &#61537;&#61550;&#61540; &#61541;&#61542;&#61542;&#61541;&#61539;&#61556; &#61486; [**] [**] [**] [**] [**] </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- feacam_75a50119c00071xmo002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="feacam_75a50119c00071xmo002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- feacam_75a50119c00071xmo003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="feacam_75a50119c00071xmo003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a311-papacert093025.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8192977c202545c2a0e1d6dd7840cbb6_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph C. Papa, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; October&#160;29, 2025 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47;Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</font></div><div style="height:69.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a312-lindahlcert093025.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id373f4aed02540619ea9824a56778c28_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard S. Lindahl, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;October&#160;29, 2025</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a321-papacert093025.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i91c2e8a3191c41a6b9df864a3d2a1e41_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q&#160;of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;September 30, 2025&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Joseph C. Papa, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-indent:-13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;October&#160;29, 2025</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph C. Papa</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>a322-lindahlcert093025.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3afac7c7be314ddd920398c384ab198a_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;September 30, 2025&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Richard S. Lindahl, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58;&#160;October&#160;29, 2025</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ebs-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0b2479a1-7a21-4fa0-a33e-3a3a5f4f1cad,g:c7797084-9f00-4c6d-b9c9-e4498d399b6e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ebs="http://emergentbiosolutions.com/20250930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20250930">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>9952156 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
        <link:definition>9952157 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Natureofthebusinessandorganization" roleURI="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization">
        <link:definition>9952158 - Disclosure - Nature of the business and organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>9952159 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Assetsandliabilitiesheldforsale" roleURI="http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale">
        <link:definition>9952160 - Disclosure - Assets and liabilities held for sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://emergentbiosolutions.com/role/Divestitures">
        <link:definition>9952161 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Impairmentandrestructuringcharges" roleURI="http://emergentbiosolutions.com/role/Impairmentandrestructuringcharges">
        <link:definition>9952162 - Disclosure - Impairment and restructuring charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventoriesnet" roleURI="http://emergentbiosolutions.com/role/Inventoriesnet">
        <link:definition>9952163 - Disclosure - Inventories, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipmentnet" roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet">
        <link:definition>9952164 - Disclosure - Property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://emergentbiosolutions.com/role/Intangibleassets">
        <link:definition>9952165 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements">
        <link:definition>9952166 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://emergentbiosolutions.com/role/Debt">
        <link:definition>9952167 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensationandstockholdersequity" roleURI="http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity">
        <link:definition>9952168 - Disclosure - Share-based compensation and stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningslosspercommonshare" roleURI="http://emergentbiosolutions.com/role/Earningslosspercommonshare">
        <link:definition>9952169 - Disclosure - Earnings (loss) per common share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuerecognition" roleURI="http://emergentbiosolutions.com/role/Revenuerecognition">
        <link:definition>9952170 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://emergentbiosolutions.com/role/Leases">
        <link:definition>9952171 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://emergentbiosolutions.com/role/Incometaxes">
        <link:definition>9952172 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://emergentbiosolutions.com/role/Litigation">
        <link:definition>9952173 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentinformation" roleURI="http://emergentbiosolutions.com/role/Segmentinformation">
        <link:definition>9952174 - Disclosure - Segment information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandliabilitiesheldforsaleTables" roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables">
        <link:definition>9955512 - Disclosure - Assets and liabilities held for sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentandrestructuringchargesTables" roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables">
        <link:definition>9955513 - Disclosure - Impairment and restructuring charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetTables" roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables">
        <link:definition>9955514 - Disclosure - Inventories, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetTables" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables">
        <link:definition>9955515 - Disclosure - Property, plant and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsTables">
        <link:definition>9955516 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables">
        <link:definition>9955517 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://emergentbiosolutions.com/role/DebtTables">
        <link:definition>9955518 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityTables" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables">
        <link:definition>9955519 - Disclosure - Share-based compensation and stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningslosspercommonshareTables" roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareTables">
        <link:definition>9955520 - Disclosure - Earnings (loss) per common share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionTables" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables">
        <link:definition>9955521 - Disclosure - Revenue recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://emergentbiosolutions.com/role/LeasesTables">
        <link:definition>9955522 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationTables" roleURI="http://emergentbiosolutions.com/role/SegmentinformationTables">
        <link:definition>9955523 - Disclosure - Segment information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofthebusinessandorganizationDetails" roleURI="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails">
        <link:definition>9955524 - Disclosure - Nature of the business and organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandliabilitiesheldforsaleNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails">
        <link:definition>9955525 - Disclosure - Assets and liabilities held for sale - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails" roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails">
        <link:definition>9955526 - Disclosure - Assets and liabilities held for sale - Schedule of assets and liabilities held for sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetails" roleURI="http://emergentbiosolutions.com/role/DivestituresDetails">
        <link:definition>9955527 - Disclosure - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentandrestructuringchargesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails">
        <link:definition>9955528 - Disclosure - Impairment and restructuring charges - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails">
        <link:definition>9955529 - Disclosure - Impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails">
        <link:definition>9955530 - Disclosure - Impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails">
        <link:definition>9955531 - Disclosure - Impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetScheduleofInventoryDetails" roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails">
        <link:definition>9955532 - Disclosure - Inventories, net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>9955533 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails">
        <link:definition>9955534 - Disclosure - Intangible assets - Schedule of Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>9955535 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails">
        <link:definition>9955536 - Disclosure - Fair value measurements - Schedule of Fair Value Hierarchy of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails">
        <link:definition>9955537 - Disclosure - Fair value measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails">
        <link:definition>9955538 - Disclosure - Fair value measurements - Level 3 Fair Value Of Common Stock Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails">
        <link:definition>9955539 - Disclosure - Fair value measurements - Level 3 Fair Value Inputs In The Black-Scholes Option Pricing Models (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofDebtDetails" roleURI="http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails">
        <link:definition>9955540 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails">
        <link:definition>9955541 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSeniorUnsecuredNotesdue2028Details" roleURI="http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details">
        <link:definition>9955542 - Disclosure - Debt - Senior Unsecured Notes due 2028 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTermLoanAgreementDetails" roleURI="http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails">
        <link:definition>9955543 - Disclosure - Debt - Term Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtRevolvingLoanAgreementDetails" roleURI="http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails">
        <link:definition>9955544 - Disclosure - Debt - Revolving Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails">
        <link:definition>9955545 - Disclosure - Share-based compensation and stockholders' equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9955546 - Disclosure - Share-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails" roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails">
        <link:definition>9955547 - Disclosure - Share-based compensation and stockholders' equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails" roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails">
        <link:definition>9955548 - Disclosure - Earnings (loss) per common share - Schedule of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionScheduleofDisaggregationofRevenueDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails">
        <link:definition>9955549 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails">
        <link:definition>9955550 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails_1" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1">
        <link:definition>9955550 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails">
        <link:definition>9955551 - Disclosure - Revenue recognition - Schedule of Rollforward of Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionScheduleofAccountsReceivableNetDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails">
        <link:definition>9955552 - Disclosure - Revenue recognition - Schedule of Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseExpenseDetails" roleURI="http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails">
        <link:definition>9955553 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeasesSupplementalBalanceSheetsDetails" roleURI="http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails">
        <link:definition>9955554 - Disclosure - Leases - Schedule of Leases Supplemental Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails">
        <link:definition>9955555 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://emergentbiosolutions.com/role/LitigationDetails">
        <link:definition>9955556 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/SegmentinformationNarrativeDetails">
        <link:definition>9955557 - Disclosure - Segment information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" roleURI="http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
        <link:definition>9955558 - Disclosure - Segment information - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955559 - Disclosure - Segment information - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ebs_ProductAndServiceMember" abstract="true" name="ProductAndServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ContractsAndGrantsMember" abstract="true" name="ContractsAndGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts" abstract="false" name="GainLossOnDispositionOfBusinessIncludingTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" abstract="false" name="IncreaseDecreaseInLongTermIncentivePlanAccrual" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" abstract="false" name="PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" abstract="false" name="ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_PaymentsForRepurchaseOfDebt" abstract="false" name="PaymentsForRepurchaseOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ScheduleOfAccountsReceivableNetTableTextBlock" abstract="false" name="ScheduleOfAccountsReceivableNetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_NumberOfCategoriesOfPublicHealthThreats" abstract="false" name="NumberOfCategoriesOfPublicHealthThreats" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_NumberOfRevenueGeneratingProducts" abstract="false" name="NumberOfRevenueGeneratingProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_NumberOfProductAndServiceCategories" abstract="false" name="NumberOfProductAndServiceCategories" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_MarylandWarehouseSpaceMember" abstract="true" name="MarylandWarehouseSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_TravelHealthBusinessMember" abstract="true" name="TravelHealthBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RSDLMember" abstract="true" name="RSDLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_BaltimoreCamdenFacilityMember" abstract="true" name="BaltimoreCamdenFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_BaltimoreBayviewFacilityMember" abstract="true" name="BaltimoreBayviewFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DevelopmentBasedMilestonesMember" abstract="true" name="DevelopmentBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_RestructuringPlanJanuary2023Member" abstract="true" name="RestructuringPlanJanuary2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RestructuringPlanAugust2023Member" abstract="true" name="RestructuringPlanAugust2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RestructuringPlanMay2024Member" abstract="true" name="RestructuringPlanMay2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RestructuringPlanAugust2024Member" abstract="true" name="RestructuringPlanAugust2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" abstract="false" name="RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_MCMProductsSegmentMember" abstract="true" name="MCMProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_UnallocatedSellingGeneralAndAdministrativeMember" abstract="true" name="UnallocatedSellingGeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_UnallocatedResearchAndDevelopmentMember" abstract="true" name="UnallocatedResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_EmployeeBenefitsMember" abstract="true" name="EmployeeBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_EmployeeTransitionMember" abstract="true" name="EmployeeTransitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_WarrantLiabilitiesFairValueDisclosure" abstract="false" name="WarrantLiabilitiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_SeriesIWarrantsMember" abstract="true" name="SeriesIWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SeriesIIWarrantsMember" abstract="true" name="SeriesIIWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SeniorUnsecuredNotesDueAugust2028Member" abstract="true" name="SeniorUnsecuredNotesDueAugust2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ValuationTechniqueBlackScholesModelMember" abstract="true" name="ValuationTechniqueBlackScholesModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_A2024WarrantsMember" abstract="true" name="A2024WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_TermLoanDue2029Member" abstract="true" name="TermLoanDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RevolverLoanDue2025Member" abstract="true" name="RevolverLoanDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" abstract="false" name="PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentRepurchaseAmountRemaining" abstract="false" name="DebtInstrumentRepurchaseAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ebs_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_UntilTheSecondAnniversaryOfTheClosingDateMember" abstract="true" name="UntilTheSecondAnniversaryOfTheClosingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AfterTheSecondAnniversaryOfTheClosingDateMember" abstract="true" name="AfterTheSecondAnniversaryOfTheClosingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentOriginalIssueDiscountPercentage" abstract="false" name="DebtInstrumentOriginalIssueDiscountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentVariableInterestRateFloor" abstract="false" name="DebtInstrumentVariableInterestRateFloor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentAdditionalDefaultInterestRate" abstract="false" name="DebtInstrumentAdditionalDefaultInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" abstract="false" name="DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantLiquidityRequirementMinimum" abstract="false" name="DebtInstrumentCovenantLiquidityRequirementMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_DebtInstrumentBasisSpreadOnMakeWholePremium" abstract="false" name="DebtInstrumentBasisSpreadOnMakeWholePremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentPrepaymentPremium" abstract="false" name="DebtInstrumentPrepaymentPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" abstract="false" name="DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" abstract="false" name="DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" abstract="false" name="DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" abstract="false" name="DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" abstract="false" name="DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_RevolvingLoansMember" abstract="true" name="RevolvingLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RevolvingLoansUntilSeptember302025Member" abstract="true" name="RevolvingLoansUntilSeptember302025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RevolvingLoansAfterSeptember302025Member" abstract="true" name="RevolvingLoansAfterSeptember302025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" abstract="false" name="DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_LongTermIncentiveAwardMember" abstract="true" name="LongTermIncentiveAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_PerformanceStockOptionMember" abstract="true" name="PerformanceStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_OtherEquityAwardsMember" abstract="true" name="OtherEquityAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SubscriptionAgreementMember" abstract="true" name="SubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_A2025ShareRepurchaseProgramMember" abstract="true" name="A2025ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_UnitedStatesGovernmentMember" abstract="true" name="UnitedStatesGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_NonUnitedStatesGovernmentMember" abstract="true" name="NonUnitedStatesGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_JanssenPharmaceuticalsInc.Member" abstract="true" name="JanssenPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_CommercialProductMember" abstract="true" name="CommercialProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_MedicalCountermeasuresMCMProductMember" abstract="true" name="MedicalCountermeasuresMCMProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AllOtherRevenueMember" abstract="true" name="AllOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ChangeinContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeinContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_CommitmentContingenciesDisclosureTable" abstract="true" name="CommitmentContingenciesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ebs_SecuritiesAndShareholderLitigationMember" abstract="true" name="SecuritiesAndShareholderLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SECEnforcementProceedingMember" abstract="true" name="SECEnforcementProceedingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_JansenPharmaceuticalsIncMember" abstract="true" name="JansenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_CommitmentsAndContingenciesDisclosureLineItems" abstract="true" name="CommitmentsAndContingenciesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds" abstract="false" name="LossContingencyDamagesPaidValueFromInsuranceProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_LossContingencySettlementPeriod" abstract="false" name="LossContingencySettlementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" abstract="false" name="LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" abstract="false" name="LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_CommercialProductsSegmentMember" abstract="true" name="CommercialProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AdjustedGrossMargin" abstract="false" name="AdjustedGrossMargin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_RestructuringChargesAdjusted" abstract="false" name="RestructuringChargesAdjusted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_InventoryStepUp" abstract="false" name="InventoryStepUp" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DonaldDeGolyerMember" abstract="true" name="DonaldDeGolyerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_SujataTyagiDayalMember" abstract="true" name="SujataTyagiDayalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ebs-20250930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0b2479a1-7a21-4fa0-a33e-3a3a5f4f1cad,g:c7797084-9f00-4c6d-b9c9-e4498d399b6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4b1a1d67-bb1e-4268-a16d-a7b1bfddd983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ea1688b0-868c-4f20-898f-d813f1a69fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4b1a1d67-bb1e-4268-a16d-a7b1bfddd983" xlink:to="loc_us-gaap_LiabilitiesCurrent_ea1688b0-868c-4f20-898f-d813f1a69fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_17724f7c-c15e-442b-a2be-1c09f44045a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4b1a1d67-bb1e-4268-a16d-a7b1bfddd983" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_17724f7c-c15e-442b-a2be-1c09f44045a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_666bb77b-b84b-47e0-8fea-04fe150d886d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4b1a1d67-bb1e-4268-a16d-a7b1bfddd983" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_666bb77b-b84b-47e0-8fea-04fe150d886d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e123bf43-b901-467e-909c-41cbb1b3baec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4b1a1d67-bb1e-4268-a16d-a7b1bfddd983" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e123bf43-b901-467e-909c-41cbb1b3baec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2df2aadd-4506-4bbd-ae31-cac5f9b74b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_64810f93-e480-4e0f-abed-be4ff6c11edd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2df2aadd-4506-4bbd-ae31-cac5f9b74b45" xlink:to="loc_us-gaap_RestrictedCashCurrent_64810f93-e480-4e0f-abed-be4ff6c11edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f6c64d19-8b10-4827-8620-6f80b86e5c48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2df2aadd-4506-4bbd-ae31-cac5f9b74b45" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f6c64d19-8b10-4827-8620-6f80b86e5c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ca13d70f-1094-4105-b3bd-f267be16f9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2df2aadd-4506-4bbd-ae31-cac5f9b74b45" xlink:to="loc_us-gaap_InventoryNet_ca13d70f-1094-4105-b3bd-f267be16f9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c408a5a1-2b37-4b49-ab91-75ad672e4697" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2df2aadd-4506-4bbd-ae31-cac5f9b74b45" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c408a5a1-2b37-4b49-ab91-75ad672e4697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1b97add9-b179-4379-a85c-5f7417c0b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2df2aadd-4506-4bbd-ae31-cac5f9b74b45" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1b97add9-b179-4379-a85c-5f7417c0b26d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b1fcb6d5-9f7a-4637-8e29-bb2de632b6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2df2aadd-4506-4bbd-ae31-cac5f9b74b45" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b1fcb6d5-9f7a-4637-8e29-bb2de632b6fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f9441a7c-7ab3-4b51-a3b7-fc71c5b5fd18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4ea5252d-2593-477f-8a29-6926d0a10e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f9441a7c-7ab3-4b51-a3b7-fc71c5b5fd18" xlink:to="loc_us-gaap_PreferredStockValue_4ea5252d-2593-477f-8a29-6926d0a10e9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9986e349-a885-4434-8bdc-2e2b087d60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f9441a7c-7ab3-4b51-a3b7-fc71c5b5fd18" xlink:to="loc_us-gaap_CommonStockValue_9986e349-a885-4434-8bdc-2e2b087d60f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_3cd15af3-31a1-4dcb-b911-a2bf4b366e07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f9441a7c-7ab3-4b51-a3b7-fc71c5b5fd18" xlink:to="loc_us-gaap_TreasuryStockCommonValue_3cd15af3-31a1-4dcb-b911-a2bf4b366e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_42b55c6d-b96c-4d0b-afe1-e4b59bd676c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f9441a7c-7ab3-4b51-a3b7-fc71c5b5fd18" xlink:to="loc_us-gaap_AdditionalPaidInCapital_42b55c6d-b96c-4d0b-afe1-e4b59bd676c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb133014-f6f1-46bf-8231-b434c01da847" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f9441a7c-7ab3-4b51-a3b7-fc71c5b5fd18" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fb133014-f6f1-46bf-8231-b434c01da847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6691d961-3e9e-4c9a-b8d9-879e43bf8081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f9441a7c-7ab3-4b51-a3b7-fc71c5b5fd18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6691d961-3e9e-4c9a-b8d9-879e43bf8081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dd8ea52a-fae6-4df6-aba1-1cbc7b64cdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_43807ae4-7663-4cbb-90cc-c80ffeb9d25e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dd8ea52a-fae6-4df6-aba1-1cbc7b64cdf2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_43807ae4-7663-4cbb-90cc-c80ffeb9d25e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5514c6a5-1aca-459e-9885-bfefd8021740" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dd8ea52a-fae6-4df6-aba1-1cbc7b64cdf2" xlink:to="loc_us-gaap_AccountsPayableCurrent_5514c6a5-1aca-459e-9885-bfefd8021740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_a1e60a4a-b6ad-4d35-9bf8-550c4fbe2335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dd8ea52a-fae6-4df6-aba1-1cbc7b64cdf2" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_a1e60a4a-b6ad-4d35-9bf8-550c4fbe2335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_153ca79c-0c45-44e6-9003-ce01f6cef2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dd8ea52a-fae6-4df6-aba1-1cbc7b64cdf2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_153ca79c-0c45-44e6-9003-ce01f6cef2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_32496e9c-1c48-458a-8311-69155f167716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dd8ea52a-fae6-4df6-aba1-1cbc7b64cdf2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_32496e9c-1c48-458a-8311-69155f167716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d3db4651-d437-4667-b1c1-8949e8370c23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f6239bb-9422-417c-87d2-afac0073d2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d3db4651-d437-4667-b1c1-8949e8370c23" xlink:to="loc_us-gaap_StockholdersEquity_2f6239bb-9422-417c-87d2-afac0073d2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a743b05-b988-4a9c-9cc9-a71a47f5b7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d3db4651-d437-4667-b1c1-8949e8370c23" xlink:to="loc_us-gaap_Liabilities_1a743b05-b988-4a9c-9cc9-a71a47f5b7b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2a86e12f-6076-4735-aa89-5c6b23e72df7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4dbb24d2-8016-4a38-92bd-359c0a167493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a86e12f-6076-4735-aa89-5c6b23e72df7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4dbb24d2-8016-4a38-92bd-359c0a167493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_545a9b9b-5f79-4519-97f4-c27b004fc902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a86e12f-6076-4735-aa89-5c6b23e72df7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_545a9b9b-5f79-4519-97f4-c27b004fc902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9e026ebc-c45e-4b79-98db-86d5369e9fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a86e12f-6076-4735-aa89-5c6b23e72df7" xlink:to="loc_us-gaap_AssetsCurrent_9e026ebc-c45e-4b79-98db-86d5369e9fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6ca8b400-3e38-494e-9ada-31172b07f921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2a86e12f-6076-4735-aa89-5c6b23e72df7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6ca8b400-3e38-494e-9ada-31172b07f921" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e2696113-98e8-43a1-9060-4487589a85ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_ba2fad22-78e4-4568-b440-287d05737763" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e2696113-98e8-43a1-9060-4487589a85ad" xlink:to="loc_us-gaap_InterestExpenseNonoperating_ba2fad22-78e4-4568-b440-287d05737763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_5c9a6a46-a3ec-4046-a474-75d650504388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e2696113-98e8-43a1-9060-4487589a85ad" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_5c9a6a46-a3ec-4046-a474-75d650504388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_340474d9-6e7a-4c05-b744-e23f145c02a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e2696113-98e8-43a1-9060-4487589a85ad" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_340474d9-6e7a-4c05-b744-e23f145c02a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f34eb851-8363-4c83-a5d2-38863efa47ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d23ef5eb-af2e-4c63-b39a-e6030b7fbb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f34eb851-8363-4c83-a5d2-38863efa47ec" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d23ef5eb-af2e-4c63-b39a-e6030b7fbb3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cbfed270-b697-40f2-85e5-60c977ac6839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f34eb851-8363-4c83-a5d2-38863efa47ec" xlink:to="loc_us-gaap_OperatingIncomeLoss_cbfed270-b697-40f2-85e5-60c977ac6839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_b1e13a84-3f69-4794-85e8-cd3407b41ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_794a0cc0-1d4d-437e-8946-4234bab5be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b1e13a84-3f69-4794-85e8-cd3407b41ec2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_794a0cc0-1d4d-437e-8946-4234bab5be5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e167d957-2b5c-4a8a-a72a-3a99be9e33f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b1e13a84-3f69-4794-85e8-cd3407b41ec2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e167d957-2b5c-4a8a-a72a-3a99be9e33f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69607b97-2b01-4173-95d5-dd1812014018" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b1e13a84-3f69-4794-85e8-cd3407b41ec2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69607b97-2b01-4173-95d5-dd1812014018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3a43c50a-fe2e-4325-b5ef-1411c536ebe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b1e13a84-3f69-4794-85e8-cd3407b41ec2" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3a43c50a-fe2e-4325-b5ef-1411c536ebe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4e42f84c-3208-4730-bce2-a66a5e71d732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b1e13a84-3f69-4794-85e8-cd3407b41ec2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4e42f84c-3208-4730-bce2-a66a5e71d732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_403eaec9-019e-4f07-8bce-6aec78535e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a77a42db-903e-421f-b2e7-0d88ddfd491d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_403eaec9-019e-4f07-8bce-6aec78535e9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a77a42db-903e-421f-b2e7-0d88ddfd491d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dcc55268-0994-4a1d-9bd0-e99ee782bfff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_403eaec9-019e-4f07-8bce-6aec78535e9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dcc55268-0994-4a1d-9bd0-e99ee782bfff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_438f2149-e9aa-482b-988b-77bb2e9bf5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8fe98a1-df58-42f5-8f18-08d152bdf1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_438f2149-e9aa-482b-988b-77bb2e9bf5c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8fe98a1-df58-42f5-8f18-08d152bdf1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_69444657-ca6e-4be0-b39d-89384704cc73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_438f2149-e9aa-482b-988b-77bb2e9bf5c8" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_69444657-ca6e-4be0-b39d-89384704cc73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5ba4bf21-7697-48ae-9589-901991cd8d77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_58f72018-2b5b-471f-ad4c-1f9a2c709682" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5ba4bf21-7697-48ae-9589-901991cd8d77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_58f72018-2b5b-471f-ad4c-1f9a2c709682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_325d41c2-6cb0-4d38-8acc-54dda6c396de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_28611456-1ef5-46d7-a1fa-936edbb6e515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_325d41c2-6cb0-4d38-8acc-54dda6c396de" xlink:to="loc_us-gaap_NetIncomeLoss_28611456-1ef5-46d7-a1fa-936edbb6e515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4186c11e-288e-4421-b942-6a79edaacfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_325d41c2-6cb0-4d38-8acc-54dda6c396de" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4186c11e-288e-4421-b942-6a79edaacfe3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d32a9de4-58fc-446d-8625-5a491a2db1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34cf7f6b-bea8-4476-ad4c-ac79583d91b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d32a9de4-58fc-446d-8625-5a491a2db1ec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34cf7f6b-bea8-4476-ad4c-ac79583d91b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_729d6765-bfc4-45ff-8e12-8e0ba6f29756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d32a9de4-58fc-446d-8625-5a491a2db1ec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_729d6765-bfc4-45ff-8e12-8e0ba6f29756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ebe31212-5a65-4f3c-a8f2-98cdaf880562" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d32a9de4-58fc-446d-8625-5a491a2db1ec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ebe31212-5a65-4f3c-a8f2-98cdaf880562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7bd8fa8-a333-4621-8ae6-ffa72b973184" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d32a9de4-58fc-446d-8625-5a491a2db1ec" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7bd8fa8-a333-4621-8ae6-ffa72b973184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afc36908-4b05-4b1b-b443-77f925f3dad6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c496c05-323d-402f-96f7-203f0cfb421d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afc36908-4b05-4b1b-b443-77f925f3dad6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c496c05-323d-402f-96f7-203f0cfb421d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_45050d5d-38c2-427a-8cb8-da29e8c4a0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afc36908-4b05-4b1b-b443-77f925f3dad6" xlink:to="loc_us-gaap_RestrictedCash_45050d5d-38c2-427a-8cb8-da29e8c4a0bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7fb552d3-63a0-47d5-89cc-0a1c6ceb5134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_NetIncomeLoss_7fb552d3-63a0-47d5-89cc-0a1c6ceb5134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ccb54c9-fad3-4c11-8c4d-8eed4255b566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_ShareBasedCompensation_7ccb54c9-fad3-4c11-8c4d-8eed4255b566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bcad278d-f48b-46e6-a1c6-90176f24184f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bcad278d-f48b-46e6-a1c6-90176f24184f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9c1df928-ff8b-4b0e-afe3-a55049eb10e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9c1df928-ff8b-4b0e-afe3-a55049eb10e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_27040b68-71bf-417a-9a86-e9c583f34d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_27040b68-71bf-417a-9a86-e9c583f34d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_0b7814de-b6a3-4bdf-ab90-d4bc75c5bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_0b7814de-b6a3-4bdf-ab90-d4bc75c5bc4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts_3b9dcf87-5cc7-4c0c-9634-edfd63b5de8b" xlink:href="ebs-20250930.xsd#ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts_3b9dcf87-5cc7-4c0c-9634-edfd63b5de8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d81b79a5-8db6-443e-b9fd-445e87bdefc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d81b79a5-8db6-443e-b9fd-445e87bdefc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_77f58710-5f27-41da-a663-db0f0beb6fda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_77f58710-5f27-41da-a663-db0f0beb6fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_539b7c77-a564-45c4-b806-e720bf3276f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_539b7c77-a564-45c4-b806-e720bf3276f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f8ff6e59-6bd0-476e-abbc-af140e91e613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f8ff6e59-6bd0-476e-abbc-af140e91e613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_288734e6-5b38-45d0-84e7-54b5bc895e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_288734e6-5b38-45d0-84e7-54b5bc895e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f4e831d9-ed56-43b3-8e7c-dfa3e0decba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f4e831d9-ed56-43b3-8e7c-dfa3e0decba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_67c3dd51-69fd-4c14-a02e-337116261a95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_67c3dd51-69fd-4c14-a02e-337116261a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_65bbd2f6-87c0-4fbe-9386-d4fe0a357009" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_65bbd2f6-87c0-4fbe-9386-d4fe0a357009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ea824e7a-0435-44f8-97f1-ba467c15a32b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ea824e7a-0435-44f8-97f1-ba467c15a32b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_0f3b6b02-b6db-4382-b845-c25fb0781c7d" xlink:href="ebs-20250930.xsd#ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_0f3b6b02-b6db-4382-b845-c25fb0781c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_824645ef-39e2-4809-80b6-7f2aa05e8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_824645ef-39e2-4809-80b6-7f2aa05e8f58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_0b5094c0-71cd-473d-aaf8-72dac7a2477e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_0b5094c0-71cd-473d-aaf8-72dac7a2477e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a73e6b1b-371f-446d-a0c5-24bb1ceeb6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_02486440-0387-4d8e-beb5-9f36fa54edb5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a73e6b1b-371f-446d-a0c5-24bb1ceeb6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0a813b8-f298-492b-8cf0-30a10df7e25c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d1f1739a-d2b4-4c3c-a395-28ee8afc363a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0a813b8-f298-492b-8cf0-30a10df7e25c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d1f1739a-d2b4-4c3c-a395-28ee8afc363a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4e269b18-1aef-400b-807a-e19ed76af7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0a813b8-f298-492b-8cf0-30a10df7e25c" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4e269b18-1aef-400b-807a-e19ed76af7ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities_9f440f0e-e965-47b6-97df-1d7cfcccea3a" xlink:href="ebs-20250930.xsd#ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0a813b8-f298-492b-8cf0-30a10df7e25c" xlink:to="loc_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities_9f440f0e-e965-47b6-97df-1d7cfcccea3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1f56ed11-9254-4b00-b139-6869560f4256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0a813b8-f298-492b-8cf0-30a10df7e25c" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1f56ed11-9254-4b00-b139-6869560f4256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_82b9da37-908a-4c4f-a699-716bebc751fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0a813b8-f298-492b-8cf0-30a10df7e25c" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_82b9da37-908a-4c4f-a699-716bebc751fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_3c82b021-9e99-4134-b0dd-27b454524103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_3c82b021-9e99-4134-b0dd-27b454524103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_87709c10-2e84-4689-b721-19d519170176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_87709c10-2e84-4689-b721-19d519170176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt_62db862b-a23a-4785-be1a-a05eb335f925" xlink:href="ebs-20250930.xsd#ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt_62db862b-a23a-4785-be1a-a05eb335f925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_72826f61-797e-4bb3-a019-aa733d762ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_72826f61-797e-4bb3-a019-aa733d762ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_34ea1d54-a0c7-4cf9-9c76-a6b3cba87a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_34ea1d54-a0c7-4cf9-9c76-a6b3cba87a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_745d5578-65ea-4c41-9268-a0c46f1c111c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_745d5578-65ea-4c41-9268-a0c46f1c111c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e86c0a66-6584-4888-9679-b0f2d92ce69f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e86c0a66-6584-4888-9679-b0f2d92ce69f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6f3ab09-7862-4cf3-ac3f-5347f02dae00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6f3ab09-7862-4cf3-ac3f-5347f02dae00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForRepurchaseOfDebt_888b7b29-a873-4c46-941f-3a8fbe129529" xlink:href="ebs-20250930.xsd#ebs_PaymentsForRepurchaseOfDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_ebs_PaymentsForRepurchaseOfDebt_888b7b29-a873-4c46-941f-3a8fbe129529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_45aaf6fe-76d9-4145-9e32-dd82e6cf9d62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_45aaf6fe-76d9-4145-9e32-dd82e6cf9d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fe948eae-b5ca-4963-bf58-52fddaeb5c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fe948eae-b5ca-4963-bf58-52fddaeb5c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c3999aef-836e-4956-8340-de350c1fec04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a18c05a-79f9-47c1-9731-61898a6c090f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c3999aef-836e-4956-8340-de350c1fec04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9280603d-5505-476a-9ef1-ea352c48c8be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_35eebf59-3c26-40e1-9dfd-e75055dc4104" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9280603d-5505-476a-9ef1-ea352c48c8be" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_35eebf59-3c26-40e1-9dfd-e75055dc4104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_d6b61708-c7e2-43e6-a382-30fd08beb99f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9280603d-5505-476a-9ef1-ea352c48c8be" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_d6b61708-c7e2-43e6-a382-30fd08beb99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_5b443ef1-f4ef-4177-960f-6ed899d18aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9280603d-5505-476a-9ef1-ea352c48c8be" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_5b443ef1-f4ef-4177-960f-6ed899d18aa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_da59e482-206f-471e-b353-646b05257875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9280603d-5505-476a-9ef1-ea352c48c8be" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_da59e482-206f-471e-b353-646b05257875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1cebaa07-b142-4f46-b422-1436dddd7726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_75fa6337-d825-4c10-b38e-8bc78d6b4569" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1cebaa07-b142-4f46-b422-1436dddd7726" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_75fa6337-d825-4c10-b38e-8bc78d6b4569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_7729a70e-4d34-4657-a133-7f25e9a92f36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1cebaa07-b142-4f46-b422-1436dddd7726" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_7729a70e-4d34-4657-a133-7f25e9a92f36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_83c6c554-fcf3-4409-ac48-f7f855795005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c6561bb7-abdc-4450-9b34-be1ba91d4f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_83c6c554-fcf3-4409-ac48-f7f855795005" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c6561bb7-abdc-4450-9b34-be1ba91d4f5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_58c88b94-d966-4ea4-8f0f-1485f26dd86e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_83c6c554-fcf3-4409-ac48-f7f855795005" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_58c88b94-d966-4ea4-8f0f-1485f26dd86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c86acf83-0b7f-44c3-8531-0797f447afe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_83c6c554-fcf3-4409-ac48-f7f855795005" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c86acf83-0b7f-44c3-8531-0797f447afe9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8eb28978-af81-4d6d-94dc-1f20b05847d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_215b7feb-8c9d-4b67-a730-99f3afc988bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8eb28978-af81-4d6d-94dc-1f20b05847d5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_215b7feb-8c9d-4b67-a730-99f3afc988bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8f359dcf-e463-4228-bb4b-6f1f287ff86a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8eb28978-af81-4d6d-94dc-1f20b05847d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8f359dcf-e463-4228-bb4b-6f1f287ff86a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca87481a-b2fc-4ff5-9a00-08f112c88385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a845f03e-2812-4584-ad4b-63ac94b35ced" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca87481a-b2fc-4ff5-9a00-08f112c88385" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a845f03e-2812-4584-ad4b-63ac94b35ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8d34e8f6-fce0-48f4-96b0-047b1a3f75f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca87481a-b2fc-4ff5-9a00-08f112c88385" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8d34e8f6-fce0-48f4-96b0-047b1a3f75f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_32afb1c0-fa38-42f0-b16e-b54ac731a15e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure_568ae551-9811-420c-b79f-394d35c7c06f" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_32afb1c0-fa38-42f0-b16e-b54ac731a15e" xlink:to="loc_ebs_WarrantLiabilitiesFairValueDisclosure_568ae551-9811-420c-b79f-394d35c7c06f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c718e2b4-bb31-470c-85ab-f65d2c26aacc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5b42522b-f9f0-4eef-84f3-6c59cc5b660f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c718e2b4-bb31-470c-85ab-f65d2c26aacc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5b42522b-f9f0-4eef-84f3-6c59cc5b660f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae8bdac9-6fbc-4863-893b-98d90e917ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_abebf2a6-d537-404e-a70b-b7c5e9adba78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae8bdac9-6fbc-4863-893b-98d90e917ce9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_abebf2a6-d537-404e-a70b-b7c5e9adba78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0857bde8-4ac8-475d-b725-99f1235ab720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae8bdac9-6fbc-4863-893b-98d90e917ce9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0857bde8-4ac8-475d-b725-99f1235ab720" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionScheduleofAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b14d8c87-51ab-4ca2-bc10-6a5d3e942ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_440185aa-161c-4a49-b757-2c127108a97f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_b14d8c87-51ab-4ca2-bc10-6a5d3e942ae7" xlink:to="loc_us-gaap_UnbilledContractsReceivable_440185aa-161c-4a49-b757-2c127108a97f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_25355096-077f-4928-8177-315642a273b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BilledContractReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_b14d8c87-51ab-4ca2-bc10-6a5d3e942ae7" xlink:to="loc_us-gaap_BilledContractReceivables_25355096-077f-4928-8177-315642a273b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ab1a4118-587c-4b77-9ac6-e47f5c88406d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_b14d8c87-51ab-4ca2-bc10-6a5d3e942ae7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ab1a4118-587c-4b77-9ac6-e47f5c88406d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_58b2579c-2221-4ecd-bcdf-422eea54ff64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1cd16fba-860b-4fb4-ba49-e50415837113" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_58b2579c-2221-4ecd-bcdf-422eea54ff64" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1cd16fba-860b-4fb4-ba49-e50415837113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c642433d-762a-4317-8e52-4597b097d1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_58b2579c-2221-4ecd-bcdf-422eea54ff64" xlink:to="loc_us-gaap_OperatingLeaseCost_c642433d-762a-4317-8e52-4597b097d1cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cb4c3500-3091-4848-895a-6b2eab290d28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e46d394d-7cd5-44e8-8376-f18694b146b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cb4c3500-3091-4848-895a-6b2eab290d28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e46d394d-7cd5-44e8-8376-f18694b146b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9104394-7252-48bb-9a9e-124eb4bf3524" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cb4c3500-3091-4848-895a-6b2eab290d28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9104394-7252-48bb-9a9e-124eb4bf3524" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_a20c54b3-7ba9-4cb2-a428-26401585dfa0" xlink:href="ebs-20250930.xsd#ebs_AdjustedGrossMargin"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_ebs_AdjustedGrossMargin_a20c54b3-7ba9-4cb2-a428-26401585dfa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_991da802-9d36-4111-bdfb-bcb5e76593eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_991da802-9d36-4111-bdfb-bcb5e76593eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5db2ba29-3e93-450e-916c-8f3ec76ee649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5db2ba29-3e93-450e-916c-8f3ec76ee649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringChargesAdjusted_b3f3784b-e7df-4bd6-8012-0ea55eb0a51d" xlink:href="ebs-20250930.xsd#ebs_RestructuringChargesAdjusted"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_ebs_RestructuringChargesAdjusted_b3f3784b-e7df-4bd6-8012-0ea55eb0a51d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_InventoryStepUp_e314c77c-f004-430f-beb4-ab5718d073fc" xlink:href="ebs-20250930.xsd#ebs_InventoryStepUp"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_ebs_InventoryStepUp_e314c77c-f004-430f-beb4-ab5718d073fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ebee6cad-3e3a-476b-8fe9-5de007ae9309" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ebee6cad-3e3a-476b-8fe9-5de007ae9309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d40b480d-665a-4020-a6ac-3f5cb0611d90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d40b480d-665a-4020-a6ac-3f5cb0611d90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_22ee1bb2-45b9-4af7-b54c-a5081f1434fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_22ee1bb2-45b9-4af7-b54c-a5081f1434fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2240c24a-f079-4f93-81bf-9302f0992b89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2240c24a-f079-4f93-81bf-9302f0992b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_778bf217-a283-4a44-8030-556622c30b57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_InterestExpenseNonoperating_778bf217-a283-4a44-8030-556622c30b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_1c932dc7-15e0-46bd-92dd-eaa758ff7749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_1c932dc7-15e0-46bd-92dd-eaa758ff7749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0f83e57d-7b03-4f50-8ecb-8bb01a9b24b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00c5a76f-61a3-455e-ae8b-23151ff9d6e4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0f83e57d-7b03-4f50-8ecb-8bb01a9b24b9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ebs-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0b2479a1-7a21-4fa0-a33e-3a3a5f4f1cad,g:c7797084-9f00-4c6d-b9c9-e4498d399b6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ff0ce10d-5d3b-4e85-820c-429d57f9a961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_StatementTable_ff0ce10d-5d3b-4e85-820c-429d57f9a961" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89057094-1d7e-46d6-b630-ce39162a1df5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ff0ce10d-5d3b-4e85-820c-429d57f9a961" xlink:to="loc_srt_ProductOrServiceAxis_89057094-1d7e-46d6-b630-ce39162a1df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89057094-1d7e-46d6-b630-ce39162a1df5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_89057094-1d7e-46d6-b630-ce39162a1df5" xlink:to="loc_srt_ProductsAndServicesDomain_89057094-1d7e-46d6-b630-ce39162a1df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_89057094-1d7e-46d6-b630-ce39162a1df5" xlink:to="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductAndServiceMember_355d98b8-1d7a-4dbb-89b9-f296dcc4c644" xlink:href="ebs-20250930.xsd#ebs_ProductAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:to="loc_ebs_ProductAndServiceMember_355d98b8-1d7a-4dbb-89b9-f296dcc4c644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_601f0aad-1c03-4a27-a255-f754474b47fa" xlink:href="ebs-20250930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:to="loc_ebs_ContractsAndGrantsMember_601f0aad-1c03-4a27-a255-f754474b47fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8a8acd9c-41a1-4dd9-a118-27cfd381d32d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_RevenuesAbstract_8a8acd9c-41a1-4dd9-a118-27cfd381d32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c3ce4ed-447b-4abb-9950-49cb4dce8308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8a8acd9c-41a1-4dd9-a118-27cfd381d32d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c3ce4ed-447b-4abb-9950-49cb4dce8308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_71300465-0799-430f-bde7-d5f692420e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_71300465-0799-430f-bde7-d5f692420e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_77d503b1-9351-48ba-a191-d05a8c40f2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_77d503b1-9351-48ba-a191-d05a8c40f2d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba2831d6-ec9b-423e-bc4d-95001ad1055d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba2831d6-ec9b-423e-bc4d-95001ad1055d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d6dbf05a-e7b5-4911-8c66-af1819b7da98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d6dbf05a-e7b5-4911-8c66-af1819b7da98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7282be29-df6b-4c1b-994c-d15d3f852225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7282be29-df6b-4c1b-994c-d15d3f852225" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_11b2c090-b40c-4ddc-b5e7-180be040f9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_11b2c090-b40c-4ddc-b5e7-180be040f9c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a83da38-7323-4b60-866b-3bbf565bcbff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_OperatingIncomeLoss_8a83da38-7323-4b60-866b-3bbf565bcbff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_cd31f246-54ae-47f6-aa7c-7505197fdd38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_InterestExpenseNonoperating_cd31f246-54ae-47f6-aa7c-7505197fdd38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_18c51bea-4ebc-43ca-a2a3-345fad79f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_18c51bea-4ebc-43ca-a2a3-345fad79f80d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5fcf5940-1b76-4f7b-ae7e-26ca31a4a1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5fcf5940-1b76-4f7b-ae7e-26ca31a4a1e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8ed513a6-c7ed-4ddb-b4fd-cde3714baf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8ed513a6-c7ed-4ddb-b4fd-cde3714baf4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bac58222-fe74-4375-bbab-61fd9ca2d6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bac58222-fe74-4375-bbab-61fd9ca2d6d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aa9559df-bfb2-4803-9a17-790ac0eccb95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aa9559df-bfb2-4803-9a17-790ac0eccb95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_086bf939-bd03-4f7b-8ce5-97d24ab4fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_NetIncomeLoss_086bf939-bd03-4f7b-8ce5-97d24ab4fe5b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b601ec66-faa6-41fc-9f68-07a4c89511f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:to="loc_us-gaap_EarningsPerShareBasic_b601ec66-faa6-41fc-9f68-07a4c89511f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f36e95d3-2a10-45cf-926d-3a823c0d23a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f36e95d3-2a10-45cf-926d-3a823c0d23a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3e2749b1-f3f9-4a3a-ae08-476c1adfc19f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3e2749b1-f3f9-4a3a-ae08-476c1adfc19f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3f7cde4-96da-4265-9c39-4bfed524e969" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3f7cde4-96da-4265-9c39-4bfed524e969" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_295130d7-d404-4c2e-a576-1d0d685339fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4432b429-e896-4163-8bb4-2649a04c412b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_295130d7-d404-4c2e-a576-1d0d685339fd" xlink:to="loc_us-gaap_StatementTable_4432b429-e896-4163-8bb4-2649a04c412b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a577697d-a17b-476f-b965-ed831e515f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4432b429-e896-4163-8bb4-2649a04c412b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a577697d-a17b-476f-b965-ed831e515f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a577697d-a17b-476f-b965-ed831e515f8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a577697d-a17b-476f-b965-ed831e515f8c" xlink:to="loc_us-gaap_EquityComponentDomain_a577697d-a17b-476f-b965-ed831e515f8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a577697d-a17b-476f-b965-ed831e515f8c" xlink:to="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e8ce031-b297-46a0-8f24-ce167647ea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_CommonStockMember_9e8ce031-b297-46a0-8f24-ce167647ea2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_3ef1e2e6-e0a6-46f5-8171-2918086ba92e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_3ef1e2e6-e0a6-46f5-8171-2918086ba92e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d417036-0725-4c63-91ec-fcdb5fb56a07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d417036-0725-4c63-91ec-fcdb5fb56a07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00ffe2fc-8243-4a01-aa4a-748ac5c15288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00ffe2fc-8243-4a01-aa4a-748ac5c15288" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_deff608f-99d8-4fc3-b84f-7f30333763da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_RetainedEarningsMember_deff608f-99d8-4fc3-b84f-7f30333763da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_295130d7-d404-4c2e-a576-1d0d685339fd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_efcd8a34-7e57-4b0c-8744-2df848391461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_CommonStockSharesIssued_efcd8a34-7e57-4b0c-8744-2df848391461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e1243383-0bb2-4f24-97c8-ba02009f656d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockholdersEquity_e1243383-0bb2-4f24-97c8-ba02009f656d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_226bedbd-e202-4d64-9479-391ed29b3da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_TreasuryStockCommonShares_226bedbd-e202-4d64-9479-391ed29b3da7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce9f8b6f-f549-496f-a1c2-6705ec4180c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_NetIncomeLoss_ce9f8b6f-f549-496f-a1c2-6705ec4180c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b7e88da9-0fc5-4a97-8810-93ba0b0ef35b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b7e88da9-0fc5-4a97-8810-93ba0b0ef35b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8dc17403-815e-4b9b-907e-b9c6499079e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8dc17403-815e-4b9b-907e-b9c6499079e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_032e56b0-8e27-4883-994e-4a16d5e15efb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_032e56b0-8e27-4883-994e-4a16d5e15efb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d4fa0496-8046-438f-a6f9-bf3b7e151005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d4fa0496-8046-438f-a6f9-bf3b7e151005" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22554e11-7a8a-42de-9a45-a440390f3029" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22554e11-7a8a-42de-9a45-a440390f3029" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0d589a4-f4d0-4add-bfbe-0e3988d4f675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0d589a4-f4d0-4add-bfbe-0e3988d4f675" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f16202f9-f2f0-41ec-a3cd-88d2000745a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f16202f9-f2f0-41ec-a3cd-88d2000745a8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e7d4e9ec-2bd5-4ab8-a871-7a024a9149b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7a2aa8d3-454f-467d-acb7-1476ee841ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_274d49ac-bd98-4a00-8f89-fe4a2938202b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#AssetsandliabilitiesheldforsaleNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1bd19138-ff02-40fe-aef4-d7c51da1e8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1bd19138-ff02-40fe-aef4-d7c51da1e8d5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0eeeb819-6368-42e9-9cad-60443c8e783f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0eeeb819-6368-42e9-9cad-60443c8e783f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0eeeb819-6368-42e9-9cad-60443c8e783f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0eeeb819-6368-42e9-9cad-60443c8e783f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0eeeb819-6368-42e9-9cad-60443c8e783f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cbdb2ec2-7d8f-4f27-a700-b71a65479859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0eeeb819-6368-42e9-9cad-60443c8e783f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cbdb2ec2-7d8f-4f27-a700-b71a65479859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b9f1f838-38de-4721-b71f-1baafaf96162" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cbdb2ec2-7d8f-4f27-a700-b71a65479859" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b9f1f838-38de-4721-b71f-1baafaf96162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5adc7810-c3e4-432e-91d1-4c147f9a54a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5adc7810-c3e4-432e-91d1-4c147f9a54a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5adc7810-c3e4-432e-91d1-4c147f9a54a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5adc7810-c3e4-432e-91d1-4c147f9a54a5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5adc7810-c3e4-432e-91d1-4c147f9a54a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c0fdf1b-82f2-4ef4-84e9-8dcfa3481717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5adc7810-c3e4-432e-91d1-4c147f9a54a5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c0fdf1b-82f2-4ef4-84e9-8dcfa3481717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MarylandWarehouseSpaceMember_32428cd8-0717-401d-88e7-b6a2fc58d0ab" xlink:href="ebs-20250930.xsd#ebs_MarylandWarehouseSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c0fdf1b-82f2-4ef4-84e9-8dcfa3481717" xlink:to="loc_ebs_MarylandWarehouseSpaceMember_32428cd8-0717-401d-88e7-b6a2fc58d0ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_2c3b2502-16a2-4b8a-94c7-3ff81205b106" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1bd19138-ff02-40fe-aef4-d7c51da1e8d5" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_2c3b2502-16a2-4b8a-94c7-3ff81205b106" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_4716c252-d96b-4a4f-8e3f-645340099c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_4716c252-d96b-4a4f-8e3f-645340099c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4716c252-d96b-4a4f-8e3f-645340099c64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4716c252-d96b-4a4f-8e3f-645340099c64" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4716c252-d96b-4a4f-8e3f-645340099c64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c4055d04-632b-487c-ad26-a82a4dc48b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4716c252-d96b-4a4f-8e3f-645340099c64" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c4055d04-632b-487c-ad26-a82a4dc48b3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_6c41b30b-6989-462f-928a-738e129a337c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c4055d04-632b-487c-ad26-a82a4dc48b3d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_6c41b30b-6989-462f-928a-738e129a337c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1ad2ad51-7f75-4ead-9952-13134ae5b990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1ad2ad51-7f75-4ead-9952-13134ae5b990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ad2ad51-7f75-4ead-9952-13134ae5b990_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1ad2ad51-7f75-4ead-9952-13134ae5b990" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1ad2ad51-7f75-4ead-9952-13134ae5b990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1827a329-d0df-4927-bc10-74fa7c15d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1ad2ad51-7f75-4ead-9952-13134ae5b990" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1827a329-d0df-4927-bc10-74fa7c15d99a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MarylandWarehouseSpaceMember_de72412e-c730-4b1b-b9b1-63357aa4f4bd" xlink:href="ebs-20250930.xsd#ebs_MarylandWarehouseSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1827a329-d0df-4927-bc10-74fa7c15d99a" xlink:to="loc_ebs_MarylandWarehouseSpaceMember_de72412e-c730-4b1b-b9b1-63357aa4f4bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_7b8de8f1-0bd4-4775-8a23-b632266cdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_7b8de8f1-0bd4-4775-8a23-b632266cdaf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_47d4c0e5-b049-4608-8641-5f7c568fcf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_47d4c0e5-b049-4608-8641-5f7c568fcf1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_d31e4e66-d213-4211-8d92-9686f3491065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_d31e4e66-d213-4211-8d92-9686f3491065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_da699448-6777-4dc6-a4e0-367c894d18cc" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_da699448-6777-4dc6-a4e0-367c894d18cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_924091e1-76ed-4743-956b-d54f8b9ef392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_924091e1-76ed-4743-956b-d54f8b9ef392" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3e5ab8f9-d924-400a-b3f3-e590aa0418f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3e5ab8f9-d924-400a-b3f3-e590aa0418f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_31fe0ec3-0c67-4f2a-b2c0-028c854ee9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_31fe0ec3-0c67-4f2a-b2c0-028c854ee9e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_67061505-bf7b-4140-bd2b-c9a5d19a5e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_67061505-bf7b-4140-bd2b-c9a5d19a5e6b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DivestituresDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DivestituresDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4ea47dda-fddb-4e7d-ac2b-ea7282409eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4ea47dda-fddb-4e7d-ac2b-ea7282409eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5aeed6c0-f5ba-4d74-98cf-35edb7f6fefc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4ea47dda-fddb-4e7d-ac2b-ea7282409eb1" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5aeed6c0-f5ba-4d74-98cf-35edb7f6fefc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a658ab6-94d6-464c-b86b-737e0be9b5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a658ab6-94d6-464c-b86b-737e0be9b5e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5a658ab6-94d6-464c-b86b-737e0be9b5e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a658ab6-94d6-464c-b86b-737e0be9b5e6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5a658ab6-94d6-464c-b86b-737e0be9b5e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a658ab6-94d6-464c-b86b-737e0be9b5e6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_cb027fc3-87c0-49c9-8933-c235a662279e" xlink:href="ebs-20250930.xsd#ebs_TravelHealthBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_TravelHealthBusinessMember_cb027fc3-87c0-49c9-8933-c235a662279e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RSDLMember_0740f5e2-e61b-4477-b08b-504a3a55502d" xlink:href="ebs-20250930.xsd#ebs_RSDLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_RSDLMember_0740f5e2-e61b-4477-b08b-504a3a55502d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BaltimoreCamdenFacilityMember_a88c70b0-ce86-4962-983a-7b12e86e1c33" xlink:href="ebs-20250930.xsd#ebs_BaltimoreCamdenFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_BaltimoreCamdenFacilityMember_a88c70b0-ce86-4962-983a-7b12e86e1c33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BaltimoreBayviewFacilityMember_25a55d2e-9f16-467c-bb96-6762cd1ce059" xlink:href="ebs-20250930.xsd#ebs_BaltimoreBayviewFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_BaltimoreBayviewFacilityMember_25a55d2e-9f16-467c-bb96-6762cd1ce059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_de063da4-e034-4244-8867-021dae6ecc47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_de063da4-e034-4244-8867-021dae6ecc47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_de063da4-e034-4244-8867-021dae6ecc47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_de063da4-e034-4244-8867-021dae6ecc47" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_de063da4-e034-4244-8867-021dae6ecc47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_de063da4-e034-4244-8867-021dae6ecc47" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DevelopmentBasedMilestonesMember_a4f7a5e2-a920-4c27-b4f3-c2aa04deaba5" xlink:href="ebs-20250930.xsd#ebs_DevelopmentBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:to="loc_ebs_DevelopmentBasedMilestonesMember_a4f7a5e2-a920-4c27-b4f3-c2aa04deaba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SalesBasedMilestonesMember_11e05fe9-7900-42a6-b101-4ad0b10177b0" xlink:href="ebs-20250930.xsd#ebs_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:to="loc_ebs_SalesBasedMilestonesMember_11e05fe9-7900-42a6-b101-4ad0b10177b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_987fac85-6a85-4dfc-b19e-a723f57a0c75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_srt_ProductOrServiceAxis_987fac85-6a85-4dfc-b19e-a723f57a0c75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_987fac85-6a85-4dfc-b19e-a723f57a0c75_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_987fac85-6a85-4dfc-b19e-a723f57a0c75" xlink:to="loc_srt_ProductsAndServicesDomain_987fac85-6a85-4dfc-b19e-a723f57a0c75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de176bb0-9b16-4df9-9eb4-15524861ed7f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_987fac85-6a85-4dfc-b19e-a723f57a0c75" xlink:to="loc_srt_ProductsAndServicesDomain_de176bb0-9b16-4df9-9eb4-15524861ed7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductAndServiceMember_a34b5af9-72f7-44de-80c5-40e19210a8d2" xlink:href="ebs-20250930.xsd#ebs_ProductAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_de176bb0-9b16-4df9-9eb4-15524861ed7f" xlink:to="loc_ebs_ProductAndServiceMember_a34b5af9-72f7-44de-80c5-40e19210a8d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_97b24353-dca8-42ee-a447-ab1c9e4f395b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_97b24353-dca8-42ee-a447-ab1c9e4f395b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_18e225d4-1ed4-4222-b85c-3549e21e9ed0" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_18e225d4-1ed4-4222-b85c-3549e21e9ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset_8436ffcf-4c04-49ae-93d2-4bf773e7f285" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset_8436ffcf-4c04-49ae-93d2-4bf773e7f285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable_0b5e03d2-8d48-4e73-bf4d-a713b5572d6d" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable_0b5e03d2-8d48-4e73-bf4d-a713b5572d6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_de4e795d-35db-4ff3-9844-4b2f4329451c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_de4e795d-35db-4ff3-9844-4b2f4329451c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_60d4586b-0025-4542-a42a-48ff2e778efb" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_60d4586b-0025-4542-a42a-48ff2e778efb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2761390-84cd-4400-a71c-5ab901040d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2761390-84cd-4400-a71c-5ab901040d5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b25a7859-6a8a-421b-82c1-7bdaa79d8599" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b25a7859-6a8a-421b-82c1-7bdaa79d8599" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5080700f-9dc0-411d-b3ff-fb0b216dda30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5080700f-9dc0-411d-b3ff-fb0b216dda30" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a5f690f3-08ae-4f87-88de-e4d05b051f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a5f690f3-08ae-4f87-88de-e4d05b051f9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_7051b651-5715-4963-9d8b-43567ad9c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a5f690f3-08ae-4f87-88de-e4d05b051f9d" xlink:to="loc_us-gaap_RestructuringPlanAxis_7051b651-5715-4963-9d8b-43567ad9c71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_7051b651-5715-4963-9d8b-43567ad9c71a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_7051b651-5715-4963-9d8b-43567ad9c71a" xlink:to="loc_us-gaap_RestructuringPlanDomain_7051b651-5715-4963-9d8b-43567ad9c71a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_7051b651-5715-4963-9d8b-43567ad9c71a" xlink:to="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_85893c91-de40-4189-a0a1-eab775bd846d" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_85893c91-de40-4189-a0a1-eab775bd846d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_340a5f89-9dab-487e-8f5e-3e321754b503" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_340a5f89-9dab-487e-8f5e-3e321754b503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanMay2024Member_02306fab-554e-490a-aa6e-9fd5f19c11f4" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanMay2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanMay2024Member_02306fab-554e-490a-aa6e-9fd5f19c11f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2024Member_c9e2fea5-07c9-4567-a29a-c5a3c5d0b81a" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanAugust2024Member_c9e2fea5-07c9-4567-a29a-c5a3c5d0b81a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dc9b71bd-0321-41fc-a3d8-96a745a932dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dc9b71bd-0321-41fc-a3d8-96a745a932dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_27ac9238-8714-4e24-832b-2ca5bb7cad34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_27ac9238-8714-4e24-832b-2ca5bb7cad34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3664b778-838b-4536-af0b-a2f606db4e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3664b778-838b-4536-af0b-a2f606db4e29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated_5cf4bbd9-0dbb-436c-be4e-2f24aeb4ba6a" xlink:href="ebs-20250930.xsd#ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated_5cf4bbd9-0dbb-436c-be4e-2f24aeb4ba6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_d47c5998-775f-485b-854c-67de11ffcf02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_d47c5998-775f-485b-854c-67de11ffcf02" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_83696aa0-3b50-4a24-b606-7bf16b0724a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_829b77f2-066d-418d-806e-63739ec9edf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_83696aa0-3b50-4a24-b606-7bf16b0724a8" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_829b77f2-066d-418d-806e-63739ec9edf2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_4bef2397-7bae-4134-8d20-8a5301b990c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_829b77f2-066d-418d-806e-63739ec9edf2" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_4bef2397-7bae-4134-8d20-8a5301b990c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_4bef2397-7bae-4134-8d20-8a5301b990c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_4bef2397-7bae-4134-8d20-8a5301b990c4" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_4bef2397-7bae-4134-8d20-8a5301b990c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_4bef2397-7bae-4134-8d20-8a5301b990c4" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_50badb0a-39f8-4330-b829-89d109f3bf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_50badb0a-39f8-4330-b829-89d109f3bf4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_18120ee5-f353-4888-ae28-2fe6c6517295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_18120ee5-f353-4888-ae28-2fe6c6517295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ba3c46e7-6e66-4472-a913-c0f7d0532eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ba3c46e7-6e66-4472-a913-c0f7d0532eea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_274b8fd1-4094-4dd7-8a1c-b0aa83786df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_ConstructionInProgressMember_274b8fd1-4094-4dd7-8a1c-b0aa83786df3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0ec84ea1-573d-4d35-8767-129703702989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_83696aa0-3b50-4a24-b606-7bf16b0724a8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0ec84ea1-573d-4d35-8767-129703702989" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6437d8e6-0e58-4fbe-8016-ddabc4e94124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6437d8e6-0e58-4fbe-8016-ddabc4e94124" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600" xlink:to="loc_us-gaap_SegmentDomain_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600" xlink:to="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_cd7314fb-2094-471c-b35a-711cae52714f" xlink:href="ebs-20250930.xsd#ebs_MCMProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:to="loc_ebs_MCMProductsSegmentMember_cd7314fb-2094-471c-b35a-711cae52714f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1ab88b1a-6b2c-41a4-9e26-fc2751a86974" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1ab88b1a-6b2c-41a4-9e26-fc2751a86974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_18484e83-338d-4328-9ff5-5307bf989e27" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:to="loc_srt_ConsolidationItemsAxis_18484e83-338d-4328-9ff5-5307bf989e27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_18484e83-338d-4328-9ff5-5307bf989e27_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_18484e83-338d-4328-9ff5-5307bf989e27" xlink:to="loc_srt_ConsolidationItemsDomain_18484e83-338d-4328-9ff5-5307bf989e27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_18484e83-338d-4328-9ff5-5307bf989e27" xlink:to="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ab925fb8-b295-4f63-bbb6-c92401ca91ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:to="loc_us-gaap_OperatingSegmentsMember_ab925fb8-b295-4f63-bbb6-c92401ca91ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ae35ff7e-0cc9-4b62-8553-31e8ea0707f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ae35ff7e-0cc9-4b62-8553-31e8ea0707f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_29c9f45a-6ec1-499f-a996-57803f4dc008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_29c9f45a-6ec1-499f-a996-57803f4dc008" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_29c9f45a-6ec1-499f-a996-57803f4dc008_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_29c9f45a-6ec1-499f-a996-57803f4dc008" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_29c9f45a-6ec1-499f-a996-57803f4dc008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_29c9f45a-6ec1-499f-a996-57803f4dc008" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedSellingGeneralAndAdministrativeMember_bacf5c55-e157-4b48-a766-a63fdc709541" xlink:href="ebs-20250930.xsd#ebs_UnallocatedSellingGeneralAndAdministrativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_ebs_UnallocatedSellingGeneralAndAdministrativeMember_bacf5c55-e157-4b48-a766-a63fdc709541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember_39b6c391-e8fe-4948-970b-9327ff648fc9" xlink:href="ebs-20250930.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_ebs_UnallocatedResearchAndDevelopmentMember_39b6c391-e8fe-4948-970b-9327ff648fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0d92d583-9293-410e-a225-9af525b4c9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0d92d583-9293-410e-a225-9af525b4c9ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_9b5e64b3-e23a-41bc-833d-bb3d99c692b2" xlink:href="ebs-20250930.xsd#ebs_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_ebs_EmployeeBenefitsMember_9b5e64b3-e23a-41bc-833d-bb3d99c692b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0a2be495-134d-4a2b-95c0-5e9653b8472e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6437d8e6-0e58-4fbe-8016-ddabc4e94124" xlink:to="loc_us-gaap_RestructuringCharges_0a2be495-134d-4a2b-95c0-5e9653b8472e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_184b5e1e-ae33-468c-9d23-31c335f731e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_184b5e1e-ae33-468c-9d23-31c335f731e0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7089b516-65a1-4cee-9552-5beb2bf93691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7089b516-65a1-4cee-9552-5beb2bf93691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7089b516-65a1-4cee-9552-5beb2bf93691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7089b516-65a1-4cee-9552-5beb2bf93691" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7089b516-65a1-4cee-9552-5beb2bf93691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7089b516-65a1-4cee-9552-5beb2bf93691" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_edc3db49-46c3-4c6c-b928-26b2fbfffdec" xlink:href="ebs-20250930.xsd#ebs_EmployeeTransitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:to="loc_ebs_EmployeeTransitionMember_edc3db49-46c3-4c6c-b928-26b2fbfffdec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_7dde9809-66d5-4c38-808c-0e51107b5aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:to="loc_us-gaap_EmployeeSeveranceMember_7dde9809-66d5-4c38-808c-0e51107b5aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_030651aa-7017-4d96-b8b5-6e15e3b5f8d1" xlink:href="ebs-20250930.xsd#ebs_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:to="loc_ebs_EmployeeBenefitsMember_030651aa-7017-4d96-b8b5-6e15e3b5f8d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8d488c0e-985b-4b12-b5cd-ea75c60f3a87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:to="loc_us-gaap_RestructuringPlanAxis_8d488c0e-985b-4b12-b5cd-ea75c60f3a87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8d488c0e-985b-4b12-b5cd-ea75c60f3a87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_8d488c0e-985b-4b12-b5cd-ea75c60f3a87" xlink:to="loc_us-gaap_RestructuringPlanDomain_8d488c0e-985b-4b12-b5cd-ea75c60f3a87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_8d488c0e-985b-4b12-b5cd-ea75c60f3a87" xlink:to="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_76d600dc-5dec-472b-bccd-b7bd7b40ed9d" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_76d600dc-5dec-472b-bccd-b7bd7b40ed9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_779eadae-12e7-401f-b7d5-ca4b1dc6d49a" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_779eadae-12e7-401f-b7d5-ca4b1dc6d49a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanMay2024Member_c036ac3e-af5a-4576-9efd-4e77f3eecfa0" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanMay2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanMay2024Member_c036ac3e-af5a-4576-9efd-4e77f3eecfa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2024Member_9151ca43-7100-4fdc-a3b8-5cd2173e7bec" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanAugust2024Member_9151ca43-7100-4fdc-a3b8-5cd2173e7bec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_184b5e1e-ae33-468c-9d23-31c335f731e0" xlink:to="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_aac6a912-1b72-4c23-9f9b-ef2f0bb43dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:to="loc_us-gaap_RestructuringReserve_aac6a912-1b72-4c23-9f9b-ef2f0bb43dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_82a46a90-9620-412c-99dd-ec7af9340508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:to="loc_us-gaap_RestructuringCharges_82a46a90-9620-412c-99dd-ec7af9340508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_ada6edb8-b7ea-4ec0-8ece-8407ca3bd097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:to="loc_us-gaap_PaymentsForRestructuring_ada6edb8-b7ea-4ec0-8ece-8407ca3bd097" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fb9c838e-b618-4e56-bb77-fa59ce570fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02d0595d-873c-45ae-a30e-e9df2904de68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02d0595d-873c-45ae-a30e-e9df2904de68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29ab753f-f8ca-4e63-962e-eff0f3395607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02d0595d-873c-45ae-a30e-e9df2904de68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29ab753f-f8ca-4e63-962e-eff0f3395607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29ab753f-f8ca-4e63-962e-eff0f3395607_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29ab753f-f8ca-4e63-962e-eff0f3395607" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_29ab753f-f8ca-4e63-962e-eff0f3395607_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29ab753f-f8ca-4e63-962e-eff0f3395607" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_6a334a8e-0b45-4d51-a918-234ca63d12a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_6a334a8e-0b45-4d51-a918-234ca63d12a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_958b3c3b-5e76-417b-99c0-92d09b4b3d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_958b3c3b-5e76-417b-99c0-92d09b4b3d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_df1a22a2-fdd5-410d-b96c-4d7a8cc77d34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_df1a22a2-fdd5-410d-b96c-4d7a8cc77d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a5cce91e-e194-42a4-a35a-9cf993b70a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a5cce91e-e194-42a4-a35a-9cf993b70a94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_101fdbb4-e90d-481d-8a32-30865d2ed8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_ConstructionInProgressMember_101fdbb4-e90d-481d-8a32-30865d2ed8f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_32438d21-fc9c-4a87-a471-8a18dc628853" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_32438d21-fc9c-4a87-a471-8a18dc628853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_49a478b5-0854-4367-bc65-450cf406435d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_49a478b5-0854-4367-bc65-450cf406435d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e5ead76b-67ac-47c1-bc66-8e36a6832eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e5ead76b-67ac-47c1-bc66-8e36a6832eb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_25f710e0-4526-432a-9b36-7323eaaa3d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_25f710e0-4526-432a-9b36-7323eaaa3d7f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33e239d0-a3a1-4127-b7dd-1f765a29617e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33e239d0-a3a1-4127-b7dd-1f765a29617e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33e239d0-a3a1-4127-b7dd-1f765a29617e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a032b51-8516-4c55-b3fe-4096483d6767" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a032b51-8516-4c55-b3fe-4096483d6767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3b5c92a4-2923-4ae8-84d5-81acf76c6f62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a032b51-8516-4c55-b3fe-4096483d6767" xlink:to="loc_us-gaap_ProductMember_3b5c92a4-2923-4ae8-84d5-81acf76c6f62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5704a224-5092-4078-b036-14f9f9fbf72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5704a224-5092-4078-b036-14f9f9fbf72d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d68b69d8-2fb5-4dd0-be1e-c65c2c9e516d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d68b69d8-2fb5-4dd0-be1e-c65c2c9e516d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_babeb3b0-75e2-4a57-b378-4e24b9c76d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_babeb3b0-75e2-4a57-b378-4e24b9c76d67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e111c34d-2c37-4e93-b90f-9c2a62814fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e111c34d-2c37-4e93-b90f-9c2a62814fe4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6ad66672-3a82-4891-a8af-012efe6e1888" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6ad66672-3a82-4891-a8af-012efe6e1888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6ad66672-3a82-4891-a8af-012efe6e1888_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6ad66672-3a82-4891-a8af-012efe6e1888" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6ad66672-3a82-4891-a8af-012efe6e1888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_becd7293-7055-4b9a-917f-03e2dc9c63e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6ad66672-3a82-4891-a8af-012efe6e1888" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_becd7293-7055-4b9a-917f-03e2dc9c63e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ac57f92-b05e-4fea-8fac-538510e28630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_becd7293-7055-4b9a-917f-03e2dc9c63e7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ac57f92-b05e-4fea-8fac-538510e28630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53865fbe-c7fb-4b61-90fc-88342fff9549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53865fbe-c7fb-4b61-90fc-88342fff9549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53865fbe-c7fb-4b61-90fc-88342fff9549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53865fbe-c7fb-4b61-90fc-88342fff9549" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53865fbe-c7fb-4b61-90fc-88342fff9549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53865fbe-c7fb-4b61-90fc-88342fff9549" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_51c840a6-6ff5-4dbd-8167-5950e23244fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_51c840a6-6ff5-4dbd-8167-5950e23244fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd3be8f9-0ef4-4359-9b1b-39e8dd524879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd3be8f9-0ef4-4359-9b1b-39e8dd524879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_673bcf81-2a1a-42f4-b065-74e2df9616a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_673bcf81-2a1a-42f4-b065-74e2df9616a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c916dbbe-b71a-463d-8fb4-c0b1d3514694" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c916dbbe-b71a-463d-8fb4-c0b1d3514694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_be673107-60d1-46f6-b13b-bcc185006320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_be673107-60d1-46f6-b13b-bcc185006320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure_81e6e4f9-239f-44ba-838d-b334f1cf47ba" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_ebs_WarrantLiabilitiesFairValueDisclosure_81e6e4f9-239f-44ba-838d-b334f1cf47ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d7d4d387-1e65-4a9b-bf17-81059d4c2e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d7d4d387-1e65-4a9b-bf17-81059d4c2e8c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_42cd0247-25ff-4a00-b2bd-8de987c57836" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_42cd0247-25ff-4a00-b2bd-8de987c57836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_42cd0247-25ff-4a00-b2bd-8de987c57836_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_42cd0247-25ff-4a00-b2bd-8de987c57836" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_42cd0247-25ff-4a00-b2bd-8de987c57836_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_42cd0247-25ff-4a00-b2bd-8de987c57836" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIWarrantsMember_813b5ae9-57b2-4b1e-9ec8-0e54987b7738" xlink:href="ebs-20250930.xsd#ebs_SeriesIWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:to="loc_ebs_SeriesIWarrantsMember_813b5ae9-57b2-4b1e-9ec8-0e54987b7738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIIWarrantsMember_db106774-0453-40fc-b42f-2acc9bad55cf" xlink:href="ebs-20250930.xsd#ebs_SeriesIIWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:to="loc_ebs_SeriesIIWarrantsMember_db106774-0453-40fc-b42f-2acc9bad55cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_838561db-bbeb-49ee-b7b2-26adbc0f5f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:to="loc_us-gaap_DebtInstrumentAxis_838561db-bbeb-49ee-b7b2-26adbc0f5f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_838561db-bbeb-49ee-b7b2-26adbc0f5f53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_838561db-bbeb-49ee-b7b2-26adbc0f5f53" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_838561db-bbeb-49ee-b7b2-26adbc0f5f53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b93ed3f4-ac0a-4933-bc24-0c9a6d479fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_838561db-bbeb-49ee-b7b2-26adbc0f5f53" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b93ed3f4-ac0a-4933-bc24-0c9a6d479fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_e5294ec7-955c-4a85-9f44-65799b0d46c5" xlink:href="ebs-20250930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b93ed3f4-ac0a-4933-bc24-0c9a6d479fd2" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_e5294ec7-955c-4a85-9f44-65799b0d46c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96e06b25-0285-4949-9309-bb72dadf6bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96e06b25-0285-4949-9309-bb72dadf6bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5f9a7231-0a4d-48af-80a6-ea89e5069bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96e06b25-0285-4949-9309-bb72dadf6bb0" xlink:to="loc_us-gaap_SeniorNotesMember_5f9a7231-0a4d-48af-80a6-ea89e5069bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15984e8c-adea-4219-9d21-3dee6ac24212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15984e8c-adea-4219-9d21-3dee6ac24212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_151ad880-da03-4c2f-bbce-4e43e4514687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_151ad880-da03-4c2f-bbce-4e43e4514687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure_66fdff49-1b25-4bb0-8540-f97c606d9a09" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_ebs_WarrantLiabilitiesFairValueDisclosure_66fdff49-1b25-4bb0-8540-f97c606d9a09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab333d88-3f34-497c-87e5-7b1d1f9d49b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab333d88-3f34-497c-87e5-7b1d1f9d49b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_66bb4f90-5770-4cac-8761-9e218bb02ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_LongTermDebtFairValue_66bb4f90-5770-4cac-8761-9e218bb02ca1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_139d8430-8b4a-4200-a9ac-c16baa150adc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a69d08f4-d58b-41e7-ae62-b126c2aa6ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_139d8430-8b4a-4200-a9ac-c16baa150adc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a69d08f4-d58b-41e7-ae62-b126c2aa6ca0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_196e71d4-4549-4a48-9125-8c3460fa22ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a69d08f4-d58b-41e7-ae62-b126c2aa6ca0" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_196e71d4-4549-4a48-9125-8c3460fa22ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_196e71d4-4549-4a48-9125-8c3460fa22ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_196e71d4-4549-4a48-9125-8c3460fa22ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_196e71d4-4549-4a48-9125-8c3460fa22ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b4429b06-f4d4-45a8-a69c-a3c78b0a0ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_196e71d4-4549-4a48-9125-8c3460fa22ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b4429b06-f4d4-45a8-a69c-a3c78b0a0ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cceb51a2-5525-4d0a-b0ef-fdc9815363bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b4429b06-f4d4-45a8-a69c-a3c78b0a0ca9" xlink:to="loc_us-gaap_WarrantMember_cceb51a2-5525-4d0a-b0ef-fdc9815363bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_139d8430-8b4a-4200-a9ac-c16baa150adc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87daaa1f-2887-4d27-ab6a-2ce5b9c39c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87daaa1f-2887-4d27-ab6a-2ce5b9c39c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7b8c8dc3-c921-4ce5-b227-d4b49cc4f122" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7b8c8dc3-c921-4ce5-b227-d4b49cc4f122" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9aadb313-fe58-4843-8b2f-eb55f12eff0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_597dac08-987d-4594-9384-ef7a81c5f910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_597dac08-987d-4594-9384-ef7a81c5f910" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c84626f7-7eb1-40c7-aa8e-009da3deee00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c84626f7-7eb1-40c7-aa8e-009da3deee00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c84626f7-7eb1-40c7-aa8e-009da3deee00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c84626f7-7eb1-40c7-aa8e-009da3deee00" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c84626f7-7eb1-40c7-aa8e-009da3deee00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c84626f7-7eb1-40c7-aa8e-009da3deee00" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4f871196-7756-4db0-8669-6ea812da4a04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4f871196-7756-4db0-8669-6ea812da4a04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bcb228cb-a4d0-4183-8dd4-d5b678ff07b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bcb228cb-a4d0-4183-8dd4-d5b678ff07b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_204154cb-4618-4f1b-8733-aa1dd118499b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_204154cb-4618-4f1b-8733-aa1dd118499b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8df2f6f-84b2-49bb-a949-9c610e11a96a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8df2f6f-84b2-49bb-a949-9c610e11a96a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8df2f6f-84b2-49bb-a949-9c610e11a96a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8df2f6f-84b2-49bb-a949-9c610e11a96a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8df2f6f-84b2-49bb-a949-9c610e11a96a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6c55d10-b3e4-468b-b316-2ef444faffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8df2f6f-84b2-49bb-a949-9c610e11a96a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6c55d10-b3e4-468b-b316-2ef444faffaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02913ef8-e219-47df-9538-d069e0910310" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6c55d10-b3e4-468b-b316-2ef444faffaf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02913ef8-e219-47df-9538-d069e0910310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ba43f46-6395-4dec-a978-f0f4d52d4699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ba43f46-6395-4dec-a978-f0f4d52d4699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0ba43f46-6395-4dec-a978-f0f4d52d4699_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ba43f46-6395-4dec-a978-f0f4d52d4699" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0ba43f46-6395-4dec-a978-f0f4d52d4699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_de104c0a-7aea-4620-96c4-df6850fd9d43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ba43f46-6395-4dec-a978-f0f4d52d4699" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_de104c0a-7aea-4620-96c4-df6850fd9d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_eebfc057-0336-4b08-aec3-a94ef9606c17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_de104c0a-7aea-4620-96c4-df6850fd9d43" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_eebfc057-0336-4b08-aec3-a94ef9606c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_dd8d3344-1e72-4e1b-9fda-55056f0a2050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_dd8d3344-1e72-4e1b-9fda-55056f0a2050" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_dd8d3344-1e72-4e1b-9fda-55056f0a2050_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_dd8d3344-1e72-4e1b-9fda-55056f0a2050" xlink:to="loc_us-gaap_ValuationTechniqueDomain_dd8d3344-1e72-4e1b-9fda-55056f0a2050_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_eac59e65-cdb6-4d83-8447-b1991467652e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_dd8d3344-1e72-4e1b-9fda-55056f0a2050" xlink:to="loc_us-gaap_ValuationTechniqueDomain_eac59e65-cdb6-4d83-8447-b1991467652e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ValuationTechniqueBlackScholesModelMember_6e2a5d38-c61e-43f1-9cf8-5b0edcb808b2" xlink:href="ebs-20250930.xsd#ebs_ValuationTechniqueBlackScholesModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_eac59e65-cdb6-4d83-8447-b1991467652e" xlink:to="loc_ebs_ValuationTechniqueBlackScholesModelMember_6e2a5d38-c61e-43f1-9cf8-5b0edcb808b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d2fd2784-ee41-43ec-b8a3-552e69b78720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d2fd2784-ee41-43ec-b8a3-552e69b78720" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d2fd2784-ee41-43ec-b8a3-552e69b78720_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d2fd2784-ee41-43ec-b8a3-552e69b78720" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d2fd2784-ee41-43ec-b8a3-552e69b78720_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_87d9e508-1976-44d6-bfc7-b13259949190" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d2fd2784-ee41-43ec-b8a3-552e69b78720" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_87d9e508-1976-44d6-bfc7-b13259949190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2024WarrantsMember_a9841c76-d280-4623-93a7-b4e3b25b3149" xlink:href="ebs-20250930.xsd#ebs_A2024WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_87d9e508-1976-44d6-bfc7-b13259949190" xlink:to="loc_ebs_A2024WarrantsMember_a9841c76-d280-4623-93a7-b4e3b25b3149" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_db1502d5-f209-402e-9fbe-1d35c501ae1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_597dac08-987d-4594-9384-ef7a81c5f910" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_db1502d5-f209-402e-9fbe-1d35c501ae1c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b7cd0ee8-224d-4688-ac79-0167766fff08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:to="loc_us-gaap_CreditFacilityAxis_b7cd0ee8-224d-4688-ac79-0167766fff08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b7cd0ee8-224d-4688-ac79-0167766fff08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b7cd0ee8-224d-4688-ac79-0167766fff08" xlink:to="loc_us-gaap_CreditFacilityDomain_b7cd0ee8-224d-4688-ac79-0167766fff08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d3e0bee4-cd6e-4a10-9a17-87f9e6c15989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b7cd0ee8-224d-4688-ac79-0167766fff08" xlink:to="loc_us-gaap_CreditFacilityDomain_d3e0bee4-cd6e-4a10-9a17-87f9e6c15989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3b76dc29-57cb-470a-84f9-cbd57a0a1100" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d3e0bee4-cd6e-4a10-9a17-87f9e6c15989" xlink:to="loc_us-gaap_SecuredDebtMember_3b76dc29-57cb-470a-84f9-cbd57a0a1100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_687735d7-14c6-48f2-abc3-ef603c65db7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_687735d7-14c6-48f2-abc3-ef603c65db7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_687735d7-14c6-48f2-abc3-ef603c65db7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_687735d7-14c6-48f2-abc3-ef603c65db7b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_687735d7-14c6-48f2-abc3-ef603c65db7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_687735d7-14c6-48f2-abc3-ef603c65db7b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_acb57980-e9b3-4d8e-ac2a-5a75a3634032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:to="loc_us-gaap_LineOfCreditMember_acb57980-e9b3-4d8e-ac2a-5a75a3634032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5ab5ba84-318f-487c-a0e1-6864db176f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:to="loc_us-gaap_SeniorNotesMember_5ab5ba84-318f-487c-a0e1-6864db176f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c5d1622c-9010-4149-a6a2-bfc232b9fccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:to="loc_us-gaap_DebtInstrumentAxis_c5d1622c-9010-4149-a6a2-bfc232b9fccc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5d1622c-9010-4149-a6a2-bfc232b9fccc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5d1622c-9010-4149-a6a2-bfc232b9fccc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5d1622c-9010-4149-a6a2-bfc232b9fccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5d1622c-9010-4149-a6a2-bfc232b9fccc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanDue2029Member_16a01119-6c59-42be-9de2-a3c150c5885e" xlink:href="ebs-20250930.xsd#ebs_TermLoanDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:to="loc_ebs_TermLoanDue2029Member_16a01119-6c59-42be-9de2-a3c150c5885e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_26e502b7-727e-4e13-b912-c36a04ff4252" xlink:href="ebs-20250930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_26e502b7-727e-4e13-b912-c36a04ff4252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b116f67f-b4ec-41f3-97a4-5aed4e26b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b116f67f-b4ec-41f3-97a4-5aed4e26b75d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5a48af8e-20e6-4bd7-9010-03688ac356c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_LongTermDebt_5a48af8e-20e6-4bd7-9010-03688ac356c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_52a8b044-54f0-4d37-b97c-86e62a48fa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_52a8b044-54f0-4d37-b97c-86e62a48fa9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9d630574-750f-48ff-86f8-5cbc6b239911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9d630574-750f-48ff-86f8-5cbc6b239911" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:to="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_20d04a67-5000-45bb-9e85-0823641ad771" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:to="loc_us-gaap_CreditFacilityAxis_20d04a67-5000-45bb-9e85-0823641ad771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_20d04a67-5000-45bb-9e85-0823641ad771_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_20d04a67-5000-45bb-9e85-0823641ad771" xlink:to="loc_us-gaap_CreditFacilityDomain_20d04a67-5000-45bb-9e85-0823641ad771_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_20d04a67-5000-45bb-9e85-0823641ad771" xlink:to="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_29d43ae6-5950-43ee-860f-40f6e106b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:to="loc_us-gaap_SecuredDebtMember_29d43ae6-5950-43ee-860f-40f6e106b50c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e9a51310-2b10-45a7-8de3-9587d2f56ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e9a51310-2b10-45a7-8de3-9587d2f56ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:to="loc_us-gaap_DebtInstrumentAxis_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanMember_08b7bb62-f143-4227-8400-052823dea4c1" xlink:href="ebs-20250930.xsd#ebs_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:to="loc_ebs_TermLoanMember_08b7bb62-f143-4227-8400-052823dea4c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolverLoanDue2025Member_402a9434-74da-448f-8b0f-b7ba7e4146ce" xlink:href="ebs-20250930.xsd#ebs_RevolverLoanDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:to="loc_ebs_RevolverLoanDue2025Member_402a9434-74da-448f-8b0f-b7ba7e4146ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9b3f7e5b-80a0-47f3-8968-9170b26092cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9b3f7e5b-80a0-47f3-8968-9170b26092cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9b3f7e5b-80a0-47f3-8968-9170b26092cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b3f7e5b-80a0-47f3-8968-9170b26092cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9b3f7e5b-80a0-47f3-8968-9170b26092cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_14c33685-3f07-4ebb-b58c-87831bf3765e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b3f7e5b-80a0-47f3-8968-9170b26092cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_14c33685-3f07-4ebb-b58c-87831bf3765e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_81a53c2b-b1b0-4c4f-a38a-ca337a8cc28f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_14c33685-3f07-4ebb-b58c-87831bf3765e" xlink:to="loc_us-gaap_LineOfCreditMember_81a53c2b-b1b0-4c4f-a38a-ca337a8cc28f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5fa0b75e-53f5-48b8-a9b2-fda8d19e0c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5fa0b75e-53f5-48b8-a9b2-fda8d19e0c4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_ab90b0f8-2c2d-4fb5-a02d-bc2bcdfcf5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_ab90b0f8-2c2d-4fb5-a02d-bc2bcdfcf5a1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtSeniorUnsecuredNotesdue2028Details"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_us-gaap_DebtInstrumentAxis_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_339822f2-a3d7-42eb-9055-547d28bce2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_339822f2-a3d7-42eb-9055-547d28bce2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_34a05afc-a9fc-4665-a0b2-520a85969885" xlink:href="ebs-20250930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_339822f2-a3d7-42eb-9055-547d28bce2e8" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_34a05afc-a9fc-4665-a0b2-520a85969885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f97939cb-ba48-4374-be41-4674c81bdf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f97939cb-ba48-4374-be41-4674c81bdf6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f97939cb-ba48-4374-be41-4674c81bdf6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f97939cb-ba48-4374-be41-4674c81bdf6d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f97939cb-ba48-4374-be41-4674c81bdf6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d954b5da-068f-47b6-b7e1-6e744619bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f97939cb-ba48-4374-be41-4674c81bdf6d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d954b5da-068f-47b6-b7e1-6e744619bd6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a108c71e-3e6e-4921-8465-3cb91f23b277" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d954b5da-068f-47b6-b7e1-6e744619bd6a" xlink:to="loc_us-gaap_SeniorNotesMember_a108c71e-3e6e-4921-8465-3cb91f23b277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0702407d-88ae-427a-bb3b-723d34b97971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0702407d-88ae-427a-bb3b-723d34b97971" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0702407d-88ae-427a-bb3b-723d34b97971_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0702407d-88ae-427a-bb3b-723d34b97971" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_0702407d-88ae-427a-bb3b-723d34b97971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0702407d-88ae-427a-bb3b-723d34b97971" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_11a2d17d-5ead-4d8b-9cba-69f9a0044a09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_11a2d17d-5ead-4d8b-9cba-69f9a0044a09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_bdf96142-06f1-4898-a624-dd50dc2ef2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_bdf96142-06f1-4898-a624-dd50dc2ef2d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6aa56beb-c21f-42d3-8d19-40e2f3d91b25" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_srt_RangeAxis_6aa56beb-c21f-42d3-8d19-40e2f3d91b25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6aa56beb-c21f-42d3-8d19-40e2f3d91b25_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6aa56beb-c21f-42d3-8d19-40e2f3d91b25" xlink:to="loc_srt_RangeMember_6aa56beb-c21f-42d3-8d19-40e2f3d91b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f2ee6d2-5bd5-4caf-b9be-792220122896" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6aa56beb-c21f-42d3-8d19-40e2f3d91b25" xlink:to="loc_srt_RangeMember_8f2ee6d2-5bd5-4caf-b9be-792220122896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee1386d2-8b88-45a0-b697-fc751ce7967d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8f2ee6d2-5bd5-4caf-b9be-792220122896" xlink:to="loc_srt_MaximumMember_ee1386d2-8b88-45a0-b697-fc751ce7967d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5da9c85c-22b4-48ec-8ace-221144806285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5da9c85c-22b4-48ec-8ace-221144806285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ecd238cc-f813-4fe6-976a-cca4f346e9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_LongTermDebt_ecd238cc-f813-4fe6-976a-cca4f346e9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d9704974-aa39-4e55-8f8c-1e0f9e66b48f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d9704974-aa39-4e55-8f8c-1e0f9e66b48f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_b8bd9b20-2145-4b85-8e64-c994824c2ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_b8bd9b20-2145-4b85-8e64-c994824c2ed5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_ceae4b1d-63d1-490d-a371-857cef3d5742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_ceae4b1d-63d1-490d-a371-857cef3d5742" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment_2131e31f-d6c6-4f6f-8805-891d78fea7f2" xlink:href="ebs-20250930.xsd#ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment_2131e31f-d6c6-4f6f-8805-891d78fea7f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2716d913-65f3-41b5-92bc-aa9997acd03b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2716d913-65f3-41b5-92bc-aa9997acd03b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentRepurchaseAmountRemaining_f32761b7-652d-4664-8ca7-fe1b1dfcb1fd" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentRepurchaseAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_ebs_DebtInstrumentRepurchaseAmountRemaining_f32761b7-652d-4664-8ca7-fe1b1dfcb1fd" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtTermLoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_97f0bf11-877d-437b-871d-95810d07d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_DebtInstrumentAxis_97f0bf11-877d-437b-871d-95810d07d8da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97f0bf11-877d-437b-871d-95810d07d8da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_97f0bf11-877d-437b-871d-95810d07d8da" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97f0bf11-877d-437b-871d-95810d07d8da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ed5c36d6-4e64-4562-8983-4e5375a313ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_97f0bf11-877d-437b-871d-95810d07d8da" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ed5c36d6-4e64-4562-8983-4e5375a313ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanMember_3c1fc88a-79f2-41c5-b74a-f7b6d1b7c3f6" xlink:href="ebs-20250930.xsd#ebs_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ed5c36d6-4e64-4562-8983-4e5375a313ca" xlink:to="loc_ebs_TermLoanMember_3c1fc88a-79f2-41c5-b74a-f7b6d1b7c3f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_989c1a18-8f34-4384-a48b-1d19b5edaf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_989c1a18-8f34-4384-a48b-1d19b5edaf3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_989c1a18-8f34-4384-a48b-1d19b5edaf3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_989c1a18-8f34-4384-a48b-1d19b5edaf3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_989c1a18-8f34-4384-a48b-1d19b5edaf3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_824f3e65-3d83-4f34-be0b-defa993431a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_989c1a18-8f34-4384-a48b-1d19b5edaf3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_824f3e65-3d83-4f34-be0b-defa993431a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_aeb1cd19-af15-4f81-b80e-8ef8f0463d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_824f3e65-3d83-4f34-be0b-defa993431a0" xlink:to="loc_us-gaap_LineOfCreditMember_aeb1cd19-af15-4f81-b80e-8ef8f0463d14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_614e58d7-080c-44b7-ae62-2b42c58c9f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_VariableRateAxis_614e58d7-080c-44b7-ae62-2b42c58c9f2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_614e58d7-080c-44b7-ae62-2b42c58c9f2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_614e58d7-080c-44b7-ae62-2b42c58c9f2c" xlink:to="loc_us-gaap_VariableRateDomain_614e58d7-080c-44b7-ae62-2b42c58c9f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_614e58d7-080c-44b7-ae62-2b42c58c9f2c" xlink:to="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_e9a7da9b-f012-4498-a8a5-68f2e947ef20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:to="loc_us-gaap_BaseRateMember_e9a7da9b-f012-4498-a8a5-68f2e947ef20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_9b35c53c-ba90-4369-b55e-9f3c8e3cdbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_9b35c53c-ba90-4369-b55e-9f3c8e3cdbf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_VariableRateComponentAxis_5bf7c065-0b3c-42da-b12e-b2efecd94863" xlink:href="ebs-20250930.xsd#ebs_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_ebs_VariableRateComponentAxis_5bf7c065-0b3c-42da-b12e-b2efecd94863" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_VariableRateComponentDomain_5bf7c065-0b3c-42da-b12e-b2efecd94863_default" xlink:href="ebs-20250930.xsd#ebs_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ebs_VariableRateComponentAxis_5bf7c065-0b3c-42da-b12e-b2efecd94863" xlink:to="loc_ebs_VariableRateComponentDomain_5bf7c065-0b3c-42da-b12e-b2efecd94863_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:href="ebs-20250930.xsd#ebs_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ebs_VariableRateComponentAxis_5bf7c065-0b3c-42da-b12e-b2efecd94863" xlink:to="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember_77e35932-5b20-4380-82a1-3434a82d8c9e" xlink:href="ebs-20250930.xsd#ebs_UntilTheSecondAnniversaryOfTheClosingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:to="loc_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember_77e35932-5b20-4380-82a1-3434a82d8c9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember_950c068f-51ed-4ea0-96ec-a74eb363b368" xlink:href="ebs-20250930.xsd#ebs_AfterTheSecondAnniversaryOfTheClosingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:to="loc_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember_950c068f-51ed-4ea0-96ec-a74eb363b368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1958989c-2a6d-420c-bb49-95fd65859b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_CreditFacilityAxis_1958989c-2a6d-420c-bb49-95fd65859b49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1958989c-2a6d-420c-bb49-95fd65859b49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1958989c-2a6d-420c-bb49-95fd65859b49" xlink:to="loc_us-gaap_CreditFacilityDomain_1958989c-2a6d-420c-bb49-95fd65859b49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e67b2267-d6d8-4953-873b-4477e545a670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1958989c-2a6d-420c-bb49-95fd65859b49" xlink:to="loc_us-gaap_CreditFacilityDomain_e67b2267-d6d8-4953-873b-4477e545a670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1363befd-a6df-4337-b95e-92353ef12a75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e67b2267-d6d8-4953-873b-4477e545a670" xlink:to="loc_us-gaap_SecuredDebtMember_1363befd-a6df-4337-b95e-92353ef12a75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_957e3af5-a2e8-4267-87e4-c057cdc7abb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_957e3af5-a2e8-4267-87e4-c057cdc7abb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentOriginalIssueDiscountPercentage_924fb92c-1c1d-4de5-b92d-448b1a44163c" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentOriginalIssueDiscountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentOriginalIssueDiscountPercentage_924fb92c-1c1d-4de5-b92d-448b1a44163c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentVariableInterestRateFloor_fa1ffd41-bd43-4b7d-ad5b-4b3e3c1e7a18" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentVariableInterestRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentVariableInterestRateFloor_fa1ffd41-bd43-4b7d-ad5b-4b3e3c1e7a18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44f94fb2-4599-4e3f-87fd-9e3bcc6afd88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44f94fb2-4599-4e3f-87fd-9e3bcc6afd88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentAdditionalDefaultInterestRate_fb9cb598-5b4a-4043-bc31-d3c2b73fa59a" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentAdditionalDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentAdditionalDefaultInterestRate_fb9cb598-5b4a-4043-bc31-d3c2b73fa59a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold_73ec6248-ee0c-4a4a-833c-de6b75c95852" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold_73ec6248-ee0c-4a4a-833c-de6b75c95852" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_6b41f1d4-d589-4db4-a898-f27c6aed9bc5" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLiquidityRequirementMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_6b41f1d4-d589-4db4-a898-f27c6aed9bc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_69851a92-3f83-4ea7-9baa-bb246f7d7e1e" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_69851a92-3f83-4ea7-9baa-bb246f7d7e1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium_6a981440-1f8c-499b-8034-83622010cc4b" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentBasisSpreadOnMakeWholePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium_6a981440-1f8c-499b-8034-83622010cc4b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentPrepaymentPremium_7eb06f7e-d6d1-4aa7-be2f-0aeee8dd7714" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentPrepaymentPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentPrepaymentPremium_7eb06f7e-d6d1-4aa7-be2f-0aeee8dd7714" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease_9e78ca75-a99d-420c-a9db-bf81506d089e" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease_9e78ca75-a99d-420c-a9db-bf81506d089e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred_eb675726-417e-4218-a51d-95e9518bcc0d" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred_eb675726-417e-4218-a51d-95e9518bcc0d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds_87843e2a-755b-4e9c-b590-300053d891d1" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds_87843e2a-755b-4e9c-b590-300053d891d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis_1fe5b482-5e65-4215-9f01-7a615b4d3b85" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis_1fe5b482-5e65-4215-9f01-7a615b4d3b85" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis_d1b60bd6-b838-4362-8ef2-271e1bde680b" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis_d1b60bd6-b838-4362-8ef2-271e1bde680b" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtRevolvingLoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_17b129eb-7744-4730-bf89-03465e867bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_CreditFacilityAxis_17b129eb-7744-4730-bf89-03465e867bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_17b129eb-7744-4730-bf89-03465e867bd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_17b129eb-7744-4730-bf89-03465e867bd2" xlink:to="loc_us-gaap_CreditFacilityDomain_17b129eb-7744-4730-bf89-03465e867bd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_17b129eb-7744-4730-bf89-03465e867bd2" xlink:to="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dc40d499-7b77-4f6a-acc7-aaeef0b8685c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_dc40d499-7b77-4f6a-acc7-aaeef0b8685c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_f4ddb7da-8305-4fe7-b026-6b9e69f0fd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:to="loc_us-gaap_BridgeLoanMember_f4ddb7da-8305-4fe7-b026-6b9e69f0fd4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9181c043-37d9-4f6f-9819-ce473602354e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:to="loc_us-gaap_LetterOfCreditMember_9181c043-37d9-4f6f-9819-ce473602354e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_DebtInstrumentAxis_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b400271-25c6-4bc1-9557-35a93ead0115" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b400271-25c6-4bc1-9557-35a93ead0115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b400271-25c6-4bc1-9557-35a93ead0115" xlink:to="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansUntilSeptember302025Member_c3e2067e-1495-424f-8a28-80c1ee1e244d" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansUntilSeptember302025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:to="loc_ebs_RevolvingLoansUntilSeptember302025Member_c3e2067e-1495-424f-8a28-80c1ee1e244d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansAfterSeptember302025Member_7b4e8e79-f7b1-45e2-ac75-86d8d6f341ff" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansAfterSeptember302025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:to="loc_ebs_RevolvingLoansAfterSeptember302025Member_7b4e8e79-f7b1-45e2-ac75-86d8d6f341ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa38d031-dbad-4331-b08b-5273e39804f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa38d031-dbad-4331-b08b-5273e39804f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa38d031-dbad-4331-b08b-5273e39804f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa38d031-dbad-4331-b08b-5273e39804f2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa38d031-dbad-4331-b08b-5273e39804f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e57eec54-78f1-4796-9685-cb00e1f40597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa38d031-dbad-4331-b08b-5273e39804f2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e57eec54-78f1-4796-9685-cb00e1f40597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0d51027e-dfa9-43f0-9909-5eae6fc39331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e57eec54-78f1-4796-9685-cb00e1f40597" xlink:to="loc_us-gaap_LineOfCreditMember_0d51027e-dfa9-43f0-9909-5eae6fc39331" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_11447f81-a68d-4c0d-9034-d955ec2f60c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_VariableRateAxis_11447f81-a68d-4c0d-9034-d955ec2f60c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_11447f81-a68d-4c0d-9034-d955ec2f60c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_11447f81-a68d-4c0d-9034-d955ec2f60c4" xlink:to="loc_us-gaap_VariableRateDomain_11447f81-a68d-4c0d-9034-d955ec2f60c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_11447f81-a68d-4c0d-9034-d955ec2f60c4" xlink:to="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_5d83a285-77bf-42b3-a2db-0ef8f5d62bef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:to="loc_us-gaap_BaseRateMember_5d83a285-77bf-42b3-a2db-0ef8f5d62bef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_1d3370cf-d540-494a-bc44-959be8b18787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_1d3370cf-d540-494a-bc44-959be8b18787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f34036d-5794-4bc8-b695-373f698bde3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f34036d-5794-4bc8-b695-373f698bde3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit_79f95b6e-c18a-47da-9cbb-ccc9be477cd3" xlink:href="ebs-20250930.xsd#ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit_79f95b6e-c18a-47da-9cbb-ccc9be477cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit_1a8ac644-a399-41e7-a9b3-610e14b2b419" xlink:href="ebs-20250930.xsd#ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit_1a8ac644-a399-41e7-a9b3-610e14b2b419" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2859cf58-7b03-418e-9604-ffb1d1638852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2859cf58-7b03-418e-9604-ffb1d1638852" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentVariableInterestRateFloor_d958f239-ccd1-4b20-b228-8c06bda10b13" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentVariableInterestRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentVariableInterestRateFloor_d958f239-ccd1-4b20-b228-8c06bda10b13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum_c3d97819-2507-46aa-8d7e-9fd85680aa2d" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum_c3d97819-2507-46aa-8d7e-9fd85680aa2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24976843-1c2f-45ef-a767-fe5d14d0a08d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24976843-1c2f-45ef-a767-fe5d14d0a08d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate_ccb64803-d5aa-477d-b4ee-2b799aca8311" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate_ccb64803-d5aa-477d-b4ee-2b799aca8311" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_51217719-42cf-4920-b47b-5314519d5a0e" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLiquidityRequirementMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_51217719-42cf-4920-b47b-5314519d5a0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_0ae42186-43c6-460a-9022-229daa5d022c" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_0ae42186-43c6-460a-9022-229daa5d022c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum_66080214-ca32-4ef4-9658-e5dfdbf15952" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum_66080214-ca32-4ef4-9658-e5dfdbf15952" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SharebasedcompensationandstockholdersequityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f61469e9-e22e-4afc-b43c-2b635c0f90b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_us-gaap_AwardTypeAxis_f61469e9-e22e-4afc-b43c-2b635c0f90b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61469e9-e22e-4afc-b43c-2b635c0f90b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f61469e9-e22e-4afc-b43c-2b635c0f90b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61469e9-e22e-4afc-b43c-2b635c0f90b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f61469e9-e22e-4afc-b43c-2b635c0f90b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c3a0bcc-892f-4c52-9f4d-09817b2f9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c3a0bcc-892f-4c52-9f4d-09817b2f9b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_41c970d0-7aaf-4925-90f5-3c79d1faf91b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_41c970d0-7aaf-4925-90f5-3c79d1faf91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6ffeb893-3b42-4ee2-8c6e-7058b68caec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_us-gaap_PerformanceSharesMember_6ffeb893-3b42-4ee2-8c6e-7058b68caec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LongTermIncentiveAwardMember_fdc6b143-fa74-4f48-b33e-e2afc49fbcd4" xlink:href="ebs-20250930.xsd#ebs_LongTermIncentiveAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_ebs_LongTermIncentiveAwardMember_fdc6b143-fa74-4f48-b33e-e2afc49fbcd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceStockOptionMember_0154b147-6bc7-435a-a9a7-dbc91f8f061e" xlink:href="ebs-20250930.xsd#ebs_PerformanceStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_ebs_PerformanceStockOptionMember_0154b147-6bc7-435a-a9a7-dbc91f8f061e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherEquityAwardsMember_c0b1c19b-83e1-425c-8bc7-824de7a621f8" xlink:href="ebs-20250930.xsd#ebs_OtherEquityAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_ebs_OtherEquityAwardsMember_c0b1c19b-83e1-425c-8bc7-824de7a621f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e66535ea-c807-4027-826e-8f3d781e79fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e66535ea-c807-4027-826e-8f3d781e79fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SubscriptionAgreementMember_0792b38d-3a28-46f4-a2b9-a3f48db11ad5" xlink:href="ebs-20250930.xsd#ebs_SubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e66535ea-c807-4027-826e-8f3d781e79fb" xlink:to="loc_ebs_SubscriptionAgreementMember_0792b38d-3a28-46f4-a2b9-a3f48db11ad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_76fc3f65-aa02-4903-9123-bb19fa3f8ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_76fc3f65-aa02-4903-9123-bb19fa3f8ffd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_76fc3f65-aa02-4903-9123-bb19fa3f8ffd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_76fc3f65-aa02-4903-9123-bb19fa3f8ffd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_76fc3f65-aa02-4903-9123-bb19fa3f8ffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_76fc3f65-aa02-4903-9123-bb19fa3f8ffd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIWarrantsMember_39b29cc1-e63a-4394-ab7c-dae9707cc53b" xlink:href="ebs-20250930.xsd#ebs_SeriesIWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:to="loc_ebs_SeriesIWarrantsMember_39b29cc1-e63a-4394-ab7c-dae9707cc53b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIIWarrantsMember_aa6ccf79-7c25-4711-a8b0-01b5497bea72" xlink:href="ebs-20250930.xsd#ebs_SeriesIIWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:to="loc_ebs_SeriesIIWarrantsMember_aa6ccf79-7c25-4711-a8b0-01b5497bea72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_36742735-bd42-44c9-bfb3-7f9f72005d06" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_srt_ShareRepurchaseProgramAxis_36742735-bd42-44c9-bfb3-7f9f72005d06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_36742735-bd42-44c9-bfb3-7f9f72005d06_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_36742735-bd42-44c9-bfb3-7f9f72005d06" xlink:to="loc_srt_ShareRepurchaseProgramDomain_36742735-bd42-44c9-bfb3-7f9f72005d06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_531becf6-dbc1-4f07-92bb-f9fc488adb09" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_36742735-bd42-44c9-bfb3-7f9f72005d06" xlink:to="loc_srt_ShareRepurchaseProgramDomain_531becf6-dbc1-4f07-92bb-f9fc488adb09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2025ShareRepurchaseProgramMember_7b8f90e2-a9a8-468a-9968-ca6f8e51bf67" xlink:href="ebs-20250930.xsd#ebs_A2025ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_531becf6-dbc1-4f07-92bb-f9fc488adb09" xlink:to="loc_ebs_A2025ShareRepurchaseProgramMember_7b8f90e2-a9a8-468a-9968-ca6f8e51bf67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_26c2fdaa-be11-4820-a911-868c24ab5246" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_26c2fdaa-be11-4820-a911-868c24ab5246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7a89a4-6e82-4c4a-b6b9-45e1ab4c3ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7a89a4-6e82-4c4a-b6b9-45e1ab4c3ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_f605e5a7-92a3-4be7-b829-243bf7189183" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_f605e5a7-92a3-4be7-b829-243bf7189183" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_338a8783-57f1-482f-84b7-f6918c4cba5c" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_338a8783-57f1-482f-84b7-f6918c4cba5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d24dad60-cdb7-4952-b1db-32c8fdfe5669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d24dad60-cdb7-4952-b1db-32c8fdfe5669" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements_b72c2b2e-e84c-44d6-9798-83e071275783" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements_b72c2b2e-e84c-44d6-9798-83e071275783" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1bf8bea4-75cc-4945-b459-658f31f6652e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1bf8bea4-75cc-4945-b459-658f31f6652e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ff781081-41f6-47e3-bba4-14ebf60c1513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ff781081-41f6-47e3-bba4-14ebf60c1513" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8394d74b-09e9-4a26-94f3-d7a578dd1899" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8394d74b-09e9-4a26-94f3-d7a578dd1899" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_59accb49-ab49-4302-9cd3-1cba45acc8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_59accb49-ab49-4302-9cd3-1cba45acc8ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4c0676a0-0541-49ff-9d97-2a71ff1625de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4c0676a0-0541-49ff-9d97-2a71ff1625de" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5f424602-3956-49b4-9a05-697367b2527e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5f424602-3956-49b4-9a05-697367b2527e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fc5bd610-ad39-40f8-a1c6-2355ab7a56ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fc5bd610-ad39-40f8-a1c6-2355ab7a56ac" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_df4744a4-7062-4c2d-b8d2-1a84441a442e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_df4744a4-7062-4c2d-b8d2-1a84441a442e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_38617014-fc70-4ce0-a4a1-7292e6866ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_38617014-fc70-4ce0-a4a1-7292e6866ff6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bfd7b693-35da-4a3a-8a6e-82f689253c72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bfd7b693-35da-4a3a-8a6e-82f689253c72" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5832033d-2169-480b-a26f-a6d556e658f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5832033d-2169-480b-a26f-a6d556e658f6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_f14697ee-56b9-4a70-b8c3-6012977436d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_f14697ee-56b9-4a70-b8c3-6012977436d1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_36148495-0c51-4704-bd2f-ecc2a912af14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_36148495-0c51-4704-bd2f-ecc2a912af14" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure_ac92b7fb-18d2-4013-ad90-262fb778691c" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_WarrantLiabilitiesFairValueDisclosure_ac92b7fb-18d2-4013-ad90-262fb778691c" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5fe6d25d-7466-429d-932f-519796278b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f649cea5-8e22-489c-afdc-d26554e95a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5fe6d25d-7466-429d-932f-519796278b3b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f649cea5-8e22-489c-afdc-d26554e95a1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf995217-7cf7-4c41-860f-2bfd28376329" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f649cea5-8e22-489c-afdc-d26554e95a1a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf995217-7cf7-4c41-860f-2bfd28376329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bf995217-7cf7-4c41-860f-2bfd28376329_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf995217-7cf7-4c41-860f-2bfd28376329" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bf995217-7cf7-4c41-860f-2bfd28376329_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf995217-7cf7-4c41-860f-2bfd28376329" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d0659585-9d72-4b70-a716-84f1c6ac715a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:to="loc_us-gaap_CostOfSalesMember_d0659585-9d72-4b70-a716-84f1c6ac715a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902c1884-d61f-4473-b4a1-03e568c72236" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902c1884-d61f-4473-b4a1-03e568c72236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e0353a2c-2987-47f1-9836-b8c6a35bc703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e0353a2c-2987-47f1-9836-b8c6a35bc703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e3e82ca-4b01-40d7-a372-76e61b5b1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5fe6d25d-7466-429d-932f-519796278b3b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e3e82ca-4b01-40d7-a372-76e61b5b1c2c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6d1e5c02-d951-4eb3-acc3-b766871e6aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6d1e5c02-d951-4eb3-acc3-b766871e6aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6d1e5c02-d951-4eb3-acc3-b766871e6aaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d1e5c02-d951-4eb3-acc3-b766871e6aaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6d1e5c02-d951-4eb3-acc3-b766871e6aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a4367bb0-4e5b-4fe4-98ae-7eab624726f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d1e5c02-d951-4eb3-acc3-b766871e6aaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a4367bb0-4e5b-4fe4-98ae-7eab624726f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2024WarrantsMember_7a2a04e0-865b-42a5-9f67-93ccd64595d5" xlink:href="ebs-20250930.xsd#ebs_A2024WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4367bb0-4e5b-4fe4-98ae-7eab624726f3" xlink:to="loc_ebs_A2024WarrantsMember_7a2a04e0-865b-42a5-9f67-93ccd64595d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ba56896-1866-45fa-ba9d-47784b0ab882" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:to="loc_srt_RangeAxis_2ba56896-1866-45fa-ba9d-47784b0ab882" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ba56896-1866-45fa-ba9d-47784b0ab882_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2ba56896-1866-45fa-ba9d-47784b0ab882" xlink:to="loc_srt_RangeMember_2ba56896-1866-45fa-ba9d-47784b0ab882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2ba56896-1866-45fa-ba9d-47784b0ab882" xlink:to="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8271a880-970d-49fc-b2fa-3901ab3baf1e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:to="loc_srt_MinimumMember_8271a880-970d-49fc-b2fa-3901ab3baf1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2176dab6-3616-43a5-b3a4-148e8a08aa1a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:to="loc_srt_MaximumMember_2176dab6-3616-43a5-b3a4-148e8a08aa1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ff922bbc-4a16-4e07-9c0c-5060cf3c1c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ff922bbc-4a16-4e07-9c0c-5060cf3c1c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bbc932a-ef98-4de1-919a-7872e8c1473e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bbc932a-ef98-4de1-919a-7872e8c1473e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_226063c3-43ee-4292-a8d8-2bc103c3041e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_226063c3-43ee-4292-a8d8-2bc103c3041e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fe2d20c7-d1ab-422f-af88-049bfe05659c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:to="loc_srt_MajorCustomersAxis_fe2d20c7-d1ab-422f-af88-049bfe05659c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fe2d20c7-d1ab-422f-af88-049bfe05659c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fe2d20c7-d1ab-422f-af88-049bfe05659c" xlink:to="loc_srt_NameOfMajorCustomerDomain_fe2d20c7-d1ab-422f-af88-049bfe05659c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fe2d20c7-d1ab-422f-af88-049bfe05659c" xlink:to="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_4e8ba6bf-fca4-41a5-ba80-3c45f67e19fc" xlink:href="ebs-20250930.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:to="loc_ebs_UnitedStatesGovernmentMember_4e8ba6bf-fca4-41a5-ba80-3c45f67e19fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember_d8eedb68-1886-4227-ae9c-151e1e16102f" xlink:href="ebs-20250930.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:to="loc_ebs_NonUnitedStatesGovernmentMember_d8eedb68-1886-4227-ae9c-151e1e16102f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JanssenPharmaceuticalsInc.Member_f8c26ef8-6117-4508-9bce-b1c822a3429b" xlink:href="ebs-20250930.xsd#ebs_JanssenPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:to="loc_ebs_JanssenPharmaceuticalsInc.Member_f8c26ef8-6117-4508-9bce-b1c822a3429b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e570713-ae4d-4937-bd48-9e647297202e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:to="loc_srt_ProductOrServiceAxis_8e570713-ae4d-4937-bd48-9e647297202e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e570713-ae4d-4937-bd48-9e647297202e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8e570713-ae4d-4937-bd48-9e647297202e" xlink:to="loc_srt_ProductsAndServicesDomain_8e570713-ae4d-4937-bd48-9e647297202e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8e570713-ae4d-4937-bd48-9e647297202e" xlink:to="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_999e2364-7ba4-4468-867d-21667020f0b4" xlink:href="ebs-20250930.xsd#ebs_CommercialProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_ebs_CommercialProductMember_999e2364-7ba4-4468-867d-21667020f0b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_e6224207-800c-4d1a-9d8d-bed8b841d4bb" xlink:href="ebs-20250930.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_e6224207-800c-4d1a-9d8d-bed8b841d4bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AllOtherRevenueMember_def79e8b-9c13-45fc-ba73-6a999efeff92" xlink:href="ebs-20250930.xsd#ebs_AllOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_ebs_AllOtherRevenueMember_def79e8b-9c13-45fc-ba73-6a999efeff92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d0c60499-8a47-4273-9d94-1d3569244ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_us-gaap_ServiceMember_d0c60499-8a47-4273-9d94-1d3569244ccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80f8b9b7-f35e-4f04-8a98-44683c7fe928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_226063c3-43ee-4292-a8d8-2bc103c3041e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80f8b9b7-f35e-4f04-8a98-44683c7fe928" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b843d7ad-3d76-4032-9139-f89af0fb424a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b843d7ad-3d76-4032-9139-f89af0fb424a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_bdf1a402-844a-4916-8e79-4974145def6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_bdf1a402-844a-4916-8e79-4974145def6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c6dedf2-3b27-445b-af6f-14e9d7bd00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c6dedf2-3b27-445b-af6f-14e9d7bd00dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_9c7c2dac-aae5-4264-8f6c-41d87b8dc600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_9c7c2dac-aae5-4264-8f6c-41d87b8dc600" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f6c36f4b-eadd-4522-b02b-01910d576f50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f6c36f4b-eadd-4522-b02b-01910d576f50" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_bdf1a402-844a-4916-8e79-4974145def6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_bdf1a402-844a-4916-8e79-4974145def6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c6dedf2-3b27-445b-af6f-14e9d7bd00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c6dedf2-3b27-445b-af6f-14e9d7bd00dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_9c7c2dac-aae5-4264-8f6c-41d87b8dc600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_9c7c2dac-aae5-4264-8f6c-41d87b8dc600" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f6c36f4b-eadd-4522-b02b-01910d576f50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f6c36f4b-eadd-4522-b02b-01910d576f50" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#IncometaxesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_764df020-9c06-4bd7-b616-dc3a429fb261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_33043542-73f6-47b2-a23a-ca40c7a65133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_764df020-9c06-4bd7-b616-dc3a429fb261" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_33043542-73f6-47b2-a23a-ca40c7a65133" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f99b5ca9-1929-4260-b84d-0d156baec108" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_33043542-73f6-47b2-a23a-ca40c7a65133" xlink:to="loc_srt_StatementScenarioAxis_f99b5ca9-1929-4260-b84d-0d156baec108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f99b5ca9-1929-4260-b84d-0d156baec108_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f99b5ca9-1929-4260-b84d-0d156baec108" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f99b5ca9-1929-4260-b84d-0d156baec108_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_56c4f26e-fb19-4f96-a2ee-aca1b1637832" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f99b5ca9-1929-4260-b84d-0d156baec108" xlink:to="loc_srt_ScenarioUnspecifiedDomain_56c4f26e-fb19-4f96-a2ee-aca1b1637832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b762411d-3b51-402a-bdfd-5a494ebeb4bd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_56c4f26e-fb19-4f96-a2ee-aca1b1637832" xlink:to="loc_srt_ScenarioForecastMember_b762411d-3b51-402a-bdfd-5a494ebeb4bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e34ba23f-3f81-4990-9443-f5d2756b6f72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_764df020-9c06-4bd7-b616-dc3a429fb261" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e34ba23f-3f81-4990-9443-f5d2756b6f72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LitigationDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:href="ebs-20250930.xsd#ebs_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:href="ebs-20250930.xsd#ebs_CommitmentContingenciesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_16738e29-6b53-431d-a7e1-540aa7c6e5cf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:to="loc_srt_LitigationCaseAxis_16738e29-6b53-431d-a7e1-540aa7c6e5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_16738e29-6b53-431d-a7e1-540aa7c6e5cf_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_16738e29-6b53-431d-a7e1-540aa7c6e5cf" xlink:to="loc_srt_LitigationCaseTypeDomain_16738e29-6b53-431d-a7e1-540aa7c6e5cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_16738e29-6b53-431d-a7e1-540aa7c6e5cf" xlink:to="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SecuritiesAndShareholderLitigationMember_3b950c93-15fe-42e7-8403-9918bd55a9e3" xlink:href="ebs-20250930.xsd#ebs_SecuritiesAndShareholderLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:to="loc_ebs_SecuritiesAndShareholderLitigationMember_3b950c93-15fe-42e7-8403-9918bd55a9e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SECEnforcementProceedingMember_12822e76-cc7f-49a1-a857-0cc8b09f4df7" xlink:href="ebs-20250930.xsd#ebs_SECEnforcementProceedingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:to="loc_ebs_SECEnforcementProceedingMember_12822e76-cc7f-49a1-a857-0cc8b09f4df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_05da6ea6-4981-4b22-b0ca-3277f0ccc8da" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:to="loc_srt_MajorCustomersAxis_05da6ea6-4981-4b22-b0ca-3277f0ccc8da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_05da6ea6-4981-4b22-b0ca-3277f0ccc8da_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_05da6ea6-4981-4b22-b0ca-3277f0ccc8da" xlink:to="loc_srt_NameOfMajorCustomerDomain_05da6ea6-4981-4b22-b0ca-3277f0ccc8da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbddad53-5550-40c0-979f-72c425b9ace9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_05da6ea6-4981-4b22-b0ca-3277f0ccc8da" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbddad53-5550-40c0-979f-72c425b9ace9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_c6ecedce-57c7-46a9-bf68-43959321e9d7" xlink:href="ebs-20250930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbddad53-5550-40c0-979f-72c425b9ace9" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_c6ecedce-57c7-46a9-bf68-43959321e9d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:to="loc_srt_ProductOrServiceAxis_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf" xlink:to="loc_srt_ProductsAndServicesDomain_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ae5940d-0b37-498d-9727-bb89195a84ba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf" xlink:to="loc_srt_ProductsAndServicesDomain_7ae5940d-0b37-498d-9727-bb89195a84ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductAndServiceMember_34360e38-fd18-42da-8da1-a729ad19fb08" xlink:href="ebs-20250930.xsd#ebs_ProductAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ae5940d-0b37-498d-9727-bb89195a84ba" xlink:to="loc_ebs_ProductAndServiceMember_34360e38-fd18-42da-8da1-a729ad19fb08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_a2dd4d76-f2c2-4df0-9bc9-d1a422b50989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_a2dd4d76-f2c2-4df0-9bc9-d1a422b50989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds_5d538673-4856-49e6-9b17-bd2eeedf78b6" xlink:href="ebs-20250930.xsd#ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds_5d538673-4856-49e6-9b17-bd2eeedf78b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencySettlementPeriod_ef96aab3-5fe3-4f2b-8c78-d73acf66d752" xlink:href="ebs-20250930.xsd#ebs_LossContingencySettlementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencySettlementPeriod_ef96aab3-5fe3-4f2b-8c78-d73acf66d752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_bd143667-0b83-4ca1-9fc5-b3eb278fb931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_bd143667-0b83-4ca1-9fc5-b3eb278fb931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms_eef17975-fa35-4e1a-af03-dc7824b6bbd7" xlink:href="ebs-20250930.xsd#ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms_eef17975-fa35-4e1a-af03-dc7824b6bbd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained_77294675-3ec3-4fc4-9372-35a0b4bd5fd6" xlink:href="ebs-20250930.xsd#ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained_77294675-3ec3-4fc4-9372-35a0b4bd5fd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_d83e96bb-8cb1-4bd3-a942-4803a0bb3326" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LitigationSettlementGain_d83e96bb-8cb1-4bd3-a942-4803a0bb3326" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_81c98dad-9189-48ff-8fd1-c1a2319194ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_81c98dad-9189-48ff-8fd1-c1a2319194ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_5b01cd9a-abf5-4543-8f48-8f0100160df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_5b01cd9a-abf5-4543-8f48-8f0100160df9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_7edfc9a7-4bf1-4306-a70d-8630bef51c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_7edfc9a7-4bf1-4306-a70d-8630bef51c16" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_a9097c84-e907-4a5a-bc5d-23f2878e0ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_a9097c84-e907-4a5a-bc5d-23f2878e0ed0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_94b8ac58-81cd-40ad-a96c-8e62af467407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_94b8ac58-81cd-40ad-a96c-8e62af467407" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b67373ad-be66-4b2c-b1dc-125a60733e60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b67373ad-be66-4b2c-b1dc-125a60733e60" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9bc8e73a-28ac-47cd-8345-2505096e61b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9bc8e73a-28ac-47cd-8345-2505096e61b3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5dc3efcd-a123-4080-afb2-c6dce007ba15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5dc3efcd-a123-4080-afb2-c6dce007ba15" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f6c8afde-c7e9-4c0b-8261-a130bd2516d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_InventoryWriteDown_f6c8afde-c7e9-4c0b-8261-a130bd2516d6" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_26e796bd-312a-4841-94d2-61d6b0cd7e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_26e796bd-312a-4841-94d2-61d6b0cd7e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_26e796bd-312a-4841-94d2-61d6b0cd7e9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_26e796bd-312a-4841-94d2-61d6b0cd7e9c" xlink:to="loc_us-gaap_SegmentDomain_26e796bd-312a-4841-94d2-61d6b0cd7e9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_26e796bd-312a-4841-94d2-61d6b0cd7e9c" xlink:to="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_7f403495-c6cf-46fe-9321-552e1ed924f8" xlink:href="ebs-20250930.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:to="loc_ebs_CommercialProductsSegmentMember_7f403495-c6cf-46fe-9321-552e1ed924f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_2356f5f2-7ae2-4d01-8973-0b5e9e459d55" xlink:href="ebs-20250930.xsd#ebs_MCMProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:to="loc_ebs_MCMProductsSegmentMember_2356f5f2-7ae2-4d01-8973-0b5e9e459d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7143c3b3-2bea-479b-9e42-efc2e8338fb6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:to="loc_srt_ConsolidationItemsAxis_7143c3b3-2bea-479b-9e42-efc2e8338fb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7143c3b3-2bea-479b-9e42-efc2e8338fb6_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_7143c3b3-2bea-479b-9e42-efc2e8338fb6" xlink:to="loc_srt_ConsolidationItemsDomain_7143c3b3-2bea-479b-9e42-efc2e8338fb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_7143c3b3-2bea-479b-9e42-efc2e8338fb6" xlink:to="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_962b9eb1-6087-4e31-95af-9afc97ec4255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:to="loc_us-gaap_OperatingSegmentsMember_962b9eb1-6087-4e31-95af-9afc97ec4255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_8547201f-7ba6-4df4-98a0-4f02ce61c87b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_8547201f-7ba6-4df4-98a0-4f02ce61c87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7e32ded8-ed48-4069-be6a-d0786472e556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_us-gaap_RevenuesAbstract_7e32ded8-ed48-4069-be6a-d0786472e556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03edde22-0da3-4aa8-8f91-91a8da501ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7e32ded8-ed48-4069-be6a-d0786472e556" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03edde22-0da3-4aa8-8f91-91a8da501ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_659e9876-454f-4265-ba15-cb1f78da1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_659e9876-454f-4265-ba15-cb1f78da1ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4dd2e32b-33e7-4dea-b7f5-d0a8ecaafa08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_659e9876-454f-4265-ba15-cb1f78da1ee4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4dd2e32b-33e7-4dea-b7f5-d0a8ecaafa08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_b893ca21-de15-4b36-9fe3-590896e58556" xlink:href="ebs-20250930.xsd#ebs_AdjustedGrossMargin"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_ebs_AdjustedGrossMargin_b893ca21-de15-4b36-9fe3-590896e58556" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_0d195765-5ddd-4a87-a376-c17a14d505d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_0d195765-5ddd-4a87-a376-c17a14d505d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_40f4bb2a-a598-48f4-82ee-a850da9dd3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_40f4bb2a-a598-48f4-82ee-a850da9dd3bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringChargesAdjusted_bde87c27-dabf-4415-a95d-72d3430ffe4e" xlink:href="ebs-20250930.xsd#ebs_RestructuringChargesAdjusted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_ebs_RestructuringChargesAdjusted_bde87c27-dabf-4415-a95d-72d3430ffe4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_InventoryStepUp_8fa8aa60-3f1d-4836-a0e4-5e4ee336496e" xlink:href="ebs-20250930.xsd#ebs_InventoryStepUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_ebs_InventoryStepUp_8fa8aa60-3f1d-4836-a0e4-5e4ee336496e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_60486186-998f-4b95-874d-a55b2859a5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_60486186-998f-4b95-874d-a55b2859a5d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_21d066b6-c4eb-4932-8b52-b3f424032a93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_21d066b6-c4eb-4932-8b52-b3f424032a93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7cfc3b2d-c907-45cd-9ac2-20ae6c341683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7cfc3b2d-c907-45cd-9ac2-20ae6c341683" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f1ce1384-f511-4881-a6cc-403750cd52a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f1ce1384-f511-4881-a6cc-403750cd52a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_826aed77-5bc1-45df-b00f-4877c33c0e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_InterestExpenseNonoperating_826aed77-5bc1-45df-b00f-4877c33c0e9e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_548dd5ed-1b26-45d5-a06b-d35a5aa97e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_548dd5ed-1b26-45d5-a06b-d35a5aa97e2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f25e99ec-5de6-452e-be76-d7e35820144b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f25e99ec-5de6-452e-be76-d7e35820144b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ec85c6e-be25-4256-8dbe-a8f3d9e7b685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ec85c6e-be25-4256-8dbe-a8f3d9e7b685" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d78b0943-ff9b-415c-8ed7-e89a148ca5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_RestructuringCharges_d78b0943-ff9b-415c-8ed7-e89a148ca5bf" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_93c43266-daf8-41b7-8543-37b57271a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_93c43266-daf8-41b7-8543-37b57271a91e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7" xlink:to="loc_us-gaap_SegmentDomain_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7" xlink:to="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_74eaa8d8-b459-42d2-8cc0-e8f64d40e137" xlink:href="ebs-20250930.xsd#ebs_MCMProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:to="loc_ebs_MCMProductsSegmentMember_74eaa8d8-b459-42d2-8cc0-e8f64d40e137" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_94483a04-8629-4933-9f5e-5caa9dbcef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:to="loc_us-gaap_AllOtherSegmentsMember_94483a04-8629-4933-9f5e-5caa9dbcef3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_65b345fc-cf79-4875-8362-2881fd5d5368" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:to="loc_srt_ConsolidationItemsAxis_65b345fc-cf79-4875-8362-2881fd5d5368" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_65b345fc-cf79-4875-8362-2881fd5d5368_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_65b345fc-cf79-4875-8362-2881fd5d5368" xlink:to="loc_srt_ConsolidationItemsDomain_65b345fc-cf79-4875-8362-2881fd5d5368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_65b345fc-cf79-4875-8362-2881fd5d5368" xlink:to="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_440d7374-4655-4ec5-bfbe-432ed7376f42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:to="loc_us-gaap_OperatingSegmentsMember_440d7374-4655-4ec5-bfbe-432ed7376f42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_6601e3e7-e163-48b3-8042-9bbb7063c3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_6601e3e7-e163-48b3-8042-9bbb7063c3b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_fc4dd9d1-a388-4741-bfc3-cef9cbc24e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_93c43266-daf8-41b7-8543-37b57271a91e" xlink:to="loc_us-gaap_DepreciationAbstract_fc4dd9d1-a388-4741-bfc3-cef9cbc24e9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4132c634-8115-436f-9128-51c5d4709f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DepreciationAbstract_fc4dd9d1-a388-4741-bfc3-cef9cbc24e9e" xlink:to="loc_us-gaap_Depreciation_4132c634-8115-436f-9128-51c5d4709f7d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="101"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DonaldDeGolyerMember_7aa1027e-4994-43f3-a365-ad878ed69952" xlink:href="ebs-20250930.xsd#ebs_DonaldDeGolyerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ebs_DonaldDeGolyerMember_7aa1027e-4994-43f3-a365-ad878ed69952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SujataTyagiDayalMember_e8104652-030b-4e23-aa2c-8488f0d03526" xlink:href="ebs-20250930.xsd#ebs_SujataTyagiDayalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ebs_SujataTyagiDayalMember_e8104652-030b-4e23-aa2c-8488f0d03526" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ebs-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0b2479a1-7a21-4fa0-a33e-3a3a5f4f1cad,g:c7797084-9f00-4c6d-b9c9-e4498d399b6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_c11641ef-b6b9-4369-9991-278414c288ab_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_aaedf285-c912-46ba-becb-016ecd36f9a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash purchase price</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1a609952-c288-4556-a7ec-b334f6f178a6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3f2b1e10-5120-4e86-9542-248fc19675e6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_45642fef-f6dc-4a83-97b6-b438eaaed235_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a07fb426-503b-4d6c-a68d-aee4f8ad8cdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts_31fd4b19-a12e-40f5-a3f7-a9b9b437db24_negatedLabel_en-US" xlink:label="lab_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on sale of business and assets held for sale</link:label>
    <link:label id="lab_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts_label_en-US" xlink:label="lab_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Disposition of Business, Including Transaction Costs</link:label>
    <link:label id="lab_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts_documentation_en-US" xlink:label="lab_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Disposition of Business, Including Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts" xlink:href="ebs-20250930.xsd#ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts" xlink:to="lab_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_A2024WarrantsMember_a2fe624f-ddca-4959-9e72-c183514f5d46_terseLabel_en-US" xlink:label="lab_ebs_A2024WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Warrants</link:label>
    <link:label id="lab_ebs_A2024WarrantsMember_ccc4ee96-d81b-4140-81b9-e2cadb93cdd6_verboseLabel_en-US" xlink:label="lab_ebs_A2024WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued related to the Term Loan Agreement</link:label>
    <link:label id="lab_ebs_A2024WarrantsMember_label_en-US" xlink:label="lab_ebs_A2024WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Warrants [Member]</link:label>
    <link:label id="lab_ebs_A2024WarrantsMember_documentation_en-US" xlink:label="lab_ebs_A2024WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2024WarrantsMember" xlink:href="ebs-20250930.xsd#ebs_A2024WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_A2024WarrantsMember" xlink:to="lab_ebs_A2024WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_3961e7ad-3dce-4e2d-b6ed-83aa917e95bd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_602c9555-9355-43b3-9dde-f54db0fba37b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_18717653-318a-4b99-83af-997efc3d1f54_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_04ec5cc8-6c38-4629-b672-a6f1fedaad15_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_333da572-a05c-4abd-adfd-b4458b5563b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_b0157f90-ddde-4e8e-9332-f8810148d401_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_c9e1b980-110c-4c82-bb04-6a15f1d6218e_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_8f1e1647-3b48-4577-b013-8c9f655d1bdd_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ca1f6e13-dea5-4341-823a-7d11909cb00d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_415cd934-c872-4cc9-a58f-4ec63df413ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_36bef00a-7624-40d8-b4dc-cc5f34831fa6_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ed6fcd9f-8cbd-41da-a5df-b661f616af38_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_67375c25-d211-4ed1-aec0-8f9372e81df4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f8180040-19f8-4769-b825-814c80bc5aaf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bb0f6627-a3bf-4c77-8241-257330c8c459_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_adc1e920-9386-4f5a-9dda-4085508baca4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per common share - basic - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8ef25672-7780-438b-9a37-c41d9d6b38f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentVariableInterestRateFloor_d874d408-cc27-4545-9a98-20eefed06051_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentVariableInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest rate floor</link:label>
    <link:label id="lab_ebs_DebtInstrumentVariableInterestRateFloor_label_en-US" xlink:label="lab_ebs_DebtInstrumentVariableInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Floor</link:label>
    <link:label id="lab_ebs_DebtInstrumentVariableInterestRateFloor_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentVariableInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentVariableInterestRateFloor" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentVariableInterestRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentVariableInterestRateFloor" xlink:to="lab_ebs_DebtInstrumentVariableInterestRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e12e5e00-6269-481c-bc1a-26e37605cfe5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_bfa4992f-dcbf-4e49-876f-fd90471b65f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_a9440b2a-3987-4104-a6d3-b4122a174173_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringPlanAugust2024Member_e9d678da-e4ce-4d2f-b0ee-d6935f097830_terseLabel_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2024 Restructuring Plan</link:label>
    <link:label id="lab_ebs_RestructuringPlanAugust2024Member_label_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan August 2024 [Member]</link:label>
    <link:label id="lab_ebs_RestructuringPlanAugust2024Member_documentation_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Plan August 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2024Member" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringPlanAugust2024Member" xlink:to="lab_ebs_RestructuringPlanAugust2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_d7fd2757-9d83-4979-9c0a-e0f65ba56cef_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_cab2d54f-62dd-4d7b-8aa5-995617c1daef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum_92737280-9268-4c19-a3f0-189564cbf9d2_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross leverage ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ebs_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_4cc94c86-83de-4744-a3dd-55a80da772f9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_c245103d-0c63-4665-a49e-608fb77f0c97_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MarylandWarehouseSpaceMember_6c4377bc-477e-4cb3-b3a9-757802dd16db_terseLabel_en-US" xlink:label="lab_ebs_MarylandWarehouseSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maryland Warehouse Space</link:label>
    <link:label id="lab_ebs_MarylandWarehouseSpaceMember_label_en-US" xlink:label="lab_ebs_MarylandWarehouseSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maryland Warehouse Space [Member]</link:label>
    <link:label id="lab_ebs_MarylandWarehouseSpaceMember_documentation_en-US" xlink:label="lab_ebs_MarylandWarehouseSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maryland Warehouse Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MarylandWarehouseSpaceMember" xlink:href="ebs-20250930.xsd#ebs_MarylandWarehouseSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MarylandWarehouseSpaceMember" xlink:to="lab_ebs_MarylandWarehouseSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5786dc0b-0d5f-4cb0-b606-bf840c9aed87_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_c700b2c7-f932-4210-8df0-7e9c517ac9f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Asset, Held and Used [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:to="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0ce266ff-14c6-40c7-a92a-ab360ceea3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a4ae7a18-d845-4c16-90dd-76d9bd3833a3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a564413f-bf97-4367-bbc4-903104c559de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_42243cec-a1ff-4500-8c04-5226c44e9245_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from divestiture of facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_cc6ceb5e-c538-4866-bfa1-f2c2d244f225_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum_f98f693b-7bbf-4a1b-b10a-c375b0631d5d_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowers&#8217; total leverage ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio For Variable Rate Reduction, Maximum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio For Variable Rate Reduction, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" xlink:to="lab_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7b5c2001-2a18-4b6f-adcb-894a79ca40ff_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_eeefe466-c8fe-48b4-95cd-92b7d3dbf60b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5cd0f153-5de0-4aa7-9ff1-119a3151dcc7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_76c39f2c-2436-4d0b-8cdf-2d6fcbd3d52d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7b0df0bb-f87e-4171-b86f-f4ac33705e5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2cb5e939-b6ac-4a91-831b-761b8fc48af1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ff1d2304-a961-4567-a768-f6074c933411_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4cef9d0e-69c7-4091-b530-3c56f818428d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DonaldDeGolyerMember_label_en-US" xlink:label="lab_ebs_DonaldDeGolyerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Donald DeGolyer [Member]</link:label>
    <link:label id="lab_ebs_DonaldDeGolyerMember_documentation_en-US" xlink:label="lab_ebs_DonaldDeGolyerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Donald DeGolyer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DonaldDeGolyerMember" xlink:href="ebs-20250930.xsd#ebs_DonaldDeGolyerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DonaldDeGolyerMember" xlink:to="lab_ebs_DonaldDeGolyerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f21d691d-0af4-473f-9138-d709baf450aa_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AllOtherRevenueMember_dc1f8af7-8766-4f6c-aa91-55a03a000534_terseLabel_en-US" xlink:label="lab_ebs_AllOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other revenue</link:label>
    <link:label id="lab_ebs_AllOtherRevenueMember_label_en-US" xlink:label="lab_ebs_AllOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Revenue [Member]</link:label>
    <link:label id="lab_ebs_AllOtherRevenueMember_documentation_en-US" xlink:label="lab_ebs_AllOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AllOtherRevenueMember" xlink:href="ebs-20250930.xsd#ebs_AllOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AllOtherRevenueMember" xlink:to="lab_ebs_AllOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a370823-2d2e-4789-b634-6fd5a49d4f55_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_65e20731-cd51-41fc-b622-b1ee449cdf14_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_e543635b-4e1b-457c-a0d4-464e3887251e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages paid</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ef9f76ec-fc86-4cae-9082-a3fc481ffc3d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9b8a227d-49d5-417e-9160-e7f68e3630b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractsAndGrantsMember_066a62af-e5a3-4318-bffe-479570b59081_terseLabel_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contracts and grants</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_label_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts and Grants [Member]</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_documentation_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember" xlink:href="ebs-20250930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractsAndGrantsMember" xlink:to="lab_ebs_ContractsAndGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1f21ca32-5dd8-4197-93ba-f81f23b716cd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_07c7b8ff-60e8-4026-bb3a-33c70a3a8424_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6ac70d2c-c278-44af-bd89-003373cacce8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_68353a2f-42a3-4f08-993d-ade202e470fc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b9fd6bbc-b449-47a7-84ba-afa0bd7a272a_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d9f3afc2-eee3-4f8d-be25-91315e7d6aad_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_590f5c94-a4e2-4f72-a1e1-d24732d7e3f0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Useful Life in Years</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_6bb409ad-5b4e-4e52-a955-a2b5210232fc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_49322bf3-4e21-4a1d-bcdd-c7191fd17175_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_65bca7f0-a4f1-428c-a1d1-9e75fa604e3f_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_739cc7be-fac2-4ee0-bcac-e4423019a90a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember_853d048b-572d-430e-8ef5-ebf9895d49de_terseLabel_en-US" xlink:label="lab_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After The Second Anniversary Of The Closing Date</link:label>
    <link:label id="lab_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember_label_en-US" xlink:label="lab_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After The Second Anniversary Of The Closing Date [Member]</link:label>
    <link:label id="lab_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember_documentation_en-US" xlink:label="lab_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After The Second Anniversary Of The Closing Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember" xlink:href="ebs-20250930.xsd#ebs_AfterTheSecondAnniversaryOfTheClosingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember" xlink:to="lab_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_513a5b2a-ef21-49e2-b5a3-0f0ac492f9c2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringPlanJanuary2023Member_207950dd-d3e3-42a7-9911-12421554d456_terseLabel_en-US" xlink:label="lab_ebs_RestructuringPlanJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">January 2023 Restructuring Plan</link:label>
    <link:label id="lab_ebs_RestructuringPlanJanuary2023Member_label_en-US" xlink:label="lab_ebs_RestructuringPlanJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan January 2023 [Member]</link:label>
    <link:label id="lab_ebs_RestructuringPlanJanuary2023Member_documentation_en-US" xlink:label="lab_ebs_RestructuringPlanJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Plan January 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringPlanJanuary2023Member" xlink:to="lab_ebs_RestructuringPlanJanuary2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_dfb30b95-00f1-4d59-8cb3-a10268e82bc9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_VariableRateComponentAxis_6fbce31a-a824-4214-978f-c5f9ee3443c7_terseLabel_en-US" xlink:label="lab_ebs_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_ebs_VariableRateComponentAxis_label_en-US" xlink:label="lab_ebs_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_ebs_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_ebs_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Rate Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_VariableRateComponentAxis" xlink:href="ebs-20250930.xsd#ebs_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_VariableRateComponentAxis" xlink:to="lab_ebs_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3c8cf447-5018-4a99-aaa4-3a9409e689e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8aa038c-666c-42ff-a91f-fcec81d2e7fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_8520feb4-103c-4b8d-bb5a-161dafbde7de_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_af760128-6dcd-4c03-bc8e-51b5317b3aa4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f6e680f0-4480-4b6b-b624-56fb5775d47d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_881fa301-70ca-455f-94ad-9cb0b779ab0c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_a3eb2f05-eb6e-4a80-b713-42d950883033_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior to August 15, 2023</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1ebdaa7-8436-4359-a1b8-e0c22901cdce_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4a5adee5-a3e6-4c90-a15e-4385c42b60c6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_636d2da7-8e9b-4d18-8bda-03219db58d58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_243a7999-fd89-4fac-8bf5-a1cf433602ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_21c91e10-88f0-451e-b488-fe7d0992d7cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentPrepaymentPremium_8862e189-3aed-4514-90c2-65cb5e6d87c9_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium</link:label>
    <link:label id="lab_ebs_DebtInstrumentPrepaymentPremium_label_en-US" xlink:label="lab_ebs_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:label id="lab_ebs_DebtInstrumentPrepaymentPremium_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentPrepaymentPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentPrepaymentPremium" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentPrepaymentPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentPrepaymentPremium" xlink:to="lab_ebs_DebtInstrumentPrepaymentPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_07b2404b-0906-4c2e-ba47-14de04a657b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_af879759-8c4f-4e05-9255-e4369c0d53bf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_d8a959ef-1313-4fac-94a4-d1d45ffda2de_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_acff02b2-f45f-4ee8-8e5d-a849b2ca9c59_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ff2e7b71-1fd3-4b98-8e81-04474cdcfc8f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a96e5ad5-2f8f-4e1f-8ca6-d7e351a856fa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6981af7c-0163-46db-bfb5-16cef184d2d2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_7f03ae4b-f3f3-4141-aafc-4ee67c87dff4_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_f675c9be-b987-44c5-9123-c1a9045dc2ea_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_45c7d92d-01f6-4694-9984-f8bc97b56792_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ea09743f-9379-4c7f-b08b-a6257c5aeed5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5a3a6bf0-8ffc-4648-86bd-a9f7cc17913d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_c59dc50c-b8c1-4e0b-ab66-eb7f197be3f8_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c6e86ca4-4b3f-4ae4-8f6a-d9612079f0bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contingent Consideration Roll Forward</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_2193bdbd-2e13-4512-ab7e-490aebc6f235_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_85e6ce37-8f47-4885-b7ab-2831b6508fad_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_902bffd2-f7fc-409d-a1e8-c77907a52e07_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_fbeee68e-f3fa-4a7e-b894-3b6cd3aa6cd0_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_5e0ad9a1-ff45-425f-842f-aa0f1b01f570_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b792daa8-a5c0-445f-9db1-08f9baa69ce1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_34eef4c4-be7c-4d64-a43f-c5e885ec78bb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate_33478b2d-916b-4082-b177-e8e401c48261_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Covenant maturity, number of days prior to the maturity date</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Maturity, Number Of Days Prior To The Maturity Date</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Maturity, Number Of Days Prior To The Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" xlink:to="lab_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_efff3061-1005-4820-b3f8-ca268c93a7e3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherEquityAwardsMember_924b7645-3a7e-4921-8303-66cb1519a745_terseLabel_en-US" xlink:label="lab_ebs_OtherEquityAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Equity Awards</link:label>
    <link:label id="lab_ebs_OtherEquityAwardsMember_label_en-US" xlink:label="lab_ebs_OtherEquityAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Awards [Member]</link:label>
    <link:label id="lab_ebs_OtherEquityAwardsMember_documentation_en-US" xlink:label="lab_ebs_OtherEquityAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherEquityAwardsMember" xlink:href="ebs-20250930.xsd#ebs_OtherEquityAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherEquityAwardsMember" xlink:to="lab_ebs_OtherEquityAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cec77f31-a61e-4f1f-8288-f4be2b87052b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LossContingencySettlementPeriod_c6c4d956-5d3f-46b0-b73d-4fec7a146b09_terseLabel_en-US" xlink:label="lab_ebs_LossContingencySettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement period</link:label>
    <link:label id="lab_ebs_LossContingencySettlementPeriod_label_en-US" xlink:label="lab_ebs_LossContingencySettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Settlement Period</link:label>
    <link:label id="lab_ebs_LossContingencySettlementPeriod_documentation_en-US" xlink:label="lab_ebs_LossContingencySettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Settlement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencySettlementPeriod" xlink:href="ebs-20250930.xsd#ebs_LossContingencySettlementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LossContingencySettlementPeriod" xlink:to="lab_ebs_LossContingencySettlementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1f57000d-ce20-4c76-8319-0c6e854f98fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation activity (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a103197c-c7f8-4e42-97da-af8c9c3e0c66_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SeriesIWarrantsMember_3f1a23a5-a5d1-463a-a91c-0db78f0c1492_terseLabel_en-US" xlink:label="lab_ebs_SeriesIWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series I Warrants</link:label>
    <link:label id="lab_ebs_SeriesIWarrantsMember_label_en-US" xlink:label="lab_ebs_SeriesIWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series I Warrants [Member]</link:label>
    <link:label id="lab_ebs_SeriesIWarrantsMember_documentation_en-US" xlink:label="lab_ebs_SeriesIWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series I Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIWarrantsMember" xlink:href="ebs-20250930.xsd#ebs_SeriesIWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SeriesIWarrantsMember" xlink:to="lab_ebs_SeriesIWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_da1c9a51-d146-45b3-bd95-c733d7cf8968_terseLabel_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of revenue generating products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_label_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Revenue Generating Products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_documentation_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the number of revenue generating products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:href="ebs-20250930.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:to="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b32f801f-17cb-42aa-a152-2f344a1fc651_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_90817da3-eaf3-4cee-8a46-4675736f45c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">All other revenues less other costs of revenue</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities_a8df003f-406a-4874-987f-4075fdd90341_negatedTerseLabel_en-US" xlink:label="lab_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments from prior asset divestiture</link:label>
    <link:label id="lab_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities_label_en-US" xlink:label="lab_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities</link:label>
    <link:label id="lab_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities_documentation_en-US" xlink:label="lab_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" xlink:href="ebs-20250930.xsd#ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" xlink:to="lab_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_dbb04a9b-f673-4a9e-a67a-1a97be03355c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_397da1b7-4a0e-4347-ae46-02c02db4a82a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_bfef3226-3a46-48e9-8b28-e8668554f6b6_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_063f26bf-9217-4485-93df-e7db28d94db5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b9d370c5-c9b1-4c43-9c3d-2414310b4563_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_d15cb047-3760-4b92-99cc-26af927c79ad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_cac24908-04ef-44c3-a9e3-f298b241c53a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement amount</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit_76b54a68-b6f0-4e52-9e6b-43578c06464e_terseLabel_en-US" xlink:label="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity, increase limit</link:label>
    <link:label id="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit_label_en-US" xlink:label="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Limit</link:label>
    <link:label id="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit_documentation_en-US" xlink:label="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" xlink:href="ebs-20250930.xsd#ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" xlink:to="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7194b3a8-d55d-47d2-bcd0-616118954167_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_cab2b6ae-c8ac-4610-b501-3e385083dbb6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a473e03c-7e06-4cc7-897a-f8ce54fb0a22_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d7efa4cb-ce15-4e8b-a160-73d08b648851_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_be3508d2-383a-4f58-96bc-aefadb013933_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_9a2a10f2-4ac7-44d1-aaa0-ade7094c1f3e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_9d987cb5-e97a-48ca-930a-50619a150d11_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_f1d29d48-c8bb-464c-b79f-9c118384792a_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billed</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_5a1e1066-af54-4aac-8314-a18a5a88b4a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_2a172ffc-cfc7-4f46-8d99-1b4b02ac2232_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6ff8889a-5652-4991-98f9-b3a911fdc663_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_427ac863-990f-4e7c-9b28-8c5bf22545cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_73c4bc09-72db-4567-952f-4c72a0094a41_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_39a0e360-6fb9-422f-af29-e3dc6eff6f83_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_7ce8b04b-7bee-46ab-84e5-2da854c0d49c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_cbdad7c5-4d9f-4bb6-ac54-514f8ec6e84c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b90ba7b5-85cc-4aeb-a900-d932012e34a1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_6c1d9f9d-d67f-4df0-8b5e-be5544241acd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance payments</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9b91944a-ea75-42ad-9715-6868ad569051_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CommitmentContingenciesDisclosureTable_99bd9730-897d-4b1b-b50f-e9430cb7f864_terseLabel_en-US" xlink:label="lab_ebs_CommitmentContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_ebs_CommitmentContingenciesDisclosureTable_label_en-US" xlink:label="lab_ebs_CommitmentContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_ebs_CommitmentContingenciesDisclosureTable_documentation_en-US" xlink:label="lab_ebs_CommitmentContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitment Contingencies Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommitmentContingenciesDisclosureTable" xlink:href="ebs-20250930.xsd#ebs_CommitmentContingenciesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable" xlink:to="lab_ebs_CommitmentContingenciesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MCMProductsSegmentMember_b47e5922-fafb-4c0c-be51-6495e89f646f_terseLabel_en-US" xlink:label="lab_ebs_MCMProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Products</link:label>
    <link:label id="lab_ebs_MCMProductsSegmentMember_label_en-US" xlink:label="lab_ebs_MCMProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MCM Products Segment [Member]</link:label>
    <link:label id="lab_ebs_MCMProductsSegmentMember_documentation_en-US" xlink:label="lab_ebs_MCMProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MCM Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember" xlink:href="ebs-20250930.xsd#ebs_MCMProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MCMProductsSegmentMember" xlink:to="lab_ebs_MCMProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringChargesAdjusted_fdec2e87-4444-4449-bde0-3ccb523eee80_negatedTerseLabel_en-US" xlink:label="lab_ebs_RestructuringChargesAdjusted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_ebs_RestructuringChargesAdjusted_label_en-US" xlink:label="lab_ebs_RestructuringChargesAdjusted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Adjusted</link:label>
    <link:label id="lab_ebs_RestructuringChargesAdjusted_documentation_en-US" xlink:label="lab_ebs_RestructuringChargesAdjusted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Adjusted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringChargesAdjusted" xlink:href="ebs-20250930.xsd#ebs_RestructuringChargesAdjusted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringChargesAdjusted" xlink:to="lab_ebs_RestructuringChargesAdjusted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e25804c2-9bd9-4b15-b1c7-cbc89469bc6f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9ddbec17-3495-426f-9699-05e604045a30_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_14f79da5-e5c2-4b46-abef-96fdd9a6c05b_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments receivable</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0f961810-752b-4f43-a9d9-5f8e1bc83b5e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe7c4b39-2d3c-4cf4-b3c1-d75b5725ff50_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_531cd991-cc6e-4e44-b391-049a8fd5ef09_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_85084052-1b10-4c06-abf0-c4dc845540eb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1ddfa7ba-1320-4438-af42-cb2b197794b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_19828c80-75da-44c0-b2bb-ad49da395913_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_543c0414-024c-489a-af1f-5a2bc4cabe9a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_81f6fce1-1b97-4aa0-b8b0-ecc75027b2b4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_59c3bc12-8530-4b7b-aa78-3385bebf9ffc_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted long-term incentive award</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b54d6c75-bdeb-4645-a377-8df884bda258_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d2157d4b-32ed-4ee6-97ff-d758cbba9736_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_a2a4f0de-881f-44de-8f64-dabf3bec065e_terseLabel_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-USG</link:label>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_label_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-United States Government [Member]</link:label>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_documentation_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-United States Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember" xlink:href="ebs-20250930.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NonUnitedStatesGovernmentMember" xlink:to="lab_ebs_NonUnitedStatesGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ba4c191f-528e-47e7-87b3-0180a1759ca8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_d944cd2a-b622-4a7f-a28f-284883b673f5_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum liquidity requirement</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Requirement, Minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Liquidity Requirement, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLiquidityRequirementMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum" xlink:to="lab_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5e75ad1-28bf-453e-b5dd-a48448d21d17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_e9dbeec1-1654-4193-a4c6-5274bb2977ba_terseLabel_en-US" xlink:label="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impairment of Long-Lived Assets Held and Used by Asset</link:label>
    <link:label id="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_label_en-US" xlink:label="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:to="lab_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e7d00fd0-e417-4450-ad0f-8115d030d510_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_d5f61642-fe1a-44aa-8eff-f611d7e680f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, current, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_4a7ece83-9f8c-4bcd-a2a0-90125915336e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db208742-a7d2-4950-8f2b-a8ab614b0ab5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RevolvingLoansAfterSeptember302025Member_4145e6f9-ca34-4c59-b241-89ca983ca17a_terseLabel_en-US" xlink:label="lab_ebs_RevolvingLoansAfterSeptember302025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Loans, After September 30, 2025</link:label>
    <link:label id="lab_ebs_RevolvingLoansAfterSeptember302025Member_label_en-US" xlink:label="lab_ebs_RevolvingLoansAfterSeptember302025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Loans, After September 30, 2025 [Member]</link:label>
    <link:label id="lab_ebs_RevolvingLoansAfterSeptember302025Member_documentation_en-US" xlink:label="lab_ebs_RevolvingLoansAfterSeptember302025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolving Loans, After September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansAfterSeptember302025Member" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansAfterSeptember302025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RevolvingLoansAfterSeptember302025Member" xlink:to="lab_ebs_RevolvingLoansAfterSeptember302025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AdjustedGrossMargin_17c7c095-be07-41f8-b7eb-1991b308a9a7_terseLabel_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment adjusted gross margin reportable segments:</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_label_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_documentation_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin" xlink:href="ebs-20250930.xsd#ebs_AdjustedGrossMargin"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AdjustedGrossMargin" xlink:to="lab_ebs_AdjustedGrossMargin" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RevolvingLoansMember_d312d930-d937-43a0-b110-8198e606ec8a_terseLabel_en-US" xlink:label="lab_ebs_RevolvingLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Loans</link:label>
    <link:label id="lab_ebs_RevolvingLoansMember_label_en-US" xlink:label="lab_ebs_RevolvingLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Loans [Member]</link:label>
    <link:label id="lab_ebs_RevolvingLoansMember_documentation_en-US" xlink:label="lab_ebs_RevolvingLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolving Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansMember" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RevolvingLoansMember" xlink:to="lab_ebs_RevolvingLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f72450e2-a633-4e54-89af-5921b9acddf8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_921a5fd9-e95d-4d5e-a815-17bdf1f5f5fa_terseLabel_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_label_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_documentation_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:href="ebs-20250930.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:to="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0f846e7e-859c-484a-bcfc-4083fd10c5b3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentAdditionalDefaultInterestRate_650139ba-6a05-4a37-9f56-512f20ad20da_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentAdditionalDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional default interest rate</link:label>
    <link:label id="lab_ebs_DebtInstrumentAdditionalDefaultInterestRate_label_en-US" xlink:label="lab_ebs_DebtInstrumentAdditionalDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Default Interest Rate</link:label>
    <link:label id="lab_ebs_DebtInstrumentAdditionalDefaultInterestRate_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentAdditionalDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Default Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentAdditionalDefaultInterestRate" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentAdditionalDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentAdditionalDefaultInterestRate" xlink:to="lab_ebs_DebtInstrumentAdditionalDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_ace0b159-3780-4725-9c5e-9a80524c0568_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_c17b7d82-29c5-483c-ae4c-b4b0d852679a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6b30442a-8e30-4761-a5b3-fb4bdeb6f5c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_069dd5a8-d501-4dc6-802b-508ea45280e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_769791b8-9bad-417e-ba6b-028e0ab24362_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_3eb88505-d513-4437-81d0-ebfa24990657_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_dc6ba6a7-b7a5-4d01-865a-21bdc2a1fdaa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Rollforward of Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementGain_f0261021-d9ae-4abc-b2cf-46bf73186d9a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement gain</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementGain_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementGain" xlink:to="lab_us-gaap_LitigationSettlementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9ce0197f-85fb-4465-856d-e71968382a4b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_63096c91-430f-440b-b7a9-f39ba1a279e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_913f7757-674c-4fcf-a9c5-857ede848652_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_9033a8a0-feb1-4ce3-a755-9aa3e52a2ced_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_BaltimoreBayviewFacilityMember_693e0e0b-cbf6-44fd-82c3-2092116bb3ca_terseLabel_en-US" xlink:label="lab_ebs_BaltimoreBayviewFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baltimore-Bayview Facility</link:label>
    <link:label id="lab_ebs_BaltimoreBayviewFacilityMember_label_en-US" xlink:label="lab_ebs_BaltimoreBayviewFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Baltimore-Bayview Facility [Member]</link:label>
    <link:label id="lab_ebs_BaltimoreBayviewFacilityMember_documentation_en-US" xlink:label="lab_ebs_BaltimoreBayviewFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Baltimore-Bayview Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BaltimoreBayviewFacilityMember" xlink:href="ebs-20250930.xsd#ebs_BaltimoreBayviewFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BaltimoreBayviewFacilityMember" xlink:to="lab_ebs_BaltimoreBayviewFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_334a4cb2-940f-4f9d-a3bd-12b997f303ec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_15884c99-065a-432c-9579-69890320351e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_2efaa7f3-d5c7-4618-9099-eecf48331df9_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ed87e4a6-f9ac-445a-8fc7-c3492b894c41_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_c1d3fc4c-3ecc-43b8-937f-549dd0e00254_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products and services sales, net</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6e134703-31da-4df2-8e16-779d2b7f123d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ff2f4bdf-7922-4e1d-9567-c205daa86c73_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_df5aa270-d7fb-43c1-8fdd-31d933d22af7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a6836bc5-8250-478d-8a5d-80dbd1055f0d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_19c728ad-2e66-4c82-9f0f-715c5790c3e9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4c9c8f95-2588-497e-a587-db42f54b1587_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_5e75c5b1-6e9d-4c4c-b7e9-6741389a64d1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, fair value adjustment</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable_2840c284-6d5f-4e54-b1cd-cb51831257af_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone Payment Receivable</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a4967dbb-0b26-4f56-96a3-6692425f1f0b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_cb5aea72-c3e2-4bdc-8912-359a4f7aebe0_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_2f2d47c4-c5ba-439c-a413-55d121183f19_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_be0a10fe-049d-4451-9cb8-b7d85aaf9a61_terseLabel_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of categories of public health threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_label_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Categories Of Public Health Threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_documentation_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the number of categories of public health threats.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:href="ebs-20250930.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:to="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b52d5ee4-e61e-4ddf-bd77-901def31b78f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_bcf53aaa-247e-4d3f-b8b9-6d7af2ae33b4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_1708bc44-bad2-4c20-9228-e63540b02073_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bbef970f-f2d6-44e4-b33a-4cb6584304a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6db87a5a-adb6-4ff5-907c-3ebbe1a02d18_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_JanssenPharmaceuticalsInc.Member_1c7242cd-a4f2-4cd2-969c-19ce92f03ebc_terseLabel_en-US" xlink:label="lab_ebs_JanssenPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc.,</link:label>
    <link:label id="lab_ebs_JanssenPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_ebs_JanssenPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc., [Member]</link:label>
    <link:label id="lab_ebs_JanssenPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_ebs_JanssenPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc.,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JanssenPharmaceuticalsInc.Member" xlink:href="ebs-20250930.xsd#ebs_JanssenPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_JanssenPharmaceuticalsInc.Member" xlink:to="lab_ebs_JanssenPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_5b204d65-7633-429e-b12c-a0e5739db432_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges incurred since inception</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_8d63f743-3aa9-4f66-94d4-b5e97d774f8c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnallocatedSellingGeneralAndAdministrativeMember_6a48dc8d-e001-423b-83dd-e620f7dad2ea_terseLabel_en-US" xlink:label="lab_ebs_UnallocatedSellingGeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SG&amp;A</link:label>
    <link:label id="lab_ebs_UnallocatedSellingGeneralAndAdministrativeMember_label_en-US" xlink:label="lab_ebs_UnallocatedSellingGeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated Selling, General And Administrative [Member]</link:label>
    <link:label id="lab_ebs_UnallocatedSellingGeneralAndAdministrativeMember_documentation_en-US" xlink:label="lab_ebs_UnallocatedSellingGeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unallocated Selling, General And Administrative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedSellingGeneralAndAdministrativeMember" xlink:href="ebs-20250930.xsd#ebs_UnallocatedSellingGeneralAndAdministrativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnallocatedSellingGeneralAndAdministrativeMember" xlink:to="lab_ebs_UnallocatedSellingGeneralAndAdministrativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds_2bb9ec91-2781-4803-9c60-51783168b69b_terseLabel_en-US" xlink:label="lab_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages paid from insurance proceeds</link:label>
    <link:label id="lab_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds_label_en-US" xlink:label="lab_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value, From Insurance Proceeds</link:label>
    <link:label id="lab_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds_documentation_en-US" xlink:label="lab_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value, From Insurance Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds" xlink:href="ebs-20250930.xsd#ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds" xlink:to="lab_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5de36fc0-2caf-4c93-954e-831369d179b0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research &amp; development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_09701882-b503-47d0-b0c3-2be66b7cadc1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f76ab592-b6a8-43bc-bd74-258826ca6d01_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_cb8a9e94-ed19-4d74-bd3d-a2b24905d096_terseLabel_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jansen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember" xlink:href="ebs-20250930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_JansenPharmaceuticalsIncMember" xlink:to="lab_ebs_JansenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_2f125e9b-b058-4ac6-84fb-48dbeef07533_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of business and assets held for sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_ba284948-e186-4247-9a9e-4a098e1b6e2d_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_31d85624-385a-4ef8-bfc1-66e75f17c867_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a7d91f28-d7ff-4e70-bbae-589969fff59c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_VariableRateComponentDomain_4c399c60-b87d-48a6-a5c0-d87d30b3e36f_terseLabel_en-US" xlink:label="lab_ebs_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_ebs_VariableRateComponentDomain_label_en-US" xlink:label="lab_ebs_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_ebs_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_ebs_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_VariableRateComponentDomain" xlink:href="ebs-20250930.xsd#ebs_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_VariableRateComponentDomain" xlink:to="lab_ebs_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_67706ace-5f2d-4a79-bd7c-893c47149a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b4ff21-6053-4032-8b2b-e4977c54b203_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a526b84e-56b8-43d5-b988-90bcc79eb205_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_89dfa0fb-9766-487b-a085-01866024c68b_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other segments</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_43e679fb-570f-47b2-979f-cfb810bc1cb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RevolverLoanDue2025Member_0a8a0c67-bb79-4eba-8242-2eb07e21c3e9_terseLabel_en-US" xlink:label="lab_ebs_RevolverLoanDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolver Loan Due 2025</link:label>
    <link:label id="lab_ebs_RevolverLoanDue2025Member_label_en-US" xlink:label="lab_ebs_RevolverLoanDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolver Loan Due 2025 [Member]</link:label>
    <link:label id="lab_ebs_RevolverLoanDue2025Member_documentation_en-US" xlink:label="lab_ebs_RevolverLoanDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolver Loan Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolverLoanDue2025Member" xlink:href="ebs-20250930.xsd#ebs_RevolverLoanDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RevolverLoanDue2025Member" xlink:to="lab_ebs_RevolverLoanDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_7b4c94a8-c97a-4e10-b71c-bc5e9a9ff238_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DevelopmentBasedMilestonesMember_47175213-fdd8-48dd-8613-83d6b256d0bb_terseLabel_en-US" xlink:label="lab_ebs_DevelopmentBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development-Based Milestones</link:label>
    <link:label id="lab_ebs_DevelopmentBasedMilestonesMember_label_en-US" xlink:label="lab_ebs_DevelopmentBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development-Based Milestones [Member]</link:label>
    <link:label id="lab_ebs_DevelopmentBasedMilestonesMember_documentation_en-US" xlink:label="lab_ebs_DevelopmentBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development-Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DevelopmentBasedMilestonesMember" xlink:href="ebs-20250930.xsd#ebs_DevelopmentBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DevelopmentBasedMilestonesMember" xlink:to="lab_ebs_DevelopmentBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PaymentsForRepurchaseOfDebt_b41061c6-06ee-4c85-80b7-c2a869f8c3c5_negatedTerseLabel_en-US" xlink:label="lab_ebs_PaymentsForRepurchaseOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of debt</link:label>
    <link:label id="lab_ebs_PaymentsForRepurchaseOfDebt_label_en-US" xlink:label="lab_ebs_PaymentsForRepurchaseOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Repurchase Of Debt</link:label>
    <link:label id="lab_ebs_PaymentsForRepurchaseOfDebt_documentation_en-US" xlink:label="lab_ebs_PaymentsForRepurchaseOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Repurchase Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForRepurchaseOfDebt" xlink:href="ebs-20250930.xsd#ebs_PaymentsForRepurchaseOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PaymentsForRepurchaseOfDebt" xlink:to="lab_ebs_PaymentsForRepurchaseOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentOriginalIssueDiscountPercentage_f8970b67-7cc4-4e99-806e-8efc1cb4314a_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentOriginalIssueDiscountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original issue discount, percentage</link:label>
    <link:label id="lab_ebs_DebtInstrumentOriginalIssueDiscountPercentage_label_en-US" xlink:label="lab_ebs_DebtInstrumentOriginalIssueDiscountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Original Issue Discount, Percentage</link:label>
    <link:label id="lab_ebs_DebtInstrumentOriginalIssueDiscountPercentage_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentOriginalIssueDiscountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Original Issue Discount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentOriginalIssueDiscountPercentage" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentOriginalIssueDiscountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentOriginalIssueDiscountPercentage" xlink:to="lab_ebs_DebtInstrumentOriginalIssueDiscountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_143cc8bb-8211-474c-ab58-5c45da2d0bd7_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringPlanMay2024Member_755716e1-7506-45e0-af65-4294831e5cf8_terseLabel_en-US" xlink:label="lab_ebs_RestructuringPlanMay2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">May 2024 Restructuring Plan</link:label>
    <link:label id="lab_ebs_RestructuringPlanMay2024Member_label_en-US" xlink:label="lab_ebs_RestructuringPlanMay2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan May 2024 [Member]</link:label>
    <link:label id="lab_ebs_RestructuringPlanMay2024Member_documentation_en-US" xlink:label="lab_ebs_RestructuringPlanMay2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Plan May 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanMay2024Member" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanMay2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringPlanMay2024Member" xlink:to="lab_ebs_RestructuringPlanMay2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_af434de2-247b-4fc5-898e-ec056365d762_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_d72249e1-b912-4cf5-baf9-118d11204e57_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_68d3ee0e-14c3-40f0-a81a-dd52cd3441e2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_de27fbf6-af0e-4f52-b3aa-c0ad4525c47f_terseLabel_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:href="ebs-20250930.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:to="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b88790bf-6c93-47cb-a7a9-728c5a9c0776_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6c6207a8-dff1-42b4-a21c-a24f87e3bcc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b787abda-128e-4cf8-bef7-d5901257614a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_f62b5867-a28f-4c83-b51c-7c9b607e8c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85f65fe3-881d-476b-bea1-9a9b2dc83ae4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_37a53279-0b4d-4ea3-aaa3-8c171805d8d0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum_2890adbc-da04-4122-87dc-667cdfb0c65c_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" xlink:to="lab_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ValuationTechniqueBlackScholesModelMember_eae6babd-c6f1-45d3-83c2-1a6bc5e445ed_terseLabel_en-US" xlink:label="lab_ebs_ValuationTechniqueBlackScholesModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black-Scholes Method</link:label>
    <link:label id="lab_ebs_ValuationTechniqueBlackScholesModelMember_label_en-US" xlink:label="lab_ebs_ValuationTechniqueBlackScholesModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Black-Scholes Model [Member]</link:label>
    <link:label id="lab_ebs_ValuationTechniqueBlackScholesModelMember_documentation_en-US" xlink:label="lab_ebs_ValuationTechniqueBlackScholesModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Technique, Black-Scholes Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ValuationTechniqueBlackScholesModelMember" xlink:href="ebs-20250930.xsd#ebs_ValuationTechniqueBlackScholesModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ValuationTechniqueBlackScholesModelMember" xlink:to="lab_ebs_ValuationTechniqueBlackScholesModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef78e172-a6fe-467a-97a2-925f4cb56b5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained_a0e27e5c-96d3-40df-9b12-e8c00f8c3f8c_terseLabel_en-US" xlink:label="lab_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of reforms to be maintained</link:label>
    <link:label id="lab_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained_label_en-US" xlink:label="lab_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Period Of Corporate Governance Reforms To Be Maintained</link:label>
    <link:label id="lab_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained_documentation_en-US" xlink:label="lab_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Duration Of Reforms To Be Maintained</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" xlink:href="ebs-20250930.xsd#ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" xlink:to="lab_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_39abe26b-79e5-4624-ab4c-26b827615b6d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_87e43010-9b84-47ec-901f-ba2b05ae8790_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2bc3d87c-27a2-49f5-8f62-1c86c689be91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e2271ac1-8866-41c7-b7d1-d3f3514d9570_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c924de10-75df-4260-9746-ef3a48c6d5cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_e3fe63ae-63e7-42b1-8de7-4cb89956b291_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds_b92c420c-410c-4247-8a67-47510e6ba1d9_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mandatory prepayment, percentage of net cash proceeds from dispositions of property and insurance proceeds</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds_label_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Dispositions Of Property And Insurance Proceeds</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Dispositions Of Property And Insurance Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" xlink:to="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bc227506-858d-41c1-846b-6a5626f8a39d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1b4d3bab-c358-4243-9b5c-cbcff1aa6723_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9785ad6f-6ff4-40a2-a29b-3e87f65a1aa7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_815ae8c6-b371-42d8-b46f-00e8ae98d1d4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_0e85913d-e038-440e-9c05-4bf1bf39fb02_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales reportable segments:</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e997bcde-5c7e-41ff-92db-5a005bf0e89f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_965c715b-8cbd-4a8b-be48-878908df961e_terseLabel_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USG</link:label>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_label_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States Government [Member]</link:label>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_documentation_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember" xlink:href="ebs-20250930.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnitedStatesGovernmentMember" xlink:to="lab_ebs_UnitedStatesGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_3309a264-9630-426f-ac07-b704fb5a0584_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_1aecc776-bc3e-4db4-b93f-d02dab196fd6_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_15607d0f-416f-4b9e-881c-432791d1ed99_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c6833692-5167-4054-bd83-647484619319_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cddb28e9-702e-4c95-ba45-335ae03f78d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_dde3add6-91d0-4b1d-8c4b-98be12d6f05f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1fffdf95-e9e9-46f5-b340-2147f06a4cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_67d5932f-5428-493e-9b96-d6f51aeb4b4d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of Exercise Price per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6c6978b0-2f39-4b8e-a3e4-60aa43407a0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a4bc25f5-2bef-43ad-b699-b5b24126549f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_3aecb79a-68e2-4266-8e54-4c671458e0bd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8bccffab-1c01-4233-a974-8688bc0ccbb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0d3da7cc-413a-4d14-befa-6b8247f8c5e6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bf272a4b-e145-4c7b-b29d-1bd360d7945a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ProductAndServiceMember_9302dccf-67ed-4e79-b2fb-d59e206d1535_terseLabel_en-US" xlink:label="lab_ebs_ProductAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and services sales, net</link:label>
    <link:label id="lab_ebs_ProductAndServiceMember_label_en-US" xlink:label="lab_ebs_ProductAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product And Service [Member]</link:label>
    <link:label id="lab_ebs_ProductAndServiceMember_documentation_en-US" xlink:label="lab_ebs_ProductAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product And Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductAndServiceMember" xlink:href="ebs-20250930.xsd#ebs_ProductAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ProductAndServiceMember" xlink:to="lab_ebs_ProductAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_ccb4d299-ff97-49fd-9285-b9ab00298092_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, asset, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LongTermIncentiveAwardMember_65bcb318-83ca-4068-9437-712ceaf9cc88_terseLabel_en-US" xlink:label="lab_ebs_LongTermIncentiveAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Incentive Award</link:label>
    <link:label id="lab_ebs_LongTermIncentiveAwardMember_label_en-US" xlink:label="lab_ebs_LongTermIncentiveAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Incentive Award [Member]</link:label>
    <link:label id="lab_ebs_LongTermIncentiveAwardMember_documentation_en-US" xlink:label="lab_ebs_LongTermIncentiveAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Incentive Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LongTermIncentiveAwardMember" xlink:href="ebs-20250930.xsd#ebs_LongTermIncentiveAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LongTermIncentiveAwardMember" xlink:to="lab_ebs_LongTermIncentiveAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_f51678aa-d036-43b0-b78a-6bbf29bd5faa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual, provision</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2935fa4b-3aaf-4e2a-af47-f9f27c3773ee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_d504ebce-e1a6-4297-84ed-222f0e5d80cb_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b1f3a237-9058-4cac-a294-d68bbfd1470e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_cfb1035b-cdde-4881-acbc-c8e3eb898cde_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0ec9ba9f-9110-4cf3-931d-b65531a30f21_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_444b04af-7577-4cff-97d1-8507afc91deb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4b3ff212-efba-4576-93e0-7b0f52945582_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_30aa0306-4622-4121-a1e4-6b01b64f673b_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_9e5b3eb6-c426-489f-8550-bdffee97764a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_63f03b4a-3e17-4ecf-a817-281cedfa3a88_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_30ea45c7-4e1b-43c7-a4f7-f1c10cdd4fb2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c7760030-983f-4ca4-bced-1553d7d1a8b1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_22f247f0-4efb-429d-ab30-4ca9608456ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_89967d6f-f303-4c8b-b9ee-98149c547d3a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1b0bf428-1146-48a6-a3b0-746f93f981a8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_679afe6b-5b2f-42db-9e0c-dbfca563c558_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b4c4e83-3d78-4439-9e38-e342665aa7e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c596e6a3-8e87-4bb8-84d8-f9ea7f4dd6df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium_888a77b2-f9f8-4f95-ad4c-722d92f32913_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on make-whole premium</link:label>
    <link:label id="lab_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium_label_en-US" xlink:label="lab_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Make-Whole Premium</link:label>
    <link:label id="lab_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Make-Whole Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentBasisSpreadOnMakeWholePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium" xlink:to="lab_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_28aff8d9-ffb0-4333-8b12-f779c54a9e8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_3ac5ac4c-7b44-4b3b-88aa-602b1fc482b2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used, Asset Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used, Asset Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_735c96c3-9975-4b48-ad5c-65bf4e19fa6e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with debt</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_7b03a890-6b17-460f-8c2b-d1e821010423_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4c489430-0b41-4a11-8c88-390940e0182a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_26fb88e6-8178-4126-851f-ad7fa14cfec9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a0371499-ff7a-4c23-9c84-b0ed4229c2a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_646d34ef-74b9-46a1-adec-534fa1760d9c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_211eb5b4-3713-426a-ab48-d4c35a6aa1c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_bca46d79-9790-4a43-b8f7-8b624d8392dc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAbstract_61b81689-d306-4feb-ae4f-d0dd05d327d6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation from reportable segments:</link:label>
    <link:label id="lab_us-gaap_DepreciationAbstract_label_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAbstract" xlink:to="lab_us-gaap_DepreciationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_52d8649e-1f81-41cc-af97-c6991ca5de21_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities - equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b41c4318-86e1-4335-9fb7-0c50f0821fd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_55974440-84e7-420c-8811-4c9dfe3d4838_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonvested options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_20e2fc77-035c-44d2-9e6b-5628901620e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments other than options, forfeited in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_456cd1e8-943c-4b15-a74f-091c441a2cd5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon the occurrence of a change in control</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_a0b0fa3a-883d-4ede-bae3-cf3e2dd7a51a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable and payable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e893c56d-10a6-4148-8d35-6e359ecccb55_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_eeed027a-4455-4ed5-b5ab-4ec4c47453cf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_652e07b1-b29e-4191-a054-cf4e40ae20b0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_ad72e96d-e02e-49a5-830b-5b9bfccb6c9e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2c6bed3c-6dc2-42df-a048-fb7d6fc4d805_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Level 3 of Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c5ecb949-2a22-4442-a159-8074c230bb84_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_21957793-0a0c-44ed-a5e0-68110e701ead_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_e856bfad-97bf-4586-a007-54fd2c32e063_verboseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">All other revenues</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_e683e3e7-7a09-4eb9-a8f6-1c6215ddb488_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_07d2ac39-3f87-480b-859c-e2760b253469_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_115f5d09-8643-4028-8448-77723bc840d6_terseLabel_en-US" xlink:label="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive plan accrual</link:label>
    <link:label id="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_label_en-US" xlink:label="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Long-Term Incentive Plan Accrual</link:label>
    <link:label id="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_documentation_en-US" xlink:label="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Long-Term Incentive Plan Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:href="ebs-20250930.xsd#ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:to="lab_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_b112f294-bb49-4917-97f4-54016f9e3f3a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fe50cd56-f1ab-43ee-9f8f-1e9f15b5f491_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_40e5df73-e8ed-4dcb-9d51-08851ad64a96_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TermLoanMember_5c5b0247-b9ed-4e73-b2e3-1f065a3fae2d_terseLabel_en-US" xlink:label="lab_ebs_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_ebs_TermLoanMember_label_en-US" xlink:label="lab_ebs_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_ebs_TermLoanMember_documentation_en-US" xlink:label="lab_ebs_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanMember" xlink:href="ebs-20250930.xsd#ebs_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanMember" xlink:to="lab_ebs_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_352e8f76-0d78-4931-9b9f-b7f08db37396_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms_25fbc69c-2963-4787-a27c-cccd0bef5048_terseLabel_en-US" xlink:label="lab_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implementation reforms, period</link:label>
    <link:label id="lab_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms_label_en-US" xlink:label="lab_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Period Of Implementation Of Corporate Governance Reforms</link:label>
    <link:label id="lab_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms_documentation_en-US" xlink:label="lab_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Period Of Implementation Of Corporate Governance Reforms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" xlink:href="ebs-20250930.xsd#ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" xlink:to="lab_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred_0416452d-816d-4d08-973f-b2d18e7e057b_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mandatory prepayment, percentage of net cash proceeds from indebtedness incurred</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred_label_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Indebtedness Incurred</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Indebtedness Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" xlink:to="lab_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a2615977-b15f-46b1-a8d5-09a8a860c625_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a25e3e64-2368-4ee6-a8c4-10446079c61d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24283c2-6824-45f9-a473-8b5611e7edc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_5c82c6ce-e960-4219-9aaf-13cbc84e5e7e_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_6c083bae-14da-4b52-9f76-97b9bf79f8db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_cfc7618e-1c50-43f7-aeae-220cd46f010f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2785be92-9e02-4814-bf3c-9823b6fdb00c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9f49770c-bde7-4a3d-a964-60df29204297_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_e4741895-f07f-47d3-809f-126e4e049720_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_b0627ae9-ca8b-456a-b7c6-2eea0ac35253_negatedTerseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Valuation Allowance</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_a0a30ba0-656f-45d4-852d-c6217f3ada8b_terseLabel_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Leases Supplemental Balance Sheets</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ebs-20250930.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e8962cad-d247-491d-b7bf-f076fb185b23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dd11cf6f-61a5-4b79-ab36-0b0f8a09df87_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_b82362d5-9fbf-457b-bccd-d9ad52862ad6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_242f2680-89c6-4a43-a02a-a2e311c0bcb5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_84d7c0c4-a011-490a-8167-d1c7b2d85945_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SujataTyagiDayalMember_label_en-US" xlink:label="lab_ebs_SujataTyagiDayalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sujata Tyagi Dayal [Member]</link:label>
    <link:label id="lab_ebs_SujataTyagiDayalMember_documentation_en-US" xlink:label="lab_ebs_SujataTyagiDayalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sujata Tyagi Dayal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SujataTyagiDayalMember" xlink:href="ebs-20250930.xsd#ebs_SujataTyagiDayalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SujataTyagiDayalMember" xlink:to="lab_ebs_SujataTyagiDayalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_edb0b120-d4ed-4621-a678-415b24130903_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SubscriptionAgreementMember_a85ea7a4-04d9-4d9b-a298-e8717d2a4187_terseLabel_en-US" xlink:label="lab_ebs_SubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription Agreement</link:label>
    <link:label id="lab_ebs_SubscriptionAgreementMember_label_en-US" xlink:label="lab_ebs_SubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Agreement [Member]</link:label>
    <link:label id="lab_ebs_SubscriptionAgreementMember_documentation_en-US" xlink:label="lab_ebs_SubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SubscriptionAgreementMember" xlink:href="ebs-20250930.xsd#ebs_SubscriptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SubscriptionAgreementMember" xlink:to="lab_ebs_SubscriptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_InventoryStepUp_e9b23fb9-2625-406a-a5b0-e154616ea77a_negatedLabel_en-US" xlink:label="lab_ebs_InventoryStepUp" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory step-up provision</link:label>
    <link:label id="lab_ebs_InventoryStepUp_label_en-US" xlink:label="lab_ebs_InventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Step Up</link:label>
    <link:label id="lab_ebs_InventoryStepUp_documentation_en-US" xlink:label="lab_ebs_InventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory Step Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_InventoryStepUp" xlink:href="ebs-20250930.xsd#ebs_InventoryStepUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_InventoryStepUp" xlink:to="lab_ebs_InventoryStepUp" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_247e1b02-979c-45ff-a46d-53485985d6e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_4917817b-5b0f-4404-ade1-1d949f23ef0b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4da6886e-8489-4d1e-a68f-7ec2cba42ddc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_35f22586-5826-49a8-81ff-e33ced1d04f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent obligations, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_aff9ece2-e624-4b39-8d5a-68e5b470e445_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis_dd430d76-1838-4d9b-8e9e-a82ea1bbb0c5_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mandatory prepayment, net cash proceeds from disposition of property threshold, per transaction basis</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis_label_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Per Transaction Basis</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Per Transaction Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" xlink:to="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_b5a005fe-e21a-4167-a328-dd4c0cf99e97_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis_d023e59d-fa5d-4b2b-b956-690ad0a84f99_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mandatory prepayment, net cash proceeds from disposition of property threshold, annual basis</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis_label_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Annual Basis</link:label>
    <link:label id="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Annual Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" xlink:to="lab_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f1af28e3-4527-4dd0-af61-1a574d8a91c3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_63820697-b2b8-455c-8ce4-301dc7e50951_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_fdf95f18-dcd6-495b-84a2-72372e13b6e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_0eb6663f-8811-4e69-83ac-025f4ac04e0f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b3078f8a-99ef-4a83-8732-2d6894c59340_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_50984c59-e377-4cc6-9498-a4d019cb9ead_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringPlanAugust2023Member_ac200446-e499-4138-aadc-c04a6bd0a8ba_terseLabel_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2023 Restructuring Plan</link:label>
    <link:label id="lab_ebs_RestructuringPlanAugust2023Member_label_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan August 2023 [Member]</link:label>
    <link:label id="lab_ebs_RestructuringPlanAugust2023Member_documentation_en-US" xlink:label="lab_ebs_RestructuringPlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Plan August 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringPlanAugust2023Member" xlink:to="lab_ebs_RestructuringPlanAugust2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3517c149-a739-40f8-9a67-fd59db611111_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_27b42df0-0cb7-4938-9ef2-7ba10ccdc2ef_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6f32f837-0e8e-495b-bdad-9977b26774c6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2d589049-f090-4996-8206-f20529ef7318_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_04cf4c02-a1b5-48f7-9a88-6a6dab64d279_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a4640722-10e4-46bb-9243-d8a8d0dbf826_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6454b95b-a07d-4d7a-b180-78582c274ee9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4769d79f-ef3d-4635-9302-115638cf2c5c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PerformanceStockOptionMember_e9529f75-3f7e-49a0-87d9-5c6a8d258287_terseLabel_en-US" xlink:label="lab_ebs_PerformanceStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Option</link:label>
    <link:label id="lab_ebs_PerformanceStockOptionMember_label_en-US" xlink:label="lab_ebs_PerformanceStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Option [Member]</link:label>
    <link:label id="lab_ebs_PerformanceStockOptionMember_documentation_en-US" xlink:label="lab_ebs_PerformanceStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceStockOptionMember" xlink:href="ebs-20250930.xsd#ebs_PerformanceStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PerformanceStockOptionMember" xlink:to="lab_ebs_PerformanceStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_d87657be-6176-44b1-ad02-3f86122ad256_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a4480d9a-34c8-4c15-82d7-002bbcf489e3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_5769abb6-b30b-4e80-bc83-b1ed00ac0a12_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_6fb5ac49-3491-4d39-a315-7788b130fc71_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_bd173d65-a18d-4c91-8437-4f361d3e66dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4ecc8e4a-26af-4f12-9d74-1a2b6067e469_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_75b4557c-3089-4d90-bc80-c60cce204e6b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_BaltimoreCamdenFacilityMember_73f2f6ed-56a4-484f-bf17-bb9acbe17fca_terseLabel_en-US" xlink:label="lab_ebs_BaltimoreCamdenFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baltimore-Camden Facility</link:label>
    <link:label id="lab_ebs_BaltimoreCamdenFacilityMember_label_en-US" xlink:label="lab_ebs_BaltimoreCamdenFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Baltimore-Camden Facility [Member]</link:label>
    <link:label id="lab_ebs_BaltimoreCamdenFacilityMember_documentation_en-US" xlink:label="lab_ebs_BaltimoreCamdenFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Baltimore-Camden Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BaltimoreCamdenFacilityMember" xlink:href="ebs-20250930.xsd#ebs_BaltimoreCamdenFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BaltimoreCamdenFacilityMember" xlink:to="lab_ebs_BaltimoreCamdenFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_ed52c0bb-4425-47c4-87f6-6ccd77b609c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_d6184391-6b57-45be-a5dd-c60b2faac0f2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8367ac95-5dff-441c-9e1f-9daa74bacde7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value per share; 200.0 shares authorized, 60.6 and 59.9 shares issued; 52.7 and 54.3 shares outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_aed6b953-ae97-4a94-9dae-099bea3db046_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_50848556-e071-4d98-ab56-a419feb27ec2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_089a1a65-c4ae-4a64-9bf4-d3f2b6aec49d_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares outstanding-diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_7eeacc4e-c239-4cad-bb9c-4a715487c057_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c27757ca-742a-43bf-928a-a43560b21f03_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_409b5c22-4069-4076-bcc4-d1959646373b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1365bbb9-620f-491b-9346-410efe9300cc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_00eac444-0159-4d1b-b663-d9bd23287f97_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a19ade63-1446-4c6e-8f99-41ed5cae4641_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_8de1cb1e-77a1-43d1-8e49-1ec992d1c07f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_22e3f963-93aa-435b-9483-19d440f77b3e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_db971a33-e712-4509-9c6b-ba9042ec22b2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease_b2c95ff7-d3ce-4396-a41c-0991f4519de9_negatedTerseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium, decrease</link:label>
    <link:label id="lab_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease_label_en-US" xlink:label="lab_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium, Scheduled Increase (Decrease)</link:label>
    <link:label id="lab_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium, Scheduled Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" xlink:to="lab_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc1c11ee-a8bf-4725-b1db-7600562a428a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_94426ec7-40a5-4c39-a4cc-1302434bf08a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_6c30f085-2be4-4076-aa52-5768fab0cd52_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_fbf222a6-24de-4176-8d08-0bdafe4c349c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Allowance for expected credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_8fd85285-1f1e-4373-95df-d28c17922a55_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award performance period</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:to="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_a82e0127-fb46-4b98-976b-b687a0ae57d6_terseLabel_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_label_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated Research And Development [Member]</link:label>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unallocated Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember" xlink:href="ebs-20250930.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnallocatedResearchAndDevelopmentMember" xlink:to="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RevolvingLoansUntilSeptember302025Member_60e92a25-c444-436c-846e-743b11212042_terseLabel_en-US" xlink:label="lab_ebs_RevolvingLoansUntilSeptember302025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Loans, Until September 30, 2025</link:label>
    <link:label id="lab_ebs_RevolvingLoansUntilSeptember302025Member_label_en-US" xlink:label="lab_ebs_RevolvingLoansUntilSeptember302025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Loans, Until September 30, 2025 [Member]</link:label>
    <link:label id="lab_ebs_RevolvingLoansUntilSeptember302025Member_documentation_en-US" xlink:label="lab_ebs_RevolvingLoansUntilSeptember302025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolving Loans, Until September 30, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansUntilSeptember302025Member" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansUntilSeptember302025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RevolvingLoansUntilSeptember302025Member" xlink:to="lab_ebs_RevolvingLoansUntilSeptember302025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_12cd0f60-ad73-492f-89d1-783c37b9db76_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_7f19b8d4-a73b-420e-ae36-323a3052f711_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ecbd749c-b0fb-4797-9523-8c29c26cb491_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_a318aa8b-1fb3-42a7-907b-cd217a97f832_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares average cost price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_fca12d39-10cd-4f3a-8f48-bd59efc1141e_terseLabel_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product and service categories</link:label>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_label_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product And Service Categories</link:label>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_documentation_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product And Service Categories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductAndServiceCategories" xlink:href="ebs-20250930.xsd#ebs_NumberOfProductAndServiceCategories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfProductAndServiceCategories" xlink:to="lab_ebs_NumberOfProductAndServiceCategories" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_df63038f-8ba1-4dcd-b48c-734f3c563d20_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_00826c0b-6a3a-4b1b-95eb-7c8e7a3b4b93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_868151a2-50f0-4b2a-9b4a-78dd09b71254_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a33ce7ab-6d06-458b-9b83-881a73115227_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6a96ad5a-4414-499f-b24d-fd8df04450d3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_5d7919e9-25f0-42d1-b9a8-f973d2b6bea3_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c2547d49-c141-4af3-9fa7-387c0e60f24e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ed32fda-37b3-444e-86fe-18991b3d3a80_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50ba5457-63ff-44a8-9710-3c172d44a7e6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentRepurchaseAmountRemaining_94459c35-cb8e-4528-a9bc-16fa238d54b5_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentRepurchaseAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase amount remaining</link:label>
    <link:label id="lab_ebs_DebtInstrumentRepurchaseAmountRemaining_label_en-US" xlink:label="lab_ebs_DebtInstrumentRepurchaseAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount Remaining</link:label>
    <link:label id="lab_ebs_DebtInstrumentRepurchaseAmountRemaining_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentRepurchaseAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentRepurchaseAmountRemaining" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentRepurchaseAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentRepurchaseAmountRemaining" xlink:to="lab_ebs_DebtInstrumentRepurchaseAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ed3eab6b-d6f0-4fe2-b277-2af9dae32b5b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a128b339-2b2f-43af-a62c-fe62c7cd4507_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment_f9ecdbab-68bd-41a6-bed5-0d38adcf49cd_terseLabel_en-US" xlink:label="lab_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of debt, excluding gain on extinguishment</link:label>
    <link:label id="lab_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment_label_en-US" xlink:label="lab_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Repurchase Of Debt, Excluding Gain (Loss) On Extinguishment</link:label>
    <link:label id="lab_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment_documentation_en-US" xlink:label="lab_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Repurchase Of Debt, Excluding Gain (Loss) On Extinguishment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" xlink:href="ebs-20250930.xsd#ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" xlink:to="lab_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_48e2ecd9-c7c3-4bf4-9b06-ce262e64ea21_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8c26cf4d-a4f1-4c0f-952b-28258fb8dd12_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_cd60ee6c-6092-458d-a38d-ec58cc287912_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_be63585b-9f0e-4554-9a20-12e7873a52b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of convertible note receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_6d5bfc32-1c53-43da-a071-db983937c587_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_da2a1646-1aa9-4fa6-b875-07a94f1cc269_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, authorized, amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fa5aed71-651e-4733-8f85-d626f931fed2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d6d01de6-655b-47c2-936d-23f826c218ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of cash and cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt_fa7527b0-5ff9-49a9-9eb3-54b05addd4b1_terseLabel_en-US" xlink:label="lab_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds allocated to common stock issued in conjunction with debt</link:label>
    <link:label id="lab_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt_label_en-US" xlink:label="lab_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Allocated To Common Stock Issued In Conjunction With Debt</link:label>
    <link:label id="lab_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt_documentation_en-US" xlink:label="lab_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds Allocated To Common Stock Issued In Conjunction With Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" xlink:href="ebs-20250930.xsd#ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" xlink:to="lab_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cb245fa-dbfd-4f44-8f58-5e635bfed0a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember_22f40ca5-6dfd-4e0e-a2aa-1f08e1c660df_terseLabel_en-US" xlink:label="lab_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until The Second Anniversary Of The Closing Date</link:label>
    <link:label id="lab_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember_label_en-US" xlink:label="lab_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Until The Second Anniversary Of The Closing Date [Member]</link:label>
    <link:label id="lab_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember_documentation_en-US" xlink:label="lab_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Until The Second Anniversary Of The Closing Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember" xlink:href="ebs-20250930.xsd#ebs_UntilTheSecondAnniversaryOfTheClosingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember" xlink:to="lab_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_74455433-49f8-4ae8-9035-f49671d72efa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid for share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EmployeeBenefitsMember_f487dada-1cb3-4ef3-a5be-8f20e501442b_terseLabel_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_ebs_EmployeeBenefitsMember_label_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefits [Member]</link:label>
    <link:label id="lab_ebs_EmployeeBenefitsMember_documentation_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember" xlink:href="ebs-20250930.xsd#ebs_EmployeeBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EmployeeBenefitsMember" xlink:to="lab_ebs_EmployeeBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c079d3ab-44bf-4187-a666-9f23f3f041da_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_bd07463c-6739-495f-8d22-2737ea03fcc6_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f7642def-5f90-4b6d-89cb-054b83181919_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_af75be27-4424-4dd5-aa39-d5e9fab65055_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e2e50e9a-3bd1-42e2-a1ea-0c917c23dccb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6ae70399-8802-4097-9953-8eefecb63e9d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6230bc09-dff4-46a9-9b6b-bd16910f8d50_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TermLoanDue2029Member_26a48806-1386-436d-bcd3-a17079930584_terseLabel_en-US" xlink:label="lab_ebs_TermLoanDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan due 2029</link:label>
    <link:label id="lab_ebs_TermLoanDue2029Member_label_en-US" xlink:label="lab_ebs_TermLoanDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Due 2029 [Member]</link:label>
    <link:label id="lab_ebs_TermLoanDue2029Member_documentation_en-US" xlink:label="lab_ebs_TermLoanDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanDue2029Member" xlink:href="ebs-20250930.xsd#ebs_TermLoanDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanDue2029Member" xlink:to="lab_ebs_TermLoanDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_242d678f-0d7a-49d6-b4c1-41551c608181_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_65953cd6-41d8-4dcb-a401-65c697b84cda_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b110ff25-6fec-4ce1-9615-4c354a9b70b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_b3b699ca-af27-4fb6-a66e-734cee32b53c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4824db3b-9f28-4d04-83b4-f0b2a5b53943_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5725dce2-6c34-4f53-bdd7-378960258a32_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per common share - basic - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_667e8725-e4ac-499f-b00d-da8ce0b68e5e_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1ff6c003-e1e3-4397-936d-6cb71173b5df_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b58bb329-de8c-4163-83c6-62a50c1eadde_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c174da55-c676-4e9b-8d3d-a3c482dbcd18_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50143892-836f-4c2f-891f-d7b4d66fa7e2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b86e090d-200d-496e-9dfe-13b4bca4d05c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_af8db8af-7ee6-4c7f-895c-c23393dbcde5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable_aedd2c8e-8265-44a7-b86b-820124f9db2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excise tax liability accrued for common stock repurchases</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Excise Tax, Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:to="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f402f743-ea09-41eb-8573-48dc9863c25e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_07900bc4-c026-4efb-9a77-a5d8a5273391_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_67d4f126-7d1a-477d-b477-c2b41e4c70f6_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_e9953743-85a8-451e-8118-8f9ed603d75f_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_746821ac-c9a3-48a2-a180-1eedcd209f8e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_ae42784e-342a-4c8e-a68c-c18efd61b4d8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_2f51d0c9-4979-44c7-bb2a-8e55df576b28_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_WarrantLiabilitiesFairValueDisclosure_3c75ebaa-6cc1-4232-aa27-b8e761984976_terseLabel_en-US" xlink:label="lab_ebs_WarrantLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ebs_WarrantLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_ebs_WarrantLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liabilities, Fair Value Disclosure</link:label>
    <link:label id="lab_ebs_WarrantLiabilitiesFairValueDisclosure_documentation_en-US" xlink:label="lab_ebs_WarrantLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_WarrantLiabilitiesFairValueDisclosure" xlink:to="lab_ebs_WarrantLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_17c344f4-08d8-4b63-9ce1-eb3520065beb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_fa56d89f-74ea-40b9-8c65-e8034b7a4997_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TravelHealthBusinessMember_787a344e-0b87-40ac-a562-243ac9e390af_terseLabel_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Travel Health Business</link:label>
    <link:label id="lab_ebs_TravelHealthBusinessMember_label_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travel Health Business [Member]</link:label>
    <link:label id="lab_ebs_TravelHealthBusinessMember_documentation_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Travel Health Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember" xlink:href="ebs-20250930.xsd#ebs_TravelHealthBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TravelHealthBusinessMember" xlink:to="lab_ebs_TravelHealthBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_910d47b4-7e74-4ff3-9c32-6c526bdbbcc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold_55cb7506-c341-4bfc-b082-e6ec6c3b812a_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount outstanding threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold_label_en-US" xlink:label="lab_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Aggregate Principal Amount Outstanding Threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Aggregate Principal Amount Outstanding Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" xlink:to="lab_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_b8122a28-61d7-4fbc-a77d-098e9e4aa089_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_e191dc6e-b352-48ce-95bf-27b20a70fdea_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares, acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SeriesIIWarrantsMember_5267dde1-4136-4046-87b1-53c34be0f89d_terseLabel_en-US" xlink:label="lab_ebs_SeriesIIWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series II Warrants</link:label>
    <link:label id="lab_ebs_SeriesIIWarrantsMember_label_en-US" xlink:label="lab_ebs_SeriesIIWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series II Warrants [Member]</link:label>
    <link:label id="lab_ebs_SeriesIIWarrantsMember_documentation_en-US" xlink:label="lab_ebs_SeriesIIWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series II Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIIWarrantsMember" xlink:href="ebs-20250930.xsd#ebs_SeriesIIWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SeriesIIWarrantsMember" xlink:to="lab_ebs_SeriesIIWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_999995ba-de38-4052-935e-1d63c2860518_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0ae9866e-6a8f-4a1a-899e-d97df086951c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_46a22879-bb38-4005-beda-bf4c86f32f86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8da81f22-1437-4a33-9f01-6ba4a0a91a35_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cba3a0f2-417e-4e34-abb9-fc0bc55f0076_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_c2241c5f-d212-415f-9cca-df7436c38298_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_58b5a7a6-8b0f-4c14-a2a5-6baa5622531e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated_b2af6de6-4a6e-47e4-933d-162296466032_terseLabel_en-US" xlink:label="lab_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of currently vacant positions eliminated</link:label>
    <link:label id="lab_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated_label_en-US" xlink:label="lab_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring And Related Cost, Number Of Vacant Positions Eliminated</link:label>
    <link:label id="lab_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated_documentation_en-US" xlink:label="lab_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring And Related Cost, Number Of Vacant Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" xlink:href="ebs-20250930.xsd#ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" xlink:to="lab_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset_f6258c2a-bc05-4284-bb9c-b1c0dbfef8f4_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in contingent consideration, asset</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change In Amount Of Contingent Consideration, Asset</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change In Amount Of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_981a293f-8677-4907-b9ef-db73f7ae62cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_839870be-4d76-495a-8150-78edf8eab923_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f1aba52b-862f-4350-833e-9c063e2e9505_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_316865e9-4762-4083-b399-f303d414c74e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_f1414c3f-bf51-469e-b147-4d3da8f1e76b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment and restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3752aad9-e778-43ac-bd97-096d949622fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7c4e29ad-e32c-4e0d-9944-1f7877831a93_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_520f46b7-5176-4f52-a384-4b5cf083dbb4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_d46a40f6-22f2-4a0a-b011-7214fcd165ee_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_48da0f7f-64d9-47c2-a35c-fdc3dfac2c59_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_c97635f2-1013-4b5a-9892-a0b2bff46729_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accruals</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e3722586-0e58-4eb1-8d7a-6e365e036313_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e9276b31-6d64-49c6-94db-e3e1a2406b91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_A2025ShareRepurchaseProgramMember_8764e609-e5ca-4244-9286-b363642e7a5c_terseLabel_en-US" xlink:label="lab_ebs_A2025ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Share Repurchase Program</link:label>
    <link:label id="lab_ebs_A2025ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_ebs_A2025ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_ebs_A2025ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_ebs_A2025ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2025ShareRepurchaseProgramMember" xlink:href="ebs-20250930.xsd#ebs_A2025ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_A2025ShareRepurchaseProgramMember" xlink:to="lab_ebs_A2025ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_586e6518-6e70-442b-833d-dbe487e13310_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_96f672fc-d59c-4031-a628-4a4983595aae_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6b3e71d4-6cd8-44ca-a6ae-603e6cd2c4b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b2bb3cc4-8086-4830-809f-bec538a6dad6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_843d5fe6-0393-4197-9a90-d580c6ff54b6_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_353a7696-121a-4442-988b-46a5dc230314_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2eed9029-8c13-4443-a970-f10edd529a1e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_5d4b84eb-5dce-456f-8281-fae0fa2ccb83_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CommercialProductsSegmentMember_d39eddbc-d6a5-4cfc-a607-d05eeaca0ab2_terseLabel_en-US" xlink:label="lab_ebs_CommercialProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Products</link:label>
    <link:label id="lab_ebs_CommercialProductsSegmentMember_label_en-US" xlink:label="lab_ebs_CommercialProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Products Segment [Member]</link:label>
    <link:label id="lab_ebs_CommercialProductsSegmentMember_documentation_en-US" xlink:label="lab_ebs_CommercialProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember" xlink:href="ebs-20250930.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CommercialProductsSegmentMember" xlink:to="lab_ebs_CommercialProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8e909fb9-5117-4d33-a3f7-5fe378561b3d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f340566d-eb54-45de-97dc-c40263367830_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7bfb407e-a251-4382-8ff0-d63cd78884df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_e39a92ca-4873-482e-b44e-732d8a3638a6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, accrual, current</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_c4c05509-27b9-4f2c-bcdc-69bbc613b57c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Medium-Term Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b0e97e13-db1a-4b8f-a801-6f5fc9f92e83_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77291585-ae85-4fb6-8f0f-8490a279ad14_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_035fce81-8291-4e66-86c8-8d766c3b89ad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements_bd3f3a79-41cd-41be-9b42-f427ed21fe28_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of vesting increments</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Vesting Increments</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Vesting Increments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" xlink:to="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b8bf327e-6f3b-484a-a432-b8a6fa36013b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4796abe7-970a-428d-8152-d273efef1103_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_bc9b018c-240c-4b46-9b1a-ff2d9853b3cb_terseLabel_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Notes Due August 2028</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_label_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Notes Due August 2028 [Member]</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_documentation_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Notes Due August 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:href="ebs-20250930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:to="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_0f6483a5-5ce6-48f5-ac33-cb8cf913a6c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workforce reduction</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eabafb58-3c01-4433-b957-4ffcb80fc0cd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_158e2b3e-ff45-4313-a2d9-fb9246e4a351_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RSDLMember_29bbe262-b67f-4047-8bcf-fb5145557f8a_terseLabel_en-US" xlink:label="lab_ebs_RSDLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSDL</link:label>
    <link:label id="lab_ebs_RSDLMember_label_en-US" xlink:label="lab_ebs_RSDLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSDL [Member]</link:label>
    <link:label id="lab_ebs_RSDLMember_documentation_en-US" xlink:label="lab_ebs_RSDLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RSDL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RSDLMember" xlink:href="ebs-20250930.xsd#ebs_RSDLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RSDLMember" xlink:to="lab_ebs_RSDLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_13c534bd-c8f9-4542-87d4-904c317b5bc4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_18378b95-1621-4257-a6da-92326c1a77bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c1de6002-f65a-4ca9-9891-d105c4238ede_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d07d9793-7774-4d29-b121-2a4d7be09c27_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4c46676d-31ec-4a63-8818-d7ae09877c0a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of the business and organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_765cc042-1007-460e-9a59-83597aec1c13_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of debt, net of lender fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_44d9f01c-cbb7-4b0a-b1f0-466dfa89c78f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b9417829-69e7-448e-b72b-af8879277c1c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_55b263ce-9b44-40d2-8163-07eb4c0c50f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3e6d8fca-0e12-417e-9475-b9e2974dff4c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_4dace248-1251-411b-bb10-58aa7bfd9e7a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_0173128d-0d62-4970-b047-6cf1b4236655_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 7.9 and 5.6 common shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f7a27028-f47d-4d8e-92de-08d55ff0b43c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e628c8e-4c3c-4cb5-afcd-6e01f8159994_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_a9655bd3-d425-4f92-be75-5c54d8517e14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SecuritiesAndShareholderLitigationMember_233c1bef-22d8-403a-8e05-b79749b80dc8_terseLabel_en-US" xlink:label="lab_ebs_SecuritiesAndShareholderLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities And Shareholder Litigation</link:label>
    <link:label id="lab_ebs_SecuritiesAndShareholderLitigationMember_label_en-US" xlink:label="lab_ebs_SecuritiesAndShareholderLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities And Shareholder Litigation [Member]</link:label>
    <link:label id="lab_ebs_SecuritiesAndShareholderLitigationMember_documentation_en-US" xlink:label="lab_ebs_SecuritiesAndShareholderLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities And Shareholder Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SecuritiesAndShareholderLitigationMember" xlink:href="ebs-20250930.xsd#ebs_SecuritiesAndShareholderLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SecuritiesAndShareholderLitigationMember" xlink:to="lab_ebs_SecuritiesAndShareholderLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CommitmentsAndContingenciesDisclosureLineItems_4de71351-a742-433f-be30-d6cff839b8ad_terseLabel_en-US" xlink:label="lab_ebs_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_ebs_CommitmentsAndContingenciesDisclosureLineItems_label_en-US" xlink:label="lab_ebs_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_ebs_CommitmentsAndContingenciesDisclosureLineItems_documentation_en-US" xlink:label="lab_ebs_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems" xlink:href="ebs-20250930.xsd#ebs_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="lab_ebs_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_21b78e0e-acb7-4d3d-a496-8286adb5c794_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_53f7e06d-ec8d-4e8d-a12c-9760c76201b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_45709f03-aef2-48f2-99c1-84fc9106097a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SECEnforcementProceedingMember_3623c9e0-c36e-444f-9c47-4ccd81c15e47_terseLabel_en-US" xlink:label="lab_ebs_SECEnforcementProceedingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Enforcement Proceeding</link:label>
    <link:label id="lab_ebs_SECEnforcementProceedingMember_label_en-US" xlink:label="lab_ebs_SECEnforcementProceedingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Enforcement Proceeding [Member]</link:label>
    <link:label id="lab_ebs_SECEnforcementProceedingMember_documentation_en-US" xlink:label="lab_ebs_SECEnforcementProceedingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SEC Enforcement Proceeding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SECEnforcementProceedingMember" xlink:href="ebs-20250930.xsd#ebs_SECEnforcementProceedingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SECEnforcementProceedingMember" xlink:to="lab_ebs_SECEnforcementProceedingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7cbfa4e4-f22a-46b3-b8d3-3eaa17abf707_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d71bcca-6059-41d0-9138-a96383beb440_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90aaf4e6-c6b7-43a1-a6d7-e0d652873fac_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares outstanding-basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_2d6b5e90-3ef6-4102-8353-bb736f0b847f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c642847a-d060-405c-9164-74b7cae09ea0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_28bceb9d-aa9c-40fd-be65-a9e1c688fd92_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a4f45158-7a8a-4109-a3e5-f4f373fadd62_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of product and services sales, net</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ef9c2e43-e33c-4344-bc08-ffb93e3231eb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_e1861df6-61c1-41bb-ae7e-76e0e9b132a8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f23a38d1-96b5-4ef1-b12a-f34098751071_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EmployeeTransitionMember_3236a72e-cf58-47e3-a5e0-d6c6aa6cdd42_terseLabel_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee transition</link:label>
    <link:label id="lab_ebs_EmployeeTransitionMember_label_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Transition [Member]</link:label>
    <link:label id="lab_ebs_EmployeeTransitionMember_documentation_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Transition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember" xlink:href="ebs-20250930.xsd#ebs_EmployeeTransitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EmployeeTransitionMember" xlink:to="lab_ebs_EmployeeTransitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit_4d3a2996-e62d-49a3-a95b-5d6dfe792e8a_terseLabel_en-US" xlink:label="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity, decrease limit</link:label>
    <link:label id="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit_label_en-US" xlink:label="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Decrease Limit</link:label>
    <link:label id="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit_documentation_en-US" xlink:label="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Decrease Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" xlink:href="ebs-20250930.xsd#ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" xlink:to="lab_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SalesBasedMilestonesMember_73ae92f7-ac6a-4865-ba30-4a5c9d4e357e_terseLabel_en-US" xlink:label="lab_ebs_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_ebs_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_ebs_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_ebs_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_ebs_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SalesBasedMilestonesMember" xlink:href="ebs-20250930.xsd#ebs_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SalesBasedMilestonesMember" xlink:to="lab_ebs_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d611f017-b0d5-407b-9419-fff46454e7aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_36af22e4-68c5-492c-9994-595543663070_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_7c54f654-1d59-40e7-aff7-380ce788e301_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_538a9e33-2b8f-484b-82ea-a4e0448d1c0d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_70e42be4-2a54-4075-8b3e-3c58bbccfaae_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CommercialProductMember_985d9ebc-3a48-404d-b684-3c64f8105b57_terseLabel_en-US" xlink:label="lab_ebs_CommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Product sales</link:label>
    <link:label id="lab_ebs_CommercialProductMember_label_en-US" xlink:label="lab_ebs_CommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Product [Member]</link:label>
    <link:label id="lab_ebs_CommercialProductMember_documentation_en-US" xlink:label="lab_ebs_CommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember" xlink:href="ebs-20250930.xsd#ebs_CommercialProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CommercialProductMember" xlink:to="lab_ebs_CommercialProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4554d17a-c83d-4c38-96ab-03aa69e5406f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_fe5bc896-3fe3-496c-9b63-f3b2a8455252_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_74eb92e1-debb-488d-94f6-ef617ec025ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f8fd15ff-184d-413c-a778-2ed885b1f7c3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5f5d61bf-653f-42e3-a765-9bee562afb92_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c39d7c8-7f69-452a-939c-4061531ebe1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_d171044d-dd66-4ceb-ac57-e7a00694768a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from legal settlements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLegalSettlements" xlink:to="lab_us-gaap_ProceedsFromLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_e0a8db80-84dc-4677-a7df-567e6d29ac82_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_e5a4c9f3-35fe-4100-b972-18ef6369bb28_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_4dffec55-49b7-4d66-99e1-3f5aee4af719_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fa60ad16-45b2-4b50-a089-63a8a8938a2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4e441dbf-a7e1-4e50-95ad-179745e08b58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Hierarchy of Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_caa78e60-fb53-4373-8bb0-16531e2e495d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_3fe88d8a-94fa-42c1-8d5b-21d8aae3c553_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds allocated to warrants issued in conjunction with debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ea98ea7b-9141-415a-9646-5fd7efe92439_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_eb3f5e08-75c0-4072-989e-76521ef95358_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_dd8a02bb-c010-4ded-9d5c-942a46d746ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1c30e0f3-2690-48c0-b467-b2e38e324496_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_60b14fda-9faf-47b7-92d3-bed57b65b450_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_fb8277a5-4fb6-4f42-be7e-68af27fbaf7e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchased face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7a53281b-3d0b-459c-8aec-f522f9070919_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5e73d236-6f7f-4950-9fa2-e61458fcadd5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8615325d-b555-4c40-9d03-b3ac4daa0c9f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4bdef019-8605-429c-89a5-13e680935e78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_690a92c3-6b3c-432d-82d7-c5893a8ad11d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_5aa270dc-fef6-4884-9f99-8f4e1d8b525b_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_96481813-cccb-4621-9bad-22ee2f78bff7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_82ff50f7-69fc-4b69-ad19-ad88090f25a9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MedicalCountermeasuresMCMProductMember_9e8d62fa-1744-4577-868f-ceb878c4a499_terseLabel_en-US" xlink:label="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Product sales</link:label>
    <link:label id="lab_ebs_MedicalCountermeasuresMCMProductMember_label_en-US" xlink:label="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Countermeasures (MCM) Product [Member]</link:label>
    <link:label id="lab_ebs_MedicalCountermeasuresMCMProductMember_documentation_en-US" xlink:label="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Countermeasures (MCM) Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember" xlink:href="ebs-20250930.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MedicalCountermeasuresMCMProductMember" xlink:to="lab_ebs_MedicalCountermeasuresMCMProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_eeabe231-e807-4dde-9863-6fd480a79745_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c2a9ea3e-1902-4b86-902e-4c7ba8422186_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a27c9e61-5bd3-4256-b1fb-047421efec96_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ebs-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0b2479a1-7a21-4fa0-a33e-3a3a5f4f1cad,g:c7797084-9f00-4c6d-b9c9-e4498d399b6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:type="simple" xlink:href="ebs-20250930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fe1ebc45-77dc-47c9-b3fe-4292885e3384" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_DocumentType_fe1ebc45-77dc-47c9-b3fe-4292885e3384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fc1919a0-027c-4cce-acb6-107314057fca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_DocumentQuarterlyReport_fc1919a0-027c-4cce-acb6-107314057fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_316094bb-f93b-42d7-a60a-4254f59054ad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_DocumentPeriodEndDate_316094bb-f93b-42d7-a60a-4254f59054ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_257bdbd5-2b12-4c3a-aa38-bac8b82cf1e9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_DocumentTransitionReport_257bdbd5-2b12-4c3a-aa38-bac8b82cf1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_022bf0e5-6d7e-43ba-a0e8-529d80a054ba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityFileNumber_022bf0e5-6d7e-43ba-a0e8-529d80a054ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_446d36b3-0cca-4cd5-9884-263bc6bea528" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityRegistrantName_446d36b3-0cca-4cd5-9884-263bc6bea528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_942525df-8ccf-48fd-8e36-37fe96490d4b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityIncorporationStateCountryCode_942525df-8ccf-48fd-8e36-37fe96490d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4e3d0482-2b67-48a9-9980-d5f3c93d1540" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityTaxIdentificationNumber_4e3d0482-2b67-48a9-9980-d5f3c93d1540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2e5010cd-9dd1-4b5d-8005-ef9159f4cf58" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityAddressAddressLine1_2e5010cd-9dd1-4b5d-8005-ef9159f4cf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_99aeca2a-4a16-4e94-b9f1-8b763939921a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityAddressCityOrTown_99aeca2a-4a16-4e94-b9f1-8b763939921a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5a3eba85-15d4-4489-8bfd-ae3333bd35e9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityAddressStateOrProvince_5a3eba85-15d4-4489-8bfd-ae3333bd35e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a2bc74e8-88b1-498d-a867-55d22a02a8df" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityAddressPostalZipCode_a2bc74e8-88b1-498d-a867-55d22a02a8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_468dc98f-52d3-4622-988e-a4ac08bd680e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_CityAreaCode_468dc98f-52d3-4622-988e-a4ac08bd680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f072e03f-37b3-4959-8437-85892dd2dd9d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_LocalPhoneNumber_f072e03f-37b3-4959-8437-85892dd2dd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7aabb672-27d9-43e6-b5ae-cef941736929" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_Security12bTitle_7aabb672-27d9-43e6-b5ae-cef941736929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b75bff6a-1661-413d-9bdd-30f15ec2fbe6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_TradingSymbol_b75bff6a-1661-413d-9bdd-30f15ec2fbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_90396d69-f8a0-4e0e-97b1-3e10598deda8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_SecurityExchangeName_90396d69-f8a0-4e0e-97b1-3e10598deda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c8b95095-88e4-423d-81df-d574a6541bd9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityCurrentReportingStatus_c8b95095-88e4-423d-81df-d574a6541bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2c5816cf-936d-413f-891b-bf8c57924ca8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityInteractiveDataCurrent_2c5816cf-936d-413f-891b-bf8c57924ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5e75749f-ba7f-43eb-b7ad-8606da7d3a22" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityFilerCategory_5e75749f-ba7f-43eb-b7ad-8606da7d3a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_34df0cc5-cfcc-41e7-8eed-f92d6c0aa04a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntitySmallBusiness_34df0cc5-cfcc-41e7-8eed-f92d6c0aa04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_23c72645-92f2-4dcc-a97d-c7c05cac8199" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityEmergingGrowthCompany_23c72645-92f2-4dcc-a97d-c7c05cac8199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1663df34-73db-45fa-a7d3-fc1cd4b9ed05" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityShellCompany_1663df34-73db-45fa-a7d3-fc1cd4b9ed05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_74fbfeca-9245-4f88-9c05-de8032b49945" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_74fbfeca-9245-4f88-9c05-de8032b49945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e5597a02-42bf-475d-844c-28d7fa0e53b6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_EntityCentralIndexKey_e5597a02-42bf-475d-844c-28d7fa0e53b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6e58caba-8317-4346-97e4-381c5eb0a0a2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_CurrentFiscalYearEndDate_6e58caba-8317-4346-97e4-381c5eb0a0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8046fe7a-b5e7-4940-9b29-46a8ebed2dd7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_AmendmentFlag_8046fe7a-b5e7-4940-9b29-46a8ebed2dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1dd5cd26-0397-45f2-8d48-1e0fd459c862" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_DocumentFiscalYearFocus_1dd5cd26-0397-45f2-8d48-1e0fd459c862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d58cfd6c-634e-4f84-8edd-37c35bb00523" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9446574f-35d6-4bb9-a4a7-a1aa967a8549" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d58cfd6c-634e-4f84-8edd-37c35bb00523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_70d471b2-8953-4ae8-b3c2-796b8c858717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0349566d-a8dc-4dca-843d-e5e3851a571d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_70d471b2-8953-4ae8-b3c2-796b8c858717" xlink:to="loc_us-gaap_AssetsAbstract_0349566d-a8dc-4dca-843d-e5e3851a571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0349566d-a8dc-4dca-843d-e5e3851a571d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54d3f150-c5da-4571-8993-0f74dce4d9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54d3f150-c5da-4571-8993-0f74dce4d9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_8805faba-9b3e-43bb-a636-3bd9d0b9983f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:to="loc_us-gaap_RestrictedCashCurrent_8805faba-9b3e-43bb-a636-3bd9d0b9983f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8dd95097-c725-4c77-ad24-3f6821bc5d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8dd95097-c725-4c77-ad24-3f6821bc5d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6832080f-d1ab-4914-ab93-a98129a4734a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:to="loc_us-gaap_InventoryNet_6832080f-d1ab-4914-ab93-a98129a4734a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccd991b3-cd02-4d72-bd4b-55b213105347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccd991b3-cd02-4d72-bd4b-55b213105347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_19f3267f-4b69-4608-afe6-66ab35971a91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_19f3267f-4b69-4608-afe6-66ab35971a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_41d80439-9e2d-4fed-8ecc-f994252cc145" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_72e9f2f9-cc77-45ed-9cd1-4dcf38965c3f" xlink:to="loc_us-gaap_AssetsCurrent_41d80439-9e2d-4fed-8ecc-f994252cc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f466d1e-8db3-4989-9a5d-738225457e95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0349566d-a8dc-4dca-843d-e5e3851a571d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f466d1e-8db3-4989-9a5d-738225457e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1ac48d8e-eed1-4caf-8b29-adaaf93a9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0349566d-a8dc-4dca-843d-e5e3851a571d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1ac48d8e-eed1-4caf-8b29-adaaf93a9e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c1ea181e-3504-4679-bc7e-0c95efc70bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0349566d-a8dc-4dca-843d-e5e3851a571d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c1ea181e-3504-4679-bc7e-0c95efc70bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e0f08caa-5d67-41b1-be69-b59d361ac6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0349566d-a8dc-4dca-843d-e5e3851a571d" xlink:to="loc_us-gaap_Assets_e0f08caa-5d67-41b1-be69-b59d361ac6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_70d471b2-8953-4ae8-b3c2-796b8c858717" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_181f5a0b-1204-4d5e-940d-3cb9e6adb6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:to="loc_us-gaap_AccountsPayableCurrent_181f5a0b-1204-4d5e-940d-3cb9e6adb6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d1431e4-bf5f-48db-a9e7-1299f6b5f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1d1431e4-bf5f-48db-a9e7-1299f6b5f7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_252988a6-3a4c-4d8c-9428-1725eb433099" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_252988a6-3a4c-4d8c-9428-1725eb433099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ae4bdaf8-69b2-40b0-88e7-5300463a0bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ae4bdaf8-69b2-40b0-88e7-5300463a0bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_eadf645d-bd2d-4170-a07d-9443acab783a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_eadf645d-bd2d-4170-a07d-9443acab783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_62d501b0-27ac-4469-9e10-cd0c9f742c77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_48d2ed3d-d7dd-4832-8ada-702ea2dedb4f" xlink:to="loc_us-gaap_LiabilitiesCurrent_62d501b0-27ac-4469-9e10-cd0c9f742c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7dabfac0-e9ce-4a6b-9150-eb0c7372be2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7dabfac0-e9ce-4a6b-9150-eb0c7372be2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08129c37-9efb-4a89-8cd4-db7ce7d3c727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08129c37-9efb-4a89-8cd4-db7ce7d3c727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_91fb14aa-a6d8-41ba-b45e-6b23f892236f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_91fb14aa-a6d8-41ba-b45e-6b23f892236f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ecc73689-b9d0-4973-a012-5f077ae4afcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:to="loc_us-gaap_Liabilities_ecc73689-b9d0-4973-a012-5f077ae4afcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5a48d742-eef1-42d6-8baa-7fc8b2bb81d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:to="loc_us-gaap_PreferredStockValue_5a48d742-eef1-42d6-8baa-7fc8b2bb81d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_935e587c-92ff-4acf-bf8e-68f2dbaf0961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:to="loc_us-gaap_CommonStockValue_935e587c-92ff-4acf-bf8e-68f2dbaf0961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_1785b64f-9559-46e8-bcc5-6a873a4d5903" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:to="loc_us-gaap_TreasuryStockCommonValue_1785b64f-9559-46e8-bcc5-6a873a4d5903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_411d755b-d526-42e2-9ca5-2279d1eeb7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:to="loc_us-gaap_AdditionalPaidInCapital_411d755b-d526-42e2-9ca5-2279d1eeb7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f438ca4-9b87-4442-9107-dba683ab0e89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f438ca4-9b87-4442-9107-dba683ab0e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3975caf0-601d-4f58-9b79-2786d971db57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3975caf0-601d-4f58-9b79-2786d971db57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_148254da-b324-460a-8a39-0212f8b41a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cbcc466c-fd8e-401f-8836-85c54e3a5055" xlink:to="loc_us-gaap_StockholdersEquity_148254da-b324-460a-8a39-0212f8b41a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bc98f26a-eebd-4dab-8cbd-9c928f4b5d57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49b2ad85-92dd-4030-985a-c7ed3124db6b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bc98f26a-eebd-4dab-8cbd-9c928f4b5d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_94b53b1c-a85f-4b43-b9e3-d930dfd73def" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bc8b8f6-6579-47ae-8d5d-d4f96f371bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_94b53b1c-a85f-4b43-b9e3-d930dfd73def" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bc8b8f6-6579-47ae-8d5d-d4f96f371bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5bc8b8f6-6579-47ae-8d5d-d4f96f371bb6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28d1a2f6-0fd0-4847-b42f-0292b60d9149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28d1a2f6-0fd0-4847-b42f-0292b60d9149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8365be1b-3d6d-42f4-8051-6d2e6acd8c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8365be1b-3d6d-42f4-8051-6d2e6acd8c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_885bdb92-fce9-4f90-8f6e-c9a7db4c00c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_885bdb92-fce9-4f90-8f6e-c9a7db4c00c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e8755479-c3fb-4b0a-ab03-b8a16dc4a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e8755479-c3fb-4b0a-ab03-b8a16dc4a45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0833680d-bf60-49c7-b4ef-97e09a2924a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0833680d-bf60-49c7-b4ef-97e09a2924a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a428fb9b-4572-4684-a937-5fb3ad3b280b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a428fb9b-4572-4684-a937-5fb3ad3b280b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_298de596-50de-4f5b-ac55-3af2660ae013" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_CommonStockSharesIssued_298de596-50de-4f5b-ac55-3af2660ae013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b2e847ca-ae90-45d4-a0b4-6ca8aae8e818" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b2e847ca-ae90-45d4-a0b4-6ca8aae8e818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_3eaafb39-d6f0-4be6-a292-93b2229c63fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ce14ff7-5a78-4b89-8444-75af5efcb7d7" xlink:to="loc_us-gaap_TreasuryStockCommonShares_3eaafb39-d6f0-4be6-a292-93b2229c63fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a0c07a3e-413b-4fcf-bc8b-d12174154fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ff0ce10d-5d3b-4e85-820c-429d57f9a961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a0c07a3e-413b-4fcf-bc8b-d12174154fcc" xlink:to="loc_us-gaap_StatementTable_ff0ce10d-5d3b-4e85-820c-429d57f9a961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89057094-1d7e-46d6-b630-ce39162a1df5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ff0ce10d-5d3b-4e85-820c-429d57f9a961" xlink:to="loc_srt_ProductOrServiceAxis_89057094-1d7e-46d6-b630-ce39162a1df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_89057094-1d7e-46d6-b630-ce39162a1df5" xlink:to="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductAndServiceMember_355d98b8-1d7a-4dbb-89b9-f296dcc4c644" xlink:href="ebs-20250930.xsd#ebs_ProductAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:to="loc_ebs_ProductAndServiceMember_355d98b8-1d7a-4dbb-89b9-f296dcc4c644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_601f0aad-1c03-4a27-a255-f754474b47fa" xlink:href="ebs-20250930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_33248789-d53b-43d4-8168-226943a90e51" xlink:to="loc_ebs_ContractsAndGrantsMember_601f0aad-1c03-4a27-a255-f754474b47fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ff0ce10d-5d3b-4e85-820c-429d57f9a961" xlink:to="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8a8acd9c-41a1-4dd9-a118-27cfd381d32d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_RevenuesAbstract_8a8acd9c-41a1-4dd9-a118-27cfd381d32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c3ce4ed-447b-4abb-9950-49cb4dce8308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8a8acd9c-41a1-4dd9-a118-27cfd381d32d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c3ce4ed-447b-4abb-9950-49cb4dce8308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_71300465-0799-430f-bde7-d5f692420e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_71300465-0799-430f-bde7-d5f692420e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_77d503b1-9351-48ba-a191-d05a8c40f2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_77d503b1-9351-48ba-a191-d05a8c40f2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba2831d6-ec9b-423e-bc4d-95001ad1055d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba2831d6-ec9b-423e-bc4d-95001ad1055d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d6dbf05a-e7b5-4911-8c66-af1819b7da98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d6dbf05a-e7b5-4911-8c66-af1819b7da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7282be29-df6b-4c1b-994c-d15d3f852225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7282be29-df6b-4c1b-994c-d15d3f852225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_11b2c090-b40c-4ddc-b5e7-180be040f9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3edf2055-c829-4b79-9daf-7413033be225" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_11b2c090-b40c-4ddc-b5e7-180be040f9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a83da38-7323-4b60-866b-3bbf565bcbff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_OperatingIncomeLoss_8a83da38-7323-4b60-866b-3bbf565bcbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_cd31f246-54ae-47f6-aa7c-7505197fdd38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_InterestExpenseNonoperating_cd31f246-54ae-47f6-aa7c-7505197fdd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_18c51bea-4ebc-43ca-a2a3-345fad79f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_18c51bea-4ebc-43ca-a2a3-345fad79f80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5fcf5940-1b76-4f7b-ae7e-26ca31a4a1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5fcf5940-1b76-4f7b-ae7e-26ca31a4a1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8ed513a6-c7ed-4ddb-b4fd-cde3714baf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_657824bd-e2b3-4c88-8979-11b128494288" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8ed513a6-c7ed-4ddb-b4fd-cde3714baf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bac58222-fe74-4375-bbab-61fd9ca2d6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bac58222-fe74-4375-bbab-61fd9ca2d6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aa9559df-bfb2-4803-9a17-790ac0eccb95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aa9559df-bfb2-4803-9a17-790ac0eccb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_086bf939-bd03-4f7b-8ce5-97d24ab4fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_NetIncomeLoss_086bf939-bd03-4f7b-8ce5-97d24ab4fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b601ec66-faa6-41fc-9f68-07a4c89511f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:to="loc_us-gaap_EarningsPerShareBasic_b601ec66-faa6-41fc-9f68-07a4c89511f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f36e95d3-2a10-45cf-926d-3a823c0d23a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_bebcce78-565a-478f-9768-96ef285fcc42" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f36e95d3-2a10-45cf-926d-3a823c0d23a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_58ee9eda-d9f3-4171-8009-4224d30b8591" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3e2749b1-f3f9-4a3a-ae08-476c1adfc19f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3e2749b1-f3f9-4a3a-ae08-476c1adfc19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3f7cde4-96da-4265-9c39-4bfed524e969" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_974176ab-f4f2-4d26-b8b2-d8ea90dd5e8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e3f7cde4-96da-4265-9c39-4bfed524e969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fc30498-1a01-42b6-bd48-91a49ab491a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_82e925b6-e6ed-44a6-bd1a-9f50aca549b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fc30498-1a01-42b6-bd48-91a49ab491a5" xlink:to="loc_us-gaap_NetIncomeLoss_82e925b6-e6ed-44a6-bd1a-9f50aca549b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9decf75e-a039-4f01-93c5-818dd0d63419" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fc30498-1a01-42b6-bd48-91a49ab491a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9decf75e-a039-4f01-93c5-818dd0d63419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_53a9aa38-5d9e-4329-99ad-dc9b8c9fe919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9decf75e-a039-4f01-93c5-818dd0d63419" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_53a9aa38-5d9e-4329-99ad-dc9b8c9fe919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d3190a07-4091-4891-ad80-a2cb27215846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9decf75e-a039-4f01-93c5-818dd0d63419" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d3190a07-4091-4891-ad80-a2cb27215846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dff1173c-a455-422e-ae58-f3af13aed775" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fc30498-1a01-42b6-bd48-91a49ab491a5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dff1173c-a455-422e-ae58-f3af13aed775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_602f9a0a-1edc-4a32-943f-dbbba57bfa76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_602f9a0a-1edc-4a32-943f-dbbba57bfa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74a1b5b9-d7cc-4f1b-a222-89a40876e63d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_602f9a0a-1edc-4a32-943f-dbbba57bfa76" xlink:to="loc_us-gaap_NetIncomeLoss_74a1b5b9-d7cc-4f1b-a222-89a40876e63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_602f9a0a-1edc-4a32-943f-dbbba57bfa76" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7617c6e6-b360-4d3e-ab21-3a85e535c161" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_ShareBasedCompensation_7617c6e6-b360-4d3e-ab21-3a85e535c161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_95ea1dd8-8dde-4db4-924b-ff80418fdaba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_95ea1dd8-8dde-4db4-924b-ff80418fdaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_483a073e-4658-45cc-b53b-7586cb8218be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_483a073e-4658-45cc-b53b-7586cb8218be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d4ac52e5-6f9f-4d1c-954a-ca5cfe1ded36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d4ac52e5-6f9f-4d1c-954a-ca5cfe1ded36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8f76ef8a-6379-4910-9bc3-333fd641bb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8f76ef8a-6379-4910-9bc3-333fd641bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts_583b80b9-e5c4-401e-bb2e-ceff41b6417d" xlink:href="ebs-20250930.xsd#ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts_583b80b9-e5c4-401e-bb2e-ceff41b6417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a011bed3-1535-492f-a248-4a43c6da96ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a011bed3-1535-492f-a248-4a43c6da96ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_fffc2928-9ff8-4a51-8ac9-271c12af4684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_fffc2928-9ff8-4a51-8ac9-271c12af4684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_d620b7cc-b690-4690-80f1-d4ff147b956c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_d620b7cc-b690-4690-80f1-d4ff147b956c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_648e1aab-c4d7-4af1-ac37-cd74b4c47f73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_648e1aab-c4d7-4af1-ac37-cd74b4c47f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_682528d0-f443-4fb5-bb8f-375d9aa4a22b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_785cfcaa-6f11-495c-ae2c-eb55d7613877" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_785cfcaa-6f11-495c-ae2c-eb55d7613877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e4191946-a48c-46cb-b310-1674823cf3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e4191946-a48c-46cb-b310-1674823cf3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a137794-dbb2-4c0f-979f-8cd0fe38fd84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a137794-dbb2-4c0f-979f-8cd0fe38fd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_315280cd-a910-41a1-b4e6-c3fbf364f01b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_315280cd-a910-41a1-b4e6-c3fbf364f01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_03ac76ad-19ab-4c9e-8c0d-c2cee6975aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_03ac76ad-19ab-4c9e-8c0d-c2cee6975aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_998bf474-f0e7-4753-be7f-16bd0b6e474d" xlink:href="ebs-20250930.xsd#ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual_998bf474-f0e7-4753-be7f-16bd0b6e474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7abe569b-c7b3-4ba5-9cf5-9ff018197449" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7abe569b-c7b3-4ba5-9cf5-9ff018197449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_bbbecaca-644f-484b-be83-141bf7830250" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_bbbecaca-644f-484b-be83-141bf7830250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_898912ea-02f9-4464-89ba-db332542df2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9383d41-0e61-4f08-91d6-de687e24e835" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_898912ea-02f9-4464-89ba-db332542df2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa46466b-b8b5-4bd5-be19-163197e79dce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_602f9a0a-1edc-4a32-943f-dbbba57bfa76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa46466b-b8b5-4bd5-be19-163197e79dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f1d655f0-e0d0-4f5a-981b-c29fe7f61d74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f1d655f0-e0d0-4f5a-981b-c29fe7f61d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_04554a91-b947-4677-8374-b1d84ae248dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_04554a91-b947-4677-8374-b1d84ae248dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities_63abf13c-fa42-40ac-9584-256fc68d6353" xlink:href="ebs-20250930.xsd#ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:to="loc_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities_63abf13c-fa42-40ac-9584-256fc68d6353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_8b8e1ba8-a2b7-4dbc-8c70-6f6add81cb69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_8b8e1ba8-a2b7-4dbc-8c70-6f6add81cb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_2d4de39b-8a28-437d-8da4-927b907d05e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_2d4de39b-8a28-437d-8da4-927b907d05e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca84a512-5f3e-420e-bc57-7a93a45fb393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f44519fd-1777-4cc8-8b57-bcbf88b01c11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca84a512-5f3e-420e-bc57-7a93a45fb393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f2d07770-c461-4d43-bb3b-c03df9f0b387" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_f2d07770-c461-4d43-bb3b-c03df9f0b387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_0be64179-4b8a-4214-b8a1-6dd946f8235c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_0be64179-4b8a-4214-b8a1-6dd946f8235c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt_14bc055a-8482-43bd-930a-4364946be616" xlink:href="ebs-20250930.xsd#ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt_14bc055a-8482-43bd-930a-4364946be616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_81357582-7ab7-4554-9966-e8373a5ed86b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_81357582-7ab7-4554-9966-e8373a5ed86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a70d741e-7dce-4954-80d8-3e5a83d76f28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_a70d741e-7dce-4954-80d8-3e5a83d76f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_befad86c-a27e-4b40-9738-c68703adf141" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_befad86c-a27e-4b40-9738-c68703adf141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_95a6918c-135a-408c-893c-0e9124923d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_95a6918c-135a-408c-893c-0e9124923d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0bf7f0a8-2e86-4d5e-b8f9-0cd2115ab963" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0bf7f0a8-2e86-4d5e-b8f9-0cd2115ab963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForRepurchaseOfDebt_2bcd72bf-bac4-4c25-9bb3-86a7088898cc" xlink:href="ebs-20250930.xsd#ebs_PaymentsForRepurchaseOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_ebs_PaymentsForRepurchaseOfDebt_2bcd72bf-bac4-4c25-9bb3-86a7088898cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c535cf61-6767-4a7d-8815-7c3dbd75239b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c535cf61-6767-4a7d-8815-7c3dbd75239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b3d5c435-2c4f-4be1-8aeb-6ba7ee85a392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b3d5c435-2c4f-4be1-8aeb-6ba7ee85a392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c587257d-80c9-4dcd-ab7f-1baf111bfbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c587257d-80c9-4dcd-ab7f-1baf111bfbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3ae465b-06ac-4ac9-8a95-1b6f0ebb1605" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_65fbcbf1-d70d-4387-b2d0-8c30b27b0914" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3ae465b-06ac-4ac9-8a95-1b6f0ebb1605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b8263ac-23eb-459d-b8f0-85c2d2f71c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b8263ac-23eb-459d-b8f0-85c2d2f71c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3de8089-de4a-43cb-915c-6b0245b565e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3de8089-de4a-43cb-915c-6b0245b565e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f1802af-242e-4f2b-b59d-0ad055ed2414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f1802af-242e-4f2b-b59d-0ad055ed2414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65b0574d-dba5-4498-afc4-2392010c8f50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65b0574d-dba5-4498-afc4-2392010c8f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d1fc371b-6ba1-4632-9374-ceb75698d1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d1fc371b-6ba1-4632-9374-ceb75698d1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_978892c4-8739-4632-b08d-94bccb37b363" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d1fc371b-6ba1-4632-9374-ceb75698d1f0" xlink:to="loc_us-gaap_InterestPaidNet_978892c4-8739-4632-b08d-94bccb37b363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_1d6df2d2-e26d-464d-94d5-35ea167b5bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d1fc371b-6ba1-4632-9374-ceb75698d1f0" xlink:to="loc_us-gaap_IncomeTaxesPaid_1d6df2d2-e26d-464d-94d5-35ea167b5bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5b0a5ab0-2935-4111-9d7d-d9f9c6d5ed53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5b0a5ab0-2935-4111-9d7d-d9f9c6d5ed53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cf0ff243-156c-4400-bddf-433e1c8cc2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5b0a5ab0-2935-4111-9d7d-d9f9c6d5ed53" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cf0ff243-156c-4400-bddf-433e1c8cc2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6f97236-05de-4546-9805-2ad9b145a6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5b0a5ab0-2935-4111-9d7d-d9f9c6d5ed53" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f6f97236-05de-4546-9805-2ad9b145a6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_5fcf762c-41d7-4745-9059-3c0a14a370ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5b0a5ab0-2935-4111-9d7d-d9f9c6d5ed53" xlink:to="loc_us-gaap_StockIssued1_5fcf762c-41d7-4745-9059-3c0a14a370ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_2f40445c-3773-469c-a786-fba0f1f7fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5b0a5ab0-2935-4111-9d7d-d9f9c6d5ed53" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_2f40445c-3773-469c-a786-fba0f1f7fe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0c99a9bb-7485-4873-a69e-a29598724d35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83e5eda8-84b0-4d3c-9615-30ddb16b1cb6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0c99a9bb-7485-4873-a69e-a29598724d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33020eec-ab15-4e1f-b0fd-9e3f4455f001" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0c99a9bb-7485-4873-a69e-a29598724d35" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33020eec-ab15-4e1f-b0fd-9e3f4455f001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_0e56175f-a6fb-43cf-bc8c-999b9a15616c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0c99a9bb-7485-4873-a69e-a29598724d35" xlink:to="loc_us-gaap_RestrictedCash_0e56175f-a6fb-43cf-bc8c-999b9a15616c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_85ce5191-4d2c-4527-958c-554ef058584e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0c99a9bb-7485-4873-a69e-a29598724d35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_85ce5191-4d2c-4527-958c-554ef058584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_75fd081a-4e27-4bd5-b8f3-81b1a6c311e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4432b429-e896-4163-8bb4-2649a04c412b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_75fd081a-4e27-4bd5-b8f3-81b1a6c311e2" xlink:to="loc_us-gaap_StatementTable_4432b429-e896-4163-8bb4-2649a04c412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a577697d-a17b-476f-b965-ed831e515f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4432b429-e896-4163-8bb4-2649a04c412b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a577697d-a17b-476f-b965-ed831e515f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a577697d-a17b-476f-b965-ed831e515f8c" xlink:to="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e8ce031-b297-46a0-8f24-ce167647ea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_CommonStockMember_9e8ce031-b297-46a0-8f24-ce167647ea2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_3ef1e2e6-e0a6-46f5-8171-2918086ba92e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_3ef1e2e6-e0a6-46f5-8171-2918086ba92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d417036-0725-4c63-91ec-fcdb5fb56a07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d417036-0725-4c63-91ec-fcdb5fb56a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00ffe2fc-8243-4a01-aa4a-748ac5c15288" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00ffe2fc-8243-4a01-aa4a-748ac5c15288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_deff608f-99d8-4fc3-b84f-7f30333763da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f2096d88-afd8-4824-b271-0f90a84987a6" xlink:to="loc_us-gaap_RetainedEarningsMember_deff608f-99d8-4fc3-b84f-7f30333763da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_295130d7-d404-4c2e-a576-1d0d685339fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4432b429-e896-4163-8bb4-2649a04c412b" xlink:to="loc_us-gaap_StatementLineItems_295130d7-d404-4c2e-a576-1d0d685339fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_295130d7-d404-4c2e-a576-1d0d685339fd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_efcd8a34-7e57-4b0c-8744-2df848391461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_CommonStockSharesIssued_efcd8a34-7e57-4b0c-8744-2df848391461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e1243383-0bb2-4f24-97c8-ba02009f656d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockholdersEquity_e1243383-0bb2-4f24-97c8-ba02009f656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_226bedbd-e202-4d64-9479-391ed29b3da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_TreasuryStockCommonShares_226bedbd-e202-4d64-9479-391ed29b3da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce9f8b6f-f549-496f-a1c2-6705ec4180c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_NetIncomeLoss_ce9f8b6f-f549-496f-a1c2-6705ec4180c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b7e88da9-0fc5-4a97-8810-93ba0b0ef35b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b7e88da9-0fc5-4a97-8810-93ba0b0ef35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8dc17403-815e-4b9b-907e-b9c6499079e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8dc17403-815e-4b9b-907e-b9c6499079e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_032e56b0-8e27-4883-994e-4a16d5e15efb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_032e56b0-8e27-4883-994e-4a16d5e15efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d4fa0496-8046-438f-a6f9-bf3b7e151005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d4fa0496-8046-438f-a6f9-bf3b7e151005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22554e11-7a8a-42de-9a45-a440390f3029" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_22554e11-7a8a-42de-9a45-a440390f3029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0d589a4-f4d0-4add-bfbe-0e3988d4f675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0d589a4-f4d0-4add-bfbe-0e3988d4f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f16202f9-f2f0-41ec-a3cd-88d2000745a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f16202f9-f2f0-41ec-a3cd-88d2000745a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e7d4e9ec-2bd5-4ab8-a871-7a024a9149b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_CommonStockSharesIssued_e7d4e9ec-2bd5-4ab8-a871-7a024a9149b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7a2aa8d3-454f-467d-acb7-1476ee841ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_StockholdersEquity_7a2aa8d3-454f-467d-acb7-1476ee841ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_274d49ac-bd98-4a00-8f89-fe4a2938202b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9004efb-a625-4133-a75e-b88f769eea7f" xlink:to="loc_us-gaap_TreasuryStockCommonShares_274d49ac-bd98-4a00-8f89-fe4a2938202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ebs-20250930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f007d267-b12d-4d5e-87f0-cc8cd089a014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c96e30a9-c837-4db5-8885-2973193e49c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f007d267-b12d-4d5e-87f0-cc8cd089a014" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c96e30a9-c837-4db5-8885-2973193e49c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization" xlink:type="simple" xlink:href="ebs-20250930.xsd#Natureofthebusinessandorganization"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abd60faa-051b-4eda-9c31-d69038835856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fa350392-7f4c-4cf5-8d01-a389f77501ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abd60faa-051b-4eda-9c31-d69038835856" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fa350392-7f4c-4cf5-8d01-a389f77501ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="ebs-20250930.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c3dd081-320c-4e6c-9c25-933634ddd922" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f56e75b0-bc99-40d1-8d65-9e21516cb0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c3dd081-320c-4e6c-9c25-933634ddd922" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f56e75b0-bc99-40d1-8d65-9e21516cb0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale" xlink:type="simple" xlink:href="ebs-20250930.xsd#Assetsandliabilitiesheldforsale"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5eb49c60-2663-436a-b83d-01dd88fa5453" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_993edecc-73f6-47c4-a034-2131445f9183" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5eb49c60-2663-436a-b83d-01dd88fa5453" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_993edecc-73f6-47c4-a034-2131445f9183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Divestitures" xlink:type="simple" xlink:href="ebs-20250930.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_35c215b0-a3e2-410f-96e8-6b0825a20d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_13fcbff3-4b18-4d4e-a629-75caf56ff9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_35c215b0-a3e2-410f-96e8-6b0825a20d0b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_13fcbff3-4b18-4d4e-a629-75caf56ff9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Impairmentandrestructuringcharges" xlink:type="simple" xlink:href="ebs-20250930.xsd#Impairmentandrestructuringcharges"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Impairmentandrestructuringcharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a9b7459a-54c9-44bd-a43a-8d661c18db85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_0f3debe6-ec18-4a7c-aba3-4a53a921b080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a9b7459a-54c9-44bd-a43a-8d661c18db85" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_0f3debe6-ec18-4a7c-aba3-4a53a921b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="simple" xlink:href="ebs-20250930.xsd#Inventoriesnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7dbd0f03-72f0-43e0-a96b-04ff9311466c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_f7bef6d8-e51d-4594-88cd-cc8d588a3b77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7dbd0f03-72f0-43e0-a96b-04ff9311466c" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_f7bef6d8-e51d-4594-88cd-cc8d588a3b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="simple" xlink:href="ebs-20250930.xsd#Propertyplantandequipmentnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_172905b7-1ab5-4d1c-9dfd-b2355302f10b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c9c80606-a725-490d-8ac9-811e9394e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_172905b7-1ab5-4d1c-9dfd-b2355302f10b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c9c80606-a725-490d-8ac9-811e9394e84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Intangibleassets" xlink:type="simple" xlink:href="ebs-20250930.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b1c5908-ae23-4bd5-acb1-b54244bf356f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b892d33b-360b-4701-a404-3426fc57002f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b1c5908-ae23-4bd5-acb1-b54244bf356f" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b892d33b-360b-4701-a404-3426fc57002f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="ebs-20250930.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_083efcdd-9452-405e-b6cc-c0fb5b5ccde8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ebd7ae82-8a9f-4bcb-b314-785516dddb74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_083efcdd-9452-405e-b6cc-c0fb5b5ccde8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ebd7ae82-8a9f-4bcb-b314-785516dddb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:type="simple" xlink:href="ebs-20250930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e57966f1-faf0-428e-a3c8-1c38be646152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e65f5be8-73ff-4463-8fa4-12b2559711db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e57966f1-faf0-428e-a3c8-1c38be646152" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e65f5be8-73ff-4463-8fa4-12b2559711db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity" xlink:type="simple" xlink:href="ebs-20250930.xsd#Sharebasedcompensationandstockholdersequity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ab640f96-91c6-477e-ac0a-7391805dabc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_21967972-68cd-475c-85ec-33414a445e16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ab640f96-91c6-477e-ac0a-7391805dabc8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_21967972-68cd-475c-85ec-33414a445e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Earningslosspercommonshare" xlink:type="simple" xlink:href="ebs-20250930.xsd#Earningslosspercommonshare"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Earningslosspercommonshare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d2d6023-3a3d-4270-9121-71f4d518a0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_015dd5ec-bfde-4fa8-9fdc-38d99e5803d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d2d6023-3a3d-4270-9121-71f4d518a0a8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_015dd5ec-bfde-4fa8-9fdc-38d99e5803d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="simple" xlink:href="ebs-20250930.xsd#Revenuerecognition"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05e15d22-dd0a-40a1-aaee-615fdfcf3697" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_c7ae8dc4-f846-4fa2-a605-021534c9bf55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05e15d22-dd0a-40a1-aaee-615fdfcf3697" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_c7ae8dc4-f846-4fa2-a605-021534c9bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:type="simple" xlink:href="ebs-20250930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_311e7119-3290-45ab-8f1e-66bd8345e2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_741ff8cf-035d-4897-9ded-019ca8d65188" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_311e7119-3290-45ab-8f1e-66bd8345e2e3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_741ff8cf-035d-4897-9ded-019ca8d65188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="simple" xlink:href="ebs-20250930.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b073a2ec-58dc-48ae-b34a-283a22359af5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d98e9b22-ffcb-4045-9bb1-968f54607d40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b073a2ec-58dc-48ae-b34a-283a22359af5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d98e9b22-ffcb-4045-9bb1-968f54607d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Litigation" xlink:type="simple" xlink:href="ebs-20250930.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61d870cc-c1f2-4522-984f-3d6b6937b578" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_c9dd2e1c-a3b8-4393-af89-22eb11091a70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_61d870cc-c1f2-4522-984f-3d6b6937b578" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_c9dd2e1c-a3b8-4393-af89-22eb11091a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Segmentinformation" xlink:type="simple" xlink:href="ebs-20250930.xsd#Segmentinformation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Segmentinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ca9d9950-4344-41f1-972c-cadd6ac078f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5551599c-67e2-4ce7-b3eb-af84bb97a800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ca9d9950-4344-41f1-972c-cadd6ac078f4" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5551599c-67e2-4ce7-b3eb-af84bb97a800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="ebs-20250930.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3e927ec1-2ccd-454b-9685-cff69c880d19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6f226695-965c-40b5-ac1e-ce4edb2fd28f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3e927ec1-2ccd-454b-9685-cff69c880d19" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6f226695-965c-40b5-ac1e-ce4edb2fd28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c4321162-d25d-482d-bfa8-0c5c64906de7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3e927ec1-2ccd-454b-9685-cff69c880d19" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c4321162-d25d-482d-bfa8-0c5c64906de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_20df3fa4-5771-479a-bde5-c6832f37193c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3e927ec1-2ccd-454b-9685-cff69c880d19" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_20df3fa4-5771-479a-bde5-c6832f37193c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#AssetsandliabilitiesheldforsaleTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_275b3ccf-2a2c-459b-a141-81c7caeabaab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_bac29709-cad7-4530-b2c0-36569c54b8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_275b3ccf-2a2c-459b-a141-81c7caeabaab" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_bac29709-cad7-4530-b2c0-36569c54b8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_979ca2a8-cd39-438b-b105-a31892b7df34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_b2c969b4-6859-4eaa-bc61-a7fde402161d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_979ca2a8-cd39-438b-b105-a31892b7df34" xlink:to="loc_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_b2c969b4-6859-4eaa-bc61-a7fde402161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4b2850b5-eaa7-47cd-93d5-36e83c4cf490" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_979ca2a8-cd39-438b-b105-a31892b7df34" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4b2850b5-eaa7-47cd-93d5-36e83c4cf490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0026d502-c1a6-4d65-88f1-0ad3b9ff8b75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_979ca2a8-cd39-438b-b105-a31892b7df34" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0026d502-c1a6-4d65-88f1-0ad3b9ff8b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#InventoriesnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_28388d8c-f133-4a51-8aff-dd269d169f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7be9c50f-d24b-480e-8ecc-71b1e7240240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_28388d8c-f133-4a51-8aff-dd269d169f5c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7be9c50f-d24b-480e-8ecc-71b1e7240240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#PropertyplantandequipmentnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_eb819729-cc5a-4850-a100-70b6dcab7277" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c7a84af1-4752-4e95-bf3a-80c9c10ad49d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_eb819729-cc5a-4850-a100-70b6dcab7277" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c7a84af1-4752-4e95-bf3a-80c9c10ad49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad1ab40b-f3e5-485b-aa9a-e5a4b179737a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_80e1925d-7e30-48aa-b078-2c84359207c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad1ab40b-f3e5-485b-aa9a-e5a4b179737a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_80e1925d-7e30-48aa-b078-2c84359207c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_71425e90-5a97-4ab6-94f8-d8dd2838128a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad1ab40b-f3e5-485b-aa9a-e5a4b179737a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_71425e90-5a97-4ab6-94f8-d8dd2838128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ba6407ad-102f-480f-bd71-c0cb80961131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1511848d-dcbf-4d59-9cb4-cb5331def82f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba6407ad-102f-480f-bd71-c0cb80961131" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1511848d-dcbf-4d59-9cb4-cb5331def82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_995f2bc0-b381-47b2-be3a-339b16406faf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba6407ad-102f-480f-bd71-c0cb80961131" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_995f2bc0-b381-47b2-be3a-339b16406faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7ad4d246-c5b7-430a-b270-cd70d893ff7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba6407ad-102f-480f-bd71-c0cb80961131" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7ad4d246-c5b7-430a-b270-cd70d893ff7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_61a2bfc4-bf2d-4723-a377-a1d56248da09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_763f2dc8-5579-45cb-89e9-97ae015f8ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61a2bfc4-bf2d-4723-a377-a1d56248da09" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_763f2dc8-5579-45cb-89e9-97ae015f8ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#SharebasedcompensationandstockholdersequityTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_aa32b568-8943-4136-aff7-874506e7bb73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_757572a4-621c-483a-9535-be3799c69806" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_aa32b568-8943-4136-aff7-874506e7bb73" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_757572a4-621c-483a-9535-be3799c69806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2c86a043-88eb-4ba5-b28e-62a3a4c05e27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_aa32b568-8943-4136-aff7-874506e7bb73" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2c86a043-88eb-4ba5-b28e-62a3a4c05e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#EarningslosspercommonshareTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EarningslosspercommonshareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d49a99ee-8107-459b-b851-d2874734d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d9a0fbff-35a8-4472-8275-b8c2f7282160" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d49a99ee-8107-459b-b851-d2874734d8da" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d9a0fbff-35a8-4472-8275-b8c2f7282160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c1c756d0-b81a-4b21-9a59-44cd95f32d30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_5cbeacd1-79fe-4e7b-b9c1-42c79b689c38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c1c756d0-b81a-4b21-9a59-44cd95f32d30" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_5cbeacd1-79fe-4e7b-b9c1-42c79b689c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b34dd7f1-cc95-42fa-912f-88065fa9f744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c1c756d0-b81a-4b21-9a59-44cd95f32d30" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b34dd7f1-cc95-42fa-912f-88065fa9f744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_3754e7f2-f8b4-4468-b9ae-812aa6f3dd16" xlink:href="ebs-20250930.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c1c756d0-b81a-4b21-9a59-44cd95f32d30" xlink:to="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_3754e7f2-f8b4-4468-b9ae-812aa6f3dd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_188a3dd0-e3a0-48b6-a9e0-ba9b170d276a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_40b3276b-bb4a-4af1-b4fa-5ca42dfd3957" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_188a3dd0-e3a0-48b6-a9e0-ba9b170d276a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_40b3276b-bb4a-4af1-b4fa-5ca42dfd3957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_9d683166-8928-4e97-8aa3-16a90c83c3fe" xlink:href="ebs-20250930.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_188a3dd0-e3a0-48b6-a9e0-ba9b170d276a" xlink:to="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_9d683166-8928-4e97-8aa3-16a90c83c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentinformationTables" xlink:type="simple" xlink:href="ebs-20250930.xsd#SegmentinformationTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5102ae33-ffb2-4ef4-876d-93bae4092b94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_308f3810-4b39-45c1-84eb-1f08011f89b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5102ae33-ffb2-4ef4-876d-93bae4092b94" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_308f3810-4b39-45c1-84eb-1f08011f89b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e337edb2-2d8f-433e-a242-69d81074688b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5102ae33-ffb2-4ef4-876d-93bae4092b94" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e337edb2-2d8f-433e-a242-69d81074688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#NatureofthebusinessandorganizationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0af7185-c3c3-4bb0-a7da-068f63db12f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_9b140cb1-8a20-4b9c-bc6e-f760191e349e" xlink:href="ebs-20250930.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0af7185-c3c3-4bb0-a7da-068f63db12f6" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_9b140cb1-8a20-4b9c-bc6e-f760191e349e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_3ec81409-95d8-40f3-a7c8-00f0b0de9566" xlink:href="ebs-20250930.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0af7185-c3c3-4bb0-a7da-068f63db12f6" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_3ec81409-95d8-40f3-a7c8-00f0b0de9566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductAndServiceCategories_54477a4d-c027-421a-87ad-eb7dfb805daa" xlink:href="ebs-20250930.xsd#ebs_NumberOfProductAndServiceCategories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0af7185-c3c3-4bb0-a7da-068f63db12f6" xlink:to="loc_ebs_NumberOfProductAndServiceCategories_54477a4d-c027-421a-87ad-eb7dfb805daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_31d90a53-6cea-4eb8-9e1c-cb755108f10b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0af7185-c3c3-4bb0-a7da-068f63db12f6" xlink:to="loc_us-gaap_NumberOfOperatingSegments_31d90a53-6cea-4eb8-9e1c-cb755108f10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3ad79aa9-ed9a-4f9c-be8f-6ed1739b66b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0af7185-c3c3-4bb0-a7da-068f63db12f6" xlink:to="loc_us-gaap_NumberOfReportableSegments_3ad79aa9-ed9a-4f9c-be8f-6ed1739b66b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#AssetsandliabilitiesheldforsaleNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a084701c-eacc-4f8a-a694-5faaad4ca735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a084701c-eacc-4f8a-a694-5faaad4ca735" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0eeeb819-6368-42e9-9cad-60443c8e783f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0eeeb819-6368-42e9-9cad-60443c8e783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cbdb2ec2-7d8f-4f27-a700-b71a65479859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0eeeb819-6368-42e9-9cad-60443c8e783f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cbdb2ec2-7d8f-4f27-a700-b71a65479859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b9f1f838-38de-4721-b71f-1baafaf96162" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cbdb2ec2-7d8f-4f27-a700-b71a65479859" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b9f1f838-38de-4721-b71f-1baafaf96162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5adc7810-c3e4-432e-91d1-4c147f9a54a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5adc7810-c3e4-432e-91d1-4c147f9a54a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c0fdf1b-82f2-4ef4-84e9-8dcfa3481717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5adc7810-c3e4-432e-91d1-4c147f9a54a5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c0fdf1b-82f2-4ef4-84e9-8dcfa3481717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MarylandWarehouseSpaceMember_32428cd8-0717-401d-88e7-b6a2fc58d0ab" xlink:href="ebs-20250930.xsd#ebs_MarylandWarehouseSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3c0fdf1b-82f2-4ef4-84e9-8dcfa3481717" xlink:to="loc_ebs_MarylandWarehouseSpaceMember_32428cd8-0717-401d-88e7-b6a2fc58d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1bd19138-ff02-40fe-aef4-d7c51da1e8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3439406d-a9a5-4558-a165-b60a0e233bbb" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1bd19138-ff02-40fe-aef4-d7c51da1e8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_2c3b2502-16a2-4b8a-94c7-3ff81205b106" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1bd19138-ff02-40fe-aef4-d7c51da1e8d5" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_2c3b2502-16a2-4b8a-94c7-3ff81205b106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5e8d926b-761d-4ef6-ad02-0834f5547fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5e8d926b-761d-4ef6-ad02-0834f5547fe9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_4716c252-d96b-4a4f-8e3f-645340099c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_4716c252-d96b-4a4f-8e3f-645340099c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c4055d04-632b-487c-ad26-a82a4dc48b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4716c252-d96b-4a4f-8e3f-645340099c64" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c4055d04-632b-487c-ad26-a82a4dc48b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_6c41b30b-6989-462f-928a-738e129a337c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c4055d04-632b-487c-ad26-a82a4dc48b3d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_6c41b30b-6989-462f-928a-738e129a337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1ad2ad51-7f75-4ead-9952-13134ae5b990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1ad2ad51-7f75-4ead-9952-13134ae5b990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1827a329-d0df-4927-bc10-74fa7c15d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1ad2ad51-7f75-4ead-9952-13134ae5b990" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1827a329-d0df-4927-bc10-74fa7c15d99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MarylandWarehouseSpaceMember_de72412e-c730-4b1b-b9b1-63357aa4f4bd" xlink:href="ebs-20250930.xsd#ebs_MarylandWarehouseSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1827a329-d0df-4927-bc10-74fa7c15d99a" xlink:to="loc_ebs_MarylandWarehouseSpaceMember_de72412e-c730-4b1b-b9b1-63357aa4f4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_895e8be8-7ae6-4430-be46-6b1591f0e208" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_7b8de8f1-0bd4-4775-8a23-b632266cdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_7b8de8f1-0bd4-4775-8a23-b632266cdaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_47d4c0e5-b049-4608-8641-5f7c568fcf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_47d4c0e5-b049-4608-8641-5f7c568fcf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_d31e4e66-d213-4211-8d92-9686f3491065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_d31e4e66-d213-4211-8d92-9686f3491065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_da699448-6777-4dc6-a4e0-367c894d18cc" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance_da699448-6777-4dc6-a4e0-367c894d18cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_924091e1-76ed-4743-956b-d54f8b9ef392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_0ef2da43-a6e5-4269-8ed5-6d0559b4a80f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_924091e1-76ed-4743-956b-d54f8b9ef392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1a87e48c-811d-46ec-9777-b308e2c389f6" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3e5ab8f9-d924-400a-b3f3-e590aa0418f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3e5ab8f9-d924-400a-b3f3-e590aa0418f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_31fe0ec3-0c67-4f2a-b2c0-028c854ee9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_31fe0ec3-0c67-4f2a-b2c0-028c854ee9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_67061505-bf7b-4140-bd2b-c9a5d19a5e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_79e2d2d1-c601-4978-9fb8-1a6962fecab7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_67061505-bf7b-4140-bd2b-c9a5d19a5e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DivestituresDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DivestituresDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1f225c85-51aa-4b34-a93c-a9397351ed87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1f225c85-51aa-4b34-a93c-a9397351ed87" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4ea47dda-fddb-4e7d-ac2b-ea7282409eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f5b4f6f8-d465-4a45-a4c6-528f1c0fed8f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4ea47dda-fddb-4e7d-ac2b-ea7282409eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5aeed6c0-f5ba-4d74-98cf-35edb7f6fefc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4ea47dda-fddb-4e7d-ac2b-ea7282409eb1" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5aeed6c0-f5ba-4d74-98cf-35edb7f6fefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a658ab6-94d6-464c-b86b-737e0be9b5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a658ab6-94d6-464c-b86b-737e0be9b5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5a658ab6-94d6-464c-b86b-737e0be9b5e6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_cb027fc3-87c0-49c9-8933-c235a662279e" xlink:href="ebs-20250930.xsd#ebs_TravelHealthBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_TravelHealthBusinessMember_cb027fc3-87c0-49c9-8933-c235a662279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RSDLMember_0740f5e2-e61b-4477-b08b-504a3a55502d" xlink:href="ebs-20250930.xsd#ebs_RSDLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_RSDLMember_0740f5e2-e61b-4477-b08b-504a3a55502d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BaltimoreCamdenFacilityMember_a88c70b0-ce86-4962-983a-7b12e86e1c33" xlink:href="ebs-20250930.xsd#ebs_BaltimoreCamdenFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_BaltimoreCamdenFacilityMember_a88c70b0-ce86-4962-983a-7b12e86e1c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BaltimoreBayviewFacilityMember_25a55d2e-9f16-467c-bb96-6762cd1ce059" xlink:href="ebs-20250930.xsd#ebs_BaltimoreBayviewFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4bbf00d7-c32e-43ef-a864-43e41c07bb39" xlink:to="loc_ebs_BaltimoreBayviewFacilityMember_25a55d2e-9f16-467c-bb96-6762cd1ce059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_de063da4-e034-4244-8867-021dae6ecc47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_de063da4-e034-4244-8867-021dae6ecc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_de063da4-e034-4244-8867-021dae6ecc47" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DevelopmentBasedMilestonesMember_a4f7a5e2-a920-4c27-b4f3-c2aa04deaba5" xlink:href="ebs-20250930.xsd#ebs_DevelopmentBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:to="loc_ebs_DevelopmentBasedMilestonesMember_a4f7a5e2-a920-4c27-b4f3-c2aa04deaba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SalesBasedMilestonesMember_11e05fe9-7900-42a6-b101-4ad0b10177b0" xlink:href="ebs-20250930.xsd#ebs_SalesBasedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2e8b0c5c-2270-473a-8d65-9de9c6fb23ab" xlink:to="loc_ebs_SalesBasedMilestonesMember_11e05fe9-7900-42a6-b101-4ad0b10177b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_987fac85-6a85-4dfc-b19e-a723f57a0c75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_srt_ProductOrServiceAxis_987fac85-6a85-4dfc-b19e-a723f57a0c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de176bb0-9b16-4df9-9eb4-15524861ed7f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_987fac85-6a85-4dfc-b19e-a723f57a0c75" xlink:to="loc_srt_ProductsAndServicesDomain_de176bb0-9b16-4df9-9eb4-15524861ed7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductAndServiceMember_a34b5af9-72f7-44de-80c5-40e19210a8d2" xlink:href="ebs-20250930.xsd#ebs_ProductAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_de176bb0-9b16-4df9-9eb4-15524861ed7f" xlink:to="loc_ebs_ProductAndServiceMember_a34b5af9-72f7-44de-80c5-40e19210a8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c8a96cb1-5b77-4f99-b6ce-a9d4351c1d14" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_97b24353-dca8-42ee-a447-ab1c9e4f395b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_97b24353-dca8-42ee-a447-ab1c9e4f395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_18e225d4-1ed4-4222-b85c-3549e21e9ed0" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable_18e225d4-1ed4-4222-b85c-3549e21e9ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset_8436ffcf-4c04-49ae-93d2-4bf773e7f285" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset_8436ffcf-4c04-49ae-93d2-4bf773e7f285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable_0b5e03d2-8d48-4e73-bf4d-a713b5572d6d" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable_0b5e03d2-8d48-4e73-bf4d-a713b5572d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_de4e795d-35db-4ff3-9844-4b2f4329451c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_de4e795d-35db-4ff3-9844-4b2f4329451c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_60d4586b-0025-4542-a42a-48ff2e778efb" xlink:href="ebs-20250930.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_60d4586b-0025-4542-a42a-48ff2e778efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2761390-84cd-4400-a71c-5ab901040d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2761390-84cd-4400-a71c-5ab901040d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b25a7859-6a8a-421b-82c1-7bdaa79d8599" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b25a7859-6a8a-421b-82c1-7bdaa79d8599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5080700f-9dc0-411d-b3ff-fb0b216dda30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4a83fe05-bc01-4e42-bc19-ff85b5a183eb" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5080700f-9dc0-411d-b3ff-fb0b216dda30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_af5775c4-3525-4e16-96c9-425f75c9d680" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a5f690f3-08ae-4f87-88de-e4d05b051f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_af5775c4-3525-4e16-96c9-425f75c9d680" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a5f690f3-08ae-4f87-88de-e4d05b051f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_7051b651-5715-4963-9d8b-43567ad9c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a5f690f3-08ae-4f87-88de-e4d05b051f9d" xlink:to="loc_us-gaap_RestructuringPlanAxis_7051b651-5715-4963-9d8b-43567ad9c71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_7051b651-5715-4963-9d8b-43567ad9c71a" xlink:to="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_85893c91-de40-4189-a0a1-eab775bd846d" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_85893c91-de40-4189-a0a1-eab775bd846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_340a5f89-9dab-487e-8f5e-3e321754b503" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_340a5f89-9dab-487e-8f5e-3e321754b503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanMay2024Member_02306fab-554e-490a-aa6e-9fd5f19c11f4" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanMay2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanMay2024Member_02306fab-554e-490a-aa6e-9fd5f19c11f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2024Member_c9e2fea5-07c9-4567-a29a-c5a3c5d0b81a" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_eba1bf38-e560-42a2-9618-3757d49e0e5d" xlink:to="loc_ebs_RestructuringPlanAugust2024Member_c9e2fea5-07c9-4567-a29a-c5a3c5d0b81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a5f690f3-08ae-4f87-88de-e4d05b051f9d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dc9b71bd-0321-41fc-a3d8-96a745a932dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dc9b71bd-0321-41fc-a3d8-96a745a932dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_27ac9238-8714-4e24-832b-2ca5bb7cad34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_27ac9238-8714-4e24-832b-2ca5bb7cad34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3664b778-838b-4536-af0b-a2f606db4e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3664b778-838b-4536-af0b-a2f606db4e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated_5cf4bbd9-0dbb-436c-be4e-2f24aeb4ba6a" xlink:href="ebs-20250930.xsd#ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated_5cf4bbd9-0dbb-436c-be4e-2f24aeb4ba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_d47c5998-775f-485b-854c-67de11ffcf02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c5babd07-965a-4da8-be5e-8af6e108f5ce" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_d47c5998-775f-485b-854c-67de11ffcf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ffab4f85-027d-4944-b0b5-0b44a4775e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_829b77f2-066d-418d-806e-63739ec9edf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ffab4f85-027d-4944-b0b5-0b44a4775e69" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_829b77f2-066d-418d-806e-63739ec9edf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_4bef2397-7bae-4134-8d20-8a5301b990c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_829b77f2-066d-418d-806e-63739ec9edf2" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_4bef2397-7bae-4134-8d20-8a5301b990c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis_4bef2397-7bae-4134-8d20-8a5301b990c4" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_50badb0a-39f8-4330-b829-89d109f3bf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_50badb0a-39f8-4330-b829-89d109f3bf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_18120ee5-f353-4888-ae28-2fe6c6517295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_18120ee5-f353-4888-ae28-2fe6c6517295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ba3c46e7-6e66-4472-a913-c0f7d0532eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_ba3c46e7-6e66-4472-a913-c0f7d0532eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_274b8fd1-4094-4dd7-8a1c-b0aa83786df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain_085d6cf5-46e8-4765-8c7a-4b2353a190f9" xlink:to="loc_us-gaap_ConstructionInProgressMember_274b8fd1-4094-4dd7-8a1c-b0aa83786df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_83696aa0-3b50-4a24-b606-7bf16b0724a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_829b77f2-066d-418d-806e-63739ec9edf2" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_83696aa0-3b50-4a24-b606-7bf16b0724a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0ec84ea1-573d-4d35-8767-129703702989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_83696aa0-3b50-4a24-b606-7bf16b0724a8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0ec84ea1-573d-4d35-8767-129703702989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fbc6f655-9721-4684-b593-863892697434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_fbc6f655-9721-4684-b593-863892697434" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b02cf19b-6d4d-4d0d-9b2b-d6c4fe371600" xlink:to="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_cd7314fb-2094-471c-b35a-711cae52714f" xlink:href="ebs-20250930.xsd#ebs_MCMProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:to="loc_ebs_MCMProductsSegmentMember_cd7314fb-2094-471c-b35a-711cae52714f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1ab88b1a-6b2c-41a4-9e26-fc2751a86974" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_017365d9-7800-4ad8-8d2a-784067a3b4ea" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1ab88b1a-6b2c-41a4-9e26-fc2751a86974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_18484e83-338d-4328-9ff5-5307bf989e27" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:to="loc_srt_ConsolidationItemsAxis_18484e83-338d-4328-9ff5-5307bf989e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_18484e83-338d-4328-9ff5-5307bf989e27" xlink:to="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ab925fb8-b295-4f63-bbb6-c92401ca91ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:to="loc_us-gaap_OperatingSegmentsMember_ab925fb8-b295-4f63-bbb6-c92401ca91ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ae35ff7e-0cc9-4b62-8553-31e8ea0707f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1b7b46df-45b5-4825-8c14-dd3d839b51fc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ae35ff7e-0cc9-4b62-8553-31e8ea0707f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_29c9f45a-6ec1-499f-a996-57803f4dc008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_29c9f45a-6ec1-499f-a996-57803f4dc008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_29c9f45a-6ec1-499f-a996-57803f4dc008" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedSellingGeneralAndAdministrativeMember_bacf5c55-e157-4b48-a766-a63fdc709541" xlink:href="ebs-20250930.xsd#ebs_UnallocatedSellingGeneralAndAdministrativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_ebs_UnallocatedSellingGeneralAndAdministrativeMember_bacf5c55-e157-4b48-a766-a63fdc709541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember_39b6c391-e8fe-4948-970b-9327ff648fc9" xlink:href="ebs-20250930.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_ebs_UnallocatedResearchAndDevelopmentMember_39b6c391-e8fe-4948-970b-9327ff648fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0d92d583-9293-410e-a225-9af525b4c9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0d92d583-9293-410e-a225-9af525b4c9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_9b5e64b3-e23a-41bc-833d-bb3d99c692b2" xlink:href="ebs-20250930.xsd#ebs_EmployeeBenefitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_70744d2f-f324-4a5f-8074-023ee97da1ef" xlink:to="loc_ebs_EmployeeBenefitsMember_9b5e64b3-e23a-41bc-833d-bb3d99c692b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6437d8e6-0e58-4fbe-8016-ddabc4e94124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8805e9e8-3fbd-4545-acad-6b28be73e274" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6437d8e6-0e58-4fbe-8016-ddabc4e94124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0a2be495-134d-4a2b-95c0-5e9653b8472e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6437d8e6-0e58-4fbe-8016-ddabc4e94124" xlink:to="loc_us-gaap_RestructuringCharges_0a2be495-134d-4a2b-95c0-5e9653b8472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1b18b158-272d-4b84-906d-a4966fd9c240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1b18b158-272d-4b84-906d-a4966fd9c240" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7089b516-65a1-4cee-9552-5beb2bf93691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7089b516-65a1-4cee-9552-5beb2bf93691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7089b516-65a1-4cee-9552-5beb2bf93691" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_edc3db49-46c3-4c6c-b928-26b2fbfffdec" xlink:href="ebs-20250930.xsd#ebs_EmployeeTransitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:to="loc_ebs_EmployeeTransitionMember_edc3db49-46c3-4c6c-b928-26b2fbfffdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_7dde9809-66d5-4c38-808c-0e51107b5aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:to="loc_us-gaap_EmployeeSeveranceMember_7dde9809-66d5-4c38-808c-0e51107b5aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_030651aa-7017-4d96-b8b5-6e15e3b5f8d1" xlink:href="ebs-20250930.xsd#ebs_EmployeeBenefitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7eeccfa0-d20c-4f9d-a171-6d532e870472" xlink:to="loc_ebs_EmployeeBenefitsMember_030651aa-7017-4d96-b8b5-6e15e3b5f8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8d488c0e-985b-4b12-b5cd-ea75c60f3a87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:to="loc_us-gaap_RestructuringPlanAxis_8d488c0e-985b-4b12-b5cd-ea75c60f3a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_8d488c0e-985b-4b12-b5cd-ea75c60f3a87" xlink:to="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanJanuary2023Member_76d600dc-5dec-472b-bccd-b7bd7b40ed9d" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanJanuary2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanJanuary2023Member_76d600dc-5dec-472b-bccd-b7bd7b40ed9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2023Member_779eadae-12e7-401f-b7d5-ca4b1dc6d49a" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanAugust2023Member_779eadae-12e7-401f-b7d5-ca4b1dc6d49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanMay2024Member_c036ac3e-af5a-4576-9efd-4e77f3eecfa0" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanMay2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanMay2024Member_c036ac3e-af5a-4576-9efd-4e77f3eecfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlanAugust2024Member_9151ca43-7100-4fdc-a3b8-5cd2173e7bec" xlink:href="ebs-20250930.xsd#ebs_RestructuringPlanAugust2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0042f1a8-01d1-400f-bb79-75a91336f48c" xlink:to="loc_ebs_RestructuringPlanAugust2024Member_9151ca43-7100-4fdc-a3b8-5cd2173e7bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_184b5e1e-ae33-468c-9d23-31c335f731e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e93c5a9f-6a7d-4670-97a3-75a4ee5ddf65" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_184b5e1e-ae33-468c-9d23-31c335f731e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_184b5e1e-ae33-468c-9d23-31c335f731e0" xlink:to="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_aac6a912-1b72-4c23-9f9b-ef2f0bb43dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:to="loc_us-gaap_RestructuringReserve_aac6a912-1b72-4c23-9f9b-ef2f0bb43dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_82a46a90-9620-412c-99dd-ec7af9340508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:to="loc_us-gaap_RestructuringCharges_82a46a90-9620-412c-99dd-ec7af9340508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_ada6edb8-b7ea-4ec0-8ece-8407ca3bd097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:to="loc_us-gaap_PaymentsForRestructuring_ada6edb8-b7ea-4ec0-8ece-8407ca3bd097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fb9c838e-b618-4e56-bb77-fa59ce570fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a389d7fa-f596-444c-9d68-38cb137f6c8c" xlink:to="loc_us-gaap_RestructuringReserve_fb9c838e-b618-4e56-bb77-fa59ce570fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3bafd244-e30b-4412-adc1-70727174687c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8332ba68-73c6-4c93-a15c-436af8d00afa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bafd244-e30b-4412-adc1-70727174687c" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8332ba68-73c6-4c93-a15c-436af8d00afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_62313399-9de3-4617-965f-18a047045f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bafd244-e30b-4412-adc1-70727174687c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_62313399-9de3-4617-965f-18a047045f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2f326e41-f8cd-4b36-b018-7f98069a80a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bafd244-e30b-4412-adc1-70727174687c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2f326e41-f8cd-4b36-b018-7f98069a80a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1f20b7c9-16e0-476e-9e73-ca5810703e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3bafd244-e30b-4412-adc1-70727174687c" xlink:to="loc_us-gaap_InventoryNet_1f20b7c9-16e0-476e-9e73-ca5810703e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_6c635de6-565c-47ca-9f53-b22b27f1587f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02d0595d-873c-45ae-a30e-e9df2904de68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_6c635de6-565c-47ca-9f53-b22b27f1587f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02d0595d-873c-45ae-a30e-e9df2904de68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29ab753f-f8ca-4e63-962e-eff0f3395607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02d0595d-873c-45ae-a30e-e9df2904de68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29ab753f-f8ca-4e63-962e-eff0f3395607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_29ab753f-f8ca-4e63-962e-eff0f3395607" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_6a334a8e-0b45-4d51-a918-234ca63d12a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_6a334a8e-0b45-4d51-a918-234ca63d12a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_958b3c3b-5e76-417b-99c0-92d09b4b3d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_958b3c3b-5e76-417b-99c0-92d09b4b3d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_df1a22a2-fdd5-410d-b96c-4d7a8cc77d34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_df1a22a2-fdd5-410d-b96c-4d7a8cc77d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a5cce91e-e194-42a4-a35a-9cf993b70a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a5cce91e-e194-42a4-a35a-9cf993b70a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_101fdbb4-e90d-481d-8a32-30865d2ed8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75eadd70-8d60-4539-b5a8-b48da1f11e42" xlink:to="loc_us-gaap_ConstructionInProgressMember_101fdbb4-e90d-481d-8a32-30865d2ed8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02d0595d-873c-45ae-a30e-e9df2904de68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_32438d21-fc9c-4a87-a471-8a18dc628853" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_32438d21-fc9c-4a87-a471-8a18dc628853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_49a478b5-0854-4367-bc65-450cf406435d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_49a478b5-0854-4367-bc65-450cf406435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e5ead76b-67ac-47c1-bc66-8e36a6832eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_e0647192-2251-40da-a4dd-facafe21e7e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e5ead76b-67ac-47c1-bc66-8e36a6832eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_25f710e0-4526-432a-9b36-7323eaaa3d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c57e2c76-5c8a-4878-a12b-fe461261ec79" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_25f710e0-4526-432a-9b36-7323eaaa3d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e69fb65f-6be4-4724-8b21-77387dca85d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33e239d0-a3a1-4127-b7dd-1f765a29617e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e69fb65f-6be4-4724-8b21-77387dca85d6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33e239d0-a3a1-4127-b7dd-1f765a29617e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33e239d0-a3a1-4127-b7dd-1f765a29617e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a032b51-8516-4c55-b3fe-4096483d6767" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8a64da5-ba4e-4ef9-b044-87c6cc628bb8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a032b51-8516-4c55-b3fe-4096483d6767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3b5c92a4-2923-4ae8-84d5-81acf76c6f62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a032b51-8516-4c55-b3fe-4096483d6767" xlink:to="loc_us-gaap_ProductMember_3b5c92a4-2923-4ae8-84d5-81acf76c6f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33e239d0-a3a1-4127-b7dd-1f765a29617e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5704a224-5092-4078-b036-14f9f9fbf72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5704a224-5092-4078-b036-14f9f9fbf72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d68b69d8-2fb5-4dd0-be1e-c65c2c9e516d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d68b69d8-2fb5-4dd0-be1e-c65c2c9e516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_babeb3b0-75e2-4a57-b378-4e24b9c76d67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_babeb3b0-75e2-4a57-b378-4e24b9c76d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e111c34d-2c37-4e93-b90f-9c2a62814fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e12de28a-b4dd-4445-9083-454dcb8365b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e111c34d-2c37-4e93-b90f-9c2a62814fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8c7b8d6b-53ae-4414-b1ff-ab32cb90a7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d5cf72f4-cf00-4e3b-9588-9cd7d2c30803" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8c7b8d6b-53ae-4414-b1ff-ab32cb90a7ea" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d5cf72f4-cf00-4e3b-9588-9cd7d2c30803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_155a6ff8-819c-4405-b3a7-506caccdbaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_155a6ff8-819c-4405-b3a7-506caccdbaa9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6ad66672-3a82-4891-a8af-012efe6e1888" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6ad66672-3a82-4891-a8af-012efe6e1888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_becd7293-7055-4b9a-917f-03e2dc9c63e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6ad66672-3a82-4891-a8af-012efe6e1888" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_becd7293-7055-4b9a-917f-03e2dc9c63e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2ac57f92-b05e-4fea-8fac-538510e28630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_becd7293-7055-4b9a-917f-03e2dc9c63e7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2ac57f92-b05e-4fea-8fac-538510e28630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53865fbe-c7fb-4b61-90fc-88342fff9549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53865fbe-c7fb-4b61-90fc-88342fff9549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_53865fbe-c7fb-4b61-90fc-88342fff9549" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_51c840a6-6ff5-4dbd-8167-5950e23244fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_51c840a6-6ff5-4dbd-8167-5950e23244fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd3be8f9-0ef4-4359-9b1b-39e8dd524879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd3be8f9-0ef4-4359-9b1b-39e8dd524879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_673bcf81-2a1a-42f4-b065-74e2df9616a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_244f8b75-62ab-45ff-9e9c-7f10b6fe5dd1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_673bcf81-2a1a-42f4-b065-74e2df9616a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e0cc1ff7-8fdc-4e72-965c-877971733edc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c916dbbe-b71a-463d-8fb4-c0b1d3514694" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c916dbbe-b71a-463d-8fb4-c0b1d3514694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_be673107-60d1-46f6-b13b-bcc185006320" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_be673107-60d1-46f6-b13b-bcc185006320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure_81e6e4f9-239f-44ba-838d-b334f1cf47ba" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_ebs_WarrantLiabilitiesFairValueDisclosure_81e6e4f9-239f-44ba-838d-b334f1cf47ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d7d4d387-1e65-4a9b-bf17-81059d4c2e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d5f9f8f-56eb-440f-958b-09267cc9602b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d7d4d387-1e65-4a9b-bf17-81059d4c2e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fce1ac81-9737-4385-a748-f3acba98577b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fce1ac81-9737-4385-a748-f3acba98577b" xlink:to="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_42cd0247-25ff-4a00-b2bd-8de987c57836" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_42cd0247-25ff-4a00-b2bd-8de987c57836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_42cd0247-25ff-4a00-b2bd-8de987c57836" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIWarrantsMember_813b5ae9-57b2-4b1e-9ec8-0e54987b7738" xlink:href="ebs-20250930.xsd#ebs_SeriesIWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:to="loc_ebs_SeriesIWarrantsMember_813b5ae9-57b2-4b1e-9ec8-0e54987b7738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIIWarrantsMember_db106774-0453-40fc-b42f-2acc9bad55cf" xlink:href="ebs-20250930.xsd#ebs_SeriesIIWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5c0fb608-21de-4286-abd0-8cc745ef9a37" xlink:to="loc_ebs_SeriesIIWarrantsMember_db106774-0453-40fc-b42f-2acc9bad55cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_838561db-bbeb-49ee-b7b2-26adbc0f5f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:to="loc_us-gaap_DebtInstrumentAxis_838561db-bbeb-49ee-b7b2-26adbc0f5f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b93ed3f4-ac0a-4933-bc24-0c9a6d479fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_838561db-bbeb-49ee-b7b2-26adbc0f5f53" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b93ed3f4-ac0a-4933-bc24-0c9a6d479fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_e5294ec7-955c-4a85-9f44-65799b0d46c5" xlink:href="ebs-20250930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b93ed3f4-ac0a-4933-bc24-0c9a6d479fd2" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_e5294ec7-955c-4a85-9f44-65799b0d46c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96e06b25-0285-4949-9309-bb72dadf6bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c4eb5ab0-cdff-422f-b2ff-7520eb43f6d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96e06b25-0285-4949-9309-bb72dadf6bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5f9a7231-0a4d-48af-80a6-ea89e5069bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96e06b25-0285-4949-9309-bb72dadf6bb0" xlink:to="loc_us-gaap_SeniorNotesMember_5f9a7231-0a4d-48af-80a6-ea89e5069bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c296cd7e-6499-4d13-a20b-a868cc167819" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15984e8c-adea-4219-9d21-3dee6ac24212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15984e8c-adea-4219-9d21-3dee6ac24212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_151ad880-da03-4c2f-bbce-4e43e4514687" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_151ad880-da03-4c2f-bbce-4e43e4514687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure_66fdff49-1b25-4bb0-8540-f97c606d9a09" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_ebs_WarrantLiabilitiesFairValueDisclosure_66fdff49-1b25-4bb0-8540-f97c606d9a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab333d88-3f34-497c-87e5-7b1d1f9d49b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab333d88-3f34-497c-87e5-7b1d1f9d49b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_66bb4f90-5770-4cac-8761-9e218bb02ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b0d8e9b5-3a27-4788-8f4a-4de0fc07cca3" xlink:to="loc_us-gaap_LongTermDebtFairValue_66bb4f90-5770-4cac-8761-9e218bb02ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_55198c3c-8280-4ca5-b691-e5ebf2afba95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a69d08f4-d58b-41e7-ae62-b126c2aa6ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_55198c3c-8280-4ca5-b691-e5ebf2afba95" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a69d08f4-d58b-41e7-ae62-b126c2aa6ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_196e71d4-4549-4a48-9125-8c3460fa22ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a69d08f4-d58b-41e7-ae62-b126c2aa6ca0" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_196e71d4-4549-4a48-9125-8c3460fa22ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b4429b06-f4d4-45a8-a69c-a3c78b0a0ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_196e71d4-4549-4a48-9125-8c3460fa22ad" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b4429b06-f4d4-45a8-a69c-a3c78b0a0ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_cceb51a2-5525-4d0a-b0ef-fdc9815363bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b4429b06-f4d4-45a8-a69c-a3c78b0a0ca9" xlink:to="loc_us-gaap_WarrantMember_cceb51a2-5525-4d0a-b0ef-fdc9815363bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_139d8430-8b4a-4200-a9ac-c16baa150adc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a69d08f4-d58b-41e7-ae62-b126c2aa6ca0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_139d8430-8b4a-4200-a9ac-c16baa150adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_139d8430-8b4a-4200-a9ac-c16baa150adc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87daaa1f-2887-4d27-ab6a-2ce5b9c39c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_87daaa1f-2887-4d27-ab6a-2ce5b9c39c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7b8c8dc3-c921-4ce5-b227-d4b49cc4f122" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7b8c8dc3-c921-4ce5-b227-d4b49cc4f122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9aadb313-fe58-4843-8b2f-eb55f12eff0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d6e80d2b-a43b-4bd7-9c3c-39fddcc283cd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9aadb313-fe58-4843-8b2f-eb55f12eff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e6619a0d-c917-47ac-86fe-a6812acefb27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e6619a0d-c917-47ac-86fe-a6812acefb27" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c84626f7-7eb1-40c7-aa8e-009da3deee00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c84626f7-7eb1-40c7-aa8e-009da3deee00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c84626f7-7eb1-40c7-aa8e-009da3deee00" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4f871196-7756-4db0-8669-6ea812da4a04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4f871196-7756-4db0-8669-6ea812da4a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bcb228cb-a4d0-4183-8dd4-d5b678ff07b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bcb228cb-a4d0-4183-8dd4-d5b678ff07b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_204154cb-4618-4f1b-8733-aa1dd118499b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_57c05194-8cf3-44d3-b5c9-e89f6e7e37e9" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_204154cb-4618-4f1b-8733-aa1dd118499b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8df2f6f-84b2-49bb-a949-9c610e11a96a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8df2f6f-84b2-49bb-a949-9c610e11a96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6c55d10-b3e4-468b-b316-2ef444faffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8df2f6f-84b2-49bb-a949-9c610e11a96a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6c55d10-b3e4-468b-b316-2ef444faffaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02913ef8-e219-47df-9538-d069e0910310" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6c55d10-b3e4-468b-b316-2ef444faffaf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02913ef8-e219-47df-9538-d069e0910310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ba43f46-6395-4dec-a978-f0f4d52d4699" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ba43f46-6395-4dec-a978-f0f4d52d4699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_de104c0a-7aea-4620-96c4-df6850fd9d43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0ba43f46-6395-4dec-a978-f0f4d52d4699" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_de104c0a-7aea-4620-96c4-df6850fd9d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_eebfc057-0336-4b08-aec3-a94ef9606c17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_de104c0a-7aea-4620-96c4-df6850fd9d43" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_eebfc057-0336-4b08-aec3-a94ef9606c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_dd8d3344-1e72-4e1b-9fda-55056f0a2050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_dd8d3344-1e72-4e1b-9fda-55056f0a2050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_eac59e65-cdb6-4d83-8447-b1991467652e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_dd8d3344-1e72-4e1b-9fda-55056f0a2050" xlink:to="loc_us-gaap_ValuationTechniqueDomain_eac59e65-cdb6-4d83-8447-b1991467652e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ValuationTechniqueBlackScholesModelMember_6e2a5d38-c61e-43f1-9cf8-5b0edcb808b2" xlink:href="ebs-20250930.xsd#ebs_ValuationTechniqueBlackScholesModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_eac59e65-cdb6-4d83-8447-b1991467652e" xlink:to="loc_ebs_ValuationTechniqueBlackScholesModelMember_6e2a5d38-c61e-43f1-9cf8-5b0edcb808b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d2fd2784-ee41-43ec-b8a3-552e69b78720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d2fd2784-ee41-43ec-b8a3-552e69b78720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_87d9e508-1976-44d6-bfc7-b13259949190" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d2fd2784-ee41-43ec-b8a3-552e69b78720" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_87d9e508-1976-44d6-bfc7-b13259949190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2024WarrantsMember_a9841c76-d280-4623-93a7-b4e3b25b3149" xlink:href="ebs-20250930.xsd#ebs_A2024WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_87d9e508-1976-44d6-bfc7-b13259949190" xlink:to="loc_ebs_A2024WarrantsMember_a9841c76-d280-4623-93a7-b4e3b25b3149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_597dac08-987d-4594-9384-ef7a81c5f910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b46bff20-52a4-4036-921b-1590b42676c1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_597dac08-987d-4594-9384-ef7a81c5f910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_db1502d5-f209-402e-9fbe-1d35c501ae1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_597dac08-987d-4594-9384-ef7a81c5f910" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_db1502d5-f209-402e-9fbe-1d35c501ae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a272c6ba-7631-45c9-8c6c-e7a8128a3704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a272c6ba-7631-45c9-8c6c-e7a8128a3704" xlink:to="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b7cd0ee8-224d-4688-ac79-0167766fff08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:to="loc_us-gaap_CreditFacilityAxis_b7cd0ee8-224d-4688-ac79-0167766fff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d3e0bee4-cd6e-4a10-9a17-87f9e6c15989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b7cd0ee8-224d-4688-ac79-0167766fff08" xlink:to="loc_us-gaap_CreditFacilityDomain_d3e0bee4-cd6e-4a10-9a17-87f9e6c15989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3b76dc29-57cb-470a-84f9-cbd57a0a1100" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d3e0bee4-cd6e-4a10-9a17-87f9e6c15989" xlink:to="loc_us-gaap_SecuredDebtMember_3b76dc29-57cb-470a-84f9-cbd57a0a1100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_687735d7-14c6-48f2-abc3-ef603c65db7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_687735d7-14c6-48f2-abc3-ef603c65db7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_687735d7-14c6-48f2-abc3-ef603c65db7b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_acb57980-e9b3-4d8e-ac2a-5a75a3634032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:to="loc_us-gaap_LineOfCreditMember_acb57980-e9b3-4d8e-ac2a-5a75a3634032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5ab5ba84-318f-487c-a0e1-6864db176f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fcacb2e-0cbb-4af1-ab2b-05e10edf7aaa" xlink:to="loc_us-gaap_SeniorNotesMember_5ab5ba84-318f-487c-a0e1-6864db176f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c5d1622c-9010-4149-a6a2-bfc232b9fccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:to="loc_us-gaap_DebtInstrumentAxis_c5d1622c-9010-4149-a6a2-bfc232b9fccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5d1622c-9010-4149-a6a2-bfc232b9fccc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanDue2029Member_16a01119-6c59-42be-9de2-a3c150c5885e" xlink:href="ebs-20250930.xsd#ebs_TermLoanDue2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:to="loc_ebs_TermLoanDue2029Member_16a01119-6c59-42be-9de2-a3c150c5885e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_26e502b7-727e-4e13-b912-c36a04ff4252" xlink:href="ebs-20250930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbd092f8-74be-4c0a-a883-d73e60ab02ec" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_26e502b7-727e-4e13-b912-c36a04ff4252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d42e0253-a42e-445f-a381-896ecf0fd902" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b116f67f-b4ec-41f3-97a4-5aed4e26b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b116f67f-b4ec-41f3-97a4-5aed4e26b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5a48af8e-20e6-4bd7-9010-03688ac356c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_LongTermDebt_5a48af8e-20e6-4bd7-9010-03688ac356c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_52a8b044-54f0-4d37-b97c-86e62a48fa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_52a8b044-54f0-4d37-b97c-86e62a48fa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9d630574-750f-48ff-86f8-5cbc6b239911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7ad5310-b1af-4764-bc1c-78bb84952cf4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9d630574-750f-48ff-86f8-5cbc6b239911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8533529c-7a19-46a8-862c-4169123bd6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8533529c-7a19-46a8-862c-4169123bd6cb" xlink:to="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_20d04a67-5000-45bb-9e85-0823641ad771" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:to="loc_us-gaap_CreditFacilityAxis_20d04a67-5000-45bb-9e85-0823641ad771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_20d04a67-5000-45bb-9e85-0823641ad771" xlink:to="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_29d43ae6-5950-43ee-860f-40f6e106b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:to="loc_us-gaap_SecuredDebtMember_29d43ae6-5950-43ee-860f-40f6e106b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e9a51310-2b10-45a7-8de3-9587d2f56ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_084469c0-e78f-4743-bb29-a72dbd14df53" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e9a51310-2b10-45a7-8de3-9587d2f56ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:to="loc_us-gaap_DebtInstrumentAxis_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_548dcbaa-d2ab-4c0e-8b16-e6d37951e2d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanMember_08b7bb62-f143-4227-8400-052823dea4c1" xlink:href="ebs-20250930.xsd#ebs_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:to="loc_ebs_TermLoanMember_08b7bb62-f143-4227-8400-052823dea4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolverLoanDue2025Member_402a9434-74da-448f-8b0f-b7ba7e4146ce" xlink:href="ebs-20250930.xsd#ebs_RevolverLoanDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_728345ea-0c2a-4e42-a270-430f1437b42c" xlink:to="loc_ebs_RevolverLoanDue2025Member_402a9434-74da-448f-8b0f-b7ba7e4146ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9b3f7e5b-80a0-47f3-8968-9170b26092cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9b3f7e5b-80a0-47f3-8968-9170b26092cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_14c33685-3f07-4ebb-b58c-87831bf3765e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b3f7e5b-80a0-47f3-8968-9170b26092cf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_14c33685-3f07-4ebb-b58c-87831bf3765e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_81a53c2b-b1b0-4c4f-a38a-ca337a8cc28f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_14c33685-3f07-4ebb-b58c-87831bf3765e" xlink:to="loc_us-gaap_LineOfCreditMember_81a53c2b-b1b0-4c4f-a38a-ca337a8cc28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29762512-e60c-45cf-90f0-8f1f67914297" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5fa0b75e-53f5-48b8-a9b2-fda8d19e0c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5fa0b75e-53f5-48b8-a9b2-fda8d19e0c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_ab90b0f8-2c2d-4fb5-a02d-bc2bcdfcf5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6780033d-d7d7-409d-ab54-45b7335ed944" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_ab90b0f8-2c2d-4fb5-a02d-bc2bcdfcf5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtSeniorUnsecuredNotesdue2028Details"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5afea3b1-fce7-4b3f-a58e-3b890b0a9c87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5afea3b1-fce7-4b3f-a58e-3b890b0a9c87" xlink:to="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_us-gaap_DebtInstrumentAxis_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_339822f2-a3d7-42eb-9055-547d28bce2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eef8e6c5-bd7c-4ad0-b5bd-f6a9ff35afde" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_339822f2-a3d7-42eb-9055-547d28bce2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_34a05afc-a9fc-4665-a0b2-520a85969885" xlink:href="ebs-20250930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_339822f2-a3d7-42eb-9055-547d28bce2e8" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_34a05afc-a9fc-4665-a0b2-520a85969885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f97939cb-ba48-4374-be41-4674c81bdf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f97939cb-ba48-4374-be41-4674c81bdf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d954b5da-068f-47b6-b7e1-6e744619bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f97939cb-ba48-4374-be41-4674c81bdf6d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d954b5da-068f-47b6-b7e1-6e744619bd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a108c71e-3e6e-4921-8465-3cb91f23b277" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d954b5da-068f-47b6-b7e1-6e744619bd6a" xlink:to="loc_us-gaap_SeniorNotesMember_a108c71e-3e6e-4921-8465-3cb91f23b277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0702407d-88ae-427a-bb3b-723d34b97971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0702407d-88ae-427a-bb3b-723d34b97971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_0702407d-88ae-427a-bb3b-723d34b97971" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_11a2d17d-5ead-4d8b-9cba-69f9a0044a09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_11a2d17d-5ead-4d8b-9cba-69f9a0044a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_bdf96142-06f1-4898-a624-dd50dc2ef2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_becaeb78-2432-4c76-81f0-ad754d214ccf" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_bdf96142-06f1-4898-a624-dd50dc2ef2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6aa56beb-c21f-42d3-8d19-40e2f3d91b25" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_srt_RangeAxis_6aa56beb-c21f-42d3-8d19-40e2f3d91b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f2ee6d2-5bd5-4caf-b9be-792220122896" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6aa56beb-c21f-42d3-8d19-40e2f3d91b25" xlink:to="loc_srt_RangeMember_8f2ee6d2-5bd5-4caf-b9be-792220122896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee1386d2-8b88-45a0-b697-fc751ce7967d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8f2ee6d2-5bd5-4caf-b9be-792220122896" xlink:to="loc_srt_MaximumMember_ee1386d2-8b88-45a0-b697-fc751ce7967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ea1910-d837-493c-9aed-7e2b76a0c316" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5da9c85c-22b4-48ec-8ace-221144806285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5da9c85c-22b4-48ec-8ace-221144806285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ecd238cc-f813-4fe6-976a-cca4f346e9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_LongTermDebt_ecd238cc-f813-4fe6-976a-cca4f346e9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d9704974-aa39-4e55-8f8c-1e0f9e66b48f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d9704974-aa39-4e55-8f8c-1e0f9e66b48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_b8bd9b20-2145-4b85-8e64-c994824c2ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_b8bd9b20-2145-4b85-8e64-c994824c2ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_ceae4b1d-63d1-490d-a371-857cef3d5742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_ceae4b1d-63d1-490d-a371-857cef3d5742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment_2131e31f-d6c6-4f6f-8805-891d78fea7f2" xlink:href="ebs-20250930.xsd#ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment_2131e31f-d6c6-4f6f-8805-891d78fea7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2716d913-65f3-41b5-92bc-aa9997acd03b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2716d913-65f3-41b5-92bc-aa9997acd03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentRepurchaseAmountRemaining_f32761b7-652d-4664-8ca7-fe1b1dfcb1fd" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentRepurchaseAmountRemaining"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3216ba1a-84de-4e0a-a926-a2ac1cf2f7da" xlink:to="loc_ebs_DebtInstrumentRepurchaseAmountRemaining_f32761b7-652d-4664-8ca7-fe1b1dfcb1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtTermLoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a64585ef-170c-4607-a932-67acd3cf2961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a64585ef-170c-4607-a932-67acd3cf2961" xlink:to="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_97f0bf11-877d-437b-871d-95810d07d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_DebtInstrumentAxis_97f0bf11-877d-437b-871d-95810d07d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ed5c36d6-4e64-4562-8983-4e5375a313ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_97f0bf11-877d-437b-871d-95810d07d8da" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ed5c36d6-4e64-4562-8983-4e5375a313ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanMember_3c1fc88a-79f2-41c5-b74a-f7b6d1b7c3f6" xlink:href="ebs-20250930.xsd#ebs_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ed5c36d6-4e64-4562-8983-4e5375a313ca" xlink:to="loc_ebs_TermLoanMember_3c1fc88a-79f2-41c5-b74a-f7b6d1b7c3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_989c1a18-8f34-4384-a48b-1d19b5edaf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_989c1a18-8f34-4384-a48b-1d19b5edaf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_824f3e65-3d83-4f34-be0b-defa993431a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_989c1a18-8f34-4384-a48b-1d19b5edaf3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_824f3e65-3d83-4f34-be0b-defa993431a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_aeb1cd19-af15-4f81-b80e-8ef8f0463d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_824f3e65-3d83-4f34-be0b-defa993431a0" xlink:to="loc_us-gaap_LineOfCreditMember_aeb1cd19-af15-4f81-b80e-8ef8f0463d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_614e58d7-080c-44b7-ae62-2b42c58c9f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_VariableRateAxis_614e58d7-080c-44b7-ae62-2b42c58c9f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_614e58d7-080c-44b7-ae62-2b42c58c9f2c" xlink:to="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_e9a7da9b-f012-4498-a8a5-68f2e947ef20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:to="loc_us-gaap_BaseRateMember_e9a7da9b-f012-4498-a8a5-68f2e947ef20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_9b35c53c-ba90-4369-b55e-9f3c8e3cdbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6a19fca3-0da5-48bd-86e3-194c2a8432bd" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_9b35c53c-ba90-4369-b55e-9f3c8e3cdbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_VariableRateComponentAxis_5bf7c065-0b3c-42da-b12e-b2efecd94863" xlink:href="ebs-20250930.xsd#ebs_VariableRateComponentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_ebs_VariableRateComponentAxis_5bf7c065-0b3c-42da-b12e-b2efecd94863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:href="ebs-20250930.xsd#ebs_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_VariableRateComponentAxis_5bf7c065-0b3c-42da-b12e-b2efecd94863" xlink:to="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember_77e35932-5b20-4380-82a1-3434a82d8c9e" xlink:href="ebs-20250930.xsd#ebs_UntilTheSecondAnniversaryOfTheClosingDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:to="loc_ebs_UntilTheSecondAnniversaryOfTheClosingDateMember_77e35932-5b20-4380-82a1-3434a82d8c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember_950c068f-51ed-4ea0-96ec-a74eb363b368" xlink:href="ebs-20250930.xsd#ebs_AfterTheSecondAnniversaryOfTheClosingDateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_VariableRateComponentDomain_639e4856-1ffa-491a-8830-7eb39b5b5dbf" xlink:to="loc_ebs_AfterTheSecondAnniversaryOfTheClosingDateMember_950c068f-51ed-4ea0-96ec-a74eb363b368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1958989c-2a6d-420c-bb49-95fd65859b49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_CreditFacilityAxis_1958989c-2a6d-420c-bb49-95fd65859b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e67b2267-d6d8-4953-873b-4477e545a670" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1958989c-2a6d-420c-bb49-95fd65859b49" xlink:to="loc_us-gaap_CreditFacilityDomain_e67b2267-d6d8-4953-873b-4477e545a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1363befd-a6df-4337-b95e-92353ef12a75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e67b2267-d6d8-4953-873b-4477e545a670" xlink:to="loc_us-gaap_SecuredDebtMember_1363befd-a6df-4337-b95e-92353ef12a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a9e1d3f-cf2f-4c7c-b7ae-43db426c0137" xlink:to="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_957e3af5-a2e8-4267-87e4-c057cdc7abb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_957e3af5-a2e8-4267-87e4-c057cdc7abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentOriginalIssueDiscountPercentage_924fb92c-1c1d-4de5-b92d-448b1a44163c" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentOriginalIssueDiscountPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentOriginalIssueDiscountPercentage_924fb92c-1c1d-4de5-b92d-448b1a44163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentVariableInterestRateFloor_fa1ffd41-bd43-4b7d-ad5b-4b3e3c1e7a18" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentVariableInterestRateFloor"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentVariableInterestRateFloor_fa1ffd41-bd43-4b7d-ad5b-4b3e3c1e7a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44f94fb2-4599-4e3f-87fd-9e3bcc6afd88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_44f94fb2-4599-4e3f-87fd-9e3bcc6afd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentAdditionalDefaultInterestRate_fb9cb598-5b4a-4043-bc31-d3c2b73fa59a" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentAdditionalDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentAdditionalDefaultInterestRate_fb9cb598-5b4a-4043-bc31-d3c2b73fa59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold_73ec6248-ee0c-4a4a-833c-de6b75c95852" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold_73ec6248-ee0c-4a4a-833c-de6b75c95852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_6b41f1d4-d589-4db4-a898-f27c6aed9bc5" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLiquidityRequirementMinimum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_6b41f1d4-d589-4db4-a898-f27c6aed9bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_69851a92-3f83-4ea7-9baa-bb246f7d7e1e" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_69851a92-3f83-4ea7-9baa-bb246f7d7e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium_6a981440-1f8c-499b-8034-83622010cc4b" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentBasisSpreadOnMakeWholePremium"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium_6a981440-1f8c-499b-8034-83622010cc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentPrepaymentPremium_7eb06f7e-d6d1-4aa7-be2f-0aeee8dd7714" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentPrepaymentPremium"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentPrepaymentPremium_7eb06f7e-d6d1-4aa7-be2f-0aeee8dd7714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease_9e78ca75-a99d-420c-a9db-bf81506d089e" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease_9e78ca75-a99d-420c-a9db-bf81506d089e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred_eb675726-417e-4218-a51d-95e9518bcc0d" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred_eb675726-417e-4218-a51d-95e9518bcc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds_87843e2a-755b-4e9c-b590-300053d891d1" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds_87843e2a-755b-4e9c-b590-300053d891d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis_1fe5b482-5e65-4215-9f01-7a615b4d3b85" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis_1fe5b482-5e65-4215-9f01-7a615b4d3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis_d1b60bd6-b838-4362-8ef2-271e1bde680b" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_099287ae-cf07-4924-a1db-f66a8db5c09a" xlink:to="loc_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis_d1b60bd6-b838-4362-8ef2-271e1bde680b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#DebtRevolvingLoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_08c90928-7db0-4fa7-86e9-329c4c812f53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_08c90928-7db0-4fa7-86e9-329c4c812f53" xlink:to="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_17b129eb-7744-4730-bf89-03465e867bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_CreditFacilityAxis_17b129eb-7744-4730-bf89-03465e867bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_17b129eb-7744-4730-bf89-03465e867bd2" xlink:to="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dc40d499-7b77-4f6a-acc7-aaeef0b8685c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_dc40d499-7b77-4f6a-acc7-aaeef0b8685c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_f4ddb7da-8305-4fe7-b026-6b9e69f0fd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:to="loc_us-gaap_BridgeLoanMember_f4ddb7da-8305-4fe7-b026-6b9e69f0fd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9181c043-37d9-4f6f-9819-ce473602354e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_669c0136-beaf-4e1b-972b-c29e2c559211" xlink:to="loc_us-gaap_LetterOfCreditMember_9181c043-37d9-4f6f-9819-ce473602354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_DebtInstrumentAxis_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b400271-25c6-4bc1-9557-35a93ead0115" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0fd9a5b8-2ef9-4609-b8b6-e3c93feeef91" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b400271-25c6-4bc1-9557-35a93ead0115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b400271-25c6-4bc1-9557-35a93ead0115" xlink:to="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansUntilSeptember302025Member_c3e2067e-1495-424f-8a28-80c1ee1e244d" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansUntilSeptember302025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:to="loc_ebs_RevolvingLoansUntilSeptember302025Member_c3e2067e-1495-424f-8a28-80c1ee1e244d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RevolvingLoansAfterSeptember302025Member_7b4e8e79-f7b1-45e2-ac75-86d8d6f341ff" xlink:href="ebs-20250930.xsd#ebs_RevolvingLoansAfterSeptember302025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_RevolvingLoansMember_e8e3fded-6bf7-4610-b39c-d6cd817e5785" xlink:to="loc_ebs_RevolvingLoansAfterSeptember302025Member_7b4e8e79-f7b1-45e2-ac75-86d8d6f341ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa38d031-dbad-4331-b08b-5273e39804f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa38d031-dbad-4331-b08b-5273e39804f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e57eec54-78f1-4796-9685-cb00e1f40597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa38d031-dbad-4331-b08b-5273e39804f2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e57eec54-78f1-4796-9685-cb00e1f40597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0d51027e-dfa9-43f0-9909-5eae6fc39331" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e57eec54-78f1-4796-9685-cb00e1f40597" xlink:to="loc_us-gaap_LineOfCreditMember_0d51027e-dfa9-43f0-9909-5eae6fc39331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_11447f81-a68d-4c0d-9034-d955ec2f60c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_VariableRateAxis_11447f81-a68d-4c0d-9034-d955ec2f60c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_11447f81-a68d-4c0d-9034-d955ec2f60c4" xlink:to="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_5d83a285-77bf-42b3-a2db-0ef8f5d62bef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:to="loc_us-gaap_BaseRateMember_5d83a285-77bf-42b3-a2db-0ef8f5d62bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_1d3370cf-d540-494a-bc44-959be8b18787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_abddd677-5272-48cf-9a2c-86eb830bfdb9" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_1d3370cf-d540-494a-bc44-959be8b18787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_39881535-3f04-41f2-b39a-23521b48eaa9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f34036d-5794-4bc8-b695-373f698bde3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f34036d-5794-4bc8-b695-373f698bde3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit_79f95b6e-c18a-47da-9cbb-ccc9be477cd3" xlink:href="ebs-20250930.xsd#ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit_79f95b6e-c18a-47da-9cbb-ccc9be477cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit_1a8ac644-a399-41e7-a9b3-610e14b2b419" xlink:href="ebs-20250930.xsd#ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit_1a8ac644-a399-41e7-a9b3-610e14b2b419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2859cf58-7b03-418e-9604-ffb1d1638852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2859cf58-7b03-418e-9604-ffb1d1638852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentVariableInterestRateFloor_d958f239-ccd1-4b20-b228-8c06bda10b13" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentVariableInterestRateFloor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentVariableInterestRateFloor_d958f239-ccd1-4b20-b228-8c06bda10b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum_c3d97819-2507-46aa-8d7e-9fd85680aa2d" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum_c3d97819-2507-46aa-8d7e-9fd85680aa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24976843-1c2f-45ef-a767-fe5d14d0a08d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24976843-1c2f-45ef-a767-fe5d14d0a08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate_ccb64803-d5aa-477d-b4ee-2b799aca8311" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate_ccb64803-d5aa-477d-b4ee-2b799aca8311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_51217719-42cf-4920-b47b-5314519d5a0e" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLiquidityRequirementMinimum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum_51217719-42cf-4920-b47b-5314519d5a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_0ae42186-43c6-460a-9022-229daa5d022c" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantLeverageRatioMaximum_0ae42186-43c6-460a-9022-229daa5d022c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum_66080214-ca32-4ef4-9658-e5dfdbf15952" xlink:href="ebs-20250930.xsd#ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23eceef0-a6c3-4f4b-8385-69211daa3a6e" xlink:to="loc_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum_66080214-ca32-4ef4-9658-e5dfdbf15952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SharebasedcompensationandstockholdersequityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cb2a50e2-0241-41fc-89e5-7a14f6bdd5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cb2a50e2-0241-41fc-89e5-7a14f6bdd5cd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f61469e9-e22e-4afc-b43c-2b635c0f90b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_us-gaap_AwardTypeAxis_f61469e9-e22e-4afc-b43c-2b635c0f90b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f61469e9-e22e-4afc-b43c-2b635c0f90b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c3a0bcc-892f-4c52-9f4d-09817b2f9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c3a0bcc-892f-4c52-9f4d-09817b2f9b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_41c970d0-7aaf-4925-90f5-3c79d1faf91b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_41c970d0-7aaf-4925-90f5-3c79d1faf91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6ffeb893-3b42-4ee2-8c6e-7058b68caec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_us-gaap_PerformanceSharesMember_6ffeb893-3b42-4ee2-8c6e-7058b68caec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LongTermIncentiveAwardMember_fdc6b143-fa74-4f48-b33e-e2afc49fbcd4" xlink:href="ebs-20250930.xsd#ebs_LongTermIncentiveAwardMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_ebs_LongTermIncentiveAwardMember_fdc6b143-fa74-4f48-b33e-e2afc49fbcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PerformanceStockOptionMember_0154b147-6bc7-435a-a9a7-dbc91f8f061e" xlink:href="ebs-20250930.xsd#ebs_PerformanceStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_ebs_PerformanceStockOptionMember_0154b147-6bc7-435a-a9a7-dbc91f8f061e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherEquityAwardsMember_c0b1c19b-83e1-425c-8bc7-824de7a621f8" xlink:href="ebs-20250930.xsd#ebs_OtherEquityAwardsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99b031f1-f617-4128-952f-3b27c3d3f1a3" xlink:to="loc_ebs_OtherEquityAwardsMember_c0b1c19b-83e1-425c-8bc7-824de7a621f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e66535ea-c807-4027-826e-8f3d781e79fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_828e66ae-e0f1-4dc0-bc8c-afad6d551ceb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e66535ea-c807-4027-826e-8f3d781e79fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SubscriptionAgreementMember_0792b38d-3a28-46f4-a2b9-a3f48db11ad5" xlink:href="ebs-20250930.xsd#ebs_SubscriptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e66535ea-c807-4027-826e-8f3d781e79fb" xlink:to="loc_ebs_SubscriptionAgreementMember_0792b38d-3a28-46f4-a2b9-a3f48db11ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_76fc3f65-aa02-4903-9123-bb19fa3f8ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_76fc3f65-aa02-4903-9123-bb19fa3f8ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_76fc3f65-aa02-4903-9123-bb19fa3f8ffd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIWarrantsMember_39b29cc1-e63a-4394-ab7c-dae9707cc53b" xlink:href="ebs-20250930.xsd#ebs_SeriesIWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:to="loc_ebs_SeriesIWarrantsMember_39b29cc1-e63a-4394-ab7c-dae9707cc53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeriesIIWarrantsMember_aa6ccf79-7c25-4711-a8b0-01b5497bea72" xlink:href="ebs-20250930.xsd#ebs_SeriesIIWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_58b5bd9b-d9cc-4a1d-bb6e-2f0c12caa866" xlink:to="loc_ebs_SeriesIIWarrantsMember_aa6ccf79-7c25-4711-a8b0-01b5497bea72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_36742735-bd42-44c9-bfb3-7f9f72005d06" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_srt_ShareRepurchaseProgramAxis_36742735-bd42-44c9-bfb3-7f9f72005d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_531becf6-dbc1-4f07-92bb-f9fc488adb09" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_36742735-bd42-44c9-bfb3-7f9f72005d06" xlink:to="loc_srt_ShareRepurchaseProgramDomain_531becf6-dbc1-4f07-92bb-f9fc488adb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2025ShareRepurchaseProgramMember_7b8f90e2-a9a8-468a-9968-ca6f8e51bf67" xlink:href="ebs-20250930.xsd#ebs_A2025ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_531becf6-dbc1-4f07-92bb-f9fc488adb09" xlink:to="loc_ebs_A2025ShareRepurchaseProgramMember_7b8f90e2-a9a8-468a-9968-ca6f8e51bf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60329772-912c-436c-86c3-2334dd5ffc88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_26c2fdaa-be11-4820-a911-868c24ab5246" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_26c2fdaa-be11-4820-a911-868c24ab5246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7a89a4-6e82-4c4a-b6b9-45e1ab4c3ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9e7a89a4-6e82-4c4a-b6b9-45e1ab4c3ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_f605e5a7-92a3-4be7-b829-243bf7189183" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod_f605e5a7-92a3-4be7-b829-243bf7189183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_338a8783-57f1-482f-84b7-f6918c4cba5c" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_338a8783-57f1-482f-84b7-f6918c4cba5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d24dad60-cdb7-4952-b1db-32c8fdfe5669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d24dad60-cdb7-4952-b1db-32c8fdfe5669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements_b72c2b2e-e84c-44d6-9798-83e071275783" xlink:href="ebs-20250930.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements_b72c2b2e-e84c-44d6-9798-83e071275783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1bf8bea4-75cc-4945-b459-658f31f6652e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1bf8bea4-75cc-4945-b459-658f31f6652e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ff781081-41f6-47e3-bba4-14ebf60c1513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ff781081-41f6-47e3-bba4-14ebf60c1513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8394d74b-09e9-4a26-94f3-d7a578dd1899" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_8394d74b-09e9-4a26-94f3-d7a578dd1899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_59accb49-ab49-4302-9cd3-1cba45acc8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_59accb49-ab49-4302-9cd3-1cba45acc8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4c0676a0-0541-49ff-9d97-2a71ff1625de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4c0676a0-0541-49ff-9d97-2a71ff1625de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5f424602-3956-49b4-9a05-697367b2527e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5f424602-3956-49b4-9a05-697367b2527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fc5bd610-ad39-40f8-a1c6-2355ab7a56ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fc5bd610-ad39-40f8-a1c6-2355ab7a56ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_df4744a4-7062-4c2d-b8d2-1a84441a442e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_df4744a4-7062-4c2d-b8d2-1a84441a442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_38617014-fc70-4ce0-a4a1-7292e6866ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_38617014-fc70-4ce0-a4a1-7292e6866ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bfd7b693-35da-4a3a-8a6e-82f689253c72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bfd7b693-35da-4a3a-8a6e-82f689253c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5832033d-2169-480b-a26f-a6d556e658f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5832033d-2169-480b-a26f-a6d556e658f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_f14697ee-56b9-4a70-b8c3-6012977436d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_f14697ee-56b9-4a70-b8c3-6012977436d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_36148495-0c51-4704-bd2f-ecc2a912af14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_36148495-0c51-4704-bd2f-ecc2a912af14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_WarrantLiabilitiesFairValueDisclosure_ac92b7fb-18d2-4013-ad90-262fb778691c" xlink:href="ebs-20250930.xsd#ebs_WarrantLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9d0970-e123-41c9-8777-35fe04925938" xlink:to="loc_ebs_WarrantLiabilitiesFairValueDisclosure_ac92b7fb-18d2-4013-ad90-262fb778691c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7430782a-5a37-43b7-b836-2b503b0ca6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f649cea5-8e22-489c-afdc-d26554e95a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7430782a-5a37-43b7-b836-2b503b0ca6bf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f649cea5-8e22-489c-afdc-d26554e95a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf995217-7cf7-4c41-860f-2bfd28376329" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f649cea5-8e22-489c-afdc-d26554e95a1a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf995217-7cf7-4c41-860f-2bfd28376329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf995217-7cf7-4c41-860f-2bfd28376329" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d0659585-9d72-4b70-a716-84f1c6ac715a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:to="loc_us-gaap_CostOfSalesMember_d0659585-9d72-4b70-a716-84f1c6ac715a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902c1884-d61f-4473-b4a1-03e568c72236" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_902c1884-d61f-4473-b4a1-03e568c72236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e0353a2c-2987-47f1-9836-b8c6a35bc703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a696705-e990-4151-89c3-98c25a211cb4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e0353a2c-2987-47f1-9836-b8c6a35bc703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5fe6d25d-7466-429d-932f-519796278b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f649cea5-8e22-489c-afdc-d26554e95a1a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5fe6d25d-7466-429d-932f-519796278b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e3e82ca-4b01-40d7-a372-76e61b5b1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5fe6d25d-7466-429d-932f-519796278b3b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e3e82ca-4b01-40d7-a372-76e61b5b1c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e1c8281a-afce-4bf0-b586-36f0f7c0f2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e1c8281a-afce-4bf0-b586-36f0f7c0f2e5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6d1e5c02-d951-4eb3-acc3-b766871e6aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6d1e5c02-d951-4eb3-acc3-b766871e6aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a4367bb0-4e5b-4fe4-98ae-7eab624726f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d1e5c02-d951-4eb3-acc3-b766871e6aaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a4367bb0-4e5b-4fe4-98ae-7eab624726f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_A2024WarrantsMember_7a2a04e0-865b-42a5-9f67-93ccd64595d5" xlink:href="ebs-20250930.xsd#ebs_A2024WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a4367bb0-4e5b-4fe4-98ae-7eab624726f3" xlink:to="loc_ebs_A2024WarrantsMember_7a2a04e0-865b-42a5-9f67-93ccd64595d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ba56896-1866-45fa-ba9d-47784b0ab882" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:to="loc_srt_RangeAxis_2ba56896-1866-45fa-ba9d-47784b0ab882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2ba56896-1866-45fa-ba9d-47784b0ab882" xlink:to="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8271a880-970d-49fc-b2fa-3901ab3baf1e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:to="loc_srt_MinimumMember_8271a880-970d-49fc-b2fa-3901ab3baf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2176dab6-3616-43a5-b3a4-148e8a08aa1a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_886a908b-f9f6-48f0-8329-445fcf4c5432" xlink:to="loc_srt_MaximumMember_2176dab6-3616-43a5-b3a4-148e8a08aa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7fdef8aa-a18f-476d-8618-42202683f8df" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ff922bbc-4a16-4e07-9c0c-5060cf3c1c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ff922bbc-4a16-4e07-9c0c-5060cf3c1c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bbc932a-ef98-4de1-919a-7872e8c1473e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6f54e1da-82fd-475c-b758-1a96c8d6b42d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6bbc932a-ef98-4de1-919a-7872e8c1473e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0a1a99f8-27bb-4cbc-bc06-b882dd737623" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e6c84417-7530-4879-ac12-d53f92d95b38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a1a99f8-27bb-4cbc-bc06-b882dd737623" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e6c84417-7530-4879-ac12-d53f92d95b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94888bb7-f944-4c03-915a-f8253d5a33be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e6c84417-7530-4879-ac12-d53f92d95b38" xlink:to="loc_us-gaap_NetIncomeLoss_94888bb7-f944-4c03-915a-f8253d5a33be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af2121a3-3972-41f4-a9f0-18d6dfed9856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a1a99f8-27bb-4cbc-bc06-b882dd737623" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af2121a3-3972-41f4-a9f0-18d6dfed9856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b89cad9c-1dcd-429c-a897-df7c185bf987" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af2121a3-3972-41f4-a9f0-18d6dfed9856" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b89cad9c-1dcd-429c-a897-df7c185bf987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_088ae543-618f-4420-9fab-0c0592005c20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af2121a3-3972-41f4-a9f0-18d6dfed9856" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_088ae543-618f-4420-9fab-0c0592005c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cf63eabe-7352-42f5-9b1b-05aa66b3a096" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_af2121a3-3972-41f4-a9f0-18d6dfed9856" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cf63eabe-7352-42f5-9b1b-05aa66b3a096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f2ecc4ff-7d12-4276-aed5-4d2d7db72a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a1a99f8-27bb-4cbc-bc06-b882dd737623" xlink:to="loc_us-gaap_EarningsPerShareBasic_f2ecc4ff-7d12-4276-aed5-4d2d7db72a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e140a70c-25ad-4de3-b48e-81891298041f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a1a99f8-27bb-4cbc-bc06-b882dd737623" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e140a70c-25ad-4de3-b48e-81891298041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4a2166d2-d490-4180-891c-54962a6c3dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a1a99f8-27bb-4cbc-bc06-b882dd737623" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4a2166d2-d490-4180-891c-54962a6c3dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b9382e70-4ea6-4d76-8084-9705b923d72a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b9382e70-4ea6-4d76-8084-9705b923d72a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fe2d20c7-d1ab-422f-af88-049bfe05659c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:to="loc_srt_MajorCustomersAxis_fe2d20c7-d1ab-422f-af88-049bfe05659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fe2d20c7-d1ab-422f-af88-049bfe05659c" xlink:to="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_4e8ba6bf-fca4-41a5-ba80-3c45f67e19fc" xlink:href="ebs-20250930.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:to="loc_ebs_UnitedStatesGovernmentMember_4e8ba6bf-fca4-41a5-ba80-3c45f67e19fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember_d8eedb68-1886-4227-ae9c-151e1e16102f" xlink:href="ebs-20250930.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:to="loc_ebs_NonUnitedStatesGovernmentMember_d8eedb68-1886-4227-ae9c-151e1e16102f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JanssenPharmaceuticalsInc.Member_f8c26ef8-6117-4508-9bce-b1c822a3429b" xlink:href="ebs-20250930.xsd#ebs_JanssenPharmaceuticalsInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5717e168-9b13-4a05-b0c0-4e3f704f3064" xlink:to="loc_ebs_JanssenPharmaceuticalsInc.Member_f8c26ef8-6117-4508-9bce-b1c822a3429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e570713-ae4d-4937-bd48-9e647297202e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:to="loc_srt_ProductOrServiceAxis_8e570713-ae4d-4937-bd48-9e647297202e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8e570713-ae4d-4937-bd48-9e647297202e" xlink:to="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductMember_999e2364-7ba4-4468-867d-21667020f0b4" xlink:href="ebs-20250930.xsd#ebs_CommercialProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_ebs_CommercialProductMember_999e2364-7ba4-4468-867d-21667020f0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MedicalCountermeasuresMCMProductMember_e6224207-800c-4d1a-9d8d-bed8b841d4bb" xlink:href="ebs-20250930.xsd#ebs_MedicalCountermeasuresMCMProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_ebs_MedicalCountermeasuresMCMProductMember_e6224207-800c-4d1a-9d8d-bed8b841d4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AllOtherRevenueMember_def79e8b-9c13-45fc-ba73-6a999efeff92" xlink:href="ebs-20250930.xsd#ebs_AllOtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_ebs_AllOtherRevenueMember_def79e8b-9c13-45fc-ba73-6a999efeff92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d0c60499-8a47-4273-9d94-1d3569244ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_751c2ef1-179a-4bcb-84f1-5557004f729f" xlink:to="loc_us-gaap_ServiceMember_d0c60499-8a47-4273-9d94-1d3569244ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_226063c3-43ee-4292-a8d8-2bc103c3041e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ea74460a-a2c9-4a4e-844d-94a2e1e7a116" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_226063c3-43ee-4292-a8d8-2bc103c3041e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80f8b9b7-f35e-4f04-8a98-44683c7fe928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_226063c3-43ee-4292-a8d8-2bc103c3041e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80f8b9b7-f35e-4f04-8a98-44683c7fe928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ced96e53-fe54-4e10-a476-64cacfb90634" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ced96e53-fe54-4e10-a476-64cacfb90634" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b843d7ad-3d76-4032-9139-f89af0fb424a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b843d7ad-3d76-4032-9139-f89af0fb424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9444b633-c41d-4a57-9692-e1887819c6da" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_bdf1a402-844a-4916-8e79-4974145def6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_bdf1a402-844a-4916-8e79-4974145def6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c6dedf2-3b27-445b-af6f-14e9d7bd00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c6dedf2-3b27-445b-af6f-14e9d7bd00dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_9c7c2dac-aae5-4264-8f6c-41d87b8dc600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_9c7c2dac-aae5-4264-8f6c-41d87b8dc600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f6c36f4b-eadd-4522-b02b-01910d576f50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3992838a-94d7-48ae-bd4a-f6276b399cc9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f6c36f4b-eadd-4522-b02b-01910d576f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bd2173fa-ca48-42f7-b42c-c7e28dd45ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_83af1781-8d9a-48b9-afc8-5e3bff889ef0" xlink:href="ebs-20250930.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bd2173fa-ca48-42f7-b42c-c7e28dd45ec8" xlink:to="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_83af1781-8d9a-48b9-afc8-5e3bff889ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_03f2b9db-bec1-4a41-a230-03b7fbec3efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_83af1781-8d9a-48b9-afc8-5e3bff889ef0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_03f2b9db-bec1-4a41-a230-03b7fbec3efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6bb7f472-cec9-487c-ac21-e2d9628539ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_83af1781-8d9a-48b9-afc8-5e3bff889ef0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6bb7f472-cec9-487c-ac21-e2d9628539ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f3a11d0c-acfd-4ee8-9053-cb8469ae930c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_83af1781-8d9a-48b9-afc8-5e3bff889ef0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f3a11d0c-acfd-4ee8-9053-cb8469ae930c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#RevenuerecognitionScheduleofAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c0cc95f-e708-4415-98a0-11e0bfc19ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_6f001891-b578-4b2e-8947-5b7c268e5fba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c0cc95f-e708-4415-98a0-11e0bfc19ae3" xlink:to="loc_us-gaap_BilledContractReceivables_6f001891-b578-4b2e-8947-5b7c268e5fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_329c3823-fe3e-4f33-ac56-cad5983b13dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c0cc95f-e708-4415-98a0-11e0bfc19ae3" xlink:to="loc_us-gaap_UnbilledContractsReceivable_329c3823-fe3e-4f33-ac56-cad5983b13dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0ab61703-62e3-40d7-a965-182973386f09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c0cc95f-e708-4415-98a0-11e0bfc19ae3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0ab61703-62e3-40d7-a965-182973386f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e2020120-a155-451b-98f2-ed7a39729dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c0cc95f-e708-4415-98a0-11e0bfc19ae3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e2020120-a155-451b-98f2-ed7a39729dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_873f4d65-cb04-4f97-bde8-16f1f6bb771e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_13de0478-6c35-4da8-9965-f62816f6b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_873f4d65-cb04-4f97-bde8-16f1f6bb771e" xlink:to="loc_us-gaap_LeaseCostAbstract_13de0478-6c35-4da8-9965-f62816f6b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_10fada41-7c7f-4838-8a49-79ff1cc67cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_13de0478-6c35-4da8-9965-f62816f6b9fc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_10fada41-7c7f-4838-8a49-79ff1cc67cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_522e32ae-7ad3-4225-8aad-10f7a11b5611" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_13de0478-6c35-4da8-9965-f62816f6b9fc" xlink:to="loc_us-gaap_OperatingLeaseCost_522e32ae-7ad3-4225-8aad-10f7a11b5611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ef665463-88e7-4163-8ba9-59307ce481ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_13de0478-6c35-4da8-9965-f62816f6b9fc" xlink:to="loc_us-gaap_LeaseCost_ef665463-88e7-4163-8ba9-59307ce481ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cf576d50-6dd4-4ff0-92a6-88fbe15c2436" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf576d50-6dd4-4ff0-92a6-88fbe15c2436" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ceb50d7c-28bb-4196-bfd3-ac47fed9dbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ceb50d7c-28bb-4196-bfd3-ac47fed9dbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_59fad8c9-39cd-4bdb-8fb4-e61be47fe07a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_59fad8c9-39cd-4bdb-8fb4-e61be47fe07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3476b829-6ca7-40ca-814d-cfd33faa7882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3476b829-6ca7-40ca-814d-cfd33faa7882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_90552519-1606-4638-ac57-1b0bcfbaa42d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:to="loc_us-gaap_OperatingLeaseLiability_90552519-1606-4638-ac57-1b0bcfbaa42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e4d79be7-2f62-4b06-acdd-406cdc0f4848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e4d79be7-2f62-4b06-acdd-406cdc0f4848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2f3efe7b-0e74-4e1b-b33e-fbe51e18c46d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2f3efe7b-0e74-4e1b-b33e-fbe51e18c46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3e93c543-dde5-4cd6-b648-7d30d18f6fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5a097866-e71f-4e17-8d36-c5571c8b1516" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_3e93c543-dde5-4cd6-b648-7d30d18f6fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_89b4d729-1afd-4b73-9e11-088009c33e34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf576d50-6dd4-4ff0-92a6-88fbe15c2436" xlink:to="loc_us-gaap_LeaseCostAbstract_89b4d729-1afd-4b73-9e11-088009c33e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e7eac24-a475-407f-8978-7fa3535df0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_89b4d729-1afd-4b73-9e11-088009c33e34" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7e7eac24-a475-407f-8978-7fa3535df0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1d5db96f-9b84-4dc0-b2fa-f75ad5b30825" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_89b4d729-1afd-4b73-9e11-088009c33e34" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1d5db96f-9b84-4dc0-b2fa-f75ad5b30825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3081ffd7-88c1-4ce8-ad60-c7a930ef1d11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_33043542-73f6-47b2-a23a-ca40c7a65133" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3081ffd7-88c1-4ce8-ad60-c7a930ef1d11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_33043542-73f6-47b2-a23a-ca40c7a65133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f99b5ca9-1929-4260-b84d-0d156baec108" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_33043542-73f6-47b2-a23a-ca40c7a65133" xlink:to="loc_srt_StatementScenarioAxis_f99b5ca9-1929-4260-b84d-0d156baec108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_56c4f26e-fb19-4f96-a2ee-aca1b1637832" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f99b5ca9-1929-4260-b84d-0d156baec108" xlink:to="loc_srt_ScenarioUnspecifiedDomain_56c4f26e-fb19-4f96-a2ee-aca1b1637832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b762411d-3b51-402a-bdfd-5a494ebeb4bd" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_56c4f26e-fb19-4f96-a2ee-aca1b1637832" xlink:to="loc_srt_ScenarioForecastMember_b762411d-3b51-402a-bdfd-5a494ebeb4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_764df020-9c06-4bd7-b616-dc3a429fb261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_33043542-73f6-47b2-a23a-ca40c7a65133" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_764df020-9c06-4bd7-b616-dc3a429fb261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e34ba23f-3f81-4990-9443-f5d2756b6f72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_764df020-9c06-4bd7-b616-dc3a429fb261" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e34ba23f-3f81-4990-9443-f5d2756b6f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LitigationDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_53e141aa-dedb-48d3-8983-847c5a618140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:href="ebs-20250930.xsd#ebs_CommitmentContingenciesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_53e141aa-dedb-48d3-8983-847c5a618140" xlink:to="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_16738e29-6b53-431d-a7e1-540aa7c6e5cf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:to="loc_srt_LitigationCaseAxis_16738e29-6b53-431d-a7e1-540aa7c6e5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_16738e29-6b53-431d-a7e1-540aa7c6e5cf" xlink:to="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SecuritiesAndShareholderLitigationMember_3b950c93-15fe-42e7-8403-9918bd55a9e3" xlink:href="ebs-20250930.xsd#ebs_SecuritiesAndShareholderLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:to="loc_ebs_SecuritiesAndShareholderLitigationMember_3b950c93-15fe-42e7-8403-9918bd55a9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SECEnforcementProceedingMember_12822e76-cc7f-49a1-a857-0cc8b09f4df7" xlink:href="ebs-20250930.xsd#ebs_SECEnforcementProceedingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_53e89e66-186e-45e6-b1e0-dc6301b25a3d" xlink:to="loc_ebs_SECEnforcementProceedingMember_12822e76-cc7f-49a1-a857-0cc8b09f4df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_05da6ea6-4981-4b22-b0ca-3277f0ccc8da" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:to="loc_srt_MajorCustomersAxis_05da6ea6-4981-4b22-b0ca-3277f0ccc8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbddad53-5550-40c0-979f-72c425b9ace9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_05da6ea6-4981-4b22-b0ca-3277f0ccc8da" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbddad53-5550-40c0-979f-72c425b9ace9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_c6ecedce-57c7-46a9-bf68-43959321e9d7" xlink:href="ebs-20250930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbddad53-5550-40c0-979f-72c425b9ace9" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_c6ecedce-57c7-46a9-bf68-43959321e9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:to="loc_srt_ProductOrServiceAxis_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ae5940d-0b37-498d-9727-bb89195a84ba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_89b329e6-21fd-44e8-8ca6-c7b8ff5cb7bf" xlink:to="loc_srt_ProductsAndServicesDomain_7ae5940d-0b37-498d-9727-bb89195a84ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductAndServiceMember_34360e38-fd18-42da-8da1-a729ad19fb08" xlink:href="ebs-20250930.xsd#ebs_ProductAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ae5940d-0b37-498d-9727-bb89195a84ba" xlink:to="loc_ebs_ProductAndServiceMember_34360e38-fd18-42da-8da1-a729ad19fb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:href="ebs-20250930.xsd#ebs_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentContingenciesDisclosureTable_6107c90c-68cb-4dff-9f6b-4b0c7e2a9190" xlink:to="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_a2dd4d76-f2c2-4df0-9bc9-d1a422b50989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_a2dd4d76-f2c2-4df0-9bc9-d1a422b50989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds_5d538673-4856-49e6-9b17-bd2eeedf78b6" xlink:href="ebs-20250930.xsd#ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds_5d538673-4856-49e6-9b17-bd2eeedf78b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencySettlementPeriod_ef96aab3-5fe3-4f2b-8c78-d73acf66d752" xlink:href="ebs-20250930.xsd#ebs_LossContingencySettlementPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencySettlementPeriod_ef96aab3-5fe3-4f2b-8c78-d73acf66d752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_bd143667-0b83-4ca1-9fc5-b3eb278fb931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_bd143667-0b83-4ca1-9fc5-b3eb278fb931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms_eef17975-fa35-4e1a-af03-dc7824b6bbd7" xlink:href="ebs-20250930.xsd#ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms_eef17975-fa35-4e1a-af03-dc7824b6bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained_77294675-3ec3-4fc4-9372-35a0b4bd5fd6" xlink:href="ebs-20250930.xsd#ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained_77294675-3ec3-4fc4-9372-35a0b4bd5fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_d83e96bb-8cb1-4bd3-a942-4803a0bb3326" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementGain"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LitigationSettlementGain_d83e96bb-8cb1-4bd3-a942-4803a0bb3326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_81c98dad-9189-48ff-8fd1-c1a2319194ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_81c98dad-9189-48ff-8fd1-c1a2319194ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_5b01cd9a-abf5-4543-8f48-8f0100160df9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_5b01cd9a-abf5-4543-8f48-8f0100160df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_7edfc9a7-4bf1-4306-a70d-8630bef51c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_7edfc9a7-4bf1-4306-a70d-8630bef51c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_a9097c84-e907-4a5a-bc5d-23f2878e0ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_a9097c84-e907-4a5a-bc5d-23f2878e0ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_94b8ac58-81cd-40ad-a96c-8e62af467407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_94b8ac58-81cd-40ad-a96c-8e62af467407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b67373ad-be66-4b2c-b1dc-125a60733e60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b67373ad-be66-4b2c-b1dc-125a60733e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9bc8e73a-28ac-47cd-8345-2505096e61b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9bc8e73a-28ac-47cd-8345-2505096e61b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5dc3efcd-a123-4080-afb2-c6dce007ba15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5dc3efcd-a123-4080-afb2-c6dce007ba15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f6c8afde-c7e9-4c0b-8261-a130bd2516d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_CommitmentsAndContingenciesDisclosureLineItems_145c2d0f-bd5c-4f49-a033-bf77c9ab87e1" xlink:to="loc_us-gaap_InventoryWriteDown_f6c8afde-c7e9-4c0b-8261-a130bd2516d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentinformationNarrativeDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SegmentinformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentinformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b6f79650-c541-483c-8931-c75a68aa7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_880449fb-d92b-4f61-b7bc-3a0b99cc86a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b6f79650-c541-483c-8931-c75a68aa7eb0" xlink:to="loc_us-gaap_NumberOfReportableSegments_880449fb-d92b-4f61-b7bc-3a0b99cc86a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ddaefb81-16e2-46e8-95ae-c89ff15d876d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ddaefb81-16e2-46e8-95ae-c89ff15d876d" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_26e796bd-312a-4841-94d2-61d6b0cd7e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_26e796bd-312a-4841-94d2-61d6b0cd7e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_26e796bd-312a-4841-94d2-61d6b0cd7e9c" xlink:to="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CommercialProductsSegmentMember_7f403495-c6cf-46fe-9321-552e1ed924f8" xlink:href="ebs-20250930.xsd#ebs_CommercialProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:to="loc_ebs_CommercialProductsSegmentMember_7f403495-c6cf-46fe-9321-552e1ed924f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_2356f5f2-7ae2-4d01-8973-0b5e9e459d55" xlink:href="ebs-20250930.xsd#ebs_MCMProductsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3481e7d5-3569-4337-952f-f77eac723f98" xlink:to="loc_ebs_MCMProductsSegmentMember_2356f5f2-7ae2-4d01-8973-0b5e9e459d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7143c3b3-2bea-479b-9e42-efc2e8338fb6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:to="loc_srt_ConsolidationItemsAxis_7143c3b3-2bea-479b-9e42-efc2e8338fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_7143c3b3-2bea-479b-9e42-efc2e8338fb6" xlink:to="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_962b9eb1-6087-4e31-95af-9afc97ec4255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:to="loc_us-gaap_OperatingSegmentsMember_962b9eb1-6087-4e31-95af-9afc97ec4255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_8547201f-7ba6-4df4-98a0-4f02ce61c87b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e403fda9-2a8d-4910-bbd0-f7251e8d41c6" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_8547201f-7ba6-4df4-98a0-4f02ce61c87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f38445ce-96ef-44fd-825d-87d59e220069" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7e32ded8-ed48-4069-be6a-d0786472e556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_us-gaap_RevenuesAbstract_7e32ded8-ed48-4069-be6a-d0786472e556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03edde22-0da3-4aa8-8f91-91a8da501ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7e32ded8-ed48-4069-be6a-d0786472e556" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03edde22-0da3-4aa8-8f91-91a8da501ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_659e9876-454f-4265-ba15-cb1f78da1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_659e9876-454f-4265-ba15-cb1f78da1ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4dd2e32b-33e7-4dea-b7f5-d0a8ecaafa08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_659e9876-454f-4265-ba15-cb1f78da1ee4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4dd2e32b-33e7-4dea-b7f5-d0a8ecaafa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_b893ca21-de15-4b36-9fe3-590896e58556" xlink:href="ebs-20250930.xsd#ebs_AdjustedGrossMargin"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_ebs_AdjustedGrossMargin_b893ca21-de15-4b36-9fe3-590896e58556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_18c53425-79f6-47e9-9e6f-e13aea1d2613" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_0d195765-5ddd-4a87-a376-c17a14d505d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_0d195765-5ddd-4a87-a376-c17a14d505d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_40f4bb2a-a598-48f4-82ee-a850da9dd3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_40f4bb2a-a598-48f4-82ee-a850da9dd3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringChargesAdjusted_bde87c27-dabf-4415-a95d-72d3430ffe4e" xlink:href="ebs-20250930.xsd#ebs_RestructuringChargesAdjusted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_ebs_RestructuringChargesAdjusted_bde87c27-dabf-4415-a95d-72d3430ffe4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_InventoryStepUp_8fa8aa60-3f1d-4836-a0e4-5e4ee336496e" xlink:href="ebs-20250930.xsd#ebs_InventoryStepUp"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_ebs_InventoryStepUp_8fa8aa60-3f1d-4836-a0e4-5e4ee336496e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_60486186-998f-4b95-874d-a55b2859a5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_60486186-998f-4b95-874d-a55b2859a5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_21d066b6-c4eb-4932-8b52-b3f424032a93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_21d066b6-c4eb-4932-8b52-b3f424032a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7cfc3b2d-c907-45cd-9ac2-20ae6c341683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7cfc3b2d-c907-45cd-9ac2-20ae6c341683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f1ce1384-f511-4881-a6cc-403750cd52a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f1ce1384-f511-4881-a6cc-403750cd52a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_826aed77-5bc1-45df-b00f-4877c33c0e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_InterestExpenseNonoperating_826aed77-5bc1-45df-b00f-4877c33c0e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_548dd5ed-1b26-45d5-a06b-d35a5aa97e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_548dd5ed-1b26-45d5-a06b-d35a5aa97e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f25e99ec-5de6-452e-be76-d7e35820144b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f25e99ec-5de6-452e-be76-d7e35820144b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ec85c6e-be25-4256-8dbe-a8f3d9e7b685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ec85c6e-be25-4256-8dbe-a8f3d9e7b685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d78b0943-ff9b-415c-8ed7-e89a148ca5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_64a5fc50-5ec1-4b86-a082-9d5da2f57d89" xlink:to="loc_us-gaap_RestructuringCharges_d78b0943-ff9b-415c-8ed7-e89a148ca5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20250930.xsd#SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_393f0539-9cfa-4603-9e0c-3a6c948f211a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_393f0539-9cfa-4603-9e0c-3a6c948f211a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de8d9a1b-9b2b-4f8e-ae76-507f67de86c7" xlink:to="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MCMProductsSegmentMember_74eaa8d8-b459-42d2-8cc0-e8f64d40e137" xlink:href="ebs-20250930.xsd#ebs_MCMProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:to="loc_ebs_MCMProductsSegmentMember_74eaa8d8-b459-42d2-8cc0-e8f64d40e137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_94483a04-8629-4933-9f5e-5caa9dbcef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fe2637e9-ee5e-441f-bbe0-cd19292a676b" xlink:to="loc_us-gaap_AllOtherSegmentsMember_94483a04-8629-4933-9f5e-5caa9dbcef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_65b345fc-cf79-4875-8362-2881fd5d5368" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:to="loc_srt_ConsolidationItemsAxis_65b345fc-cf79-4875-8362-2881fd5d5368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_65b345fc-cf79-4875-8362-2881fd5d5368" xlink:to="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_440d7374-4655-4ec5-bfbe-432ed7376f42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:to="loc_us-gaap_OperatingSegmentsMember_440d7374-4655-4ec5-bfbe-432ed7376f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_6601e3e7-e163-48b3-8042-9bbb7063c3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_11a1d896-0897-455e-85ff-09662b325b3c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_6601e3e7-e163-48b3-8042-9bbb7063c3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_93c43266-daf8-41b7-8543-37b57271a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f6ef12e0-08d9-48db-b24f-f65078026d2a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_93c43266-daf8-41b7-8543-37b57271a91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_fc4dd9d1-a388-4741-bfc3-cef9cbc24e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_93c43266-daf8-41b7-8543-37b57271a91e" xlink:to="loc_us-gaap_DepreciationAbstract_fc4dd9d1-a388-4741-bfc3-cef9cbc24e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4132c634-8115-436f-9128-51c5d4709f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAbstract_fc4dd9d1-a388-4741-bfc3-cef9cbc24e9e" xlink:to="loc_us-gaap_Depreciation_4132c634-8115-436f-9128-51c5d4709f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DonaldDeGolyerMember" xlink:href="ebs-20250930.xsd#ebs_DonaldDeGolyerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ebs_DonaldDeGolyerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SujataTyagiDayalMember" xlink:href="ebs-20250930.xsd#ebs_SujataTyagiDayalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ebs_SujataTyagiDayalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ebs-20250930_g1.jpg
<TEXT>
begin 644 ebs-20250930_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
M 0(#! 4&!P@)"@L0  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B
M<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ
M\?+S]/7V]_CY^A$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B
M,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:
MHJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ
M\O/T]?;W^/GZ_\  $0@!9 O; P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^J/^
M$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <
MH /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'
M_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?
M^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3'0O^
M@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3
M'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@
M _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_
M !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X
M%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"
M-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,=
M"_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* -
M6PU2SU53)8SPW2(=K-#(D@4XS@E&8 XYP><4 7J "@ H * "@ H * "@ H *
M &22I"I>1@BCJS$ #MR3P* &PSQW"[X761<XRC!AGTR"1F@"6@ H * "@ H
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@">V\3Z1>RK
M!;7UG-*YPL<=Q"[L<9PJJY8G )X'2@#<H * "@ H * "@ H * "@ H * "@#
M.U#6+'2=OV^Y@M/,SL\^6.+?MQNV[V7=MW+G&<9&>HH S?\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H ?'XLT64X34+)CUPMU 3C\'H U;;4+:]_P"/::*;
MC/[MU?CIGY2>,]Z += !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U'5;/2(_.OYX;
M6/\ OS2)&OT!<@$^PYH \OU;XY>%=+RJ3R7K#JMM$S?^/R&*,Y_V7(I7 \WU
M+]I51E=.TXGT>>?'YQQH?TE'XT7 XF^_:%\2W/$"6=J.VR%F;\3+(X/X*/IW
MI#.:N?C-XNN>&U!D .0(X;=.V.JPAB/8DC- &+)\2?$\G!U.]&/[LSK_ .@D
M4 1?\+#\2_\ 04O_ /P)E_\ BJ )(_B/XFBY74[WG^].[?\ H1.* -:U^,'B
MVS^YJ,C< ?O(X)>!_P!=(F.?4YS[T =%9?'_ ,46I!E:UNAZ2P;<]?\ GBT7
M^0/?(!V>G?M*SIQJ&G1R=/F@G:/'K\DB29SV^=<>_6G<1Z'I7Q_\,WY"W)N;
M%CU,T6] ?0- TK8SQDHOJ<#."X'J6C^)]*\0 '3+NWNB1G;'(I<#_:CSO7_@
M2@]^],#=H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * ,>]\1:7ILA@O+RUMY0 3'+/%&X!Y!*NX.".AQS0!4_X3'0O^@C8?
M^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3'0O^
M@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3
M'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@
M _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_
M !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X
M%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"
M-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,=
M"_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #
M_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\
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M_BJ #^U;+_GXA_[^I_\ %4 ']JV7_/Q#_P!_4_\ BJ #^U;+_GXA_P"_J?\
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C
M8?\ @7!_\<H /^$QT+_H(V'_ (%P?_'* 'Q^+=%E81QZA9.[D*JK=0$DDX
M#Y))X ')- '04 % !0 4 % !0 4 % $4T\=LAEF98XUY9G(50/<D@#\30!A'
MQ?H:D@ZC8@C@@W4&0?\ OY0!JV6IVFI*6LYX;E1U,,B2 ?4H2* +M !0 4 ?
ME;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H * "@ H *
M/,OC)_R*.H_[D/\ Z4PTF!\C_#'XB3^ K_+[I-.N2!<PCDCL)8P<#S$],@.N
M5.#M94,^^[&^@U*".[M'6:"90\<B'*LI&00?Z=0>#@U0BU0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'AWQA^)X\(VYTK3'!U2Y3EA@_9HV&-Y])6_Y9*1P/WAX
M"!T!X)\"6+^+868DL8;DDDY))C.23W)[FD,^[*H04 % !0 4 % !0 4 % !0
M 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14
ME S]#:H04 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 H)!R."* -RP\4:OI7_
M !Y7MW;^T4\J#MU"L 1P.",<#TH&=[I7QN\5Z65#72W:*?N7,2/GV+H$E(/_
M %TSZ$4 >J:'^TE&V$UFQ9?66T<-^4,I7\3YQX[<<NXCV[PY\1= \5;4T^[C
M,S?\L)/W4V?01R;2Y'<Q[Q[T =M3 * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H BN+B*TC::=UBC099W8*JC
MU9F( 'N30!XMXF^/.@:&3%8;]4G7M#\D(.>09V!SQR#$DJG/7KA7 ^?_ !#\
M=/$FM92VD3383QMMEP^/>9]S@^\9C^G7*&>27=[<7\AGNI9)Y6ZO*[.Y^K,2
M3^)H$5J "@ H * "@ H * "@ H * "@!R.T;!D)5E.00<$'U!'2@#TKP_P#%
MWQ-X=VI%=M=0KC]U=CSUPO10S$2HN.,)(HQCT& 9[QX:_:)TZ]VPZY;O8N<
MS19FASW8K@2H/91,?>G<1[WI.M6.NP"ZTV>*ZA/\<3A@#UVM@Y5O56 8=P*8
M&G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY
M_P"1LG_ZX6__ *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0 4
M % !0 4 % !0 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\
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M9^T;_P C';?]@V+_ -*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5=3PRGD?0@FA&O0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!]B?LV_P#()OO^OM?_ $2E- ?1U, H
M * "@ H * "@ H * "@#S+XR?\BCJ/\ N0_^E,-)@?GU2 ]W^#?Q0/A6X&CZ
MF_\ Q++A_D=CQ:RL?OY_YXN?]8,@(?W@Q\^XV&?;2L' 92"",@CD$'H0>X-4
M(6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 4 % !0 4 % !0 4 % !0 4 % !0  XY% 'JGA/XQ>(/"I6(S&^M%X\BY)?
MZ8CE_P!:F!]T;C&/^>9H&?5/@OXOZ)XP*V^\V-ZW'V><@;SZ0R\))[+\DA[1
MX&:8CU6F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
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M315(SR.@04 % !0 4 % !0!]<_LU?\>6H_\ 7>#_ - >FAGTS3$% !0 4 %
M!0 4 % !0!\6?M&_\C';?]@V+_TINZE@> 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;?AK_D+67_ %]V
M_P#Z.2@9^F]4(* "@ H * "@#Y=^/WCV2WQX8L'*%T$EZRD@[6YC@^C+B23'
M52B]"P*8S6^#/PJATRWB\0:O&)+R=1);1. 5MXSRDA4\><XPRG_EFI&,.6V@
M$&N_M"_V)J-UIO\ 9?F_8KF:W\S[9MW^3(T>_;]E;;NVYV[FQG&3UHN(RO\
MAIC_ *A/_D]_]QT7 V]$_:-TV]F$6IV<M@C''FI*+A5SW<>7$X7U*JY]C1<#
MTCQMX'TSXCZ<K IYYC#VEXF"0&&Y/F'WX7SEEY&#N7#8- 'RO\/?%-[\,/$#
MZ;J>8[9YOL][$3\J,#M6X7J#LR&W+D20DXSE"%L,^[001D<@U0C\K:D H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#[$_9M_Y!-]_P!?:_\ HE*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_
MY%'4?]R'_P!*8:3 _/JD 4 ?5'P1^*6/+\,ZQ)Q]VQG<\^UL['_R 2>/]5G'
MEJ&AGU53$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!ROC+Q?9>"M.?4KXYQ\L40.'FE()6-
M>#C.,LV"$4%B#@ @'YZ^)?$E[XKOY-3U!]\LIX49V1H/NQQ@D[44=!U)RS$L
M23(S!H$>R? ;_D;(/^N%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % '
MQG^T?_R';3_KP7_T?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ]%^$O\ R-FF_P#79O\ T5)0,_0V
MJ$% !0 4 % !0 4 % !0 4 % !0!\K?M,_\ ,)_[?O\ VSI,#Y6I % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %  #CD4 >\_
M#[XX7_API9:T7O[ 84.3NN(1_LLQ'FH/[CG(  1U VD&?8VC:U9:_:I?:=*E
MQ;R#Y70]^ZL.JL/XE8!AW%4(TZ "@ H * "@ H * "@ H * "@ H * "@ H
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M /A'X\_\C9/_ -<+?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5"
M"@ H * "@ H * "@ H * "@ H ^;/C1_R%+?_KU'_HV6O"QGQK_#^K/L\H_@
MS_Q_^VQ/':\T^C"@#3TG5[K0[E+RR<QRQG\&'=6'1E;H0?T(!JX2=-J4'9HP
MJTH5X.G45XO\/-=F?5W@WQK:^+(/EQ%=QC][!GD=MZ9^]&2?JI.UNQ;Z&C65
M9=I+=?JO+\CX+%X.>$EKK3?PR_1]G^>Z\NTKK/-"@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!EZUK-KX?LY=1OW$5O;KN=C^051W9F(55'+,0!UH _/OQ_XZN_'>HM
M>3YCMH\K;09^6*,GOS@R/@&5NY  PBJ!(SA:!!0![)\!O^1L@_ZX7'_HLT#/
MNZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/-
M@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /1?A+_R-FF_]=F_]%24#/T-JA!0 4 % !0 4 % !0 4 % !0 4 ?
M*W[3/_,)_P"W[_VSI,#Y6I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 =KX(\>:CX%N_M-BVZ%R//MV)\J91ZC^%P,
M[) -RYQRI96!GWIX0\8:?XTL5O\ 3FR/NR1-@20OW2103CU5@2K#E3UQ0CJ:
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H AN;F*RB:>X=8
MHHU+.[L%55'4LQP !ZF@#Y,^(WQWENR^F^&&:&'E7O<%9'['[.#S&O\ TT($
MAX*B/&6D9\T.[2,7<EF8DDDY))Y))/))/4T"&T % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0![?\.?C/?>$REAJF^^TT84 G,UN.
MG[IF/SH!_P LG( P-C)R&!GVAHVM66OVJ7VG2I<6\@^5T/?NK#JK#^)6 8=Q
M5"-.@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+
M?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3=U+ \ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%8]2M@!<PCC/831CO&_<=8WRIX*,[ ].I@% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $-Q<16D33SLL44
M2EW=R%55499F)P  .23P!0!\(?%?XER>.+S[-:%DTNU8^2AX,K\@SN.N2,B-
M3]Q.P9FJ1GD5 @H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KL
MW_HJ2@9^AM4(* "@ H * "@ H * "@ H * "@#Y6_:9_YA/_ &_?^V=)@?*U
M( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H ZWP7XQO?!&H)J%D<K]V:$DA)H^Z-CN.J-@E&P<$9!!GZ#^&?$EGXK
ML(M3T]]\4HY4XWQN/O1R#^%U/4=""&4E64FA&]0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!DZYKMEX;LWU#4I5@MXARQY))Z*JC)9V/"JH)/T
MS0!\,?$?XJ7WCJ4P1YM=,C;,=N#RY'22<CAW[J@^2/@ %LNTC/*J!!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =KX(\>
M:CX%N_M%BVZ%R//MV)\N91ZC^%P,[) -R]]REE(,^\?!OC/3_&UD+[3GY7"S
M0M_K(7(SM<=P>=CCY7 .#D,!0CK* "@ H * "@ H * "@ H * "@ H * "@
MH * "@#X1^//_(V3_P#7"W_]%BI&>-T""@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@
M9]W50@H * "@ H * "@ H * "@ H * /FSXT?\A2W_Z]1_Z-EKPL9\:_P_JS
M[/*/X,_\?_ML3QVO-/HPH * "@">WN)+.19X&:.6-@R.IPRL.001T---IW6C
M1$HJ:<))--6:>S1].> OB''XB5;&^(COU'!X5)P.Z]A)CED'!P63C*K[U#$*
MI[D])_@_^#Y?<?$8W /#-U:6M+\8^3\NS^3[OU*O0/#"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M='P Z$' .5%".NH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MS%55F !\">/O']]X\O3<7),5K$2+>V!RD2GN>FZ5N-\A&3]U0J!5$C.#H$%
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MJ?%T??U\_P _7?XS'9>Z-ZV'5X;RCUCYKO'\O3;V*O4/G0H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * /L'X >.CJ-LWAN]?,UFN^U+'EH,_-%GN86(*CD^6V  L5-
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH ]D^ W_ "-D'_7"X_\ 19H&?=U4(* "@ H * "@ H * "@ H * "@#YL^-'
M_(4M_P#KU'_HV6O"QGQK_#^K/L\H_@S_ ,?_ +;$\=KS3Z,* "@ H * "@!0
M<<C@B@1[_P##_P")?F;-+UE\-]V*Y=OO>B3$]^RR$_-P'Y^8^QA\3M3JOTD_
MR?\ G]Y\GCLOM>OAEIO*"6WG'R[KITTT7NM>N?+!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\$_'+_D;KS_<MO\ TFBJ1GD= @H * "@ H *
M "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H ^+/VC?\ D8[;
M_L&Q?^E-W4L#P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(C<<46 ^NM"T*R\-V<>G:;&(+>(<*.I)ZL['EG8\LQY/T %4(UZ /RMJ0"@
MH * "@ H * "@#[@^&O@+P_JGANPN[RPMIYY8B7D>,%F/F.,D]S@ 4QG<_\
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M H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
MH * /4_@WI%GK?B2&TU"%+F!HIR8Y!N4E8R5./4'D4#/L;_A67A?_H&6G_?H
M4Q!_PK+PO_T#+3_OT* #_A67A?\ Z!EI_P!^A0 ?\*R\+_\ 0,M/^_0H /\
MA67A?_H&6G_?H4 '_"LO"_\ T#+3_OT* #_A67A?_H&6G_?H4 '_  K+PO\
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MD\,["I&>/4""@ H * "@ H * "@ H * "@#MO#'P\UWQ<0VFVKF$G!N)/W<
M]?WC8#XSRL8=O]F@9[_X?_9OMX@)-<O'E;O%:J$0'T\V0,S#Z11GWIV$>Q:1
M\,?#.AX-KI]NS #YYE-PV1W!G,FT_P"[M]L#BBP'<11)"HCC4(B\!5   ] !
MP/PI@/H * "@!KQK*I1P&5A@@@$$>A!X(H X76/ACX9UL'[3I]NK$'YX%^SO
MD]R83'N(Z_/N'J".*5@/'/$/[-\#@R:%>-&W:*[&Y3])HE#*!Z&*0^]%@/GS
MQ-X"UOP@W_$TM7CBS@3+B2$YZ#S4RH)[*Q5_]FD,X^@04 % !0 4 % !0 4
M% !0 4 >A?#CQ[<> ]2%PNY[*<JEW"/XT!X=02!YL>2R$XSED)"N30,_06PO
MX-3MX[RT=9H)T#QNO1E89!'<>X(!!R" 015"+= !0 4 % !0 4 % !0 4 %
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M!EI_WZ% !_PK+PO_ - RT_[]"@ _X5EX7_Z!EI_WZ% !_P *R\+_ /0,M/\
MOT* #_A67A?_ *!EI_WZ% !_PK+PO_T#+3_OT* )(?AQX:MI%FBTZU22-@ZL
M(QE64Y4CW! (I@=K0 4 % !0 4 % !0 4 1RPI.ACE571N"K ,I'N#D'\: ,
M)O"&AL<MIUB2>I-K 3_Z+H U;+3;735*6<,5LIQE8HTC!QTR$ '';TH N4 %
M !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?_1DE- >B4P"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_ -OW_MG2
M8'RM2 * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@
MH * "@ H * "@ H X/QQ\.]+\=0;+Q/*ND&(KJ,#S8_0'IYD>>3&QQR2I5CN
MI ?"?B_P??\ @J^;3]17!^]%*N?+F3/#H2!]&4_,IX(Z90SE:!!0 4 % !0
M4 % !0!]@?LZ^*#=V-QH,S9>S;SX 2<^3*<2*!V5)3N^LU- ?25, H * "@
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M * "@ H * "@ H * "@#Z/\ @1\0SI=P/#>H/_HMTV;5F/$4[=8L]DF/W1G
MEZ#]XQ AGV'5""@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_
M /18J1GC= @H * "@ H * "@#ZP_9H_U.J?[]I_*XIH9]14Q!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\ C_\ ;8GCM>:?
M1A0 4 % !0 4 % !0 4 >M^ /B,^A%=.U(E['HC\EX,]!ZM%ZKU7.5X&T^C0
MQ'L_<G\'XK_@>7W'S^.P"KWK4-*G5;*7^4O/KU[GTM#,DZ++$P=' 964@JRD
M9!!'!!'((KW4TU=;'Q33BW&2LUHT]TR2F(* "@ H * "@ H * "@ H * "@
MH * "@ H * /@GXY?\C=>?[EM_Z315(SR.@04 % !0 4 % !0!]<_LU?\>6H
M_P#7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'SC^TE_R";'_K[;_T2])@?'=( H * "@ H * "@#U7X)_\CCI_P#V]?\
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M@SZ\TW3;72+=+.QB2W@B&$CC4*H'T'4GJS'+,<EB22:H1=H * "@ H * "@
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M]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\Y_&FWE%_;7&UO*-OL
M#X.W>)'8KGINVD''7'->'C$^>+Z<MK^=V?8Y1)>SG"ZYN:]NMK)7]+GBU>8?
M2A0 4 % !0 4 % !0 4 % 'I?@3X@3>&7%I=[IK!SRO5H2>KQ_[/=H^AZKAL
M[NZAB'1?++6'Y>:_R/%QN!CB5[2G:-5?=+R?GV?WZ;?45I=PW\*7%LZRQ2#<
MCJ<@CV/Z$=000<$5[\6I)2B[I['PTHRIR<)IJ2T:>Z+%40% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_W+;_ -)HJD9Y'0(* "@ H * "@ H
M ^N?V:O^/+4?^N\'_H#TT,^F:8@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /G']I+_ )!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!ZK\$_^
M1QT__MZ_]([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#\K:D H * "@ H * "@ H _0[X2_\BGIO_7 _P#HR2F@
M/1*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
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M * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!\K4@"@ H * "@ H
M* /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H * "@
M H ^6_VB/!X9(?$MLN&4K;W6!U!_U,IP.QS$S$Y.8E' I,#Y1I % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H *
M"@ H * "@#]#OA+_ ,BGIO\ UP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0
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M&?/- @H * "@ H * "@#Z/\ V;?^0M??]>B_^C5H0S[#JA!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\K?M,_\PG_ +?O_;.DP/E:D 4 % !0 4 % !0![)\!O^1L@_ZX7'_H
MLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 87B?1(_$>E76ER@$7
M4+HN>BOC,;_\ D"N/=><CB@#\S9(VB8QN-K(2I!Z@@X(_ U(#* "@ H * "@
M H * /NKX":B;[PM'$?^7.XG@'T)$X_+S\?3%- >T4P"@ H * "@ H * "@
MH * "@#R/XS^,#X4T)XK=MMYJ)-O"1U1"/WT@X_A0[ 005>1&'0T@/@FD 4
M% !0 4 % !0 4 % 'V'\&?A0-(2/Q#K,?^FN-UK X_U"$<2NI_Y;,"=JG_5+
M@G]X?W;0SZ/IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /DKXS
M_"867F>(]$3]R27O+9!_J^I:XC _Y9D\RH/]63O7]WN$:&?,5(04 % 'L?@3
MX,:MXNVW5T#IVGMR)9%_>2#K^YB)!(.1B1]J8.5WD%:!GV%X3\$:3X+@\C2X
M0C,,23/AIY>_SR8!QGD(H5 >0HJA'6T % !0 4 % !0 4 % !0 4 % !0 4
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M * "@ H * "@ H * "@ H * "@#YQ_:2_P"038_]?;?^B7I,#X[I % !0 4
M% !0 4 >J_!/_D<=/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _*VI * "@ H * "@ H * /T.^$O_(I
MZ;_UP/\ Z,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0
M4 % !0 4 % !0 4 % '1>%?$][X/U"/4]/;$D?#(<[)8R1NBD (RC8'N&"LN
M&4$ S]"_"7BJS\8Z='J=@?E?Y9(S]^*0 ;HW]USP>C*0PX(JA'2T % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?'_QK^*?]J._AW1Y/]%C8K=S(
M?]<ZGF%"/^62$'>>1(PP/D7,DC/FV@04 % !0 4 % !0 4 % !0![)\!O^1L
M@_ZX7'_HLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7
M_P!'SU+&?/- @H * "@ H * "@#Z/_9M_P"0M??]>B_^C5H0S[#JA!0 4 %
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MP)\9?%1\3^(9EB;=:Z?FUAP<J2A/FN,<'?)N 8?>14YXJ1GE% @H * "@ H
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M-'^IU3_?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H CFA2X1HI5#HX*LK
M%64C!!!X((X(-)I-6>PTW%J479K5-;IGS/X^^'+Z"6U#30TEB>73JT&3^;1>
MC<E>C_WCX-?#NE[\-8?E_P #S^_N_M<#CU7M1K653H]E/_*7EUZ=CR:O//H
MH * "@ H * "@ H * "@#H_#/B>[\+70N;0Y4\21,3LD7T([$?PL.5/J"0=J
M=25&7-'YKHSBQ&&ABH<E3?I);I_Y=UU/K/PYXDL_$UJ+JS;D8$D9^_$Q'W6'
MY[6'RL!D'J!]'3J1JQYH_-=4? XC#SPL_9U%Z/I)=U^JW1OUL<@4 % !0 4
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M: ]$I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!YE\9/\ D4=1_P!R'_TIAI,#\^J0!0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M6.-!T"J,#ZD]68\LQ+$DDFJ$7: "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H S=7T>TUZTDT_48EGMI@ \;$@'!##!4AE(8 AE(((!!% $F
MFZ9:Z/;I9V$4=M!$,+'&H51[X'4GJS'+,>6))S0!>H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H *
M "@ H * /K#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4
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M!0 4 % !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_P!RV_\ 2:*I&>1T""@ H *
M"@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!Z
MK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@#]#OA+_ ,BGIO\
MUP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD 4 %
M!0 4 % !0 4 % !0 4 % 'LOPC^)K^"KO[#?,S:5=-\XZ^1(>!,@_NG $JCD
MJ P!90K S[JBE2=%EB8.C@,K*0RLK#(92,@@@@@C@CD50A] !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >/?%GXFQ^"+3[)9%7U6Z4^4O!\A#QY[KZ_\\E88
M9@2051E* ^$YIGN)&FE8O)(Q9V8Y9F8Y+$GDDDY)/4T@(J "@ H * "@ H *
M "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5""@ H * "@ H * "@ H * "@
MH * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4 ?1_[-O\ R%K[
M_KT7_P!&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/_;]_P"V=)@?*U(
MH * "@ H * "@#V3X#?\C9!_UPN/_19H&?=U4(* "@ H * "@ H * "@ H *
M "@ H * "@ H * /B_\ :."CQ!:D'YCI\8(]A<7.#^))_*I8'S[0 4 % !0
M4 % !0!]'_LV_P#(6OO^O1?_ $:M"&?8=4(* "@ H * "@ H * "@ H ^4?V
MD?$!,EEH<9.%#7<HSP2Q:*'\5 F//9@:3 ^6Z0!0 4 % !0 4 % !0!]P_ O
MP6/#VCC5+A<7FI@2<CE+?K$GMYG^M;U#1@C*4T![C3 * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _*VI *
M"@ H * "@ H * /T.^$O_(IZ;_UP/_HR2F@/1*8!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_
M )%'4?\ <A_]*8:3 _/JD 4 % !0 4 % !0 4 % !0 4 % !0!]*?!/XI?V8
MZ>'-8DQ:R';:3.>(7)XA<G_EFY/R$G$;?*?D;* SZ^JA!0 4 % !0 4 % !0
M 4 % !0 4 % !0!P?Q"\>6O@+3C=2XDNI<K;09P9'[DXY$:9!=N.R@[F6D!^
M?>L:O=:]=RZA?R&:XN&+NQ]3T '154855&%50%  %(9FT""@ H * "@ H *
M"@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@ H * "@ H
M * "@#XS_:/_ .0[:?\ 7@O_ */GJ6,^>:!!0 4 % !0 4 % 'T?^S;_ ,A:
M^_Z]%_\ 1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_V_?\ MG28'RM2
M * "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H * "@ H * "@ H *
M"@ H * "@ H * "@#X?_ &@[L7/B<1C'^C6<$1Q[M+-S[XE'3MCOFI \-H *
M "@ H * "@ H ^D_V;(B=2OY.RVT:X_WI,_IL_6A#/K^J$% !0 4 % !0 4
M% !0 4 ?G7\3]:_M[Q+?W0.Z-)C!'CIL@Q"I'LVPO]6-2,X&@04 % !0 4 %
M !0!VGP^\,'Q=KEKIC F%G\R<CC$$?SR<\X+ ;%./ONM S]'$18U"( JJ
M,  <  #@ #@ =*H0Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^
M$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H * "@ H * /K#]FC_ %.J?[]I_*XI
MH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'CA0 4 % !0 4 % !0 4 % 'P3\<O^1NO/\ <MO_ $FBJ1GD= @H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M H ^N?V<?#@@M+O79 -]PXM83SD1QX>4CMM=R@Z]8CT[M ?3-, H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+?_T6*D9XW0(*
M "@ H * "@ H ^L/V:/]3JG^_:?RN*:&?45,04 % !0 4 % !0 4 % !0 4
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MWK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /RMJ0"@ H * "@ H * "@#[0^'7Q/\-:)X=L;"^O5AN((BLB&
M*=BI+N<96)E/!!X)IC.U_P"%R>$?^@BG_?FY_P#C-%Q!_P +D\(_]!%/^_-S
M_P#&:+@'_"Y/"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3P
MC_T$4_[\W/\ \9HN ?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%/^_-S_\
M&:+@'_"Y/"/_ $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_  N3PC_T
M$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\ OS<__&:+
M@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/"/\ T$4_
M[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\ \9HN ?\
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MN%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\
M1\]2QGSS0(* "@ H * "@ H ]N^!WBK2_"FHW<^KSBUCEMPB,5D;+"16QB-'
M(X!.2 />@9]+_P#"Y/"/_013_OS<_P#QFG<0?\+D\(_]!%/^_-S_ /&:+@'_
M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M7.I$@2JAC@!_BGD!6( =]I.]A_<1CVI ?G S%B23DGDD]2:0"4 % !0 4 %
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M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M@ H * "@ H ^<?VDO^038_\ 7VW_ *)>DP/CND 4 % !0 4 % !0!ZK\$_\
MD<=/_P"WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /1?A+_ ,C9IO\ UV;_ -%24#/T-JA!0 4
M% !0 4 % !0 4 % !0 4 % 'F7QD_P"11U'_ '(?_2F&DP/SZI % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!IZ-K%UH%Y%J-@YAN+=@R,/R((/#*PRK*>&4D
M'@T#/T&^'_CFU\=Z<+R#$=Q%M2Y@SS%(1U'.3&^"8V/4 @_,K ,1W-, H *
M"@ H * "@ H ;)(L2EW(5%!9F8@  #)))X  Y)/ % 'PY\8/B<WC"Y.FZ<Y&
ME6S<$<?:9%X\UAU\M3D1*>H_>, S!4D9XE0(* "@ H * "@ H * "@ H * "
M@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "@ H * "@ H *
M "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z,_#+_D5],_Z](OY4P.YI@% !0
M4 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0 4 % !0 4
M % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'Q+\=?'*^(M272+-MUGII8,RG*R7)X=N#@K$/W:G^\92"0PJ1G@] @H
M * "@ H * "@ H _2/P!I!T+P_86+ J\=M&S@C!$D@\V08]I'8?X4P.OI@%
M!0 4 % !0 4 % !0!\Z?M(7IBT>SM!_RVNS(?I%$XQ^<H/3L.1W3 ^.*0!0
M4 % !0 4 % '1^#],&LZU8V#?<N+N!'_ -PR+O\ R3<:!GZ7U0@H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_ /18J1GC
M= @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#]./#7_ "";+_KTM_\ T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'QG^T?_P AVT_Z\%_]'SU+&?/- @H LV=Y/I\R75K(\,T3!DD1BK*PZ%2,
M$&@#[;^%GQ<@\8(NFZF4M]50 #HJ70 Y>,=%EX)>(<?Q1_+N5&![=3 * "@
MH Y?Q3X3M/%5MY%R-LJ F&8#YHV/Y;D/\2'@CD88!ASU:4:RL]^C[?\  \CN
MPV)GA)\T-8OXH]&OT?9_IH?)_B#P]>>&KIK2]7:1DHXSLD7^\C8&1ZCJIX8
MU\[4IRI/EDO\GYH^^H5X8F"J4GZKK%]FOZOT,*LCJ"@ H * "@ H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0
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M 4 % !0 4 % !0!\K?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0![)\!O\
MD;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0 4 % '@WQC^**
M>&+=M&TMP=3N$Q(ZGFUC8?>..DSJ?W8R"@/F''R;D!\3$YY-( H * "@ H *
M "@ H Z_P%H)\2Z]9:<5+1RSJTH'_/&/]Y+ST'[M6 )[D#DG% S](ZH04 %
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M !N@ _X6UXL_Z"4W_?,7_P ;H ^Y/ ]U<WV@Z?=7SF6XGM(99'.,L9$#AC@
M9(89P.M4(ZF@ H * "@ H * "@ H * "@#X1^//_ "-D_P#UPM__ $6*D9XW
M0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _3CPU_R";+_ *]+?_T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'QG^T?\ \AVT_P"O!?\ T?/4L9\\T""@ H DAF>W=98F:.2-@RLI*LK Y#*1
M@@@\@CD&@#[(^$_QB37PFC:ZXCU #;#<,0J7..BMT"SXZ?PRGIAR%9@?0U,
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M/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _*VI * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H ]%^$O_ "-FF_\ 79O_ $5)0,_0VJ$% !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'I7PS^(=QX"OP[;I-/N"%N80>W02QCH)(^O^VN4
M)&0RFPS[]L+^WU2WCO+-UF@G0/&Z]&5AD'U'N" 0<@@$$50BW0 4 % !0 4
M?/?QH^*/_"/Q-H.DOC4)E_?RJ>;:-AG:I'2:13P>L:'<,,R,J ^,:0!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0
M 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]&?A
ME_R*^F?]>D7\J8'<TP"@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/\
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MKD#W,I!/X[1^52QGS=0(* "@ H * "@ H ]Z_9UB63Q),S=8]/F9?J9[9/\
MT%C_ #H0'VQ5 % !0 4 % !0 4 % !0 4 ?,W[2O_'EIW_7>?_T!*3&?(U(0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z5>!T,
M?A[2T/5=.LP?J+>,50'44 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__
M *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?IQX:_Y!-E_UZ6__HI*H#:H * "@ H * "@ H * "@ H *
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MD@(W5K?GMW:+U3JO5.ZMZ%#$.E[D]8?^D_\  \ON\_ QV 5>]6BDJG5;*?\
ME+SZ]>Z^F89H[A%EA97C<!E92"I!Z$$<$?2O>335UL?%-.+<9)IK=/1HDIDA
M0 4 % 'Q=\?/">H6FL2:^4WV%V(4$B9/END2Q[)1CY2Q3*'E6!QG<"*D9\_4
M""@ H * "@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0
M4 % !0!ZK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /1?A+_R-FF_]=F_]%24#
M/T-JA!0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD
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M\D(#URSD N0 9X?0(* "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H
M* "@ H * "@ H * "@ H * /C/\ :/\ ^0[:?]>"_P#H^>I8SYYH$% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HS\
M,O\ D5],_P"O2+^5,#N:8!0 4 % !0 4 % !0 4 % !0 4 % !0!\K?M,_\
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M - 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!^F'@\8T/3@?^?&U_P#1$=4!T5 !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'Z<>&O^039?]>EO_Z*2J VJ "@ H * "@ H *
M"@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ6,^>:!!0 4 % !0 4 ?3
M'PF^,QTX1Z'XADS; !+>[<DM%V6*8\YB[))UCX5LQX,8,^N58. RD$$9!'((
M/0@]P:H0M !0 4 5KRSAU"%[:Y19895*NC#((/\ (CJ",$$ @@@&IE%23C)7
M3Z%PG*G)3@VI)W370^7/'7P_F\,.;JUW36#GANKQ$_PR8'3LK]#T;#8W?/U\
M.Z+YHZP[]O7_ #/N<%CHXE>SG[M5=.DO./GW7W:;>;5Q'M!0 4 % !0 4 %
M!0 4 % 'I'@7Q_-X7<6MSNFT]SR@Y:(GJ\>>V>63.#R1ALY[:%=T7RO6';MY
MK_(\7&X&.*7/"T:JZ])>3_1_H?4EG>0ZA"ES;.LL,JAD=3D$'^1'0@X((((!
M!%?01DI)2B[I['PTX2IR<)IJ2=FGT+-40% !0!6O+.#4(7M;I%FAE4J\;@,K
M*>H(/!_R: /B7XI_"*?P>[:EI@>?2F.6[O:DG 63NT9R DOK\LF&VL\C/$*!
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?./[27_()L?\ K[;_ -$O28'QW2 * "@
MH * "@ H ]5^"?\ R..G_P#;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4 %
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M^-<UN[\17LNHZA(9;B=MS$]!Z*H_A1!A44<*H I#,J@04 % !0 4 % !0 4
M.1&D8(@+,Q   R23P  .22>@H ^X_@_\,5\'VHU+44!U6Z3D$?\ 'M&W/E+_
M --&&#*W&#^['"L78'%?M+_ZG2_]^[_E;T,9\GTA!0 4 % !0 4 % 'LGP&_
MY&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0!\9_M'_P#(=M/^
MO!?_ $?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /T9^&7_(KZ9_UZ1?RI@=S3 * "@ H * "@ H * "@
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M_P"/+3O^N\__ * E)C/D:D(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#].?#BE-*LU8$$6MN"#P01$F01ZU0&S0 4 % !0 4 %
M!0 4 % !0!\(_'G_ )&R?_KA;_\ HL5(SQN@04 % !0 4 % !0 4 % !0 4
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M(X- 'QQ\6/@X^@&36="0R6!)::W4%FMNY9>I:#U[Q#KE,LLC/GB@04 % !0
M4 ?7/[-7_'EJ/_7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?
M_(XZ?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KLW_HJ2@9^AM4(* "@ H *
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M7GC;47U&\.T?=AB!.R&(?=1<]_XG;JSDG@8 D9R5 @H * "@ H * "@ H *
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M &_?^V=)@?*U( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /0/AQX%G\=ZHMJH9+.';)=RC^"//"*3QYDI!5!R
M1\SX*HU S]";*SATZ".TMD$4,"+'&B]%10 H'T [\^O-4(LT % !0 4 % !0
M 4 % !0 4 % 'S!^TM;EK?3+C'$<ERF>>LBPL!Z<^6??CCO28'R92 * "@ H
M * "@ H ]'^$>H#3?%>G2GI),T!_[;QO"/R9P?P[]*!GZ%U0@H * "@ H *
M"@ H * "@#YF_:5_X\M._P"N\_\ Z E)C/D:D(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#]0]*_P"/*W_ZXQ?^@+5 7Z "@ H
M* "@ H * "@ H * /A'X\_\ (V3_ /7"W_\ 18J1GC= @H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]./#7_()LO\
MKTM__1250&U0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_P#R';3_ *\%
M_P#1\]2QGSS0(* "@ H * "@ H ^AOV;_P#D.W?_ %X-_P"CX*$,^S*H04 %
M !0 4 (0&&#R#P0: V/G[Q_\,S;[]3T5,Q\M-;*/N<9+Q#NOK&.5ZIE?E7Q<
M1AN6]2DM.L>WFO+RZ>FWUN!S#FM0Q+UVC-]?*7GV?7KKJ_#*\H^I"@ H * "
M@ H * "@ H * .M\)>+[OPG<>;#F2W<_O8"2%<>HZ[9!_"X!/8@J2#T4JLJ+
MO';JNC_X/F>?BL+#%QY9:27PRMJO\UW7ZGUCH>NVGB&U6\LG#HWWEXWQMW1U
M_A8?D1@J2I!/T5.I&K'F@_\ ->3/@:U&>'FZ=56:V[-=T^J_X9ZFO6ISA0 4
M ! (P>0: /D[XL_!C[-YFN>'(_W0!>YLT!RG=I;=>?DZEXA]S&8P5^1$,^7J
M0@H * "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H ^<?VDO^038_]?;?^B7I,#X[I % !0 4 % !0 4
M>J_!/_D<=/\ ^WK_ -([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#\K:D H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14E S]#:H04
M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
M% !0 4 3VO\ KH_]]?YBD,_4NK$% 'FOQ-^'L'CS3]B;8]0MP6MIB.^,F)SU
M\N0X!/.QL. <%60'P#?64^FSR6ETC0SP.4D1AAE93@@C_(/4<4@*M !0 4 %
M !0 4 % !0!9L[R;3YDNK9VAFA8/&Z'#*RG(8$="#0!V?C?XAZGX[:#[>52.
MVC55BCX0R;0))B/[\A' Z(N%7^(L#.#H$% !0 4 % !0 4 % !0![O\ !OX7
MGQ3<#6-30_V9;/\ (C#BZE4_=P>L*'_6'&'/[L9^?:#/ML  8' %4(* /EW]
MI?\ U.E_[]W_ "MZ3&?)](04 % !0 4 % !0![)\!O\ D;(/^N%Q_P"BS0,^
M[JH04 % !0 4 % !0 4 % !0 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _1GX9?\BOIG_7I%_*F!W-, H * "@ H * "@ H * "@ H * "@ H ^5OVF
M?^83_P!OW_MG28'RM2 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * -[PUX;O?%=_'IFG)OFE/).0D:#[TDC ':BCJ
M<9)PJ@L0"#/T(\%^#[/P3IJ:;9C)'S32D8::4@;G;T'&$7G:@"Y)R36PCK*
M"@ H * "@ H * "@ H * "@ H \)_:&LOM/AI)@.;:\A<GC(5DEB(SUP6=,@
M8R0">E)@?$=( H * "@ H * "@"[IMZ^F74-Y$2)+:6.92."&C<.I!['(% S
M]/K2YCO88[F$[HYD61#ZJZAE/X@BJ$3T % !0 4 % !0 4 % !0!\S?M*_\
M'EIW_7>?_P! 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % #D4NP5>K$ ?4\4 ?J7;PK;1)"F2L:J@SUPH &<8&<#G@50$M
M!0 4 % !0 4 % !0 4 % 'PC\>?^1LG_ .N%O_Z+%2,\;H$% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?IQX:_Y!-E
M_P!>EO\ ^BDJ@-J@ H * "@ H * "@ H * "@ H * "@ H ^,_VC_P#D.VG_
M %X+_P"CYZEC/GF@04 % !0 4 % !0!]#?LW_P#(=N_^O!O_ $?!0AGV95""
M@ H * "@ H * /$_'_PT%[OU/1TVS\M+;K@"3N7B':3U3H_5</P_E8C#7_>4
MEKUCW\UY^77UW^EP.8>SM0Q#]W:,GO'REY>?3KIM\\,I0E6!!!P0>"".H(]:
M\4^PWU0V@84 % !0 4 % !0 4 % '0^&_$UYX7NA<V;<' DB/W)5'\+#L>NU
MARIZ<$@[4ZDJ3YH_-=&<>(P\,5#DJ+T?6+[K]5LSZS\->)K/Q1:BZM&P1Q)$
MV-\;>C =CU5APP]""!]%2JQJQYH_-=5_7<^!Q&'GA9^SJ+T:V:\OU70Z&MSC
M"@ H * /FGXL?!@:EYFM^'8\71)>XM%P!+W:2$<8E[M'TEZH!)Q(K#/D1E*$
MJP((."#P01U!'K2$)0 4 ?7/[-7_ !Y:C_UW@_\ 0'IH9],TQ!0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?./[27_()L?^OMO_ $2])@?'
M=( H * "@ H * "@#U7X)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4
M % 'VO\ #CX<>'-8\.6-[>V,4UQ-$6DD8R L?,<9.' Z #@4QG;_ /"I?"?_
M $#8/SD_^.46$'_"I?"?_0-@_.3_ ..46 /^%2^$_P#H&P?G)_\ '*+ '_"I
M?"?_ $#8/SD_^.46 /\ A4OA/_H&P?G)_P#'*+ '_"I?"?\ T#8/SD_^.46
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MD]N=:TM/^)E;)^\1>MS$HZ8[S1@?N\<NN8_F(C 0'Q000<'@BD E !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!Z3\,_A]/X\U#RSNBL+<AKJ8#H.T2'
MIYDF,#^XNYR#@*P,^_K"PM]+MX[.SC6&"!0D<:C"JHZ ?U)R2<DDDDU0BW0
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M_P#'*+ =S86$&EV\=G:((8(%"1HN<*HZ 9)/'N:8%N@ H * "@ H * "@ H
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M)[>5CRO?_4-%^.:: ]5I@% !0 4 % !0 4 % !0!\S?M*_\ 'EIW_7>?_P!
M2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &
M]X6LO[2UBQL_^>]W;Q_0/*BDG@\ ')X/':@9^FE4(* "@ H * "@ H * "@
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M?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE, H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_UT?^
M^O\ ,4AGZEU8@H * "@#Y+^.'PP^RL_B;2$_=.=U["@^XQZW"@?PL?\ 7#'R
MM^\Y#.50SYAI""@ H * "@ H * "@ H * "@ H * "@ H * .F\(^%+SQEJ,
M>F6 ^9_FDD/W(HP1OD<^BYX'5F(4<D4#/T,\+^&K/PCI\6EZ>NV*(99C]Z20
M@;Y7/=W(R>P&%4!5 %".@H * "@#Y=_:7_U.E_[]W_*WI,9\GTA!0 4 % !0
M 4 % 'LGP&_Y&R#_ *X7'_HLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?
M&?[1_P#R';3_ *\%_P#1\]2QGSS0(* "@ H * "@ H ^C_V;?^0M??\ 7HO_
M *-6A#/L.J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'RM^TS_P PG_M^_P#;.DP/E:D 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'J?@
M'X3ZIXW=9R#9Z=GYKF13\X!P1 AP96R""V1&N#EMP"D&?;?A?PGIO@ZS%CI<
M7EIP7<_-)*X&-\KX&YCZ !5Z(JKQ5".DH * "@ H * "@ H * "@ H * "@
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M4 % !0 4 % !0!ZA\&M._M+Q98J?NP-).WMY43LG_D38/Q_"@9^@54(* "@
MH * "@ H * "@ H * /A'X\_\C9/_P!<+?\ ]%BI&>-T""@ H * "@ H * /
MK#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO3>TOT?9_@^G9=S78>6% !0 4 >,?%'X2V_C2,W^GA+?5D'WNB7( P(Y<='
M "2XR/N/E=I1 ?#]_87&ESO:7D;03PL5>-QAE8=B/U!'!&""0<T@/J[]FK_C
MRU'_ *[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_ .1QT_\
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M0 4 % !0 4 % !0 4 7]+TRYUFZBL;*-IKBX<)&B]23[] !U9B0JJ"S$ $T
M?H%\.? 5MX"TX6R8DO)]KW4V/ON!PB]_*CR0@/7+.0"Q >P'H-, H * "@#Y
M=_:7_P!3I?\ OW?\K>DQGR?2$% !0 4 % !0 4 >R? ;_D;(/^N%Q_Z+- S[
MNJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_R';3_KP7_T?/4L9\\T""@
MH * "@ H * /H_\ 9M_Y"U]_UZ+_ .C5H0S[#JA!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\
MK?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!U7AKP3K'BZ3R]*MI)ESAI2-D*>N^5L(#CG:"7/\*D
M\4#/JCP3\ ].T0K=ZXRZC=+R(@"+5#_ND!IC[R!4YP8B0#3L(]^1%C4(@"JH
M   P !P  .  . !TI@.H * "@ H * "@ H * "@ H * "@ H * "@ H ^%_C
MSH7]D^)6ND&(M1B2<8& '4>5(/\ >)02-_UTJ1GBM @H * "@ H * "@"[IN
MH3:3=0WULVR:VD26-O1D8,/PR.1W'% 'Z4>&=>@\3Z9;ZK;?ZNZC#;<YV/TD
MC/NCAD)[D9'!J@-V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H Q_$&LP^'M.N-3N/]7:1/(1G&XJ/E0>[MA%]V% 'YGWMY+J%Q+=W
M#%YKB1Y9&/5G=BS'\6)-2!5H * "@ H * "@ H ^E?V;=)\W4+[4R.+>!(%)
M_O3/O./<+#@GKAL=":$!]>U0!0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M % !0 4 % !0 4 % !0!\X_M)?\ ()L?^OMO_1+TF!\=T@"@ H * "@ H *
M/5?@G_R..G_]O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_
M -&24T!Z)3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H *
M "@ H GM?]='_OK_ #%(9^I=6(* "@ H * ,[5M*MM<M)=/OD$MO<(4=#W!Y
M!'HRD!E8<JP# @@&@#\^OB%X$NO >HFTES):RY>UGQQ)'GH<<"2/(61>W# ;
M'4F=AG!T""@ H * "@ H * "@ H * "@ H <JER%4$L2  !DDGH .Y/84 ?<
M7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:-QYK=O\ 5J<!B[ ]NI@% !0 4 %
M'R[^TO\ ZG2_]^[_ )6])C/D^D(* "@ H * "@ H ]D^ W_(V0?]<+C_ -%F
M@9]W50@H * "@ H * "@ H * "@ H * "@#XS_:/_P"0[:?]>"_^CYZEC/GF
M@04 % !0 4 % !0!]'_LV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQGO@9Q^63^9H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /G']I+_D$V/_7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_Y''3_ /MZ_P#2
M.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _*VI * "@ H * "@ H * /T.^$O\ R*>F_P#7 _\ HR2F@/1*8!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >9?&3_D4=1_W(?\ TIAI,#\^J0!0 4 % !0 4 % $]K_ *Z/
M_?7^8I#/U+JQ!0 4 % !0 4 <IXS\(6?C739--O!@GYH90!NAE ^5U_DZ\;D
M)7(R" #\]/$?AZ\\*W\NF:@NR:!L9'W74_=D0\91QRIP#V8!@0)&8= @H *
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M "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@ H *
M/9/@-_R-D'_7"X_]%F@9]W50@H * "@ H * "@#,UK1[;Q!93:;?+YEO<H4=
M>A]0RGLRL R'LP![4 ?G3XR\*77@S4Y=+N^?+.Z*3&%EB;[DB_4<, 3M<,N2
M5J1G+4""@ H * "@ H * "@#V+X0?$9O!5_]DO6/]EWK 2YY$,GW5G ]!PLH
M'+)AL,T:@@S[N1UD4,A#*P!!!R"#R""."".AJA#J "@ H * "@ H * "@ H
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^,_VC_\
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M_E\U_=\NGIM[57JGS04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!\X_M)?\@FQ_P"OMO\ T2])@?'=( H * "@ H * "@#U7X)
M_P#(XZ?_ -O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_T9
M)30'HE, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /,OC)_R*.H_P"Y#_Z4PTF!^?5( H * "@ H *
M"@">U_UT?^^O\Q2&?J75B"@ H * "@ H * /+OBC\.H?'=AF$+'J5J";:0X&
M[N8)#_<<]"?]6_S#@N&0'P-=VDUA,]M<HT4T+,DB.,,C*<,K ]"",4@*] !0
M 4 % !0 4 % !0 4 >[?!OX8'Q5<#5]30_V9;/\ *C#BZE4_<YZPH?\ 6'D,
M1Y0S\Y4&?;:J%  & . !T JA"T % !0 4 % !0!\N_M+_P"ITO\ W[O^5O28
MSY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@ H *
M"@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1_P"S
M;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!
M\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
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M 009^AGA[Q!9^)[&+4]/<203+G_:1A]Z-Q_"Z'AA^()4@FA&U0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 R65($:65@B("S,Q"JJJ,EF)P  !
MDD\ <F@#X.^+GQ&;QO?BWM"1IEFS"$=/-?HT[#@\CB,'[J9. SN*D9Y#0(*
M"@ H * "@ H * /H?]GGPQ_:&JRZW,O[K3T*1'L9Y@5XXYV1;\]""\9H0S[+
MJA!0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?\ ZX6__HL5(SQN@04 % !0
M 4 % !0!]8?LT?ZG5/\ ?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /C/]H_\
MY#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4 ?0W[-_\ R';O_KP;_P!'P4(9
M]F50@H * "@ H * "@ H * "@ H * "@"AJ>EVVL6[V=X@EAD'*GL>S*>JL.
MH88(J)04URR5T:TZDZ,E4INTEU_1]UY'RKXT\#7/A.7>N9K)SB.;'W2<_NY,
M='&.#]UQR,'*K\]6H.B^\>C_ $?G^9]Y@\;'%JS]VHMX]_->7XK\7P=<AZH4
M % !0 4 % !0 4 % "T >[_#_P")>S9I>M/\OW8;EST]$F)[=ED)XX#\?,/6
MP^)M:G5>G27Z/_/[SY7'9?O7PR\Y07YQ_5?=V/?0<\BO9/DPH * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G']I+_ )!-C_U]M_Z)
M>DP/CND 4 % !0 4 % !0!ZK\$_^1QT__MZ_]([B@#[]J@"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\K:D H * "@ H *
M "@ H _0[X2_\BGIO_7 _P#HR2F@/1*8!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_D4=1_W(
M?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$% !0 4 % !0 4
M% 'SY\:?A@/$$#:]I2?\3"W7,\:CFYB4=0.\T0''>1!LY98U*&?&'2D(* "@
M H * "@ H * /2/AI\/I_'NH>4=T5A;D-=3#LI/$2'IYLF"!V50SG. K S[_
M +"PM]*MX[.S188($"1QKP%51@#U/N222<DDDDU0BW0 4 % !0 4 % !0!\N
M_M+_ .ITO_?N_P"5O28SY/I""@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?
M=U4(* "@ H * "@ H * "@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$%
M !0 4 % !0 4 ?1_[-O_ "%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /
ME;]IG_F$_P#;]_[9TF!\K4@"@ H * "@ H * /9/@-_R-D'_ %PN/_19H&?=
MU4(* "@ H * "@ H * "@#Y+^//P[^S.?%&G)B.0@7R*/NN2 MQ@=I"0DO3#
M[7Y+N0AGS#2$% !0 4 % !0 4 % $UO<26DJ3P,T<L3*Z.I(964@JRD<@@@$
M$=#0!]_?"WX@Q^.M-#3%5U&U 2ZC&!D_PS(!_!)@Y ^XX9<;=I9@>G4P"@ H
M * "@ H * "@ H * "@ H * "@ H * "@#&\1:'!XDTZXTJZ_P!5=1E"<9*M
MU1P,C+1N%=>VY1GB@#\V=9TBXT&]FTV\79/:R-&X[94\,O3*L,,I[J0>]2,S
M*!!0 4 % !0 4 % !0!Z1\./B+=^ ;S<N9K"<C[3;YZ@<"2//"RJ.G9Q\K?P
MLH,^]M%UFT\06D>H:?(LUO,N58?JK#JK*>&4X*D$$50C4H * "@ H * "@ H
M * "@ H * "@ H * "@ H *  D 9/ % 'QU\9?BQ_;3/H&BR9L5.+F=#_P ?
M# \QH1U@4@98?ZUNG[L R2,^<J!!0 4 % !0 4 % !0 ^.-IG6.,%G<A54#)
M))P !W)/ % 'Z,_#SPHO@S1+?3<#S\>;<L/XIY #)R"00F!$I'5$4]2:8';4
MP"@ H * "@ H * "@ H * "@ H ^$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H
M* "@ H * /K#]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4
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M0>001P01R".M>WOJCXYJVCT:'4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?
M_1DE- >B4P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H \R^,G_(HZC_ +D/_I3#28'Y]4@"@ H * "@
M H * )[7_71_[Z_S%(9^I=6(* "@ H * "@ H * "@#Y#^-WPO\ [.=_$FD)
MBWD.Z\A4<1.Q_P!<@'_+-R?W@Q\CG=G:Q"2,^::!!0 4 % !0 4 =+X2\*WG
MC'48],L%^=^7D/W(HQC?(Y]%!X'5F(1?F84#/T,\+>&;/PCI\>EZ>NV*(99C
MC?)(<;Y'(ZNV/H  J@*H H1T- !0 4 % !0 4 % !0!\N_M+_P"ITO\ W[O^
M5O28SY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@
MH * "@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1
M_P"S;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[
M9TF!\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@
MH * "@""ZM8KZ%[:X1989D:.1&&59&!5E(]""0: /SW^)?@67P)JC6P#-93[
MI+24\[H\\HQZ&2+(5^F05? #BI&>>4""@ H * "@ H * "@#IO"/BF[\&ZE%
MJED?FC.V2,G"RQ-C?$_LP&0<':P5Q\RB@9^B7A[7[3Q/80ZG8-O@G7(S]Y&'
M#1N.SHV58<C(R"5()H1M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '
MS+^T#X&^U0KXFLU_>0!8KP*/O19Q',<#),9/EN3D[&3HL9I,#Y'I % !0 4
M% !0 4 % !0!Z#X!^(NH> KKS+<^=9R$>?:LQ"..,LG7RY0!A7 /HRLO% S[
MJ\*>+]-\96@O=,D#@8$D;8$L+'^&1,G:>#@\JP!*L15".GH * "@ H * "@
MH * "@ H * "@ H * "@"O=W<-A"]S<NL,,2EGD=@JJHZEF. !0!\;?%/XRR
M>) ^D:&6AT[[LLW*R7..J@<%(3_=/SR#[VU24,C/GZ@04 % !0 4 % !0 4
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MO9^_3^'JNW_ _(^SP.8*K:C7=JG26REZ]I?@_70\>KS3Z(* "@ H * "@ H
M* "@ H ]4\!?$23P\5L;\M)8$_*>KP$]U[F//+)VR63G*MWT,0Z7N3UA^7IY
M>7W>?@XW +$7JT;*KUZ*7KV?9_)]U].6]Q'=1K-"RR1R*&5E.593R"".H->^
MFFKK9GQ,HN#<9*S6C3W3):9(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?_(XZ
M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE
M, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_
MUT?^^O\ ,4AGZEU8@H * "@ H * "@ H * (Y8DG1HI55XW4JRL RLK##*RG
M((()!!&".#0!\(_%KX:/X(O/M=FI;2KISY3<GR7.6,#DY/0$Q,3ET!!)9&-3
ML,\?H$% !0 4 7M,TVYUBZBL;*-IKB=PD:+U)/Z  9+,<!5!8D $T ?H%\./
M -MX"TX6Z[9+R?#W4X'WGQPBGKY4>2$'&3N<@%B ]@/0J8!0 4 % !0 4 %
M!0 4 ?+O[2_^ITO_ '[O^5O28SY/I""@ H * "@ H * /9/@-_R-D'_7"X_]
M%F@9]W50@H * "@ H * "@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ
M6,^>:!!0 4 % !0 4 % 'T?^S;_R%K[_ *]%_P#1JT(9]AU0@H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H ^5OVF?\ F$_]OW_MG28'RM2 * "@ H * "@ H ]D^ W_ "-D'_7"
MX_\ 19H&?=U4(* "@ H * "@ H * "@ H XOQ[X,M_'&E2:=-A)A^\MY2/\
M53 ':3CG8V2L@'52<?,%(0'YWZGIMQH]U+8WB&*XMW:.1#V93@\C@@]589#
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MOXF:KXZDVW#?9[)6S':1D^6,=&D/!ED _B8 #G8B9(*&>=4""@ H * "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_ -&24T!Z)3 * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H * "@ H GM?]='_OK_
M #%(9^I=6(* "@ H * "@ H * "@ H R]:T:U\064NG7Z"6WN%*NO?U#*>S*
M0&5NS 'M0!^>_CWP1=^!-2:QN,O ^7MI\866+. >,@.O21,Y4X(RK*QD9Q-
M@H <JER%4$L2  !DDGH .Y/84 ?<7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:
M-QYK=O\ 5J<!B[ ]NI@% !0 4 % !0 4 % !0 4 ?+O[2_\ J=+_ -^[_E;T
MF,^3Z0@H * "@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "
M@ H * "@ H * "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % 'T?\
MLV_\A:^_Z]%_]&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@
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M!F[JFU?E)D6F@/?J8!0 4 % !0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?0W[-__
M "';O_KP;_T?!0AGV95""@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H /^%A^)?^@I?_ /@3+_\
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M9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$%
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M4+R>"64AXY)Y&1AY;G#*6((R >>XH ^YJH04 % !0 4 % !0 4 % !0 4 %
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M,^@*,!TYZTK@>3Z[\1O$7B/*WU].T;<&*-A#$1Z&.((K?\"#'OG- SB:!!0
M4 % !0 4 % !0 4 % !0 4 ?0GP4^&)U^==>U6/_ $"W?,$;CBXF4_>(/WH8
MB.<_+(_R?,JR+0,^SJH04 % !0 4 % !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % &UI/B/4]!#C3+JXLQ+M+B"5X]^W
M.W=M(SC<<9Z9/K0,U_\ A8?B7_H*7_\ X$R__%4 '_"P_$O_ $%+_P#\"9?_
M (J@ _X6'XE_Z"E__P"!,O\ \50 ?\+#\2_]!2__ / F7_XJ@ _X6'XE_P"@
MI?\ _@3+_P#%4 '_  L/Q+_T%+__ ,"9?_BJ #_A8?B7_H*7_P#X$R__ !5
M!_PL/Q+_ -!2_P#_  )E_P#BJ #_ (6'XE_Z"E__ .!,O_Q5 !_PL/Q+_P!!
M2_\ _ F7_P"*H /^%A^)?^@I?_\ @3+_ /%4 '_"P_$O_04O_P#P)E_^*H /
M^%A^)?\ H*7_ /X$R_\ Q5 !_P +#\2_]!2__P# F7_XJ@ _X6'XE_Z"E_\
M^!,O_P 50 ?\+#\2_P#04O\ _P "9?\ XJ@ _P"%A^)?^@I?_P#@3+_\50 ?
M\+#\2_\ 04O_ /P)E_\ BJ #_A8?B7_H*7__ ($R_P#Q5 !_PL/Q+_T%+_\
M\"9?_BJ #_A8?B7_ *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H ]6^#
M'B_6M8\2PVM_?75S T,Y,<LTCH2L9()5F(R#R/2@#[+JA!0 4 % !0 4 % !
M0 4 % !0 4 ?&?[1_P#R';3_ *\%_P#1\]2QGSS0(* "@ H * "@ H ^AOV;
M_P#D.W?_ %X-_P"CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M-&5./W<;#][D89AY7/S[4,^U54*  , < #H!5"%H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
M* "@ H * "@ H * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4
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M H * "@ H * "@ H * "@ H ^<?VDO\ D$V/_7VW_HEZ3 ^.Z0!0 4 % !0
M4 % 'JOP3_Y''3_^WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /L3]FW_D$WW_7VO_HE
M*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0 4 %
M!0 4 % $]K_KH_\ ?7^8I#/U+JQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!\N_M+_ .ITO_?N_P"5O28SY/I""@ H * "
M@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H
M^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4 % !0 4 % !0
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M&2QXMYCPLH[!'X27T 5\_(0QL,^Y 01D<@U0@H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /GOXL?!U?$6_6=#41ZA]Z: 85+GU=>@2?U)^67OA\LR
M^-IH9+9VAF5HY$)5D8%65@<$,#@@@\$'D4@(J "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /8OA?\ "FY\;3+>W@:W
MTF-OFDZ/.5ZQPY[=GDQM7D#+\ &?<>G:=;:1;1V5E&L%O H2.-!A54?J23DL
MQ)9F)9B6)-4(NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?
M_KA;_P#HL5(SQN@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0
M4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@ H * "@#Z
M&_9O_P"0[=_]>#?^CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '(>+O!MIXL@V2XBN8Q^ZG RR]]K#C<A/52>"25(.<\M:C&LM
M=)+9_IZ'HX7%SPDKQU@_BCT?FNS\_O/E#6M$N_#]RUG>H8Y%Y!_A=<D!T/\
M$IQP?P(!! ^>G"5-\LU9_P!:H^]HUH8B"J4G=?BGV:Z,R*S.@* "@ H * /H
MCX*?\>MY_P!=8_\ T!J]G!;3]5^I\?F_QT_\+_-'MM>L?,A0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?./[27_ "";'_K[;_T2])@?'=(
MH * "@ H * "@#U7X)_\CCI__;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'V)^S;_R"
M;[_K[7_T2E- ?1U, H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?
MGU2 * "@ H * "@ H GM?]='_OK_ #%(9^I=6(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /EW]I?\ U.E_[]W_ "MZ3&?)
M](04 % !0 4 % !0![)\!O\ D;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4
M% !0 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H
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M[."VGZK]3X_-_CI_X7^:/;:]8^9"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_
M .1QT_\ [>O_ $CN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
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M?8_P[^"UAX2*7^I%;[4EPRDC]Q W_3)6^^X/25QD$ HJ$9+L(]OI@% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__ *+%2,\;
MH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MKV<%M/U7ZGQ^;_'3_P +_-'MM>L?,A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?./[27_()L?^OMO_ $2])@?'=( H * "@ H * "@#U7X
M)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?8G[-O_ "";[_K[7_T2E- ?
M1U, H * "@ H * "@ H * "@#S+XR?\ (HZC_N0_^E,-)@?GU2 * "@ H *
M"@ H GM?]='_ +Z_S%(9^I=6(* "@ H * "@ H * "@ H * "@ H * "@ H
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M^P\-6PLM+@2VA7G:@Y8_WG8Y9V/=G).,#. !5"-B@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H ^$?CS_ ,C9/_UPM_\ T6*D9XW0(* "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H *
M "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_UT?^^O\
M,4AGZEU8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\ 1\]2QGSS0(* "@ H * "@ H
M^AOV;_\ D.W?_7@W_H^"A#/LRJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 07-M%>Q-;W"+)%("KHPRK ]014M*2Y9*Z?0J,
MG!J<&TUJFMT?,?CSX=R^'6:]L0TM@QR>[09/"MW*<X5^WW7YPS>#7P[I>]#6
M'Y>OEY_?Y_;X+'K$)4JME5Z=I^:[/NOFNR\MK@/=/HCX*?\ 'K>?]=8__0&K
MV<%M/U7ZGQ^;_'3_ ,+_ #1[;7K'S(4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\C_\,U7O_01A_P"_#_\ Q=*PP_X9JO?^@C#_
M -^'_P#BZ+ '_#-5[_T$8?\ OP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-
M5[_T$8?^_#__ !=%@#_AFJ]_Z",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@#_
M (9JO?\ H(P_]^'_ /BZ+ '_  S5>_\ 01A_[\/_ /%T6 /^&:KW_H(P_P#?
MA_\ XNBP!_PS5>_]!&'_ +\/_P#%T6 /^&:KW_H(P_\ ?A__ (NBP!_PS5>_
M]!&'_OP__P 718 _X9JO?^@C#_WX?_XNBP!_PS5>_P#01A_[\/\ _%T6 /\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M^"USX*UB/5I;R.X6..1/+6)E)\Q2N<ER.,YZ46 ^@:8@H * "@ H * "@ H
M* "@ H * "@ H * "@ H \)^(OP4A\97XU2PG2QGD7%P&C+K*PX60!67:^/E
M?J& 4\-N+*P'GO\ PS5>_P#01A_[\/\ _%T6&'_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KT?\Q&'_ +\/_P#'*+ ?37AFPO\ 2].AL]4G6]N8
M%V&=5*F15X0N&+$OMP';/SD;CR33$;U !0 4 % !0 4 % !0 4 % !0 4 %
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M,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M>/DQC'>@1[?3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * &NBRJ4<!E8$,I (((P00>""."#P12WT8TVG=:-;'SEX_^&S:9
MOU/25+6O+2PCDP^K(.IB[D=8QSROW?$KX;DO.G\/5=O^!^1]C@<P52U#$.T]
MHR_F\GVE^?KOT7P4_P"/6\_ZZQ_^@-6V"VGZK]3CS?XZ?^%_FCVVO6/F0H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /,OB?X E^(%G!:0SI
M:FWF,I9T+@@H5P &7!YSFD!XI_PS5>_]!&'_ +\/_P#%T6&'_#-5[_T$8?\
MOP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-5[_T$8?^_#__ !=%@#_AFJ]_
MZ",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718 _P"&:KW_ *",/_?A_P#XNBP'
M7>!/@?<^#];MM9EO8ITMO-S&L3*6\R"6(88N0,&3=TY Q181]%4P"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H Q-)T&TT6:X>R3RA=,LCH/N
M!AN!*+CY0>I . ?N@#BL84XTW)PTYK-KIUV.JK6G6C!5'?D32?6VF[Z_GW-N
MMCE"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
+* "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>feacam_75a50119c00071xmo001.jpg
<TEXT>
begin 644 feacam_75a50119c00071xmo001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!622+59YH95;/*N'&2,'(QQQZT >I45P7_"E_ '_ $ G_P# ZX_^.4?\*7\
M?] )_P#P.N/_ (Y0!WM%<%_PI?P!_P! )_\ P.N/_CE'_"E_ '_0"?\ \#KC
M_P".4 =[17!?\*7\ ?\ 0"?_ ,#KC_XY1_PI?P!_T G_ / ZX_\ CE '>T5P
M7_"E_ '_ $ G_P# ZX_^.4?\*7\ ?] )_P#P.N/_ (Y0!WM%<%_PI?P!_P!
M)_\ P.N/_CE'_"E_ '_0"?\ \#KC_P".4 =[165X?\-Z3X6TYM/T:U-M:M(9
M2AE>3YB "<N2>P[UJT %%%% !1110 4444 %%%% !1110 4444 07MW!I]C<
M7MRX2"WC:61S_"JC)/Y"N'\'?$6;Q-H6LW5UI@L;[3XA<+;,Y.^%X_,B?/\
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M-TE[1UN4#%YVDWEPA!&.6[Y&: .YL]2O$\,_VEJ4$!N4A>:2*QD,J,!D@(Q
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MD]L9YZ^G2I:* .;?P_JL,U[%INK16MC>SF>0&W+31,V-_EON &2"1E3@D]>
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MAU!?<1U SA1D>G6@#N:*Y[_A.O#'_08M_P F_P */^$Z\,?]!BW_ ";_  H
MZ&BN>_X3KPQ_T&+?\F_PH_X3KPQ_T&+?\F_PH Z&BN>_X3KPQ_T&+?\ )O\
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M:I-IHLM* ,S002*S@Q"3()<@8SZ'I5#3?&^HR1:W%J-C!'?6*1_9HXR<32,
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M]L:%AH0L99+C^T+N:[GE5[BXEV;I54$*A 4!4&>B@'.3GDY -:BBB@ HHHH
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MW [&YP2.2 .F :S#X2U/^R]0D^TDW#7%S=VMF-H02X9(,OUVA!&<=F&<\8H
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MGTH U&U&XN;6VGTJT6Z6=2^^:7R50<<-P6#<]-O8YQWELM2BN],%\P\A!O\
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M".EPQ39:(2V,89DS\K8QP&&" ><$9P>* .LW#U%&X>HK _X03PC_ -"QH_\
MX!1_X4?\()X1_P"A8T?_ , H_P#"@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_
MX4?\()X1_P"A8T?_ , H_P#"@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_X4?\
M()X1_P"A8T?_ , H_P#"@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_X4?\()X1
M_P"A8T?_ , H_P#"@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_X4?\()X1_P"A
M8T?_ , H_P#"@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_X4?\()X1_P"A8T?_
M , H_P#"@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_X4?\()X1_P"A8T?_ , H
M_P#"@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_X4?\()X1_P"A8T?_ , H_P#"
M@#?W#U%&X>HK _X03PC_ -"QH_\ X!1_X4?\()X1_P"A8T?_ , H_P#"@#?W
M#U%&X>HK _X03PC_ -"QH_\ X!1_X50U;PQX+TBR^T2^%-+E9I$BBABL8B\L
MC$*JC( Y)ZD@ 9)X% '7;AZBC</45P$FE>%;2WE^W> +."Z62.*&!;*%Q<-(
M2%"/]W/!SDC:!D\8)KW-IX2LEE@N_ .GQ:@KP*EK]F@/FB:01JROTP&.#G!'
MX@D ]'W#U%&X>HKSB>T\(VJ313^ K&+4(I8(_LC6MOEQ,Q5'5Q\NW*L.H(VG
MCIG;TWP?X:O(7>Z\$Z39L&P$:W@DW#URH(H MZ@1_P )[H7(_P"/&]_]"MZE
MN=$N)I+JWCO8DTZ\E$L\1B)?MO56W8"MCG()&YO48Y^^\%^%T\;:+;KX=TH0
MR6=XSQBSCVL5:#!(QR1N./J:U8_"7@66Z>UCT+0'N$^]$MM$77ZC&: -K4(K
MZ?8EG<VL*_Q--"9&![%?F S]?_K55N=(']C0:3;OFV9PMR\C99X\EGSZESP>
MGWR:SKOPGX$L%1KS0_#]NKG:IFMH4#'T&1S1/X3\"6T*S7&A^'XHG.%>2VA5
M2?8D4 ='<B5[=UMIDAFQ\CNF]0?<9&1^(JC:6-U_:/V_4+F"25(C#$D$9155
MB"Q.6)))5?ICWS60?"W@(6HNCHOAX6Q.T3?9X=F?3.,5);>#_ ][&9+70-!G
M0'!:*UB8 _4"@"U;:)<0R6D$E[$^G64ID@B$1#]"$5FW8*KGC !.%]#F[#:.
M=:N+^=D(6,06R@YVIPSGV+-@8]$6LB?P=X+MG@27PUHX>>3RHP+&,EFP6_N^
MBD_A3+CPKX"M)T@N=%\/0S2#*1R6\*LP]@1S0!H:MI=]J%_;S0WUJMM -PMI
M[=I%,@.0YPZYQQ@'@'GKC$US875U8V_F7D(U"WF\Z.=82$W<C&S=G!5BI^;O
MFLT>#O!)G> >']",J+N>,6L6Y1ZD8X%1IX6\!26CW2:+X>:VC^_,+>$HOU.,
M#J* -%--ODL=0*:C%'J5XV[[0L.4BPH4!4)YP!W/4D^U.T?3KW30L,MU9O;*
MK?)#;NCLY(.]G:1B3][/<DYS6?;>#_!%[$);70-!GC/1XK6)A^8%3_\ "">$
M?^A8T?\ \ H_\* )Y].U"[D2&ZU"W>R2=)L+ 5E;8X=5+;L=0,D#D<8'6MC<
M/45@?\()X1_Z%C1__ */_"C_ (03PC_T+&C_ /@%'_A0!O[AZBC</45@?\()
MX1_Z%C1__ */_"C_ (03PC_T+&C_ /@%'_A0!O[AZBC</45@?\()X1_Z%C1_
M_ */_"C_ (03PC_T+&C_ /@%'_A0!O[AZBC</45@?\()X1_Z%C1__ */_"C_
M (03PC_T+&C_ /@%'_A0!O[AZBC</45@?\()X1_Z%C1__ */_"C_ (03PC_T
M+&C_ /@%'_A0!O[AZBC</45@?\()X1_Z%C1__ */_"C_ (03PC_T+&C_ /@%
M'_A0 W(_X6+U'_()_P#:M=#N'J*X/_A"_"__  GGV;_A'=*\C^S/,\O[''MW
M>;C.,=<=ZO:OX4\+:99-<Q^"]*NE3+2;;>WC\M0"2Q+X&.* .NW#U%&X>HKD
M])\)^$M5TFUOV\&Z;:_:(Q((9K&+>H/3. <'&#^-5!HW@8^*6T'_ (132_.$
M/F>=]AB\O?P3'G&=^TAL>AH [?</44;AZBO.;&S\(W7V2:?P%8VUC=SFWANF
MM;=EW[BJA@/F7<1@''4C.,U7AG\ 3>$K37QX.L ES<+;K;&QA\P,3WXQC;\_
M^[0!Z=N'J*-P]17G+1> 8M:M=-F\):;&US<7%LLQL8MBO$T:_,<<!FD4#W('
M>EN(? =K#)-+X0TX1QI?.Q6QB)Q:R!'[=R<C]<4 >B[AZBC</45P-MH7A^Y@
ME9/AUIYE54= L-NT<J-GE9!\N1CD>XZYJA;0>&+K3]*NH_AU8?\ $U :U1H;
M8%D\LR;B>@X'2@#TW</44;AZBO/YM&\.175E9CX>Z:]Y=0S3^2(K?Y$C9%.6
MZ'/F+T]ZJP0>$;Z2WBL/ %A/+)'*[HT%LGEF.4Q,"3P?F!Y!((YH ]*W#U%&
MX>HKSR;2_#<=[-:Q?#FRN)+:VBN+A8;>VRF_=A0"1N(V'I5F^TCP5;Z/I^I6
M?A'2KV/4'B6V6.TA3=Y@W*<L  ,4 =UN'J*-P]17GMO9>"9/)^T^#-.M5:\:
MQF>2T@989L J"RY!#9 !'? .#Q6EIOAOP5J6EMJ0\*Z3#9DLT<LME$ \8Z2=
M.%(&1GM@]Z .PW#U%&X>HKS*]/@:QMVED\&:8"8(9HU:SB4MYTC)"#\OREMI
M8YZ 'O6Y=^'_  %ID4!U/0M LY)4W;'M8SC&-QSM^Z,C+<#D4 =CN'J*-P]1
M7G=S'\.[:^DM3X;TC,5\MC(YLH@H<Q-*<<<X52/KQ6C_ &-\."]JHTKP\3=*
MCPXM8CO5CA3TXR>!GJ>!S0!V>X>HHW#U%<C#X>^'US]L,&B:#(+/(N"EG&1$
M02"#QU&T\>U8^E_\*XU.Y@B7P[H\'GV\$T1FLXE+&9G"IC'#?*/Q< <T >C;
MAZBC</45Q8TGX;%KE1I?AW_1E9Y2;6(!54X8YQR 2 <=#P:M6'A;P'JD4DMC
MH.ASI&_EN4LXSM; .#QZ$'Z$'O0!U6X>HHW#U%><Z:/AS?J"_AS2+;_18[LF
M6SBP$D8B, XY9L X']X5H3Z7\-+:WAN)],\.QQ3(\D;-:Q?,J$!ST_A)&?3O
MTH [;</44;AZBN3LO#7@#44F>ST309U@;;(R6D9"\9].F.<]*P+(>!K^RGOH
M/!VDM91F,B98(&^1W"Y91DH<'?M/)'H<B@#TO</44;AZBL#_ (03PC_T+&C_
M /@%'_A1_P ()X1_Z%C1_P#P"C_PH W]P]11N'J*P/\ A!/"/_0L:/\ ^ 4?
M^%'_  @GA'_H6-'_ / */_"@#?W#U%<]K!'_  E_AKD?>N?_ $53O^$$\(_]
M"QH__@%'_A5/5/"O@G2;"2]N?"^DE$*J%2PC9G9F"JJC')+$ >YH ZO</44;
MAZBN!;3/!MO!<OJ'@2WLI(?+VQ2:? YF,C;45"A92Q;C&01D$\<U#<6O@RRB
MG%]X"M[:[C6-DM'LK8O,KR+&"C!BAPS*#EAC(]1D ]$W#U%&X>HKSN:U\%VL
M-S]J\!V\%Y T ^QO8VQDD$T@C0JP8H1N.#\PQCG'&=?3O"/AF]1VN/ =C8%2
M %N;2V8O[CRV;]<4 =;N'J*-P]17#^+?!?A:U\&:[<6_AS2HIHM/N'CD2SC#
M(PC8@@@<$&KJ^$_ T/V>"?0] 2XE5=D;VT09\\< C)YH ZO</44;AZBN;N/!
MG@JU@:>X\/:'#"G+226D2JOU)%1IX3\"26ANTT/P^ULO)F6VA*#_ (%C% '4
M;AZBC</45RL/A;P%<QR20:+X>E2(;I&CMX6"#U) XI;;PMX"O7*6FB^'IW R
M5BMX6('X"@#J=P]11N'J*YF[\'>"[&SFNKCPUHZPPH7<_88SP/8+S]*2Z\)>
M!K"(2WF@Z!;1DX#36L2 GTR1UH Z?</44;AZBN8_X1'P-NA7^P= W39$0^RQ
M9DQUV\<X]J6/PAX'FN)+>+0=!>:/[\:VL19?J,9% '3;AZBC</45RUKX5\!7
MS,MIHOAZX9.&$5O"Y7ZX%6O^$$\(_P#0L:/_ . 4?^% &_N'J*-P]16!_P (
M)X1_Z%C1_P#P"C_PH_X03PC_ -"QH_\ X!1_X4 ;^X>HHW#U%8'_  @GA'_H
M6-'_ / */_"C_A!/"/\ T+&C_P#@%'_A0!O[AZBC</45@?\ "">$?^A8T?\
M\ H_\*/^$$\(_P#0L:/_ . 4?^% &_N'J*-P]16!_P ()X1_Z%C1_P#P"C_P
MH_X03PC_ -"QH_\ X!1_X4 ;^X>HHW#U%8'_  @GA'_H6-'_ / */_"C_A!/
M"/\ T+&C_P#@%'_A0!T&<]**J:=I>GZ1:_9M-LK>S@W%O*MXPBY/4X'?BK=
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MM4LWATR='6&^B\V.1%B>,*P_X&#^%=-10!R*>"R?"-_HLLEH!=W'GB**#;!
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M* .AHKGO^$Z\,_\ 06B_[X;_  H_X3KPS_T%HO\ OAO\* .AHKGO^$Z\,_\
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M%0Q74+%Y"Y3"HV0-@;.,_-D_+QD&K]OXG\%6EK):VUQ8PV\F=\4=N51LC!R
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MA8BH3'H3L?\ WE]ZVM9EFUO4KQ=.2VN%T^W"QRFY"B*X)63>1@Y"[8CGW84
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M/WJLZA:F,WMS??;]GG,ZZC9W9VP1@]"FX$!0,, K X)/). #KZ*** "BBB@
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MVZNCB"(.@VHP094>@]!4M% !4,MK;SR))+;Q22("%9T!*@\$ ]LU-10 @ 4
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M.%+;<>V:Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDM+Y8OG@E8M$T@&P,"HR"2%R#P2.,9( .@HHHH **** "BBB@ HHHH ****
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MT"C..U5SXBTT+*QDGS%,(&7[-+N\PKNVA=N3QSP.G-+8Z_IVHS>5;2S,^QG
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M"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML;K;QHQ!.,K][!Z$<TS1=2TJ'09=5:>&0V1N=SHX)57E+8Q_M;5QZ\8KJ:*
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M/JP_O<==10!SMMK&FOXQO(UO[9G>UMXE42KEG#S94<]1D<>XKHJ** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .>_P":B_\ <)_]JTGB*\:74=,TBW>U
M-Q+*+EHIY=@9(SE1D G)?:0,<A&I?^:B_P#<)_\ :M=#0!S&@W%K]EN]/OY+
M0/I-PSXCFW)$GWEY.,!,E.>FRI?#5QIUW9RW,<\$LEO<W>760'8CSNV3ST(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]_S47_N$
M_P#M6NAKGO\ FHO_ '"?_:M=#0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!FZU;F:P,AUBYTJ.#,DEQ
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M;03\J+&W)Z[^,\U?\/:-J>D^*[J*=#)ID%DD%C<E\DIO9A&W?*9QGN-IZYH
MHI>:=+;)<1_$756B=@B,HMB&)!; _<<\ G\*M^5 =)DU3_A8.J?8(VVO.6M
MJ-G&"?(X.2!@U7M?#^J-H7@FU#W-C/8IBYEA$9>'_1W7'SAE/S$#H>M5(O#F
MMW832+E$^6]FN[Z_NXO-BOB%5(CL5EQE6!P,!3#WXR :^HV/]DI&U]XZUF#S
M21&K"U+.1R< 09./:J=Q<6%HL#3?$75%6X0/"P^RD2*<X((@P>A_*DTFWUK1
M[K3[S4K"YOVM;.337D@"ESLD!24*6SB10I."2"!GUK4N+.]O-.T1QI26;IJ:
MW,MM&RGRDRYRV.-QW MC/)/)ZT 9\\EG;21)/\0]4C:1%D&[[*,*WW2W[CY0
M>V<9HNGM+&[EM;KXA:K#-"0) _V4!"0"-Q\C X(//K4\L5]IK>(;,Z+<:@=3
MF>6"2/9Y<@>-4V2%B-NW;CD8VXQD\5B-X/UZ+1];MTOKIPWD1O:*8PFHQI:P
MQRC>5WJS;74'<,$#CO0!U+>';U%W/XRUM1TR1:#_ -H4@\/7K%0/&6MG<-RX
M%IR/4?N.G(_.J?B2*ZU"065K#(K-I<QMHCP5E<K'N^J*Y_[Z-9JZ/K&G:N(E
M@NO[(LMMM ]JP\TVS>9(57G(VL+>/CG:N?< '0_\(UJ'_0X:[_WS:_\ QBC_
M (1K4/\ H<-=_P"^;7_XQ5C1[J\@T^QM=3AN#>/B-G.UL'87^8@\X "D]V^M
M8GB!?$$FK7QL(KYHEM)5B2.0(A;R6*L#G#9=@N,!@5!!V\4 :7_"-:@?^9PU
MW_OFU_\ C%+_ ,(UJ'_0X:[_ -\VO_QBN>DTO7[&PMULI-0^S+*T(MPY+)#&
MFR( !U(W%=Q;=D9 /&:;<6WC(B]62>YEFCM9%4QH$27_ $?:N"'P&,IW<#(P
M1G&,@'1?\(UJ!_YG#7?^^;7_ .,4O_"-:A_T.&N_]\VO_P 8J0B>W\)7%KHL
M4ZSVD!M[;S0"Q95 !&XX)'OQD8-8<T.NEY$M!K"QL@-B9IE.R7?AFE.<[  K
M!6SD,PQG:  ;'_"-:A_T.&N_]\VO_P 8I/\ A&]0S_R.&N_]\VO_ ,8K*'_"
M3WLT$&V]M4$KB>8E!PUR'PO)R%B0H#C_ ):#K6?<#5M*=]3N?MAN(EABLT>?
M)F#WCLT(R>7,2Q+D\\9S0!TW_"-:A_T.&N_]\VO_ ,8J*/0[F9Y$C\;:R[1G
M#A3:$J?0_N>*TM-DNX],FCEW7-_;DB0L=B2RE0^$/9 6VCTQWQ7$PZ!=.D=K
M%I=W%9"2V02R*L=Q$GG!Y(RR-^\0;%&XC/).6Y( .H_X1O4!_P SAKO_ 'S:
M_P#QBE_X1K4/^APUW_OFU_\ C%<Q]B\2ZE.%O(;Y;:6:VEDC:3'EN)&<C(;E
M5V(I*A00P.#C-;GA1/$,=O=3ZJ9Y93!'^YE4)NG 8OM.]@!DJ. %XR!U) +?
M_"-:A_T.&N_]\VO_ ,8IK>'+Y!EO&.N 9 R1:]3P/^6%8FEV_B>>Z5+N74([
M21XGF);:^!'*9 #N)&7,2\!1P2 .M%C8>(+RYTJ#5EOF,4]O)*V]?)\M( _S
M<_,_V@8SC/RCMU -9]&FCF$,GCC5UE. $9K0,<]./)H;1IED6-O'.KAVX52U
MID\XX'D^O%5[N%M0\6^=>:'<-;V#!K5A"I$\H&1(S9SA>BCUR3T7&7I'@N^O
M+6XBU5HX$D@@MY08%>1P$#R,CD_)F264=,\9':@#>FT*ZMU5I_&NLQ!CM4O]
MD7)].8>M2_\ "-:A_P!#AKO_ 'S:_P#QBJVKVLG_  D%U<7&B/JL4MBD%HF$
M*(^Y_,5MQ^3=F/+8Y"^V#FRP^)8=ZVD=]&\<DB2@2!HQ;>8%C$()YD$?S9(S
MD$'J!0!LCPY?$D#QCKA*]0!:\?\ D"A?#E\V=OC'7#@X.!:\'_OQ7-#3?$Z7
M,K6C7UO'=SR2(7Q)(C@K'&9#O'RB.,, 20<G(+8KK_#^Z5]5O1_Q[W=Z9(/=
M%C2/</8M&S ]P0>] %?_ (1K4/\ H<-=_P"^;7_XQ1_PC6H?]#AKO_?-K_\
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M49/[,N[N*QN6EAC+) R;7E8(& 7ZDX^N: ,!K%4M[RX;Q]J@ALF*W3[[/$)
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M !BC_A&M0_Z'#7?^^;7_ .,5T-% '/?\(UJ'_0X:[_WS:_\ QBC_ (1K4/\
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M1^8JO!KFD7,RPP:I92RN<*D=PC,Q]@#7 :??RZIX]T?1==BCEU/3[&]AO%9
M4N%)MRDP!XVN!G'8AAVK7\':1IL?B#Q7(FGVBO!JX$3+"H,8^S0G"G'')/3U
MH ZR[U33[!U2\OK6V9AE5FF5"1[9-$NJ:?!;1W,U_:QP2'"2O,H5OH2<&N(\
M1Q3S?$VU%OHEGJ[#1G)BNI5C5!YR_,"5;GMT[UBW?A[4=)NM!C.G:6UQ?:]<
M74>F&4BUA4VD@V;MA_NEN$QN/3O0!ZI:WUI?1F2SNH+A <%H9 X!^HID&JZ=
M<WDEI!?VLMS']^&.96=?JH.17DUX;Z*/QG>K:VVBZK:::MM)8Z?DEH2Q;[2'
MVKN^7>%(&5P0>:Z/QCI6B:9X$BN]$M+2"YMG@;29;95#&4NH0*PY;=G!ZY!.
M: .TDUG2X;DVTFI6:7 .#$TZA@?3&<U:,T0F6$R()64LJ%AN(&,D#T&1^=</
MH.C:/J6H>,GU33[*Y7^UW5GN(5;"?9X.,D<#DUC>"YI&U7P;)/([(^EZE%;2
M2')DC6>+RN3U_=JI^G- 'J(FB:22-94+Q@%U##*YZ9':JMOJ^F7:S-;:C:3+
M ,RF.=6$8_VL'C\:\U\2N'UWQ,KN5T^34-)MM0<-@"$GYU8]@0R@^S5VEWI7
MABSUO2=]K;VU]*);>UCACV^<A0ET95&"@49^;@''?% &E'K^C2R+''J]@[N0
MJJMRA))Z #-6+O4;'3]GVV]M[;?G;YTJINQUQD\]17(:%HNE+\1/$P73+,"&
M.Q:+$"_NSMD.5XX.0.GI4_B"SMK[XC>&8;NVAN(OL=\=DJ!USF#G!H ZDW]F
M+/[8;N 6N,^?Y@V=<?>SCK5>/7M'EW>7JMB^U2S;;A#@#J3STKR[Q7:P61\9
M:?I$$"6'E:;)+;J-L*737&", 8&4$9; ]#WKM=/\/7,_VJVU;0?#UM:7%L\+
MMI[,9&##!4YC7@@GOZ4 =3+-%!$99I4CC&,N[  9Z<FJ,FOZ-%(T<FKV"2(2
MK*UR@*D=01FN&TVXGUR/0/"EVQDN-,N';5"?XEM6 BS_ -=&,3^X!JOX7TK4
MKJWU&6#0O#EU =7OOWUZS><?])DSG$;#Z<T >G)/%*[I'*CO&0'56!*Y&1GT
MX.:@O=4T_3=GVZ^MK7S#A//F5-Q]LGFN?\-@#QIXR &!]KMO_26.JGARPL=4
M\1>*IM5MH+G48[_R-MP@<QVWEH8U4'HIRQXZDGTH ZVYU"RLHDENKRW@C<X5
MY9 H;Z$GFFKJFGM9M>+?6IM5.&F$R[ ?=LX[BO(U1FFTBTL+"#4K"#Q)>PZ?
M;3R!8FA%N^5#$,-JOY@'!^Z *N>(_#%PFA:]?7^FV&F6VHOI]L=/LI-ZL%N5
MW2.0JC<0^.!T'6@#U::Y@MH?.GGCBBR!O=PJ\].356?7-)M9FAN-4LHI4.&2
M2X16'U!->1^)+F?5/!<.@W$A>;0 QOCW9XI!#!G_ 'P3)_P$5NZ=INHWGB3Q
M7)::-H%[&-6*F34682 ^1#P,1M\OX]2: /2(KNVG<)%<12,T8E"HX)*'HWT/
MK4,^K:;:@FXU"UA <H?,F5?F !(Y/7!''O7G>K:=J$7Q"N-5TF)1J6DZ+9LM
MG"<1SQ&2<20CIU"C:<<,J^]6?#+Z5XE\/^*]16""[MY=1GE@::(,5S;Q=B.#
MV/N* .]M-3L+\L+.^MKDIRPAE5]OUP:2\U73M.9%OK^UM6D^X)YE0M],GFL/
MP!86=KX&T&:WM((99M-MC(\<85G/EJ<DCKU[UBZ';0WA\4WLVE6VJZVNJ2P2
M07)4,(00(ERP.U/+PPXP<GUH [V2>&&!IY942%1N:1F 4#USZ4//#&B/)*BJ
MY"JS, &)X 'J37D\FJ6NH>&]&\-V>CW;6KW\XN[""07#+;VTIW*#D H9/+4?
M[.1VI\&HRW'@O2]+NTGCO-(\06-FZ7 Q)Y8G0Q,P]3&4_$&@#T=O$.B(Q5M8
MT]6!P0;E 0?SJ]%<0S[O)FCDV$!MC [20#SCV(/XUQ5]HFDGXHZ5&=+LBCZ5
M=NZFW3#,)8,$C')Y//N:K:/_ ,)#'XH\7)HL.E&V&I1@B[>16#?9H> %4C&,
M4 =K-J^F6\<<D^HVD229V,\ZJ'QP<$GG%(-:THVQN1J=D;<-L,OGKM#=<9SC
M/M7D>BVMY>)X)C@L=,O+C[)JA:*^)$7_ !\1Y(PK'/IQ70^)]/OK?1M"A?1]
M$BNGUZ$K;6[D6\GR/C>?+SGK_">@H ] M-0LK]6:SO+>Y"_>,,H?'UP:;;ZK
MIUW<R6UM?VLUQ%_K(HYE9D^H!R*\XM(U/BO6I=8M[+P[+8Z1*CQ:=ES/ ^";
M@.%7<$V$ ;<@D^HRZQL6T"3PR-0TO2+FQ2XB@L-5TIC#+N=2JEXR/F5@?FPQ
M'?'% 'H<6L:9/<_9H=1LY)\D>4DZELCJ, YJTDT4CR(DB,\9VNJL"5.,X/IP
M0?QKQ 6-Y'\/)-4DTO1AI]M?37$EXA(O@B7;$E,J 'XP/FZ?E7HWA9U_X2OQ
MDI.&^W02;3P=IM8L'Z<'\C0!OS:QIEO'')/J-I$DF=C/.JAL'!P2><'K4]M=
M6]Y")K6XBGB/ >)PR_F*\=T6&ZN9?!_V+3]/OW>UU:18KZ0I&5-RA# A'YP1
MCCOUIQ+CPYXGO9HX=*:XU&TM-5TZTRHLX5D59')&,[XV)+@ %<>AH ]:M=6T
MV^N)+>TU"TN)H_OQQ3*[+]0#D59>:*)HUDD1&D;:@9@"QP3@>IP"?PKAM?BT
MW1-2T&2'PU;+:1WEO%:WMK.D+1O(WE[0H&67#<C."/I6EXM_Y#_@[_L+M_Z3
M3T =(EU;R6[7"3Q-"N[=('!48ZY/3C!S]*CNM2L;&W6XN[VWMX&QMDFE5%.>
MF"3BO&K267POX$U.\=W;1M:2_BFR<BUNM\J(WLD@"J?1@O\ >-=9X9M;74?%
MLRZI#%/);:/8_8(YE#!8F5O,9 >Y< $^RB@#T"*6.>)98I%DC<95T.0P]0:?
M6)X;BT2UAU"UT-@((;V19HTSLBF(!=4SP!SG"\ D]\UMT %%%% !1110 444
M4 <]_P U%_[A/_M6NAKGO^:B_P#<)_\ :M=#0 5SWA#_ (\M3_["UY_Z.:NA
MKGO"'_'EJ?\ V%KS_P!'-0!T-%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M- 99I&DD;+#<S')/![DDUT=% &!>>"/#5_>/=W6DP27$@4/(2P+!5"C.#V
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MO)*X<*O&!\_TJ'0+^]U1[O3]9DU:"2]A.IV^]I;9HFR0\*,""50-%T.#N)H
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M*-;GCVPHY5,0+\I&$!QGG/- '0?VOXD_Z%8?^#"/_"C^U_$G_0K#_P &$?\
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M/_!A'_A1_:_B3_H5A_X,(_\ "NAHH Y[^U_$G_0K#_P81_X4?VOXD_Z%8?\
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M#_P81_X4?VOXD_Z%8?\ @PC_ ,*Z&B@#GO[7\2?]"L/_  81_P"%']K^)/\
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M&**\N&TZ]CL)%BB!,DSML4)DC/S<=N15G_A+DCLK^\O-$U>RM[*UDNI)+B%
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M-;.UVH"R(\**FX>[!3G_ 'C6E:>+]/GFO(+R&[TR:TM_M4J7\83]SR"X()!
M(YYXJO!XXLGDMFN=-U6RL[IUC@O;JW"1.S'"YY+)N.,;U7J* (]2\"V]XUT]
MM>RV;RO921>7&K"$VS93 /!'3KZ5-;>$/,U![[7-4GU>4VLEFB2Q1QQI%)C>
M-J 9+;0"2>@I)_&]O%?7]M#H^LW2V$WDW$UM;"1%;:K$##;CPP/ [UH6GB;3
M+^\TZWM)C.-1M'O+>5!\C1H4!R>H/[Q>,>M &.? \\UBFDWGB&^N=#3:OV)X
MT#R(.D;R@;F3@#L2."377@ # &!6+=^*M+L9=52ZD>(:6L33L4R#YF=@4#)8
MDC&,=2!56W\8P27:VESI.JV-S-$\EK%<PJ#<[!N*IAB-V.=K$']: .DHKE;+
MQQ'?:M)IL>@:XEQ$8Q-O@0"(/G:S'?TX)XSTJ_K?B:#1+^RL387][=7B2/%'
M9QJQVQ[=Q.6']\4 ;=%<RWCG2X]&O]0D@O8WT]XX[FSD@VW",Y 3Y2<$'<,$
M'!YYXI__  EQ6WNKB?P]K=O%;0/.[2P)R%&2!ASDXZ"@#HZ*R[W7[&RTBWU,
ML\L%RT*0"(9:4RL @4>^X'Z9K*B\<1W3S_8] UNZBAGDMS-# A1GC<HV,N#C
M(- '4T50L=7MK_4=1L8ED$U@Z1S;UP,N@<8YYX8?C6??^++>UU*;3[33M1U.
MYMP#<K8Q*P@R,@,S,HW$<[02<=N: -^BN:F\<:8MAIUW:P7M]_:$SP0PV\/[
MT2(K%U96*[2NQL@^E5[GXA:58Z9J5W>VFI6TFG+$\]I+;XFVR-L1E&<,"V1P
M>QH ZVBL'6?%^DZ'X?M=:N9)'M+IHU@\E=S/O&5P,^F3] :KR>,XO[1OK.UT
M36+UK*;R)I+:%"@?:K8!+@]&';O0!TU%84/BW39/$EOX?E$UOJ<]DMZD,R@9
M4DC;D$_.-IR/0'KBH[GQ?;PQWCP:;J5X+.Y>VG^S1*VQE17)Y8<8<?D: .AH
MK%\/>(X_$=JMU!INH6MO)$DL4MU&JK*K#(*X8]L'\:@O/%UO!J%S966F:EJD
MMJ0MR;&%66%B,[2S,H+8(.U<GD4 =#16'-XMTJ+PM_PD2O++9' 58XSYC.7V
M! AP=^[Y<>M2S>)-/BTC3M4#O):ZA)!' T8SDS$!"?;YAF@#7HKE)_'4<&JK
MIC>'M=:Z='DC1;>/YT0@,P^?IEE_.MK3-9M]5GOX(4E22QF6"99% PQC63CG
MT<?CF@#1HKE6\>6#1::UII^I7CZ@L[PQ6\*E@L3A')RPQR16WI6IOJEN\KZ=
M>V)5MNR\159N.HPQXH OT444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!SW_-1?\ N$_^U:Z&N>_YJ+_W"?\ VK70T %<IX>TVPU/3M1CO[*V
MND36+QE6>)7"GS6Y (ZUU=<]X0_X\M3_ .PM>?\ HYJ -"?P_HMU?+?7&D6$
MUVN,3R6R-(,=/F(SQ5Q;6W03!8(E$[%I0$ \PD $MZG  Y["I:* ,RV\.:'9
M1316FC:=!'.NR5(K5%$B^C #D>QJ]);032QRR0QO)'G8S*"5R,'![9'%2T4
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MLT4L36\1CE):1"@PY/4D=ZBM]/BM[ZZO<L]Q<[0SM_"BCY4'HH)8_5C5NB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#R/0)K#3X+F/4-:\36-PNHW;FUM[68Q &X=E(
MQ"P(((/7O5C4DU#2?$VN^*;#3KBYEM]02-8DB.9X9;.%>/4"58B?3:U>J44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU%_[A/\ [5KH: .>_P"$PM?^@3KW_@JF_P#B:PO"WBJW@M-1!TS6FW:G=O\
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MQP 3@(-GU)/48YKVGC?41J=G)>PP#35@9+]XP?W4HN)(?-&?^6>Z/G/0,#G
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MH[L#DGYSQ]*ELO%\]JNNW5U<276G:9:B1WN+0VDJS<GR]K8)RNT@[1U')SP
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MESA1-!"!(JMN"L220#W )(S[5N4 %%%% !1110 4444 %%%% !1110 4444
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MBM;:2-E(B5I<[=L:A6(P,$Y) !QCJ< #8[NUO=5AT.[L;I?L3I)!<2S!P\B
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MZ?:1Z4_A6]TV&"U@ME*1I</*C1DGH[!6#*R]>V5(/IG:=I]G<F!KZPF>WU=
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M1G25D(\MBR,"I&&4L<,.>:8GAC3%T[4+*1)ITU&,QW<DT[/)*I4K@L3D  D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDDC8 ':8RX;<<C QDY&,Y% '<45P%Y!X3LOL9>3Q)*EXJ-;R6]YJ,J2[E+*
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MJ_\ X.;O_P".T =#17/?\(5I'_/75_\ P<W?_P =H_X0K2/^>NK_ /@YN_\
MX[0!T-%<]_PA6D?\]=7_ /!S=_\ QVC_ (0K2/\ GKJ__@YN_P#X[0!T-%5-
M.TVWTJU^SVS7!CW%LSW$DS9/^T[$X]LU;H **** "BBB@ HHHH **** "BBB
M@ HHHH **HZGJUGH\"37K2JCMM'EP/*<XST0$BLS_A-]"_Y[7G_@NN/_ (B@
M#H:*Y[_A-]"_Y[7G_@NN/_B*/^$WT+_GM>?^"ZX_^(H Z&BN>_X3?0O^>UY_
MX+KC_P"(H_X3?0O^>UY_X+KC_P"(H Z&BN>_X3?0O^>UY_X+KC_XBC_A-]"_
MY[7G_@NN/_B* .AHKGO^$WT+_GM>?^"ZX_\ B*/^$WT+_GM>?^"ZX_\ B* .
MAHKGO^$WT+_GM>?^"ZX_^(H_X3?0O^>UY_X+KC_XB@#H:*Y[_A-]"_Y[7G_@
MNN/_ (BC_A-]"_Y[7G_@NN/_ (B@#H:*Y[_A-]"_Y[7G_@NN/_B*/^$WT+_G
MM>?^"ZX_^(H Z&BN>_X3?0O^>UY_X+KC_P"(H_X3?0O^>UY_X+KC_P"(H Z&
MBN>_X3?0O^>UY_X+KC_XBC_A-]"_Y[7G_@NN/_B* .AHKGO^$WT+_GM>?^"Z
MX_\ B*/^$WT+_GM>?^"ZX_\ B* .AHKGO^$WT+_GM>?^"ZX_^(H_X3?0O^>U
MY_X+KC_XB@#H:*Y[_A-]"_Y[7G_@NN/_ (BC_A-]"_Y[7G_@NN/_ (B@#H:*
MY[_A-]"_Y[7G_@NN/_B*/^$WT+_GM>?^"ZX_^(H Z&BN>_X3?0O^>UY_X+KC
M_P"(H_X3?0O^>UY_X+KC_P"(H Z&BN>_X3?0O^>UY_X+KC_XBC_A-]"_Y[7G
M_@NN/_B* .AHKGO^$WT+_GM>?^"ZX_\ B*/^$WT+_GM>?^"ZX_\ B* .AHKF
MU\>>'7D>-;JZ9X\;U%A<$KGID;.*?_PF^A?\]KS_ ,%UQ_\ $4 =#17/?\)O
MH7_/:\_\%UQ_\11_PF^A?\]KS_P77'_Q% '0T5SW_";Z%_SVO/\ P77'_P 1
M1_PF^A?\]KS_ ,%UQ_\ $4 =#17/?\)OH7_/:\_\%UQ_\11_PF^A?\]KS_P7
M7'_Q% '0T5SW_";Z%_SVO/\ P77'_P 11_PF^A?\]KS_ ,%UQ_\ $4 =#17/
M?\)OH7_/:\_\%UQ_\11_PF^A?\]KS_P77'_Q% '0T5SW_";Z%_SVO/\ P77'
M_P 11_PF^A?\]KS_ ,%UQ_\ $4 =#17/?\)OH7_/:\_\%UQ_\11_PF^A?\]K
MS_P77'_Q% '0T5SW_";Z%_SVO/\ P77'_P 11_PF^A?\]KS_ ,%UQ_\ $4 =
M#17/?\)OH7_/:\_\%UQ_\11_PF^A?\]KS_P77'_Q% '0T5SW_";Z%_SVO/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWB$4<$\BLBJ!@#A0> /6MJ@ HHHH **** "BBB@ HHHH **** "BBB@#GO\
MFHO_ '"?_:M=#7/?\U%_[A/_ +5KH: "N>\(?\>6I_\ 86O/_1S5T-<]X0_X
M\M3_ .PM>?\ HYJ +-]J]W#=7$-CIZW0M(A+.6FV'G)"(-IW-@9P2HY7GGB2
MZU9L6*Z=#'<RWJF2(R2F--@ )8MM)[C  [^@)JK=-?:=J.H26UA+=B\C1H2A
M4!90I4J^2,+@*<\_Q>V:U_HWE6.BVL]K+?V-C'LDCAX?S @5),9!( WC /\
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MCSA*T04[@.K+Q[$9Q0!ZG17F \07YU@Z:-9\5&:(PK=%;"Q;[*TH!4.JJ6.
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MO_\ &: .AHKGO^$8O/\ H;=>_.W_ /C-'_",7G_0VZ]^=O\ _&: .AHKGO\
MA&+S_H;=>_.W_P#C-'_",7G_ $-NO?G;_P#QF@#H:*Y[_A&+S_H;=>_.W_\
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M)#M!!PMND3$^Y*%OQJ]_PC%Y_P!#;KWYV_\ \9H_X1B\_P"AMU[\[?\ ^,T
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MVU\':/HL^II/<6.JIJ$MR4(\W$YE(QV)SCZUL_\ ",7G_0VZ]^=O_P#&:/\
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M8U>TDDMM5AOE@MX"L4:(C*44DEB6+9))QZ 5H_\ ",7G_0VZ]^=O_P#&:/\
MA&+S_H;=>_.W_P#C- &/JG@.YU*WURS.HK%:ZSJ<5U<;%^<0*B!HP>FXF,<]
M,$U _P .[J/1M?TF#5WEM=3N8+N-KH;I(Y5=6E+$  AM@[#!S6__ ,(Q>?\
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M&+S_ *&W7OSM_P#XS1_PC%Y_T-NO?G;_ /QF@#H:*Y[_ (1B\_Z&W7OSM_\
MXS1_PC%Y_P!#;KWYV_\ \9H Z&BN>_X1B\_Z&W7OSM__ (S1_P (Q>?]#;KW
MYV__ ,9H Z&BN>_X1B\_Z&W7OSM__C-'_",7G_0VZ]^=O_\ &: .AHKGO^$8
MO/\ H;=>_.W_ /C-'_",7G_0VZ]^=O\ _&: .AHKGO\ A&+S_H;=>_.W_P#C
M-'_",7G_ $-NO?G;_P#QF@#H:*Y[_A&+S_H;=>_.W_\ C-'_  C%Y_T-NO?G
M;_\ QF@#H:*J:=926%KY,M_=7S;BWFW6S?\ 3Y%48_"K= !1110 4444 %%%
M% !1110 4444 %%%% &)JEI;W_B#3;>[A2:'[/</Y;C*[@8@#CUY/YU6U;1-
M+L;:WN+2P@@F6]M0LD: $9GC!Y]P2/QK5O\ 3#>W$%Q'>W-I-"KHKP!#E6VY
M!#JP_A%5GT.:8Q"YUO4)XTECE\MU@ 8HP=<E8P<94="* ,R_@U'_ (3:QLX]
M?U&*UN;6XN6A1(,*8WA"J"8R<8D;.23TYK+M?'-_IVDI/JMBLWFQSR6\D4I+
MRE)UB"L@3Y<F1,$;N >,\5W#VEN][%>-$#<11O$DG=58J6'XE%_*JDGA_29;
M=8)+&)XDCDB5&!("R$,X_$J#^% %/2?$4E]IE_=W=B]HUD6W;]Z)(H0-N5I4
M0XYP20,$'MS7/GQKJ=_/#;6=C#%=+=6V5\Y_+FCE67C<\2D8,1Y52#V)Y%==
M;Z)IUK8W-G';!H+K=]H$K-(9LKM.]F)+?* .3T %5/\ A$-#VN#9%F<QDR-/
M(7S'NV'>6W97>V#GC- &0?&]T\-XT.DQO)IL$D]^C76T($DDC(C.SYR?)<C.
MWMG&>%N_'L5I#<$Z?(\UMYQFB5\E54IY9Z=7\V(@8X#-UV\[$GA30Y8887T]
M/+B4H%#,-ZD[F5\'YP3DD-D$DD]:M2Z+ID\M[++8PN][$L-R67/FHN< _3)H
M I:'K\VJ6MZ]QI\EK+:MC!60)(-NX%3(B,>X/R]1WK*LO&US,EFUWI,<!O([
M.:$1W1D^2XDV?-E!AER#@9!]:Z2QTBQTV&:*UA*B9MTK.[.SG 'S,Q)/  Y/
M %02^'=)FMEMWLD\M(8X$ 9@52,[D (.1M(!!'((H Y_4/'5S:MJ!M](29+"
M.YFG+W6PF.%]K;1L.6/4 X'O1-XDUR76[:P@L+6.ZCNY()X3=DQ2+]G$JGS/
M+W#&X<!>H]*WHO#&BPVTUNEA&(IXI(902QWHYRX))R<GDGK3KSPYI5_,TUQ:
M9F:3S?,21D</L"9#*00=H"\=J .;A^(9NKB%;;1[F6/;!]HVK([1M(>0NV,J
M=O4DLN1TI'\>WRB +HBL]S]H>%4FED)CA<(2VR%BI+$8'(QU(/!Z-O#&BM+!
M)_9\:F!8T14)5-L9R@*@[6VGD9!QVI;CPWI%U;0P268$<._R]DC(5#G+C<I!
MPQZC.#0!@2^*]1OY+1["R-M9_P!H6MM/).^V8&14=E,97@8D52=P.<\<9K2U
MGQ-+I&MVMDUDOV:41[KN61D3+.5V@A"NX8!PS+G( SSBX?#.C&\BN_L,:RQ,
MC($)50R#"-M!VY   .,XXZ5+>:%INH7B7=U:B290HSO8!PK;E# '# $D@,#@
MDT <MJ/C2^.CBYBM$M8[V%Y;&=9O,<A74?.A4!25;(P6]#@U<L/%-[=/+;VE
MB+EK8RRW+W%TL96/[1-$H3"88XA<X.W  !8DYK77PMHJO,PL$/FAE8%F*J&8
M,P4$X0%@"0N,D<T3>&-&G*&2Q0["QP&8!MSEV# 'Y@6);#9&3TH YFS\8:@D
M^H22QPR6<%M$T7GW 5S(]U-%R5CZ?(. "?E  8M5>\\<ZE+ TT5HMO%#;7YN
M%60K('A$95D\R+_;'WE'7H<#/6R^%M%FR6L5!VA<I(RG D,@.01R')8'J"3C
M&::WA+0FA\IM/4H3(QR[98R*%?)SD[@!G/4C/7F@#+O?&DUE'/>-IB-IZW%Q
M:QR"X_>-+"LA.4VX"DQ. =Q/0XP>-/1-;NM2O+FTO;&.UFB@AN5$4YE#1R[]
MN257# QMD<CIS4LGAK1YKN:YDL4:2;?O!9MN67:S!<[0Q4D%@,D$\U>AL;:W
MN'N(H565XDA9AU*)NVC\-S?G0!R6F>-)Y'T>">S98;R&$BZN92"[29X!6,1E
M@<<$J3GA>F;OB+Q>VA:@+=;..X1%B>8B5MZJ[E<A51@,8SERH/0'KC1C\+Z+
M%-!+'8JI@"!%5V"_)]PE<X8KV)!([4^_\.:3J=RUQ>6@ED=51_WC!7"DE=R@
MX8@DD$C([4 8#^,]4,KB#1+9XR;T1,]\5+"VDV,6 C.-W;&??%.M?'9OM6CM
M[?2;A[4S10/,$D+*SHKYXC*;1O4$EP>IQC&>B&BZ<N,6B#'G8Z_\MFW2?]]'
MDU"GAK1X[R*[2R598MI7#-MRJ[58KG:6"@ ,1D #F@#G;3QW>W%MI[2:-#'-
MJ=O!<62"\+ B4@8D/EC9@$'@-GZU6C\<ZE9B6VN---W?B:Z=HXC(RI'')M55
M,<3%B>Q8+TY(-=8_AO2)+6&V:Q3RH8$MX@"08XT(*A2#D8*@@CD$=:@;PCH3
M6R6YL (T,A^65PS;SEPS Y8,1D@D@]Z ,E_%&H7VH:>;*T$&GMJ2VLLDLF)F
M_=%RIC*_*,X&=V<CIBK.O^+VT35%M5LX[B-?)\XB5MZ"1]F=JHP '7+LH/05
MJ'PYI']HI?BR07$;B12K,%#A=H;:#MW;?ESC...E%[X<TG4;MKF[M!)*P0/^
M\8*^PY4LH."5/()&1VH HZ-XFEU/6[K3;BR6T>(2,BO(WF,JOMW;6100<@Y1
MF'.">F<VZ\>M83ZC'=Z88S;;Q#&7<2S$2K&I"F/!5BP.4+X!Y&>*Z.RT+3-/
MO'N[6U$<S!AG>Q"!FW,%!.%!(!(4#) J$^%M%:2X=K!'\\.'5V9E&\[GVJ3A
M2Q )*@9/- &):>*M4U#5]+METX6J/=2PW/F^8H=1#O5H]\:DCDYR!RN.0<TE
MUKVK6GC&\MA&DT)-O:V=N9PB&1U=V=SY9(^6-NA/0#'.1OP>'-*MS"8[4AXI
M_M"R-*[.9-NW<6)W-\O')/  [5+=Z)IU\9C<6RLTQ1G<,5;*?=((.5(R<$8-
M '*7_C;5&L=02PTNW2[L[.YFG>6Z.R)HF9/EPAWY(!&=O'7!J:R\3:Q#JMTE
M[:P2V8OK6U+K/\T+2PQ'"KL&\;WR22#\W3C%=%#X?TJ"!H8[*,1O"T#@Y.]&
M)9@<]<DDDGDDFEAT+3((?*CM1L\V.;YF9B7C"A&))R2 B_E0!DZIXBN=/\02
MV-O;&YD=;1(TDG$<8:5IQNR$+#_5<]>V ,'++_Q!=R^ M0U:%!:7L!FB(5A(
M$DBE:)L$@9&4.,@<'I6]+I5C/>B\EMD:X'ED2'.?DW;/RWO_ -]4C:38/I\U
M@ULAM9G=Y(N<,SN78_BS$_C0!R1\::C:3RVTUA'<7,E[=) (VE*B&$J"6V1,
MP.74=".3R.E3CQM?SLC6VA@1-);1$75R8I$>= R@IL.-I8!N<^@/2MR?PSI%
MR\CR6A#R2F8O'*Z,'888@J01D=0, ]\U/'H6EPH$BLHD17B=548 ,8 3 [8
M 'TH ATS4[K5]">ZB@A@O \T'ENY>-9(Y&C/( )7*D] <>E<7J_C2^TSX?*[
MZE;IK<T%VZ7,JJBCRBW*J>"Q(557GDYY ->B6MI!9PF*WC$<9D>0J/[SL68_
MBS$_C4)TJQ.ERZ8;=/L4J/&\/.&5\[A^.3^= %BWGBN;:*>&19(I$#HZ'(8$
M9!!]*RO%0NE\.7US9ZA<64UK!).KP+&=Q5"0#O5AC/I@^]:B6\4<\DR*1)(%
M#G)YQTX[=:6X@BNK:6WG0/#*A1T/1E(P1^5 '$2ZOK>BRV9CG?5HSI4]_.MY
M*D)^4Q?=*1>A; ([G)X%7;7QN;W7%LX-*N'M#<+;&X"2$JQ0-N.(]FT$@$[\
M]\8KHI-*L9L>9;(V+=K49S_JFQN7Z':/RJNGAW24OTOELU$Z$,"&;;N"[0VW
M.TL%XW8SCO0!C7_B+4M-\2:@GV:.XTV 60;=-L>,RR,A*@*=W8D$CIQ4,GCJ
M:"SBOIM+06EU%)+9LMSEW",!\Z[?D)!R,%NF#BNGGTJQN7G>:V1VG\OS"<_-
MY;;D_(\U3'A;1 ;@G3XV%PCQNK,Q4*YRX52<(&/)VXR1F@"E<^*+D:Z=)L].
MCFF%Y]FWRW)C4 0),6.$)Z-@#U Y&>&>)O%[>'KDQK9QW*QPK/,!*V]4+$<*
MJ-CH3ERJ]L]<:MEX>TK3Y5EMK0+*)#+YC.SN7*A"Q9B23M '/I2:CX<TG5IW
MFOK02N\8B?YV4.@)*A@" V"21G."<C% &#<^.9;%;BZNM+5;".2\B22.XW2,
MUN')^0J  PC;'S<'\ZT-&U/5)M<U>#588;=;:"WD2*&7S5&[S-QW;5)^Z!@C
MMQUK3;1--= CV<3())9=K#(W2;A(2#UW;VS]:33=$T_2&F:R@,;S!1([2,[,
M%SM!+$G@$@>W% '*+XRU(3P7TUI;PV5SIJW-M"UUG>7EC52YV95@'^ZN[.<#
M)J,^/KL2)=RV*165M;7\EY$'?>3!Y9&P-&IY#]"%ZGT&>C'@_05#[=/"[@%!
M$K@Q@,'4(<_( P! 7&#TJ1/"VB1JH%@A :1CN9CN,BA9-V3\VX 9!SDC/7F@
M"+P_X@N-8:[CN=-EM9+<(P.V0)(&SPIDC0D@J<\8Y'/-8]IXYO+M$C&D11WT
MDT,0M9;EXVC\P.<N&B!&-AY 93V)Q73:=HVGZ4LJVD&WS<"1G=I&8 8 )8DX
M Z#H*RKGP1H\L5O%#"T"13QR'$CD[4#;44[LHH+$@+@#L* ,F?XARQR201Z+
M-/<VJ.]W%"9),;99(]L92,AB3$Y&[8.G3G%N_P#%5Y_9FH7L-B$L(7G@2X2Z
M59M\3%6.QD( +*P'+'@$C!XUI/"FARQ11/IZ;(E*!0[#>I;<5?!^<%B20V<D
MDGK3I?#&C3W$T\MBCO-NW@LVW+##$+G 8@<D $]S0!R*>+M1TN_U&YU/S9XP
M]V(+:&160>7-!$BX$0;),O7)[\'C&O:^,+^]GCLH=%VW[O)A9Y)(8FC148LK
M/$&/+JN-@YSS@9.Y+X?TF?S/-L8G\Q95<,"<B4JS_F44_@*A_P"$6T8V_DFT
M)'FF4R&9_,+E=I)DW;CE0%Y/08Z4 8$NK:U<> /#=U;SA;[4#9+<3[E1AYFW
M<1\C+DGCIQDXITWCNXM["&^;2$:"\B:6QVW7SR .JXD&S"$AP>"W0@XKJ4TJ
MQCL;2R2V1;:T\OR(QG$>S&S'TP*J+X6T5))7%@F9,Y!9BJ@L'(4$X0%@"0N,
MD#- $6I:OJ5A'I,*Z=;2W]_.8#']J*Q1D1O(3OV9(PA'W1U[5A1?$1I4DG&C
M7!MF#_9I ) '82!%#LT81=Q8$%6; SFNSFM(+B:WFEC#26[F2)C_  ,5*DC_
M ("S#\:S1X6T023N=/C;SU='5BS* YRX52<+N(!.T#)YH QM2\9:AIERMC+H
MJR7^R25D@FDE38NS&"D1;)+XPRJ.#SC&4M_%E]=:K-96&FM/+([NJWEP(?*5
M8+9]N!&2,F?&#D@YYQP-A_"6B20B-[(GEB7\Z3S'W !@S[MS A5!!)!"@=A4
M%YX.TJ]U."[:'RTC64/%$63>SK$F<J01A(57'0@T 1>%_$5SKUQ?W+1HFG^5
M;S6OS9<+)"LA##'7YO4UC:IXRU6;04DM;**TEU&S%W8S"YW$1&2)3O!C(5\3
M(0/F'7GCGL[;2[*RN9+BVMUADDC2-MA(4J@PHV].!QTZ<54A\+:+ )!'8(%D
M 4J68A5#!MJ@GY%W ':N!D=* *>I37[:KH^AQW\MI]HMYII[J,(TCF+RQL4L
MNW),A).WHIP!VYV^UKQ%!?#2K6[2X-KJ3PM=2,L;S(+3SU1L1LN03@E0,A1T
MW$CN=1TJRU6)([V 2"-M\;!BKQMC&592"IP2,@]ZBAT'2[>""&*RC5('>1.N
M=[*59B>I)#-DG).: ..T#QM?BWL+.ZLKF^F MEN[E0[MOF57R-D(3:JR*3DJ
M0,]<9-J3QW?PZ=::A/HL,5I<K)(LK73E$12!\["(A&.6(W$+@<L#P.B_X1G1
MOM$$XL4#P",( S!?W?\ JRRYPQ7L2"1VI+CPQHUU;P02V2F*"-HD5791L;ED
M."-RG RIR#Z4 :X((!!R#WHH    & ** "BBB@ HHHH **** "BBB@ HHHH
M*YVTTC3M0U/69;RRAGD6\"AI$#$#R8N/IR:Z*LE]%E%W=7%OK%_;"YD$CQQK
M"5#;57C=&3T4=Z ,C4([;P_-JUQ80"W6+2))RL&$)9=Q!&01GW(/T-3V/BF:
MX\1C29[(6Z-E89)78--A V5^0(W\7"L2,9('.-"/08VDN6OKVYOQ<0&V=;@1
M@>6<Y'R(O7/>I(= TN#4?M\5HJW.2P;<<!B-I8+G 8C@L!DCO0!C/XQF/B.7
M38-)GEMXKI;1YUCE.'*AMV1&4"@L <N#U..F:,?C34-46 V%C!#Y>J1:?=>9
M<AOGP?,5<*<J/EPW&<G@=^GE\/Z5/J)OY+-3<E@Q<,P!8+M#$ XW <!L9 [T
MS_A&M&"(BZ?$BHL2J$RN!$28^A[9.#[F@#F(?B)<3VANH]"G,$L8DMG82HK
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M;2(([F^@MIK.-;LLI$Q( D;8-I7&3@-GH*Z:PT73],BECM+?8)0 Y9V<L ,
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M4!9QKI9^UA$6?,DQB.Q=P*_)EAG()P.M=+)X8T662-WT^(F/IU ;YR^&&<,
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M5;$G1=W+8&2!F*7Q]?*PN7LDBMK)[H7J9<,ZQ6ZS H'C5AD/T('(ZD<UT_\
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M9%GM &5BH)&R8]AC<?3-7I/'%S!:0W\NEQ_8;E))H&6Y)<1QL-[.NS"G9N;
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MYRALM\^PIN.>IVDCGUH YX^+]0BNK6PGTJV6_OEB>U5+LM'A]Q.]M@*E0AZ
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M;5'2!MT0'R^6<$?*1C'!(^AQ44.@:3;PF&'3[>.(K&FQ4P-J.708] S,1]:
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MM(UM&7>1)68CDNF-I^HP,4 <9:_$.\N[&*ZCT1]EU'#):F3S8UQ)-%&%=VC
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MY+7"@1D<#:05QZ$$ @]L50F\):!<6\<$VE6[QHKJ%9<Y#G+!O[V3R<YYYZT
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MW1,@EN+NX:YN)1&$WN0!T'3"JH_#/>M.@ HHHH **** "BBB@ HHHH ****
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M9B$37,C)&A8,512V$&0.F.@'08H QXO'UM#<O92PR3-;F2"242(7:6)"SDH
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M88R5R#@C ).*R;[QO*=.BG@LGMTO%66QG=E82H)45LJ/NDJ^1UXZX/%=#?\
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MKY-*L9H;^*2V1H]0S]J4Y_>Y01G/_ 5 _"J<OA;1YKZ2\:U<3RN'=DGD0,P
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M9]^L-:-921Q>4T9O#  N$#A@N"#N/(YZTEGXIN-2\77-A_:$T-A>O-:6;1P
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M>@KLM0TG3M55%U"QMKM8R2@GB#[<]<9IG]AZ3]MCO?[-M/M4:A4F\E=R@#
M..P)'T- ')6?C"^NY+.*]MT@N3<1%H%$D957BF;G.5D7,> RL0>>!CFO_P )
MYK26D,KZ9 [G38M4D2%9&'ER;ML>[HK#8V6/'(XZFNSM= T>R&+72[.$;P_[
MN!5^8 @'@=@S#Z$^M+/H.D7(MA/IEG*+50L >%3Y2C& O' X''L* ,7Q3KM[
MHE_:7,15[**RO+JX@V_-+Y2*P /8\G\ZO:5JU[)J5YIVHQVQF@MH;H26A8J5
MD+C;@\Y!C//<$<"M2XL+2\DADN;6&9X26B:1 Q0D8.,],@XJ/3]*T_2HWCT^
MQM[1'.66",(">@SCVXH XZ;Q%KE[8Z)<POIT+:E+;SP1),VY8W#$K(/X@!MY
M& 3QQUIFH>/;^RTJ:Y6VMGN+..YDNHD25]PAE>/((&(U;RV(+$^F#@FNPM]"
MTBTE:6WTRSBD9Q(62%02PS@].HR?S/K3+GP[HEX<W.D6,WW_ /66ZM]]BS=1
MW8DGW.: .>N_&-_82SW,UE;OI\=W<VH2-F\YC%!)-N].?+*X]P<]JANO&6K6
M%P;.>ULYKF5;1H&M=\BCSO.SN7J<"$XQC=D=,\=?)IEF\106\<9WM(KH@#)(
MRE2X..&PQ&?<UBZ3X(TG38[Q)88;L7:QI(KVT2(5C+%?D10,Y8G.,YQTP  !
MT/B2<^$9]6N+>."XA=XBDF[:SB38. "W)Q\N"<G'6LNR\6ZQJ%Y_9T-K:)=B
M[DMVEGCDC7"P1RAO+/S GS,8)]_:NL&E:>-,_LT6-N+$KM^S>4/+QG.-O3KS
M3+31M+L&#6FG6L#*Q<&*)5.X@ G@=2 !GVH R!XDN;GP[H%];6\276LF%4$K
M$QPEXFD).,$X"D <9)'2N0UO7-?U&:5[>\2S^RP2Q.L+N%:07(@9P01GCIG.
MW)[C->DRZ7I\VG+I\ME;O9(JJMNT8**%^Z O08P,>F*:FCZ9'"L*:?:K$B"-
M4$*@!<[MH&.F><>M '%#QSJ%I:W<@T[?;6R7D4;/YF2]LK_,SM][<8CP.1D9
M)YQTM_JU]IGAZ*ZNA:"^DD2,(BR.F7; "JH+.0#T &2.PY%QM!TA[J>Y;2[-
MI[A&2:0P*6D5AA@QQSD8!]:LWEC::A:FVO+:*> D'RY$#+D'(.#Z&@#@%\::
MM-<Q2QPQ"?YK0P2%DC,AO(H Y')7 <G')'(K1C\9WZ:M)!/91BU@N3:32A74
M!UCW,^\_*%S_  ]=OS9[5TT.A:1;JJPZ99QJA#*$@4 $,&!'']Y5/U -.;1=
M+?4#J#Z=:M>$8,YA4N>-O7&>G'TXH Y"U\<ZE//]D-I;BXG%L;>1HY8HU\YG
M'(<!F V<'"[B0,"FV?BW4]/MYHKZ.&XN9[FZAM&5R5:X6X\M8O9<.I'<!6]*
MZJ/PSH4,$L$6CV"12J%D1;=0& .0#QR >GI3/^$;L%NM.>&-(+6PD::&TAB1
M8_-*LN_@9SAV_$YZB@"CXI\17NA2P&&WB:W$+S7$SJ[B,*5^\$RRJ022^U@,
M<BL_6?%MR-"N&@5(Y9)=0MD=&^9/(CF97'OF-?SKJ;[2--U1HFO["VNFBSL,
MT0?;G&<9]<#\A4;>']&>[ENWTJR:XFR))3 I9\KM.3CG*D@^HH YH>)]9@NK
M;2GAL)+V8VQ6978QJDJ3'GN64PGT# CI58^,-4DL[=KNVMXQ<Q^9']FE8%2E
MU%"P)/4'S,CT&0<]:["UT32K%0MIIMI !)YH$<*KA\;0W ZX)&?3BGG2=.*H
MIL+8K&"$'E+\H+!R!QQ\RJWU /:@#@$\6Z]IRK=W<L%W$L-^QA2,J79+M(8^
M1G &X=NF>IYK8M/%6KW=XFF+9V\-\99!YMPKQQLBQH_W#\RL2X&">@+<]*Z(
M^']&9V9M*LBS-*Q)@7DR<2'I_%@9]>]-_P"$<T3[$+(Z18FU$GFB(P+MWXQN
MQCKCC/IQ0!!X1NI[WP;HMU=2F6XFL89))"<EF* DY[\U3UWQ)=Z3K4%NL$0L
M=L337#J[A2[E<-LR8^!D,PVD\9&":VGTNR>UM;86\:06KH\,:*%5"GW< = /
M:DNM(TV^NH;J[L+:>XAQY<LD09EP<C!/H>?K0!S%SXWFM[&SG%I"TES%<L%,
MA 5HYXX5R>RYDR3VQ4.H:UX@MM<6*.739)+6QO)9XTD<QML^SLN5ZH^'(P2<
M!L\YQ74+X>T5)KB9=)L1+<!UF<6ZYD#<L&XY!/)]:DM]%TNTC\NWTZUB38Z8
M2)1\KX+#IT.U<^N!Z4 9][K5TT>C1V$4*W&J<JUQDI&!&7/ P6/&,9'<]L5A
M6/B35UU*[N)3936!O[2V98YC)L,L,0/EM@ J&;/(YR>G?L+K2]/OK-+2[LK>
M>V3!2*2,,JX&!@'I@4)I>GQQ^6EC;*F]'VK$H&Y  AQCJH50/3 ]* .*3Q]J
M#9V6EM+YT,4]JP66-"'GCBQN8 NN) 0X !QT-7/^$JU<WEQIJP6 O;3[0\LK
MLRQ.D2Q-A1U!(F7)).W!/.:Z&#PYHEJQ:#2+&(G'*6ZCHP8#IT#*I^H%4]>\
M)V6NJH<K!\SL^VWB?>S *7^=3AP% #?SH P[#QU?7][;A--'V8RVT$Q"M]Z:
M.-RP?[H"^:/E/) /L#H>(_$FIZ5?W45E:VDL5I:174GG.RL^^1DVC X^[G//
MTYXV(/#VD6\MK,FG6QN+6-8H9FC!D55&U?FZ\#C\35N:QM+AI&FM89&D01N7
M0$LH)(!]0"2<>] ''WGC#4[7[3:&*S:_M99E<1Q2R!U2.)]P5?NC]ZH+,P (
M[YP+FF^+Y]0U"SL/LB)<W0BN%7<3MM7AWF3\'!C^N#6Y=:%I%[)YEUIEG.^\
MN6DA5B6( )Y'<*H_X"/2H[30[:SU>34$/S?9TM8(@BJEO$O.Q<#."<'G/08Q
MB@#!O=<U/3O$6K.I@FT^WDLXVA=CY@\TA#L[#D@\YW=..M/\-^+KS6]1A273
MS%:744LL+[&4H$8  D\/D')*_=(QSG-=#+HNESZ@FH2Z=:O>H05N&A4N".GS
M8SQVI;;1]-LKR6\M;"VAN9L^9+'$JLV3DY('<\GWH YMO$FN3:J+6UM]/6*6
M^GLHFE9R5,:%][ =00I&T8['/:J=MX^NKIM,GCM83;W+6D<R(DC&-YT1L&3
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M881;PB\F/V3F1O)61;F6)GQUQ^Z) ZG(&>]=9::%I%@H%IIEG  XD CA5<,
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MK5ON\G6]/BW/YC;-'1<O_>.'Z^]!\-:T9Y9SK>GF:9-DLG]D)N=?1COY'L:
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M/Q':HN2<+I:@9)R?X_6@#I**Y[^RO$__ $,]O_X+!_\ %T?V5XG_ .AGM_\
MP6#_ .+H Z&BN>_LKQ/_ -#/;_\ @L'_ ,71_97B?_H9[?\ \%@_^+H Z&BN
M>_LKQ/\ ]#/;_P#@L'_Q=']E>)_^AGM__!8/_BZ .AHKGO[*\3_]#/;_ /@L
M'_Q=']E>)_\ H9[?_P %@_\ BZ .AHKGO[*\3_\ 0SV__@L'_P 71_97B?\
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M2R;3IDM9K)3'"7C,B>60 4*Y!(X4\$<J/<$ 71)YY;2:*YE,TMM<20&4@ N
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MI-7M)KU+V7P;JKW:?<G:QB+K]&W9'4TMYK%KJ*HM]X.U6Z5#E1/91.%/MEJ
M-?PV8SX9TSRE98Q;1A0S!N H'4  CW 'T%:E<Z/%,@  \-:Z .@%LG_Q=+_P
ME4G_ $+>O?\ @.G_ ,70!T-%<]_PE4G_ $+>O?\ @.G_ ,71_P )5)_T+>O?
M^ Z?_%T =#17/?\ "52?]"WKW_@.G_Q='_"52?\ 0MZ]_P" Z?\ Q= '0T5S
MW_"52?\ 0MZ]_P" Z?\ Q='_  E4G_0MZ]_X#I_\70!T-%<]_P )5)_T+>O?
M^ Z?_%T?\)5)_P!"WKW_ (#I_P#%T =#17/?\)5)_P!"WKW_ (#I_P#%T?\
M"52?]"WKW_@.G_Q= '0T5SW_  E4G_0MZ]_X#I_\71_PE4G_ $+>O?\ @.G_
M ,70!T-%<]_PE4G_ $+>O?\ @.G_ ,71_P )5)_T+>O?^ Z?_%T =#17/?\
M"52?]"WKW_@.G_Q='_"52?\ 0MZ]_P" Z?\ Q= '0T5SW_"52?\ 0MZ]_P"
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M_P )5)_T+>O?^ Z?_%T =#17/?\ "52?]"WKW_@.G_Q='_"52?\ 0MZ]_P"
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M]"WKW_@.G_Q='_"52?\ 0MZ]_P" Z?\ Q= '0T5SW_"52?\ 0MZ]_P" Z?\
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M5)_T+>O?^ Z?_%T =#17/?\ "52?]"WKW_@.G_Q='_"52?\ 0MZ]_P" Z?\
MQ= '0T5SW_"52?\ 0MZ]_P" Z?\ Q='_  E4G_0MZ]_X#I_\70!T-%<]_P )
M5)_T+>O?^ Z?_%T?\)5)_P!"WKW_ (#I_P#%T =#17/?\)5)_P!"WKW_ (#I
M_P#%T?\ "52?]"WKW_@.G_Q= '0T54TZ^;4+7SVL[JT.XKY=T@5_K@$\5;H
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M.,.LB [DXY0CL#4=WX)UV]LO/N+ZWGUBT.GM;S2D[)VMLNV_ R SO)TYX!H
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M$LT$UE*DP\UML9$97<0QZ$"I;7QUH-TP19[B*8W45F8)[66*199 2@*LH(!
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M_P!!S3/_  +C_P :/^$GT#_H.:9_X%Q_XT :M%97_"3Z!_T'-,_\"X_\:/\
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M _Z#FF?^!<?^-'_"3Z!_T'-,_P# N/\ QH U:*RO^$GT#_H.:9_X%Q_XT?\
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M7<"W$<-A(I<XB;=_K6[2$;0.PY[5+J/CB1;^6'3X)!''# Y^V64T#;GN$B.
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M*6YZ4EIXLEBLX Z#69IUGFAETU50-#$5#%Q(PV,"^TKD\CMT !T/]D:9_P!
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MPJY10!3_ +(TS_H'6G_?A?\ "C^R-,_Z!UI_WX7_  JY10!3_LC3/^@=:?\
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M*-OIP*;J_ARRUIG>Z:96>V>US&V,(S*QQQURBUKT4 9^G:9)8-(SZG?7F\
M7+(0OTVJ*HCPE9"Y#"YO/L@N?M8L/-'D>;NW[L8W??\ FVYVYYQ6]10!@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BJNH/?I:$Z;#;37.1A+F5HTQWY56/Z5D?:/&7_0+T'_ ,&,W_QB@#H:*Y[[
M1XR_Z!>@_P#@QF_^,4?:/&7_ $"]!_\ !C-_\8H Z&BN>^T>,O\ H%Z#_P"#
M&;_XQ1]H\9?] O0?_!C-_P#&* .AHKGOM'C+_H%Z#_X,9O\ XQ1]H\9?] O0
M?_!C-_\ &* +7BO_ )$[7/\ L'S_ /HMJO:;_P @NT_ZXI_Z"*Y+Q-<>+3X4
MU@3:;HBQ&QFWLFH2E@NPY(!A&3CW%7+"X\8?V=:[-,T,KY*8)U&8'&!_TPH
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M4?:/&7_0+T'_ ,&,W_QB@#H:*Y[[1XR_Z!>@_P#@QF_^,4?:/&7_ $"]!_\
M!C-_\8H Z&BN>^T>,O\ H%Z#_P"#&;_XQ1]H\9?] O0?_!C-_P#&* .AHKGO
MM'C+_H%Z#_X,9O\ XQ1]H\9?] O0?_!C-_\ &* .AHKGOM'C+_H%Z#_X,9O_
M (Q1]H\9?] O0?\ P8S?_&* .AHKGOM'C+_H%Z#_ .#&;_XQ1]H\9?\ 0+T'
M_P &,W_QB@#H:*Y[[1XR_P"@7H/_ (,9O_C%'VCQE_T"]!_\&,W_ ,8H Z&B
MN>^T>,O^@7H/_@QF_P#C%'VCQE_T"]!_\&,W_P 8H Z&BN>^T>,O^@7H/_@Q
MF_\ C%'VCQE_T"]!_P#!C-_\8H Z&BN>^T>,O^@7H/\ X,9O_C%'VCQE_P!
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MBN>^T>,O^@7H/_@QF_\ C%'VCQE_T"]!_P#!C-_\8H Z&BN>^T>,O^@7H/\
MX,9O_C%'VCQE_P! O0?_  8S?_&* .AHKGOM'C+_ *!>@_\ @QF_^,4?:/&7
M_0+T'_P8S?\ QB@#H:*Y[[1XR_Z!>@_^#&;_ .,4?:/&7_0+T'_P8S?_ !B@
M#H:*Y[[1XR_Z!>@_^#&;_P",4?:/&7_0+T'_ ,&,W_QB@#H:*Y[[1XR_Z!>@
M_P#@QF_^,4?:/&7_ $"]!_\ !C-_\8H Z&BN>^T>,O\ H%Z#_P"#&;_XQ1]H
M\9?] O0?_!C-_P#&* .AHKGOM'C+_H%Z#_X,9O\ XQ1]H\9?] O0?_!C-_\
M&* .AHKGOM'C+_H%Z#_X,9O_ (Q1]H\9?] O0?\ P8S?_&* .AHKGOM'C+_H
M%Z#_ .#&;_XQ1]H\9?\ 0+T'_P &,W_QB@#H:*Y[[1XR_P"@7H/_ (,9O_C%
M'VCQE_T"]!_\&,W_ ,8H Z&BN>^T>,O^@7H/_@QF_P#C%'VCQE_T"]!_\&,W
M_P 8H Z&BJFG/J+VN=4@M8;C<?EMIFE3;VY95.>O:K= !1110 4444 %%%%
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M;8O01<*K(RQN0 S;5WD#"98%1NQR".HJ?4M>TS2)$COKH1,ZE\!&;:H(!9L
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M'C\*Y:SL-4AU6VAMM/OX(4NI9)[:Y\J:UB#!_P!Y#(?G#$MP > Q!4"N_HH
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M;D!L8*!AR.<C'3COJ:B)'&L<:JB*,*JC  ] * ,#PY*XN]558I#:SZC.\$@
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MG_@!%0!T-%<]_8WB+_H:Y/\ P BH_L;Q%_T-<G_@!%0!:\5_\B=KG_8/G_\
M1;5>TW_D%VG_ %Q3_P!!%<EXFTC7D\*:P\GB=Y(UL9BR?88AN&PY&1TJY8:/
MX@.G6I7Q3(H,*8'V&(XX% '545P^HW6J:;=/;/XHOIYHXQ+,MKI"2^4ASAFV
MCC.#@=3@X%:4&G:Y<VL=S!XN:2&5!(CK81$,I&01]10!TU%>=#7;\?;C)XBU
M:);&)IKEI=#51$JH7Y)']T<>M:&J3:CHX)O/&$R8M)KPXTV,_NHMN\\#MO7C
MOF@#M:*X2:_U"#4'M&\57I$<R6\DZZ0AACE;;M1GQ@$[E]AD9(JQJ;:QI<T%
MO)XGO9[B=6=(;;2HY'*KC<V . -RC\10!V=%<;I[ZEJDPBL_&,LC&VCNA_Q+
M8U_=N6"GD<'*-D=1CFLO^W[IHQ+'XIU*:'[-'=O)#HBNL<3@E6;"G'"GCVH
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M-<G_ ( 14?V-XB_Z&N3_ , (J .AHKGO[&\1?]#7)_X 14?V-XB_Z&N3_P
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M[&\1?]#7)_X 14?V-XB_Z&N3_P  (J .AHKGO[&\1?\ 0UR?^ $5']C>(O\
MH:Y/_ "*@#H:*Y[^QO$7_0UR?^ $5']C>(O^AKD_\ (J .AHKGO[&\1?]#7)
M_P" $5']C>(O^AKD_P# "*@#H:*Y[^QO$7_0UR?^ $5']C>(O^AKD_\  "*@
M#H:*Y[^QO$7_ $-<G_@!%1_8WB+_ *&N3_P BH Z&BN>_L;Q%_T-<G_@!%1_
M8WB+_H:Y/_ "*@#H:*Y[^QO$7_0UR?\ @!%1_8WB+_H:Y/\ P BH Z&BN>_L
M;Q%_T-<G_@!%1_8WB+_H:Y/_   BH Z&BN>_L;Q%_P!#7)_X 14?V-XB_P"A
MKD_\ (J .AHJIIUM=VMKY=[?F]EW$^:8ECX],+Q5N@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH R/%?_(G:Y_V#Y_\ T6U7M-_Y
M!=I_UQ3_ -!%4?%?_(G:Y_V#Y_\ T6U7M-_Y!=I_UQ3_ -!% &)<6NL:9KFH
MWNF64%['J"1G$EQY1BD12O/!RA&T\<@@\'-;5D;T1K'>K$TB1INFB.%D?'S8
M7JHSTY/6K5% '*ZKX?O;RR\8Q1>7NU:T,-MEL?-Y!3YO3DUG:[X&DE6X_LKS
M"9M&O;)OM-Y++^\D\K9C>S8'R-DCVKNZ* .*U#0=7DUZ:YLK6.VGDN8Y%U"V
MO'B4QC;D30\K(VT%><Y&.5[:/B?2KG4+FSECTZ.]CB5QF.[>UN(F.W#)(I'R
MG'(R.@/.,5TE% '&V6F^)-(N8;XPPZI<RZ?':SAKG849'D93N*_,,28+8!^7
M..>*^C^ 3!F#4KF=K<:;:6;"UNI(EE,:N'W!2#@[AC/8FNZHH Y*V\%VTFHZ
MQ)?>?]CN;N.2&UBN72%HU@A0!T4@'YHSP<Y &:K/I6N'0M?T0:=#Y=^U^8KK
M[2,?OC(R97&>K &NVHH X9?#^H3:/<V(TV>W:18?GN-7ENE.R1&("N3MX!Y'
MTJA/X&U:2W>/= YACN+.T^<_+:^1,D(/'WLRX/L!7I%% '"1^'M1DT.ZT]=.
MGMY)(8U$EQJ\MRI*NIP%<D+P#R/I6CH_AJ[T?Q;<7$4D9T?[*R6L>?G@9I S
M1X_N @D>F['0"NJHH X:#P=J%UI7A_3+ZZ-M;:;IOE2_9]CF2=D\LC#JPVA-
MXSC)W^U.TC3O$FC:@LTEE%J!&GP6)E^U!&;R99MKG(ZLCH3[YKMZ* .1U_PG
M>>(]3O9I=1FLH5M!;6GD"-CDL'9VW*2/F6+&T@_)G-0#3/$4"7S"T2635##<
MS&WOC T$ZQ)&R[MIS'^[!!'/)XKM:* .!;P-J5[;WAOM4G%_)I]K MS#=2HD
MLT:L',B*0&5B><C."<8I(?#^IPZM<WKZ*^)Q;LD5IK$EO'$4B12FU" P!4X)
M'(Q]*[^B@#B;30=0L_$5[=MIT\R3WYN$ECU>6) I"]80=IQ@Y!'-95SX#U>7
M3-0L4:W$%Y;W4CQE_O7)\Y8B>.A65"3V,2UZ710!P]KH&H67B&^NVTZ>9)KX
M7$<L6KRQ(%VH/FA!VGE3G(.>]0/X*U&-;&:T>&.8ZF);^,M\LT"WAG1A_MJ.
M/HS#L*[^B@#)T[3I[;7]9O)-OE7;0F+!Y^5-IS^-8>J>';Z:]U.?[!:WMO<7
M\=P(6G:*4*MNL>Z.1>4<,#]03R,UV5% ')'0]7N/ &LZ3<2%KJ[@N8K9)K@R
MF)74A$:4C+8SU.>N,G&35_L"_GTZ6T739[<M-;2%KG5Y;L$1SH[ !R=ORJW3
MKP*[>B@#E-!\-7FB^(M1<21OI)M8X;%<_/"H=V,9_P!E2_R^V!VK/G\+ZBOA
MSPC:?9S/+I42)<QP7SVQ)$!C^61<'[Q_$5W=% '%?\(G<:E>VTES]OTZ**QF
MMU:#596F5VD5@?,W988!.&R!P,503PMJL,VFO)IHE%K9-:N+'4Y+0,WF9\S*
MD$[A\Q!)P2>O6O1** .12UU^QU>[O++2H)1=6-M"HN+X_NGC\S.YMI9A\XYZ
MG!JP?#<]MX7T'2+>193ILMGO=OEW+$R[B/P'2NFHH X"Q\%:C82>'9;>2%!#
M)&VIP[N'9$95D0_WL':?4;?[M:U[X;N[V/Q+&)(XSJ$\,ULS<C,<<8&X>FZ/
MGVKJ:* .=AM-6U/7["_U"SAL8K".3:B3^:TLC@+U &$ !Z\DD<#'-=/!\5WK
M&MW.I/</;WMXDT=O'=.L4B+!"GSH" ?F1N#G(QFNJHH XN70]9,5QHZVUN;*
M;51??;3/RL9N!.R[,9W9!4<XZ'/:H+;P7=68L+Q7DFN8-2FN)K.6[D:W>-YG
M8,J$[5=0RL, <@COD=W10!Q.GZ!J]OKD,J6L=@@GD>\EMKQS!=(0W2W/"N25
M)/&"#RW>&VT7Q)!I>B6*V=HCZ#"WD3FXRMS(MN\,?R[<J#OW'/3&!GK7>44
M>>3^!-2L+&2UT_4)+U+G3397 NMB893NC<;5&>6ESG)^?KQ6SI?AJ[TKQG)=
MPR1G1OLLH@BS\T,DDB,Z ?W,H6'H6(Z 5U5% &3X:T^?2O#]M97.WSHR^[:<
MCEV(_0UE3^'+Z;3M6C1H5N)=634;7>QV-Y;1.JO@9 )C(/7&<\UU=% '/V=I
MJ=]XD@U?4+2*R2UM9;>*%9O,9S(T;,Q(   \I0!WR<XP*R+3PKJUM?V>MF^=
M]0-\\]U:DIY0CEPKJ&";CM18\9;!,8KMZ* .+TC0]9AC\-Z;=VUO':Z$^[[4
ML^XW 6%X4PN,KD/N.>F,#/6IM0\-7EYI7B*T^3.HZC%<18D*_NPL .2.0?W;
M=/:NNHH XB_\$2?VE<7&FN0ODVSQ?:KJ64--#<><%)8L0IP!D=,YQ2:[H.L^
M)Q--<6L-D8[.2UAB%SN9VDDB9V+ #: (AC')R3Q@5W%% '#7W@Z[CGU-+)VN
M8+V*'RY;RZ>66!DD5C&&<D[&'S8SPP/J,=''I\Z>+KG4CM^SR6$-NO/.Y9)&
M/'IAQ6M10!@^'] 71]0UNX$,:"\O/,AVG.(MBG;[#S#,V!QER>]4I=/UO3VU
MBUT^TM;F'4IGFBGEGV>2SH%8.NTE@",C'4''&,GJZ* .0T'P7'I=W>2SR7,H
M5X!;!+R5$D2.WBC^>-6"$ED;J#QBNHLT\JQMX_L\=MMC5?(CQMCP/NC  P.G
M3M4]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTO%?_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\
MQJNAHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH Y[^TO%?
M_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\ QJNAHH Y[^TO%?\ T+=A_P"#4_\
MQJC^TO%?_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#
M4_\ QJNAHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH Y[^
MTO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\ QJNAHH Y[^TO%?\ T+=A_P"#
M4_\ QJC^TO%?_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A
M_P"#4_\ QJNAHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH
M Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\ QJNAHH Y[^TO%?\ T+=A
M_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\
MT+=A_P"#4_\ QJNAHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJ
MNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\ QJNAHH Y[^TO%?\
MT+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO
M%?\ T+=A_P"#4_\ QJNAHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U
M/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\ QJNAHH Y[^TO
M%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJ
MC^TO%?\ T+=A_P"#4_\ QJNAHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV
M'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\ QJNAHH Y
M[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U
M/_QJC^TO%?\ T+=A_P"#4_\ QJNAHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?
M_0MV'_@U/_QJNAHH Y[^TO%?_0MV'_@U/_QJC^TO%?\ T+=A_P"#4_\ QJNA
MHH Y[^TO%?\ T+=A_P"#4_\ QJC^TO%?_0MV'_@U/_QJNAHH J:=-?3VN_4;
M.*TGW$>7%/YPQV.[:OY8JW110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%,F:1()&AC$DH4E$+;0Q[#/:@!]%85MXA>\.FQP68:>YW&YB\W!M0O#
M;OEY(;Y<<9/3C)&[0 4444 9'BO_ )$[7/\ L'S_ /HMJO:;_P @NT_ZXI_Z
M"*H^*_\ D3M<_P"P?/\ ^BVJ]IO_ ""[3_KBG_H(H LT5DZCJEW::C#:6]E#
M,)())O,EN?+"A"H;/RG^^OZU#<:W?6NDWMW+I:B6TDVM%YYQ(NQ6!1MGS$E@
MN,=01F@#<HK(DUME\-3ZLEKF2WCD:6W:3&UHR0Z[L'H5;MSCWI]MJES]NBM+
M^R6W>=&>)HYO,5MN,@\ @\YZ8]Z -2BBL"_U^6VUUM-273(L11NOVNY,;2%R
MPPHQS]W]: -^F1PQ1%S'&B&1M[[1C<W3)]3P*JWTNH"2**P@A8N&9YIF(1,8
MP,#DDY]AP>>@)I5\=1T];AXQ&X>2)U5MP#(Y1L' R,J<' XQP* +(AB$[3B)
M!,RA&D"C<5!) )] 6/'N:DJ.>1HK>21(FE=%++&N,N0.@SQDUFVM_?IJ<-EJ
M$%LK3PO-&;>0MLVE05;(&?OCYN/H.,@&M4$5G:P7,]S#;0QSW!4S2H@#28&!
MN/4X' S5.WU"[?6YK&XM8HHA%YL4B3%V<;MO(V@+^9IFIWFIV8N;B.&R%E!%
MYC232L&P 2W 4\#% %^ZL[6^C6.[MH9T1Q(JRH& 8'(8 ]QZT]88DF>98D$L
M@"NX4;F S@$]\9/YFF6<LT]C;RW$/DSO&K219SL8C)7/?!XJ/4[W^S]/EN1'
MYCKM5$W;0SL0J@GL,D9/:@"W1698:A<MJ$VG7Z0+=1Q+.I@8E71B1T/((*X_
M$>X&G0 45B2:].(9KV'3FETR!F#S"7$C!20S)'CYE&#W!.. >,V9O$&D6\S0
MR:C;"90"8PX+8(R#M'.,<YH TJ*RM1\1:9IMI:W4MW"8;J1$B<2#:P8@;@>X
M&<U<BU&SGLVO(KJ)[902TJL"H Z\T 6:*I:5>G4+ 7/F6T@:20*]L^]"H=@O
M/K@#(['(I(-:TRYO/LD-] \^2 BN/F(Z@>I'<#I0!>HK-?Q!H\=TULVI6PF1
M_+=/,&4;T;^[U'6M*@ HK/UC6;31+2.XO)41'FCB&Y@.6<+GGTSGZ"I[;4;*
M\MGN;>ZAE@0D-(K@JN!DY/TH LT52LM7T_479+.\AF=1N*HW.W^\/4>XXJ[0
M 45AMK.I&\O8(-,MW%M+Y09[PJ9"4#C V'G!''UJ]#JMK(]I!+*D%Y=0^<EK
M(P$F,9/R]>.] %ZH);.UN+B"XFMH9)K<DPR.@+1DC!VD],CCBL^[\3:5:Z+)
MJJWD$UJC% \<@(9P<%0>F>#^57;34K*_B>6TNH9HT.&9'!"_6@">.&*'?Y<:
M)O8NVT8W,>Y]33ZHV>LZ;J$QBM+V&:3;O"HV2R_WAZCD<CBHX?$&CW-PL$&I
M6TDC,4 20'YAGY<_WN#QUXH TJ*S]0UFQL&:&6\MHKDIN5)7V@9X!;^ZI/&3
M4FDWK:EHUC?/&(VN;>.8H#D*64'&>_6@"Y15'6-4M]%TFZU&Z8"*WC9R"P&X
M@9P,]STI(M5MK^UG?3+FVN9(US@294'MDC..E %^BLC1?$6GZS;6S0W,)N)8
M%E:%'W8X&X ]\$X..G?%6'UO3([W[&]] MQN"%"XX8]%)Z!CD8'4YH OT45D
M:SK$^F.JV]DMR?L\UPY:7RPJQ[<C[IR3OX^AH UZ*R++6F<7)U&"*Q6"*.9I
M#/N38^[DL0,8VG-7++4['4=_V2YCE,>-ZJ?F7/3(ZC.#CUH MT5FKX@T=WC1
M=3M"TC[$ E&2V0,?F0/J0.]1'Q5H(9E_M>S)4D$+*#R#@CCN.XZCO0!KT4U'
M61%=&#(PRK*<@CU%17=Y;6$!GNIXX8@0-SM@9/0#U)]* )Z*JP:G8W-G)=PW
M43V\>?,<-PF.2&]"/0UDZ)XC_MRZ;[,U@UN"^ ER6F"JQ4,5VXY.._&>] '0
M445CS>)])MM7GTVXO((988DD8O(!]XL,?4;<_B* -BBLB_UR+3-8M[6\>"*V
MN())(Y"YWET9 5"XYR'SQSP:NMJ=BE@+]KN 6C %9MXVG/ P>^3Q0!:HJM9:
MA::C&TEI<),JMM;:>5/H1U!Y'!JS0 45@RZ]>FSFU"STA[JQC#%2DP$TP&?F
M1,8*G''S D<@'C.A>ZQING2B.\O887*[]KM@A?[Q]![GB@"]15*\UC3M/,8N
M[V"%I1NC5W +CC[HZGJ.GK4%_K^GV.@SZP;B.2UCC9PRN,.5!^4'UR",>M &
MI152TU.QOTD>TNX9UC^^8W!V_6H8M?TB>2&.+4[5WG)$864$MR5_F"/J,4 :
M-%43K.FB]^QF]A^T;MFS=_%_=STW>W6G7NJ6.G,BW=U'$S@E58\D#J<=<#N>
M@H N45D7WB72K&RMKQKVW>WN95BCD252K98*2#T(&>:T+6\MKZ 3VL\<T1)&
M^-LC- $]%%49-1"ZW!ID<>]VA:>5LX$: A5^I8DX]E;TH O45ST'BI)-.U&X
MDM'CN+*=H!;AP3*V\QH5.!PS@J">X/I5R+7[)=-LKN]ECM7NX5E6(ON." >P
MR0,C)Q0!JT55FU*QM[..[FNX$MI,;)F<;&STP>AS3;?5M.NVG6WO;>4P<R[)
M =@YY/MP?R/I0!<HK.M]<TV^E-O9WUM+<E2R1[\%P.X'4K[C(JMI'B2RU*.&
M*2XMTOG+(T"2;L.I.5![G SCKCG% &U115*^EU 2116$$+%PS/-,Q"(!C P.
M23GV'!YZ @%VBL4:Y*VB1W:6RF[DN#:K#YGR&42&,G=C[H*ELXS@=,\5)!J\
MD$>H+J:1QRV$8FD:$DJ\1!(8 \C[KC'^S[T :U%8]EJ6H&]M[?4K6&'[7$TD
M7E.6*%<9C;(Y.#G(XX/MF'^V[OS/M7V:+^S?MGV/=O/F[O,\K?C&,>9QCT^;
M/:@#>HJC+J(@UJVT^6/"W,3O%+GJZ$;D(]<'(^C>G-Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BJNH2WT-H7TZUAN;C(Q'-.85QW.X
M*W\JR/[0\6_]"]I?_@W?_P",4 =#4=Q))%;R210M-(JDK$I +GT!) 'XUA?V
MAXM_Z%[2_P#P;O\ _&*/[0\6_P#0O:7_ .#=_P#XQ0!6TZQU+3[^#4_L4LEU
MJ;8U1-\8$6!A&'S=%'RX&<CD\CGJJY[^T/%O_0O:7_X-W_\ C%']H>+?^A>T
MO_P;O_\ &* .AHKGO[0\6_\ 0O:7_P"#=_\ XQ1_:'BW_H7M+_\ !N__ ,8H
M M>*_P#D3M<_[!\__HMJO:;_ ,@NT_ZXI_Z"*PY[GQ3<P203^&M(DBD4HZ-J
MS$,I&""/(Z8IR7OBR-%1/#FE*JC  U9\ ?\ ?B@!OB/3/[4U2U2XTB>^LA:S
M12-')&NUI"F/O.#P%;\Q5G7K6[O6T^RMXKD6WVA9)YX&C!C"<IPYY^<*W /"
MGUJ+^T/%O_0O:7_X-W_^,4?VAXM_Z%[2_P#P;O\ _&* *4^GZI!9^(M/BMKR
M\BO("T,TLD +RLFQ@ "N%QM/('._VS<LM);3]1M]1M;.X_TA/)N8;F<2R0CJ
M&5F9L#(^90<'@XR.5_M#Q;_T+VE_^#=__C%']H>+?^A>TO\ \&[_ /QB@#H:
MQM3:Z8W5NFAB[$\7EK+YD>Q@1TDW$, "3T#<>_%5_P"T/%O_ $+VE_\ @W?_
M .,4?VAXM_Z%[2__  ;O_P#&* $U"+58;.PTV&"ZNK=80MU<V\D:ROM &T;W
M7;NY)89(Z#!.1JV)=-+0)I_V0QJ5CM2R_*!D*,J2!D =,XS67_:'BW_H7M+_
M /!N_P#\8H_M#Q;_ -"]I?\ X-W_ /C% %RRO=8F\."\N](6WU7RV8V"W*N-
MX)VKYG3GCGMFJNB+>+=O)>Z;=+=3+F>[F>+''W415=B%&3@?4DDDFF_VAXM_
MZ%[2_P#P;O\ _&*/[0\6_P#0O:7_ .#=_P#XQ0!)YE]_PD_G_P!D7?V;R?L_
MG>9#C[^=V-^=N.>F?:KNL6DM_9+:1@%)94$Y)X\H,"X]\@%?^!5G?VAXM_Z%
M[2__  ;O_P#&*/[0\6_]"]I?_@W?_P",4 :>I:/9:L(Q>1NXCSMV3/'C/7[I
M&>E1#2;*PTBXM(+*2X@D!+VYD+F3(P1F1O3W JC_ &AXM_Z%[2__  ;O_P#&
M*/[0\6_]"]I?_@W?_P",4 +HFCFWU.?4GM9+8O$(8XYYS-,1G)+N6;T "AB
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MFC8O&K,C(Q )1L97V.,C\JP/[0\6_P#0O:7_ .#=_P#XQ1_:'BW_ *%[2_\
MP;O_ /&* -#6[::ZTPK;IYDJ30S!,@%_+E5R 3QDA2!GC-5KU;S6=)NH#I\E
MHWR,B73H1-A@Q5MA;"G&T^S'CU@_M#Q;_P!"]I?_ (-W_P#C%']H>+?^A>TO
M_P &[_\ QB@"95O-2U6QN)=.EL8[0NS/,\9:0LI78NQF^7G<<XY5>#VVZY[^
MT/%O_0O:7_X-W_\ C%']H>+?^A>TO_P;O_\ &* *C6+KXCN]1F\/7D\JW(DM
MIXY81P(A'T,@./O<$=Q4FH6.JZU!IEE=6\MH_DB6YU"VD0/!+MY2/YLC)R"0
M",''?*S_ -H>+?\ H7M+_P#!N_\ \8H_M#Q;_P!"]I?_ (-W_P#C% ");7]Y
MX.GLGTU+*Z6,Q1P!E"-M^Z1M)"@^A/'OU,]]'>:]HVH6#6,]@9H&C1[AXSN)
M'3",W'KGUJ'^T/%O_0O:7_X-W_\ C%']H>+?^A>TO_P;O_\ &* (;&QNY=4L
MI;JUU0&V9GWW-S"T:DHR_*$RS?>[A?7J,4Q;._'AYXAI,RW!U7[48M\6YD^U
M>=NSOQ]WCKG(].:L_P!H>+?^A>TO_P &[_\ QBC^T/%O_0O:7_X-W_\ C% $
MC)>V%[J7EZ6U\E[()$=9$51^[5-LFX@X^7.5#<'ID<S^&+:XL?"^EV5U;^1/
M:VL<#ID$910I(P3P<<=\=:J?VAXM_P"A>TO_ ,&[_P#QBC^T/%O_ $+VE_\
M@W?_ .,4 :>LVDFH:'J%E"5$MQ;21(6.!EE(&?SJ.._O9XIM^C7<.V(D"22$
MEV_NKM<C\215#^T/%O\ T+VE_P#@W?\ ^,4?VAXM_P"A>TO_ ,&[_P#QB@"&
MTL[VWL/"L TV539%1<!7CQ$!"\?][GE@?ESP/7BJ+:%?16MWILD.J7,,TDI#
M0W,*0NLC%OFW?.I^;G //(S6I_:'BW_H7M+_ /!N_P#\8H_M#Q;_ -"]I?\
MX-W_ /C% '0CI6?K@G?1;R&VM9+F::)XE2-E!RRD9RQ Q6=_:'BW_H7M+_\
M!N__ ,8H_M#Q;_T+VE_^#=__ (Q0 NH6-YJOAVWC6&:UN8)(I?)>1 S;&!QN
M!91G&0?7&<4:39S_ -JF]GMM35D@:(->SPL3EE. L9/]WJ2,=NII/[0\6_\
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MA>TO_P &[_\ QBC^T/%O_0O:7_X-W_\ C% '0UCW(N[+79;V'3Y[R*>VCBQ
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MQ;_T+VE_^#=__C%']H>+?^A>TO\ \&[_ /QB@#H:*Y[^T/%O_0O:7_X-W_\
MC%']H>+?^A>TO_P;O_\ &* .AHKGO[0\6_\ 0O:7_P"#=_\ XQ1_:'BW_H7M
M+_\ !N__ ,8H Z&BN>_M#Q;_ -"]I?\ X-W_ /C%']H>+?\ H7M+_P#!N_\
M\8H Z&BN>_M#Q;_T+VE_^#=__C%']H>+?^A>TO\ \&[_ /QB@#H:*Y[^T/%O
M_0O:7_X-W_\ C%']H>+?^A>TO_P;O_\ &* .AHKGO[0\6_\ 0O:7_P"#=_\
MXQ1_:'BW_H7M+_\ !N__ ,8H Z&BN>_M#Q;_ -"]I?\ X-W_ /C%']H>+?\
MH7M+_P#!N_\ \8H Z&BN>_M#Q;_T+VE_^#=__C%']H>+?^A>TO\ \&[_ /QB
M@#H:*Y[^T/%O_0O:7_X-W_\ C%']H>+?^A>TO_P;O_\ &* .AHKGO[0\6_\
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MG ZCO3&\2:$FFIJ3:UIRV,C[$N3=((F;T#9P3P>/:N#U3P+=:2+;4T1]<?\
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M ZZBJ.C#&BV8*WJXB7Y;YMTXX_C.3EO7FKU !5'4=9TS2%C.HW]O:B3.SSI
MI;'7&>N._I5ZN9O3/I7B^;59+"ZN[:XL([=&MH_,:%T>1F!7J X=>>GR<XXH
M Z.*6.>%)H9%DB=0R.AR&!Z$$=12R21PQ/+*ZI&BEF=C@*!U)/85Y]>6NLD-
MY.F7UA.UK#_9=O93$06LFYBXDV$)W4MN!!&0N><PZGH&LW.CWZK_ &E+<7L>
MK12QO=.5*EI/LX"EMJC 3&,<''0F@#TGJ,BBO.I]/U(6]S<QQZP5FOHHHQ)<
M7#>3:BW0Y,2N&;]X"#@ALDY. 06:;;:XMO;#5X-;E982EHMO.Z%91<2\R'>1
M@Q^3@N6& PR23D ]%CECF3?%(KKDKE3D9!P1^!!'X4^O,8=+U&RLY+9[77/(
M0WP@2VGD#?:&G9HV)#<J4*X).T'=G!//5>%]/U&&XU&[U:2Y>\>547=.QBV"
M*/.Q,[0-^_D#/6@#I**** "BBB@ HHHH *R9-3OGO[JVLM.CF6W94=Y+CR\D
MJ&X&T]B*UJP([^/3=9U47$%[B65'C:*RFE5AY2#JBD=0: +=KJ5VVII97MBE
MNTD+S(R3^8"%* @_*,??'ZUH03PW5O%<6\BRPRH'CD0Y5E(R"#W!%8T-XFH>
M);::"&[$<5G.KO-:2P@%GB(&749/RMT]*Y32;;Q%!J.@R7*ZG-*+:U2Y29Y
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MA]H66U^WK#IZ!U()=8$C#Q[F4@ E#C((/&10!W]QJ%I:V1NY9XQ %+!@P.X
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MD:26-TR<?-PK=>E=)?W]OIEHUU=,ZPJ0"4C9SR<=%!/Z4 6:*Y[_ (3;0O\
MGO=_^ %Q_P#$4?\ ";:%_P ][O\ \ +C_P"(H Z&BN>_X3;0O^>]W_X 7'_Q
M%'_";:%_SWN__ "X_P#B* .AHKGO^$VT+_GO=_\ @!<?_$4?\)MH7_/>[_\
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M LODT^WFN+5S)Q=B+*RXX^7:XV]_O ^U %K_ (3?0?\ GM>?^"^X_P#B*/\
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MR2$Y1<85&8=<X[4 6/\ A-]!_P">UY_X+[C_ .(H_P"$WT'_ )[7G_@ON/\
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MTN)+S;%)YVQO+;YO*;:^!C^]@#U)&,Y% %7_ (3?0?\ GM>?^"^X_P#B*/\
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M\]KS_P %]Q_\11_PF^@_\]KS_P %]Q_\170T4 <]_P )OH/_ #VO/_!?<?\
MQ%'_  F^@_\ /:\_\%]Q_P#$5T-% '/?\)OH/_/:\_\ !?<?_$4?\)OH/_/:
M\_\ !?<?_$5T-% '/?\ ";Z#_P ]KS_P7W'_ ,11_P )OH/_ #VO/_!?<?\
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ME1P^\*)3R$#=L9Q\N<<5TE9<^M&#4TL/[-O9)'5G1D$>UE4J&/+@X!=>V>:
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M"HJ2!FSE@>@[ UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS$ @L<NH R.N<\5HUG:C9W$ES;7UDT?VJW5T"2DA)$?:64D E3E%(.#TZ<T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M())8\LRDCC VAN,[CC9?3K&2T2T>SMVMDQMA:)2BXZ87&!4@MH!Y.(8_W/\
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MNR662/SS->J(>6 >+R]ORD9( ^\"!DGG/5W.L6%GJEEID]QMO;X.;>((Q+A
M"QX&  ".3BG_ -EZ?]N^W?8+7[7_ ,]_)7S/^^L9J/\ LBU.O?VRP9KL6WV5
M"3PB;MQP/4G&?]T4 7Z*** .>\&VR)H,-WOG>>YRTK2SO)DAFZ!B0/PQ6/XG
MU[6].\164-O#:2VL$GGSRB=XUAB=6C7S@%;C>V00?X"2  6&UX.GB?PU:Q)*
MC2Q B1 P)0[FX([5O%5.<@'(P>.M %*[EO;?1VF\VS6ZBC#R/+N6'CEN^0,9
MYYQ[US7@G6-9U*2ZBU&WAM0LKW CDE>25XI69HF7*KM3&0,\_*00I&*[(@$$
M$9!Z@T8&<XY]: .?\36R+)IM\KSI.E];1 I.ZJ5:4 @J#M.03U%=#6!XGFBV
M:=;^:GGMJ%JRQ[AN($JY('7'%;] !1110 4444 %%%% !1110 4444 5[^^M
MM,T^XO[V80VMO&TLLC9PJ@9)X]J=:74-]9P7=NQ:&>-9(V*E25(R#@X(X]:K
MZQI-KKFERZ=>AC;2E#(JG&\*P;:?8XP?8FKP    P!0 5P1-VFBQW#W5@]G!
MJ3S>0L96=MMRQ"H^X@L3@8V_,#MXSFN\90RE6 ((P0>]4X-'TNUF6:WTVSAE
M7H\<"JP_$"@#*U)+F7Q1;6T>K36UM-:RR31H5R2K1A0I/W<[CD]?3'6K+>;:
MZ_86[7L[PO8S!A(R_,R-'AN /FPS?Y%7)]'TRZG::XTZTEE;J\D"LQ_$BI;N
MQM+^(17EK!<QAMP2:,. ?7![T <U:ZG)-H=H$U-FAGU.:U>^#*Q6,22A<-C&
M251 ?]KCG%6+QKC1K76'LM3DO)HK0216<["1H&&[+Y^\0>.#G[AQUK>%E:"&
M6$6L(BE),B>6-KY&#D=^*2TL;33XC%96L%M&3DI#&$&?7 H YW37U*+4;!S.
M3;7.X2&>^27SAL+!HP%'.0.%PN">.F-\ZI8+JRZ4UY"-0:+SUMBXWF/.-V/3
M-%OI>GVEP]Q;6%K#-)]^2.%59OJ0,FI3:VYNQ=FWB-R$\L3;!O"YSMW=<9YQ
M0!FW,D2^+M/W.@(L;K.2/[\%9>H:M=:EJ5I;6:RK:R"X!"7 A::2*380&P3@
M8+8&"01V!%;]QH^F7<S37.G6DTK=7D@5F/XD4]],L);(64EC;/:CI T2E!W^
M[C% ',3ZAJ]KHIC>9"_]H+;-,+A&>&(J" [[=H;<0F2.C*>O-7M-.IP7=U:R
MN1&;8R1Q2W8FE5\XR#@':<]\X(XZUN16=K#:_98K:&.WP5\E$ 3!ZC'2FV>G
M6.G(R65G;VRL<L((E0$^^!0!R6B6^H2WFA2B*=M.AAC,#(8Q"L9ML<C._?O)
M'IC'O3Y5EMH?$.JQ:C.CVUTSQQ*X$8VHA(88^;=T.>G;!YKI;;1["TNFN;>W
M"2,6/#':I8Y8A<X7)Y. ,T\Z5IQBEB-A:^7*VZ1/)7#MZD8Y- &/-:?;O%UZ
M/M]Q B6%N2L$@0L=\^"3UX].ASSFH3?7>H>'=#\N^C6\NU1I%,ODFX C)958
M*=ISAN!V(XKH!IUBLK2"SMQ(T?ELPB7)3&-I..F .*8VE:<]H+1M/M6MAR(3
M"I0=_NXQ0!2\.S2/#>PS37#R07)C9)W5S'\B':'7[PYSD\\X/2K5MJ]IJ>GW
M%UI-Q!?"(O&/*D# R+U4D=#G'YU:MK:WLX%@M8(X(5^['$@51] *2WM;>SC:
M.VMXH$9BY6) H+'DG [GUH XTWJO_89@\1W$EU>W"+<Q*ZG<-I+#9C]U@@#M
MZ')(-:,DKW,&J7UQK$UE+9RR($5@$MU4_*67'S;EPW/9L#%:3:1)-JB74]Q%
MY,<OFI%%!L9F (&]\G=C)Z <X^E7)M.L;BZCNIK*WEN(O]7,\2LZ?0D9% &%
M<WTVGSV6KZC<7%O:7%J1/;Y&V"79O'&,] XZ]=OK6IH5M=VVDPB_GFFNI/WD
MGFL"8R>=@( X7IGOC-7Y8HYTV2QI(F0=KJ",@Y!_ C-/H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **R)+O4KR_
MNX-.:UACM&6.1[B-I#(Y4/M #+M 5E^;GDGCCF)=1U:?[+9"WMK;49(VEN"Y
M,L<"AL# !4N6[<C@$GI@@&Y16?IM[//+<VEXD:W=LP#&/.R16&5=0>0#R,'.
M"IY/!*:+KFG^(+ WNFS-+;B1XBS1LAW*<$88 ]: -&BBN4_X2#4GOKS2X)+"
M;5!-MMX1&P"1C:6DD^?./F &.I' /. #JZ*R]3OGL_L4;3/$\L\2O*MLSH<L
M%*D_P[B< D\9I=3UZTTJXCMYX[EY9(WE40P-)\J8W'(&!C(_IS0!IT5S=_XG
MA.EM>VDS0I!+;O*;B!AO@DD"[@#@X(W$'_9Z5IVNM6UU.8&2XMY?+,JK<Q&/
M>@QEAGTR,CJ,C(&: -&BLJW\06=S+"JI<I'.<03R0,L<IZC!/KVSC/;-%UXA
ML;/43I\@N&N]H=(HX&8R#U7 Y [GH.] &K161JUY=1V%K>V<OE(980\<L!RR
MO(BX(."I 8]NM7+[48-.^S^>)?W\RPH4C+#<>F<=![F@"W152+48)M4N-/42
M^? BR.3&0N&SC#=#T/'M5HD*I8G  R30 M%8$%YKU[8PZC:QV(AGVNEI(K"3
MRV(Y,F[&[:<[=O7C/>KMUK=M:W,D BNIVA ,QMX&D$61D9QWQS@9."#CD4 :
M5%9&L7LZ:+_:.G746Q5$H.S>LJG&,'/&0>M7KZ^@T^ 2SESN8(B(A9W8] JC
MDG@GV )/ - %FBN?LO$"S:OJJ7$A@MK.VBG9)XC&\.3)NW$]1A 01QUYXJ]:
MZU;W-RD!ANK=Y03#]H@:,2 <G&>^.=IP< G'!H TJ*QH?$]A/)M1+L1B?[,\
MK6[JB2[MFTDC^]QGIR.:V: "BBL[7[FXLO#^H7=I(J3V]N\R%TW#*@M@C(ZX
MQ0!HT51M=6MKV_N;.#S7>V.V23RF\L-@$J'Q@D9&0#Q46F7YO+K4!YDA6*10
ML,EN8VC&P<<_>R<G/OB@#3HKGAXSTMDWB*_VE9'!^QR#*QG$AZ=%. ?J,9S3
MFUXVWB"[L)!+=+]GAN88[: LRJQD!R1QCY!C."<G&: -^BLU]<L1:6]Q&TDW
MV@D0QQ1L9'(ZC;C(Q@@YQ@\'%26^JV]S:SS1I/N@.V6$Q,)%; .-O4\$$8X.
M>* +U%96F>(;#6/*:Q^T2PRIN6<0.(^F<;B,9'?T.1U&*6PGN_[8O[.YG29(
MHXI8RL>P@.7&#SS]T<T :E%9W]M6F-1)$P&G'%QF)ACY=WR\?-P0>/6KEK<)
M=VL5S&'5)4#J)$*-@\\@\@^QH EHJK?:A!I\:-*)&:1_+CCC0L\C8)P /8$^
M@ )-4K?Q)ITYO 3/";)0USYT+)Y7&<'(Y..>,Y!!&<T :]%9]IK%O=W(MS%<
MV\S*7C6XA:/S%'4C/ID9'49Y%1VD]V-?OK.>=)85@BFB CVE-S2 @G//""@#
M4HK'U'7+>V%S"AG#P+^]GCMVDC@)&1NQ[$$@= 03@4RTU]#I.F2S1RS7EW:I
M.8;:(L>5!)]%&3W/YT ;=%94_B+3K?3H[YVG,,DP@PL#LZR$[=I0#<#GC&.I
M'K5BSU*._6=8DDAGBX:*>,JRDC()'<'U'H1U!H NT5EZ-<WLTFHPW\L$LEM=
M")7AB,:E3%&_0LW=SWK'D\07"WT<OVG*O>_9A9I 6 C\_P C>[@?*2P)&2 0
M,8)R: .LHK EUQ[+Q#>V,R3W*);Q7$:V]LS-&K&0-N(Z_<&!U.3@'%.OM<^S
M:CICQ.UQ9WT+F.."$NSL K*01VP3UX]Z -VBL\:U9_V8VH%I%B5_+93&V\/N
MV;-N,[MV!COD8ZTZQU6&_GFMQ#<PSPJKO'/$4^5MVT@]#]T]"<8YH O445BW
MGBC3K%)Y9ENC;0,4DN$MV:,.#@KD#DYXXXSQG/% &U16;<:U;P2K$(;J:8QB
M5HX8&9HT/0L.W0\=3@X!P:#KMCYE@J&:07QQ Z0L5)P203CY3@'@X/!]* -*
MBJ5EJEO?W-W;PK,'M)/*E+Q,HW8!P"1@\$'CU%7: "BBLS4M7:POK.SAL+B\
MGN5=PL+(NU4VY)+L/[XZ4 :=%,EFB@"^;*D>]@J[V W,>P]ZJ:=JUKJ<"20O
MM9]Y$3D!\*Q4G&>F1U]Q0!>HJA<ZO:6UU:VYD#O<7!M_D8'RV$;R?-SQ\J'\
MQ5DW"O:-<6P^TC8601,O[ST )..?KB@":BL_2-5_M:VFD-K-:R0S-!)%,5+!
MEZ\J2._K6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCM=-FEFNIVW7L\(:YN&D^[.\:*-Q./X1QU..IJ61I!XNMEE@C*FTG\F596W
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M4@JW'FLNQLP/)\J@ *0R@<>^<T ==17#?;=;N+:]U!)#%<03RJ/,O42&+:Q
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M!QNYR?KFN0\(ZWK6IZS>K=Q6UO;3R?:X"9'D,\&Q8PT60H5=R;N<G#CCY@2
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MN+R+7$%J[PQ&S/VJZBPTEO'O&75>Y_D,G#8P="X?S[[3=/74IEM)K=Y!-'(
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MM(%MP<B)8P$!SG..G7FF7&E:=>7"7%S86L\R?=DEA5F7Z$C(JUD$D C(ZTM
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M\L2LR?0D<476G6-\5-Y96]P5X4S1*^/ID59HH CA@BMH5A@B2*)1A410JCZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF5T>.1I%:*60NZ-E5/<?BBGVK;U-=8:XL#I<EDD(N ;T7*L6:''(CQT;Z\4
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MR;3B4^PK"K"5>/G\PG@\],=JT: ,O4_MZM)-'?V]C9PQ>8TKQ[R6YSNR0 @
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MRX)H Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HJK>:G8:>4%[?6UL9/N":54W?3)YJPDB2H'C=74]&4Y!
MH =1110 44U'61=R,&4]P<BHVNX$OHK)I +B6-Y4C[E$*AC^!=?SH FHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+N!IDO8V,<I!.XGROG,IW= 1A5"YQQ6K<Z'>VFK3(+*^N="%UO%M#<G<28%
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MM,9;>X3=OSS@G&02W.#G% '5X\89 ^TZ!D]/W$W/_C]+L\9#_EXT'_OQ-_\
M%UQMRVOZDMGK%OHJ12:%9P,L"N8MDI59)XTCVG(,6V,#(P2PKT.6\@U#1[Q[
M5BX$3 _*0<E P'/LP_.@#,5/%R@!+CP^ Q)&()>2>2?O_C2G_A+PK,;OP^ O
M4^3+Q_X_7&::;WPS'X7@N;>ZGTVVMGOH) A9HA]D?? W?(8C;ZAMO\-5[G3=
M7L='U#3M7TX!-=@$TPAE,H-UYH,N?E&W<C@ <\1=: .[(\8*0#=: ">F89N?
M_'ZC0^*I)"8[OPZTF,96&4G'_?=<DT.HWNIZ0]W%<%M(^T:;O9"/,<6TV^7W
M#@0D'UR*TOAVEC%%9(LFBFZ^PHI2UTIK>=3A<[Y"YW>_ R>?:@#H-OC'=M^T
MZ!G&<>1-_P#%T@'C @$76@8;H?)FY_\ 'ZYR"354\5KXJ:Q(L;B[:Q+^82XM
M21'&?+V\#S5$F<\+(U9N@6>HZ59>"[!H+B6PN)([I'*DFUD^S2>9&WH"6W+[
MEAV% ':(WBZ7/EWGA]\==L,I_P#9Z:TOBQ&*O?>'58=08I0?_0ZY3PG!IIL_
M!BZ/8K%JL$4?]HRPVQC*Q_9V#K*V #E]O!).[![$UTFN:!IEYXRT2>?2;2<R
M"X\^1[96W810NXD<^V: )VD\6(?FOO#R_6*4?^ST]?\ A+W&4N] 8>T,I_\
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MQ-_\71L\9?\ /QH/_?B;_P"+KH:* .>V>,O^?C0?^_$W_P 71L\9?\_&@_\
M?B;_ .+KH:* .>V>,O\ GXT'_OQ-_P#%T;/&7_/QH/\ WXF_^+KH:* .>V>,
MO^?C0?\ OQ-_\71L\9?\_&@_]^)O_BZZ&B@#GMGC+_GXT'_OQ-_\71L\9?\
M/QH/_?B;_P"+KH:* .>V>,O^?C0?^_$W_P 71L\9?\_&@_\ ?B;_ .+KH:*
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MTC1+O467S!!$75%ZR-_"H]R< ?6@#-V>,O\ GXT'_OQ-_P#%T;/&7_/QH/\
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M=&SQE_S\:#_WXF_^+KBYH3J&JVMCI8AO='.JR+9I<3OY+ 6I+JK#)*!\XQD
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M TLUQ-,@9YHXT;=N/?,LJ,?<UG)XIU"#2(XX)K6PAL[I-*>5X0(_/\\*^!P
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M3J* &M&CE2R*Q4Y&1G!I<#G@<]:6B@!-HXX''3VHVJ5*[1@]1BEHH 3:NT#
MP.@Q2"-%=G"*&;JP')IU% ";5P1@8/7CK1M7&,#&<XQ2T4 -,:,ZN44NO1B.
M12LJNI5E#*>"",@TM% "!5  "@!>G'2C SG'/K2T4 -**P8%00W4$=:0Q1E
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MI.]K8"UE>=WR[G9N;H?[G?UI9=&U&/['+!+:SW*7;W=R\VY!(QC:,!0,X #
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M]XO^^Q1]JM_^>\7_ 'V*R/\ A"_"O_0LZ-_X Q?_ !-'_"%^%?\ H6=&_P#
M&+_XF@#7^U6__/>+_OL4?:K?_GO%_P!]BLC_ (0OPK_T+.C?^ ,7_P 31_PA
M?A7_ *%G1O\ P!B_^)H U_M5O_SWB_[[%'VJW_Y[Q?\ ?8K(_P"$+\*_]"SH
MW_@#%_\ $T?\(7X5_P"A9T;_ , 8O_B: -?[5;_\]XO^^Q1]JM_^>\7_ 'V*
MR/\ A"_"O_0LZ-_X Q?_ !-'_"%^%?\ H6=&_P# &+_XF@#7^U6__/>+_OL4
M?:K?_GO%_P!]BLC_ (0OPK_T+.C?^ ,7_P 31_PA?A7_ *%G1O\ P!B_^)H
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MTG4<,(ERO<Y/4FI6\*7_ -A:&!="LI%N8+E#9V#1JS1.&PX#\CC';&37844
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M#:WI:3W$+7]NLENC23 R ;%7!8GZ9&?3(SUK#_X1&7RYE^U1_O--L[(?(>#
M[L6^AWC\JKR^"7DMM3M#(K+<)>?9YWN)28VN-Q(,6=G&]AD=>. : -FY\6:+
M:PQ2M?1NDERMJ"A!P[#(S[8YSZ$&MJN;U+P[<7-]+>V\T7F?:[>ZCCDRH/EJ
M5*D@'&03S@UTE !7/^.O^2?>)/\ L%W/_HIJZ"N?\=?\D^\2?]@NY_\ 134
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M",X)Y956,D_[XSVKZEH **Q]2\4:1I.MZ;H]Y=!+_4F*VT(4L6QW..@[9/\
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M\OXYKM9KS_7$3L-PV[0!W  / !&#R.:GL=(@L&N95DGEN+G'FSRON=@HPH]
M!DX '<GJ30!R4?B+Q6?"]_J-Q!HR26%Q<I-(DT@#B)V7"H4/)P,'=SZ#-6KC
MQ'XET;3E.K:5IC7 2)1,M\T<<TLC$!%!C)!& 3DX .<]<;4/AC3X=-NM/)N)
M+>YE,TJR3%B7+[R<]LMR:T6LXGNI)Y"\F]%3RW8F,;2QR%/ )W<GO@>E ' 1
M^+_%+:7IVH2P:4MF;<O=74;2O&&# <X0[!UZYQUSQ6AKWB'Q9I^E7&H1Z5I]
MJELTBE)I99C,1]U@40!$.#\S$ <$E<5NR>%]/>Q2Q!N$L@GEO;),1'*N2<,/
M?)SC&1P<CBI;G08;J*2)[R_$<K2&15N6PROU3V7TQ@CL10!E1ZMXH/B,6;6.
MCM;2VAGC5+R3<"&4$E_+P1\W "CZTMGJNH7?C#4K%KMX[>TGCC2%+)G5@8$D
M.Z7&%.6/7';UK730[6/58]022X62*+R4C$A\M4X^7;TQP#^%,'A^U36)M3CF
MNXIIY%DE1+AA&[*H497H>% _"@#FM%UK7;NTT%KF_MV_MNV9T9+;#6\@02=-
MV&4@,.0"#CGFMKPA=:EJ&C"]U&\2=Y))%54A$839(R]CSG J;2/"VF:*\+VJ
MW#M!$8(#/.\@AC.,J@8X7.!TYX%:.GV%OIEFMI:J5A5F8 DGEF+'D^Y- %FB
MBB@ KG_'7_)/O$G_ &"[G_T4U=!7/^.O^2?>)/\ L%W/_HIJ -]?N#Z4M(OW
M!]*6@ HHHH **** "BBB@ HHHH **** "BBB@ KGK[_DH.B?]@Z^_P#0[:NA
MKGK[_DH.B?\ 8.OO_0[:@#;NFN4@)M(HI9LC"2RF-3Z\A6/Z50^T>(/^@9IG
M_@PD_P#C-:M% '">-O%'B'1=+AM+73[ :KJDHL[$17KR,)&'W]IB PHY))QT
MK@[BVU+X:^*?# M?#[ZE,FGW$,@LI9)&NI&9269O+&#NYYS@=^*]+_X1R_O/
MB9_PD&H-"VGV-EY&FQJQ++(Y_>NPQP<#;UZ5UE 'DFM^&?&OC>W>[U^RLH+"
M.%WM=#CO&#>;M.UI6"$.1V4$#I[YR-*\(^-M8\):=_;.F6YL-*LPMEH<MP8C
M/,BX628;2&YZ(2H]<<Y]RHH ^;-<\$IX/\(:>WB"QT[^T]7U",7VH27;,T:;
MC*Z[=F$X7!*DD^X.*Z^?1?$7Q92'5=0M!IVA(A.G68O6AD9^,7!/E-G_ &00
M./KD^E^(/"NC>*%LUUBS%TEG.)XD9B!N QR!U'L>*V0   !@#M0!Y:OPVU6]
MD5_$-W-KRH<I;WNL2" $="8U@ )^O6O)]:\+ZAX=U'PYIOBJ+3TTZP2YNGBC
MN3B=0^]F.%.W>2D8 &3M XKZJKA?$WP]3Q'\1O#_ (BG,#V>GQ.MQ!(23(02
MT>!C& Q).?0=: *'A2U\42W=SXRUBVMHY+R'%O9W&H/$EC;<$*4$9&XX!+'\
MAR*XNU^)-CKGC^+7=9>QLK:PC:/2K6[FE5&9CA[@.(6#9Q@9QCZUU?C.UO?$
MFGF&35386%SJ$T5P&#A'A@8H(2Z_<WL'8D@YSWV@&M=Q6,^B0VVI:0EOH]O;
M!5^WVS7+6VV+S?+7(&.)%4-@'$9!YQ@ S;WQ[I^K_$NPOIK_ $)++0K1WC9M
M3/E2S3#;\K>5EBJCH%X]:W'^,<4[^3HFE+KER3@0Z=)._/NS0!0/?-0:=IT>
MD6$%T/#>E1B(2!HHM+5F 2W!=]Q.3^_X R/ESSW%S^W]=V,RRA%LUNY8/+A^
M2XV0Q! V  5W3.>.,)GG&: /)M!\3:_XE^+\OBJ/PS=ZG<VVZ.&QC?"6WRE%
M#.5PH&6/(&2<UV7B31/B7_PD.C^*-7M;?6;6QN%G&C:=*0(6['!'S,"?O?,?
MPKI-'AE\,V>J0>%;/%C&US>@R0N\ET46+:-QY.YS( 1GY5&.3FNBL=;U<^&=
M2OY!%<2PMBWD2-BK#:N6( &Y5)8_+V&,Y!- '%^*Y/B9XP\(W[VVEP>'[+R&
M9[5YS)>7( R5!"X4'&,<$].AKIOA_J4UQX'TE-"L]*ELX;9(\?VD^]& ^8.!
M"<-G.14UG+J.M>(;**6[EDTZTEFG2=(S&MT%6()G'!&^27'8^6#SUKG9_"6C
M7.LZC=1G5-,\2RWTH5M()A81 _(Q&-A0J Q8]68C.>* /0OM'B#_ *!FF?\
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M:/)\9?\ /_H/_@%-_P#':Z&B@#GO)\9?\_\ H/\ X!3?_':/)\9?\_\ H/\
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M89]D.IS6;.#+.!(%C^\SHJGIVX':@#N/)\9?\_\ H/\ X!3?_':/)\9?\_\
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M:$ M@*3\I/3/KV[<\T 0>3XR_P"?_0?_  "F_P#CM'D^,O\ G_T'_P  IO\
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MCH"20.QYJ_10!#:VEM8VR6UI!%! G"QQ(%5>_ %3444 %%%% !1110 4444
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MTCN4:!K64R0*K1K\JDY^;C+ <98'N:ZV@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *" 1@C(HHH " >HINQ0Y?:-Q&"V.<4ZB@!GDQ>7Y?EILZ[=HQ
M^5.VCT'K2T4 -$: , B@-UP.M)Y4>U5V+M7[HQP/I3Z* &LB.NUE5E]",BJQ
MTVW;55U)O,:X2(PIER51203A>@)P,GKP*MT4 -=$D4JZJRGLPR*'C210KHK
M<@$9IU% !@#/'6D"@8P!QT]J6B@!,#GCKUH"J!@*,>F*6B@"O=V4%['&DRY$
M<B2H0<%64Y!!_P Y!([U.0#G('/!I:* $5510J*%4= !@"D$: L0B@M]X@=?
MK3J* $P#VJ"\LH+Z(17";D#HY7.,E6##/MD XJQ10 UD5P ZA@#D9&>:-BEP
M^T;P,!L<XIU% ##%&3DHI_"GX&<XYHHH :B+&NU%"KZ 8%.HHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>feacam_75a50119c00071xmo002.jpg
<TEXT>
begin 644 feacam_75a50119c00071xmo002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"<4M)CF@#
M+D\3:#%(\4NMZ;'(A*NCW2 J1U!&>#3?^$J\._\ 0>TO_P #(_\ &L.[^%'@
M>^O)[NYT"&2XGD:61S+(-S,<D_>]34/_  IWP!_T+D/_ '^E_P#BJ .B_P"$
MJ\._]![2_P#P,C_QH_X2KP[_ -![2_\ P,C_ ,:YW_A3O@#_ *%R'_O]+_\
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M_P#P,C_QH_X2KP[_ -![2_\ P,C_ ,:YW_A3O@#_ *%R'_O]+_\ %4?\*=\
M?]"Y#_W^E_\ BJ .B_X2KP[_ -![2_\ P,C_ ,:/^$J\._\ 0>TO_P #(_\
M&N=_X4[X _Z%R'_O]+_\51_PIWP!_P!"Y#_W^E_^*H Z+_A*O#O_ $'M+_\
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M>'?^@]I?_@9'_C1_PE7AW_H/:7_X&1_XUS?_  J#P!_T+D'_ '^E_P#BJ/\
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M_P#P,C_QH_X2KP[_ -![2_\ P,C_ ,:YW_A3O@#_ *%R'_O]+_\ %4?\*=\
M?]"Y#_W^E_\ BJ .B_X2KP[_ -![2_\ P,C_ ,:/^$J\._\ 0>TO_P #(_\
M&N=_X4[X _Z%R'_O]+_\51_PIWP!_P!"Y#_W^E_^*H Z+_A*O#O_ $'M+_\
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MJ@#HO^$J\._]![2__ R/_&C_ (2KP[_T'M+_ / R/_&N=_X4[X _Z%R'_O\
M2_\ Q5'_  IWP!_T+D/_ '^E_P#BJ .B_P"$J\._]![2_P#P,C_QH_X2KP[_
M -![2_\ P,C_ ,:YW_A3O@#_ *%R'_O]+_\ %4?\*=\ ?]"Y#_W^E_\ BJ .
MB_X2KP[_ -![2_\ P,C_ ,:/^$J\._\ 0>TO_P #(_\ &N=_X4[X _Z%R'_O
M]+_\51_PIWP!_P!"Y#_W^E_^*H Z+_A*O#O_ $'M+_\  R/_ !H_X2KP[_T'
MM+_\#(_\:YW_ (4[X _Z%R'_ +_2_P#Q5'_"G? '_0N0_P#?Z7_XJ@#HO^$J
M\._]![2__ R/_&C_ (2KP[_T'M+_ / R/_&N=_X4[X _Z%R'_O\ 2_\ Q5'_
M  IWP!_T+D/_ '^E_P#BJ .B_P"$J\._]![2_P#P,C_QH_X2KP[_ -![2_\
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MW_A3O@#_ *%R'_O]+_\ %4?\*=\ ?]"Y#_W^E_\ BJ .B_X2KP[_ -![2_\
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M;'D65O%@[ODB"\^O ZT^I*T5CRJVNKZ62RBDEDCWZI-')I\^HRQ^0%A8A&F
M+$$C<.".15_5I=6LM=T>32I"#;6EQ<2V<5Z]Q'. R J68 DX)(XX->CS:=8W
M&[S[.WEW'+;XPV3Z\TL-A9VV/(M88MH('EQA<9Z]*6M[_P!;6'_7XW/,?#VJ
MKK7]DG4-0NH]-N(KN:,M.T7F2"X8!6;(/"=!G^53><EUKNGV]G?2:A8KI[E'
MN]1EM=Y$N-VY5^8]LD<CG->COIUE) ('LX&A!R(VC!4'UQ23:987.SS[*VEV
M#";XE;:/09'%%K ]3D?''VI/!]E#I]X]G<2WEK$LL4[/MS( ?FZL.>_6N6C\
M1:C?ZY>6U_/<6<,4MG:ZB4=D$1'G9*G^$.0G([$5ZX+6W$21""/RT(*IM&%(
MZ8':D:TMG,A:WB8R@"3* [P.F?6GW_KL!RN@7"0>(]5L[6]DGTN*.-@TLQD$
M<S$Y0,Q)Z '&>])KDJS^,+.QO[R:VT]K5I$$<QB664-R"P(/"\XS74I8VD<
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MEJ;F<8"1;@N23W)Z"N'\!?\ (_>//^OZ+_T6*[35[B]M;"26QL9+R?@+%&R
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M)_\  :7_ .)H_P"%Q>!O^@R?_ :7_P")KLO[/LO^?2W_ ._8H_L^R_Y]+?\
M[]B@#C?^%Q>!O^@R?_ :7_XFC_A<7@;_ *#)_P# :7_XFNR_L^R_Y]+?_OV*
M/[/LO^?2W_[]B@#C?^%Q>!O^@R?_  &E_P#B:/\ A<7@;_H,G_P&E_\ B:[+
M^S[+_GTM_P#OV*/[/LO^?2W_ ._8H XW_A<7@;_H,G_P&E_^)H_X7%X&_P"@
MR?\ P&E_^)KLO[/LO^?2W_[]BC^S[+_GTM_^_8H XW_A<7@;_H,G_P !I?\
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M_OV*/[/LO^?2W_[]B@#C?^%Q>!O^@R?_  &E_P#B:/\ A<7@;_H,G_P&E_\
MB:[+^S[+_GTM_P#OV*/[/LO^?2W_ ._8H XW_A<7@;_H,G_P&E_^)H_X7%X&
M_P"@R?\ P&E_^)KLO[/LO^?2W_[]BC^S[+_GTM_^_8H XW_A<7@;_H,G_P !
MI?\ XFC_ (7%X&_Z#)_\!I?_ (FNR_L^R_Y]+?\ []BC^S[+_GTM_P#OV* .
M-_X7%X&_Z#)_\!I?_B:/^%Q>!O\ H,G_ ,!I?_B:[+^S[+_GTM_^_8H_L^R_
MY]+?_OV* .-_X7%X&_Z#)_\  :7_ .)H_P"%Q>!O^@R?_ :7_P")KLO[/LO^
M?2W_ ._8H.G61_Y=(/\ OV* /&_"/Q$\+Z7XN\6WUYJ/EV^H74<EL_DN=ZA,
M'@#(Y]:[+_A<7@;_ *#)_P# :7_XFNR_LZR_Y](/^_8H_L^R_P"?2W_[]B@#
MC?\ A<7@;_H,G_P&E_\ B:/^%Q>!O^@R?_ :7_XFNR_L^R_Y]+?_ +]BC^S[
M+_GTM_\ OV* .-_X7%X&_P"@R?\ P&E_^)H_X7%X&_Z#)_\  :7_ .)KLO[/
MLO\ GTM_^_8H_L^R_P"?2W_[]B@#C?\ A<7@;_H,G_P&E_\ B:/^%Q>!O^@R
M?_ :7_XFNR_L^R_Y]+?_ +]BC^S[+_GTM_\ OV* /&_"OQ&\+:=XY\7ZA=:B
MT=K?S0-;/Y$AWA58$X"Y')'6NR_X7%X&_P"@R?\ P&E_^)KLO[.LO^?2#_OT
M/\*/[/LO^?2W_P"_8H XW_A<7@;_ *#)_P# :7_XFC_A<7@;_H,G_P !I?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%&: .6\?V\=QX7D#V\$[K/;E%F'&?.0
M=<''!(SBN>O+*Q@T'4UU#3;.SU:>QNU6*",;&A5@<\* <93!(!YKN]3TC3]9
MA6#4;*"[A5MZI,@8!O7!K/7P7X;57 T*P ==K#R%Y7@X/MP/RI >=MHVH :+
M87\#-I>E7<)LY7Y6=9&!5<=]BDK^ K2L]*AEUC58I=%TYM(-]<BYN!&#*BB(
M$ #9\O/0AC]*[>;POH=Q:6]K+I%H]O;DF&)H@5CYSP.W-0'P3X99G8Z#IY9R
M2Q\A>3ZT[_K^G^0E_D<O/;0W'B:XNM+T/3M21M(MI4%TVQB"TF",HV21CJ1T
MZU:L(H)V\.65Q,+S3C:S-^]7"R3 C"E3Z O@'TKJ(/#>CVU^E]!I=K'=HH19
MEB 8*!@ 'TQQ4CZ#I4EO/;OIUNT4\AEE0QC#N>K$>OO0]]!G ZO%IKZ3XGMH
M_#IL;F.WA=TF:,QMR=A4(6"GKV[UHVVFV<4MPVK:196=_)]I@M8[:,;'AV*Q
MR=J[NG4@5TY\+Z&VG&P;2;,VA;<8/*&TD=#BHHO!WAZ!V:+1;)&9&C)6%>58
M8(^A'%)K1A<X#2K6VLK#P_I5[!%/#<2P7-B\R!L9(\R,9Z8.&^A]JZ6]\-:3
M#K^E1-8V\OG27,DCRPHS,6RW)QSC/'T%=';^'M)M8;>&#3;6.*WD\V%%B $;
M_P!Y?0TEWX:T6_OQ?W>E6L]VN")GB!88Z<TWJ(M:58Q:9IEK80%C%;1+$A?J
M0HP,_E6'\0(8IO"SF2U2Y*3PLL; ')\Q>F> 3T_&NF48JGJFDV&L6ZV^HV4-
MW"K;Q',@8!O7![TGJ-:'#:QI+/HNMW;Z+#IEJ;'RQ9MY;>9(&SO(3*C X!Z\
MGVJW9P7%IK0/]G6.FS+8N;>.S.Y;IL#[S;4Y&!QCOUKJ'\/Z5)I7]F/IMLUB
M#G[.8P4ZYZ=*>NB::D%K MC (K1@]NFP8B8<Y7T-)J_]>O\ F"?]?<<7]ETB
M/P-;:E 4.IE$9+H']^UR2/E+=22W!7\*T+32M+N/$_B&6_L;0D16[N[Q+E24
M;<<]OK71)H.E)J1U)=.MEO3UG$0W_G5>7PIH,]\][+H]F]T[;VE:%2S'U)JG
MJ"T.:T&W@EUK1;F\@B>:33I5CEE0%W ==O)YSM_0FJUE:VD8BB$$*:7<ZY<B
M4(H6.0 ,$!QP5R,>F0*[J^TBPU.W6"^LH+B)3D)*@8#\#4GV"U^Q?8_LT?V8
M+M\K:-N/3%"?]?.XK?U\K&%-H/AV>_NK&&.&&ZGM0DL,  _=!LY*XP.3Z<UD
MZ3X:TJY\0:TRV<4+VFJ0RQ-#$JD8AC..G0DG/2NML=$TW2XI(K"PM[:.3[ZQ
M1A0WUJ+3_#>C:5=/=6&EVEM<."&DBB"L?J10M/Z\[C-8=!7(/I>FW7C^_:ZL
M;67_ (ET3%I8E/.]^<D5U]8MWX6T.^O'O+O1[.:Z;&Z62$,QQ[T <'=6TMS!
MHLEKI]KJ%POVU+?[9_$BAMG)5LX[ ]?45H7^AZ8^@W;V^G6XU.PDAU"XMQ"-
MHD$:Y4#&.47H.]==?>&=%U.6*6^TJTN'B38C2Q!BH]![5-I^B:;I,<L>G6$%
MJDI!D6% N\].?6EJ!Q]I;Z;XFO\ 6-=^R6TUJEJ+>WD,2G>=FYSDCMD+^!JI
MX3L8(+'2;K5-*LK6*.*T^PSVRY9Y'0KEFVJ>=W(.1[FN\31-,CTMM+33[=+!
ML[K98P(SDY/'3D\U3MO!_AVSGBFMM#L8I8F#1ND"@H1T(]*I.S^X3V,K3K73
M].\3>)KV.QMU:W2%P8XE##]V2V#[U%IC:?XB\07\^I01S!H(7LX+D!@(60$L
M%/&=Q8$^PK7?P5X:EEDDDT&P9Y#EF,"Y8^]7+KP]I%];PV]UIEK-#" L2/&"
M$ [#TJ4-G"WD<$_AZP*60U*WAUP1V:/M8O'N(V@OQC.1R<8 I=>\.&\T>[%S
MIT>G6UW=6J0VBE"8F#X,GR94$Y'0]%]Z[B^\/:1J<,$5]IEK<1P?ZI)(@P3Z
M#MTI+KP[I%[9P6=UIEM-;0',44D0*I]!VH6UO/\ R_R#K?\ KK_F<'I6G:A?
M^,=.OO$5BJ3QPR64,4@#!D1 6DQR/F8G\ *9X5L8(M,TVYU32+&#3X8HI8+F
M% 9&G\["[B%!!Y'&2/>N^N_#>CWUQ'<7>EVL\\:>6DCQ E5YX!].35:+P7X;
M@>-XM"L(WC8.C+ HVL#D$?C36^HGMH</?VMOI-SXCOV@A.FW,[6]W"8P55B@
M,<F,8X8X)_V@>U:&J>'-+3PE;7QLX'EECL4PT2D(%8?=XR,[CFNPC\-:-#]K
M6+2K1!> BYQ$/WV?[WKUI]_X=TC5(8(K_3+6YC@&V)98@P0<<#/3H/RH3LE\
MOP!J_P"([2-'M-&2YCLUV1SW#3E H"J2 ,* !@<"JGB]W702 [)$]Q"D[J<%
M8C(H<Y[<9Y]*V+:VBM+>.W@B6*&-0J(@P% Z "GRQK+&4=0R-PRD<$4#./FC
MTO3O%&F(GAXPN[NMO>0M$D;?NR6)4-N/RYZBN7MIK6UUO_A*(=.G@WZB8_,B
MM2L36I'EJ2P&.3\WXUZ%!X7T2T\[[/I-G'YRE)-D(&\'J#[4A\*Z$=,_LTZ1
M9_8MV_R/)&S=ZX]>!26X/:QF>(=+TVXU_09)K&TE>2Y<.SPJQ8>6V,DCFJWC
MG0=.?0=5U&2VB>5;$0QJ\:E8U#9&WC@\UM7'A'P_=R+)<:+92NJA59X5)  P
M!^ JU?:%I>IVD5I?:=;W-O%_JXY8PRKQC@?2@:>J9R'B+P[8Z;9V[6-E;.]U
MJ]M-Y$@5(@P 7C"G ('/!ZFH)[/S+SQF;[3+&*5M,B)2%O-4_+*0=Q1><@=N
MPKL9?#6C3VEO:2Z5:O;V[;H8FB!6,^H':F2^%M#FDN9)-(LW>Z&)V,0)D Z!
MO6AZIH2TM\OS.9\/Z?:P26<^JZ186DFZ..P:V4'>7A.[<VQ2<C=G(Q678V7D
MV"$:7865H=2D#:E <S1 2G V[!M!("YW$#/2NV@\'^'K25)K?1+&.5,[72%0
M5R,''X$BI[7PUH]E9SVEMI=I%;7'^MB2(!7^H[U5];B2TM_74Y_4[%+[6M4G
M2#3=65(TBGM;F39);$+GY&VL!N# ]N>]9]Q:VE]<^$)=/TBTN(VL9!'#?MMV
MQA$P"VQ\D?3\:ZR7PIH,\GF2Z-9.X(.YH5)X  _0 ?A3[[PSHNIRQRWVDVEQ
M)&NQ&DB#%5]!Z"I6@S@YK:+^Q[ZQOK2W#V>LVLLD2 /##&\R'Y21TVYSD#OP
M*V=5T[39O%.I$6=J^S1#N_=*<99L9_ ?D*ZNUT;3K*QDLK:Q@BM7!#0I& K9
MZY'>H8_#FCPV$UC%I=JEK-_K85B 5_J.]#VM_6U@3M_7G<X[0+9H+C0#-I]C
MID1A#1SVC[C<MM_U;G8N..<<YQUI4CLG\'S7^H:(VIW#-<&]D5HQ+%AFS\SL
M",#@ 'H!78Q^']*BL(["/3;9;2-Q(D(C&U6!SD#UI)_#FCW=Z+VYTNUEN1C$
MKQ M^=-NXEH6]+=)-)M'BC:*-H4*(Y!*C P#BJ?B2SM;S0+X75M#.$MY&02H
M&VG:>1GH:UE  P!BJ.IZ18:Q"L.HV4%U$K;@DR!@#^-*7O)CCI8Y#5]%TR;X
M=Z?;&QMTBEDL]X2,+RTB G@=<$\UG1,XUNYMVBB?7-.TR=#,(QYC_=\M\]<E
M?ZUVG_")Z!]@^P_V-9?9=XD\GR1MW#H<>M7HM+LH+A;B*TA298A"KJ@!"#HN
M?3VIMZM][_E826B7I^9S<.F>&3H>G7=Q';(6:)Q<=)'ER" 6').[M707&L:?
M97]I87%W%%=7>[[/$Q^:3'7'YTQ/#^E1ZC_:":;:K>?\]Q$-_P"=3W&EV5U>
M6]Y/9PR7-MDPRN@+1YZ[3VS0W=A;0N+R*H:W#%+H]YYL:/M@=EW*#@[3R*OC
M@53U+2K'5[<6^H6<-U"&W".9 PSTS@_6DU=6*6C,[P\8/^$-T_[1Y?D_9E#^
M9C;C'?-9:+-#X[MOM,EM*LEM(+06T?EF) 0<2<G=VP1@=>*W['0M+TNVEMK#
M3K:W@E^_''&%5NW(I=/T/3-+,C6&GV]LTGWS%&%S^54W>5R4K*QQV@W^I6HN
M]0GCL5C?4GMIXBI:XD8R;0=^[  !&%VG@=16I?6,UC?:SK%MKJ0*R(\D B1@
MK(F ')R<$=AM/O6\=$TTZB-1-A;_ &X<"?RQO_.F77A_2+Z\6[NM,M9KA,;9
M)(@6'XU(^IST\MYJ.MZ//:/%:7\FGR2$W,)EB"DID;0RG=G'.>F:HW<\UK\+
MV:RC:0K<;)@6VAE^TXEP>R'YL>BFNTU#2;'585AO[.&YC4Y594# '\:L+:PK
M;?9A$@AV[/+V_+M],>E/I_7<%N<]I[7<@NM!O7L@1:"1);")HDC5LKMP6;D8
MZY&?05F646JVGB/0M/E.G+';Q.&6UWEGC"XW-D (,[?EYR><\5U5EHNG:;!)
M!96,%O%)RZ1QA0WUI^G:38:5&T=A90VL9.2L2!0?RHZW%T+U%%% PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BC-% !1110 4444 %%%% !1110 4AI:* .%U6'XEG5;DZ5<Z
M&MAO_<"=6WA??CK5/R/BW_S]^'?^^7_PKT:B@#SGR/BW_P _?AW_ +Y?_"CR
M/BW_ ,_?AW_OE_\ "N@?QWHZK R)J$J3NT<3Q6,KAW5F4J"%ZY5N*FC\8Z=-
M=/;Q6VIR21LJOLL)F",0" Q"\'!&<]* .9\CXM_\_?AW_OE_\*/(^+?_ #]^
M'?\ OE_\*Z4^-="6UU:Y:[Q'I+F.\)1LQL/;'/7M5BZ\4Z396-A>W-SY=O?R
M+' [*0&9AD9XX_&@#DO(^+?_ #]^'?\ OE_\*/(^+?\ S]^'?^^7_P *ZRZ\
M4Z59M<I+,QDMY$B:-8V9F=EW!5 &6.#GC-6=,UNSU>*1[5GS$VR2.5&C=#Z,
MK $?C0!Q7D?%O_G[\._]\O\ X57OI/BO8:?<WDMUX?,=O$TKA4;)"@DXX]J]
M.K*\3?\ (J:Q_P!>,_\ Z : /._#^J?%+Q'H5IJ]I<:"MO=*719$8,!DCG ]
MJT_(^+?_ #]^'?\ OE_\*U/A3_R2_0?^N!_]#:NRH \Y\CXM_P#/WX=_[Y?_
M  H\CXM_\_?AW_OE_P#"O1J* /.?(^+?_/WX=_[Y?_"CR/BW_P _?AW_ +Y?
M_"O1J* /.?(^+?\ S]^'?^^7_P */(^+?_/WX=_[Y?\ PKT:B@#SGR/BW_S]
M^'?^^7_PH\CXM_\ /WX=_P"^7_PKT:B@#SGR/BW_ ,_?AW_OE_\ "CR/BW_S
M]^'?^^7_ ,*]&HH \Y\CXM_\_?AW_OE_\*/(^+?_ #]^'?\ OE_\*]&HH \Y
M\CXM_P#/WX=_[Y?_  H\CXM_\_?AW_OE_P#"O1J* /.?(^+?_/WX=_[Y?_"C
MR/BW_P _?AW_ +Y?_"O1J* /.?(^+?\ S]^'?^^7_P */(^+?_/WX=_[Y?\
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M\._]\O\ X5Z#;W$=U DT+!XW4,K Y!!J6@#SGR/BW_S]^'?^^7_PH\CXM_\
M/WX=_P"^7_PKT:B@#SGR/BW_ ,_?AW_OE_\ "CR/BW_S]^'?^^7_ ,*]&HH
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M._\ ?+_X4>1\6_\ G[\._P#?+_X5TDOC;18EC;SII%:%)V:*!W$4;<JSD#Y
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M#N67:WS ]"?<\UZ'M [4;1G.*.@'%2^&+JYU+3+J...TM7AC34+52""8SN0
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M\EL+ZX$\T<BR66H?9XCA%!S'O]0>#GBO0-H]*-HI];ATL+7,?$7_ ))UK_\
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M%% !1110 4444 %%%% !1110 5YQ9_\ )?\ 4?\ L#)_Z$M>CUYQ9_\ )?\
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MPH_X6GX'_P"ACM/_ ![_  K8_P"$4\._] #2_P#P#C_PH_X13P[_ - #2_\
MP#C_ ,* ,?\ X6GX'_Z&.T_\>_PK.U_XF>#+KPYJEO!X@M7EEM)411NRS%"
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M?^/?X4?\+3\#_P#0QVG_ (]_A6Q_PBGAW_H :7_X!Q_X4?\ "*>'?^@!I?\
MX!Q_X4 8_P#PM/P/_P!#':?^/?X4?\+3\#_]#':?^/?X5L?\(IX=_P"@!I?_
M (!Q_P"%'_"*>'?^@!I?_@''_A0!C_\ "T_ _P#T,=I_X]_A1_PM/P/_ -#'
M:?\ CW^%;'_"*>'?^@!I?_@''_A1_P (IX=_Z &E_P#@''_A0!C_ /"T_ __
M $,=I_X]_A1_PM/P/_T,=I_X]_A6Q_PBGAW_ * &E_\ @''_ (4?\(IX=_Z
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M^%I>"/\ H8[3_P >_P */^%I^!_^ACM/_'O\*UQX4\._] #2_P#P#C_PI?\
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M''_A0!C_ /"T_ __ $,=I_X]_A1_PM/P/_T,=I_X]_A6Q_PBGAW_ * &E_\
M@''_ (4?\(IX=_Z &E_^ <?^% &/_P +3\#_ /0QVG_CW^%'_"T_ _\ T,=I
M_P"/?X5L?\(IX=_Z &E_^ <?^%'_  BGAW_H :7_ . <?^% &/\ \+3\#_\
M0QVG_CW^%'_"T_ __0QVG_CW^%;'_"*>'?\ H :7_P" <?\ A1_PBGAW_H :
M7_X!Q_X4 8__  M/P/\ ]#':?^/?X4?\+3\#_P#0QVG_ (]_A6Q_PBGAW_H
M:7_X!Q_X4?\ "*>'?^@!I?\ X!Q_X4 8_P#PM/P/_P!#':?^/?X5S_CCXC>$
M-1\#ZU9VFNVTUQ-:ND<:[LL2.G2NX_X13P[_ - #2_\ P#C_ ,*X_P"*/AW1
M+/X;ZU/;:/I\,R0962*V167GL0* %\*_$GP=9>$-&M;G7[6.>&RACD1MV58(
M 1T]:U_^%I^!_P#H8[3_ ,>_PJSHGA?P_)H.GN^A:8S-;1L6:TC))*C)Z5?_
M .$4\._] #2__ ./_"@#'_X6GX'_ .ACM/\ Q[_"C_A:?@?_ *&.T_\ 'O\
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MK8_X13P[_P! #2__  #C_P */^$4\._] #2__ ./_"@#'_X6GX'_ .ACM/\
MQ[_"C_A:?@?_ *&.T_\ 'O\ "MC_ (13P[_T -+_ / ./_"C_A%/#O\ T -+
M_P# ./\ PH Q_P#A:?@?_H8[3_Q[_"C_ (6GX'_Z&.T_\>_PK8_X13P[_P!
M#2__  #C_P */^$4\._] #2__ ./_"@#'_X6GX'_ .ACM/\ Q[_"C_A:?@?_
M *&.T_\ 'O\ "MC_ (13P[_T -+_ / ./_"C_A%/#O\ T -+_P# ./\ PH Q
M_P#A:?@?_H8[3_Q[_"C_ (6GX'_Z&.T_\>_PK8_X13P[_P! #2__  #C_P *
M/^$4\._] #2__ ./_"@#.LOB/X0U&]AL[37;::XF<)'&N[+,>@Z5U%9</AK0
MK>9)H-%TZ*6,[D=+5%93Z@@<5J4 %%%% !1110 4444 %%%% !1110 4444
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M **** "O.+/_ )+_ *C_ -@9/_0EKT>O/+6+;\>;V3=]_1EX],.M 'H=%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\+=(: 9F73$*8_O;.*K66D>'9_"]G?:C%;I+(D;37;?+*TO!(+]?O=J .O\
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M8RWES<Q6L\:Q&XDWLH* D9^M=/3 **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ K@K_P#Y+GI'_8$F_P#1E=[7!7__ "7/2/\ L"3?^C* .]%% HH
M*XCX3?\ )/K?_K[N_P#THDKMZXCX3?\ )/K?_K[N_P#THDH [>BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<[X]_Y)_P"(/^P?-_Z :Z*N=\>_\D_\0?\ 8/F_] -
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MBUW]<!!_R72Y_P"P*/\ T8M '?T444 %%%% !1110 5P5_\ \ESTC_L"3?\
MHRN]K@K_ /Y+GI'_ &!)O_1E '>BB@44 %<1\)O^2?6__7W=_P#I1)7;UQ'P
MF_Y)];_]?=W_ .E$E ';T444 %%%% !1110 4444 %%%% !1110 5Q?Q:_Y)
M?KO_ %[_ -:[2N+^+7_)+]=_Z]_ZT =)H/\ R+VF_P#7K%_Z"*T*S]!_Y%[3
M?^O6+_T$5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'4&8WBW@RZ?*X!7 ^3[I#8_+FN=OO#<MGXCTJ&UAUF6TMX9PMY!+$&@:1T(
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M]7T7PU?VT\-J;F[MW9'A,@#'WW#@<\=ZWO\ A&HQJ-U?#4K\2W-N+=@&3:H
MP&'R=>I^IZ4B^%K1?#\&C_:KPQVY5H9_,42QE3E2"!CCZ46V^7YA_7X&G9QW
M<=N%O)XIY<_?BB,8Q]"S?SJ>4.87$;!9"IVLPR >Q(XS533=,&G1.AO+R[=V
MW-)=2[S^ & H]@!5[MBF!QG@R+5?LLSSZA;20+?7(9!:L&)\QNC>8<#/;!XX
M]ZH/XWNV^UW$,T02&9TCM/[/G=Y%4X/[P< G'H1[UTT/A>W@OFN(;_4(X6E,
MQM$GVQ;R<D\#=R>2,X/I2OX9A^T/);:AJ%I%(Q>2WMY55&8]3RI*Y_V2*2Z
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MYUF^)]$:=KNULK/5G6^1O-2"6)+9W88S)D[QVSMZX[T.]OZ\O^"-;_UY_P#
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M4R"1RA/49ZU8N_#$=XFGK)J>H*;)@ZLC1@R,. 7^3G@D<8ZT7U3$UHTC+O\
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M9')^IZ?08'M5HC-#5P6AP%I=)KMWX<@M+F^AQ;M=7.V\E&54[=C_ #?-\_\
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M[O3X(?$+W%J\-D;_ 'B-[1@&1D0 [0O()!J7P9J=C_9<UG$LD;)<7,OEFV=
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M'->VL$Z0RW,,<K_=C9P&;Z#O7%>"H-:AU.^74I[J.*9S=P(8442J_!+G:2K
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M7#)'9M&P9SDX8RMQGVK=(SWI-U&Z@#C9O *7TVK7&I7-M=7-]]R3[/(GE#&
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M8'' IGC(8L-,_P"PK:?^C5KHLG\*Q-<TB[UBXL56_B@M+>XBN'B-N7=V1PP
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ME^N_]>_]: .DT'_D7M-_Z]8O_016A6?H/_(O:;_UZQ?^@BM"@ HHHH ****
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MZBT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<!!_R72Y_P"P*/\ T8M=_7 0?\ETN?\
ML"C_ -&+0!W]%%% !1110 4444 %<%?_ /)<](_[ DW_ *,KO:X*_P#^2YZ1
M_P!@2;_T90!WHHH%% !7$?";_DGUO_U]W?\ Z425V]<1\)O^2?6__7W=_P#I
M1)0!V]%%% !1110 4444 %%%% !1110 4444 %<;\5HVD^&.O!<<6Q8_05V5
M<E\4"!\,?$6?^?-Z -S0?^1>TW_KUC_]!%:-9V@_\B_IW_7K%_Z"*T: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M0?\ )=+G_L"C_P!&+7?UP$'_ "72Y_[ H_\ 1BT =_1110 4444 %%%% !7!
M7_\ R7/2/^P)-_Z,KO:X*_\ ^2YZ1_V!)O\ T90!WHHH%% !7$?";_DGUO\
M]?=W_P"E$E=O7$?";_DGUO\ ]?=W_P"E$E ';T444 %%%% !1110 4444 %%
M%% !1110 5Q?Q:_Y)?KO_7O_ %KM*XOXM?\ )+]=_P"O?^M '2:#_P B]IO_
M %ZQ?^@BM"L_0?\ D7M-_P"O6+_T$5H4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5SOCW_DG_B#_ +!\W_H!KHJYWQ[_ ,D_\0?]@^;_
M - - "> /^2?>'_^O"+_ -!%='7.> /^2?>'_P#KPB_]!%='0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7 0?\ETN?\ L"C_ -&+7?UP$'_)=+G_ + H
M_P#1BT =_1110 4444 %%%% !7!7_P#R7/2/^P)-_P"C*[VN"O\ _DN>D?\
M8$F_]&4 =Z**!10 5Q'PF_Y)];_]?=W_ .E$E=O7$?";_DGUO_U]W?\ Z424
M =O1110 4444 %%%% !1110 4444 %%%% !7%_%K_DE^N_\ 7O\ UKM*XOXM
M?\DOUW_KW_K0!TF@_P#(O:;_ ->L7_H(K0K/T'_D7M-_Z]8O_016A0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^/?^2?\ B#_L'S?^
M@&NBKG?'O_)/_$'_ &#YO_0#0 G@#_DGWA__ *\(O_0171USG@#_ ))]X?\
M^O"+_P!!%='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 0?\ETN?^P*
M/_1BUW]<!!_R72Y_[ H_]&+0!W]%%% !1110 4444 %<%?\ _)<](_[ DW_H
MRN]K@K__ )+GI'_8$F_]&4 =Z**!10 5Q'PF_P"2?6__ %]W?_I1)7;UQ'PF
M_P"2?6__ %]W?_I1)0!V]%%% !1110 4444 %%%% !1110 4444 %<7\6O\
MDE^N_P#7O_6NTKB_BU_R2_7?^O?^M '2:#_R+VF_]>L7_H(K0K/T'_D7M-_Z
M]8O_ $$5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S
MOCW_ ))_X@_[!\W_ * :Z*N=\>_\D_\ $'_8/F_] - "> /^2?>'_P#KPB_]
M!%='7.> /^2?>'_^O"+_ -!%='0 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %<7\6O^27Z[_U[_UKM*XOXM?\DOUW_KW_ *T =)H/_(O:;_UZQ?\
MH(K0K/T'_D7M-_Z]8O\ T$5H4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5SOCW_DG_B#_L'S?^@&NBKG?'O_ "3_ ,0?]@^;_P! - ">
M /\ DGWA_P#Z\(O_ $$5T=<YX _Y)]X?_P"O"+_T$5T= !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^/?^2?^(/\ L'S?
M^@&NBKG?'O\ R3_Q!_V#YO\ T T )X _Y)]X?_Z\(O\ T$5T=<YX _Y)]X?_
M .O"+_T$5T= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^1>TW_KUB_]!%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<[X]_Y)_P"(/^P?-_Z :Z*N=\>_\D_\0?\ 8/F_] - "> /^2?>'_\
MKPB_]!%='7.> /\ DGWA_P#Z\(O_ $$5T= !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<!!_R72Y_[ H_]&+7?UP$'_)=+G_L"C_T8M '?T444 %%%% !
M1110 5P5_P#\ESTC_L"3?^C*[VN"O_\ DN>D?]@2;_T90!WHHH%% !7$?";_
M ))];_\ 7W=_^E$E=O7$?";_ ))];_\ 7W=_^E$E ';T444 %%%% !1110 4
M444 %%%% !1110 5Q?Q:_P"27Z[_ ->_]:[2N+^+7_)+]=_Z]_ZT =)H/_(O
M:;_UZQ?^@BM"L_0?^1>TW_KUB_\ 016A0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7.^/?\ DG_B#_L'S?\ H!KHJYWQ[_R3_P 0?]@^
M;_T T )X _Y)]X?_ .O"+_T$5T=<YX _Y)]X?_Z\(O\ T$5T= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<!!_R72Y_[ H_]&+7?UP$'_)=+G_L"C_T8
MM '?T444 %%%% !1110 5P5__P ESTC_ + DW_HRN]K@K_\ Y+GI'_8$F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P$'_ "72Y_[ H_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<[X]_Y)_X@_P"P?-_Z :Z*N=\>_P#)/_$'_8/F_P#0#0 G@#_DGWA_
M_KPB_P#0171USG@#_DGWA_\ Z\(O_0171T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[X]_P"2?^(/^P?-
M_P"@&NBKG?'O_)/_ !!_V#YO_0#0 G@#_DGWA_\ Z\(O_0171USG@#_DGWA_
M_KPB_P#0171T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P$'_)=+G_L"
MC_T8M=_7 0?\ETN?^P*/_1BT =_1110 4444 %%%% !7!7__ "7/2/\ L"3?
M^C*[VN"O_P#DN>D?]@2;_P!&4 =Z**!10 5Q'PF_Y)];_P#7W=_^E$E=O7$?
M";_DGUO_ -?=W_Z424 =O1110 4444 %%%% !1110 4444 %%%% !7%_%K_D
ME^N_]>_]:[2N+^+7_)+]=_Z]_P"M '2:#_R+VF_]>L7_ *"*T*S]!_Y%[3?^
MO6+_ -!%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M[X]_Y)_X@_[!\W_H!KHJYWQ[_P D_P#$'_8/F_\ 0#0 G@#_ ))]X?\ ^O"+
M_P!!%='7.> /^2?>'_\ KPB_]!%='0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7 0?\ )=+G_L"C_P!&+7?UP$'_ "72Y_[ H_\ 1BT =_1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7 0?\ETN?\ L"C_ -&+7?UP$'_)
M=+G_ + H_P#1BT =_1110 4444 %%%% !7!7_P#R7/2/^P)-_P"C*[VN"O\
M_DN>D?\ 8$F_]&4 =Z**!10 5Q'PF_Y)];_]?=W_ .E$E=O7$?";_DGUO_U]
MW?\ Z424 =O1110 4444 %%%% !1110 4444 %%%% !7%_%K_DE^N_\ 7O\
MUKM*XOXM?\DOUW_KW_K0!TF@_P#(O:;_ ->L7_H(K0K/T'_D7M-_Z]8O_016
MA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^/?^2?\
MB#_L'S?^@&NBKG?'O_)/_$'_ &#YO_0#0 G@#_DGWA__ *\(O_0171USG@#_
M ))]X?\ ^O"+_P!!%='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 0?
M\ETN?^P*/_1BUW]<!!_R72Y_[ H_]&+0!W]%%% !1110 4444 %<%?\ _)<]
M(_[ DW_HRN]K@K__ )+GI'_8$F_]&4 =Z**!10 5Q'PF_P"2?6__ %]W?_I1
M)7;UQ'PF_P"2?6__ %]W?_I1)0!V]%%% !1110 4444 %%%% !1110 4444
M%<7\6O\ DE^N_P#7O_6NTKB_BU_R2_7?^O?^M '2:#_R+VF_]>L7_H(K0K/T
M'_D7M-_Z]8O_ $$5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5SOCW_ ))_X@_[!\W_ * :Z*N=\>_\D_\ $'_8/F_] - "> /^2?>'
M_P#KPB_]!%='7.> /^2?>'_^O"+_ -!%='0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7 0?\ETN?^P*/_1BUW]<!!_R72Y_[ H_]&+0!W]%%% !1110
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MW?\ Z425V]<1\)O^2?6__7W=_P#I1)0!V]%%% !1110 4444 %%%% !1110
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MTC_L"3?^C*[VN"O_ /DN>D?]@2;_ -&4 =Z**!10 5Q'PF_Y)];_ /7W=_\
MI1)7;UQ'PF_Y)];_ /7W=_\ I1)0!V]%%% !1110 4444 %%%% !1110 444
M4 %<7\6O^27Z[_U[_P!:[2N+^+7_ "2_7?\ KW_K0!TF@_\ (O:;_P!>L7_H
M(K0K/T'_ )%[3?\ KUB_]!%:% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<[X]_Y)_X@_P"P?-_Z :Z*N=\>_P#)/_$'_8/F_P#0#0 G
M@#_DGWA__KPB_P#0171USG@#_DGWA_\ Z\(O_0171T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5P$'_)=+G_ + H_P#1BUW]<!!_R72Y_P"P*/\ T8M
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MQ[_R3_Q!_P!@^;_T T )X _Y)]X?_P"O"+_T$5T=<YX _P"2?>'_ /KPB_\
M0171T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P$'_)=+G_L"C_T8M=_
M7 0?\ETN?^P*/_1BT =_1110 4444 %%%% !7!7_ /R7/2/^P)-_Z,KO:X*_
M_P"2YZ1_V!)O_1E '>BB@44 %<1\)O\ DGUO_P!?=W_Z425V]<1\)O\ DGUO
M_P!?=W_Z424 =O1110 4444 %%%% !1110 4444 %%%% !7%_%K_ ))?KO\
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ME$E=O7$?";_DGUO_ -?=W_Z424 =O1110 4444 %%%% !1110 4444 %%%%
M!7%_%K_DE^N_]>_]:[2N+^+7_)+]=_Z]_P"M '2:#_R+VF_]>L7_ *"*T*S]
M!_Y%[3?^O6+_ -!%:% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<[X]_Y)_X@_[!\W_H!KHJYWQ[_P D_P#$'_8/F_\ 0#0 G@#_ ))]
MX?\ ^O"+_P!!%='7.> /^2?>'_\ KPB_]!%='0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7 0?\ )=+G_L"C_P!&+7?UP$'_ "72Y_[ H_\ 1BT =_11
M10 4444 %%%% !7!7_\ R7/2/^P)-_Z,KO:X*_\ ^2YZ1_V!)O\ T90!WHHH
M%% !7$?";_DGUO\ ]?=W_P"E$E=O7$?";_DGUO\ ]?=W_P"E$E ';T444 %%
M%% !1110 4444 %%%% !1110 5Q?Q:_Y)?KO_7O_ %KM*XOXM?\ )+]=_P"O
M?^M '2:#_P B]IO_ %ZQ?^@BM"L_0?\ D7M-_P"O6+_T$5H4 %%%% !1110
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M> /^2?>'_P#KPB_]!%='7.> /^2?>'_^O"+_ -!%='0 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %<7\6O^27Z[_U[_UKM*XOXM?\DOUW_KW_ *T
M=)H/_(O:;_UZQ?\ H(K0K/T'_D7M-_Z]8O\ T$5H4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5SOCW_DG_B#_L'S?^@&NBKG?'O_ "3_
M ,0?]@^;_P! - "> /\ DGWA_P#Z\(O_ $$5T=<YX _Y)]X?_P"O"+_T$5T=
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<!!_P ETN?^P*/_ $8M=_7
M0?\ )=+G_L"C_P!&+0!W]%%% !1110 4444 %<%?_P#)<](_[ DW_HRN]K@K
M_P#Y+GI'_8$F_P#1E '>BB@44 %<1\)O^2?6_P#U]W?_ *425V]<1\)O^2?6
M_P#U]W?_ *424 =O1110 4444 %%%% !1110 4444 %%%% !7%_%K_DE^N_]
M>_\ 6NTKB_BU_P DOUW_ *]_ZT =)H/_ "+VF_\ 7K%_Z"*T*S]!_P"1>TW_
M *]8O_016A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M.^/?^2?^(/\ L'S?^@&NBKG?'O\ R3_Q!_V#YO\ T T )X _Y)]X?_Z\(O\
MT$5T=<YX _Y)]X?_ .O"+_T$5T= !1110 4444 %%%% !1110 4444 %%%%
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MIO\ UZQ?^@BM"L_0?^1>TW_KUB_]!%:% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<[X]_Y)_P"(/^P?-_Z :Z*N=\>_\D_\0?\ 8/F_
M] - "> /^2?>'_\ KPB_]!%='7.> /\ DGWA_P#Z\(O_ $$5T= !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %<!!_R72Y_[ H_]&+7?UP$'_)=+G_L"C_T
M8M '?T444 %%%% !1110 5P5_P#\ESTC_L"3?^C*[VN"O_\ DN>D?]@2;_T9
M0!WHHH%% !7$?";_ ))];_\ 7W=_^E$E=O7$?";_ ))];_\ 7W=_^E$E ';T
M444 %%%% !1110 4444 %%%% !1110 5Q?Q:_P"27Z[_ ->_]:[2N+^+7_)+
M]=_Z]_ZT =)H/_(O:;_UZQ?^@BM"L_0?^1>TW_KUB_\ 016A0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7.^/?\ DG_B#_L'S?\ H!KH
MJYWQ[_R3_P 0?]@^;_T T )X _Y)]X?_ .O"+_T$5T=<YX _Y)]X?_Z\(O\
MT$5T= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<[X]_Y)_X@_P"P?-_Z :Z*N=\>_P#)/_$'_8/F
M_P#0#0 G@#_DGWA__KPB_P#0171USG@#_DGWA_\ Z\(O_0171T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOCW_DG_ (@_[!\W
M_H!KHJYWQ[_R3_Q!_P!@^;_T T )X _Y)]X?_P"O"+_T$5T=<YX _P"2?>'_
M /KPB_\ 0171T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P$'_)=+G_L
M"C_T8M=_7 0?\ETN?^P*/_1BT =_1110 4444 %%%% !7!7_ /R7/2/^P)-_
MZ,KO:X*__P"2YZ1_V!)O_1E '>BB@44 %<1\)O\ DGUO_P!?=W_Z425V]<1\
M)O\ DGUO_P!?=W_Z424 =O1110 4444 %%%% !1110 4444 %%%% !7%_%K_
M ))?KO\ U[_UKM*XOXM?\DOUW_KW_K0!TF@_\B]IO_7K%_Z"*T*S]!_Y%[3?
M^O6+_P!!%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<[X]_P"2?^(/^P?-_P"@&NBKG?'O_)/_ !!_V#YO_0#0 G@#_DGWA_\ Z\(O
M_0171USG@#_DGWA__KPB_P#0171T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5P$'_)=+G_L"C_T8M=_7 0?\ETN?^P*/_1BT =_1110 4444 %%%% !7
M!7__ "7/2/\ L"3?^C*[VN"O_P#DN>D?]@2;_P!&4 =Z**!10 5Q'PF_Y)];
M_P#7W=_^E$E=O7$?";_DGUO_ -?=W_Z424 =O1110 4444 %%%% !1110 44
M44 %%%% !7%_%K_DE^N_]>_]:[2N+^+7_)+]=_Z]_P"M '2:#_R+VF_]>L7_
M *"*T*S]!_Y%[3?^O6+_ -!%:% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<[X]_Y)_X@_[!\W_H!KHJYWQ[_P D_P#$'_8/F_\ 0#0
MG@#_ ))]X?\ ^O"+_P!!%='7.> /^2?>'_\ KPB_]!%='0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7 0?\ )=+G_L"C_P!&+7?UP$'_ "72Y_[ H_\
M1BT =_1110 4444 %%%% !7!7_\ R7/2/^P)-_Z,KO:X*_\ ^2YZ1_V!)O\
MT90!WHHH%% !7$?";_DGUO\ ]?=W_P"E$E=O7$?";_DGUO\ ]?=W_P"E$E '
M;T444 %%%% !1110 4444 %%%% !1110 5Q?Q:_Y)?KO_7O_ %KM*XOXM?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 0?\ETN?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7.^/?^2?\ B#_L'S?^@&NBKG?'O_)/_$'_ &#YO_0#0 G@#_DGWA__
M *\(O_0171USG@#_ ))]X?\ ^O"+_P!!%='0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7 0?\ETN?^P*/_1BUW]<!!_R72Y_[ H_]&+0!W]%%% !1110
M 4444 %<%?\ _)<](_[ DW_HRN]K@K__ )+GI'_8$F_]&4 =Z**!10 5Q'PF
M_P"2?6__ %]W?_I1)7;UQ'PF_P"2?6__ %]W?_I1)0!V]%%% !1110 4444
M%%%% !1110 4444 %<7\6O\ DE^N_P#7O_6NTKB_BU_R2_7?^O?^M '2:#_R
M+VF_]>L7_H(K0K/T'_D7M-_Z]8O_ $$5H4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5SOCW_ ))_X@_[!\W_ * :Z*N=\>_\D_\ $'_8
M/F_] - "> /^2?>'_P#KPB_]!%='7.> /^2?>'_^O"+_ -!%='0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<!!_R72Y_P"P*/\ T8M=_7 0?\ETN?\ L"C_ -&+0!W]%%%
M!1110 4444 %<%?_ /)<](_[ DW_ *,KO:X*_P#^2YZ1_P!@2;_T90!WHHH%
M% !7$?";_DGUO_U]W?\ Z425V]<1\)O^2?6__7W=_P#I1)0!V]%%% !1110
M4444 %%%% !1110 4444 %<7\6O^27Z[_P!>_P#6NTKB_BU_R2_7?^O?^M '
M2:#_ ,B]IO\ UZQ?^@BM"L_0?^1>TW_KUB_]!%:% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<[X]_Y)_P"(/^P?-_Z :Z*N=\>_\D_\
M0?\ 8/F_] - "> /^2?>'_\ KPB_]!%='7.> /\ DGWA_P#Z\(O_ $$5T= !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<!!_R72Y_[ H_]&+7?UP$'_)=
M+G_L"C_T8M '?T444 %%%% !1110 5P5_P#\ESTC_L"3?^C*[VN"O_\ DN>D
M?]@2;_T90!WHHH%% !7$?";_ ))];_\ 7W=_^E$E=O7$?";_ ))];_\ 7W=_
M^E$E ';T444 %%%% !1110 4444 %%%% !1110 5Q?Q:_P"27Z[_ ->_]:[2
MN+^+7_)+]=_Z]_ZT =)H/_(O:;_UZQ?^@BM"L_0?^1>TW_KUB_\ 016A0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^/?\ DG_B#_L'
MS?\ H!KHJYWQ[_R3_P 0?]@^;_T T )X _Y)]X?_ .O"+_T$5T=<YX _Y)]X
M?_Z\(O\ T$5T= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<!!_R72Y_[
M H_]&+7?UP$'_)=+G_L"C_T8M '?T444 %%%% !1110 5P5__P ESTC_ + D
MW_HRN]K@K_\ Y+GI'_8$F_\ 1E '>BB@44 %<1\)O^2?6_\ U]W?_I1)7;UQ
M'PF_Y)];_P#7W=_^E$E ';T444 %%%% !1110 4444 %%%% !1110 5Q?Q:_
MY)?KO_7O_6NTKB_BU_R2_7?^O?\ K0!TF@_\B]IO_7K%_P"@BM"L_0?^1>TW
M_KUB_P#016A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7.^/?^2?^(/^P?-_Z :Z*N=\>_\ )/\ Q!_V#YO_ $ T )X _P"2?>'_ /KP
MB_\ 0171USG@#_DGWA__ *\(O_0171T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5P$'_ "72Y_[ H_\ 1BUW]<!!_P ETN?^P*/_ $8M '?T444 %%%%
M !1110 5P5__ ,ESTC_L"3?^C*[VN"O_ /DN>D?]@2;_ -&4 =Z**!10 5Q'
MPF_Y)];_ /7W=_\ I1)7;UQ'PF_Y)];_ /7W=_\ I1)0!V]%%% !1110 444
M4 %%%% !1110 4444 %<7\6O^27Z[_U[_P!:[2N+^+7_ "2_7?\ KW_K0!TF
M@_\ (O:;_P!>L7_H(K0K/T'_ )%[3?\ KUB_]!%:% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<[X]_Y)_X@_P"P?-_Z :Z*N=\>_P#)
M/_$'_8/F_P#0#0 G@#_DGWA__KPB_P#0171USG@#_DGWA_\ Z\(O_0171T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5P$'_)=+G_ + H_P#1BUW]<!!_
MR72Y_P"P*/\ T8M '?T444 %%%% !1110 5P5_\ \ESTC_L"3?\ HRN]K@K_
M /Y+GI'_ &!)O_1E '>BB@44 %<1\)O^2?6__7W=_P#I1)7;UQ'PF_Y)];_]
M?=W_ .E$E ';T444 %%%% !1110 4444 %%%% !1110 5Q?Q:_Y)?KO_ %[_
M -:[2N+^+7_)+]=_Z]_ZT =)H/\ R+VF_P#7K%_Z"*T*S]!_Y%[3?^O6+_T$
M5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOCW_DG_
M (@_[!\W_H!KHJYWQ[_R3_Q!_P!@^;_T T )X _Y)]X?_P"O"+_T$5T=<YX
M_P"2?>'_ /KPB_\ 0171T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P$
M'_)=+G_L"C_T8M=_7 0?\ETN?^P*/_1BT =_1110 4444 %%%% !7!7_ /R7
M/2/^P)-_Z,KO:X*__P"2YZ1_V!)O_1E '>BB@44 %<1\)O\ DGUO_P!?=W_Z
M425V]<1\)O\ DGUO_P!?=W_Z424 =O1110 4444 %%%% !1110 4444 %%%%
M !7%_%K_ ))?KO\ U[_UKM*XOXM?\DOUW_KW_K0!TF@_\B]IO_7K%_Z"*T*S
M]!_Y%[3?^O6+_P!!%:% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<[X]_P"2?^(/^P?-_P"@&NBKG?'O_)/_ !!_V#YO_0#0 G@#_DGW
MA_\ Z\(O_0171USG@#_DGWA__KPB_P#0171T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5P$'_)=+G_L"C_T8M=_7 0?\ETN?^P*/_1BT =_1110 4444
M %%%% !7!7__ "7/2/\ L"3?^C*[VN"O_P#DN>D?]@2;_P!&4 =Z**!10 5Q
M'PF_Y)];_P#7W=_^E$E=O7$?";_DGUO_ -?=W_Z424 =O1110 4444 %%%%
M!1110 4444 %%%% !7%_%K_DE^N_]>_]:[2N+^+7_)+]=_Z]_P"M '2:#_R+
MVF_]>L7_ *"*T*S]!_Y%[3?^O6+_ -!%:% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<[X]_Y)_X@_[!\W_H!KHJYWQ[_P D_P#$'_8/
MF_\ 0#0 G@#_ ))]X?\ ^O"+_P!!%='7.> /^2?>'_\ KPB_]!%='0 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ K!\;N(_ ?B!B,C^SK@?G&PK>KG?'O_ "3_ ,0?]@^;_P!
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M?^1>TW_KUB_]!%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<[X]_Y)_P"(/^P?-_Z :Z*N=\>_\D_\0?\ 8/F_] - "> /^2?>'_\
MKPB_]!%='7.> /\ DGWA_P#Z\(O_ $$5T= !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %><6?_ "7_ %'_ + R?^A+7H]><6?_ "7_ %'_ + R?^A+0!Z/
M1110 4444 %%%% !7G>K?\EXT#_L#S_^A&O1*\[U;_DO&@?]@>?_ -"- 'HE
M%%% #)O]3)_NFN(^$'_).+/_ *^;K_T?)7;S?ZF3_=-<1\(/^2<6?_7S=?\
MH^2@#NJ*** "BBB@ HHHH **** "BBB@ HHHH *XOXM?\DOUW_KW_K7:5Q?Q
M:_Y)?KO_ %[_ -: .DT'_D7M-_Z]8O\ T$5H5GZ#_P B]IO_ %ZQ?^@BM"@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\>_\D_\0?\
M8/F_] -=%7.^/?\ DG_B#_L'S?\ H!H 3P!_R3[P_P#]>$7_ *"*Z.N<\ ?\
MD^\/_P#7A%_Z"*Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O.+/_DO
M^H_]@9/_ $):]'KSBS_Y+_J/_8&3_P!"6@#T>BBB@ HHHH **** "O.]6_Y+
MQH'_ &!Y_P#T(UZ)7G>K?\EXT#_L#S_^A&@#T2BBB@!DW^ID_P!TUQ'P@_Y)
MQ9_]?-U_Z/DKMYO]3)_NFN(^$'_).+/_ *^;K_T?)0!W5%%% !1110 4444
M%%%% !1110 4444 %<7\6O\ DE^N_P#7O_6NTKB_BU_R2_7?^O?^M '2:#_R
M+VF_]>L7_H(K0K/T'_D7M-_Z]8O_ $$5H4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5SOCW_ ))_X@_[!\W_ * :Z*N=\>_\D_\ $'_8
M/F_] - "> /^2?>'_P#KPB_]!%='7.> /^2?>'_^O"+_ -!%='0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N=\>_\D_\ $'_8/F_] -=%7.^/?^2?^(/^P?-_Z : $\ ?\D^\/_\
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M)]X?_P"O"+_T$5T= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %><6?_)?]1_[ R?\ H2UZ/7G%G_R7_4?^P,G_ *$M 'H]%%%
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M?_7S=?\ H^2NWF_U,G^Z:XCX0?\ ).+/_KYNO_1\E '=4444 %%%% !1110
M4444 %%%% !1110 5Q?Q:_Y)?KO_ %[_ -:[2N+^+7_)+]=_Z]_ZT =)H/\
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M_P!#!_Y)7'_QNC_A=OP\_P"A@_\ )*X_^-U<_P"%2^ _^A:M/^^G_P#BJ/\
MA4O@/_H6K3_OI_\ XJ@"G_PNWX>?]#!_Y)7'_P ;H_X7;\//^A@_\DKC_P"-
MU<_X5+X#_P"A:M/^^G_^*H_X5+X#_P"A:M/^^G_^*H I_P#"[?AY_P!#!_Y)
M7'_QNC_A=OP\_P"A@_\ )*X_^-U<_P"%2^ _^A:M/^^G_P#BJ/\ A4O@/_H6
MK3_OI_\ XJ@"G_PNWX>?]#!_Y)7'_P ;H_X7;\//^A@_\DKC_P"-U<_X5+X#
M_P"A:M/^^G_^*H_X5+X#_P"A:M/^^G_^*H I_P#"[?AY_P!#!_Y)7'_QNC_A
M=OP\_P"A@_\ )*X_^-U<_P"%2^ _^A:M/^^G_P#BJ/\ A4O@/_H6K3_OI_\
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M*H_X5+X#_P"A:M/^^G_^*H I_P#"[?AY_P!#!_Y)7'_QNC_A=OP\_P"A@_\
M)*X_^-U<_P"%2^ _^A:M/^^G_P#BJ/\ A4O@/_H6K3_OI_\ XJ@"G_PNWX>?
M]#!_Y)7'_P ;H_X7;\//^A@_\DKC_P"-U<_X5+X#_P"A:M/^^G_^*H_X5+X#
M_P"A:M/^^G_^*H I_P#"[?AY_P!#!_Y)7'_QNN,MOB;X.B^+EYKS:TO]FRZ:
MMNLOV:;)<,#C;LSV-=__ ,*E\!_]"U:?]]/_ /%4?\*E\!_]"U:?]]/_ /%4
M 4_^%V_#S_H8/_)*X_\ C='_  NWX>?]#!_Y)7'_ ,;JY_PJ7P'_ -"U:?\
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MS_H8/_)*X_\ C=7/^%2^ _\ H6K3_OI__BJ/^%2^ _\ H6K3_OI__BJ *?\
MPNWX>?\ 0P?^25Q_\;H_X7;\//\ H8/_ "2N/_C=7/\ A4O@/_H6K3_OI_\
MXJC_ (5+X#_Z%JT_[Z?_ .*H I_\+M^'G_0P?^25Q_\ &Z/^%V_#S_H8/_)*
MX_\ C=7/^%2^ _\ H6K3_OI__BJ/^%2^ _\ H6K3_OI__BJ *?\ PNWX>?\
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M:!K'2A*J[BGG-D#U^]TH N?\+M^'G_0P?^25Q_\ &Z/^%V_#S_H8/_)*X_\
MC=5Y/!/PIAEBBET[2T>559 TS#(;[I^]W[5,OP_^&#J632=-8"?[,2)6XEZ;
M/O?>]J '?\+M^'G_ $,'_DE<?_&Z/^%V_#S_ *&#_P DKC_XW36^'WPQ43EM
M(TT"WD$4W[UOW;G&%/S<'D?G3[_X<?#72[<3WVB6%O$6"!Y'8 L>@^]UH 3_
M (7;\//^A@_\DKC_ .-T?\+M^'G_ $,'_DE<?_&ZK2>"_A3%!'-)INEK')G8
MS2L-V.N/F[4DO@WX30R^7)8:4K[5;!F;HW0_>[T 6O\ A=OP\_Z&#_R2N/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:O1*!]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ Q1BBB@ Q1@>E%% !1BBB@ P/2C%%% !1B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>feacam_75a50119c00071xmo003.jpg
<TEXT>
begin 644 feacam_75a50119c00071xmo003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWPA\.ZOJFF7EK:66G):2^9+##9)BY'HV,?UKT  *  , < "EHHZ6#K<****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC!MDEV@$LH)QMP1\V<?C7!^)(%U'P-<)H_@J\TF2>YMR(%T]4EDV2!F++%G
M SC=C/:MOQ#)JNF^)=$\46.E7VIV*VCVMS:V\9\^,,0P81M@YR,$=>!1Z_UI
M_F'I_6I=NO%^AWPT&4W.J0?;+T1P+%&\8:0$J8Y>,8SU!/:MD^([,7SVRQ7+
MK',MNTZ1YC$C$ *3G/<<XQ[UR7B^YO-7/A.[CT75(Q#JD5U-$UJSO#$.I<)N
M /MDFC5-,O8?$ZZAX?BU6TOI[Q%NH&0FTN(N TA/W5(7W#$CH:%^O^0/]/\
M,Z2\\9Z58W,<<YF$#W MA=! 8A*3@*3G/7C.,9[U)XO\21>%/#-UJSQ^<T>%
MCC!QO=CA1^9KA?#VE-H^I3Z-JO@3[?=?:WDM]76TA>)T9BP9Y&(*D9]SQ79^
M.?#3^*_"-UI4,BQ7#;9(6/W0ZG(S[<4OLIC^U8K7=IXHM?#\FH)K9DU..(S&
MU-O&+=B!DH/EW@=L[JK:+\3=(UB'3$B@O6O;^W:=((X&(^7[P#' .#[_ %Q5
MBXU_4[GPZUHF@:@NMRPF$V[PD0HY&"QF^X4!YX8G':N,M-)C\#>,_!6FLL]T
M+;3+I9&MXC(Q8D$D*.2,GL,T_M-=/^ _^ 3]E/K_ ,,=?JGC^V@\.+JFG6=Q
M<M]L6SDA90CPN6"D.">O/ZBKEEKVG7?B^:S,FI0:A'9K)+:S@K"B9SNQ]TMV
MR">F,UR5]X>U270-9U%;"X$E_K4-^MJ%S*L*,HR5'\1"DXZ].]6+FSN]7^(N
MH.MEJ-M;7>BFS6Y>U=560[C][&!P0>OMUXI?G_\ :_YZ#_K\?\CJ8?&FE2W-
MG&1<QP7KF.TNGBQ#.PSPK9[X.,@9[9JH?B+HGV?4+A8K\P:?.(+J0VQ41'U(
M;!QSZ9]JYJ+2]4U7P;H'A>?3;NTOM.N8!<S&(B)4A_C1^C;@!@+D\\@5EWMI
MJ$OAWX@6\>DZH9M2O-]FOV&7,JE0,CY>.0>M-Z7_ *[?YO[AK6W]=_\ @'L$
MEU!#9O=R2!;=(S(SGH% SG\JX[PUXAN?%-^MZ=:M[.V<E[;2XC&TTL0/#R;L
ML PYP .#UK8DL'UOP(^G?O()+JP,'[U&1D8ICD$9'-<G!I%UJ-EX2TU=*N;"
M_P!%FC-Q<&'8B)&N&"/T<28_A)X/.*=K2M_7K\B;WC<[S6-8L]#L/MEZS",N
ML:JBY9W8X50/4FL:;Q]HUMI&H:C<+>1+ITWDW4)MRTD38R,A<C&#USCWI_C=
MM0&BP"PLWN-UW$)S'%YLD,6>9$7G+#C& <=>U>>WVDZE!H/CVRCTG5Y6U&6-
MK-GA:1IAL R2,]P>O3OBIOH_Z[?\$I)77]=STNQ\5:??:K'IP2XAGFM_M4/G
M1[1+'W(Y[9Z'%<AXM\4M=WOAJ32;S4H+>;6(8"Z#9#=)OPPSU(X]@1GJ*K7M
MI?:EXJT?[/::C#&=#FLWN&LY56*5P H8E>.G7M5>ZBU>3PIX3TT>'=2:^T?4
M;8W,:0C;MB)RRN2%8$#/!^N*K[2]5^?^7YDW?+\OT/1?$7B33_"^G+?:EYX@
M:01@PPM)@G@9P./J:BMO%>FSZG-I\HGM+F.#[2%N4V;XO[ZG/('?N/2L'XMN
M?^%<W3^6V?.MSLXS_K4XZXS^-9^MZ%>^--82ZM(+FS@MM*FMA+<Q-$7ED ^4
M \D#')Z<\$U/1_UTO^97;^NITO\ PG&DK="WF2[A=X&G@W0$^>B\G8%R2?\
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M12(VY%;:5R,X/44M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9+-$<C(C+1XW'V&<UO7;7ND>*="TZ+4K^XL]:AEBG66<LR.J;A(C=5^@XZ8
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<?\3;S4-,
M\"ZAJ>F:C/975HGF(T04AO9@P/'Y4F[*XTKNQV%%>:>%I-6UW0-&N8O%MZVK
M2VT5Y<6[B$QE"P!! 3*YYQSVK8U/XE:7I/B"XT6ZT[5%NX86G'[I LJ#NA+C
M=GL.M4U9V_K0E.^IV=%<W?>-+'3DLHY[*_\ MUY&TL=@L:F<(HRS,-V  />J
MM]\1]#L;?1;DBZFMM7?R[>:&,%0_]ULD$'\#TI#.NHKE'^(&D)$?W-]]I:\>
MRBM/)Q+-(N"=H)QC!SDD5SGBSXB12>'-*U#2;R^T];G4%@>1K16((/S1,K-P
M?<9Z=:%K;^MP>AZ=17/?\)EIS:S=:9%#=S/:R)#/-%&&CC=\;5/.>_7&!ZU7
MO/B!H=EJ<]FS3R);3)!=7,: PV\CG"J[9SGZ X[XH ZFBJ][?VNGZ?-?7<Z1
M6L*&225CP%'>N>TCQ]I.LWD5I#%=P7%Q;FYM8[B-4-S%_>3YC^1P: .IHKRC
MP1XB\4>,_$]_=&[DLK#3[UHI+1HD,;1@?=R"6$F><YQ6AXR\9:BGCK2?!6BR
MK;W-XHEN;O:&:&,YX4'C=QGGVH[>8=_(]'HKR_Q7XEU7X<Z]HLMSJ<^IZ/J$
MOD3K=*GF1'CYE*JO'/0CM6[/\2M+AUS4='73=5FO-/B,TRQ0(P,8Q\P._ISW
MQ1=6N!V=%><^+?B9%8^%](U30H9+N+5;A(8IU"X3)Y!!/WN",=/4U*_BNZF^
M)NDZ2TM]81RV32R6,]O&1(<\-O5CC&",4=;?UW%?2YZ#17(V_P 2/#]Q?10*
M]P+:>Y-I#?-&!;R3#^ -G.<\9(Q[U6O/BCH]CJ.KV,UAJGGZ5'YMR%A0@)D#
M<#OY'(HN,[>BN9O/'>C6>GZ/??Z5/;ZLZI;/!"6Y8<%O2NFHL%PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHL<ID PP??C<".0?<5S6D:E=6W@?2;9KB?[)=^(WM+J9Y69A#YC_ "EB<X.
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ML+. Q/I]:HZ/XQT?7-9O]+LKD/<63^6P/&XXR<>PZ9HW 9!X$\,6HC^S:/!
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M4Y!'K61I^L6QAU*YFUBSN;>WN&!:/"B!<#",<G)]_>CK?^NWZATM_7?]"N?
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M5!#XFT.XBN98M5M62V&9F\P?NQZFA^8#M&T#3/#]D;/2[=H+8DGRC*[J,\G
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MK-J?@F[MGAL[)=1N%6Q0%FMR5?B5SD[R>W'XU[4MM DGF)!&K_W@@!_.E%O
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MAG3<6 'T!%=3J.FKJ-HMGYS0VQ.)4C 'F)W3/8'OCFGOIMJYMLQ@);?ZJ-0
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M+%$C'C<% )_&D^SVV&C$,6&Y9=HY]R*EK2Q2>MSR>[NH;;X>>#-5CWR:7;+
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M!SR.*]%T:X:[T6QN&MC;-) C& C'EY ^7\*MO#%)C?$C8Z;E!Q3Z+C"BBBD
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M"Q_M$Z?,[W"EXWW;<[0#D9Z\_G0FCZWJYT#^U=,^SMHC&5V6=&%TX0JOEX/
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M9[DQSRM)B6%<Y!))&[//:K4NB:SXG\)7.F7VAP:$UN\<EA$+I9]TB'=N9E&
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MUFSU_28-3L&=K:8$H77:3SCI7(6^O7WBV[OH;2[ET^"UT^*<JB*6>25-V&W
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MNKV4LMS L2@,ZQ@YSUZGH,5<TSQ%=CQ8^E:Q>7=A>O<OY%O-;C[/<PC.WRI
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M-$NM$31IM,MGTV/&RW*?*N.A'H?>E?PSHDFB?V,VEVW]F_\ /L$ 3USQW]Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK.J?>8+]3BG5PGQ@
ML[:Z^&6L//!'(\,6^)F4$HV1R#VI2=E<<5=V.X$L;'"NI/H#3Z^<0ECK^D>#
M=#\-0K8^*(HHYY+EH_LW[O;R=Q \S..V<X->F>)OB'+I'B&70;%+5[NUL#=R
MO<EB)&'2)0O.X^O;/0U3T_'\"5J>A45YGJ/Q(U1-4\)P6-A;I#KXP4NE<20,
M" <X//)]!4=A\6R/!^OZQJ5C$MQI-X;0)"Q"S-G"GG)'OUI=_P"O(:U/4**\
MQ/Q5EL--U:XOK&.Y^QVD5U%+9AA%(7P#&2V<%2>3W'84S3_B1JX\1VMCJT6G
M0VDFD#5GD@C=BJ;=Q3); ('\6/PH_K\_\@_K\O\ -'J-&:\NT[XJ7<J>']0O
MM/@CTS7;F2V@$9;S8"" I8GA@?8#'O53PKK>OZGX^\;^=>6KKIX$"(\#;=JE
M\!<,,>_7-'_!_ /^!^)ZV&##(((]J6O'_ GB:XL/AQ#>:7H@ FU26*8H[/';
M@L-TK;FSCGID?6K)^).I:KX)\7W%J+6#4-%9T6XB4M'*HZ,H)X)]R?QH>B;_
M *Z?Y@M7_7]=#U?.>E%>2:5XXN?#/P^\*B[EMI[W5V6.!Y%95C7JSR'<2V,C
MICK5R[^*T]GX?DE;3D?4_P"TAIT/WE@F)Y60$\[<=O;K3:LVOZ_K42>E_P"O
MZT/30Z,Q4,I([ TZO%_"T,T'[0VLK/';),U@KO\ 9D*(Q(4DX.<$]^36O\:?
M$NH:/I>DZ5IT[VTFJW/E2SIPRQC&0#V)R/RI=%;K_G8:W?E_E<]/$B$X#J2.
MV:0RQ@X,B ^FX5S+^ -!.@'3;>T2W<QX%U'D2[O[Q?.3SV)KSOQ)I%@O[0GA
MN!K.W9)+(/*#&,2,"_S$=SQ37Q)"O[K9[8S!1EB /4TWSHL9\Q/^^A5#Q!:V
M]YX=U""YACFB:W?*2*". 2.#7COPHT33-0^#>I"ZL8)&EGD5W:,%L#&.>O':
MIOOY%6V\SW+>NW=N&WUSQ2JRL,J01Z@UX-I=Q)\,-7N/!OB,"Z\+ZBK/87$R
M[E1F'W3GISU]^>]>R^&[.UT[PU806<$<,*VZ$+&N!]T<_6JZ7)OK8U&8*,L0
M![F@NHQE@,],GK7A5GXOL-=U6Z\1^+;6]FT(7XL=/1 K6T)_O2+N!)..N"!4
MFJ7@U[6OB%-, \>DV,45AZ0\L=R>A.!R*F^E_G^I5M;?+\;'N+,JC+$ >I-+
MG(R*\2T;7+CQ?XH\$V.J@3VSZ.;R>*104EER4W$=^A/XUI?#ZZGUWX9ZU8W=
MQ<!+"YGAA>.4JP11E5W#GBG+W4WVO^#L*/O6^7XJYZT"#T(-(TD:G#.H/H37
MG?P/D>;X864DKL[M-*69CDD[SU-<W\=+:T36/"-T]JCNU\%D*Q;FD0%?E( R
MWTIM6DD).Z;/:%D1CA74GT!IU>>V;:5+::OXGT;18M/O=)$\,8EM3#Y@5 QW
MH,$9[=ZCT'X@:OJ/A6U\47FG6<>D"VFEO7CD;?&R?="J>H/2D,]&HKS/2?B=
M>37?AHZG8V\5IXB$GV4PEM\#*0 'SPV01R,8K*G^*_B"&P\677V#3670+M8/
MXQYP+E>F>.F:'H![#17F^C?$35;GQCHFCZEIUI##K-C]L@,$C,T0VE@K$\-P
M.P%=?HUUK\]_J2:OIUK:VL<N+*2&;>TJ>K#M_GBG85S9HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;_"C_A*M%_Y_E_[]M_A0!L45C_\ "5:+_P _R_\ ?MO\*/\ A*M%_P"?Y?\
MOVW^% &Q16/_ ,)5HO\ S_+_ -^V_P */^$JT7_G^7_OVW^% &Q16/\ \)5H
MO_/\O_?MO\*/^$JT7_G^7_OVW^% &Q16/_PE6B_\_P O_?MO\*/^$JT7_G^7
M_OVW^% &Q16/_P )5HO_ #_+_P!^V_PH_P"$JT7_ )_E_P"_;?X4 ;%%8_\
MPE6B_P#/\O\ W[;_  H_X2K1?^?Y?^_;?X4 ;%%8_P#PE6B_\_R_]^V_PH_X
M2K1?^?Y?^_;?X4 ;%%8__"5:+_S_ "_]^V_PH_X2K1?^?Y?^_;?X4 ;%%8__
M  E6B_\ /\O_ '[;_"C_ (2K1?\ G^7_ +]M_A0!L45C_P#"5:+_ ,_R_P#?
MMO\ "C_A*M%_Y_E_[]M_A0!L45C_ /"5:+_S_+_W[;_"C_A*M%_Y_E_[]M_A
M0!L45BGQ;H0D$9U! [ L%V-D@8R<8]Q^8IW_  E6B_\ /\O_ '[;_"@#8HK'
M_P"$JT7_ )_E_P"_;?X4?\)5HO\ S_+_ -^V_P * -BBL?\ X2K1?^?Y?^_;
M?X4?\)5HO_/\O_?MO\* -BBL?_A*M%_Y_E_[]M_A1_PE6B_\_P O_?MO\* -
MBBL?_A*M%_Y_E_[]M_A1_P )5HO_ #_+_P!^V_PH V**Q_\ A*M%_P"?Y?\
MOVW^%'_"5:+_ ,_R_P#?MO\ "@#8HK'_ .$JT7_G^7_OVW^%'_"5:+_S_+_W
M[;_"@#8HK'_X2K1?^?Y?^_;?X4?\)5HO_/\ +_W[;_"@#8HK'_X2K1?^?Y?^
M_;?X4?\ "5:+_P _R_\ ?MO\* -BBL?_ (2K1?\ G^7_ +]M_A1_PE6B_P#/
M\O\ W[;_  H V**Q_P#A*M%_Y_E_[]M_A1_PE6B_\_R_]^V_PH V**Q_^$JT
M7_G^7_OVW^%'_"5:+_S_ "_]^V_PH V**Q_^$JT7_G^7_OVW^%'_  E6B_\
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M5Q?@704\2^#K&&]UN.;3K6Z:>2PBC4$,LA90[YSCOT&:IJTVNG_!$O@3Z_\
M /5IVE2"1H4$DH4E$+8#'L,]J2V>9[6)[F)8IRH+QJVX*>X![UX[H]IHESX8
M\7W<MUOFM;RZ$$_VU]ZHP 7YMV2"1QGK4O\ ;6F10>'V\1B2?PY<:.(HY5B>
M5$NMV&W!02'V]#C(.<4E_E^*;&_\_P +'L507MP]K933I"TS1J6$:D MCW/%
M>/\ B.:T6_@L]3U"\L]$FT^*/3+FYT^2X?=R"P(^9)/ND$C/TY%>FPR+8>#T
M:\OF=8K3#W-T/*9OEP&8'H3QUI/X6P6Z1CVOQ!@EL-.U&ZTJ\M;"_D$45P[(
MP5B< , Q(R>*[*O$="*6GA_PYK5]=R:GH-JQ6ZM0P(L9<Y20J@RP&1PV<9S5
M[QEJ5EJ'B*5=2U<V^D7EG&-,O(;%[I=V2&,;(?DDSCG&>!38?U^)Z=X@U231
M/#]_JD5M]I:TA:;RMX7<%&3R?;-2:+J!U;1+'43&(C<P)*4!SMW#.,]Z\LU=
MH&L_$]IX@DDGO$TI1I4ES&5>1?(.YD'9RWW@.?7BH=)^P0W5M)=0^5#>^&/*
MQ-"R>=*N 5P1RWZXZ4;7_KH_\@[?UV_S/9ZJR:C:Q:C#I[3+]JF1I$CSSM'4
M_3FO'--UG3[73/#J>)X+EO#[Z48%:2UE94N@WS%AMSG;C:V#WQ6X]CHL?C?P
M[<2PL;+^R9$BNKU")20R[&+, P8#)SP0.>*.O]>?^0?U^1Z/82WDMMNOK9+>
M;>PV))O&T$[3G ZC!QVJU7B.CW__ !3'AX32-<:!'JMRFJ9<R!5+-Y7F=24R
M03G@\9IFLB*UM=0,5X\>A_VW:'3-ERRH5_Y;;,'E!GZ#G&*%K_7I_F#T_KU_
MR/<:P]8URXM-2M]*TVVAN-1GB>=4GE,:;%(!^8 G.2,<5SW@^ZL4\?>++"QG
MA^S#[-)%#$X*[MA\PJ.F<XS[]:H>(1I!^+=@&CT][W^S90GG*A/G[E\L$G^+
MT[^E)]/ZZ NIZ/;O+);1O/$(I2H+QAMVT]QGO4M>+Z<7GTOPY+9%XO%J7^W5
M06*RF+YO-,W^QC;@GCIBM_X76>F7*:C>H_GW=MJ%PD<AN&D98V(QG).0<<9]
M*JVK_KM_F+;^O7_([#4_$<&GZE!I<-O->:A.I=;>#&50?Q,20%'UJE=^,#91
M:AY^CWJ3V-N+F6(E/FCYR5;.#C%8MPW_  C?Q4O-8U0LFF:E910173 F.%T/
M*L?X0<YR<"M/Q7J^E7/@W6IX;F!T-G)&MR&&QR0<(K]&.>PS4-VC?U+BKRL_
M(W-$U1M9TB#4/LDELDZ!T21E)*D9!X)%87_";RF;6HDT"]=M(Q]IQ+%W7>-O
MS<_+4'AOQ9HMGX0T>!=1M9[PP11+:PS*TA<@#&T'(]\]*P['6M+&K?$0G4K0
M";88B9UP^+<*=O///''>KGHW;I?]":>J5^MCL++Q=9ZKX4.OZ7%)=Q*A=X%9
M5D0K]Y2"< C'2M?3[MKW3X;MX&M_-0/Y;L"0",C)'%>::G83Z5H?_"3^%PMY
M:7ED(M3L[=@RR_)M\U<?QKSG'7!KM[J"[N/ CP6)*W;Z>%BYP=VSBE+12?;_
M ((HZM+O_P  ?8>)8M5O9$L+2>:RB8J]]\JQ9'7:2<MCID"H;+Q=:7D]KBWG
MCM+R1HK2[;;LF89Z<Y&<'&>N*X;2;7Y= L?#=]>;GMY(-4M))W=(5\LC+(QQ
M&V_&,8SGO4UE$U[H'@_P_!E=1TZ[B>]AQAH!%G<6'8'C'KGC-.VMOZ]0OI?^
MO0[*/QA9R7*8MYOL+W7V-+WY?+,N=NWKG&[Y<XQFK+>(X%\5Q^'VM;A9Y+=K
MA9BH$952 <'.<\^E>>Q6DA\$6'@Y"?[9CU5/,CQ\RQK<>:93_L[1G/?..M=%
MJ%[:)\8=)C>ZA5QIDT94R '<74A<>I'04ENOG^5_S&]+_P!=;?D=S1110 44
M44 %%%% &/XK_P"16U'_ *Y?U%;%8_BO_D5M1_ZY?U%;% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6#X>_Y#'BG_L*+_Z26U;U
M8/A[_D,>*?\ L*+_ .DEM0!O4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &/<_\ (YZ9_P!@^[_]&6U;%8]S_P CGIG_ &#[O_T9;5L4 %%%
M% !61?Z))=:K%J-MJ5S:3I$8L(%="I.?NL#S[UKT4 5[2T2T5]IW22-ODD(
M+MZG%6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\5_\BMJ
M/_7+^HK8K'\5_P#(K:C_ -<OZBMB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KQ;XF>*O&UK\3]+\,^%=52U^VV
M:.L;PQ,ID+29)9E)'"C\J]IKQ+QE_P G,^$O^O-/_0IZ #^R?CU_T']/_P"^
M8/\ XU1_9/QZ_P"@_I__ 'S!_P#&J]MHH \2_LGX]?\ 0?T__OF#_P"-4?V3
M\>O^@_I__?,'_P :KVVB@#Q+^R?CU_T']/\ ^^8/_C5']D_'K_H/Z?\ ]\P?
M_&J]MHH \2_LGX]?]!_3_P#OF#_XU1_9/QZ_Z#^G_P#?,'_QJO;:* /$O[)^
M/7_0?T__ +Y@_P#C5']D_'K_ *#^G_\ ?,'_ ,:KVVB@#Q+^R?CU_P!!_3_^
M^8/_ (U1_9/QZ_Z#^G_]\P?_ !JO;:* /$O[)^/7_0?T_P#[Y@_^-4?V3\>O
M^@_I_P#WS!_\:KVVB@#Q+^R?CU_T']/_ .^8/_C5']D_'K_H/Z?_ -\P?_&J
M]MHH \2_LGX]?]!_3_\ OF#_ .-5TGP^L_&BVVMIK&KV']IKJ6+EFL_,W-]G
MA*D%'08V;1C;VKTFL'P]_P ACQ3_ -A1?_22VH F^R>(O^@QIW_@M?\ ^/4?
M9/$7_08T[_P6O_\ 'JV** ,?[)XB_P"@QIW_ (+7_P#CU'V3Q%_T&-._\%K_
M /QZMBB@#'^R>(O^@QIW_@M?_P"/4?9/$7_08T[_ ,%K_P#QZMBB@#'^R>(O
M^@QIW_@M?_X]1]D\1?\ 08T[_P %K_\ QZMBB@#'^R>(O^@QIW_@M?\ ^/4?
M9/$7_08T[_P6O_\ 'JV** ,?[)XB_P"@QIW_ (+7_P#CU'V3Q%_T&-._\%K_
M /QZMBB@#'^R>(O^@QIW_@M?_P"/4?9/$7_08T[_ ,%K_P#QZMBB@#'^R>(O
M^@QIW_@M?_X]5&TD\27.H:A;'5--46LB(&_LY_FW(&_Y[>]=-6/I7_(>UW_K
MO%_Z)2@ ^R>(O^@QIW_@M?\ ^/4?9/$7_08T[_P6O_\ 'JV** ,?[)XB_P"@
MQIW_ (+7_P#CU'V3Q%_T&-._\%K_ /QZMBB@#'^R>(O^@QIW_@M?_P"/4?9/
M$7_08T[_ ,%K_P#QZMBB@#'^R>(O^@QIW_@M?_X]1]D\1?\ 08T[_P %K_\
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M?]>:?^A3U[;7B7C+_DYGPE_UYI_Z%/0![;1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8/A[_D,>*?^PHO_ *26U;U8/A[_ )#'BG_L*+_Z26U
M&]1110 4444 %%%% !1110 4444 %%%% !1110 5CZ5_R'M=_P"N\7_HE*V*
MQ]*_Y#VN_P#7>+_T2E &Q1110 4444 %%%% !1110!CZA_R,^C?[EQ_Z"M;%
M8^H?\C/HW^Y<?^@K6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 8]S
M_P CGIG_ &#[O_T9;5L5CW/_ ".>F?\ 8/N__1EM6Q0 4444 %%%% !1110
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MI_\ :%M]L)P(?,&\GTQ5Z@ HHHH Q]0_Y&?1O]RX_P#05K8K'U#_ )&?1O\
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M;4?^N7]16Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"<G\!S7HM>5?\(I\7?\ HH%E_P" *?\ QNC_ (13XN_]% LO_ %/_C=4W?\
MKYDI6_KY'JM%>5?\(I\7?^B@67_@"G_QNC_A%/B[_P!% LO_  !3_P"-TAGJ
MM%>5?\(I\7?^B@67_@"G_P ;H_X13XN_]% LO_ %/_C= 'JM%>5?\(I\7?\
MHH%E_P" *?\ QNC_ (13XN_]% LO_ %/_C= 'JM%>5?\(I\7?^B@67_@"G_Q
MNC_A%/B[_P!% LO_  !3_P"-T >JT5Y5_P (I\7?^B@67_@"G_QNC_A%/B[_
M -% LO\ P!3_ .-T >JU@^'O^0QXI_["B_\ I);5Q'_"*?%W_HH%E_X I_\
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M;?*^+8EC]3#^E5<FQT]%8/\ PCU__P!#9K?_ 'S:_P#QBC_A'K__ *&S6_\
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M>7]JA*!_0]OUK"N-!O1XMTZ/_A*-8+-8W1$A6VW*!);\#]SC!SZ=ATYSK?\
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M_P#"/7__ $-FM_\ ?-K_ /&*/^$>O_\ H;-;_P"^;7_XQ1Y?UT_R#K?^NO\
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M /Z&S6_^^;7_ .,4 ;U%8/\ PCU__P!#9K?_ 'S:_P#QBC_A'K__ *&S6_\
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M]*^EPM_D=S17#7?B75+OX:?\)#;F6PNTA68J\2$.<C(P<\<X[&NW0EHU)ZD
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M9_X'1_\ QVC_ (27XQ_]"'IG_@='_P#':]5HH \J_P"$E^,?_0AZ9_X'1_\
MQVC_ (27XQ_]"'IG_@='_P#':]5HH \J_P"$E^,?_0AZ9_X'1_\ QVC_ (27
MXQ_]"'IG_@='_P#':]5HH \J_P"$E^,?_0AZ9_X'1_\ QVC_ (27XQ_]"'IG
M_@='_P#':]5HH \J_P"$E^,?_0AZ9_X'1_\ QVC_ (27XQ_]"'IG_@='_P#'
M:]5HH \J_P"$E^,?_0AZ9_X'1_\ QVM;PI!X]>+4[W4[32=*NKV]\YK:0&;
M$448(9),8.SH><Y]J[^B@!D/FB",3E#+M&\H"%+8YP#VS3Z** "L$Q>+<G%W
MHF/^O67_ ..5O44 8/E>+O\ G[T3_P !9?\ XY1Y7B[_ )^]$_\  67_ ..5
MO44 8/E>+O\ G[T3_P !9?\ XY1Y7B[_ )^]$_\  67_ ..5O44 8/E>+O\
MG[T3_P !9?\ XY1Y7B[_ )^]$_\  67_ ..5O44 8/E>+O\ G[T3_P !9?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8,C#*LIR"/6EH **** "BJ]U?6EBJ->74%NKL$0S2! S'H!GJ?:K% !1110
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M;C0E&_,DB^8=FS ^4]N<_ACO6OX4\/ZQH^OZ]?7YL3#J=P+A1!([,A "X.5
MZ#K5Z7=MM?S1&ME?R_4B\7^*=5T%[J2WM[.&SM;7SS/>;B+A\_ZJ/:PP<#J<
M]N*;)XNU"_O-.L]*AM8)KK3AJ!DO0S(1_<7:1SZGL.QI-?\ "&IZIK6J7,5S
M:/;WVG_9$%P&+6K<Y* #!#9YY!XKG;S1-;N[W3M!MI?#MW<Z7IT:SV^H1RE
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M'*TY:NX+:QO:2L,6C6:PSK/"L"!)@>'4#@UR/Q/N-/O_ (<ZNL<UK<O%&KJ
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M4UUV!'6-@X4;C]UO0X!Q3=,\ >)M$L=&N=+U#3(M7T^%[602B1[>XB9BPW8
M8$$GI6UXE\.^(]<@T$^=I;7%A>QWLY)DC1F0_=088X]R<U6G,FN_Z_Y$J]FO
M+]/\RO/XOUV)/%Z"/3C-HFQX&,;[9$(+88;LYP,9%6HO$=]K[0:98VU@T[Z>
MEY>_:E9HMK\",*#G)YY.<#L:AU#P=J\U[XC:TN+)8-<MT60REMT,BJ1P ,%3
MGKP1[TFE>$-<T*_M-0L[VPGN&L8[*]21'1&"$['3&3N X(. <=JGI9^7Y/\
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M A+F?2A?3.MU]G9F+;00=CY /)&!UI+7^O7_ "8/3^O3_,]0HKSB?4O%4/\
M8?AR\>W?5KF*:2>6"\,6]4(VX?RS\V#D_+VIT5]XFM#HWAK6+R..^OKB7-W;
M2;W$"#<!N*CYST)Q[T ;D_Q T.WMM7N)!>^7I,@CNO\ 1'R"?08SCW.![UT=
MK<QWEI#<Q9\N9 ZY&#@C(KQN_MY;71?B?!-</<,D:@22?>8;!C/J:WFU+6M4
MFMM T9O*>UTF"<L+OR&+., _<?<!@<<=:%M]WY/_ "![_?\ I_F>F45YOJ>K
MZ]HEOI3^)9;F"W2W9;F^TM3+&DX. THQG;C!Z8SFO0+"19=.MI%N%N5:)2)U
MZ2<#YA]>M %BBN6\8W5S#)I<46HO:6\TSB9+8$W,V$.U8@ <\\GT KA_^$G\
M0W'@70+Y=4F@N'UG[%,Q12TB>:5&[WP.<4+4'IK_ %U_R/8:R)_$NGVWB:T\
M/R>>+ZZC:2/]RWED*,GYSP?PS7#WOBV_\,WWC"V>YEO%L8[:2U,YR4>;"XR/
MX03FI9].NM/^*GA(7&I7%[OM[LEIL<-Y?.,=![4+5K^N@/1?UY'I5%<KXWO[
M_3K>QG@BOVT]9C]N?3QNF1-IVD#J1NQG':L+4M1N!8>'O$MEXAN[G2?M"QWA
MCPB/&SD!F!&1M. ?I0M09Z/56ZO5M9[6(P7$AN)/+#11EE3@G+G^$<=:\U\6
MZAK-IH>H^(-,UVZC@?48K>"+AE">8(V*Y'&6W?E6CK[ZSH/B'PQ!%KMU-;W^
MHF.:.15Y4C.,XZ#TH6MOZ[?Y@]+_ -=_\CM[[2--U,H=0TZTNRGW?M$*R;?I
MD<59BBCAC6.*-8T4855& !]*\?N-=U^#PWXPU-];N7FT;53';A0JJ4&SY6&.
M1R>*Z#Q'K-\NN20SZG/IEF-+^T6DD/\ RUGR<JW!SVPO>E?2_P#6UQVUM_6]
MCT.BO,UUKQ1=KH6C7'&J7MD]Y<#SA:LN" $!"-C&<D8J>\N?%FC>&[ ZU]HG
M6*Z<7LVE-YLZPX)0GY1G!QNP.U-Z?UYV$M3T6BLKPW?0ZEH5O=V^H?;XI<E9
M]NTD9/!'8CH1[5JTVK M0HHHI %%%% !56_TVPU6W^SZC96UY!G/EW$2R+GU
MPP(JU10!#:VMO8VR6UI;Q6\$8PD42!%4>P' J:BB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *R]?T*V\1:6;"ZDEC3S$E62(@,K(P92,@CJ/2
MM2B@#DM3\ 6>H:Q%JT6K:M87XB6&::SG"&X4=-_RG/4\C%7]0\+0W]I+9_VA
M?0VLUN+:6%'4J\>"#]Y3@D'DC!K>HHZ6#S.>E\(6AU'[;:W=W9R?8Q9E82NT
MHOW?O*>1_P#KS60OPTM%T73]*&MZI]FL;O[9#_J=WF Y&3Y?(!)_.NXHH_K]
M0_K]#@?$'A);"W\0:LEYJEY/JL4<-Q&@C^5!A0RA4!^4$G&><4WPYIDBZG:7
M6E^+]=U2%7Q<0:@08]FT]MBD-G&*] HH6@/4R-=\.VNO"T>:6:WN;.7SK:Y@
M($D;=#C((((Z@C!JG/X.MKC2]3M#?7BS:GQ=W8V&608VXY7:!CC '%='12MT
M"YG:)I7]BZ1;Z<MY<74=N@CCDG";@H  'RJ >GI46CZ&VD37LK:E=WC7<GFL
M;@1_*>G&U1Q[5K44[ZW#I8YG2?!=OI6J:I>#4KVXCU-B]S:3"/R6)&,@! 1Q
M[\]Z=IOA"/1HVMM-U;4;:P+96T#HR)GJ%+*64>P-=)10!BOX=5M:LM034;N-
M+1&6.U788CN^\3E2V3ZYJMK?A&/6=?T_6?[5OK.YL PA%MY8&&^\&W(20?3.
M*Z.B@#G(O"$/_$X6[U&\O8=6&+B*98@N=@3*[4!' %5]0\"6=[I>D:;#J%[9
MVNER)+ D'E\NARK,60YKJZ*/Z^X#.U;1X-:T&XTF]DE:*XB\J212%<^_ P#W
MZ8K"?P#;O=M=_P!L:F+E[ :>\FZ/YH@<CC9C/X5UU%%@.,B^'-K#;Z% FLZG
MY>B-NM0?)]Q\W[OG@XIUY\.=-N]/U#31J&HP:;?3>?):12($1\@DKE20"1TS
MBNQHH AM;<6MK% )))!&H7?*VYF]R>YK,7PSIR^+)/$@1OM\EL+9N1MV@DYQ
MC[W.,^E;-%'6X=+&/X=\,Z=X7M;FWTY76.XN'N&#$'!;L/8=A63#\/M/M==N
M-2M-2U2VAN93//80SA;>5SR25QGGN <5UU%'F!D:=X>M],UC4=1@N+C-_()9
M8&8>6'"A<CC/0#J:@TOPCI>D0ZK%;+)LU.5Y)@S?=#9RJXZ+RQ ]6-;U%'D!
MR%G\/K*SET>1-4U)GTB-HK4LZ<1D8VG"\X'?K3KSP'!>Z?:6\FL:DL]M=F\2
M\3RA,7.>K;.F#CITXKK:* ,BQTZ]M]<O+J34+N6UEC51!.RE588^9  -HZYS
MU)[8Y=XA\/V7B73!87QD$0D20-&<,"ISU]#T/L:U:* ,>/PSIT/B9]?CC*WK
MVXMN,;0H.<@8Z]OPK#F^'-K/::Y;-K.IB+6I?-N@/)SGC[O[OC@#\J[2B@#E
MH_!$*Z[9ZM-JU_<2VMH;-8Y%BV/$>H8! 3GZU'HO@&VT"XD-AK.KI9G>8K%I
MU:"$MSE5V]B<@$D5UM% '##X96BZ$ND#6]5%LM[]N!_<[O,W;NOE],\XKJM2
MTW^T]&FTZ2[FC$T?EO-&%WD'@]01S]*OT4/56#K<XVU^'EO9S:)+'K6I$Z-$
M8K8,(<;3UW?N^>,#\*C_ .%9:6^EWUC<:AJ$PN[O[:)BT:R03YSO0J@P<_6N
MVHHW Y.Y\"I>^&9]#N]?UBXCG8&2XFE1Y2!SMR4P!GT&:L'P=;_VC:Z@NHWR
M74-F+%Y$*#SH@<@-\O!!SRN*Z2B@#C;+X;Z9IVFZ?:VE_J4<NGRF6VNO-5I$
MW?>7E=NT]QC%$GPUT>XBU9+JZU"X_M21992\P^21<8=, 888'-=E10!S>F>$
M%T[3Y+9M;UB[D<KBYN;@-(@4Y 4@  >O'-7M*T&#2[V]OC<37-Y>[/.GFV@D
M(,*,* .,GM6M10!S]WX3MKC69]4@O;RSFN8?)N5MV4+,O;(*G!'J,&LFW^&E
MC:0Z+#!J^JK'H\IFME9XV^8]<Y0\>PQ7;44+0'J<K!X$LTFUYY]0O;E-;7%W
M')Y87.-H*[4!&![TD?@*S%_I-[-J>I3S:9$88=\BJ&0@#:P51G@#Z]\UU=%
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MZC)K.J_;);0VCR+(@#(1@Y79MS@^GOUKKJ*/Z_0#E3X"TV3P9%X8N;F[N+2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,!?"&GQ_:E
M@GO8(+N1Y9X(YR$=F^\>>>?8ULVEK!8VD-I:Q+%!"@CCC7HJ@8 %344 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M',REMRG!^[D?J:WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-+O8B*0EP6QG!P!TZ<5#X5N+BW\:Z#'!)>-:7VF2223W,AW7C KB7R\G9G/
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M$?BS1)KS3;1+PF;4HA-9CR7 F3&[(;;CIS@G--F\8>'[:]:UN-4AA=',;22
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M\@3"X^TIL.6V[0<]:T]5N[FQT^2YM;073QC<8_-$?RCJ<D&L8>$V_P"$G7Q
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M1M/O$C@$5Q:339!*@ %7V\'C/2M+PGH]SH7AJVTZYG,LD0./F+>6I.0@)Y(
MXR?2MNBFW=M]Q)6278\P?P5XAD^Q2RQ6,]]::P+U[N28[[B/YL _+\NT$#'3
MBJ]UX.\4W.A>+['[#8K)K=UY\3?;#B,9&0?D]J]7HJ;:6_KI_D5?6_\ 77_,
MX2ST#7]+U>74;2WM)%U"TCANX'G(\F1!MW*VWYACM@5J^ ]%U'P]X7ATW4S;
MF:)VP8"2,$YYSWYKIJ*JY-M+'FNL^#_$$VB^+=+LH;.5-8NS<0RR3E"H95!!
M&T]-OXYJ:?POKNI>(K*:[L;6.P&DOIUP4NRSC>H!91M&<8KT2BIMT_K:WY#O
M_7SN<7X1T[QAI,=OI&J2:=)IMFHCBNXF;SI4484%<87MDY-6_&GA_4=6&F:C
MHL\,6JZ7.9H!-]R0,-K*Q[9'>NIHIMW!:'%:UHWB/Q%X:M?ML5A!JEM>PW:V
M\4K-&WEMG:7(SS].*R=6\+>*+V]\3745OI^W6=.6T6)KA@8VVL,[MO(&[TY]
MJ]+HH:OI_78$['G.L>&_$=]X.\.:5#8V?VG3KB"6;==X4B+C .SG=^GO6AKN
MB>(X_$]KXF\/?8S=/:BUO;*ZD(1U!+*0X'4%CVYKMJ*;>M_._P"@DM+'"7VB
M>);GQCH.KO;64J644@G(N"G+]E&T\+QU/-9%KX*\1?V!>6TUO9QW)UI-4A47
M)97 DW%"=HP<=^:]2HI+3^O.XWK_ %Y6_4S-6TPZYX=N]-NB(FNX&B<H<[21
MV]<5@^&[?QK868LM5&FS1V<>R"6*1@]S@87<,83MG&:[&BCN!YZOA_Q+9ZWI
MWB"SM;4ZE.I35T>[(CD3/ 3Y?X>QQ4VEZ%XK\/:S>6NF26$VAW=PUPKSLPEM
MBQRP  PW/J17>44; ]3AM$\.:M'XC\4S:G:VZV.M!%5H[C<ZA4*<C:.N<]>*
MD\(Z;XNT&.+1;S^SKC2;0%+>[5V$S1C[JE,8&!QG-=K10M 9Y]H7AW7[)-?6
M]TS398M2OVNC!)/YBO&PP4.5Z\#GFJ ^'VLVFFQW.CS06-]::@;RQLWD,L,*
M,NUHMQ&<'KTXKU"BC;;^K?\ # ]?Z_KN<1J>A>)==TJQO+S[!;ZO87:74%O$
M[-$=H(*EB,_,"><<5+I&C:\OCR\U^]ALX+:ZLXX&B24NZLA)X. #UKLJ* _K
M]3E=9T+4(_%MGXFT=89;A+=K.YMII-@EB)W AL'!! [<UQ/C70I]%T:UNF\I
MM0U'Q#%=R(&.Q6(P%!]  .:]@K,U;P]I6N^3_:=FMSY+;HPS, I]1@]?>A:-
M?UUN#U3_ *Z6.:O?"FHZ])K6H7ZP6EW>:8VG6\,<GF+&IR=S-@9))]. *IW?
MA[Q)<WG@V;[#98T4YG'VL_-^["?+\OX_I7H:J$0*O0# YI:%IM_6_P#F&ZU_
MJYP"^$M8L;36]#LQ;2:5JDTDR3O(5>V\S[Z[<?-ZCD=:C@\,:WIGC0ZC96%K
M)IT.DKIL(:ZVNVTDAB-O'7&*]#HI6_KY6_4/Z_7]#E?AYHNI>'?!UKI.J10I
M/;,X!AEWJP+%L]!CKC\*HWNCQ7WQ*M+FTN5,!M_-U")""'>-AY.?0Y+'_@-=
MQ6=I6@Z5H:3)I=A!:"9S))Y2XWMZFJO[UQ6TL<O/H?BC1O%U]J/AYK"XL-4*
MO<P7CLIAD QO4@'.1CCCI5+Q#X.UW6+G65E-I>)=V2PVD\[D?9G ^8!,$?,>
M=PYY]J]&HJ;:6*OK<\_L_#_B*+QGH>J365G]FLM-^PR[;H[LDKE@-O.,?C75
MZ=?:A<:MJ-O=6L"6L#+]GFBD+%P<Y##'!&.V>M:M%4W<E*QQVJZ+K-U\2-'U
MJ"VMSI]C!+"[-/AV\P#D+M[8]>:@L_"M\?&%CK<EE96$\*M]LGM)#_IA9<89
M, <'G)R:[BBDM!O4P_&7_(EZS_UZ2?RK3T[_ )!EI_UQ3_T$4^ZM8+VUEM;F
M-9()5*.C=&!ZBF6.GVVFVXM[1"D0.0I=FQ^9-"Z@^A =$TUIGF:U4RO.+AI"
MQ+;P, YSG '&.GM5B]L;;4;8VUW'YD+,&9-Q ;!R <=1D=.A[U8HH KVUC;6
M;SO;PK&9W\R3;T9L8SCZ 5AZO_R.OA[_ ';C_P! %=)5'^Q[#^U!J9@S> $+
M(78[<C!P,X''H* +U%%% !1110 4444 %%%% !1110!4O'OTGM19PP21-)BX
M:1RI1,=5 ')S5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+:1:#IR6\K*\D2VZA69>A(QU%3/X7T&26XE;1[(R7$?E3,85S(G]UO45K44
M<ZG@/PE&8RGAS3%\IMT>+9?E/J..*\\U_P"%$FL>)]5U&>TOPUU.7BDT^_2*
M/&."ZN"V[UQQZ"O9:*5@.<T[PI;-X;TS3M?CAU:XLT'[ZYC#G>.XS^5="B+&
MBHBA448  X IU%4W=W$E8S1X>T9=4.J#2[07Y.?M'E#?GIG-1IX7T&+5SJR:
M19KJ)8L;H0CS,GJ=W6M:BD,1D5T*.H92,$$9!K*MO"^@V=W]JMM(LH9\Y\Q(
M5!SZUK44 9VI:#I.L/&^I:;:W;1_<,T08K],U%J/A?0=6>%]1TBRNF@7;$9H
M5;8/09Z5K44 9&G^%M!TIYWL-'LK9KA2DQBA5?,7T;'6HY/!_AN;3X]/ET/3
MWLXW,B0- I16/4@8QFMNB@#/N-"TJ[TZ+3[C3K:6SB*F.!XP44CI@=L46^A:
M3:7D]W;Z=:Q7-PH2:5(@&D4=B>]:%% &?IVA:3I"R+IVG6UJLI)<0Q!0Q/KB
MJDG@[PU+9?8I-"T]K7S#+Y)MUV[SU;&.M;=% &!)X(\+2RB63P_IS2!=@8VZ
MDA<8QG'3%<]XQ^'ECJ'AN'2M%TFVM[870GFBM6%N_ QE#]T-T^\",5Z!10]0
M6AYO\/\ P!<>%=;GO8I]1@LI(/+:TO;M)V9\_>R@   _&O0[FV@O+=X+F&.:
M%QADD4,#^!J6BAZ@M#,T[PYHND3&73]+M+60C!>*(*<>F:CD\+:!+JIU231[
M)K\G/VDPCS,_[W6M>B@#!C\$^%X5G6/0-.1;@;9@+=1Y@SGGCFIU\*Z NDG2
MAHUB-/+;_LWDKY>[UVXQFM>B@#/FT/2KG3!ID^G6TEB.EN\0*?E4-WX7T&_L
M(+&[TBRGM(.8H9(59$^@/2M:B@"*VMH;.VCM[>)(H8U"I&@P% [ 56U#1M,U
M5=NH6%O<C '[V,-P#D=:O44 0O:V\EH;1H4-NR;#%M^4KTQCTK,T[PCX=TBZ
M-UIVB6%K.009(8%5B#UY%;-% &-;^$O#MHMTMOHEA$MT"MP$@4"4'^]QS7.^
M/_"$M_\ #RZ\/>&=,MXVF=-L:%8D0!@2?TKNZ*35U8:=G<YWPIX?M=+TRUGD
MTBVL]4,"Q7#H%+-CCEAU!QFKNG>&M#TB[EN].TFSM+B7/F2PQ!6;//)'6M6B
MJ;N[DI65C/.@Z2=5_M3^S;7[?C'VGRAYF/KUH&A:4NH+?C3K87:9VS>4-XSU
MY_&M"BD,SQH6DKJK:JNG6HU!AAKD1#S"/KUK/D\"^%)I)I)/#NFN\QS*S6ZD
MN<YYXYKH** ,IO#6AMI]O8-I-F;2V??#"85V1MZJ.QHG\,Z'<RW,D^D64CW2
MA)V:%295'0-QR*U:* ,V3P]HTL-G#)I=HT=D0;93$"(2.FWT_"FP>&]$M=6?
M5;?2K.+4'SNN4B D.>N6ZUJ44 00V=M;SSS0P1QRW#!IG50#(0, D]^!BJT>
MA:3%JCZI'IUJE_)]^X6(!V^IK0HH I:OI5IKFDW.F7\?F6MRA21<XX]O>H-)
MTR:UT9--U&6.]6(>6KLG+H.FX=,XK4HH R[#PWHFES&:PTJTMI#_ !11!34^
MHZ1IVKQ+%J-C;W2*<@31AL'\:NT4 4K'2--TVV:WL;&WMX7SN2*,*#]<51LO
M!WAO3;T7MEH=A;W0.1-% JMGZBMNBCS YR]\)62K=RZ+:66G:A> I/>QP 2;
M6^\1CJWIFK5KX4T2VT*ST;^SX)K*SVM%',@?##G=S_%GG-;-% !THHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBHH;F"XW^1-'+L;:VQ@VT^AQT- $M%%% !1110 4444
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MIROVB3:-H..=J@Y^HH73Y_U_D-]?Z_K_ ")/'.M+HEA82RZ3#J$,U]#"1*P
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M4UK_ %W5_P! V_KSM^IZK17+^,]7FTNVTFUBG: :CJ$-G)< X,:,?FP>Q(&
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MM+B(6Y4"610$ER,Y0YYQT/2K5>1:IJ>L10?$=4US4%;3A%):N'4&+*,2J\8
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M4FMI)?6T\Q!N(K:Z:**X(Z>8H^]6CIVE3V>M:A>M>73P7.T+;RSET0C/*#^
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M=KWG]P'&[CKQ0->TIM3_ +-&H6YO?^>&\;ORH7D#*+>$K-_%3>(6N[UKIH3
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MOMW "FWEUI^M:YX2O](E@\JUAF^W,",0P&,#9)V'S<8->DQPQ0@B*)$!Z[5
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M''TH6C3\_P!;@]5;R_2QYYXQ8Z-JESJND:A9K.+=(KC2;N,>7=H"2HC/4/\
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M,<8YY&#]*]8TW3XM-MVCC5 TDC2R%%V@L>I [59$4:EB(U!;[Q Z_6F]7?\
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M--U87<=G+<*TJV^2 GF$[2P!SUQVS5#7/#/BJ[M/%\4.BHZZS)$T 6[C#)M
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MS.D/8M(\\)V.V#D@.21QCBEK;^NW^8]/Z]5_P2+2OB'JD?AO0;W4]%,LFKW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JCJFCV&LV\<-_!YJQR"2,AV1D<=&5E((/)Y!J]10!4LM
M-MK 'R?-9B,%YYGE?'IN<DX]LU;HHH **** "BBB@ HHHH 0* 20 ">OO2T4
M4 %%%% !1110 4444 %%%% !1110!EWOA[3=0OTOIHI4NU78)X+B2%ROH2C
MD>QJ_;6T-I%Y4*[5SDY)))]23R3[FI:* "BBB@ HHHH Q].\+Z5I6K7>J6D5
MPMY=G,[O=RN)#VRK,1QVXXK8HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LC3/#&E:1JEYJ5E%.EU>D&X=[J602$="59B,CM
MQQ6O10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+#R#('(P2.N!Z4 ;E%<]X3\3OXFAU%Y-/:R>RO&M61I1(25 .<@8'7IS70T
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MG S^5 &E1110 4444 %%%<_X=\32:[J&LV<NG-9OIMSY!W2AS)QG=P..OJ:
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MY\<^.+.Y0W%L]O$QBG8R+D@GHQ.!GMT%=3-X#\,7!D\[2(7227SFC+-Y>_\
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M(&X9N1]#716?A?1[#69]7MK5TOYQB67SY#O';(+8X[<<=JN:GI5CK-G]DU"
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MD)TYS'>MON5^U38E;U;Y^:E'@?P]]JM[DV+M-;1&&%FN96V(1@KRW3%)>?\
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M5'3< <$CL<9%5T\#>'8[PW<=C(EP8O(\Q+J4'9C&WAN!_7GK4VTM_6S*>O\
M7I_D>>>$]2FUG3?!.BZH[2V%U'=M*LC<3M$?D1O4 <X[X%=/\.;6*RUKQC;0
M<11ZIA%SG:/+7 _"MZ+P/X<@TE-+CTT+9QR^=''YLF8W_O*V[*GZ$5<TOPWH
M^BW-Q<Z?8107%QCSI1DN_P!2<FJOK?\ KH2_Z_$U****0PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX1SM(4_+UX-8&@RZCINDZ1K":=?7$&F:K>-=6P@=9!'*QVNJD9;&>WK5/?\
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MF7P!9V\D4T4T+R+)'-$T9!+LPX8#L17;U4MR5L%%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !117/>+O%!\*V=I<_V=+>+<7*6WR2*@0L< G//Y#\J .AH
MKBM0\<WFF/JUI<Z+&NH6-J+V.'[9\EQ!D@D/LX8$'*X_&IT\:3MJFAVO]D[H
MM6LS<QNER"ZL%W%-I4 ]1@[A^%&_]>O^3#^OZ^\ZZBO/8_B5?2^&;GQ!'X7E
M:PMO.$I%['O1HVQR".0>>03TZ&M:W\:2)J&F0ZII@LK;5(#+:7"W'F#<%#%'
M&T;3@Y&"<X[4 =917&GQV8[>UU2;2RF@W4PACO1/EQD[59H]O"D]#N)YY K0
MM/$TM_JUW;6E@LMM:W7V6647 \Q7XRQCV_<&>N<^V.: .BHKA+WXG6%KJ*1Q
MQ07%I]I%J[1W.9U;.TMY6WE0>IW ^U:^G^*9=4U"XCL]/66T@NC:O*MQ^]5@
M<,S1[>%]]V?:A:[ ]-SI**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .=\3^&)/$<^F.-1-JMA<K=(JPA]SKD#))Z8)XKH1D* 3DXY-+10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <Y;>%Y;?QK=>)#
MJ1=KB!;=K?R0%"*25P<YSSUKHZ**/(/,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X'XMLZ^&-.:) \@U:U*J3C)W=,]J[ZL?7O#&E>)8X(]5BGE
M2!Q)&L=U+$ PZ-A&&2.Q/2CJO5!T9SM_X8U+Q%J&JZE=0)8O+I9T^UA>0.V2
M2S.Q7( R0 ,GN>*H1:'XG2^\)W:Z3"!I-L8+F-[M=S?* 2F,@].,X]\=:]'C
MC$421J6*J  68L?Q)Y/U-.H6FW];_P";#??^MO\ )'DTFDZGH?P7\2V.IV9M
MYMMS,I\Q'#!R6'W2>E:UKH5]XJL_#?\ :%G]CL+"UWEC*KM,[1!%VXZ* 2<G
M!Z<5V>M:)8^(=-DT[4DEDM9/OQQSO%N'H2A!(]NE3Z?86^EV$-E:B000J%02
M2M(0!T&YB2?SHMO?R_ 'Y>?XG Q>$=:N/"-OX.OH(_LEM<)B_64%7@1]RC;]
M[?@ =,=\U;U3PO>7OBBTU.UTU+&^BO%:34(9P%EM@3E73J6(XZ$>]=Y11?6X
M>1P&@:;XO\-7UQH]O96-WHTER\T%\]SL>%78LP*;3N()..GUIU[X7O;KQ/::
MK:Z;'I]_'=!I[^"<;)X 3\KIU+$8[8'K7>T4+2WD#UOYE2QGO9C<?;+-;;9,
MRP[9A)YD8Z.>!M)]*MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>redactedmod13-acam2000001.jpg
<TEXT>
begin 644 redactedmod13-acam2000001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9)-%" 99$3/3<
MP&:C^VVO_/S#_P!_!65XD\(Z+XLCMX]9M6N%MRS1@2LF"<9^Z1Z"N?\ ^%-^
M!_\ H$O_ .!4O_Q5 ':_;;7_ )^8?^_@H^VVO_/S#_W\%<5_PIOP/_T"7_\
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MF'_OX*/MMK_S\P_]_!7%?\*;\#_] E__  *E_P#BJ/\ A3?@?_H$O_X%2_\
MQ5 ':_;;7_GYA_[^"C[;:_\ /S#_ -_!7%?\*;\#_P#0)?\ \"I?_BJ/^%-^
M!_\ H$O_ .!4O_Q5 ':_;;7_ )^8?^_@H^VVO_/S#_W\%<5_PIOP/_T"7_\
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MV?&+>'CHDX=8BWV@W4FS> &,?WOO;3G\#0!ZO]MM?^?F'_OX*/MMK_S\P_\
M?P5Y!;^"O"-XT4UMX)U&2PG=HX;D7C?,1G#%=^50D<-1H7@3PYJ^M7FGS>"9
M;5;*017,IU0N$8H'& &YX8=* /7_ +;:_P#/S#_W\%'VVU_Y^8?^_@KP2RTK
MPAJ&KW^F6O@J66YMM5FTZ-5U1QYGEAB7)8@+PO3GZUU6G> _A[>:1?7UQH=Q
M9MI[.EW#+=2%HBHR>C$'CD?6@#U'[;:_\_,/_?P4?;;7_GYA_P"_@KQ^/P?X
M*BM_MFH^#]1L]/>W:XCN6NF8;0,X8!\J2.@-(/!W@ZW>(:IX-O;!;F*22V9[
MYFWE%+;&P_RL0.E 'L/VVU_Y^8?^_@H^VVO_ #\P_P#?P5XI;>&_!?V&VNM1
M\'7=G'>V;7=FW]H,ZS!4\S;D-E6VY.".QK0\-> _"/B"4>9X72WA:$2ATUCS
MFYQ@%5;(ZT >M_;;7_GYA_[^"C[;:_\ /S#_ -_!7%?\*;\#_P#0)?\ \"I?
M_BJ/^%-^!_\ H$O_ .!4O_Q5 ':_;;7_ )^8?^_@H^VVO_/S#_W\%<5_PIOP
M/_T"7_\  J7_ .*H_P"%-^!_^@2__@5+_P#%4 =K]MM?^?F'_OX*/MMK_P _
M,/\ W\%<5_PIOP/_ - E_P#P*E_^*H_X4WX'_P"@2_\ X%2__%4 =K]MM?\
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M"X@,6Q&U!O+D$CA!B3=@8)YSTK5\/_#3PAK$,TEQX=6VV,%'E:J9P>/5&XH
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M-I9N3&%D1E7:"/?FL.S^$_B32?#6LZ=;36ES/+JEM=VCS3, \<1)^<XR#TH
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M444 %%%% !1110 4444 %<I\0O\ D68?^PE9?^E$==77*?$+_D68?^PE9?\
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M^@[;_P#?+_X4?\+*\'?]!VW_ .^7_P * .KHKE/^%E>#O^@[;_\ ?+_X4?\
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MC_A97@[_ *#MO_WR_P#A0!U=%<I_PLKP=_T';?\ [Y?_  H_X65X._Z#MO\
M]\O_ (4 =717*?\ "RO!W_0=M_\ OE_\*/\ A97@[_H.V_\ WR_^% '5T5RG
M_"RO!W_0=M_^^7_PH_X65X._Z#MO_P!\O_A0!U=%<I_PLKP=_P!!VW_[Y?\
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M_P#A0!U=%<I_PLKP=_T';?\ [Y?_  H_X65X._Z#MO\ ]\O_ (4 =717*?\
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M:7;W-A!;ZC/<!9HMO!A9'=)$]00H!]#D5TOBR\GT;PY/>Z;80W-XLL,<4+
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M.^;_ &3;-K,=[)9O:AOD8Q#=(RMCIL&1[D"NEUOPTVKZC8W\.J75C<V:.BO
M$.X/C.=P/I5"#X>:(LT4EZCZB$\QRMX%D#R2,"\AX^\< >PH IW.MZE<:SHL
M.E+I4EEK$4DUO+)&V55$5N<=2=WX50T/Q3>ZIK36LUYH\)2\DMC:_9G,C!6(
MX;ISC-=)IO@VTTRYTV6*ZN&33FN#;1-MVJLN,ITZ+CBHK#P?/IEY)):>(-0C
MMI+E[EK7;&4RS;B,[<XR?6@#I?L\'_/&/_OD4?9X/^>,?_?(J2B@"/[/!_SQ
MC_[Y%'V>#_GC'_WR*DHH C^SP?\ /&/_ +Y%'V>#_GC'_P!\BI** (_L\'_/
M&/\ [Y%'V>#_ )XQ_P#?(J2B@"/[/!_SQC_[Y%'V>#_GC'_WR*DHH Y3Q'!$
M/%'A8") #=2Y^4?\\FINM^)8+#Q'I^CVEK!-)),BWCG $"L"5^I..GIS4OB/
M_D:?"W_7U+_Z*:K.J^#-"UB_2_N;&+[6LR3-,JC<Y48 )[C&/R% #O%E\-"\
M*:EJD%O TMK 9%#K\N1ZUQ<GCJYBL]2>W_LO44M;03F\MHV\J&0L (W]2021
M@]%-=18^"8;7P==>&[G5M1OX;G=ON;J7?* V. <=!BG:OX(L=5N9YQ<W%JUS
M;"WN! 0!+M(*,P(^\N.#Z$T 8MKXGN!:N5N=)U.YFFCM[:.W@>("1R>6+=L
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M"UMB7TR[O"77@-$L97\/G.:WK?0+.'PK'X=;?+8K9_8FW'YFCV;#DCOBL8>
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M%<X#8SQD<CV- '8?;;3_ )^H?^_@H^VVG_/U#_W\%<]_PKGP?_T+]G_WR?\
M&C_A7/@__H7[/_OD_P"- '0_;;3_ )^H?^_@H^VVG_/U#_W\%<]_PKGP?_T+
M]G_WR?\ &C_A7/@__H7[/_OD_P"- '0_;;3_ )^H?^_@H^VVG_/U#_W\%<]_
MPKGP?_T+]G_WR?\ &C_A7/@__H7[/_OD_P"- '0_;;3_ )^H?^_@H^VVG_/U
M#_W\%<]_PKGP?_T+]G_WR?\ &C_A7/@__H7[/_OD_P"- '0_;;3_ )^H?^_@
MH^VVG_/U#_W\%<]_PKGP?_T+]G_WR?\ &C_A7/@__H7[/_OD_P"- '0_;;3_
M )^H?^_@H^VVG_/U#_W\%<]_PKGP?_T+]G_WR?\ &C_A7/@__H7[/_OD_P"-
M '0_;;3_ )^H?^_@H^VVG_/U#_W\%<]_PKGP?_T+]G_WR?\ &C_A7/@__H7[
M/_OD_P"- '0_;;3_ )^H?^_@H^VVG_/U#_W\%<]_PKGP?_T+]G_WR?\ &C_A
M7/@__H7[/_OD_P"- '0_;;3_ )^H?^_@H^VVG_/U#_W\%<]_PKGP?_T+]G_W
MR?\ &C_A7/@__H7[/_OD_P"- '0_;;3_ )^H?^_@H^VVG_/U#_W\%<]_PKGP
M?_T+]G_WR?\ &J.K^#O VB:9-J%WH%MY,0&1'&69B3@ #/))(% '7_;;3_GZ
MA_[^"C[;:?\ /U#_ -_!7F;6G@2TM[F35?!<VG2P*C+#-"&:;><*$*L06)XQ
MD$5#<0^!["TNGU+P1+974$'VA;65%W2Q[@N5(<C.2,@D8H ]2^VVG_/U#_W\
M%'VVT_Y^H?\ OX*\QFM? ]I#=K>^"9;2]MX5F^R3(FZ5"P7*,'*G!(!Y&,UK
MZ+X0\,:KY_VCP2NG^7MV^>R-OSGIL<],=_6@"?QA=VS>)?!I6XB(74G)(<<?
MN7K2O%U)]2N'MM8TU[&= H@N$W&(XY((/.?0UR?BGP-X8M?$'A2&#1;6..XU
M!HYE .'7RG.#SZ@5T+^!O D5RMM)I.F).V-L3-ACGT&<T 1W?AJUV:7):WFG
M32V,#6[)?1K*DJ$@^ORD$<8['%27/A^TN]'%L\^CPSI="ZC$-N@A#  89,_-
MD#J>>GI3[CP%X(M(C+<Z-I\,8ZO(=H_,FF'P/X#6W^T-I6F"#./,+?+^><4
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M_0OV?_?)_P : .A^VVG_ #]0_P#?P4?;;3_GZA_[^"N>_P"%<^#_ /H7[/\
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MNHT16\J!=X;8N><8!'XUWBJJ*%4!5 P .@%+10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5D^)-(?7-#FLHIEAF+))%(PR%=&#+D>F1
M6M10!Q6J>&?$/B2WD_M/4;.U:)HI;2"V0R1K*C;M[E@"<],#&![U6UGPCX@\
M2V]W)J=QIL-U]E^S6R6^\IDNK,S,1GG:, #CWKOJ* .#U;PAK?B&2]N]3ETU
M;AK46MK!$7,84NKN78C)R54<#BM[PWI5QI?VA9M.TNS63:1]A=VW$9^]N45O
M44 <=XQ_Y&;P9_V$W_\ 1+UD^+K-]9\33-9::\]QIMJ##<PJNZ*Y)#(220<
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M.G=1SEE_*L]OA[>VUO!9VXTV[L;34)+JWBNRX+(\9!60@'+!CP>X ]*]&HH
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M27&0!(>@1-Q/4] >,5Z510!1T73O[)T2QT_>9#;0)$7/\1 P35ZBB@ HHHH
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MHKFO^%A^#?\ H:-)_P# I/\ &C_A8?@W_H:-)_\  I/\: .EHKFO^%A^#?\
MH:-)_P# I/\ &C_A8?@W_H:-)_\  I/\: .EHKFO^%A^#?\ H:-)_P# I/\
M&C_A8?@W_H:-)_\  I/\: .EHKFO^%A^#?\ H:-)_P# I/\ &C_A8?@W_H:-
M)_\  I/\: .EHK M/''A6_NXK2T\0Z;/<2L%CBCN59F/H!GFM^@ HHHH ***
M* "BBB@ HHHH **** "BBB@".>>*VA::>18XD&6=S@#\:9:7MKJ$'GV=S%<1
M9(WQ.&&1UY%9GBS5$TCPS>W3(DDFS9%$Q'[R1B%5>?<BN6\)3#PSJ;Z1=V+Z
M?!=6@N(@\T;[I(P!(1L8XW JWX-0!VR:QICW7V9-0M6GW;/+$J[MWIC/6FOK
M>E17+6TFHVJ3J<-&TJA@?<5P^GKIUNVA+;_V1J=D]QNM)8OW=W&6#'<1SO(S
M\Q^7U(J[?137?BW5;.RLM%N!-#$LC7DY#*<'.$"'?Z_>6@#K;G6--LYEBN;^
MVBD9=P5Y "1Z_2K:2)*BO&ZNC#(93D&N!O["]TW5M)T_38],OKR'2I(RNH,5
M#@/'C& 3] >W>M+P_J4.D^!WG=FDGM3)YMOL$;+*7)\H+DXY(4#/3% '20ZA
M;3W5W;H^7M-HF)&%4D9QGIG')],BHX=:TNY<I!J-K(P!8A)5) '4]>@K(2Q@
MTKP1>C5IS&;B"6:_G&<AI 2Y'LN<#T"BLG2DM;?Q+I=L\.C7;"TE6"[L/D9(
MP%SOCY&T\<[NO:@#K6UK2UM$NFU"U%N[;5E,HVD^@/K2WFL:;I[(MY?VUNSC
M*B64*2/7FO+F6'2]!D5=DVFZE=Y0 !A!<B7GZ!UQ^(_VJZ/6WL9-5UN6&ZT>
M>2&)+>]LM3&S V;QMDYV@JX_A(S^- '<QR)+&LD;!T<!E93D$'H13JH:')%+
MH&G200-!"UM&4A?K&NT84_0<5?H **** "BBB@ HHHH **** "BBB@ HHHH
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MV/3/'I0!ZS37D2-2TCJJCJ6.!3JXCX@ZC':/IB36JW-O$[W=S%+(%1X47#
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M"U_[\K_A1_96G?\ /A:_]^5_PJW10!4_LK3O^?"U_P"_*_X4?V5IW_/A:_\
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MJ[L?>- 'H<UA9W+AY[6&1U&T,Z D#TI@L+!K=H%M;<PELL@0;2P]1Z\52O\
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MBR0V=O&ZC"LL8!%6J* *ATK3V+%K&V.YMQS$.3Z].M3K!"DAD6)%<J%W!1G
MZ#/I4E% !6>="TDWJWITRS^U*VX3>2N\'USC.:T** *LFFV,TK2RV<#R-U=H
MP2?QI?[.LL1#[)!B+_5_NQ\GT]*LT4 ,$,2S-,(U$K *S@<D#H,TD4$,"%(8
MDC0DDJB@#)ZFI** *L6FV,$OFQ6=O')_?6, _G3;K2-.O9UFNK"VGE7[KR1!
MB/Q-7** *LNFV,TGF2V<#OC&YHP3BFRZ3IT]M]FFL+:2#.?+:)2N?7&*N44
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M=+TNY:+1H;"YD;>UO#,"LC! H.0 %SM Z>]8UG!XJ@TW["FEQ6S27_GM<+?
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M?3$FO(D:'SA("?NY48S72U&T$3,6:)"3W*BI* "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E_$?
M_(T^%O\ KZE_]%-745R_B/\ Y&GPM_U]2_\ HIJZB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#UY=S7NG6L4 6#*AU@"G+'A<-_*NB\1:%JVJ:1H7AV-8I515EO)KE6:)_+7
M1MISRQS^% "W\%UI;1+J'Q(-J95W1B:&W3</49'(IEWYMAY7VOXF+!YR"2/S
M([==Z?WAGJ/>LS2WU+2[K3X-=TBZOFL[26P:2&W,BR@.-C<^JX_*HM'L[GP]
MJ-O)J6AW=Q;S6#HEO'!YHBW3LRQGL,*10!KW9DL&C6[^)JP&6,2QB2.W7<AZ
M,/4>]).[VIB$_P 3EC,L8EC#1VXW(>C#U'O6)IWA#Q&EVJVLQTZ4:00GF0I*
MBLT[N(3N!QA2!QTJ&VL[FPGL#;P:YIMNFF10>7#:+<,'5WW*Q*GUSD8SF@#I
M)5F@N(K>7XEA)I@ICC:.W#.&^Z0/?M3FAN4U+^SF^).+W=M^SF*WWY]-N,YK
M'UC3[HZA>7-IINH"\N4@\M9;=)[>]PH^^-H\IAT/(QUI\NFWD&N2/;:1>+=S
MZDDTMM-&L]K(-W,R28!C..<9XZ8- &UJ%CJ&DHCZC\0Y+19#A#/! FX^V1S4
M$ZS6MO!//\2Q'#< F%WBMP) /[I[U?U^&2R\7V6L3:9-J-D+1X,11>8UNY8$
M,%_VAQD5S5GX7U:YU6QE1;G289;F\N4"QHQMXWV;4(.5&<$X[9H WQIFJ-I_
M]H#X@3&RV[_M'V>#9M]=V,8J"*"ZFL9KV+XD%[6'_6S+%;E$^IQ@5H>,=*O;
MCPQ:06T;WQM;J":XA  :XC1LLN.!D]<=\5BZ[;2ZS&U[IWA>58K>YMIIED01
MO>HA;<GED<[<@C/4\4 3H)I+)KQ/B8&M48(TPCM]H8G !/J:EOK:\TPM]N^(
MS6VW&[SH8%QG..H[X/Y&L+Q%HT_B>>6XMM#N;;3Y9+.":.2,(;@"92S;>H"K
MD9/K5[1M&UJVO/$-EJ4#W$4-@MM973?,;A!OVY_VP" : )/M:>2DO_"THO+<
MD*VRWPQ !./P(_.K)@NAIBZF?B018,VU;DQ6_EDYQC=C&<\5"?#^IW">%(K5
MWL)(-/F2:;R$D",5C #!ACG!_*N?'A76=:TBW\,O9BW\J>XN=0GNU)BFE)VJ
M4VXX.[< .FV@#JKZQO\ 3%C:_P#B');"3[AF@@7=],CFJUU(UE(D=U\3DA>1
M0R+)';@L",@CUXJAHO\ :]C=VUYK^BW-Z8;)M/W1Q>9MDC<KNQUQ(NTY_.MV
M739)X/"#IHBV(AU#S);52'%NGV>< $X'=E_$T 4W\V.\2T?XF*MRX4K$8[<,
M=W3CWIL[O;7KV<_Q.6*Y1@C1/';AE8X(!'8\C\ZH7NGW<%GXET:7P[/=7NH7
M$K6E['$I5U<#8S/_  [/TP,52N/"6NO8^(_->>XMVO(C/:") UY$L$0<HY!(
M8X('/:@#L'\.Z_&NY_&]VJ^K6D('\J1?#^NMLV^.+H[QE<6L/S?3CFJWB^>>
MYDL[."%Y(SI]S=Q6Y7F29%41@CV+YQZX/:N6T_1_$NA7EI8&.[:PTRW5(KN)
M=\@29DW[1SEE",.G0YH [7_A&O$7_0Z7O_@'#_A1_P (UXB_Z'2]_P# .'_"
MIM#U>YMM/L[75HKO[9)(45I(\DJSN4W$<9"*,^]9OBF[U^+Q):KI\-^]DL67
M2W4 .<,2=W.>@&#@\@@T 7!X;\0,,CQK>$>UI#_A1_PC7B+_ *'2]_\  .'_
M  KCK:U\6V&A0O:W.IF-)(8#$V=VTQEI9/NELF3"@X. 3]:L_:?'QNXDDCN,
MQVZ$*G 8>62Q8XP6W?+U&"!QS0!U \-^(2,CQK>$?]>D/^%'_"->(O\ H=+W
M_P  X?\ "F>&+B>W\#/:6*7,^HZ?;["+H$%YS&),9/7E@/;IVK">?Q+]G*12
MZZT;PLT<C0H)'N0HP.GRQDD]0!QZ4 =!_P (UXB_Z'2]_P# .'_"@^&_$ (!
M\:WF3T_T2'G]*YV>_P#&4[I;+#>PSMY_FRJGR(2T<<>W/4#<[_A6;J)\0V-S
M<7UW=ZD$TX3-922/CSSYRJ%('!)56Q[.* .T_P"$:\1?]#I>_P#@'#_A4:Z#
MKC2-&OCJY+K]Y1:PY'U&*TO#MW=2VTT5^TCZB/W\\9^Y"7Y$2GOM&!^O>O/+
MC1M0<:E]GL-0B%RFZ27RREQ \D\8DC\P'$J["S XX"]>: .U_P"$;\0 9/C6
M\QZ_9(?\*/\ A&O$/_0ZWO\ X"0_X5QUR?%E_=RV4L.J0Z?(JQOL8EH\3H!@
MA1_ &)QG.>M=%X*E\42ZC=-K"S" 1G*2# #[CM5,@=%'N#P<T 7_ /A&O$7_
M $.E[_X!P_X4C^'=?C4L_C>[51U+6D( _2N4M;KQOJ>HB%_MUE#<2PM*3R80
M&9I%5BH ^50G (R>]/DA\3:K]CTS4!J)AEGA!S&-GD[B[&1N[<!>WZF@#HYM
M&UBW<)/X]GB<C(5[>!21^(I'TC5HR _C^9220-UO ,D=NE4/%-I9Z]XPMK'4
M]'G:RM/+8W*V9D-P_54#@?*BYR?4\>M<]H_@O6=9GG^UPV=HDD4DCO>V9F97
MGE=V\OYU"LJ[!DYH [5_#VO1IO?QQ=JO]YK6$#^5.'AKQ"1D>-;PC_KTA_PJ
MAK>EO;:MI:7%C>ZII-II[0QPI\^^<8"EQZD#ACP#FL[S_%MOE+*QO()K=L0V
M9(D@6#RLC+G[[[^.O;IB@#?_ .$<U_?L_P"$VN]P&=OV2'./RH'ASQ Q('C:
M\)4X(%I#Q^E<1./&(O[V]LH]3992MO%+*FV9@D8<#A3A3)(_4?P@$@5W?A(7
M$UYJ][,P=99(H]Z_=>1(PLA'MNR/PH 9_P (UXB_Z'2]_P# .'_"C_A&O$7_
M $.E[_X!P_X5U=% '*?\(UXB_P"ATO?_  #A_P */^$:\1?]#I>_^ </^%=7
M10!RG_"->(O^ATO?_ .'_"C_ (1KQ%_T.E[_ . </^%=710!RG_"->(O^ATO
M?_ .'_"C_A&O$7_0Z7O_ (!P_P"%=710!YGKOA_7(_$7AU'\67<CR7,@1S:Q
M QGRV.0,<^G-=#_PC7B+_H=+W_P#A_PI_B/_ )&GPM_U]2_^BFJ]IWB?3]1>
M7;((D$\L,+2,!Y_E'#LOL""/PS0!G?\ "->(O^ATO?\ P#A_PKC-!U3Q#J/B
M7Q7IVH>,GL[71)XHDG:WA&\.'Y;(P/NUZ-9^([.^UE=/ARPDM1=03J04F3=M
M.#[''YUXY!;23>-O'LT:LS6VL64PS;?:(QA9AF2,$%EY[<YP: /1_P"R]4^S
MPW'_  L"7R9V"Q2>1!MD)Z ''.:L_P#"->(O^ATO?_ .'_"N"A\+^)=8TFRT
MM;> ):QSW@:?=;JDTLC^5L #8*J-V.VX<UW/A'QE)KKSZ?=:3?VE[86\37#S
M1;8W<K\P0]3@YH :-%UAKB6W'CRX,T2AY(Q;0;D4]"1C@4S^R]4-K'=?\+ E
M^SR,%27[/!M8DX !Q@\US%II_B.SUE?%$UA&8=4EFAN41V,RP2#]UN0K@;"B
M]"?O&LC2="US^Q+'0KBQN!8Z>Z:A$Q'WF<KA/^ LTI_ 4 =S'9WTUP((OB*[
MS%MH188"V?3&*GCTC5IH(YX_'T[Q2DB-UMX"KX!)P<<\ G\#7/\ @Z.XL;V"
M"YO+F(B]G)M#I0(PTKD?OMN>00<YXSBJ>@:)K.B0^'+!+6:33+B-[E@1S:3"
MTF5E/LS."/?/K0!TMM:7MXS+;?$9IF5=[".&W;"^O Z5)_9FIFVAN?\ A8,O
MD3$"*3R(-KD] #CFN4L-/>^T;PW#8:3<07NGV<HOIVMS'\IMV7R\D#<2Q7UZ
M52/AW6OLFF:0;*==/T:[AN8"!Q)YK(VW_@&Z4'Z"@#M([2]EF\J/XC,\F2-B
MPP$Y'48Q4ITO5!;Q7!^($PAEYCD^SP;7X)X..> 3^%<]X76:SMC9W$LZRF6Z
M MCI?0M)(5_?8[Y!S[XJ'1]!U;2+WP=IQM9)M()6YRPS]E?[.RR1MGL6;(_$
M4 =':V-_>S>5:_$1YY.?DC@@8_D!39+6\AOA8R_$=DNR0/(:&W#Y/3C&:UO"
MNFK9RZR[6B0L^IS-&WE@$H0N,>U<9=6@33-;T"[\/W%QKEW=S/!>)!D3;FW1
MR^;T7:"!C/&R@#?-CJ N_LI^(<GV@/L\KR(-V[TQCK2WMCJ&FR1QWWQ$>V>7
M[BS00(6^F1[TGAO0-2CUK5;N>[1(O[39_+>S0F4!$^8.>0"1V]*S_'MIG6FN
MHXKM+E[/R8G^QB[M[D9),3)C*G..<CK0!>O+6\T^2..\^(S6[R#<BRPVZEAZ
MC(JTNAZV[2*GCJY9HP&=5M825!Z$\=\&L"%1IEY?OK_AF2[?4;6W%LD%MYH
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M>E:?XF\;^(1KL,=X]DT<-M:S_,D<17.\*>Y)(S[4 =S+<P01B2::.-#P&=P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=:**
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M;V+2KN6*.X;&Z2-5#?,1P2,D9]JYO4KG6I+.SN_[2NI\0M>ZE9V%RL4\:O\
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MKM<3)<, _08.01TK=^&=WJ=[JWBN76+0VVH+/!%.F/E+I%M++Z@XR/K7H]%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUO6M8_L&]TC4]/BLM98JJ261=H2L3NP)WC/*$=!0!I_\+(\/?WK[_P  I/\
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M+^5 '*?\+(\/?WK[_P  I/\ "C_A9'A[^]??^ 4G^%=7Y:?W%_*CRT_N+^5
M'*?\+(\/?WK[_P  I/\ "C_A9'A[^]??^ 4G^%=7Y:?W%_*CRT_N+^5 '*?\
M+(\/?WK[_P  I/\ "C_A9'A[^]??^ 4G^%=7Y:?W%_*CRT_N+^5 '*?\+(\/
M?WK[_P  I/\ "C_A9'A[^]??^ 4G^%=7Y:?W%_*CRT_N+^5 '*?\+(\/?WK[
M_P  I/\ "C_A9'A[^]??^ 4G^%=7Y:?W%_*CRT_N+^5 '*?\+(\/?WK[_P
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M\^)F:2*R57)61<.&5BI3'=MRD<5Q.DVUWH/A6\&L66K/9:O>3RSSQ,?M5NI
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M7344 8>C^&UT;6-1O8M0O)8+M8UCLY),PVRH, 1KVSWK<HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Y?Q'_R-/A;_ *^I?_135U%<OXC_ .1I\+?]?4O_ **:NHH *\P^'/\
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M/5'^(/BDV,A8+.EV64;3ALXCXP1WICQZ%&(BWCSQ?F4%D7SGW$ X)QY6<9H
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M?_B*/^$!?_H<?%7_ ('K_P#$4 =C17'?\("__0X^*O\ P/7_ .(H_P"$!?\
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M550JJ HX  XI$C2,$(BJ"<\#%<E_8WCG_H;[#_P4#_XY1_8WCG_H;[#_ ,%
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M0K,EUH/EDJWW6'[S!!QV- 'I]%<A_8WCG_H;[#_P4#_XY1_8WCG_ *&^P_\
M!0/_ (Y0!U]%<A_8WCG_ *&^P_\ !0/_ (Y1_8WCG_H;[#_P4#_XY0!U]%<A
M_8WCG_H;[#_P4#_XY1_8WCG_ *&^P_\ !0/_ (Y0!U]%<A_8WCG_ *&^P_\
M!0/_ (Y1_8WCG_H;[#_P4#_XY0!U]%<A_8WCG_H;[#_P4#_XY1_8WCG_ *&^
MP_\ !0/_ (Y0!U]%<A_8WCG_ *&^P_\ !0/_ (Y1_8WCG_H;[#_P4#_XY0!U
M]%<A_8WCG_H;[#_P4#_XY1_8WCG_ *&^P_\ !0/_ (Y0!U]%<A_8WCG_ *&^
MP_\ !0/_ (Y1_8WCG_H;[#_P4#_XY0!U]%<A_8WCG_H;[#_P4#_XY1_8WCG_
M *&^P_\ !0/_ (Y0!U]%<A_8WCG_ *&^P_\ !0/_ (Y1_8WCG_H;[#_P4#_X
MY0!U]%<A_8WCG_H;[#_P4#_XY1_8WCG_ *&^P_\ !0/_ (Y0!U]%<A_8WCG_
M *&^P_\ !0/_ (Y1_8WCG_H;[#_P4#_XY0!U]%<A_8WCG_H;[#_P4#_XY1_8
MWCG_ *&^P_\ !0/_ (Y0!U]%<A_8WCG_ *&^P_\ !0/_ (Y1_8WCG_H;[#_P
M4#_XY0!U]%<A_8WCG_H;[#_P4#_XY1_8WCG_ *&^P_\ !0/_ (Y0!U]%<A_8
MWCG_ *&^P_\ !0/_ (Y1_8WCG_H;[#_P4#_XY0!U]%<A_8WCG_H;[#_P4#_X
MY1_8WCG_ *&^P_\ !0/_ (Y0!U]%<A_8WCG_ *&^P_\ !0/_ (Y1_8WCG_H;
M[#_P4#_XY0!U]%<A_8WCG_H;[#_P4#_XY1_8WCG_ *&^P_\ !0/_ (Y0!U]%
M86BZ?XCM+MWUC7;;4(#&0L45CY!5LCG=O.>,C'O6[0 4444 %%%% !1110 4
M444 %%%% !1110 45EZY8:K?V\2:3K/]ERJ^7D^RI/O&.F&Z?6L+_A'/&?\
MT/I_\%$/^- '8T5QW_".>,_^A]/_ (*(?\:/^$<\9_\ 0^G_ ,%$/^- '8T5
MQW_".>,_^A]/_@HA_P :/^$<\9_]#Z?_  40_P"- '8T5QW_  CGC/\ Z'T_
M^"B'_&C_ (1SQG_T/I_\%$/^- '8T5QW_".>,_\ H?3_ ."B'_&C_A'/&?\
MT/I_\%$/^- '8T5QW_".>,_^A]/_ (*(?\:/^$<\9_\ 0^G_ ,%$/^- '8T5
MQW_".>,_^A]/_@HA_P :/^$<\9_]#Z?_  40_P"- '8T5QW_  CGC/\ Z'T_
M^"B'_&C_ (1SQG_T/I_\%$/^- '8T5QW_".>,_\ H?3_ ."B'_&C_A'/&?\
MT/I_\%$/^- '8T5QW_".>,_^A]/_ (*(?\:/^$<\9_\ 0^G_ ,%$/^- '8T5
MQW_".>,_^A]/_@HA_P :/^$<\9_]#Z?_  40_P"- '8T5QW_  CGC/\ Z'T_
M^"B'_&C_ (1SQG_T/I_\%$/^- '8T5QW_".>,_\ H?3_ ."B'_&C_A'/&?\
MT/I_\%$/^- '8T5QW_".>,_^A]/_ (*(?\:/^$<\9_\ 0^G_ ,%$/^- '8T5
MQW_".>,_^A]/_@HA_P :/^$<\9_]#Z?_  40_P"- '8T5QW_  CGC/\ Z'T_
M^"B'_&C_ (1SQG_T/I_\%$/^- '8T5QW_".>,_\ H?3_ ."B'_&C_A'/&?\
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MDV8US5SO2&!CY415-J#<1D^I.*F_X1SQG_T/I_\ !1#_ (T?\(YXS_Z'T_\
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M/M[:>*"+<!LN'#%6 !4G.2#@<4 84'Q!OEUIHS9F:Q2TO)WWND;AHI44#).
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MT[]U-/%/;7$WE1 9?88L<GH?GXI\GB*YN_#?B&3[))I]_IT,@*,ZOM;R1(C
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M+>00P%+>W: *L;2-WD8DDR>W2@"CHGC>+6?$=SH_V)H7A:1=SS+O.QL9,?!
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MT;S;BW_=7"R%IH4+LJC R"!P>.>U:>D^+CK/A?4]42&"UDLUDZSB1 53<"V
M&7KR"H/'<8-7)O!^ASOODM&+>?+<9$KCYY5*.>O<$_3M4]AX:TO3K6]MX87=
M+XDW)FE:1I?E"\EB3]T 4 <Q\/?$>KZQ+>1:L)U*6\-Q&+F$1.2X.XJ!P8\C
MY2>?6F-\4K=+N[MCI<CO# TR"*Y1RX614P<<*?F!ZFNMTW0-/TDRM:QR;I$6
M-FEE:0[%Z*"Q. ,]!67'\/\ P[%(KK:S';$8$5KJ0JB%@Y4 M@#<H- &==>.
M[]#)8PZ QU42SQ^1]J78JQQI(7WXYXD7 QU[]ZOKJ>LW7PZAU.R-L-2DLA,6
MN,A%.W). .3Z#I5V^\(Z-J,[SSV\GG/*TIDCG=&W,@1N5(X*JH(Z<5H0:9:6
MVDII<496S2'R%3<3A,8QGKTH X&[\1>(%TW0[[9?_P!G_P!DQW>H75G'$2'*
MJ22)". ,G"@FO09KM(-->\&98TB,HP0-PQGJ< 9]ZRY_!^BW,%M!);R>3;VZ
MVJQK.X5HEQA6 /S#@=<U;31H397UG<NUQ;7;-NC<G"HPQL'/ Q0!RFG_ !,3
M4II;:#26>[22!$C2Y1E;S=V/G P,%#GK[9JAKGQ*OO\ A'-1ETO2&%]:V<LU
MPS3KMMF61H^./WF&4GMQ^5=78^"="T^]^V06\YG_ '6'DN9'QY>=@^9CP-QX
MJ&[^'_AR]BEBFLY=DRR+*$N)%WAW+L&PW(W$GV[4 +K?BJ319=*MTL#=R7D,
MLSMYPC$:1*K.>0<\-P/:N:E^)TVH:<7TRP\B9F@DB::3<K1/(J'.!\K?,..>
MO4XKN[G1;"\NK6YG@WR6L<D41+' 60 ,".AR%'6LN/P+H$<#0"VG,918U5KF
M0^6JMN4)EOEP0#QZ4 4KSX@6]EI<%ZUA*_F_:?W:2#(\DD'MSG'%0/X]OH)I
MX[KPU/ +4PFZ)ND;RED;:N,9W$9!(!Z=ZTCX!\.M([M:2MN,IVFYD*KYAR^!
MNP,GGBM*Y\/:9=M>--;EC>>7Y_[QANV'*]^,$=J .2LOB#,-/>7^S9KJ.W42
MW,[3*FQ&E=!@ <D;"<>@Z^NCIOCEM2U.SB72)4L;Z>:"WNS,IW&/.=R8RN=I
MQU_"M&W\&Z);65Q:);.8;A!'*#*V64.S@=>.7;\ZQ]+\!O9>*HM4>6W6VMI)
MI((H?,!8R9ZJ6VKC/.T<F@#MZ*** "BJVHW;V.G3W4=I-=O$A800 %Y#Z+D@
M9KD?^$^U/_H0O$W_ 'ZB_P#CE ';T5Q'_"?:G_T(7B;_ +]1?_'*/^$^U/\
MZ$+Q-_WZB_\ CE ';T5Q'_"?:G_T(7B;_OU%_P#'*/\ A/M3_P"A"\3?]^HO
M_CE ';T5Q'_"?:G_ -"%XF_[]1?_ !RC_A/M3_Z$+Q-_WZB_^.4 =O17$?\
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MF6V$MM=9F*SQRN"IE(+]^<D X[4 &NZE=07^C:?:L(Y;VY_>MC.V-1N8#W.
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MH!5L74GS@MNPWS?,-Q)Y]: .?T;XDR7&EWDAL9+R6RN!;S,KB/,CRE455/4
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MBTW2$D:"(!C(97SDEB?N]#ZYKK* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YIO'&DKK=_IC+<;K%
M6-Q.(\QQ[4WG)SD<=R,&J7_"S-":&-HH[R:>2=($MHX@9275F0XST.P_UJ35
M?A_IVLZY)J-[/*ZR*ZF)54'YH]A&_&[&.<9QFLR[^'#0C31IEZT<L.H1SO<+
M'&C1QI'(HP N&.6&<]<F@#5O/B%H]EI\=[+#>^4=PE(A_P!05;:P?)P"#V&3
M1_PL#3F:]\FPU.=+28P/)%;Y0N.H#9QTP<G YJA>_"[3;T9>\G\UXG2:1HT<
MN68LSC(^1B3U';BK=S\/K*XTY;,W4F%OFO@6C5P788P5.01]: *L/Q.TV6[E
MD-M.NF):1W"W6T<L[E F,]=PQ3/%7Q"%E\-M2\3:"(Y+BTDCC,5TA(1C(BD,
M 1V;L:?%\+],2Q2T:]N7B6,(<A?F*RF5">,?*21CH1UJSJ?P^L]2\#WOAEKQ
MXH[R19))XXD4Y#JW"@ #[H% %>#XF:8^GJ"KRWPM=Y6-<(\PCWM&I)SG_.:C
MLOB9 9;O^T],N;..&*W,>0"TKRJ3M S[<?0YJ>P^&>E:>X\N:0Q[""IC3)<I
ML+;\;L=\9QFFR?#2RN,-<ZA/-($B"L\:$!X]P1R",'Y6((Z&@#2L/'.F:IJ%
MI9V,%[.]PI8ND.5AP2IWG/RX(Q3KCQOI-MJ4MFXN=L4PMI+D1?N5F/2,M_>.
M:GT'PO;:#*989GD=H?*;*JH/SLV<  #EN@JI=^![.ZOI93=W*6LUT+R6T!&Q
MYQC#9ZXX!QTXH M6?BW3[KP[/KDL=S:64).6N8]A<<891W!S@&N(U/XP00>,
M='L;4PQZ9+',^HFXC/FP[$+C&&QR![UW<_ABRN_"H\/7!>2T$2Q[LX;Y2"#^
M8KCKSX+Z/J.JV]]=WTS&-)$DCCA2(2!TV_P@8QU^M &_#\0]&N8,V\=Y-<F3
MRQ:1Q;IB=I;(&<8V@G.:JR_$:WMKJ=9])U(0B:&& I!EY'D0L%VDY!X-3V_@
M&VM462"_FAO8Y?,BN88HXRORE"-H&T@J3U'O4Q\$PG5+>];4KIQ#-#.8WPV^
M2-2H8GKR#0!"WQ'T1()9WCO4@19&25X,++Y?WPISR10_CZP^T0(4FM +@QW*
MWD)1E3R7D# >A"=_>FS?#NPFA:V-[=?8U\TV\&1B%I"2Y!ZGJ< ]*M:EX(T_
M5=4DO;F64B1@7B' (\IXL9^DA_*@"]I7B2TU:TN+I8+NUA@02,UU"8PR$9##
MU&!6:/'^F&!9?L>ICS65;93:G-SNS@Q\X/"D\XXK0TWPXEEIUQ8W-]<WL,T0
M@VS$#9&%*A1CV/7J:SAX%B\FW4ZO?E[-D-BY8?Z.%# <8PW#$$GD\4 13_$G
M180K"&_ECVYF>.WR+?#^61)SD$-QBEN/B-I-L 'L]2,@:4/"MOEX_+ +%AG@
M88&GQ> -/AM+F!;B<FY7]](V"SOYOFLY]RQ/X5)/X'LY]1O+QKF8/="<, !@
M>:J*<?38/SH DL/'&E:E<)!"ETLCRQQ*)8MN?,5F1A_LD(W/M4-W\0-*LYD2
M2"]93%YSR1P[EB3S#'N8YX&Y31+X&MVG%Q!?W$%P@M0DB*IV^0KJ#@\<B0YI
M!X"LQIL]D;RX99K/[(SM@MM\QI,_7+&@!(O'5HKR1207-S,MQ,FVSMV?9&C[
M=S?_ %JKZO\ $G3].%[!'97K7D$,LD,<L7EB?R_O;<G..^2.0#BK2>!X()VG
MM=2O+:21Y3,T3 >8CMN*^V">".:H-\+],>]EN&NY2)#.=NQ0W[Y2&R^-S8SQ
MD]J )K3X@6S&=+JUN#<B7"6MO$6D5!#'(S,,XP/,ZCU%3P?$30[K4([6 74J
M220QBX2+,0:5=R GMGI44?P^@BD>ZBU6[CU!R0UTBJ"5:..-EQC'(B4^QJ6U
M^'^FV4?E6\TR1"XM9U7@X,"@*,^^.: +NK^,M+T2ZEM[TRH\;P)G;PWFL54C
MV&"3Z &L;_A9%JGB&[M7L[AM/@A1_M$<6[:3*\99N>$RHP?K6KXB\&:=XEO8
M;J[:17BMYK<!.A$B%<GW 9L?6JT7@"PALY[9+F;;-816+$XSMC9FW?4ECF@!
M8_'-HD:));W5U<LT[,EE 7V1I,T89AUZK^)SBG:-XUAU'59--N+6XAF-W<V\
M,OE$12>4Y& V?O;0":1? MO#()K34;RUG99(I9(B 9(WE>7;[89S@CFKMOX5
MMK>ZLYUGE)M;JXNE![M,22#],T 9UQXZM]/U:\L;FVN+AXYVCB2TB+-A8U=B
MV3Z-6;XJ^)MOIOAF^O\ 1K:>ZGAMTE64VY:&,N 5$A!!!P?PR*WO^$/M/[<G
MU7[1+YLS2L5P,#?&J']%%8M_\+K.ZT*XTBWU:]M;:ZACCN%CVD2%  K<]. ,
M@<'% %SPOXZ@UGP[:7ETA6Z(MH[@1IA!+-$L@VY).W#BJZ_$FR;4Y&:WGBTA
M+'[4MU+$5,V9 BF/GE3D8^M.TWX;6FF1VL,6IW1MX?L[/$57;+)#&(U8]^54
M9'2E_P"%:Z?)!]FN+ZZGM8[9;6VB?;B"-7#H!QS@J.N<B@"1_B;H %JL8NI9
M[AW3[/'&#(A3;NR,\_>7@9)S6UK?B.UT*RBNKBWNY5EZ"&+)48R2V<!>/4U@
MW7PVL+K35LWNF&6=I66WC ?=C^'&%("@!AR*TM<\&6>MV^G123.GV %8RRK(
M""H4Y# C.!P>HH EO/%VG6GAZPUM4N+FUOC&+=8(]SN7&5&VLJX^)6D W%O;
M17,EXB/Y4+(%\R1%RT8Y^\ #GZ&M2#PG;0>']&T@7$C1:5)$\3D#+^6" #^=
M4(?A[ID&K3WL<KA97FE\ORTRLDH(9M^-Q'S' S@4 0:7\1;%DM+;5@8-0D5/
M.$:?NXI' *H23G)!%2-\2]$CLX+J:&^A2=6=!)#@F-0,R=?N\]>].'P[TM=5
M^W1R,I9DDE0QHV]U4*"&(W+P!D TM[\/=.O+;3X_/=);.U%F)#$C[XP!V8$
M\=10!+!\0-&GOWMU6Z$*RM%]K,7[C<$\S[^>Z\BF-\1-'CLA=2P7\22,@MQ)
M;E?M&X$J4).#D*3U' J=?!&G""2W\R3R)+TW908 &8S'M'M@U4F^'EI<V5O;
MW&HWDYLV4V9FVNL(52H&PC:W#$$D9/'I0!+K'CBVM?!\7B'2H&U"&69(E1#@
M@E]IS[@Y&/6K6G>--,U'4(K...YC>9WBCDDBQ&\J [T#=RN#GZ&B?P?9R^%%
MT%97BC4AQ,B*&WAMV[ &.M0Z=X*MM.U&VN5OKF2&VEDN(K=L;5FD!WOG&>=S
M''09H S=3\?75AKLVGKI$[QPZA!:%U7<9!)&[?*,]<J,5;E^)/AZ&.V:22=3
M*F]U,?,"[BN7&>/F!'&>E7+GPA;W&OC5?M<R_P"DQ71A &TO&K*#GKT;]*RG
M^&&DM/YZS2"5LK*S1H^]2Y< ;@=I!8C([4 ;&O>+].\/SV<%Q'<SRW8+1);Q
M[V*C&3C(SU' R:R_$/Q#L=-TK5I+193<6L$X@FFA/D/<)&S^63D'/'(X],UI
M>*/"-MXHLH[6>X>&)5*$"-7!4C'&X<'T8<BLN_\ AK87ME<V!U"[6QF65EMR
M0RI*\9C,F3R3AB<$XS0 W2_B#')90M>P237<P39;V4)9S^Z5W.">@W>O<5(G
MCLG6(;7[!-+;R33H9(XFW1K'$CX*GDM\_:EM_AW:6C03VNI7<%Y"GEI<1XSL
M**C#!XY" ^QIUU\/;2YA\O\ M&\3,LLCN&RS"2-8V!)YZ(#F@"&3XC6\MQ90
MV.FW;R2W\=G/'*H5H@ZE@V,^@Z?6G:3\1],N[&SDN?-W2)%]HGBB/DPO)@(&
M).1G(_.DM/AQ:6<\<\5_*DB7$-P/+B1%#1A@,*!C!#$'\Z+/X::=96T-I'?7
M?V0&%KB#(VSM$04)XR.@SCKB@#4T?QGIVLZFMA##=Q22)*\3S1;4E$;!7VG/
M."1^=17?CK2K'6)--N(KR.5?,"R-#A)"B[F"DG)X'7&/>K-GX6MK.]TJZ2:0
MMIT=S'&"!AA,RLV?IM%8\WPUT^;6)]0-W*&EFEFQY:EMTBE6!?&X@ \ G H
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MXOM<2170B1%,H48SG&5)![5+<^"+;)_LN^GTT/ D$RQJKK(J#"DA@0& XR*
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MY4C X4=!73:9:7%E9+!=7TE[*"29I$52?P7B@"Y1110 4444 %%%% !1110
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M=Z1EBN[Y3DC>WYT ,\8:]J&A66C"*[BBDN[D0S7#6QD &QFR(P<]1TS7.?\
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M--DU>\U&&:&.VDG:R32Y(^@. )BQ![<XYJ7Q7KGC3PWX/O-9DO=)D(MA(!'
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MS07>MZW=I(%V^?=@F)E8,'0A1A@12CP-IC03B:YOY[N:5)C?23_OU= 0A4@
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MCNK9H##'!&'0*-X?<,N=N"!@+@4 ;6A>+[77-#O=2CA=!9EA*FX$$JN[Y6.
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M171O=+EN%^UW<-O-&P ?RBQVXZCY5//<@TWQ7XWGD\!>)=3T*1H6T](EAO
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M>%Y-'\,%H518SNGX"'*?Q<X/3-6I?#OBQXD633_#7EQ)(JY:;"J[;G[]R,T
M:(\>W)T^?4_[(A73@94@D>]"N[QMMP4V\ G/3<>.G-8%W\1-6O[9I;6UBM([
M=[N&Z59B78QVXE5D+1@C[W<=1WHA\-:SJR2WMMI_A"ZCN-V98'E92<Y8J5;
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MW4=-@_X1^Y60RZZ]U'%?M]M9;L3,V'1HR#F,=2.!@<5Z^R6\4:EUB1(^5)
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MI-?7&G+)(Q6Z@4P@(2?O*0SA2?:O6$TVPCMC;)96RP%MQB6)0I/KC&,U8$:
MJ0BC:,+QT'M0!YE9ZI+J/PA\1ZC$\Z-(UXT>\D.GS' ]1BJKZS8>&M86?P_,
M]S&NE.]S:Q3M+&;C*B($$G#,QQQSBO5O)B\MH_+38V<KM&#GVIB6MO&FU+>)
M5R&PJ #/K0!Y%86UP="US1_$%G?QWEM8O?V;74^7+,G[P@HY! <9 /3-.UMK
MZWEM+7PWIU_+'H]M'?3&WF&TW#X.'WN"PV!^!G[PXKUYHHW;<T:L<%<D9X/4
M4JQHF[:BC=UP.M ''ZQ?)K]WH5I'.4TVZB:^N"I(\R- "%/L21GZ5S_@BRFU
MC6;/4KQW:-;9M1\EQE1+/*S*W7J$"@>E>C2:7:R7EM=&,+);*R1[>!M88(QZ
M5:2-(_N(J\ ?*,<#I0!Y;J/C+Q#'';WB75K!9WMS<I$S1JHCBA.,EF."S'I[
M T2>-M?E>&+[596MX!9HEL8]QNS-R[CG(4+TQW!S7I[VMO)$(I((GC!R$9 0
M#ZXJO=Z397UQ:SSP*TMLXDB8<$$=/PYZ4 ><:A\0[V32&2$VTMS+%<R/"%)V
M)YGE0H<'(8D@G\:9/XDU_2[*V$%S9V^G->2V-ME H2& %=VYVP22IQGL*]1%
MI;+G;;Q#)R<(.3US2R6MO+$(I((GC!R$9 1GZ4 >2ZGXPUJ_T=[6XN[2UGDB
MMX1 B$O<F=B-R\Y "^G?/:NV\$)Y<&M(C%K9-4E2 YSD*J!L>V\/^M=#/8V]
MPK;HD#E-@D"C<H]CVI-/L+?3+&*SM4V0Q# &<D^I)[D]: +-%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5R$'B34V\4ZIH4R6L;H5%C<;6VLQ4.
M5<9Z[3QCT-=?7)3>&]2NM3UN:1[6%+N2*:TFC=FDBDC4*I8%0,''.#W(H =I
M_C%#X>T6ZO8)9]2U*S2Z%I8Q%V"L <X)X R!DD<U/?\ BZV3PG<ZWI\,USY0
M8&+RB&1QG(=3@KC'-8[>!;J'3]",:6%Y>:?IL5A-'<221QR!%'S*Z@D<CNIX
M-:]KX:=?"^H:8T5G:2WBOD6N]D4D8!);EC[X% &II&J_VK;^8;.[MB%4D7$6
MS=D?P^M:-9.CIK<8$6IIIZ0QQA$^S2.[.1W.X# QVY^M:U ')1ZMXDF?59X(
M]/E@L+MX?)PZO(BA6X;. V&],<5;N/&6G1-&L%O>WLAA6>1+2 R&%&&07]"1
MVZ\=*J1:/XD1]4MXY=-MK>_NWF^T([R2QHP5<!2H&["]<X&>AJG>>")+?57N
MM.M-/NX9HXTDCO)Y8F0H@0%60'(( R".HZ\T =#)XGTP:;:7T$DETEZ<6R6Z
M%GE/7 ';&#G.,=Z;:>)K2\MKV6.VOEELL">W> K*I(R!COQSP2*SF\-W]E9Z
M5+I/]GPWFGE_]'*NL#J^=R@\LO\ O8/TK06+7VL+QYETTW<H"Q0([B-!T.Z3
M;N8]_NCT]Z &Z5XMTW6(Q/:+=&S:'SA=O RPD8R1N/&1GZ4RR\8Z;>W=O"(;
MV&.Z.VVN)[<I%.>P4GN><9 SVJ/1M&U%?"ZZ#J\=DL$=FEJLEK,[%\+M)(9%
MQT![UE:5X.O+.YM$N++1VCMG#"Z629I& Z'RS\JM[[C]* .CO/$%M87?DW%O
M=I$&5&N3"?*4G&,MZ<CD# ]:=J6O6^FW45J8+JYN)$,@CMHMY" X+'IQ^I[5
MR>L>"]8OWU 1_P!F2O<3F9+RYEE\Q5R"L>P#:H  &0??&:UM<T;5M3DA;['I
M-S&( K1SSR1-%)_$4D1"2/;C..U %ZX\5Z;;Z;9WN+B0WI*VUND),TI&<@)U
MXP2<XQWJUH^MVFM1S&W6:*:W?RY[>XC*21,0" P/J""",@YKG;SP7<W.EZ-Y
MLT%Y?Z8' 6X9UCD5P R[A\PQ@8;D\<CFM?PWHTNE?:I)K.QM7G*_):.\G"@_
M>=\$]?08]Z +.B^(-/U]+MM/D=Q:SM;R[XRN'7KC/45J5E:'#K4*78UF:SE9
MKAFMS;*5Q$>@;(^]6K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'E'[0O_)-8_P#L(1?^@O7RO7U1^T+_ ,DUC_["$7_H+U\KT %%%% !1110
M 4444 %%%% !1110 4444 %%%% '7?"W_DI_A[_K\7^1K[1KXN^%O_)3_#W_
M %^+_(U]HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% %/5HK*;2KE-1<+9E,S%G*#:.>2.U8>A6[W&HW>L6
MMHEC926XAMH @4SX)(E8=NN .N,YZU<\6W&@P:!(GB3!TV9T1U,;ON8'<O"
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M_P!!:3_P"G_^(H_X6GX-_P"@M)_X!3__ !% '8T5QW_"T_!O_06D_P# *?\
M^(H_X6GX-_Z"TG_@%/\ _$4 =C17'?\ "T_!O_06D_\  *?_ .(H_P"%I^#?
M^@M)_P" 4_\ \10!V-%<=_PM/P;_ -!:3_P"G_\ B*/^%I^#?^@M)_X!3_\
MQ% '8T5QW_"T_!O_ $%I/_ *?_XBC_A:?@W_ *"TG_@%/_\ $4 =C17'?\+3
M\&_]!:3_ , I_P#XBC_A:?@W_H+2?^ 4_P#\10!V-%<=_P +3\&_]!:3_P
MI_\ XBC_ (6GX-_Z"TG_ (!3_P#Q% '8T5QW_"T_!O\ T%I/_ *?_P"(H_X6
MGX-_Z"TG_@%/_P#$4 =C17'?\+3\&_\ 06D_\ I__B*/^%I^#?\ H+2?^ 4_
M_P 10!V-%<=_PM/P;_T%I/\ P"G_ /B*/^%I^#?^@M)_X!3_ /Q% '8T5QW_
M  M/P;_T%I/_  "G_P#B*/\ A:?@W_H+2?\ @%/_ /$4 =C17'?\+3\&_P#0
M6D_\ I__ (BC_A:?@W_H+2?^ 4__ ,10!V-%<=_PM/P;_P!!:3_P"G_^(H_X
M6GX-_P"@M)_X!3__ !% '8T5QW_"T_!O_06D_P# *?\ ^(H_X6GX-_Z"TG_@
M%/\ _$4 =C17'?\ "T_!O_06D_\  *?_ .(H_P"%I^#?^@M)_P" 4_\ \10!
MV-%<=_PM/P;_ -!:3_P"G_\ B*/^%I^#?^@M)_X!3_\ Q% '8T5QW_"T_!O_
M $%I/_ *?_XBC_A:?@W_ *"TG_@%/_\ $4 =C17'?\+3\&_]!:3_ , I_P#X
MBC_A:?@W_H+2?^ 4_P#\10!V-%<=_P +3\&_]!:3_P  I_\ XBC_ (6GX-_Z
M"TG_ (!3_P#Q% '8T5QW_"T_!O\ T%I/_ *?_P"(H_X6GX-_Z"TG_@%/_P#$
M4 =C17'?\+3\&_\ 06D_\ I__B*/^%I^#?\ H+2?^ 4__P 10!V-%<=_PM/P
M;_T%I/\ P"G_ /B*/^%I^#?^@M)_X!3_ /Q% '8T5QW_  M/P;_T%I/_  "G
M_P#B*/\ A:?@W_H+2?\ @%/_ /$4 =C17'?\+3\&_P#06D_\ I__ (BC_A:?
M@W_H+2?^ 4__ ,10!V-%<=_PM/P;_P!!:3_P"G_^(H_X6GX-_P"@M)_X!3__
M !% '8T5QW_"T_!O_06D_P# *?\ ^(H_X6GX-_Z"TG_@%/\ _$4 =C17'?\
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MT_!O_06D_P# *?\ ^(H_X6GX-_Z"TG_@%/\ _$4 >:_\,SP?]#5)_P"  _\
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M/_ *?_XB@#L:*X[_ (6GX-_Z"TG_ (!3_P#Q%'_"T_!O_06D_P# *?\ ^(H
M[&BN._X6GX-_Z"TG_@%/_P#$4?\ "T_!O_06D_\  *?_ .(H [&BN._X6GX-
M_P"@M)_X!3__ !%'_"T_!O\ T%I/_ *?_P"(H [&BN._X6GX-_Z"TG_@%/\
M_$4?\+3\&_\ 06D_\ I__B* .QHKCO\ A:?@W_H+2?\ @%/_ /$4?\+3\&_]
M!:3_ , I_P#XB@#L:*X[_A:?@W_H+2?^ 4__ ,11_P +3\&_]!:3_P  I_\
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M"S_>*'#?D>*RKK1KV+XAPZO%9*UM#H,MOF,#'G>:K!0/H#7'6WA;6_"]W#J
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MUJ.BVEY?6+V%U-&'EM7;<8F_NDX&?RJ_0 4444 %%%% !1110 4444 %%%%
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MLK(7<6G(HN7W$!97QM7@'@*=S'L"*98^-46W#ZO!'$9'"VTME(;B*Y^7<=A
M!. .01Q0!9_X0'PO_P! F/\ [^/_ (T?\(#X7_Z!,?\ W\?_ !JQ_P )AH1^
MSE;Y&6=4964$A0YPFX_PY)P,U4OO'6CP0W(MKJ.6XB#"-7RJ2,K!6"M@YP2,
MXS0 _P#X0'PO_P! F/\ [^/_ (T?\(#X7_Z!,?\ W\?_ !K.T3XAVFI/J<EY
M&MG:6HD>)W+9ECC;:[8*@?>X !-=#J'B#3],@@ENI)%\Y"Z(L;,VT#)) '
M/- &?_P@/A?_ *!,?_?Q_P#&C_A ?"__ $"8_P#OX_\ C5B7Q=HL5K-<_; \
M,31*S("V3( 4 ]2<BL&S^)VFW#V[SV\UO;2Q2S&1T;*HL@1&(QT;).>@QWH
MUO\ A ?"_P#T"8_^_C_XT?\ " ^%_P#H$Q_]_'_QJ?\ X3'0Q<3PF\QY/F;I
M"A"$H,N W0D#J/:L2]^)FG0R1&T@ENHI6AC7:CA]TC'!VE?N[0S9[XH U/\
MA ?"_P#T"8_^_C_XT?\ " ^%_P#H$Q_]_'_QIFJ>-;"UTZ*YLW6X>1/."<C]
MT'",Q].3QGJ16[?2W::?))I\,4]SM!BCED**Q]V ../:@#%_X0'PO_T"8_\
MOX_^-'_" ^%_^@3'_P!_'_QK(M?&VL1VPO=8TK3[*Q&H?8'F6^+;&$IC9CE
M !@GK3-<^)4-B\PTQ-/O8TO+:T6=KT+%F56)+. 0 NW]: -K_A ?"_\ T"8_
M^_C_ .-'_" ^%_\ H$Q_]_'_ ,:DT+Q#+?Z1>:A?'31';%B6T^]%RFT+N.6
M&#[52MO%.KS01W\F@%--G@>>&83@NH"EE\Q<?+D>A/6@"S_P@/A?_H$Q_P#?
MQ_\ &C_A ?"__0)C_P"_C_XU!8^.M.U"70H;6XLIIM20O-'%<J[6^(C(<@<]
M1CG%9<?Q*:?0=<U&/2SYNGE7MX3+C[3$Q(5P<<9(8=^E &W_ ,(#X7_Z!,?_
M '\?_&C_ (0'PO\ ] F/_OX_^-4!\0[-HX)DMG:*6Q:XV@_O!*)5C\G;Z[FQ
MU[47?C'4]+M-1?4-(MXY;:S>ZC6*[#CY1G:_ *GD=B* +_\ P@/A?_H$Q_\
M?Q_\:/\ A ?"_P#T"8_^_C_XUD#QY>0:+J.HW%MI%PMJL>U=.U(7'+-MR^%&
MQ1USST-;OACQ!-KUA/<36T*>4^U7MIQ/%*-H.588]<$$#D4 0_\ " ^%_P#H
M$Q_]_'_QH_X0'PO_ - F/_OX_P#C6%:?$B>ZL]1NUTN'R[2UGN#$MT#-&8U)
M"RIC*9QU&:L:1XPUS6K622SL] GF$*RI##J^]N2,A@$RO&?Q&* -7_A ?"__
M $"8_P#OX_\ C1_P@/A?_H$Q_P#?Q_\ &F>%_$.K:UI%QJ6H:9:VD2J3"(;D
MRERI8-G*C'0>O6L33OB-=7&G2:E=6FE&V6(/Y-GJ(FN-S$*JE-HQEB!R>* -
M[_A ?"__ $"8_P#OX_\ C1_P@/A?_H$Q_P#?Q_\ &LO4?'&IZ%9WCZSHL5O<
M)8RWELL=UO27RQDH6VC#?@:+;QEK%WJ+Z7;:?I-U?& SQFUU'S(@ R@B1@F5
M.&R.#G!H U/^$!\+_P#0)C_[^/\ XT?\(#X7_P"@3'_W\?\ QK%T_P ?:B;"
MTU#6--L;"RN;P6JRB]W!.6#,V5  !4=^<UIKXRCO+/Q//IQMITT>$O#-'+YB
M3-Y6_G;Z'C@T 3_\(#X7_P"@3'_W\?\ QH_X0'PO_P! F/\ [^/_ (UR_@_X
MJ2:RVDV^K6<5O-?V?G+/"2(S+O=1'@Y()"<<G)S5KQ7X^U#1_!WA_6["TM?-
MU._AMGBGW,J(ZN3@@CGY1S^E &]_P@/A?_H$Q_\ ?Q_\:/\ A ?"_P#T"8_^
M_C_XUD?\)AXDCU36;6?0K!8M)MQ<S.M\Q)5E=EP-G7Y.?3-4U^(^HCP]>:PU
MEHLZ06RSB"TU7S9,L0 &4)\O6@#H_P#A ?"__0)C_P"_C_XT?\(#X7_Z!,?_
M '\?_&JB>.X9]<\,Z=;6ID&LPM-(Y?'V<>4[J",<DE&&..AK2F\0M%XOMM"^
MPRB.6"24W3\)E=IVKZ_>Y]* (/\ A ?"_P#T"8_^_C_XT?\ " ^%_P#H$Q_]
M_'_QI_A_Q5%XAUC5[2WMV6WL#$([ACQ/NWY91_=RA />JO\ PFL?_";OX?%H
M3$J%1=;^#,%WF/'KMYH G_X0'PO_ - F/_OX_P#C1_P@/A?_ *!,?_?Q_P#&
ML#3_ (CW5S-I_G6.GF.^F:)([:^\R>/ ;YGCVC ^7DYXS5OPEXWOO$MQ;;X-
M&BBF0OY<6IB2X4#UCV@_7GB@#4_X0'PO_P! F/\ [^/_ (T?\(#X7_Z!,?\
MW\?_ !JF/'D$7C#6]"N[<0)IML+E+@OGS1L#L,8XP"*SA\2I1X6TS56TAA=7
M<LPDM/-YABA+>:Y..<!>F.IQ0!N_\(#X7_Z!,?\ W\?_ !H_X0'PO_T"8_\
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MU#;_ !%LI].TU]UG]ON]1%D]DMTIDC'FM'NQUZ*#C'>@#2_X0'PO_P! F/\
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MG- ' "TNEMK.X'Q-80WK[;9Q:6N)F_V?EY-:G_"*>)1G_BN[[GK_ *!;<_\
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MQ2SER#F!U=L_\!W*GX5VOB#1A<^(/#NHV]FKSV]_F><*-R1>1,.3Z;F7CU-
M'.1V&GZOX/U7P#9^(8KF[$4D43O&V8X]PP">C[>A(/IFI(M A\6*\EAX@BNM
M,CNT+AK??+#)'MW)'(3E =H/ _B..#69)I/B>UM;2TM=)F2XL(;J$70D0I(T
MS85EP<\ [CD#&*6*#Q#\,C,]IH]QXAM;J&(&*QBV&.1 $R0 W50.<=J .LUK
MPE-JOB>/5H]0>U5--ELAY61(K.ZL'!]MO2J<?@>^-Q>7LNM+%J$\*0I-9VHA
M7"OORZ@_.3T.>V17: Y .,9[4M '#CX?O*+BYGU&./4I+B*XBEMK41QQO&"
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M_P#0CZK_ -_H?_BJ .OHKD/^$NUW_H1]5_[_ $/_ ,51_P )=KO_ $(^J_\
M?Z'_ .*H Z^BN0_X2[7?^A'U7_O]#_\ %4?\)=KO_0CZK_W^A_\ BJ .OHKD
M/^$NUW_H1]5_[_0__%4?\)=KO_0CZK_W^A_^*H Z^BN0_P"$NUW_ *$?5?\
MO]#_ /%4?\)=KO\ T(^J_P#?Z'_XJ@#KZ*Y#_A+M=_Z$?5?^_P!#_P#%4?\
M"7:[_P!"/JO_ '^A_P#BJ .OHKD/^$NUW_H1]5_[_0__ !5'_"7:[_T(^J_]
M_H?_ (J@#KZ*Y#_A+M=_Z$?5?^_T/_Q5'_"7:[_T(^J_]_H?_BJ .OHKD/\
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M5'_"7:[_ -"/JO\ W^A_^*H Z^BN0_X2[7?^A'U7_O\ 0_\ Q5'_  EVN_\
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MA6M7'A"_MIY+:_U5KFU4(MSL!MX'!12X&5)4$].IKKO"^GWUI97\%SHPT[S
M-@_M-KSS#@@\L!MQQ]<^U #].\=:+JNFV5]:/,\=W<&V52@#QR#)PPSQP,_0
MBK$7BW3IM'TC5%6?[/JK!;<%!N!,;R?,,\<(WKSBN-MOA]J&G3>'+V&:"$6P
M3^UHB_RN41@K@^HS@^WTJWIOACQ +70]*GCT]=*T8R/%<17#.]S^ZDCC^7:
MO$F3R>E &RGQ"T*3P[I>MJUQ]EU*X6V@38-_F,2,$9XQ@YYIUMX\TZ>\CMWL
MM1@2:5X8;B6 >5*Z9R%()_NGJ!TKBX/ASK2M;(LMLUA;-#<6\0D^[,3'YI^@
M"-C_ 'S5JR\#ZVNKV\GV"WMOL]W+,UZ;]I3*C%CM6';M4G<.<]J .IL?'5O?
M6+WZZ+K,5BMN]R+F6! C(JEN"'/4#BHS\0]-BMY)KO3]4M,637T:S0KF:(8R
M4*L03\PX)!YKF=$\*ZUI^B2Z7-H44,LNGRVGVLZR\BLS1D#$17 R<=#Q1?\
MP[U*VLIUT\)/]LT4V,Z7%RW[B4 $%"<X5B,$#V- '5OXXAAT^6]N="UJVB38
M%\V! 92Q 4+A^3DCTK1T?Q':ZO<S6@MKNSO(461[:\B\M]AZ,.2",@C()YKA
MHO#VMSZ))#:Z!# ^89HW;6VN%F,;JVWYEPN0#R,UTFB6^H7/BVXU?6/L-G=?
M9!:Q6%O<^<RINW%G;"\Y[ 4 6'\<:6MZ8!!?O +D6C7J6Q,"RD[=I?ZG!.,
M]Z8WCW25N'#07XLDF^SG4#;'[-YF=N-_IGC.,9[UC:=_:>F^=HMC?:*;%KV2
MY^VM>@RK"TADD7RMN-V"PSNP!SVJ&/2]5O\ 3)/"=M/H\VE&3<;R*[W3+#OW
M8\H#[W;=NQ0!T</CC1KBTOKB)Y3]BNQ:3Q[!O#E@H.,\J2>OL>XJ&+QS!)K#
MZ8VAZU%/&GF2-);H%1,D;R=_3@UR&H>$99X[$:7J5@FIK?.MU!]H4^=;FZ:8
M#_> (/YBNO\ L?VKQAJUU!<VTBR::MKL64%U<,Q.1V'(H DTGQO8ZM=V%O\
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MK3$L<=PF_P Z<<;@>@V!L'ODXH V]6\96>E:F;'^S]2O'6T6\>2S@$BI$68
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MO$&I0BYO[JZVM<VUI_9RQ*48I&KS,V1SDY Y XK"N_$OB'5M+U."2ZO$ANK
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M?:O!:27*1O%&]W<*Q#@%<@IP3D<&KFI:YXXT>-)-1?P=;+(<(9+NX&X^WR4
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MM)(\-^\02+M?D8SO!STK(D\)>(FTW7X;:1X6^S6D;6_EH5NU2$+(BN02I."
M1T->N44 >37NEW+223:=HVH6TT\4 BMY(TN+:X55  E#C,;#&"0>V>:L7FG:
MPNG:QH TBX>?4-6^UQ3ICR1$SHQ);/!&",=:]1HH \L@T?Q%#KT7C#RE/VC4
M-LMKY1\]+4_NP"<XP  ^,=2:S_#WA?6]&7PPD5K(=/N;M9[V%^MK*F\;L>C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '(_%+_ ))AXA_Z\V_F*G^'/_)-O#?_ &#H?_0!4'Q2_P"2
M8>(?^O-OYBI_AS_R3;PW_P!@Z'_T 4 =/1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F:
M[K']B:>+O[!>7N7">5:1&1^<\X].*YO_ (6-_P!2IXD_\ 6KMZ* .(_X6-_U
M*GB3_P  6H_X6-_U*GB3_P  6KMZ* .(_P"%C?\ 4J>)/_ %J/\ A8W_ %*G
MB3_P!:NWHH XC_A8W_4J>)/_  !:C_A8W_4J>)/_  !:NWHH \D^('CG^T?
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M* *&JZ1::Q:/;72ML<;6*,58KW7(YP>X[TV/0M-BOTO4M5$R6RVJ?W5C#;@
M.G7O6C10 SR8_-\WRT\S&-^T9QZ9H:&-W5WC1F7[K%02/I3Z* &>3$8S'Y:>
M6>J[1@_A2>1#DGRH\E@Q.T=1P#]:DHH C6WA0.%AC ?[^%'S?7UIOV.VQC[-
M#C_<'^>P_*IJ* (FMH&4JT,94MNP5'7U^M!MH&E\TP1F3^^4&?SJ6B@" 6=J
ML;1BVA"-U4(,'\*>;>!LYAC.0 <J.0.@_"I** &20Q2@"2-'VG(W*#@TU;:W
M0 +!$ "" $'!' _*I:* &+#$DAD6)%<]6"@$_C33;0&7S3#'YG]_:,_G4M%
M$/V2VV[?L\6WCC8,<=*<+>!0 (8P NT84=/3Z5)10!&MO @4+#& H(4!1P#U
MQ5#4]!L-6BCBNHB8D96*(=H?:<A6QU4'MTK3HH J6^FVUM?W-\BDW%S@2.QR
M<#HH]!UX]ZMT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
MA_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_
M -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\
M50!U]%<A_P )W+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )
MW+_T)_B?_P  A_\ %4?\)W+_ -"?XG_\ A_\50!U]%<A_P )W+_T)_B?_P
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MVDV<_P //%"ZC 8-4TJ[Q'8B63;9!G4?(2<LK#G)]:?XOCO;3Q-_Q26G7?\
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MM;B]\SP>OV*QN/L]S>K9QF.,\9)Q\V!D<XH Z_\ X2KP]_T'--_\"D_QI/\
MA*O#O_0<TW_P)3_&N9C_ .$;N=1N;6Q\$K=I;3"&2>*UAV9P#W(.,$=J99W'
MA&^U/[-%X3B-J9VMEO?LD9B,BYR"!\RC(/) '% '4_\ "5>'?^@YIO\ X%)_
MC2_\)5X>_P"@YIO_ (%)_C7+64WA.]GAV^$%2SN2PMKUK)/*FVYZ8Y .."0
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MO_@2G^-+_P )5X>_Z#FF_P#@4G^-9.D:/H6J!VE\&Q6*J%*FXMHOGSZ;2?\
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M]K"C,SQ0(1\HR>U4],7P'J>B+JJ:=I$5OM5I/,AC!B+#(#>AH WO^$K\/?\
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MIO\ X%)_C1_PE?A[_H.:;_X%)_C3?^$1\.?] +3O_ 9/\*/^$1\.?] +3O\
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MT^X,%U=!)%V@KL9L%CA1P.I) %6K*^MM0M_/M91)'N*YP1@@X(P>>"* ./\
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M])HH \HNOAGK$MK:Z?\ :H'M?LZ13LLKIMS*9)0!R6W;CC<<#TJ>Y\ :W=7
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MT5]!?\,S1_\ 0V-_X+__ +91_P ,S1_]#8W_ (+_ /[90!\^T5]!?\,S1_\
M0V-_X+__ +91_P ,S1_]#8W_ (+_ /[90!\^T5]!?\,S1_\ 0V-_X+__ +91
M_P ,S1_]#8W_ (+_ /[90!P/P._Y*WI'^Y/_ .B7KZ[KR/P/\#T\&>+;371X
M@:[-N)!Y)L_+W;D*_>WG'7/2O7* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#".NW9\4W&C
M1:9O6&U6X\_SP,[BP48QZJ16<_BO5QI]A<)X?5I;NX:#RS>*-I'3G'?!_*K-
M_#J&F^+&U>UTZ74+>YLTMI$@=%>-E=F#?.R@J=WKGCI69?:=J<>B:);W&CW%
M_+'=&XN4LY8U$8^;C+NF3\PZ>AH V=,UO4KZ*^672!%<VZ(\2+<ATF# D8<#
M':CP]K>IZQ+<?:](6SAA=HMXN5DRZG!& /UIFA37MI8RVXT.^MK*RMXHK2"9
MX6FEV@@@%9"O0+U([TWPK+?J;V&\T6^L1)<RSI).\+*0S9 ^21CG\,>] &VN
MH6;Z@^GK=0F\2,2- '&]4/&XCKBK-84$4H\:W4IT&&.$V:@:L"N^4[A^Z(^]
M@=?3BMV@ K/U?5!I=O$4@>YN9Y1#! AP9'()ZG@  $D^@K0K(UVWO3]COM/A
M6XGLI3)]G9@OFJ492H)X#?-D9XXYH RF\5:O M_'<^&Y8[FTMQ<*!<*8Y5+$
M8#XQD8)P:G@\5R7KZ-)9Z<9;34<AI6E"M"RYW*5(SD8(IUU>:QJ.D7Y.@W$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YCQ!?7=IKME -=@TRT
MGMIG+31H1O1HP.6(ZASQ[56L_&$ZZ';SS6QU"]N+F2"U2T78+D*3^\4,?E7
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MK+GOA3G/45IIIE_=Z=J%KJM['*+R,Q!8(]JQ*5(.,G)/.:^?_P#AI+Q'_P!
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M+VG_ $*\W_@8/_B*/^&E[3_H5YO_  ,'_P 10![Q17@__#2]I_T*\W_@8/\
MXBC_ (:7M/\ H5YO_ P?_$4 >\45X/\ \-+VG_0KS?\ @8/_ (BC_AI>T_Z%
M>;_P,'_Q% 'O%%>#_P##2]I_T*\W_@8/_B*/^&E[3_H5YO\ P,'_ ,10![Q1
M7@__  TO:?\ 0KS?^!@_^(H_X:7M/^A7F_\  P?_ !% 'O%%>#_\-+VG_0KS
M?^!@_P#B*/\ AI>T_P"A7F_\#!_\10![Q17@_P#PTO:?]"O-_P"!@_\ B*/^
M&E[3_H5YO_ P?_$4 >\45X/_ ,-+VG_0KS?^!@_^(H_X:7M/^A7F_P# P?\
MQ% 'O%%>#_\ #2]I_P!"O-_X&#_XBC_AI>T_Z%>;_P #!_\ $4 >\45X/_PT
MO:?]"O-_X&#_ .(H_P"&E[3_ *%>;_P,'_Q% 'O%%>#_ /#2]I_T*\W_ (&#
M_P"(H_X:7M/^A7F_\#!_\10![Q17@_\ PTO:?]"O-_X&#_XBC_AI>T_Z%>;_
M ,#!_P#$4 >\45\W77[2>M&ZD-IH=@EOGY%F9V<#W((!_*H?^&DO$?\ T!=*
M_P#(G_Q5 'TO17S1_P -)>(_^@+I7_D3_P"*H_X:2\1_] 72O_(G_P 50!]+
MT5\T?\-)>(_^@+I7_D3_ .*H_P"&DO$?_0%TK_R)_P#%4 ?2]%?-'_#27B/_
M * NE?\ D3_XJC_AI+Q'_P! 72O_ ")_\50!]+T5\T?\-)>(_P#H"Z5_Y$_^
M*H_X:2\1_P#0%TK_ ,B?_%4 ?2]%?-'_  TEXC_Z NE?^1/_ (JC_AI+Q'_T
M!=*_\B?_ !5 'TO17S1_PTEXC_Z NE?^1/\ XJC_ (:2\1_] 72O_(G_ ,50
M!]+T5\T?\-)>(_\ H"Z5_P"1/_BJ/^&DO$?_ $!=*_\ (G_Q5 'TO17GGPG^
M(-_\0-.U*YO[2VMFM94C40;L$$$\Y)]*]#H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!_T+DO\ X$0__%T?\*;^('_0N2_^!$/_ ,70!PM%=U_PIOX@?]"Y+_X$0_\
MQ='_  IOX@?]"Y+_ .!$/_Q= '"T5W7_  IOX@?]"Y+_ .!$/_Q='_"F_B!_
MT+DO_@1#_P#%T <+17177@+Q=9W4EO-X:U4R1G#>7:O(OX,H(/X&H?\ A"_%
M7_0M:S_X 2__ !- &'16Y_PA?BK_ *%K6?\ P E_^)H_X0OQ5_T+6L_^ $O_
M ,30!AT5N?\ "%^*O^A:UG_P E_^)H_X0OQ5_P!"UK/_ ( 2_P#Q- &'16Y_
MPA?BK_H6M9_\ )?_ (FC_A"_%7_0M:S_ . $O_Q- &'16Y_PA?BK_H6M9_\
M "7_ .)H_P"$+\5?]"UK/_@!+_\ $T 8=%;G_"%^*O\ H6M9_P# "7_XFC_A
M"_%7_0M:S_X 2_\ Q- &'16Y_P (7XJ_Z%K6?_ "7_XFC_A"_%7_ $+6L_\
M@!+_ /$T 8=%;G_"%^*O^A:UG_P E_\ B:/^$+\5?]"UK/\ X 2__$T >X_L
MU?\ ("U[_KYC_P#037N5>-?L]:1J>D:-K::EIUW9/)<1E%N8&C+#:>1N S7L
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAWQU)X:UZUU:QT/2TGMR<%5D!((*D9+G&02.E<G10![A_P -*:O_ -"]8_\
M?YZ/^&E-7_Z%ZQ_[_/7A]% 'N'_#2FK_ /0O6/\ W^>C_AI35_\ H7K'_O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^!T'_P 71_PB^J?W;3_P.@_^+K'HH V/^$7U3^[:?^!T'_Q='_"+ZI_=M/\
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MA1_PH#QS_P \;#_P*'^%9/\ PN;X@?\ 0Q2?^ T/_P 11_PN;X@?]#%)_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\*0N?\ H<?#/_@4?\* /*J*]5_X4A<_]#CX9_\  H_X4?\ "D+G_H<?#/\
MX%'_  H \JHKV6R^!5@\!-]X_P!(@FW?=@595QZY,B\^V*L?\*'T/_HH^G_^
M Z?_ !Z@#Q*BO;?^%#Z'_P!%'T__ ,!T_P#CU'_"A]#_ .BCZ?\ ^ Z?_'J
M/$J*]M_X4/H?_11]/_\  =/_ (]1_P *'T/_ **/I_\ X#I_\>H \2HKVW_A
M0^A_]%'T_P#\!T_^/4?\*'T/_HH^G_\ @.G_ ,>H \2HKW2U_9[TV]E\JT\?
M6MQ)C=LBLU<X]<":KG_#,O\ U-W_ )3?_MM 'S_17T!_PS+_ -3=_P"4W_[;
M1_PS+_U-W_E-_P#MM 'S_17T!_PS+_U-W_E-_P#MM'_#,O\ U-W_ )3?_MM
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M_P!_HO\ XW1_PSAX1_Z">M_]_HO_ (W0!\PT5]/?\,X>$?\ H)ZW_P!_HO\
MXW1_PSAX1_Z">M_]_HO_ (W0!\PT5]/?\,X>$?\ H)ZW_P!_HO\ XW1_PSAX
M1_Z">M_]_HO_ (W0!\PT5]/?\,X>$?\ H)ZW_P!_HO\ XW1_PSAX1_Z">M_]
M_HO_ (W0!\PT5]/?\,X>$?\ H)ZW_P!_HO\ XW1_PSAX1_Z">M_]_HO_ (W0
M!\PT5]/?\,X>$?\ H)ZW_P!_HO\ XW1_PSAX1_Z">M_]_HO_ (W0!\PT5]/?
M\,X>$?\ H)ZW_P!_HO\ XW1_PSAX1_Z">M_]_HO_ (W0!>_9^_Y)DO\ U^S?
M^RUZG7/^#O"%AX)T(:1ITUS-;B5I=URRLV6QG[H QQZ5T% !117CWC3XZ_\
M"(>+K_0?^$<^U_9"@\_[=Y>[<BM]WRSC[V.O:@#V&BOG_P#X::_ZE'_RI?\
MVJC_ (::_P"I1_\ *E_]JH ^@**^?_\ AIK_ *E'_P J7_VJC_AIK_J4?_*E
M_P#:J /H"BOG_P#X::_ZE'_RI?\ VJC_ (::_P"I1_\ *E_]JH ^@**^?_\
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MM>ZW;0)-8F29X+7SE>5 -VP@]"2<9JYK%[XFTG3[-UFMKBY-\8R@BQY\.UF
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MS6%>>#];O;>PM)?$2FVL9TFB'V4;G*'Y0YSSCVQ5_5/#>HWAU2.TU5+:#4D
MF!M][*=FPE23W % %Z]U[[/<V]K:V,]Y=31>?Y<9"A$]6)Z9/ K+U/Q7>1^%
MVU2TTR>&=;H6[0W2A2OSA2>O(/8U;GT+41=V5]9:G'#=0VXMYP\&Z.91R.,@
M@@Y[]ZEO-#N=2\/S:?>Z@9+B1Q()UB"A"&#* OH,4 :EI/-/&6FMFMV!P%9@
M<CUXIUVSI93M$P601L58C.#C@XJMIT&IQ/(VH7L,X; 1(H=@7U/4DU:NHGGM
M)HHW".\;*K$9"DC ..] 'FX\>:N_AA(1]G7Q!CS7S&=@@"AS+MSTP0OU85U^
MK^)$T)@MU;L\:(&>;S$3([E5)R<=ZI-X/E/AU;!;JW%]]G%HU[]F^8PC^'&?
MI5?4_!-SJ!U,"_M5.HC][-)9K)*GR!2$8GA>,@=LF@#8U3Q VGWUG9P:;<WD
MMVI:,PX"@#J6)Z#WJ2+7DGT,ZE':395BCP,55D8-M.23@ 8ZYZ5$FCW_ /:F
MFWDFH1LMI"T4B"''F9ZD'/'050D\)7,NF+;37T$S)?&]426^8V)W?*RYY +9
M'N!0!<LO%EG<Z?J-W*AA&GG]\%=9!@KN!4J<'(/YU!%XN=M;LM+GT6^MY+U6
M>"20KM*J,G.#P0,<>],T_P )RVTFK?:[N&2WU)1OB@MA$(V"A05Q[#\ZR=-M
M+Z^\<:==F_OKRVT^.9&-Q8M;HFY=HP2!O8^W0?6@#1;X@6* W+6<XTL3>5]N
MW)M^]MW[<[MF>^/>GWGC86M[/;+H]].8;I;0O'MP9'&5 R>AR.>U5H? K6F^
M"VDTS[)OS&9=-1Y8USG;N/WO3)&:NMX6N&N+R8Z@NZ?4(;U?W7W=F!MZ\Y Z
MT $GC6U6VL/+M)WO+W?LM-RJRA#ARQ)P #@9]Z7_ (3.V&A7FI&RNO,LI5AN
M+4!3(I)&,8.&!W C!YS5:;P0)/L\WGVTES;22^6;BU$B&*1@S(5)ZY Y'-3R
M>%KJ30[BP2[L[=YIDES;V:HBA6# ;0>>0.30!=TWQ U]=S64^G7%G>QP+<"&
M4J=R$D#!!QG(P:9X=UF_U6V#W5@8QYDBF0,,#:Q X_"IDT:X'BD:R]VK+]B%
MJ81'C)#;MV<^I/%0V6CZI83^5!J<0L?/:7RS;Y?#')7=G'4]<4 ;U?'OQH_Y
M*YKW^]#_ .B8Z^G[>WUN?QY>W<\KPZ+;VR0VT(((GD/S-(>XQG;SZ5\Q_&:"
M9_BUKK+$[ M#R%)_Y8QT >?T5+]FG_YX2?\ ?!H^S3_\\)/^^#0!%14OV:?_
M )X2?]\&C[-/_P \)/\ O@T 145+]FG_ .>$G_?!H^S3_P#/"3_O@T 145+]
MFG_YX2?]\&C[-/\ \\)/^^#0!%14OV:?_GA)_P!\&C[-/_SPD_[X- $5%2_9
MI_\ GA)_WP:/LT__ #PD_P"^#0!%14OV:?\ YX2?]\&C[-/_ ,\)/^^#0!%1
M4OV:?_GA)_WP:/LT_P#SPD_[X- $5%2_9I_^>$G_ 'P:/LT__/"3_O@T 145
M+]FG_P">$G_?!H^S3_\ /"3_ +X- $5>T?LZ:H+3Q-J5C]DN93>QH/.CCRD.
MP.V7/\.>@]Z\<^S3_P#/"3_O@U[;^SA8S?V]K5PTDT2101@Q8PLA);D_3!_.
M@#T?XZ?\DFU3_KI!_P"C5KY&KZY^.G_))M4_ZZ0?^C5KY&H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#UO]G7_DHUU_V#
M9?\ T9'7U)7RW^SK_P E&NO^P;+_ .C(Z^I* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HKF);2+7/%6H6>H[I;:U@B\JW+84E
M\DN0.IXP#VQ4-P+O1+?3M!T2[5I[N:4+=7I,WE*,L1C(+$= ,_RH ZVBN)GU
MS7K/2=?M9;BRDU328HYENE@(CF5PQ *;LJ?E(/)Z@^U:FF76N0:VVFZK=65P
M9;4W$;V\#1B)@V"O+'<.1SQ0!T5%<-X0@\1/J6JO<ZY;36T6IRI)#]A(+8 ^
MZWF':/;!J_J=WXD7Q?#ING76GBUN;5YP9[=BT&QHU)X<;\[SQ\N/>@#JJ*Y?
M7=1U:U%I9V=Y$+\QEYA%I[3[L=P/,7:,^I)J-?$>H3^%M*N42"+4=0N1:!I$
M(CC?<P+%<YZ(<+GJ0,T =917.00>*(EU"WO-1L)4^SAK6[2T*,LF6W!H]YR
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M&DO$7_0%TO\ \B?_ !5>+44 >T_\-)>(O^@+I?\ Y$_^*H_X:2\1?] 72_\
MR)_\57BU% 'M/_#27B+_ * NE_\ D3_XJC_AI+Q%_P! 72__ ")_\57BU% '
MM/\ PTEXB_Z NE_^1/\ XJC_ (:2\1?] 72__(G_ ,57BU% 'T=X3^.FJ:Q;
M:[=7^CV?EZ98&[$<#LAD(=5QD[L#YO2J7_#32_\ 0I'_ ,&/_P!JKS7P%_R
MO&W_ &!&_P#1L=<10!] _P##32_]"D?_  8__:J/^&FE_P"A2/\ X,?_ +57
MS]10!] _\--+_P!"D?\ P8__ &JC_AII?^A2/_@Q_P#M5?/U% 'T#_PTTO\
MT*1_\&/_ -JH_P"&FE_Z%(_^#'_[57S]10!] _\ #32_]"D?_!C_ /:J/^&F
ME_Z%(_\ @Q_^U5\_44 ?0/\ PTTO_0I'_P &/_VJC_AII?\ H4C_ .#'_P"U
M5\_44 ?0/_#32_\ 0I'_ ,&/_P!JH_X::7_H4C_X,?\ [57S]10!] _\--+_
M -"D?_!C_P#:J/\ AII?^A2/_@Q_^U5\_44 ?2GAW]H-=?\ $FFZ1_PC)@^V
MW*0>;]NW;-Q SCRQGKTS7M=?$WP[_P"2D>&_^PC!_P"ABOMF@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/'7A4
M^-/"5UH0O/L?GM&WG>5YFW:X;[N1Z>M>0_\ #,K?]#:/_!=_]MKZ!HH ^?O^
M&96_Z&T?^"[_ .VT?\,RM_T-H_\ !=_]MKZ!HH ^?O\ AF5O^AM'_@N_^VT?
M\,RM_P!#:/\ P7?_ &VOH&B@#Y^_X9E;_H;1_P""[_[;1_PS*W_0VC_P7?\
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M^(H_X9X\:?\ /;2?_ AO_B*^IZ* /EC_ (9X\:?\]M)_\"&_^(H_X9X\:?\
M/;2?_ AO_B*^IZ* /EC_ (9X\:?\]M)_\"&_^(H_X9X\:?\ /;2?_ AO_B*^
MIZ* /EC_ (9X\:?\]M)_\"&_^(H_X9X\:?\ /;2?_ AO_B*^IZ* /EC_ (9X
M\:?\]M)_\"&_^(H_X9X\:?\ /;2?_ AO_B*^IZ* /EC_ (9X\:?\]M)_\"&_
M^(H_X9X\:?\ /;2?_ AO_B*^IZ* /EC_ (9X\:?\]M)_\"&_^(H_X9X\:?\
M/;2?_ AO_B*^IZ* /EC_ (9X\:?\]M)_\"&_^(H_X9X\:?\ /;2?_ AO_B*^
MIZ* /EC_ (9X\:?\]M)_\"&_^(H_X9X\:?\ /;2?_ AO_B*^IZ* /EC_ (9X
M\:?\]M)_\"&_^(H_X9X\:?\ /;2?_ AO_B*^IZ* /G;0?@YXK\/:'XG69+.Y
MEOM,-M!%;399G\Q&_B  X4]ZX/\ X4W\0/\ H7)?^_\ %_\ %U]BT4 ?'7_"
MF_B!_P!"Y+_W_B_^+H_X4W\0/^A<E_[_ ,7_ ,77V+10!\=?\*;^('_0N2_]
M_P"+_P"+H_X4W\0/^A<E_P"_\7_Q=?8M% 'QU_PIOX@?]"Y+_P!_XO\ XNC_
M (4W\0/^A<E_[_Q?_%U]BT4 ?'7_  IOX@?]"Y+_ -_XO_BZ/^%-_$#_ *%R
M7_O_ !?_ !=?8M% 'QU_PIOX@?\ 0N2_]_XO_BZ/^%-_$#_H7)?^_P#%_P#%
MU]BT4 ?'7_"F_B!_T+DO_?\ B_\ BZ/^%-_$#_H7)?\ O_%_\77V+10!\=?\
M*;^('_0N2_\ ?^+_ .+H_P"%-_$#_H7)?^_\7_Q=?8M% 'ROX*^%7C;2_'&A
MW][H4D5K;WL4LLAFB.U0P). V:^J*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ?)J#W@:ZC:1Q))'%<.D<C_WBH/7@?6DO_"^GZE>B[N'O?-!W+Y=Y(@4XQD
M, .* *NL7FO#Q%9Z=I<MA'!/ \DDEQ"SLA4CH PSG-58O$.J2Z1879%JLO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M JEA%$C1CYDSC<3[FH;SQ#XML[:*'^T+J:.X%K-<W;1HAMQ)$S.JE8FVC<%
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MK%,(<?*W<-TS@U?LM8\4W[VP74;ID@@NKB,1(O\ I9C*F-'8QKD'E<A5S^M
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M*ZED.& /*\9Y]*26:.",R32)'&O5G8 #\37 >%)I85\8WNGW-WJ;[DDMYKI
MKSLMNN!PJ@C(VYP.G?K7+6MUKGBC2X;/5-0NY(FNK!I<(N5=I5#J<PJ !UV\
MXQR2* /9X;B&X#&":.4*<$HP;!_"GDA5+,0 !DD]J\,M[[7O#FF6EII]Q<VL
M#)+.LK(O[Z;SF7:0(6W?*!\ORYSUX&-;6=4U74].UZ"XU34X;\QW,8TV*T!B
M$*QG:P;;D9/.[)ZXQZ 'KW6BN9TCQ7I$FI6'AQ+N:;47TZ.[4O&?GCVCYB<
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M<.LD;.X)"XRNT*#GVKH?%=I,?$.A"+4[^W2^NS!-'#-M7:(G;@8X.5% $_\
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M5ZL/^9*UC_ON#_XNNKHH Y,>*=5 P/!.KCG/#P?_ !=+_P )5JW_ $)6L?\
M?<'_ ,775T4 <H/%6K#IX)UC_ON#_P"+H_X2O5\Y_P"$*UC_ +^0?_%UU=%
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MCP__ -=YO_05KW6O"OVEO^01X?\ ^N\W_H*T ?.M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5]*?LV?\BIK/\ U_#_ - %?-=?2G[-G_(J:S_U
M_#_T 4 >UT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R'C3_D,>%?^PG_
M .R-77UR'C3_ )#'A7_L)_\ LC4 :%]XI@T[5;NSN8&CCMK9;AYV<;2K$JH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !15'5[9[K3G1-2FT[!#&XAVY4#K]X$8KC6\A=/M;\>/M8>VNV*
MP/'#&YD(SG $1/8]J /0*\M^-/@?6_&VGZ3#HL,4CVTLC2>9*$P" !U^E69[
MZQM;XV<_C_7(YAY>[=:KM3> 4W-Y.U<@CJ170GPMJ8!)\8ZR /:'_P"-T ?.
MO_"A/'?_ #YV?_@4M'_"A/'?_/G9_P#@4M>X63VNH7_V*V^(.K//\P4&.-5?
M;][:QB ;&#T)IEC<V6I79M;3XA:N\OS%<PHJOMZ[6,0#8]B: /$O^%">._\
MGSL__ I:/^%">._^?.S_ / I:]RA^SW%A:7L'C_5Y;>[+B!HXXVWE 68 "+.
M0%;CVK/36=+>.XD'C_7PEM_KF:P*A#D#!S!URPXZ\T >._\ "A/'?_/G9_\
M@4M'_"A/'?\ SYV?_@4M>Y:;Y.KR7$=IX\ULR6T8EECEMTB94.?FP\0)'!Y%
M+$+>;05UR/X@ZH=-8D+/MB&2&*X \O).01C&: /#/^%">._^?.S_ / I:/\
MA0GCO_GSL_\ P*6O:)M0L(+$WLGC_7?(4L'*V@8QX&3O40Y3CGY@*'U"PCM8
M;A_'^NJD[%8E-H/,?'4A/)W8YZXQ[T >+_\ "A/'?_/G9_\ @4M'_"A/'?\
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MA_\ C= '445R_P#PBNI_]#AK/_?,/_QNC_A%=3_Z'#6?^^8?_C= '445R_\
MPBNI_P#0X:S_ -\P_P#QNC_A%=3_ .APUG_OF'_XW0!U%%<O_P (KJ?_ $.&
ML_\ ?,/_ ,;H_P"$5U/_ *'#6?\ OF'_ .-T =117+_\(KJ?_0X:S_WS#_\
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MMJ0Z^,=9'X0__&Z!X6U(]/&.LG\(?_C= '445R__  BNI_\ 0X:S_P!\P_\
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MC/UK"L_!FJV6E?V=%XPU(0K (8<0P@Q 8P00N<\4 =A12("J*I8L0,9/>EH
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MTB2TO%N9A$H"R,,X_$D@DGK0!Q\?PROX?/DNM52Y5BCO"J8,F&!<=AE@&'_
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M1M=W(OU:'R0&W *'^;)P?NYXJA'X:\1R>'K#PBVB^6+;4EN7U7SHS&467?N
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M_P#!<_\ \:H_X4EX/_Y_/%G_ (+G_P#C5>_T4 > ?\*2\'_\_GBS_P %S_\
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M$DM/^?/5O_!9/_\ $4?\)):?\^>K?^"R?_XBMBB@#'_X22T_Y\]6_P#!9/\
M_$5J02K/ DRJZJZA@)$*,/J#R#[&I** "BBB@ HHHH *R_$G_(LZG_UZR?\
MH)K4K+\2?\BSJ?\ UZR?^@F@"AX _P"2?Z#_ ->4?\JZ.N<\ ?\ )/\ 0?\
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M-</X=U33-9\57WBTW=G::?!:F"U0RJKR1@Y>5USPO3&>WUK0\7):S>(/!5]
ML3M-J@Q,H!+IY$I'/<4 ;.I^-O#FCW<MKJ&J16\T6-ZNK?+D9ZXQ6C<ZSIUE
MI!U6YNXHK$()/.<X7:>AKEO&K_VUJ^F^#[=03??Z3?N!S';(>?\ OI@%_.D^
M(H@MK+P_)<JJZ;;ZK ;C/W$09 +>P.* -ZW\7:!=:)+K$.J0-I\)VR39P$.<
M8(ZYR1Q5K2-<TW7K5KG3+N.YB5MC%.JMZ$'D&O'?$ES9W-YXAFTN:)+6XU73
MHH+U' MX;@')D8X(*C SZUM^$Y/^)CK<%_KZ17BZI"\FHV;JL5V2ORP@8P#@
M<@9//6@#O4\7:%)K)TA-1C:_60Q&$ DAQU&<8S2#Q?H+:R=(&I1&_67R3" 2
M0_\ =Z8S7$PWS>&_%>G0:5XAM=7MM8U"5KBR"1M)$6!9I%9/FP",?-0M]_PC
M?B^S32=>M=6@UO59&N+ )&SP;^2ZLOS87 'S=A0!Z%JVM:;H=J+G4[V&UA+!
M0TC8R?058GO;:VL7O9YTCMD3S&E8X4+C.:X;Q+;6DOPRU>0:G_;!B68I=2E7
M9"6Y4$#C'2H/&<6JW]EIE@FDW-YHBV@GN_(=097"_(AR1\H(W'UX'K0!W]A?
M6NIV$%]93+-;3H'CD7HRGN*J:UXATGP[;)<:M>Q6L<C;$+]6/7  Y-<W\/+J
M];X5Z4]K8 7,5LJ0Q3R!%DQT.1G /T[5EWE]+!\0M&O/%UO96$)L;B.$F?S(
M1)N4_>8* Q7=0!V5UXLT&RTRUU*?4X%L[L[8)021(<$\8]@:=#XGT:X-H(KU
M"+N.26%MI 9(\;SDCC&1UKS31[2UG\*V&H1^(X=%:TO+^YL?.6-EDC9R =K]
M5P3T_O=JOZK/<^*?@U-KEQ9XU1;.1%:$%=R%P'91Z,JY^E '<:1XOT#7OM']
MF:I;W'V==\NTXVK_ 'N>W'6H+;QWX9O+2]NK;5X)H;)/,G*9.U>F[&,D>XKS
M7QI<6.KS ^%)(9A%H$_GFSP0L9*;5;'? ; Z]:V;==!\1^-](M=)-O<:>="D
MCO%A/'E,5"HQ7H<_0\&@#U&-UDC61#E6 (/L:=2*H10JC  P!2T %%%% !11
M10 4444 %%%% !1110 4444 8'B_Q'<^&-(BOK70[[6)'G$1M[)"SJ"K'<0
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ML$7&YCDC@9Z=3V!K$U+XB6QDMH](M[BXBDNX8)+SRAY*[QNVYR#NVD'ICWH
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M0#M$L:N2<D= >23W H YR;QM+=:_)K-W\+/$=S<E(DC\VV8B,(6(Q\GJQ/U
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M ]S7M5% 'E7_  M_6?\ HFGB;_OP_P#\11_PM_6?^B:>)O\ OP__ ,17JM%
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M$T\3?]^'_P#B*]5HH \J_P"%OZS_ -$T\3?]^'_^(H_X6_K/_1-/$W_?A_\
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M+\1;B6)+!_ FOZ7;0(HCWV<K*0,#;\L9(XYZ5Z?10-.SN>8:E\4;^UU)TM/
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M1I6-P6^$6M$W/^O)L3^]_P![]W\WXTD/Q#:VABA@^$&L1112"6-([#:J..C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;3- .;"-U_T:.VPSY^1"Q'XY8Y-<3=^,-2LO"=U =6D&KR7RV=O+=6BI-!N
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MB!4*46-Q\Q?&XL&XXXKMJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>redactedmod13-acam2000002.jpg
<TEXT>
begin 644 redactedmod13-acam2000002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RY/$N
M@PRO%+K>FI(C%61KN,%2.H(SP:9_PE7AW_H/:7_X&1_XUAW?PH\#WUY/>7.@
M0R7$\C2RN99!N9CDGAO4U%_PIWP!_P!"Y#_W^E_^*H Z'_A*O#O_ $'M+_\
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MJ@#H?^$J\._]![2__ R/_&C_ (2KP[_T'M+_ / R/_&N>_X4[X _Z%R'_O\
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M  IWP!_T+D/_ '^E_P#BJ .A_P"$J\._]![2_P#P,C_QH_X2KP[_ -![2_\
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M_P #(_\ &C_A*O#O_0>TO_P,C_QKG?\ A3_P_ )_X1V# Z_OY?\ XJD/P?\
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MNGAV _2>7_XJ@#HO^$J\._\ 0>TO_P #(_\ &C_A*O#O_0>TO_P,C_QKG/\
MA3_P_(R/#L'_ '_E_P#BJ#\'_A^.OAV ?6>7_P"*H Z/_A*O#O\ T'M+_P#
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M]I?_ (&1_P"-<X/A#\/CG'AZWX_Z;R?_ !5+_P *?^'^<?\ ".P9_P"NTO\
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M[_T'M+_\#(_\:/\ A*O#O_0>TO\ \#(_\:Y[_A3O@#_H7(?^_P!+_P#%4?\
M"G? '_0N0_\ ?Z7_ .*H Z'_ (2KP[_T'M+_ / R/_&C_A*O#O\ T'M+_P#
MR/\ QKGO^%.^ /\ H7(?^_TO_P 51_PIWP!_T+D/_?Z7_P"*H Z'_A*O#O\
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M^%.^ /\ H7(?^_TO_P 51_PIWP!_T+D/_?Z7_P"*H Z'_A*O#O\ T'M+_P#
MR/\ QH_X2KP[_P!![2__  ,C_P :Y[_A3O@#_H7(?^_TO_Q5'_"G? '_ $+D
M/_?Z7_XJ@#H?^$J\._\ 0>TO_P #(_\ &C_A*O#O_0>TO_P,C_QKGO\ A3O@
M#_H7(?\ O]+_ /%4?\*=\ ?]"Y#_ -_I?_BJ .A_X2KP[_T'M+_\#(_\:/\
MA*O#O_0>TO\ \#(_\:Y[_A3O@#_H7(?^_P!+_P#%4?\ "G? '_0N0_\ ?Z7_
M .*H Z'_ (2KP[_T'M+_ / R/_&C_A*O#O\ T'M+_P# R/\ QKGO^%.^ /\
MH7(?^_TO_P 51_PIWP!_T+D/_?Z7_P"*H Z'_A*O#O\ T'M+_P# R/\ QH_X
M2KP[_P!![2__  ,C_P :Y[_A3O@#_H7(?^_TO_Q5'_"G? '_ $+D/_?Z7_XJ
M@#H?^$J\._\ 0>TO_P #(_\ &C_A*O#O_0>TO_P,C_QKGO\ A3O@#_H7(?\
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MC((GEP?_ !ZE_P"%.^ /^A<A_P"_TO\ \50!T/\ PE7AW_H/:7_X&1_XT?\
M"5>'?^@]I?\ X&1_XUSW_"G? '_0N0_]_I?_ (JFO\(?A]&I9_#UNJCJ6GD
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ML7; [#+' H TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /.]0_Y+UHW_ &")_P#T
M(5Z#*[1PNZ(9&520@ZL?2O/M0_Y+UHW_ &")_P#T(5WUW)/%9S26T/G3JA,<
M>X+N;L,GI0!B6>LZG'?V%MJUG;P-?A_*CBE+M&57<0W&#QW'>NAKC_#D6KIJ
M0NM5T:Z-]<9$UY--$4@3J$C56)"YQ]>IKL* "BBB@ HHHH \V\0?\EZ\(_\
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MR:+X>DB,J6&G-&/XQ&A'YT]- T*1=R:98LOJL2F@#EO^%T> ?^@\O_@/)_\
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M4_X71X!_Z#R_^ \G_P 31_PNCP#_ -!Y?_ >3_XFNK_X1W1?^@59_P#?E?\
M"C_A'=%_Z!5G_P!^5_PH Y3_ (71X!_Z#R_^ \G_ ,31_P +H\ _]!Y?_ >3
M_P")KJ_^$=T7_H%6?_?E?\*/^$=T7_H%6?\ WY7_  H Y3_A='@'_H/+_P"
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M^$=T7_H%6?\ WY7_  H Y3_A='@'_H/+_P" \G_Q-'_"Z/ /_0>7_P !Y/\
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M . \G_Q-'_"Z/ /_ $'E_P# >3_XFNK_ .$=T7_H%6?_ 'Y7_"C_ (1W1?\
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M_P !Y/\ XFNK_P"$=T7_ *!5G_WY7_"C_A'=%_Z!5G_WY7_"@#E/^%T> ?\
MH/+_ . \G_Q-'_"Z/ /_ $'E_P# >3_XFNK_ .$=T7_H%6?_ 'Y7_"C_ (1W
M1?\ H%6?_?E?\* .4_X71X!_Z#R_^ \G_P 31_PNCP#_ -!Y?_ >3_XFNK_X
M1W1?^@59_P#?E?\ "C_A'=%_Z!5G_P!^5_PH Y3_ (71X!_Z#R_^ \G_ ,31
M_P +H\ _]!Y?_ >3_P")KJ_^$=T7_H%6?_?E?\*/^$=T7_H%6?\ WY7_  H
M\AO/B7X2E^+>FZXFK*=.ATZ6"27RGX=B,#&,_I79_P#"Z/ /_0>7_P !Y/\
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M73GZ5R<7]B7$.D1^&;.2#5+:-_[1*P.CK'Y;!Q,Q W$MC&23Z5Z\T\2OL:5
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ME-9G3HW@G*F59&9S(5Z;B22<9/4T^V\+:'9R/);Z;#&[QM$S#.2C8R.O0X%
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M?&3^_P"&O^^G_P#B:-GQD_O^&O\ OI__ (FNL/CC05LIKI[F6-86C5XW@=9
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M)HSGZ, :N4 >->&_$/Q7\4Z2=2T\Z L'FO#B;<K;D.#P >,UK[/C)_?\-?\
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M=*'$8+L9G8 CC( 'ZUZ#10 51UK_ ) 6H?\ 7M)_Z":O51UK_D!:A_U[2?\
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M6  ';->DT4 8?A47"Z6R7-IJ5LRN<#4;D3R,/7<">*W*** ///@O_P B"?\
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M\DIT+_<E_P#1KUW% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.UOUC'2[BX\8)JLY46]I:-;VR@Y+-(RF1CZ?<0#\:V: "BBB@ HHHH ****
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M ![_  H_X6GX(_Z&.T_\>_PK1_X0?PE_T*VB?^"^+_XFC_A!_"7_ $*VB?\
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M *&.T_\ 'O\ "C_A:?@C_H8[3_Q[_"M'_A!_"7_0K:)_X+XO_B:/^$'\)?\
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M_H8[3_Q[_"N7^#WA7P[J7PMT>[O]!TNZN9#/OFGLXW=L3.!EB,G@ ?A7<_\
M"#^$O^A6T3_P7Q?_ !- &=_PM/P1_P!#':?^/?X4?\+3\$?]#':?^/?X5H_\
M(/X2_P"A6T3_ ,%\7_Q-'_"#^$O^A6T3_P %\7_Q- &=_P +3\$?]#':?^/?
MX4?\+3\$?]#':?\ CW^%:/\ P@_A+_H5M$_\%\7_ ,31_P (/X2_Z%;1/_!?
M%_\ $T 9W_"T_!'_ $,=I_X]_A1_PM/P1_T,=I_X]_A6C_P@_A+_ *%;1/\
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M+W3[:PN%7#VUJ^Z-/8' K3HH 0DA20,GT]:\^N/">L3^%FA@BAM]2\R='5Y
M5E@EE9\$CH1N!'N".]>A44 %%%% !1110 4444 %%(65<;F R<#)ZT$A022
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M#_U^2?\ HR"@#VVBBB@ KS#X9_\ )0?B/_V$8_\ VI7I]>8?#/\ Y*#\1_\
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M987MK8:.+<-',)/WIDSR"OIBM6LU-#LX_$$FMJ9OMDD @;,AV;0<_=Z9K2H
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M\#SW%VR>7Y]S(7=4SG:/09YXH Y&^M#'=R7VHMJ05KP-%J=G?.T2)O&U3&'
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MT]L5)X2W6>K:M;R:6FAXM8I!9QN'3H<R#'&>Q^G-=3%H6GQ:1)I?DE[63<9
M[EF<DY+%CR3GG-&G:):::TSQF:668!7EGD+L5'09/89H X#PS%*-?T.Z?3OL
M*3F?%^'#-J658@.!R,@;QNZ;<#&:]0K)LO#FGV%VMQ")B8\F&-Y2R0YR#L4]
M."1]#6M0 5XE\4/^2W^ ?^NL7_HZO;:\2^*'_);_  #_ -=8O_1U 'MM%%%
M!1110 4444 %>)?'7_D;? /_ %^2?^C(*]MKQ+XZ_P#(V^ ?^OR3_P!&04 >
MVT444 %>8?#/_DH/Q'_[",?_ +4KT^O,/AG_ ,E!^(__ &$8_P#VI0!Z?111
M0 4444 %%%% !1110 4444 %%%% !67XF_Y%36/^O&;_ - -:E9?B;_D5-8_
MZ\9O_0#0!R7P1_Y)%HGUN/\ T?)7H->??!'_ ))%HGUN/_1\E>@T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q?Q;_Y)7X@_Z]Q_Z&M=
MI7%_%O\ Y)7X@_Z]Q_Z&M $/P=./A+H)P3B*3@?]=7K6M?&NGW+.6M;^"%)S
M;O/- 1&K@X()[<UD_!TX^$N@D]HY/_1KU!H&CMJK:G;7E_J45K+J$TYLOLXC
MCD3?D$NR;L'T#"@#NI;RU@F2&:YACED^XCR %OH#UJ1IHDD6-I461_NJ6 +?
M05Y1X@TDRZWK2ZO)M>Y?_1V&CR7+-"  @CD5Q@C'3 YY[UMZ]I5K=V'A9-1B
MO+FYADC%Q<"!UE\KRF#[BF=NXX!&>] ';R7L"6DERLL;QH#R'&"?3/2BRN&N
M[&"X>(Q-(@8H2#MSVR*QIM-T2W\-SP6^F#[%<<^0ENWS-V)3&1R!VJE;BXNO
MA]+I]K#=0W<=F(]I0QMG'12>^ ?TH ZF&ZM[G?Y$\4NP[6\MPVT^AQTK.UCQ
M!:Z/:33$?:'@&^6&&1/,5.[8)' KF-,BTR;Q'I+:#I]W;-:QE;R0P-$NS;@(
M^X ,V[TS]:YO5--MV\)R:?)X>U";Q,'WSW,=LQWR[P7D$G0JPSQZ'&* /8:C
MGGAMHC+/+'%&.KR,% _$TY&#HK@$!AD9&#7)>+8;?^V=*O-6M)KO1X%DW1QQ
M&0).2NQW4<D!0XSV)H ZHW5N+;[29H_(QN\S<-N/KTK'T'Q/%X@*/:V4Z6TD
M7FQSN\>&4]/E#%AD<\@5B^'[*T&CZP7LIH_#]S.'L[*>!B4&!N(3!(4N"P'X
M\5;\ 6&G6/AK3H[>P^RWRV,"W>;=HV+A!D$D#)SF@#K*YVX\8VEM=7D,EAJ6
MVSD"7$RVY*1_*&R2.V"#GTKHJX?^SY-5\1Z_;/J6I6=I=RHABAM@%F40HK?O
M&C)'0C@CIQ0!V$M_9P1QR374,:2X\LO(%#9],]:DDGBBV^9*B;SA=S 9/M7F
M7B31S%XIF:^94T]K2."R\S3'O$50N&4;6&UB<=N>.:OZCI<$WPYL;.Y2]N)H
MV0V[M;.LT8#CD ;BA"Y')SB@#O1<VY1W$\6R,X=MXPI]_2L?1O$\.NSC[):3
M?9F4LER7CVL <?=#;AGMD4VPTKP]9Z3<_9-/5+2<!9U,#YDQZJ1D]>N*Q_!N
MF6MIX0ABTVQ%EK7]GA'=[9HR)-O&XD<_-B@#L$O+66X>WCN87F3[T:N"R_4=
M12M=VR%PUQ$I3&_+@;?KZ5YE86.FYT.TT?2-0M=?M;F-Y[B6!E*J&'GF60\,
M'7>!C.21C%;=UIFBW/CVXN;S3Y)(S:(F3;2&-Y=[Y)P,$A2.3TS0!V+7MHC;
M7NH5;.,&0 YQG^7-*+NV:V%RMQ$8",^:'&W\^E><Z_X9TR?4M8V:0S$?8]I2
M%\%02'VX&#\NT'':BYBGTVQU.RCL/+L?[;9A(]DTZV\)B4AT08S\V[GD DYH
M ]'6YMW@$ZSQ-">1('!7\^E)#=VURSK!<12F,X<(X;:?0XZ5YSI4<ESX8\4V
MMS:WKVTK%K82V;1>8"@&50#CYO3ZUM:1I=CH^LZ*-.L7MTET^1)V6)P&.4*[
MR1USOZ\\GUH ZLWUH+G[,;J 3@9\HR#=^76B:\M;>1(Y[F&*23[BNX4M] >M
M>>Z?;:+)IMI9:OI-W+K\5R))FCMW\QI@^3*),8V'&>N,<8JGKFER+X@U@ZI*
M,73YMB^D/=EHMH 1'5QM(.3C ]<T >INZQJ6=@JCJ6. *<#D9%<?KL%HOPY6
M#6;+4]5A6*)9(8$9;B0@C!PAR#T)YKJK/8+*#RT>-/+7:CYW*,< Y[T 22/Y
M<3OM9MJD[5&2?8#UK/T?5QJ\$TGV.XM&BD\MH[@ -T!S@$^M:+L$1G.<*,G
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MHH **** #%%%% !1110 4444 %%%% !C-%%% !1110 8HHHH **** "BBB@
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M%'_D:? ?_86_H* /3**** "O//A]_P CQX__ .PC'_Z :]#KSSX??\CQX_\
M^PC'_P"@&@#T.BBB@ HHHH **** "BBB@ HHHH **** "JNI_P#(*O/^N#_^
M@FK55=3_ .03>?\ 7!__ $$T <;\&O\ DEFE?]=+G_THDKO*X/X-_P#)+-*_
MZZ7/_I1)7>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=G!')S7JE% "+]T<8XZ5YKXP_P"2R>!?]VY_] KTNO-/&'_)9/ O^[<_^@4
M>ET444 %%%% !1110 5YG\4?^1H\!_\ 86_H*],KS/XH_P#(T> _^PM_04 >
MF4444 %>>?#[_D>/'_\ V$8__0#7H=>>?#[_ )'CQ_\ ]A&/_P! - 'H=%%%
M !1110 4444 %%%% !1110 4444 %5=3_P"05>?]<'_]!-6JJZG_ ,@J\_ZX
M/_Z": .-^#7_ "2S2O\ KI<_^E$E=Y7!_!K_ ))9I7_72Y_]*)*[R@ HHHH
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M$;N[.UT^32IK&TOK.-XMB6VRW='(++L7IRJD$?UH =X2U>?5FUDS/=?Z/?\
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MBBB@ HHHH **** "BBB@ KS3QA_R63P+_NW/_H%>EUYIXP_Y+)X%_P!VY_\
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M"HKY]_X:9D_Z%-?_  8?_:Z/^&F9/^A37_P8?_:Z /H*BOGW_AIF3_H4U_\
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M !1110 5YIXQ_P"2R>!O]VX_]!KTNO-/&'_)9/ O^[<_^@4 >ET444 %%%%
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M,=@UBFNZ0+5CDQ?:!@_K5C0+_P !W]Y)9:#=Z9/<2QOOBMI02R'[W&??GZT
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MS?\ @'/_ /$4?\+O^'O_ $'F_P# .?\ ^(H ]"HKSW_A=_P]_P"@\W_@'/\
M_$4?\+O^'O\ T'F_\ Y__B* /0J*\]_X7?\ #W_H/-_X!S__ !%'_"[_ (>_
M]!YO_ .?_P"(H ]"HJ"QO(-1L+:^M7\RWN8EFB?!&Y& (.#R.".M3T %%%%
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MW*P_&?\ R(OB#_L&W/\ Z*:@#B-%_P"3:IO^P'=?^@R5\IU]6:+_ ,FU3?\
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M?$U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?<?@K_D0_#O\
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MZZ7/_I1)7>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MA^,_^1%\0?\ 8-N?_135N5A^,_\ D1?$'_8-N?\ T4U 'B/B_P#Y-E\-_P#7
MS'_[5KPJOL'X=V.G:A\(="CU2SMKJV2 R%+B$2*"&;G!!YZT1M\.)2-OA^RP
M8TFW-H#@!')",28L!20<'IQ0!\?45]P-X.\(HP5O#FB GH#8Q<_^.U%/X8\%
MVUQ#!-X?T1)9\B-381?-@9/\- 'Q)17W#_PAOA+;N_X1O1-OK]ABQ_Z#2?\
M"'>%#&73PSHSC&1ML8N?IQ0!\/T5]JZ9X>\(:I'.R>$],A:"8PR1S:="&5@
M>P(Z,*O?\(7X5_Z%G1O_   B_P#B: /ARBON/_A"_"O_ $+.C?\ @!%_\37"
M?%[2=(\-_#^YU+2-#T>UO$FB59!IT#8!;!X9"* /E>BM[_A,=6_YYZ5_X*+3
M_P"-4?\ "8ZM_P \]*_\%%I_\:H P:*WO^$QU;_GGI7_ (*+3_XU1_PF.K?\
M\]*_\%%I_P#&J ,&BM[_ (3'5O\ GGI7_@HM/_C5'_"8ZM_SSTK_ ,%%I_\
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M\ (O_B: /ARBON/_ (0OPK_T+.C?^ $7_P 31_PA?A7_ *%G1O\ P B_^)H
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M5XCLGO-'OHKRV20Q-)'G 8 $CGV(_.M*@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\T\8?\ED\"_[MS_Z!7I=>:>,/^2R>!?]
MVY_] H ]+HHHH **** "BBB@ KS/XH_\C1X#_P"PM_05Z97F?Q1_Y&CP'_V%
MOZ"@#TRBBB@ KSSX??\ (\>/_P#L(Q_^@&O0Z\\^'W_(\>/_ /L(Q_\ H!H
M]#HHHH **** "BBB@ HHHH **** "BBB@ JKJ?\ R"KS_K@__H)JU574_P#D
M%7G_ %P?_P!!- '&_!K_ ))9I7_72Y_]*)*[RN#^#7_)+-*_ZZ7/_I1)7>4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A^,_^1%\0?\
M8-N?_135N5A^,_\ D1?$'_8-N?\ T4U &'\,[A;3X1:/<O\ <AM'D;Z!F-7$
MU#Q%!I4&MW$EHUNX$TUF(B&CB.#\KYY8 \Y&#[56^%T23_"?1(9!E)+5E8>H
M+,#5V+PWJGDP:;<:LCZ/!@"-8<2R(/NHS9Z# R0,F@"G;^*[NUU+6;+[!J&J
M_8KDLTD*(!%$45E7MN/+<=<8JYXCU2:3PI%KNCZE)%'B*5-B(RRH[*.=P)Z'
MMBH#X<\16U_J=QIVN6T2:C-YLB26N[RCM505^;KA1G/' J:_\*W3^&+?P_IU
M]%!9Q0QQ%IHB[G800<Y'7% &[JMU+9Z7<3PV\T[HO"0XW?49XXZ_A5.TU:&W
M\*P:I=32M$MNLCO(HWMQW XR?05--;:K+I1@^UVPNVR&E\D[-I_V=W7\:HV6
M@W2^'I-(U*[BGA\H1QO#"49<9YY)R>F/I0!##XO9]=L])GT34+>:[5I(GD";
M=BC))P>",CCWJS<>)4L]2CM;JQGACEN%MXYF9,,S'"G .=I. #[US^D6]_?>
M-;.[EOKV]AL8)8R\UBULB[L =0-[''4=,>],_P"%>WL8MXH+^P5;>^6]%P]E
MNN)F63>!(^>?3(Q0!LZAXEU&S\4_V9#HES=P?9O-WQ% 2=P&1EAQSCZU=U3Q
M$NG7%I9Q6-Q=ZA=(9$M8L;E08W,Q)P "0/J:-3TO4)=4M]1TV[@AG2!H)%FB
M+JRD@@C!&""#^=9NN^#VUB?3]0D>QGU&TC:)C>6@EBE1B"1L/0Y P1SUH NC
MQ9:C2);R6UNHKB*;[,UDR#SO-.,(!G!R""#G&.:I:-KU[?\ C*[L+B"[M$2S
M67[+<*F 2Y&Y67J"/4]J?#X3DBTOR8I[.TNTN%N87LK)8HXV Q@J/O @D')[
MTNEZ!K4/B9M:U+5K>X+V_P!G,$5N455!)&T[CSD\YH ZBN3N?$&H6OBEX-]O
M+I44T5M.1$0\<L@)4;MV. 4)X_C%=6X8HP0@-C@D9 -<<W@59]+OUNO[.FU:
MYE>5-1-D#)&Q.002<Y7C&#Q@4 3:EXX33=0N+1M&U"4P31P;XPI#/)_JP.>Y
MX]JMGQ9";6S,=E<R7MW(\26:XW*R??W'. !Z^X]:I2^$]1N9)9KC4X&F>XM;
M@%;<@ PG//S=_P!*F/AF^@FCN[/4(TNX+B>2(O$2C1RX+(PSSRJG(QTH G_X
M2V#[!<W'V&[$UI.D-U;,%#PEL$,><%<,#D=:N?VW_P 3J;3/L4_F):FYC?Y=
MLH! (7GKD@<U23PU,^GZJMU?F6^U(JTDPCPB%0 H5<]!CUYYJ.RT37$ULZK>
MZI:22"S:UCBCMBJH200V=V3R.10 :1XQ759+/=I-_:6]X[1PSSJH4NH)(.#D
M9VM@]\5''XGU(^)+[3O[!NY((#&%D0IP&SECENG'%26_AR_@TW1[3[? S6%S
MY[/Y!_>#YA@#=Q]X\_2K-YI.J+K$]]I=];P"YC1)5G@+D%<X9<$=CC!H LZ]
MKD>@6,=U+:7=TKS)%LM8C(P+'&2!VKR3]I,Y\.:&?^GM_P#T"O6M8LM5O-.B
MATW5%LKI9$9YS 'WJ/O#&>,UY+^TG_R+FAYZ_:W_ /0* /F^BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ^H?V<O^2=WO_84D_\ 145>O5Y#^SE_
MR3N]_P"PI)_Z*BKUZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\T\8?\ )9/ O^[<_P#H%>EUYIXP_P"2R>!?]VY_] H ]+HH
MHH **** "BBB@ KS/XH_\C1X#_["W]!7IE>9_%'_ )&CP'_V%OZ"@#TRBBB@
M KSSX??\CQX__P"PC'_Z :]#KSSX??\ (\>/_P#L(Q_^@&@#T.BBB@ HHHH
M**** "BBB@ HHHH **** "JNI_\ (*O/^N#_ /H)JU574_\ D%7G_7!__030
M!QOP:_Y)9I7_ %TN?_2B2N\K@_@U_P DLTK_ *Z7/_I1)7>4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5R7Q/NYK'X9^()X&"O\ 9&3)
M&>&(4_H376UQ?Q;_ .25^(/^O<?^AK0 SX/R-)\*- 9NOE./RD<5V]<+\'/^
M23:#_P!<Y/\ T:]=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5F:SX=T?Q%#%#K&G6]['$Q9%F3<%/3(K3HH Y3_A67@C_ *%C3?\
MOR*/^%9>"/\ H6--_P"_(KJZ* .4_P"%9>"/^A8TW_OR*/\ A67@C_H6--_[
M\BNKHH Y3_A67@C_ *%C3?\ OR*/^%9>"/\ H6--_P"_(KJZ* .4_P"%9>"/
M^A8TW_OR*/\ A67@C_H6--_[\BNKHH Y3_A67@C_ *%C3?\ OR*/^%9>"/\
MH6--_P"_(KJZ* .4_P"%9>"/^A8TW_OR*/\ A67@C_H6--_[\BNKHH Y3_A6
M7@C_ *%C3?\ OR*/^%9>"/\ H6--_P"_(KJZ* .4_P"%9>"/^A8TW_OR*/\
MA67@C_H6--_[\BNKHH S]'T/2_#]FUII%C!96[.9&CA7:"Q !/UP!^5:%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XY\1]
M0N+3XV> DA8 %PIR,\/)L;]*]CKQ+XH?\EO\ _\ 76+_ -'4 >VT444 %%%%
M !1110 5XW\:M0N++Q9X!$+  W[OR,\AH@/T8U[)7B7QU_Y&WP#_ -?DG_HR
M"@#VVBBB@ KS/X;S/)X^^(JL>%U&/''LX_H*],KS#X9_\E!^(_\ V$8__:E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ KB_BW_R2OQ!_P!>X_\ 0UKM*XOXM_\
M)*_$'_7N/_0UH A^#G_))M!_ZYR?^C7KNJX7X.?\DFT'_KG)_P"C7KNJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N+^+?\ R2OQ!_U[C_T-:[2N+^+?_)*_$'_7N/\ T-: (?@Y_P DFT'_ *YR
M?^C7KNJX7X.?\DFT'_KG)_Z->NZH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KQ+XH?\ );_ /_76+_T=7MM>)?%#_DM_@'_KK%_Z.H ]MHHHH **** "
MBBB@ KQ+XZ_\C;X!_P"OR3_T9!7MM>)?'7_D;? /_7Y)_P"C(* /;:*** "O
M,/AG_P E!^(__81C_P#:E>GUYA\,_P#DH/Q'_P"PC'_[4H ]/HHHH **** "
MBBB@ HHHH **** "BBB@ K+\3?\ (J:Q_P!>,W_H!K4K+\3?\BIK'_7C-_Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB_BW_R2OQ!_P!>X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+XH?\EO\
M /\ UUB_]'5[;7B7Q0_Y+?X!_P"NL7_HZ@#VVBBB@ HHHH **** "O$OCK_R
M-O@'_K\D_P#1D%>VUXE\=?\ D;? /_7Y)_Z,@H ]MHHHH *\P^&?_)0?B/\
M]A&/_P!J5Z?7F'PS_P"2@_$?_L(Q_P#M2@#T^BBB@ HHHH **** "BBB@ HH
MHH **** "LOQ-_R*FL?]>,W_ * :U*R_$W_(J:Q_UXS?^@&@#DO@C_R2+1/K
M<?\ H^2O0:\^^"/_ "2+1/K<?^CY*]!H **** "BBB@ HHHH **** "BBB@
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M$OCK_P C;X!_Z_)/_1D%>VUXE\=?^1M\ _\ 7Y)_Z,@H ]MHHHH *\P^&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KB_BW_R2OQ!_U[C_ -#6NTKB_BW_
M ,DK\0?]>X_]#6@"'X.?\DFT'_KG)_Z->NZKA?@Y_P DFT'_ *YR?^C7KNJ
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MZYR?^C7KNJX7X.?\DFT'_KG)_P"C7KNJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\2^*'_);_ /_76+_P!'5[;7B7Q0_P"2W^ ?^NL7_HZ@#VVBBB@
MHHHH **** "O$OCK_P C;X!_Z_)/_1D%>VUXE\=?^1M\ _\ 7Y)_Z,@H ]MH
MHHH *\P^&?\ R4'XC_\ 81C_ /:E>GUYA\,_^2@_$?\ [",?_M2@#T^BBB@
MHHHH **** "BBB@ HHHH **** "LOQ-_R*FL?]>,W_H!K4K+\3?\BIK'_7C-
M_P"@&@#DO@C_ ,DBT3ZW'_H^2O0:\^^"/_)(M$^MQ_Z/DKT&@ HHHH ****
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MS[X(_P#)(M$^MQ_Z/DKT&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *YR?^C7KNJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\2^*'_);_ /_
M %UB_P#1U>VUXE\4/^2W^ ?^NL7_ *.H ]MHHHH **** "BBB@ KQ+XZ_P#(
MV^ ?^OR3_P!&05[;7B7QU_Y&WP#_ -?DG_HR"@#VVBBB@ KS#X9_\E!^(_\
MV$8__:E>GUYA\,_^2@_$?_L(Q_\ M2@#T^BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\2^*'_);_ /_76+_P!'5[;7B7Q0_P"2W^ ?^NL7
M_HZ@#VVBBB@ HHHH **** "O$OCK_P C;X!_Z_)/_1D%>VUXE\=?^1M\ _\
M7Y)_Z,@H ]MHHHH *\P^&?\ R4'XC_\ 81C_ /:E>GUYA\,_^2@_$?\ [",?
M_M2@#T^BBB@ HHHH **** "BBB@ HHHH **** "LOQ-_R*FL?]>,W_H!K4K+
M\3?\BIK'_7C-_P"@&@#DO@C_ ,DBT3ZW'_H^2O0:\^^"/_)(M$^MQ_Z/DKT&
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^+?\ R2OQ
M!_U[C_T-:[2N+^+?_)*_$'_7N/\ T-: (?@Y_P DFT'_ *YR?^C7KNJX7X.?
M\DFT'_KG)_Z->NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+XH?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NL7_HZ@#VVBBB@ HHHH **** "O$OCK_R-O@'_K\D_P#1D%>VUXE\=?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ KB_BW_R2OQ!_P!>X_\ 0UKM*XOXM_\
M)*_$'_7N/_0UH A^#G_))M!_ZYR?^C7KNJX7X.?\DFT'_KG)_P"C7KNJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\2^*'_);_ /_76+_P!'5[;7B7Q0
M_P"2W^ ?^NL7_HZ@#VVBBB@ HHHH **** "O$OCK_P C;X!_Z_)/_1D%>VUX
ME\=?^1M\ _\ 7Y)_Z,@H ]MHHHH *\P^&?\ R4'XC_\ 81C_ /:E>GUYA\,_
M^2@_$?\ [",?_M2@#T^BBB@ HHHH **** "BBB@ HHHH **** "LOQ-_R*FL
M?]>,W_H!K4K+\3?\BIK'_7C-_P"@&@#DO@C_ ,DBT3ZW'_H^2O0:\^^"/_)(
MM$^MQ_Z/DKT&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N+^+?\ R2OQ!_U[C_T-:[2N+^+?_)*_$'_7N/\ T-: (?@Y_P DFT'_ *YR
M?^C7KNJX7X.?\DFT'_KG)_Z->NZH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KQ+XH?\ );_ /_76+_T=7MM>)?%#_DM_@'_KK%_Z.H ]MHHHH **** "
MBBB@ KQ+XZ_\C;X!_P"OR3_T9!7MM>)?'7_D;? /_7Y)_P"C(* /;:*** "O
M,/AG_P E!^(__81C_P#:E>GUYA\,_P#DH/Q'_P"PC'_[4H ]/HHHH **** "
MBBB@ HHHH **** "BBB@ K+\3?\ (J:Q_P!>,W_H!K4K+\3?\BIK'_7C-_Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB_BW_R2OQ!_P!>X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+XH?\EO\
M /\ UUB_]'5[;7B7Q0_Y+?X!_P"NL7_HZ@#VVBBB@ HHHH **** "O$OCK_R
M-O@'_K\D_P#1D%>VUXE\=?\ D;? /_7Y)_Z,@H ]MHHHH *\P^&?_)0?B/\
M]A&/_P!J5Z?7F'PS_P"2@_$?_L(Q_P#M2@#T^BBB@ HHHH **** "BBB@ HH
MHH **** "LOQ-_R*FL?]>,W_ * :U*R_$W_(J:Q_UXS?^@&@#DO@C_R2+1/K
M<?\ H^2O0:\^^"/_ "2+1/K<?^CY*]!H **** "BBB@ HHHH **** "BBB@
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M$OCK_P C;X!_Z_)/_1D%>VUXE\=?^1M\ _\ 7Y)_Z,@H ]MHHHH *\P^&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KB_BW_R2OQ!_U[C_ -#6NTKB_BW_
M ,DK\0?]>X_]#6@"'X.?\DFT'_KG)_Z->NZKA?@Y_P DFT'_ *YR?^C7KNJ
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MZYR?^C7KNJX7X.?\DFT'_KG)_P"C7KNJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\2^*'_);_ /_76+_P!'5[;7B7Q0_P"2W^ ?^NL7_HZ@#VVBBB@
MHHHH **** "O$OCK_P C;X!_Z_)/_1D%>VUXE\=?^1M\ _\ 7Y)_Z,@H ]MH
MHHH *\P^&?\ R4'XC_\ 81C_ /:E>GUYA\,_^2@_$?\ [",?_M2@#T^BBB@
MHHHH **** "BBB@ HHHH **** "LOQ-_R*FL?]>,W_H!K4K+\3?\BIK'_7C-
M_P"@&@#DO@C_ ,DBT3ZW'_H^2O0:\^^"/_)(M$^MQ_Z/DKT&@ HHHH ****
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MS[X(_P#)(M$^MQ_Z/DKT&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *YR?^C7KNJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\2^*'_);_ /_
M %UB_P#1U>VUXE\4/^2W^ ?^NL7_ *.H ]MHHHH **** "BBB@ KQ+XZ_P#(
MV^ ?^OR3_P!&05[;7B7QU_Y&WP#_ -?DG_HR"@#VVBBB@ KS#X9_\E!^(_\
MV$8__:E>GUYA\,_^2@_$?_L(Q_\ M2@#T^BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\2^*'_);_ /_76+_P!'5[;7B7Q0_P"2W^ ?^NL7
M_HZ@#VVBBB@ HHHH **** "O$OCK_P C;X!_Z_)/_1D%>VUXE\=?^1M\ _\
M7Y)_Z,@H ]MHHHH *\P^&?\ R4'XC_\ 81C_ /:E>GUYA\,_^2@_$?\ [",?
M_M2@#T^BBB@ HHHH **** "BBB@ HHHH **** "LOQ-_R*FL?]>,W_H!K4K+
M\3?\BIK'_7C-_P"@&@#DO@C_ ,DBT3ZW'_H^2O0:\^^"/_)(M$^MQ_Z/DKT&
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^+?\ R2OQ
M!_U[C_T-:[2N+^+?_)*_$'_7N/\ T-: (?@Y_P DFT'_ *YR?^C7KNJX7X.?
M\DFT'_KG)_Z->NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+XH?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NL7_HZ@#VVBBB@ HHHH **** "O$OCK_R-O@'_K\D_P#1D%>VUXE\=?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ KB_BW_R2OQ!_P!>X_\ 0UKM*XOXM_\
M)*_$'_7N/_0UH A^#G_))M!_ZYR?^C7KNJX7X.?\DFT'_KG)_P"C7KNJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N+^+?\ R2OQ!_U[C_T-:[2N+^+?_)*_$'_7N/\ T-: (?@Y_P DFT'_ *YR
M?^C7KNJX7X.?\DFT'_KG)_Z->NZH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KQ+XH?\ );_ /_76+_T=7MM>)?%#_DM_@'_KK%_Z.H ]MHHHH **** "
MBBB@ KQ+XZ_\C;X!_P"OR3_T9!7MM>)?'7_D;? /_7Y)_P"C(* /;:*** "O
M,/AG_P E!^(__81C_P#:E>GUYA\,_P#DH/Q'_P"PC'_[4H ]/HHHH **** "
MBBB@ HHHH **** "BBB@ K+\3?\ (J:Q_P!>,W_H!K4K+\3?\BIK'_7C-_Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XG\3HW?XW> BJ,?W
ML9X'I-DU[97FGC#_ )+)X%_W;G_T"@#TNBBB@ HHHH **** "O$_CG&[^+?
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M10 4444 %%%% !1110 5A^,_^1%\0?\ 8-N?_135N5B>,_\ D1O$'_8-N?\
MT4U &1\*/^27:!_U[G_T-J[*N-^%'_)+M _ZX'_T-J[*@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O-/&'_)9/ O^[<_^@5Z77FGC#_DLG@;_=N/_0:
M/2Z*** "BBB@ HHHH *\S^*/_(T> _\ L+?T%>F5YG\4?^1I\!_]A;^@H ],
MHHHH *\\^'W_ "/'C_\ [",?_H!KT.O//A]_R/'C_P#[",?_ * : /0Z***
M"BBB@ HHHH **** "BBB@ HHHH *JZG_ ,@J\_ZX/_Z":M54U/\ Y!-Y_P!<
M'_\ 030!QWP:_P"26:5_UTN?_2B2N\KA/@W_ ,DLTK_KI<_^E$E=W0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'XS_Y$7Q!_P!@VY_]
M%-6Y6'XS_P"1%\0?]@VY_P#134 9/PH_Y)=H'_7N?_0VKLJXWX4?\DNT#_KW
M/_H;5V5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:>,/^2R>!?]VY_]
M KTNO-/&'_)9/ O^[<_^@4 >ET444 %%%% !1110 5YG\4?^1H\!_P#86_H*
M],KS/XH_\C1X#_["W]!0!Z91110 5YY\/O\ D>/'_P#V$8__ $ UZ'7GGP^_
MY'CQ_P#]A&/_ - - 'H=%%% !1110 4444 %%%% !1110 4444 %5=3_ .05
M>?\ 7!__ $$U:JKJ?_(*O/\ K@__ *": .-^#7_)+-*_ZZ7/_I1)7>5P?P:_
MY)9I7_72Y_\ 2B2N\H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !6'XS_P"1%\0?]@VY_P#135N5A^,_^1%\0?\
M8-N?_134 9/PH_Y)=H'_ %[G_P!#:NRKC?A1_P DNT#_ *]S_P"AM794 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5YIXP_Y+)X%_W;G_ - KTNO-/&'_
M "63P+_NW/\ Z!0!Z71110 4444 %%%% !7F?Q1_Y&CP'_V%OZ"O3*\S^*/_
M "-'@/\ ["W]!0!Z91110 5YY\/O^1X\?_\ 81C_ /0#7H=>>?#[_D>/'_\
MV$8__0#0!Z'1110 4444 %%%% !1110 4444 %%%% !574_^05>?]<'_ /03
M5JJNI_\ (*O/^N#_ /H)H XWX-?\DLTK_KI<_P#I1)7>5P?P:_Y)9I7_ %TN
M?_2B2N\H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\9
M_P#(B^(/^P;<_P#HIJW*P_&?_(B^(/\ L&W/_HIJ ,GX4?\ )+M _P"O<_\
MH;5V5<;\*/\ DEV@?]>Y_P#0VKLJ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\T\8?\ )9/ O^[<_P#H%>EUYIXP_P"2R>!?]VY_] H ]+HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>:>,/\ DLG@7_=N?_0*]+KS3QA_
MR63P+_NW/_H% 'I=%%% !1110 4444 %>9_%'_D:/ ?_ &%OZ"O3*\S^*/\
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M:/A+X>-XUF/$^KFZ5=S0_P!H'>!ZXSFI(?@[HEQ'YD/B'6I$R1N2^8CCKWH
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M%+:5_P!!W7?_  -:C_A2VE?]!W7?_ UJ /2LCU%&1ZBO-?\ A2VE?]!W7?\
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M%&1ZBO-?^%+:5_T'==_\#6H_X4MI7_0=UW_P-:@#TK(]11D>HKS7_A2VE?\
M0=UW_P #6H_X4MI7_0=UW_P-:@#TK(]11D>HKS7_ (4MI7_0=UW_ ,#6H_X4
MMI7_ $'==_\  UJ /2LCU%5=2(.E7@'),#_^@FO/_P#A2VE?]!W7?_ UJ/\
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M_MW7<_\ 7ZU 'I>1ZBC(]17FG_"E])_Z#VN^G_'ZW^-+_P *6TK_ *#NN_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>redactedmod13-acam2000003.jpg
<TEXT>
begin 644 redactedmod13-acam2000003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(]ZKR>"IDCTE;:\BWVFK2:M</)&?WTK^9N  /RC]X<=<8'7K0!1T75X-#O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(%
M4,6"@,>IQR:6B@ HHHH **** #K2*JJ,* !Z 4M% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.1YE(8JJL58#E>&&#WYX%9NE>/=0D\-:)J-YI'G3ZO>-;0I;3+@',A4'<!C
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M#C)K:GXVNET'5YK"TMS?:=>0VDO^D;XOWACPR,%^; D'! P0?3D [>BN7?5
MGC)K0:5(=6&D&X#BY/ELHD \L#IG<?O%1^52:5XNCU;2]'OH;8*NH"1Y$:7F
MV5 =Y;C^$@*1V8@>] '245RVG>-(]1U+38$LG-KJ<;26]Q')YFP!=P$J@?N]
MR\CD^AP:@\=WM]!)X?M+:&.2"]U2."=7E*^8NQVV'@_*2HS],8(- '845PNC
M>($TS4=4T6ST.XCM=,N%:]FDO%,=NLB>867<<[!V4=!V'2M.'QDAGT9KFP>"
MSUH?Z#/Y@8EBN]4D7 V%ER1@D<8.* .GJ.>3R;>67&=B%L>N!7&P?$%YH-/N
MCH-RMI>W\FG*_GQEQ,K.H&W/()0\Y&,]^M:NGZ\=8MM;M9[-K.\TYS!/$9 X
M^:,.K!AU!5A]#F@#QS_AIB?_ *%6/_P./_QNC_AIB?\ Z%6/_P #C_\ &Z\$
MHH ][_X:8G_Z%6/_ ,#C_P#&Z/\ AIB?_H58_P#P./\ \;KP2B@#WO\ X:8G
M_P"A5C_\#C_\;H_X:8G_ .A5C_\  X__ !NO!** />_^&F)_^A5C_P# X_\
MQNC_ (:8G_Z%6/\ \#C_ /&Z\$HH ][_ .&F)_\ H58__ X__&Z]&^&/Q'?X
MB6VI3/I:V'V-XU 6?S-^X,?[HQTKX^KV;X0:U?>'_ 7BS4=/BCDG2XM$!D;
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MIU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYYSM![=:Z*B@#X3_ .$;UW_H"ZC_ . K_P"%'_"-Z[_T!=1_\!7_ ,*^[**
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M@+J/_@*_^%?=E% 'PG_PC>N_] 74?_ 5_P#"C_A&]=_Z NH_^ K_ .%?=E%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
ME:UHUOK,:)>W5S'9QJS/'!</!N/&&9T(; YXSCG)S@5JUA^)-.UG4HH(=,N[
M"&$,3<1WEN\HF'9<*Z_+ZCOT/&00"OX$%^/"EO\ ;[B:Y_>R_9YISF1[?S&\
MHN>Y*;3GKSSS725C6]OXA2TMQ<:AI[W/VH-<%+5EC,&.40;R0W0[B3WXK9H
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M#Q6["W&%92A4L6(96;)SGD8Z55OO!6J:E:^(EN=2M%DU6:VN(Q';MMBDA$>
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M1M1LY;Z*.YFU=M7M+B-"?(EWAU!4GY@",'D9![5-J_A"\UVWU>:[N;:._O\
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MLJ/&N=PW\ ..Z^AXS21>%M9O_#ESHFO:U#/ UHUI%):6YB=LC E<ECEA@<#
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MZ#K-]L36M5T\$F:^,<5P J.TLF1@-E@!@$C=CIT /14MK>.=YT@B6:08>14
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MY(\X/S\ ,IZK[@C- '7K8VHMEMS:P>4#GRQ& N?4"G2VEM- ();>*2$8Q&R
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M_EA@S,-L61AW 4DKD<$>M &^+"S4J1:0 H<KB,?*?;BGI;0)</.D$:S2 !Y
M@#,!ZGJ:JZOJBZ3H5YJI@DG2U@:<QQD!F51DXR0.@K C\;_Z+;2W>FBP>] :
MR^UW<:),FP.6+#)4#(&",Y(XZX -'6M FU?6M(O/M%NMO822.\$MN9/.WH4(
MSN & V>AYK6>RM)(TC>UA9(QA%,8(4>P[5RUGX_MM0BL5M[41WEW)/&L-S.(
MU+PE0RJ^"')W KCJ,G(Q5V'Q3+)JC:<^F/%<_P!EKJ0627& 3M,;<<,#GU%
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M$T/B"74(%A\N>QE6.0I()(I PRK1N,;AU[ @@@B@#:AABMXEBAC2.-1A410
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MK7^LIJ8?YB$ D1]F,<_ZL#/N>.*O6GAS7-,UR^:PU6U31]0N#=30R0,TT,C
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MD@4-(V?N\+C:,XW'D\5H:MK:Z3>Z7;O:RR#4+K[,LJ%=L;;&;YLG/1#T%:M
M&#X/T6[\/: FF7<L$QCEED62+(SYDC2$$'IC=CKSBLC5_!E_??\ "61V]_;K
M!K\2+MDB;=$PB$1.0>1A<XQU[UVM% '%ZEX+N-9U*>2]F@2TN-%;2I%B+%U)
M;=YBDC'!'3]>U:WA^Q\1VRA=>U2SO!$GEQ&UMVC,G3YY,L?FXZ# Y/7C%CQ#
MKJ>'K&&ZEMI9TEN8;;]V5&PR.$!.3TRPZ9J]?WUOIFG7-_=/LM[:)II6QG"J
M"2?R% '/ZAX?U>/Q8==T/4+6$W-LEM>6]W"TB,$)*2+M8'<-S#'0@]J</#VH
MZ?XCN=6TR\A?[=:Q07<=T#S)&"$E!7O@D%> >.16GI>J7.H22+-ILUK&(XY8
MI6=6217!. 1R&&.1CN,$UIT <;H_@J7P_JNDS6$T+VNG:4^GA)<AY&9U<N2!
M@?,G3_:-0Z?X+U.Q@\-D7]I]IT9[@,?*8I*DH.<#(*D9]Q7<44 <4GA#5E\*
MZ]I2:C!!<ZC?2WD4T8;">9+YAC8<$KU4D=0QX%5KKX?7M^-9:74K6VDOUM'@
M^R6Q M9K<Y0KEN5SVP,^U>*^)?C+XZT[Q3J]E;:PB6]O>S0Q+]DB.U5<@#)7
M)X%9G_"\?B#_ -!J/_P#A_\ B* /HW4_#FN:_P"%[ZPU74K-;R?RO+^S0L(8
MS&X?)!;)+$<\C QCN3OV\>JKJ :YN+1[/[. 4CB97\[<<D$L1MVX&.N>]?*?
M_"\?B#_T&H__  #A_P#B*/\ A>/Q!_Z#4?\ X!P__$4 ?4=_I4^HZW:2W*6D
MVF6\;GR)%+,93@!^1C@;AC_;)K(7PG>6/C*\UC2);.RM+RR6VFMU0@M(N2DH
MQP"-V,=Q7SG_ ,+Q^(/_ $&H_P#P#A_^(H_X7C\0?^@U'_X!P_\ Q% 'TGH7
MA9],\0W&L,MI;23VPAN(;(,L=Q)N!\YE. &X(&,\,<DU1\3^#-3UZ[UGR]1M
MEM=1T\6B">%G>V(W9\O!  ;(+=_E'MCYZ_X7C\0?^@U'_P" </\ \11_PO'X
M@_\ 0:C_ / .'_XB@#ZEU;3+K4?"EYI2S0_:;FT>V,I4A 67:6QDGOG&?QK&
MOO"VJOIWA^;3K^VM]9T:/RD>2-G@F0H$=6&00#M4\'((_&OG/_A>/Q!_Z#4?
M_@'#_P#$4?\ "\?B#_T&H_\ P#A_^(H ^DM3\.ZAJ^GQVVJ_V;J<<B2?:8)H
MFCCWG;L:(_,4V@-[G=G(JG!X.U2PO=.N+75HIWBTD:7<RW<;,[@'<)%P>N<\
M'/;K7SS_ ,+Q^(/_ $&H_P#P#A_^(H_X7C\0?^@U'_X!P_\ Q% 'T+I?@W4=
M.'@]6O+65=!@>*0A&4R[H]G'7&!S[^U;'A70KGP]8W-E+=13P-=33P[(RK*)
M)&D(8Y.3EL<8Z>]?,7_"\?B#_P!!J/\ \ X?_B*^E? ^NRZQX1T*XU&Y234K
MVS^T,-H4O@@,P X !9?SH I3>"[I8O$>G6UY$NEZ_(\LV]3YMN\BA9=G9MP&
M1G&T^O2KT'AVYM/&,.K0-;BRATU=.2$EMX4.&W9QCMC'ZUTM?.GBSXZ^*]#\
M7:OI5K;:4UO9W<D,9D@<L55B!DAQS0![=X@T*YU34=%O[.ZB@GTVY:4"6,NK
MJT;1D8!'.&R/I6'+X.U1](UFQ2YLP=1U9=15SN.P!XWV$8Y_U8&??IQSXI_P
MT5XR_P"?31O_  'D_P#CE'_#17C+_GTT;_P'D_\ CE 'NMKX;U[3=;OVT[5K
M6+2-1N#=3PR0,\T,C ;_ "GW 88C/S XST-1?%&98?!Z'SHHG.HV6QI3\N1<
M1G)Y&0,9/L*\/_X:*\9?\^FC?^ \G_QRD;]H?Q@_WK+13];>3_XY0![EK7A*
M]U^VUFXDGM(K[4;!=/B*;GCAARS$YP"S$MGH!P/<G2U?1+_4]1\/W@DMD;3+
MDW$JDL0Y,;1X4XX^^3D^E?/G_#17C(?\NFC?^ \G_P <H_X:*\9?\^FC?^ \
MG_QR@#WC0/#FMZ'/)8+JMM)H8N7N(4\DBX0,Y?RBV=NT,3SC)'''9/#7AO6_
M#^S3/[6MI="MW9K9?((N=I)(C9]VW:,]0,D#'%>$?\-%>,O^?31O_ >3_P".
M4?\ #17C+_GTT;_P'D_^.4 ?0OB/1;S5[W1)[:2!%TV^%XPESF3".FT8Z<.3
MGVZ52G\.Z[:>)[[4=$U6T@M-3*->0W5NTC1NJA/,B(8#)4*,-D<9YZ5X/_PT
M5XR_Y]-&_P# >3_XY1_PT5XR_P"?31O_  'D_P#CE 'M6I^"M59/$=IIFI6J
MV&O0MYR74;,\,QB\LLI!&0P"YST([]*ENO"&JF]DGM-0LQ]JT==,NO,A;JF_
M:Z8;C[Y!!SV//2O$/^&BO&7_ #Z:-_X#R?\ QRC_ (:*\9?\^FC?^ \G_P <
MH ]JL_!NMZ+<Z9>Z3JME]JATR+3;Q;FW8Q3+']R10&R&&3QG!![5K_\ "/7T
M/BJVUJ&_CD*Z?]BG6:,[I,/O# @X7))!X..U?/W_  T5XR_Y]-&_\!Y/_CE>
M]?#CQ'>^+? >G:WJ"0I=7/F[UA4J@VRLHP"2>BCO0!G:?X'U'3=-T(PWMM_:
M6C7$[QL5;RIXIF)=&[J>1@C."H..<5->^"KFXD^V1SVXO9]8@U2Y+;MN(@JK
M$OMA1\Q[DG'.!VM% '&3Z3X@TF7Q)JFES6+7>I3PS01R1O(%V(L90@8SN"]>
M ">>.:WO$>D-K_AC4M(\X0/>VKP>9MW!"RXSCC-:M% ',)H>KCQ5:ZY-/922
M0Z;)9LBAD#,SJ^X=< % ,>^?:L6P\#:WHVG:#)I>J6<>J:5!):,9HF>"YA=@
MQ# $,I!4$8/;WKT&B@"O8Q7$%G&EU<"XN.3)(%V@L3DX&3@#. ,G@#D]:XRQ
M\"7VG:?HHAU"W>]T.YE>S<Q,JR12;@Z2<GDANHZ%1P:[NB@#C=1\%3W]O?W
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MDGFE#Q @$22-)C!]"Y'X54N?#=[:>*[CQ%H=S DU["D-[:W*GRYMGW'#+RK
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M]=6FN7U'1O+FE +"UD,L<(/W$)?:#C/)').2.U=9110 4444 %%%% !1110
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MPN.I/.37I9L[5KM;LVT)N57:)B@W@>F[KB@V=L;L79MH3<A=@FV#>%]-W7%
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M:/\ A0_CW_H'VW_@6G^- 'FM%>E?\*'\>_\ 0/MO_ M/\:/^%#^/?^@?;?\
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MX>+/^@IHO_?V7_XW1_PSAXL_Z"FB_P#?V7_XW0!X[17L7_#.'BS_ *"FB_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7>NW!ST]<8S6;X;D1OB'XV0.I99+/(!Y'[@5G:#;2W?Q*\<^1J=Q:E9;+<L
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MZ_\ L%V5VRF6'*J6VEBN_.!U..<"LOPVAMOB5XV26\DN&6VL2TDVP-]R3KM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 22, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EMERGENT BIOSOLUTIONS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Professional Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,519,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 245.5<span></span>
</td>
<td class="nump">$ 99.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">149.5<span></span>
</td>
<td class="nump">154.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">356.3<span></span>
</td>
<td class="nump">311.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">786.9<span></span>
</td>
<td class="nump">598.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">209.8<span></span>
</td>
<td class="nump">270.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">452.7<span></span>
</td>
<td class="nump">501.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,461.0<span></span>
</td>
<td class="nump">1,389.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">36.6<span></span>
</td>
<td class="nump">56.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">136.5<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt</a></td>
<td class="nump">663.1<span></span>
</td>
<td class="nump">663.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">878.5<span></span>
</td>
<td class="nump">906.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 200.0 shares authorized, 60.6 and 59.9 shares issued; 52.7 and 54.3 shares outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 7.9 and 5.6 common shares, respectively</a></td>
<td class="num">(243.5)<span></span>
</td>
<td class="num">(227.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">938.6<span></span>
</td>
<td class="nump">928.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(105.2)<span></span>
</td>
<td class="num">(212.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">582.5<span></span>
</td>
<td class="nump">482.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,461.0<span></span>
</td>
<td class="nump">$ 1,389.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">60,600,000<span></span>
</td>
<td class="nump">59,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">52,700,000<span></span>
</td>
<td class="nump">54,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 231.1<span></span>
</td>
<td class="nump">$ 293.8<span></span>
</td>
<td class="nump">$ 594.2<span></span>
</td>
<td class="nump">$ 848.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product and services sales, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">85.9<span></span>
</td>
<td class="nump">122.6<span></span>
</td>
<td class="nump">241.3<span></span>
</td>
<td class="nump">563.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
<td class="nump">61.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38.9<span></span>
</td>
<td class="nump">76.6<span></span>
</td>
<td class="nump">135.0<span></span>
</td>
<td class="nump">247.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">154.6<span></span>
</td>
<td class="nump">229.3<span></span>
</td>
<td class="nump">466.2<span></span>
</td>
<td class="nump">948.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">64.5<span></span>
</td>
<td class="nump">128.0<span></span>
</td>
<td class="num">(99.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(56.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business and assets held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">62.3<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18.9)<span></span>
</td>
<td class="nump">77.9<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57.6<span></span>
</td>
<td class="nump">142.4<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
<td class="num">(115.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
<td class="nump">26.3<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="nump">$ 114.8<span></span>
</td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="num">$ (159.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings (loss) per common share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">53.9<span></span>
</td>
<td class="nump">52.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56.5<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">56.7<span></span>
</td>
<td class="nump">52.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ProductAndServiceMember', window );">Product and services sales, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 222.0<span></span>
</td>
<td class="nump">$ 283.8<span></span>
</td>
<td class="nump">$ 561.4<span></span>
</td>
<td class="nump">$ 824.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 24.6<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Exclusive of intangible asset amortization</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ProductAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ProductAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="nump">$ 114.8<span></span>
</td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="num">$ (159.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 51.8<span></span>
</td>
<td class="nump">$ 113.0<span></span>
</td>
<td class="nump">$ 104.9<span></span>
</td>
<td class="num">$ (160.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="nump">$ 68.0<span></span>
</td>
<td class="nump">$ 114.8<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="num">$ (159.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.3<span></span>
</td>
<td class="nump">82.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent obligations, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts', window );">Loss (gain) on sale of business and assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="num">(32.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.4)<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="num">(35.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">146.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.8)<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.0)<span></span>
</td>
<td class="nump">32.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual', window );">Long-term incentive plan accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income taxes receivable and payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="num">(18.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.9<span></span>
</td>
<td class="nump">138.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities', window );">Milestone payments from prior asset divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">110.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Purchase of convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
<td class="nump">96.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from the issuance of debt, net of lender fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">219.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds allocated to warrants issued in conjunction with debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt', window );">Proceeds allocated to common stock issued in conjunction with debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Principal payments on term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal payments on revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(284.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PaymentsForRepurchaseOfDebt', window );">Repurchase of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from share-based compensation activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid for share-based compensation activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.7)<span></span>
</td>
<td class="num">(190.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143.6<span></span>
</td>
<td class="nump">44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.7<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
<td class="nump">111.7<span></span>
</td>
<td class="nump">111.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">249.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249.2<span></span>
</td>
<td class="nump">156.4<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes, net of refunds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment unpaid at period end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock in conjunction with debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable', window );">Excise tax liability accrued for common stock repurchases</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">245.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245.5<span></span>
</td>
<td class="nump">149.9<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 249.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249.2<span></span>
</td>
<td class="nump">$ 156.4<span></span>
</td>
<td class="nump">$ 105.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Business, Including Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Long-Term Incentive Plan Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PaymentsForRepurchaseOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Repurchase Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PaymentsForRepurchaseOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Allocated To Common Stock Issued In Conjunction With Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excise tax payable on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramExciseTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 649.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">$ 904.4<span></span>
</td>
<td class="num">$ (5.7)<span></span>
</td>
<td class="num">$ (21.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">663.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">909.8<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(12.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">649.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">904.4<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(159.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">508.4<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">924.4<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(181.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">663.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">909.8<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(12.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(283.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(283.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">386.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">915.3<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(295.9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">114.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 508.4<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">924.4<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(181.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">59.9<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 482.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">928.0<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(212.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 68.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 552.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">930.8<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(144.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">59.9<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 482.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">928.0<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(212.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="nump">60.6<span></span>
</td>
<td class="nump">60.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">$ 582.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (243.5)<span></span>
</td>
<td class="nump">938.6<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(105.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">$ 552.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">930.8<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(144.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(12.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">536.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (234.6)<span></span>
</td>
<td class="nump">935.2<span></span>
</td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(156.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="nump">60.6<span></span>
</td>
<td class="nump">60.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">$ 582.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (243.5)<span></span>
</td>
<td class="nump">$ 938.6<span></span>
</td>
<td class="num">$ (7.5)<span></span>
</td>
<td class="num">$ (105.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the business and organization</a></td>
<td class="text">Nature of the business and organization<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (&#8220;PHTs&#8221;). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (&#8220;CDMO&#8221;) services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following four PHT categories: chemical, biological, radiological, nuclear and explosives (&#8220;CBRNE&#8221;); emerging infectious diseases (&#8220;EID&#8221;); emerging health crises; and acute, emergency and community care. As of September 30, 2025, the Company has a portfolio of 11 products consisting of vaccines, therapeutics, and drug-device combination products, including KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray for which the Company obtained certain exclusive commercial rights for product sales and marketing in the United States and Canada. The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (&#8220;MCM&#8221;) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (&#8220;Bioservices&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the business with a focus on three operating segments: (1) a Commercial Products segment consisting of NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray and </span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">KL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray, described below; (2) a MCM Products segment consisting of our Anthrax - MCM, Smallpox - MCM and Other Products, described below and (3) a Services segment consisting of our Bioservices offerings. Commercial Products and MCM Products are our two reportable segments (see Note 17, &#8220;Segment information&#8221; for more information on our reportable segments).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Products Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Naloxone Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray is an intranasal formulation of naloxone approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) (including in over-the-counter (&#8220;OTC&#8221;) form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(naloxone HCl) Nasal Spray. On January 14, 2025, the Company announced an agreement with Hikma Pharmaceuticals Inc. (&#8220;Hikma&#8221;) in which the Company obtained exclusive commercial rights for product sales and marketing in the United States and Canada to Hikma&#8217;s KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an 8 mg naloxone agent. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">MCM Products Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BioThrax</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is procured by certain authorized government buyers for their use; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BAT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics (&#8220;Ridgeback&#8221;), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trobigard Revocation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 2, 2024, the Belgium Federal Agency for Medicines and Health Products acknowledged and confirmed Emergent&#8217;s request to revoke the Market Authorization for the Trobigard Auto-Injector.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of RSDL</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2024, the Company entered into the Stock and Asset Purchase Agreement (the &#8220;RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Agreement&#8221;) with SERB Pharmaceuticals, through its wholly owned subsidiary BTG International Inc. (collectively, &#8220;SERB&#8221;), pursuant to which, among other things, the Company sold its worldwide rights to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB (the &#8220;RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction&#8221;). See Note 4, &#8220;Divestitures&#8221; for more information on the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment:</span></div>As of the first quarter of 2025, the Company&#8217;s Services operating segment no longer met the quantitative thresholds of a reportable segment and did not meet the aggregation criteria set forth in Accounting Standards Codification (&#8220;ASC&#8221;) 280, Segment Reporting, and as such is categorized within &#8220;All other revenues&#8221; along with &#8220;Contracts and Grants&#8221; within Note 17 &#8220;Segment information&#8221;. See Note 17, &#8220;Segment information&#8221; for more information about the Company&#8217;s reportable segments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC on March 3, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2025. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement&#8217;s specified effective date. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company does not expect a material impact from this new guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a public business entity to disclose additional information about specific expense categories in the notes to financial statements on an annual and interim basis. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. A public entity should apply the amendments either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and liabilities held for sale<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Assets and liabilities held for sale</a></td>
<td class="text">Assets and liabilities held for sale<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2025, the Company classified the assets and related liabilities associated with warehouse space in Maryland as held for sale. In the accompanying Condensed Consolidated Balance Sheet as of September 30, 2025, the assets and liabilities that are expected to be conveyed are classified as held for sale and are measured at the lower of (i) the carrying value of the disposal group and (ii) the fair value of the disposal group, less estimated costs to sell. An orderly liquidation value was applied to estimate the fair value of the assets held for sale, representing Level 3 non-recurring fair value measurement. Effective with the designation of the assets as held for sale on March 10, 2025, the Company suspended recording depreciation of property, plant and equipment and right-of-use assets while these assets are classified as held for sale. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. The Company recognized a loss on assets held for sale of $12.2&#160;million during the nine months ended September 30, 2025 in &#8220;Gain (loss) on sale of business and assets held for sale&#8221; within non-operating activities on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheet as of September 30, 2025 consist of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:76.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets held for sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities held for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Divestitures<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Travel Health Business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic (&#8220;Bavarian Nordic&#8221;), the Company completed the previously announced sale of the Company&#8217;s travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, Bavarian Nordic paid a cash purchase price of $270.2&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic was required to pay milestone payments totaling $80.0&#160;million, which the Company records within &#8220;Other, net&#8221; in the Condensed Consolidated Statement of Operations, upon satisfaction of the following milestones:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On July 18, 2024, Bavarian Nordic announced that the European Medicines Agency had validated the marketing authorization application for CHIKV VLP, which triggered a development milestone payment receivable in the amount of $10.0&#160;million. The Company received this milestone payment in the fourth quarter of 2024.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On August 13, 2024, Bavarian Nordic announced that the FDA has accepted and granted Priority Review for the Biologics License Application for CHIKV VLP, which triggered a milestone payment receivable in the amount of $20.0&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company received this milestone payment in the fourth quarter of 2024.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On February 14, 2025, Bavarian Nordic announced that the FDA approved CHIKV VLP under the Priority Review, which triggered a milestone payment in the amount of $30.0&#160;million which was recorded in &#8220;Other, net&#8221; during the nine months ended September 30, 2025. The Company received this milestone payment during the first quarter of 2025.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On February 28, 2025, Bavarian Nordic announced that the European Commission approved CHIKV VLP, which triggered a milestone payment receivable in the amount of $20.0&#160;million which was recorded in &#8220;Other, net&#8221; during the nine months ended September 30, 2025. The Company received this milestone payment in the second quarter of 2025. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase and Sale Agreement, the Company may receive up to $30.0&#160;million of earn-out payments from Bavarian Nordic based on aggregate net sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in calendar year 2026.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of RSDL</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2024, the Company, through its wholly owned subsidiary Emergent BioSolutions Canada Inc., entered into the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Agreement with SERB pursuant to which, among other things, the Company sold its worldwide rights to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB. The RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction also included the sale to SERB of all the outstanding capital stock of Emergent Protective Products USA Inc. (&#8220;EPPU&#8221;), a wholly owned subsidiary of the Company, which leases a manufacturing facility in Hattiesburg, Mississippi, as well as certain assets related to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including intellectual property rights, contract rights, inventory and marketing authorizations. In addition, the employees of EPPU joined SERB in connection with the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, SERB paid a cash purchase price of $75.0&#160;million, exclusive of customary closing adjustments related to inventory. In addition, SERB will owe the Company a $5.0&#160;million payment upon achievement of a milestone relating to sourcing of a certain component of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decontamination lotion. In connection with the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transaction, the Company recognized a pre-tax gain of $60.8&#160;million, net of transaction costs of $4.1&#160;million, recorded within &#8220;Gain (loss) on sale of business&#8221; on the Consolidated Statements of Operations during the year ended December 31, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and SERB entered into a transition services agreement (the &#8220;SERB TSA&#8221;) to ensure the orderly transition of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decontamination lotion and the related assets to SERB, and a supply agreement (the &#8220;SERB Supply Agreement&#8221;) pursuant to which SERB has a suite reservation at the Company&#8217;s Winnipeg facility where the Company will perform Bioservices activities to manufacture and supply bulk lotion to SERB. The Company and SERB also entered into a reverse supply agreement (together with the SERB TSA and the SERB Supply Agreement, the &#8220;SERB Agreements&#8221;) pursuant to which SERB supplies to the Company finished RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the purposes of the Company&#8217;s performance of certain transitional distribution services under customer contracts that have not yet transferred to SERB. Under the SERB Agreements, the Company will retain a portion of net sales received upon delivery of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the delayed transfer customers. Income from performing services under the SERB TSA is recorded within &#8220;Product and services sales, net&#8221; on the Condensed Consolidated Statements of Operations and was $0.1&#160;million and $1.7&#160;million for the three and nine months ended September 30, 2025, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Baltimore-Camden Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2024, pursuant to the Asset Purchase Agreement, the Company completed the sale of its Drug Product facility in Baltimore-Camden to an affiliate of Bora. The Baltimore-Camden facility, which was part of the Company&#8217;s Services operating segment, had clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. At closing, Bora paid a cash purchase price of approximately $35.0&#160;million, which included customary closing adjustments to date for working capital and transaction expenses of the business at closing. As a result of the divestiture, the Company recognized a pre-tax loss of $36.5&#160;million, net of transaction costs of $3.8&#160;million, during the year ended December 31, 2024 recorded within &#8220;Gain (loss) on sale of business and assets held for sale&#8221; on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture, the Company entered into a Transition Services Agreement (the &#8220;Bora TSA&#8221;) with Bora to help support its ongoing operations. Under the Bora TSA, the Company is providing certain transition services to Bora, including information technology, finance and enterprise resource planning, human resources, employee benefits and other limited services. Income from performing services under the Bora TSA is recorded within &#8220;Other, net&#8221; on the Condensed Consolidated Statements of Operations and was zero and $0.4&#160;million for the three and nine months ended September 30, 2025, respectively.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Baltimore-Bayview Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2025, the Company completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International (&#8220;Syngene&#8221;). At closing, Syngene paid a cash purchase price of $36.5&#160;million. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the divestiture, the Company recognized a pre-tax gain of $7.9&#160;million, net of transaction costs of $1.2&#160;million, during the nine months ended September 30, 2025 recorded within &#8220;Other, net&#8221; on the Condensed Consolidated Statements of Operations. The Company determined that the disposal of the Baltimore-Bayview facility does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on the Company&#8217;s operations and financial results.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text">Assets and liabilities held for sale<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2025, the Company classified the assets and related liabilities associated with warehouse space in Maryland as held for sale. In the accompanying Condensed Consolidated Balance Sheet as of September 30, 2025, the assets and liabilities that are expected to be conveyed are classified as held for sale and are measured at the lower of (i) the carrying value of the disposal group and (ii) the fair value of the disposal group, less estimated costs to sell. An orderly liquidation value was applied to estimate the fair value of the assets held for sale, representing Level 3 non-recurring fair value measurement. Effective with the designation of the assets as held for sale on March 10, 2025, the Company suspended recording depreciation of property, plant and equipment and right-of-use assets while these assets are classified as held for sale. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. The Company recognized a loss on assets held for sale of $12.2&#160;million during the nine months ended September 30, 2025 in &#8220;Gain (loss) on sale of business and assets held for sale&#8221; within non-operating activities on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheet as of September 30, 2025 consist of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:76.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets held for sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities held for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Divestitures<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Travel Health Business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, pursuant to the Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic (&#8220;Bavarian Nordic&#8221;), the Company completed the previously announced sale of the Company&#8217;s travel health business, including rights to Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed typhoid vaccine; Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#8217;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, Bavarian Nordic paid a cash purchase price of $270.2&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic was required to pay milestone payments totaling $80.0&#160;million, which the Company records within &#8220;Other, net&#8221; in the Condensed Consolidated Statement of Operations, upon satisfaction of the following milestones:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On July 18, 2024, Bavarian Nordic announced that the European Medicines Agency had validated the marketing authorization application for CHIKV VLP, which triggered a development milestone payment receivable in the amount of $10.0&#160;million. The Company received this milestone payment in the fourth quarter of 2024.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On August 13, 2024, Bavarian Nordic announced that the FDA has accepted and granted Priority Review for the Biologics License Application for CHIKV VLP, which triggered a milestone payment receivable in the amount of $20.0&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company received this milestone payment in the fourth quarter of 2024.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On February 14, 2025, Bavarian Nordic announced that the FDA approved CHIKV VLP under the Priority Review, which triggered a milestone payment in the amount of $30.0&#160;million which was recorded in &#8220;Other, net&#8221; during the nine months ended September 30, 2025. The Company received this milestone payment during the first quarter of 2025.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">On February 28, 2025, Bavarian Nordic announced that the European Commission approved CHIKV VLP, which triggered a milestone payment receivable in the amount of $20.0&#160;million which was recorded in &#8220;Other, net&#8221; during the nine months ended September 30, 2025. The Company received this milestone payment in the second quarter of 2025. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase and Sale Agreement, the Company may receive up to $30.0&#160;million of earn-out payments from Bavarian Nordic based on aggregate net sales of Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Vivotif</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in calendar year 2026.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of RSDL</span><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2024, the Company, through its wholly owned subsidiary Emergent BioSolutions Canada Inc., entered into the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Agreement with SERB pursuant to which, among other things, the Company sold its worldwide rights to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to SERB. The RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Transaction also included the sale to SERB of all the outstanding capital stock of Emergent Protective Products USA Inc. (&#8220;EPPU&#8221;), a wholly owned subsidiary of the Company, which leases a manufacturing facility in Hattiesburg, Mississippi, as well as certain assets related to RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including intellectual property rights, contract rights, inventory and marketing authorizations. In addition, the employees of EPPU joined SERB in connection with the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, SERB paid a cash purchase price of $75.0&#160;million, exclusive of customary closing adjustments related to inventory. In addition, SERB will owe the Company a $5.0&#160;million payment upon achievement of a milestone relating to sourcing of a certain component of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decontamination lotion. In connection with the RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Transaction, the Company recognized a pre-tax gain of $60.8&#160;million, net of transaction costs of $4.1&#160;million, recorded within &#8220;Gain (loss) on sale of business&#8221; on the Consolidated Statements of Operations during the year ended December 31, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company and SERB entered into a transition services agreement (the &#8220;SERB TSA&#8221;) to ensure the orderly transition of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> decontamination lotion and the related assets to SERB, and a supply agreement (the &#8220;SERB Supply Agreement&#8221;) pursuant to which SERB has a suite reservation at the Company&#8217;s Winnipeg facility where the Company will perform Bioservices activities to manufacture and supply bulk lotion to SERB. The Company and SERB also entered into a reverse supply agreement (together with the SERB TSA and the SERB Supply Agreement, the &#8220;SERB Agreements&#8221;) pursuant to which SERB supplies to the Company finished RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the purposes of the Company&#8217;s performance of certain transitional distribution services under customer contracts that have not yet transferred to SERB. Under the SERB Agreements, the Company will retain a portion of net sales received upon delivery of RSDL</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to the delayed transfer customers. Income from performing services under the SERB TSA is recorded within &#8220;Product and services sales, net&#8221; on the Condensed Consolidated Statements of Operations and was $0.1&#160;million and $1.7&#160;million for the three and nine months ended September 30, 2025, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Baltimore-Camden Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2024, pursuant to the Asset Purchase Agreement, the Company completed the sale of its Drug Product facility in Baltimore-Camden to an affiliate of Bora. The Baltimore-Camden facility, which was part of the Company&#8217;s Services operating segment, had clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. At closing, Bora paid a cash purchase price of approximately $35.0&#160;million, which included customary closing adjustments to date for working capital and transaction expenses of the business at closing. As a result of the divestiture, the Company recognized a pre-tax loss of $36.5&#160;million, net of transaction costs of $3.8&#160;million, during the year ended December 31, 2024 recorded within &#8220;Gain (loss) on sale of business and assets held for sale&#8221; on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture, the Company entered into a Transition Services Agreement (the &#8220;Bora TSA&#8221;) with Bora to help support its ongoing operations. Under the Bora TSA, the Company is providing certain transition services to Bora, including information technology, finance and enterprise resource planning, human resources, employee benefits and other limited services. Income from performing services under the Bora TSA is recorded within &#8220;Other, net&#8221; on the Condensed Consolidated Statements of Operations and was zero and $0.4&#160;million for the three and nine months ended September 30, 2025, respectively.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sale of Baltimore-Bayview Facility</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2025, the Company completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International (&#8220;Syngene&#8221;). At closing, Syngene paid a cash purchase price of $36.5&#160;million. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the divestiture, the Company recognized a pre-tax gain of $7.9&#160;million, net of transaction costs of $1.2&#160;million, during the nine months ended September 30, 2025 recorded within &#8220;Other, net&#8221; on the Condensed Consolidated Statements of Operations. The Company determined that the disposal of the Baltimore-Bayview facility does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on the Company&#8217;s operations and financial results.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment and restructuring charges<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Impairment and restructuring charges</a></td>
<td class="text">Impairment and restructuring charges<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. There were no impairment charges recorded on long-lived assets during the three and nine months ended September 30, 2025.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Impairment of long-lived assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the preparation of the Company&#8217;s financial statements for the three months ended June&#160;30, 2024, due to the decision to close the Company&#8217;s Baltimore-Bayview Drug Substance manufacturing facility and the Rockville, Maryland Drug Product facility, the Company determined there were sufficient indicators of impairment for the Bayview and Rockville asset groups within the Bioservices reporting unit. As a result, the Company performed recoverability tests on those asset groups and concluded that the Bayview and Rockville asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values. The Company allocated and recognized a non-cash impairment charge of $27.2 million during the second quarter of 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the total impairment charge by asset class for the nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.428%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total impairment of long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Charges</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">January 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;January 2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees. The charges related to the January 2023 Plan consisted primarily of charges related to employee transition, severance payments and employee benefits. The cumulative amount of restructuring charge related to the January 2023 Plan since inception was $9.3&#160;million. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#8217;s classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees. The charges related to the August 2023 Plan consisted primarily of employee transition, severance payment and employee benefit charges. The cumulative amount of restructuring charge related to the August 2023 Plan since inception is $19.4&#160;million. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#8217;s classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">May 2024 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company initiated the May 2024 Plan. These strategic actions led to a reduction of the Company&#8217;s workforce by approximately 300 employees across all areas of the Company and the elimination of approximately 85 positions that were vacant, as well as the closure of the Company&#8217;s Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. Decisions regarding the elimination of positions and the closure of manufacturing facilities were subject to local law and consultation requirements in certain countries, as well as the Company&#8217;s business needs. The cumulative amount of restructuring charge related to the May 2024 Plan since inception is $18.5&#160;million. All activities related to the May 2024 Plan were substantially completed during the third quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2024 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company initiated the August 2024 Plan at the Company&#8217;s Lansing facility, which reduced the Company&#8217;s workforce by approximately 70 employees, as well as eliminated several open positions. The Company also implemented non-labor optimization efforts, such as reducing the Company&#8217;s external and vendor spend. The cumulative amount of restructuring charges related to the August 2024 Plan since inception is $2.5&#160;million. All activities related to the August 2024 Plan were substantially completed during the fourth quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#8217;s classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by reportable segment as well as amounts included within non-reportable segments, unallocated corporate selling, general and administrative (&#8220;SG&amp;A&#8221;) expense and research and development (&#8220;R&amp;D&#8221;) expense:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment restructuring costs:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other segments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs included in Cost of product and services sales, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate restructuring costs: </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by function:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"> Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee transition</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Severance payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All financial impacts of the January 2023 Plan were reflected in the Company&#8217;s consolidated financial statements by the second quarter of 2024. As a result, there was no activity related to the January 2023 Plan for the three and nine months ended September 30, 2025. The following table provides the components of and changes in the Company&#8217;s restructuring accrual for the January 2023 Plan during the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All financial impacts of the August 2023 Plan were reflected in the Company&#8217;s consolidated financial statements by the fourth quarter of 2024. As a result, there was no activity related to the August 2023 Plan for three and nine months ended September 30, 2025. The following table provides the components of and changes in the Company&#8217;s restructuring accrual for the August 2023 Plan during the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the components of and changes in the Company&#8217;s restructuring accrual for the May 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the components of and changes in the Company&#8217;s restructuring accrual for the August 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text">Inventories, net <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">356.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">311.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is stated at the lower of cost or net realizable value</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text">Property, plant and equipment, net<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024 </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">159.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">196.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">252.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">368.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500.5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">667.7&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(290.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(397.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209.8&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">270.6&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> During 2024, the Company recorded non-cash impairment charges of $27.2 million related to certain Bioservices long-lived assets. See Note 5, &#8220;Impairment and restructuring charges&#8221; for more details regarding the impairment charge.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December&#160;31, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">construction-in-progress primarily included costs incurred to advance the Company&#8217;s MCM Products capabilities. Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets</a></td>
<td class="text">Intangible assets<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s finite-lived intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company&#8217;s finite-lived intangible assets:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.601%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">402.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">452.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">353.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">501.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">402.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">452.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">353.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">501.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company&#8217;s finite-lived intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Warrant liability</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s Credit Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto (the &#8220;Term Loan Agreement&#8221;), the Company issued to the lenders warrants to purchase 1.0&#160;million shares of the Company&#8217;s common stock at an exercise price of $9.8802 per share (the &#8220;Series I Warrants&#8221;) and warrants to purchase 1.5&#160;million shares at an exercise price of $15.7185 per share (the &#8220;Series II Warrants&#8221; and, together with the Series I Warrants, the &#8220;Warrants&#8221;). The Warrants are currently exercisable and will expire on August 30, 2029. Because the Warrants could be cash settled based on events that are outside the control of the Company, it precludes the Warrants from applying the equity contract scope exception, and so are classified as a liability. As a result, the fair value of the Warrants will be remeasured each period with the gain or loss on the warrant liability included in &#8220;Other, net&#8221; on the Condensed Consolidated Statement of Operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December&#160;31, 2024, t</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the warrant liability was $14.4 million and $16.2&#160;million, respectively, and was included within &#8220;Other Liabilities&#8221; on the Condensed Consolidated Balance Sheets, as determined using the Black-Scholes method. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to calculate the fair value of the Warrants at each reporting period. Assumptions used in the Black-Scholes option pricing model take into account the agreement terms as well as the quoted price of the Company&#8217;s common stock in an active market. The volatility is based on the average historical volatility of the common stock. The expected life is based on the remaining contractual term of the Warrants, and the risk free interest rate is based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the Warrants&#8217; expected life. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company&#8217;s Level 3 warrant liability: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurement for the Company's warrant liability used the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrant Liability</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Range</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024 Warrants</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes Method</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.7%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103%</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2024, t</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company&#8217;s 3.875% Senior Unsecured Notes due 2028 (the &#8220;Senior Unsecured Notes&#8221;) was $368.6&#160;million and $369.1&#160;million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, &#8220;Debt&#8221;, for more information regarding the Company&#8217;s repurchase of a portion of the Senior Unsecured Notes during the third quarter of 2025).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the components of the Company&#8217;s debt:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2029</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">443.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">693.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">700.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were $35.0&#160;million of unamortized debt issuance costs recorded in connection with the execution of the Term Loan Agreement within a contra account to directly offset the Term Loan balance.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs associated with the Company&#8217;s Revolving Loans, as described in further detail below, were recorded as an asset within &#8220;Other long-term assets&#8221; on the Company&#8217;s Condensed Consolidated Balance Sheets. As of September 30, 2025, the Company has $3.0&#160;million in debt issuance costs associated with the Revolving Loans. If the Company draws on the capacity available under the Revolving Loans, the debt issuance costs would be reclassified to a contra account to directly offset the Revolving Loans balance.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">3.875% Senior Unsecured Notes due 2028</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company issued $450.0&#160;million aggregate principal amount of its Senior Unsecured Notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Interest on the Senior Unsecured Notes is payable on February 15 and August 15 of each year until maturity, beginning on February 15, 2021. The Senior Unsecured Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of August 15, 2023, the Company may redeem all or a portion of the Senior Unsecured Notes at a redemption price equal to 100% of the principal amount of the Senior Unsecured Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest as set forth in the related indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the Senior Unsecured Notes at a purchase price of 101% of the principal amount of such notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the indenture governing the Senior Unsecured Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">restricted payments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;7, 2025, the Board of Directors authorized the Company to repurchase up to $30.0 million in aggregate principal amount of the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior Unsecured Notes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The Company may seek to opportunistically use this authority to repurchase its Senior Unsecured Notes in open market purchases, privately negotiated transactions or otherwise. Any such repurchases will depend upon prevailing market conditions, our liquidity requirements, contractual restrictions, applicable securities law and other factors. During the three and nine months ended September 30, 2025, the Company repurchased $6.9 million principal amount of its outstanding Senior Unsecured Notes. The Company paid $5.8&#160;million in cash, including fees and accrued interest, in connection with the repurchases and recognized a gain on extinguishment of approximately $1.1&#160;million, which was included in &#8220;Other, net&#8221; on the Consolidated Statement of Operations. As of September 30, 2025, the Company had $23.1&#160;million available to repurchase additional Senior Unsecured Notes. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Term Loan Agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2024, the Company entered into the Term Loan Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto. The Term Loan Agreement provides for a term loan (the &#8220;Term Loan&#8221;) of $250.0&#160;million, which was drawn in full on the date of entry into the Term Loan Agreement (the &#8220;Closing Date&#8221;). The Term Loan was issued with an original issue discount of 3.00%.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan will accrue interest at the Company&#8217;s option at (i) the Base Rate (as defined in the Term Loan Agreement) (subject to a floor of 1.00%) plus 7.25% per annum, referred to as &#8220;Term Base Rate Loans&#8221; or (ii) Adjusted Term SOFR (as defined in the Term Loan Agreement) (subject to a floor of 2.00% until the second anniversary of the Closing Date, and thereafter, 3.00%) plus 8.25% per annum, referred to as &#8220;Term SOFR Loans&#8221;). A default interest rate of an additional 2.00% per annum would apply on all outstanding obligations that are not paid when due. If any defaulted obligations are Term SOFR Loans, then such loans would, at the end of the applicable interest period, automatically be converted to Term Base Rate Loans that would continue to be subject to the default interest rate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan will mature on the first to occur (such date, the &#8220;Term Loan Maturity Date&#8221;) of (i) August 30, 2029, (ii) the date of acceleration of the Term Loan upon the occurrence and during the continuance of an event of default and (iii) solely to the extent the aggregate principal amount of Senior Unsecured Notes outstanding exceeds $25.0 million, May 15, 2028, which is three months prior to the August 15, 2028 maturity date of the Senior Unsecured Notes. The Term Loan Agreement contains certain customary default and cross-default provisions, representations and warranties and affirmative and negative covenants, including (a) restrictions on prepayments and repurchases of indebtedness, including the Senior Unsecured Notes, subject to further customary permitted debt payments, (b) a minimum liquidity requirement of $75.0&#160;million commencing on September 30, 2024 and tested every two weeks, and (c) a consolidated gross leverage ratio tested every fiscal quarter commencing with the fiscal quarter ending December 31, 2025, initially at 5.10:1.00 with step-downs as set forth in the Term Loan Agreement. As of September 30, 2025, the Company was in compliance with all covenants under the Term Loan Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All indebtedness outstanding under the Term Loan Agreement is guaranteed by certain of the Company&#8217;s direct and indirect subsidiaries, other than certain subsidiaries that are not material, are excluded pursuant to the terms of the Term Loan Agreement, or will become guarantors on a post-closing basis (the Company and the guarantors, collectively, the &#8220;Credit Parties&#8221;). The indebtedness under the Term Loan Agreement is secured by a first-priority security interest in and lien on substantially all assets of the Company and the other Credit Parties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay the Term Loan, in whole or in part, subject to (i) through and including the first anniversary of the Closing Date, a make-whole premium plus 4.00% of the aggregate principal amount of the Term Loan subject to prepayment and (ii) after the first anniversary of the Closing Date, a 4.00% prepayment premium, which percentage shall be reduced by 0.25% as set forth on a schedule attached to the Term Loan Agreement. The Term Loan Agreement requires mandatory prepayments of the Term Loan in an amount equal to (a) 100% of the aggregate net cash proceeds from the incurrence of certain indebtedness by the Term Loan Credit Parties and (b) (subject to certain reinvestment rights) 100% of the aggregate net cash proceeds from (1) subject to certain specified exceptions, dispositions of property by the Credit Parties (provided that with respect to any dispositions occurring on or after the Closing Date, prepayment will not be required unless the net cash proceeds exceed $10.0 million in the aggregate per fiscal year or $5.0 million on a per-transaction basis) and (2) insurance proceeds received by any Credit Party or their subsidiaries resulting from theft, loss, physical destruction or damage of property.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, the Company used a portion of the proceeds of the Term Loan to repay all amounts outstanding and terminate commitments under the senior term loan facility under its Amended and Restated Credit Agreement, dated October 15, 2028, by and among the Company, the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the Administrative Agent (the &#8220;Prior Credit Agreement&#8221;), plus accrued interest and fees. The Company previously repaid all amounts outstanding under the revolving credit facility under the Prior Credit Agreement.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revolving Loan Agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2024, the Company entered into a credit agreement for asset-based revolving loans (the &#8220;Revolving Credit Agreement&#8221;) with certain subsidiary borrowers (together with the Company, the &#8220;Borrowers&#8221;), the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as agent (the &#8220;Agent&#8221;). The Credit Agreement provides for commitments with respect to the revolving loans (the &#8220;Revolving Loans&#8221;) of up to the lesser of (x) $100.0 million, which may be increased (but not above $125.0 million, or the &#8220;Maximum Revolver Amount&#8221;) or decreased (but not below $50.0 million) by the Borrowers in accordance with the terms of the Revolving Credit Agreement and (y) the Borrowing Base (as defined in the Revolving Credit Agreement). Once reduced, the facility may not be increased. Up to $5.0 million of capacity under the Revolving Loans may be used for swing loans and up to $10.0 million may be used for the issuance of letters of credit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Loans accrue interest at the Base Rate (as defined in the Revolving Credit Agreement) plus a margin of 1.25% (such loans, &#8220;Revolving Base Rate Loans&#8221;) or, at the Company&#8217;s election, at a rate equal to Adjusted Term SOFR (as defined in the Revolving Credit Agreement and subject to a floor of 0.00%) plus a margin of 2.25% (such loans, &#8220;Revolving SOFR Loans&#8221;), in each case until September 30, 2025. After September 30, 2025, the applicable margin may be reduced to 0.75% in the case of Revolving Base Rate Loans, or 1.75% in the case of Revolving SOFR Loans, provided the Borrowers&#8217; total leverage ratio is less than 4.00 to 1.00 for the most recently completed fiscal quarter and an event of default is not continuing. A default interest rate of an additional 2.00% per annum would apply on all outstanding obligations that are not paid when due.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Loans will mature on the first to occur of (i) September 30, 2029; (ii) to the extent there remain outstanding any portion of the term loans extended under the Term Loan Agreement, the date that is 90 days prior to the maturity date under the Term Loan Agreement; and (iii) to the extent any of the Senior Unsecured Notes remain outstanding, May 17, 2028, which is 90 days prior to the August 15, 2028 maturity date of the Senior Unsecured Notes. The Revolving Credit Agreement contains certain customary default and cross-default provisions (including with respect to defaults under the Term Loan Agreement), representations and warranties and affirmative and negative covenants, including (a) restrictions on prepayments and repurchases of indebtedness, including the Senior Unsecured Notes, (b) restrictions on dispositions of material intellectual property, (c) a minimum liquidity </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">requirement of $50.0&#160;million through the day prior to the first date following September 30, 2025 on which the Company&#8217;s total leverage ratio measured as of the preceding 12-month period is less than 5.25 to 1.00 (the &#8220;Covenant Conversion Date&#8221;) and (d) from the Covenant Conversion Date, a fixed charge coverage ratio requirement of at least 1.00 to 1.00. As of September 30, 2025, the Company was in compliance with all covenants under the Revolving Credit Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All indebtedness outstanding under the Revolving Credit Agreement is guaranteed by certain of the Borrowers&#8217; material direct and indirect subsidiaries, subject to customary exclusions. The indebtedness under the Credit Agreement is secured by a first-priority security interest in and lien on the ABL Priority Collateral and a second-priority security interest and lien on the Term Loan Priority Collateral (in each case as defined in the Revolving Credit Agreement).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Borrowers may elect to prepay any Revolving Loans, in whole or in part, without premium or penalty. If at any time outstanding Revolving Loans and letters of credit exceed the lesser of (i) the Borrowing Base, as adjusted for reserves established by the Agent, and (ii) the Maximum Revolver Amount, the Borrowers will be required to prepay outstanding obligations in the amount of such excess. The Agent may establish, increase or decrease reserves at its discretion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share-based compensation and stockholders' equity</a></td>
<td class="text">Share-based compensation and stockholders' equity<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share-based compensation expense relates to stock options, performance stock options, restricted stock units, performance stock units and liability classified long-term incentive awards. During the nine months ended September 30, 2025, the Company granted stock options to purchase 1.6&#160;million shares of common stock, 2.7&#160;million restricted stock units and 0.3&#160;million performance stock units. The grants were made under the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan and the Emergent BioSolutions Inc. Inducement Plan. The performance stock units settle in stock at the end of a one-year performance period based on the Company's results compared to the performance criteria. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, the Company granted an $8.0&#160;million long-term incentive award, subject to market conditions, with the option to settle in any combination of cash or shares, which is accounted for as a liability classified award. The Company&#8217;s performance stock options and the long-term incentive award are valued using Monte Carlo valuation models, and each have a performance period of five years to vest based on the Company&#8217;s stock price performance. The long-term incentive award is revalued at each reporting period until the award is earned or expires. The Company&#8217;s other equity awards typically vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the nine months ended September 30, 2025, 0.4&#160;million stock options, 0.3&#160;million of restricted stock units and an immaterial number of performance stock units were forfeited prior to the completion of the applicable vesting requirements or expiration. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products and services sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research &amp; development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2025 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31, 2025, the Company announced that its Board of Directors had authorized the repurchase of up to $50.0&#160;million of the Company&#8217;s common stock (the &#8220;2025 Share Repurchase Program&#8221;) on or before March 27, 2026. Repurchases under the 2025 Share Repurchase Program may be made from time to time on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the Company&#8217;s management based on its evaluation of market conditions and other factors, including the market price of the Company&#8217;s common shares, macroeconomic environment and other investment opportunities, consistent with the Company&#8217;s insider trading policy. The 2025 Share Repurchase Program may be suspended or discontinued at any time. The Inflation Reduction Act of 2022, which was enacted on August 16, 2022, imposed a nondeductible 1% </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">excise tax on the net value of certain stock repurchases made after December 31, 2022. Excise tax accrued during the three and nine months ended September 30, 2025 was $0.2 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2025, the Company utilized $8.9&#160;million and $15.8&#160;million to repurchase 1.1&#160;million and 2.3&#160;million shares, respectively, at an average price of $7.87 and $7.00 per share, excluding commissions and excise taxes, respectively. As of September 30, 2025, the Company had $34.2&#160;million available to repurchase shares under the 2025 Share Repurchase Program.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Issuance of Common Stock</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Term Loan Agreement, the Company entered into a Subscription Agreement, dated as of August 30, 2024 (the &#8220;Subscription Agreement&#8221;) with the lenders under the Term Loan Agreement, under which on September 17, 2024, the Company issued to the lenders 1.1&#160;million shares of common stock with an aggregate value of $10.0&#160;million, at a price per share of $8.98, which was based on the volume weighted average price per share of common stock for the 30 consecutive trading days ending on, but excluding, the tenth business day of the Term Loan Agreement. At inception, the Subscription Agreement represented a forward sale of the Company&#8217;s common stock (the &#8220;Forward&#8221;). The Forward was initially classified and recorded as a liability and was remeasured to its fair value, resulting in a $1.6&#160;million gain on settlement on September&#160;17, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2024 Warrant Issuance</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Term Loan Agreement, the Company issued to the lenders Series I Warrants to purchase 1.0&#160;million shares of common stock and Series II Warrants to purchase 1.5&#160;million shares of common stock. The Warrants are currently exercisable and will expire on August 30, 2029. Because the Warrants could be cash settled based on events that are outside the control of the Company, it precludes the Warrants from applying the equity contract scope exception, and so are classified as a liability. As of September 30, 2025, the fair value of the Warrants was $14.4 million. See Note 9, &#8220;Fair value measurements,&#8221; for more information on the accounting treatment and valuation of the Warrants. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, the Company had the following Warrants outstanding to acquire shares of its common stock:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrants Outstanding</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Range of Exercise<br/>&#160;Price per Share</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued related to the Term Loan Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$9.88 - $15.72</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">August 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2025, no Warrants expired or were exercised.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per common share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (loss) per common share</a></td>
<td class="text">Earnings (loss) per common share<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per common share is calculated using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per common share adjusts basic earnings (loss) per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units and performance stock units, as well as shares issuable upon exercises of the Warrants. Diluted earnings (loss) per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plans and pursuant to exercises of the Warrants that were excluded from diluted earnings (loss) per common share because their effect would have been antidilutive.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings (loss) per common share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(159.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities - equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (loss) per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.16&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.99&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.03)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (loss) per common share - diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.91&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.06&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.89&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.03)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates the majority of its revenues through product sales to customers. The Company also generates revenues through its Bioservices offerings and suite reservations for and to third parties and Contracts and grants revenue. The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with (a) customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Nasal Naloxone Products are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration include allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> may also be sold on consignment through third-party online retailers where revenues are recognized at the point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as SG&amp;A expenses and Cost of Commercial Product sales, respectively, in the Condensed Consolidated Statement of Operations. Revenues from OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including inventory levels within the distribution channel, product shelf life and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's revenues disaggregated by major sources for the three and nine months ended September 30, 2025 and 2024 were as follows: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">161.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">98.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">231.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">293.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; includes Services and Contracts and grants revenue.</span></div></td></tr><tr style="height:5pt"><td colspan="36" style="padding:0 1pt"><div style="margin-bottom:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">187.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">235.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">121.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">357.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">319.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">393.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">98.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">324.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">594.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">343.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">505.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; includes Services and Contracts and grants revenue.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; for the nine months ended September 30, 2024 includes $50.0 million attributable to the confidential arbitration settlement (the &#8220;Settlement Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) related to the 2022 termination of the manufacturing services agreement with Janssen (the &#8220;Janssen Agreement&#8221;).  The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, &#8220;Litigation&#8221; for additional information related to the accounting treatment and settlement of the arbitration with Janssen.</span></div></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, the Company has future contract value on unsatisfied performance obligations of approximately $322.5&#160;million associated with all arrangements entered into by the Company. The Company expects to recognize $259.2&#160;million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associated with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and that the Company does not currently have a contractual right to bill, to be contract assets. As of September 30, 2025 and December&#160;31, 2024, the</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Company had $2.3 million an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$9.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of contract assets</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within &#8220;Accounts receivable, net&#8221; on the Condensed Consolidated Balance Sheets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Condensed Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.6pt;font-weight:400;line-height:120%">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December&#160;31, 2024, the current portion of contract liabilities was $6.1&#160;million and $4.8&#160;million, respectively, and was included in &#8220;Other current liabilities&#8221; on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable and allowance for expected credit losses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Billed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">149.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, R&amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of &#8220;Cost of product and services sales, net&#8221;, &#8220;R&amp;D&#8221; expense and &#8220;SG&amp;A&#8221; expense on the Company's Condensed Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1070"><span style="-sec-ix-hidden:f-1071">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1074"><span style="-sec-ix-hidden:f-1075">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1078"><span style="-sec-ix-hidden:f-1079">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated effective annual tax rate as of September 30, 2025 and 2024 for the years ended December&#160;31, 2025 and 2024, excluding the impact of discrete adjustments, was 22% and 20%, respectively. The effective tax rate for the nine months ended September 30, 2025 and 2024 was 20% and (38)%, respectively. The increase in the estimated effective annual tax rate and the effective quarterly tax rate is primarily due to an increase in estimated profit combined with a change in jurisdictional mix of income and losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted into law in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. These impacts did not have a material effect on the tax rate for the three and nine months ended September 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation <div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Exchange Act. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth, and Stephen M. Weiss, respectively. The complaints alleged, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The lead plaintiffs in the consolidated matter (the "Lead Plaintiffs") are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. An order granting the Lead Plaintiffs&#8217; motion for class certification and appointment of class representatives was entered on June 18, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2024, the Company and the Lead Plaintiffs entered into an agreement in principle to settle the claims against the Company and each of the Company&#8217;s current and former officers and directors. On October 4, 2024, the Court granted preliminary approval of the proposed settlement, ordered notice to the settlement class and scheduled a fairness hearing for February 27, 2025. On February 6, 2025, the Lead Plaintiffs filed a Motion for Final Approval of Class Action Settlement, Certification of the Settlement Class and Approval of Plan of Allocation and Motion for Award of Attorneys' Fees, Reimbursement of Expenses and Compensatory Awards for Lead Plaintiffs. Under the settlement, the claims against the Company and its officers and directors were dismissed with prejudice and released in exchange for a payment from the Company of $40.0&#160;million, $30.0&#160;million of which was paid from insurance proceeds, and had previously been funded in the fourth quarter of 2024. The Company recorded the settlement and insurance recoverable amounts as pre-tax operating expense and income, respectively, within &#8220;Selling, general and administrative&#8221; expenses on the Consolidated Statement of Operations for the year ended December&#160;31, 2024. At the scheduled fairness hearing on February 27, 2025, the Court granted final approval of the settlement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints sought the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-DLB. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022, the Court approved the parties' joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund, respectively, in the Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints sought the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed a motion to dismiss the complaint. On March 29, 2022, an order was granted staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds, respectively, in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#8217; motion to dismiss, and on November 2, 2023, the Court approved the parties' joint stipulation to extend the stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, plaintiffs Lincolnshire and Pooja Sayal filed a motion in the United States District Court for the District of Maryland seeking preliminary approval of a stipulation of settlement with regard to the above referenced derivative matters (&#8220;Proposed Settlement&#8221;). </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Proposed Settlement intends to resolve all matters among and between the following parties: (i) Lincolnshire and Pooja Sayal, plaintiffs in the stockholder derivative action captioned In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-DLB, pending in the U.S. District Court for the District of Maryland; (ii) North Collier Fire Control and Rescue District Firefighter Pension Plan, Chang Kyum Kim and Mark Nevins, plaintiffs in the stockholder derivative action captioned In re Emergent BioSolutions Inc. Derivative Litigation, Case No. 2021-0974-MTZ, pending in the Delaware Court of Chancery; (iii) Zachary Elton, Jeffery Reynolds and Eric White, plaintiffs in the stockholder derivative action captioned Elton v. Kramer, et al, Case No. C-15-CV-21-000496, pending in the Circuit Court of Maryland for Montgomery County; (iv) Richard J. Levine and Christopher Seaver, plaintiffs in the stockholder derivative action captioned In Re Emergent BioSolutions Inc. Demand Refused Stockholder Derivative Litigation, Master File No. 8:23-cv-02969-DLB, pending in the U.S. District Court for the District of Maryland; (v) Christopher Andrews, plaintiff in the stockholder derivative action captioned Andrews v. Kramer, C.A. No. 2024-0925-MTZ, pending in the Delaware Court of Chancery; (vi) individual defendants Robert G. Kramer Sr., Fuad El-Hibri, Richard S. Lindahl, Ronald B. Richard, Zsolt Harsanyi, Louis W. Sullivan, George A. Joulwan, Jerome M. Hauer, Kathryn C. Zoon, Marvin White, Syed T. Husain, Seamus Mulligan, Adam Havey, Sean Kirk, Atul Saran and Sue Bailey and (vii) the Company, as nominal defendant (collectively with the individual defendants, the &#8220;Defendants&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement provided that no later than 20 business days following the satisfaction of all conditions precedent set forth in the Proposed Settlement, Defendants must cause their insurers to pay to the Company a settlement amount of $15.0&#160;million, less a court-approved fee and expense amount (the &#8220;Settlement Amount&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, no later than 60 days following the satisfaction of all conditions precedent set forth in the Proposed Settlement, the Company must effectuate a series of corporate governance reforms and maintain such reforms for a period of not less than four years, subject to the terms and conditions set forth in the Proposed Settlement. On May 9, 2025, the United States District Court for the District of Maryland (the &#8220;Court&#8221;) issued an order granting preliminary approval of the Proposed Settlement. The Proposed Settlement included no admission of fault, liability or wrongdoing by any of the Defendants. On August 6, 2025, the Court granted final approval of the Proposed Settlement without modification.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the Settlement Amount in September 2025. Accordingly, during the three and nine months ended September 30, 2025, the Company recorded $10.5&#160;million with respect to the Settlement Amount as a reduction of &#8220;Selling, general and administrative&#8221; expenses on the Condensed Consolidated Statement of Operations.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government investigations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions described above under &#8220;Securities and shareholder litigation,&#8221; the Company received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC (as discussed further below) and the Maryland Attorney General&#8217;s Office. The Company produced documents in response and will continue to cooperate with these government inquiries should further requests be made.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, the Company also received inquiries and subpoenas from the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries and the Select Subcommittee released its final report related to the coronavirus crisis on December 9, 2022. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Also in the second quarter of 2021, the Company also received subpoenas from the SEC related to certain disclosures regarding the incidents described above under the heading &#8220;Securities and shareholder litigation.&#8221; The Company has been cooperating with the SEC&#8217;s investigation. During the first quarter of 2025, the Company determined that a loss resulting from the investigation was probable and that the amount of loss could be reasonably estimated. As a result, the Company recorded an accrual within &#8220;Selling, general and administrative&#8221; expenses on the Consolidated Statement of Operations for the year ended December&#160;31, 2024 of $1.5&#160;million, and the related liability was included in &#8220;Other current liabilities&#8221; on the Company&#8217;s Consolidated Balance Sheet as of December&#160;31, 2024. On April 7, 2025, the Company consented to the SEC&#8217;s entry of an administrative order under which the Company agreed to cease and desist from committing or causing a violation of Section 17(a)(2) of the Securities Act of 1933 and to pay a fine of $1.5&#160;million. The Company paid the fine on April 18, 2025 and no liability balance remains on the Company&#8217;s Consolidated Balance Sheet as of September 30, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, the Company received an additional inquiry from the New York Attorney General&#8217;s Office related to certain past trading activity by the Company&#8217;s former Chief Executive Officer. The Company has produced documents and is cooperating with the New York Attorney General&#8217;s office on this matter.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, the Company met with representatives of the Department of Justice regarding the Company&#8217;s 2017 and 2019 contracts with the Department of State to provide medical countermeasures for exposure to nerve toxins. The Company has provided documents and is continuing discussions with the Department of Justice on this matter. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2022 Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the parties exchanged notices alleging material breaches of the Janssen Agreement, with each asserting the other had failed to meet key contractual obligations. Janssen subsequently initiated arbitration proceedings, and the Company responded with counterclaims. On July 3, 2024, the Company and Janssen entered into the Settlement Agreement to resolve all claims among the parties arising from the Janssen Agreement and the activities referenced above. Pursuant to the terms of the Settlement Agreement, Janssen paid the Company $50.0&#160;million on July 31, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2022, because the arbitration process with Janssen was expected to extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from &#8220;Inventories, net&#8221; and from &#8220;Prepaid expenses and other current assets&#8221; to &#8220;Other assets&#8221;, resulting in $152.7&#160;million in long-term assets related to the Janssen Agreement on the Condensed Consolidated Balance Sheet as of December 31, 2022. The long-term asset balance within &#8220;Other Assets&#8221; prior to announcing the Settlement Agreement was $158.7&#160;million. The Company recorded $50.0&#160;million in &#8220;Product and services sales, net&#8221; and &#8220;Cost product and services sales, net&#8221; on the Condensed Consolidated Statement of Operations during the second quarter of 2024 to reflect the settlement receivable as a change in the transaction price for the Janssen Agreement. Additionally, the Company recorded $110.2&#160;million in the second quarter of 2024 within &#8220;Cost product and services sales, net&#8221; on the Condensed Consolidated Statement of Operations to write down the remaining inventory to its net realizable value and for estimated disposal costs. The receivable for the settlement amount was collected during the third quarter of 2024 and there was no long-term asset balance remaining within &#8220;Other Assets&#8221; related to the Janssen Agreement as of December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment information</a></td>
<td class="text">Segment information<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, using the guidance provided in ASC 280, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 280&#8221;), along with the adoption of ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company reevaluated its reportable and operating segments. Based on updates to the Company&#8217;s internal operating and reporting structure and quantitative tests outlined in ASC 280, the Company manages its business with a focus on two reportable segments; the Commercial Products segment, which includes Naloxone products and the MCM Products segment, which includes the Anthrax - MCM products, Smallpox - MCM products and Other Products. The Company&#8217;s Services operating segment no longer meets the quantitative threshold for determining reportable segments and is now included within &#8220;All other revenues&#8221; along with the Company&#8217;s Contracts and grants business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is its President and Chief Executive Officer. The CODM evaluates the performance of the Company's reportable segments based on segment adjusted gross margin. The Company defines segment adjusted gross margin as sales less cost of sales excluding restructuring costs, changes in fair value of financial instruments, settlement charges, net and inventory step-up provision for each reportable segment. The Company does not allocate amortization of intangible assets, research and development expenses, selling, general and administrative costs, interest and other income (expense) or taxes to each reportable segment in the operating results that are regularly reviewed by the CODM. The CODM uses these reported measures to assess segment performance, allocate resources and monitor budget and guidance versus actual results. These metrics are used by the CODM to make key operating decisions, such as decisions about allocating capital and other resources to each segment. The accounting policies for segment reporting are the same as those described in Note 2, "Summary of significant accounting policies" in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2024. Intersegment revenue, cost of sales, and profit are eliminated in the segment measures regularly reviewed by the CODM as these activities are eliminated in consolidation and thus are not included in management&#8217;s evaluation of performance for each segment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by segment, as the Company's operating assets are shared or commingled. Therefore, the Company&#8217;s CODM does not regularly review any asset information by segment and, accordingly, the Company does not report asset information by segment. The measure of segment assets is reported on the Condensed Consolidated Balance Sheet as "Total assets".</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment information provided to the CODM, along with a reconciliation of segment adjusted gross margin to income before income taxes as reported in the Condensed Consolidated Statement of Operation for the three and nine months ended September 30, 2025 and 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">187.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">357.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">393.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of revenue:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">217.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">545.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">726.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">231.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">293.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">594.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales reportable segments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">152.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total of reportable segments</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">216.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">290.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">181.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">244.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">255.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total of reportable segments</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">328.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">436.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation to income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues less other costs of revenue </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(141.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory step-up provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(41.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(61.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(76.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(135.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(247.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(44.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(56.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(115.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; and &#8220;All other revenues less other cost of revenue&#8221; includes Services and Contracts and grants revenue, and Services and Contracts and grants revenue less Cost of services, respectively.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Excludes $&#8212; million and $0.2 million of restructuring costs for the three and nine months ended September 30, 2025, respectively.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> For 2025, excludes $1.8 million of inventory step-up provision for the nine months ended September 30, 2025 and $0.2 million and $(0.8) million of restructuring costs for the three and nine months ended September 30, 2025, respectively. For 2024, excludes $0.6 million of changes in fair value of financial instruments for the nine months ended September 30, 2024; it also excludes $4.9 million and $7.5 million of restructuring costs, and $1.2 million of inventory step up for each of the three and nine months ended September 30, 2024.</span></div></td></tr></table></div><div style="margin-bottom:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each reportable segment:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:42.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation from reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Items not included in depreciation from reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other segment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total depreciation</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2025, directors and officers (as defined in Exchange Act Rule 16a-1(f)) of the Company adopted written plans for the sale of the Company&#8217;s common stock intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (&#8220;Rule 10b5-1 trading arrangements&#8221;) as set forth in the table below.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Action</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Adoption date</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Rule 10b5-1 Trading Plan Provides for Purchase/Sale </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total Shares of Common Stock to be Sold</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Donald DeGolyer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">August 11, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51,081</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">October 30, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sujata Tyagi Dayal</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">August 8, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sale</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22,313</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May 27, 2026</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Sales may begin on the 91</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> day following the adoption of the Rule 10b5-1 trading arrangement.</span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Subject to early termination in accordance with the terms of the Rule 10b5-1 trading arrangement.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ebs_DonaldDeGolyerMember', window );">Donald DeGolyer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Donald DeGolyer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">August 11, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">October 30, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">445 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">51,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ebs_SujataTyagiDayalMember', window );">Sujata Tyagi Dayal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Sujata Tyagi Dayal<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">August 8, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">May 27, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">292 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">22,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ebs_DonaldDeGolyerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ebs_DonaldDeGolyerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ebs_SujataTyagiDayalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ebs_SujataTyagiDayalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC on March 3, 2025.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2025. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting standards</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement&#8217;s specified effective date. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company does not expect a material impact from this new guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a public business entity to disclose additional information about specific expense categories in the notes to financial statements on an annual and interim basis. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. A public entity should apply the amendments either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company's OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration include allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> may also be sold on consignment through third-party online retailers where revenues are recognized at the point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as SG&amp;A expenses and Cost of Commercial Product sales, respectively, in the Condensed Consolidated Statement of Operations. Revenues from OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of OTC NARCAN</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including inventory levels within the distribution channel, product shelf life and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and liabilities held for sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of assets and liabilities held for sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheet as of September 30, 2025 consist of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:76.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets held for sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities held for sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment and restructuring charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock', window );">Schedule of Impairment of Long-Lived Assets Held and Used by Asset</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the total impairment charge by asset class for the nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.428%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total impairment of long-lived assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by reportable segment as well as amounts included within non-reportable segments, unallocated corporate selling, general and administrative (&#8220;SG&amp;A&#8221;) expense and research and development (&#8220;R&amp;D&#8221;) expense:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment restructuring costs:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other segments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs included in Cost of product and services sales, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate restructuring costs: </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by function:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"> Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee transition</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Severance payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text">The following table provides the components of and changes in the Company&#8217;s restructuring accrual for the January 2023 Plan during the three and nine months ended September 30, 2024:<div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table provides the components of and changes in the Company&#8217;s restructuring accrual for the August 2023 Plan during the three and nine months ended September 30, 2024:<div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the components of and changes in the Company&#8217;s restructuring accrual for the May 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the components of and changes in the Company&#8217;s restructuring accrual for the August 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">356.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">311.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024 </span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">159.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">196.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">252.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">368.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">500.5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">667.7&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(290.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(397.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209.8&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">270.6&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> During 2024, the Company recorded non-cash impairment charges of $27.2 million related to certain Bioservices long-lived assets. See Note 5, &#8220;Impairment and restructuring charges&#8221; for more details regarding the impairment charge.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table summarizes the Company&#8217;s finite-lived intangible assets:<div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.601%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">402.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">452.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">353.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">501.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">402.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">452.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">353.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">501.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company&#8217;s finite-lived intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy of Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company&#8217;s assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Contingent Consideration Roll Forward</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company&#8217;s Level 3 warrant liability: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Level 3 of Significant Unobservable Inputs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurement for the Company's warrant liability used the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrant Liability</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Range</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2024 Warrants</span></td><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Black-Scholes Method</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.7%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the components of the Company&#8217;s debt:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2029</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">250.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">443.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">693.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">700.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(36.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">663.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products and services sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research &amp; development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, the Company had the following Warrants outstanding to acquire shares of its common stock:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Warrants Outstanding</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Range of Exercise<br/>&#160;Price per Share</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued related to the Term Loan Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$9.88 - $15.72</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">August 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per common share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings per Common Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted earnings (loss) per common share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(159.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities - equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (loss) per common share - basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.16&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.99&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.03)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (loss) per common share - diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.91&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.06&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.89&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.03)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text">The Company's revenues disaggregated by major sources for the three and nine months ended September 30, 2025 and 2024 were as follows: <div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">161.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">98.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">231.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">293.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; includes Services and Contracts and grants revenue.</span></div></td></tr><tr style="height:5pt"><td colspan="36" style="padding:0 1pt"><div style="margin-bottom:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">185.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">187.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">235.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">121.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">357.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">319.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">393.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">98.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">324.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">594.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">343.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">505.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; includes Services and Contracts and grants revenue.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; for the nine months ended September 30, 2024 includes $50.0 million attributable to the confidential arbitration settlement (the &#8220;Settlement Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) related to the 2022 termination of the manufacturing services agreement with Janssen (the &#8220;Janssen Agreement&#8221;).  The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, &#8220;Litigation&#8221; for additional information related to the accounting treatment and settlement of the arbitration with Janssen.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Rollforward of Contract Liabilities</a></td>
<td class="text">The following table presents the roll forward of the contract liability balances:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.6pt;font-weight:400;line-height:120%">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Billed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">149.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounts Receivable, Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleOfAccountsReceivableNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Leases Supplemental Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1070"><span style="-sec-ix-hidden:f-1071">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1074"><span style="-sec-ix-hidden:f-1075">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1078"><span style="-sec-ix-hidden:f-1079">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment information provided to the CODM, along with a reconciliation of segment adjusted gross margin to income before income taxes as reported in the Condensed Consolidated Statement of Operation for the three and nine months ended September 30, 2025 and 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Revenues reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">187.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">333.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">357.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">393.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of revenue:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">217.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">269.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">545.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">726.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">231.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">293.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">594.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">848.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales reportable segments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">152.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total of reportable segments</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">216.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">290.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Segment adjusted gross margin reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">181.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">244.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">255.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total of reportable segments</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">174.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">328.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">436.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation to income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other revenues less other costs of revenue </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(141.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inventory step-up provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(41.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(61.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(76.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(135.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(247.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(44.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(56.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on sale of business and assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(115.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;All other revenues&#8221; and &#8220;All other revenues less other cost of revenue&#8221; includes Services and Contracts and grants revenue, and Services and Contracts and grants revenue less Cost of services, respectively.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Excludes $&#8212; million and $0.2 million of restructuring costs for the three and nine months ended September 30, 2025, respectively.</span></div></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> For 2025, excludes $1.8 million of inventory step-up provision for the nine months ended September 30, 2025 and $0.2 million and $(0.8) million of restructuring costs for the three and nine months ended September 30, 2025, respectively. For 2024, excludes $0.6 million of changes in fair value of financial instruments for the nine months ended September 30, 2024; it also excludes $4.9 million and $7.5 million of restructuring costs, and $1.2 million of inventory step up for each of the three and nine months ended September 30, 2024.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each reportable segment:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:42.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation from reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MCM Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Items not included in depreciation from reportable segments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All other segment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Total depreciation</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>Category </div>
<div>segment </div>
<div>category </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfCategoriesOfPublicHealthThreats', window );">Number of categories of public health threats | category</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfRevenueGeneratingProducts', window );">Number of revenue generating products | product</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfProductAndServiceCategories', window );">Number of product and service categories | Category</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfCategoriesOfPublicHealthThreats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of categories of public health threats.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfCategoriesOfPublicHealthThreats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfProductAndServiceCategories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product And Service Categories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfProductAndServiceCategories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfRevenueGeneratingProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of revenue generating products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfRevenueGeneratingProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and liabilities held for sale - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-Sale, Not Discontinued Operations | Maryland Warehouse Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_MarylandWarehouseSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_MarylandWarehouseSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and liabilities held for sale - Schedule of assets and liabilities held for sale (Details) - Disposal Group, Held-for-Sale, Not Discontinued Operations - Maryland Warehouse Space<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets held for sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities held for sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_MarylandWarehouseSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_MarylandWarehouseSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 19, 2025</div></th>
<th class="th"><div>Aug. 20, 2024</div></th>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jul. 18, 2024</div></th>
<th class="th"><div>May 15, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 110,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 64,300,000<span></span>
</td>
<td class="num">(12,200,000)<span></span>
</td>
<td class="nump">24,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,100,000<span></span>
</td>
<td class="nump">293,800,000<span></span>
</td>
<td class="nump">594,200,000<span></span>
</td>
<td class="nump">848,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
<td class="nump">62,300,000<span></span>
</td>
<td class="nump">15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ProductAndServiceMember', window );">Product and services sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,000,000.0<span></span>
</td>
<td class="nump">$ 283,800,000<span></span>
</td>
<td class="nump">561,400,000<span></span>
</td>
<td class="nump">$ 824,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business | Development-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset', window );">Increase in contingent consideration, asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | RSDL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | RSDL | Product and services sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baltimore-Camden Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Baltimore-Bayview Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from divestiture of facility</a></td>
<td class="nump">$ 36,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Change In Amount Of Contingent Consideration, Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ProductAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ProductAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_DevelopmentBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_DevelopmentBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_RSDLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_RSDLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_BaltimoreCamdenFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_BaltimoreCamdenFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_BaltimoreBayviewFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_BaltimoreBayviewFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment and restructuring charges - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>employee</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>positions </div>
<div>employee</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,200,000<span></span>
</td>
<td class="nump">$ 27,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member', window );">January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Workforce reduction | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges incurred since inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member', window );">August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Workforce reduction | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges incurred since inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanMay2024Member', window );">May 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Workforce reduction | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges incurred since inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated', window );">Number of currently vacant positions eliminated | positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2024Member', window );">August 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Workforce reduction | employee</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges incurred since inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Number Of Vacant Positions Eliminated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReservePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the accrual for restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReservePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanMay2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanMay2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment and restructuring charges - Schedule Restructuring and Related Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="nump">$ 22.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate | SG&amp;A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate | R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember', window );">MCM Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All other segments | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedSellingGeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedSellingGeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="nump">$ 22.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member', window );">January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member', window );">August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanMay2024Member', window );">May 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2024Member', window );">August 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee transition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee transition | January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee transition | August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee transition | May 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee transition | August 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments | January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments | August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments | May 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments | August 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits | January 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits | August 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits | May 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits | August 2024 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanJanuary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanMay2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanMay2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlanAugust2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, net - Schedule of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 126.5<span></span>
</td>
<td class="nump">$ 95.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">115.8<span></span>
</td>
<td class="nump">86.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">114.0<span></span>
</td>
<td class="nump">129.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 356.3<span></span>
</td>
<td class="nump">$ 311.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 500.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 667.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(290.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(290.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(397.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">209.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">159.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">252.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">62.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 855.4<span></span>
</td>
<td class="nump">$ 855.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">402.7<span></span>
</td>
<td class="nump">353.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 452.7<span></span>
</td>
<td class="nump">501.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 855.4<span></span>
</td>
<td class="nump">855.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">402.7<span></span>
</td>
<td class="nump">353.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 452.7<span></span>
</td>
<td class="nump">$ 501.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Schedule of Finite-lived Intangible Assets Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Schedule of Fair Value Hierarchy of Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 105.8<span></span>
</td>
<td class="nump">$ 45.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">105.8<span></span>
</td>
<td class="nump">45.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">105.8<span></span>
</td>
<td class="nump">45.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">105.8<span></span>
</td>
<td class="nump">45.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_WarrantLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_WarrantLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 30, 2024</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">Senior Unsecured Notes Due August 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 368.6<span></span>
</td>
<td class="nump">$ 369.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIWarrantsMember', window );">Series I Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIIWarrantsMember', window );">Series II Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.7185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_WarrantLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_WarrantLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIIWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIIWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Level 3 Fair Value Of Common Stock Warrant Liability (Details) - Warrant - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Level 3 Fair Value Inputs In The Black-Scholes Option Pricing Models (Details) - Level 3 - Fair Value, Recurring - Black-Scholes Method - 2024 Warrants<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>Term</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">1.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ebs_ValuationTechniqueBlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ebs_ValuationTechniqueBlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_A2024WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ebs_A2024WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 693.1<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(30.0)<span></span>
</td>
<td class="num">(36.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt, net</a></td>
<td class="nump">$ 663.1<span></span>
</td>
<td class="nump">$ 663.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Unsecured Notes Due August 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 443.1<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Term loan due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_TermLoanDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_TermLoanDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Narrative (Details) - Line of Credit<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolver Loan Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current, net</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_RevolverLoanDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_RevolverLoanDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Senior Unsecured Notes due 2028 (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>May 07, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693.1<span></span>
</td>
<td class="nump">$ 693.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">Senior Unsecured Notes Due August 2028 | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">Senior Unsecured Notes Due August 2028 | Upon the occurrence of a change in control | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">Senior Unsecured Notes Due August 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 443.1<span></span>
</td>
<td class="nump">$ 443.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchase of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment', window );">Payments for repurchase of debt, excluding gain on extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentRepurchaseAmountRemaining', window );">Repurchase amount remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentRepurchaseAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Amount Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentRepurchaseAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Repurchase Of Debt, Excluding Gain (Loss) On Extinguishment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Term Loan Agreement (Details) - Term Loan - Line of Credit - Secured Debt - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentOriginalIssueDiscountPercentage', window );">Original issue discount, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentAdditionalDefaultInterestRate', window );">Additional default interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold', window );">Aggregate principal amount outstanding threshold</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum', window );">Minimum liquidity requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantLeverageRatioMaximum', window );">Gross leverage ratio</a></td>
<td class="nump">5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium', window );">Basis spread on make-whole premium</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentPrepaymentPremium', window );">Prepayment premium</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease', window );">Prepayment premium, decrease</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred', window );">Mandatory prepayment, percentage of net cash proceeds from indebtedness incurred</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds', window );">Mandatory prepayment, percentage of net cash proceeds from dispositions of property and insurance proceeds</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis', window );">Mandatory prepayment, net cash proceeds from disposition of property threshold, annual basis</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis', window );">Mandatory prepayment, net cash proceeds from disposition of property threshold, per transaction basis</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_TermLoanMember', window );">Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentVariableInterestRateFloor', window );">Variable interest rate floor</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_TermLoanMember', window );">Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_TermLoanMember', window );">Secured Overnight Financing Rate (SOFR) | Until The Second Anniversary Of The Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentVariableInterestRateFloor', window );">Variable interest rate floor</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_TermLoanMember', window );">Secured Overnight Financing Rate (SOFR) | After The Second Anniversary Of The Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentVariableInterestRateFloor', window );">Variable interest rate floor</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentAdditionalDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Default Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentAdditionalDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentBasisSpreadOnMakeWholePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread on Make-Whole Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentBasisSpreadOnMakeWholePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Requirement, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantLiquidityRequirementMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Annual Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Per Transaction Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Dispositions Of Property And Insurance Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Indebtedness Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maturity Date, Aggregate Principal Amount Outstanding Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentOriginalIssueDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Original Issue Discount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentOriginalIssueDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentPrepaymentPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentPrepaymentPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium, Scheduled Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentVariableInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Interest Rate, Floor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentVariableInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_VariableRateComponentAxis=ebs_UntilTheSecondAnniversaryOfTheClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_VariableRateComponentAxis=ebs_UntilTheSecondAnniversaryOfTheClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_VariableRateComponentAxis=ebs_AfterTheSecondAnniversaryOfTheClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_VariableRateComponentAxis=ebs_AfterTheSecondAnniversaryOfTheClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Revolving Loan Agreement (Details) - Line of Credit<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Loans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit', window );">Maximum borrowing capacity, increase limit</a></td>
<td class="nump">125,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit', window );">Maximum borrowing capacity, decrease limit</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum', window );">Borrowers&#8217; total leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate', window );">Covenant maturity, number of days prior to the maturity date</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum', window );">Minimum liquidity requirement</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantLeverageRatioMaximum', window );">Gross leverage ratio</a></td>
<td class="nump">5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum', window );">Fixed charge coverage ratio</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Loans, Until September 30, 2025 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Loans, Until September 30, 2025 | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentVariableInterestRateFloor', window );">Variable interest rate floor</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Loans, After September 30, 2025 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Loans, After September 30, 2025 | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Revolving Loans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Revolving Loans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio For Variable Rate Reduction, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantLiquidityRequirementMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity Requirement, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantLiquidityRequirementMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Maturity, Number Of Days Prior To The Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentVariableInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Interest Rate, Floor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentVariableInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Decrease Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Increase Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_RevolvingLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_RevolvingLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_RevolvingLoansUntilSeptember302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_RevolvingLoansUntilSeptember302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_RevolvingLoansAfterSeptember302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_RevolvingLoansAfterSeptember302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Narrative (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 17, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>increment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 30, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Nonvested options forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable', window );">Excise tax liability accrued for common stock repurchases | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=ebs_A2025ShareRepurchaseProgramMember', window );">2025 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized, amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares, acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares average cost price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIWarrantsMember', window );">Series I Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIIWarrantsMember', window );">Series II Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ebs_SubscriptionAgreementMember', window );">Subscription Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Liabilities, fair value adjustment | $</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instruments other than options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Equity instruments other than options, forfeited in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instruments other than options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod', window );">Award performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Equity instruments other than options, forfeited in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ebs_LongTermIncentiveAwardMember', window );">Long-Term Incentive Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Granted long-term incentive award | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ebs_PerformanceStockOptionMember', window );">Performance Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ebs_OtherEquityAwardsMember', window );">Other Equity Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements', window );">Number of vesting increments | increment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants in Period, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Vesting Increments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_WarrantLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_WarrantLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excise tax payable on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramExciseTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=ebs_A2025ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=ebs_A2025ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIIWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ebs_SeriesIIWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ebs_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ebs_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ebs_LongTermIncentiveAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ebs_LongTermIncentiveAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ebs_PerformanceStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ebs_PerformanceStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ebs_OtherEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ebs_OtherEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of products and services sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research &amp; development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-based compensation and stockholders' equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)<br> shares in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding | shares</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_A2024WarrantsMember', window );">Warrants issued related to the Term Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding | shares</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_A2024WarrantsMember', window );">Warrants issued related to the Term Loan Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of Exercise Price per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_A2024WarrantsMember', window );">Warrants issued related to the Term Loan Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of Exercise Price per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ebs_A2024WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ebs_A2024WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per common share - Schedule of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="num">$ (12.0)<span></span>
</td>
<td class="nump">$ 68.0<span></span>
</td>
<td class="nump">$ 114.8<span></span>
</td>
<td class="num">$ (283.1)<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="num">$ (159.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares outstanding-basic (in shares)</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.9<span></span>
</td>
<td class="nump">52.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities - equity awards (in shares)</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares outstanding-diluted (in shares)</a></td>
<td class="nump">56.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.7<span></span>
</td>
<td class="nump">52.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per common share - basic - basic (in dollars per share)</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per common share - basic - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 231.1<span></span>
</td>
<td class="nump">$ 293.8<span></span>
</td>
<td class="nump">$ 594.2<span></span>
</td>
<td class="nump">$ 848.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember', window );">Commercial Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">95.3<span></span>
</td>
<td class="nump">187.7<span></span>
</td>
<td class="nump">333.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember', window );">MCM Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">142.5<span></span>
</td>
<td class="nump">174.2<span></span>
</td>
<td class="nump">357.5<span></span>
</td>
<td class="nump">393.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_AllOtherRevenueMember', window );">All other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">133.0<span></span>
</td>
<td class="nump">171.5<span></span>
</td>
<td class="nump">269.6<span></span>
</td>
<td class="nump">343.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG | Commercial Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG | MCM Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">123.2<span></span>
</td>
<td class="nump">161.8<span></span>
</td>
<td class="nump">235.8<span></span>
</td>
<td class="nump">319.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG | All other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember', window );">Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">98.1<span></span>
</td>
<td class="nump">122.3<span></span>
</td>
<td class="nump">324.6<span></span>
</td>
<td class="nump">505.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember', window );">Non-USG | Commercial Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">74.2<span></span>
</td>
<td class="nump">95.3<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
<td class="nump">333.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember', window );">Non-USG | MCM Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">121.7<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember', window );">Non-USG | All other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JanssenPharmaceuticalsInc.Member', window );">Janssen Pharmaceuticals, Inc., | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_CommercialProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_CommercialProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_MedicalCountermeasuresMCMProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_AllOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_AllOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JanssenPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JanssenPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 322.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract with customer, asset, noncurrent</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 259.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Schedule of Rollforward of Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ChangeinContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning of period</a></td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">End of period</a></td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in the period from amounts included in contract liability at the beginning of the period:</a></td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeinContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeinContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Schedule of Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed</a></td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="nump">$ 135.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for expected credit losses</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 149.5<span></span>
</td>
<td class="nump">$ 154.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Interest on lease liabilities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Leases Supplemental Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="num">(38.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 18, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,200,000<span></span>
</td>
<td class="nump">$ 848,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,300,000<span></span>
</td>
<td class="nump">563,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ProductAndServiceMember', window );">Product and services sales, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,400,000<span></span>
</td>
<td class="nump">$ 824,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from legal settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase in other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 158,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc. | Product and services sales, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ebs_SecuritiesAndShareholderLitigationMember', window );">Securities And Shareholder Litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds', window );">Damages paid from insurance proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_LossContingencySettlementPeriod', window );">Settlement period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Settlement amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms', window );">Implementation reforms, period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained', window );">Period of reforms to be maintained</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementGain', window );">Settlement gain</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ebs_SECEnforcementProceedingMember', window );">SEC Enforcement Proceeding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual, provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Loss contingency, accrual, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Exclusive of intangible asset amortization</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Paid, Value, From Insurance Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration Of Reforms To Be Maintained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Period Of Implementation Of Corporate Governance Reforms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LossContingencySettlementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LossContingencySettlementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ProductAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ProductAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ebs_SecuritiesAndShareholderLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ebs_SecuritiesAndShareholderLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ebs_SECEnforcementProceedingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ebs_SECEnforcementProceedingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 231.1<span></span>
</td>
<td class="nump">$ 293.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 594.2<span></span>
</td>
<td class="nump">$ 848.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales reportable segments:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">85.9<span></span>
</td>
<td class="nump">122.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241.3<span></span>
</td>
<td class="nump">563.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16.3)<span></span>
</td>
<td class="num">(16.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.8)<span></span>
</td>
<td class="num">(48.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13.5)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41.1)<span></span>
</td>
<td class="num">(61.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38.9)<span></span>
</td>
<td class="num">(76.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135.0)<span></span>
</td>
<td class="num">(247.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(56.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business and assets held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.3<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57.6<span></span>
</td>
<td class="nump">142.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
<td class="num">(115.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">217.4<span></span>
</td>
<td class="nump">269.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545.2<span></span>
</td>
<td class="nump">726.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales reportable segments:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80.5<span></span>
</td>
<td class="nump">95.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216.6<span></span>
</td>
<td class="nump">290.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Segment adjusted gross margin reportable segments:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136.9<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328.6<span></span>
</td>
<td class="nump">436.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">All other revenues less other costs of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="num">(141.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16.3)<span></span>
</td>
<td class="num">(16.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.8)<span></span>
</td>
<td class="num">(48.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_RestructuringChargesAdjusted', window );">Restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_InventoryStepUp', window );">Inventory step-up provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13.5)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41.1)<span></span>
</td>
<td class="num">(61.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38.9)<span></span>
</td>
<td class="num">(76.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135.0)<span></span>
</td>
<td class="num">(247.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(56.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on sale of business and assets held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.3<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57.6<span></span>
</td>
<td class="nump">142.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.5<span></span>
</td>
<td class="num">(115.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">All other revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember', window );">Commercial Products | Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">95.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187.7<span></span>
</td>
<td class="nump">333.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales reportable segments:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.6<span></span>
</td>
<td class="nump">47.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.3<span></span>
</td>
<td class="nump">152.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Segment adjusted gross margin reportable segments:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32.3<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.4<span></span>
</td>
<td class="nump">181.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember', window );">MCM Products | Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142.5<span></span>
</td>
<td class="nump">174.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357.5<span></span>
</td>
<td class="nump">393.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of sales reportable segments:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.3<span></span>
</td>
<td class="nump">138.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Segment adjusted gross margin reportable segments:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">104.6<span></span>
</td>
<td class="nump">126.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244.2<span></span>
</td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_RestructuringChargesAdjusted', window );">Restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_InventoryStepUp', window );">Inventory step-up provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Exclusive of intangible asset amortization</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AdjustedGrossMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Gross Margin</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AdjustedGrossMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_InventoryStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Step Up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_InventoryStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_RestructuringChargesAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Adjusted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_RestructuringChargesAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_CommercialProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation from reportable segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation from reportable segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember', window );">MCM Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation from reportable segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All other segments | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation from reportable segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_MCMProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>470</ContextCount>
  <ElementCount>329</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Nature of the business and organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Natureofthebusinessandorganization</Role>
      <ShortName>Nature of the business and organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Assets and liabilities held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale</Role>
      <ShortName>Assets and liabilities held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Impairment and restructuring charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Impairmentandrestructuringcharges</Role>
      <ShortName>Impairment and restructuring charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Inventories, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Inventoriesnet</Role>
      <ShortName>Inventories, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</Role>
      <ShortName>Property, plant and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Share-based compensation and stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity</Role>
      <ShortName>Share-based compensation and stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Earnings (loss) per common share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Earningslosspercommonshare</Role>
      <ShortName>Earnings (loss) per common share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Revenuerecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Segmentinformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Assets and liabilities held for sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables</Role>
      <ShortName>Assets and liabilities held for sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Impairment and restructuring charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables</Role>
      <ShortName>Impairment and restructuring charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Impairmentandrestructuringcharges</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Inventories, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetTables</Role>
      <ShortName>Inventories, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Inventoriesnet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property, plant and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables</Role>
      <ShortName>Property, plant and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Intangibleassets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Fairvaluemeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Share-based compensation and stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables</Role>
      <ShortName>Share-based compensation and stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Earnings (loss) per common share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EarningslosspercommonshareTables</Role>
      <ShortName>Earnings (loss) per common share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Earningslosspercommonshare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Revenuerecognition</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Leases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Segment information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentinformationTables</Role>
      <ShortName>Segment information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Segmentinformation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Nature of the business and organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails</Role>
      <ShortName>Nature of the business and organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Natureofthebusinessandorganization</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Assets and liabilities held for sale - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails</Role>
      <ShortName>Assets and liabilities held for sale - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Assets and liabilities held for sale - Schedule of assets and liabilities held for sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails</Role>
      <ShortName>Assets and liabilities held for sale - Schedule of assets and liabilities held for sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DivestituresDetails</Role>
      <ShortName>Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Divestitures</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Impairment and restructuring charges - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails</Role>
      <ShortName>Impairment and restructuring charges - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails</Role>
      <ShortName>Impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails</Role>
      <ShortName>Impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails</Role>
      <ShortName>Impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Inventories, net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails</Role>
      <ShortName>Inventories, net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Intangible assets - Schedule of Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Schedule of Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Intangible assets - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Fair value measurements - Schedule of Fair Value Hierarchy of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair value measurements - Schedule of Fair Value Hierarchy of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Fair value measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Fair value measurements - Level 3 Fair Value Of Common Stock Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails</Role>
      <ShortName>Fair value measurements - Level 3 Fair Value Of Common Stock Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Fair value measurements - Level 3 Fair Value Inputs In The Black-Scholes Option Pricing Models (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails</Role>
      <ShortName>Fair value measurements - Level 3 Fair Value Inputs In The Black-Scholes Option Pricing Models (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Debt - Senior Unsecured Notes due 2028 (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details</Role>
      <ShortName>Debt - Senior Unsecured Notes due 2028 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Debt - Term Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails</Role>
      <ShortName>Debt - Term Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Debt - Revolving Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails</Role>
      <ShortName>Debt - Revolving Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Share-based compensation and stockholders' equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Share-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Share-based compensation and stockholders' equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails</Role>
      <ShortName>Share-based compensation and stockholders' equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Earnings (loss) per common share - Schedule of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails</Role>
      <ShortName>Earnings (loss) per common share - Schedule of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/EarningslosspercommonshareTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue recognition - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Revenue recognition - Schedule of Rollforward of Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails</Role>
      <ShortName>Revenue recognition - Schedule of Rollforward of Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Revenue recognition - Schedule of Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails</Role>
      <ShortName>Revenue recognition - Schedule of Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Leases - Schedule of Leases Supplemental Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails</Role>
      <ShortName>Leases - Schedule of Leases Supplemental Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Incometaxes</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Litigation</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Segment information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentinformationNarrativeDetails</Role>
      <ShortName>Segment information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Segment information - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment information - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ebs-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Segment information - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment information - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ebs-20250930.htm">ebs-20250930.htm</File>
    <File>ebs-20250930.xsd</File>
    <File>ebs-20250930_cal.xml</File>
    <File>ebs-20250930_def.xml</File>
    <File>ebs-20250930_lab.xml</File>
    <File>ebs-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ebs-20250930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="1104">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ebs-20250930.htm": {
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "ebs-20250930.htm"
     ]
    },
    "schema": {
     "local": [
      "ebs-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ebs-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ebs-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 282,
   "keyCustom": 47,
   "axisStandard": 34,
   "axisCustom": 1,
   "memberStandard": 49,
   "memberCustom": 48,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 6,
    "http://xbrl.sec.gov/ecd/2025": 2
   },
   "contextCount": 470,
   "entityCount": 1,
   "segmentCount": 100,
   "elementCount": 675,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1104,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 18,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://emergentbiosolutions.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
     "longName": "9952156 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-58",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
     "longName": "9952157 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://emergentbiosolutions.com/role/Natureofthebusinessandorganization",
     "longName": "9952158 - Disclosure - Nature of the business and organization",
     "shortName": "Nature of the business and organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies",
     "longName": "9952159 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale",
     "longName": "9952160 - Disclosure - Assets and liabilities held for sale",
     "shortName": "Assets and liabilities held for sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://emergentbiosolutions.com/role/Divestitures",
     "longName": "9952161 - Disclosure - Divestitures",
     "shortName": "Divestitures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://emergentbiosolutions.com/role/Impairmentandrestructuringcharges",
     "longName": "9952162 - Disclosure - Impairment and restructuring charges",
     "shortName": "Impairment and restructuring charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://emergentbiosolutions.com/role/Inventoriesnet",
     "longName": "9952163 - Disclosure - Inventories, net",
     "shortName": "Inventories, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet",
     "longName": "9952164 - Disclosure - Property, plant and equipment, net",
     "shortName": "Property, plant and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://emergentbiosolutions.com/role/Intangibleassets",
     "longName": "9952165 - Disclosure - Intangible assets",
     "shortName": "Intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://emergentbiosolutions.com/role/Fairvaluemeasurements",
     "longName": "9952166 - Disclosure - Fair value measurements",
     "shortName": "Fair value measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://emergentbiosolutions.com/role/Debt",
     "longName": "9952167 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity",
     "longName": "9952168 - Disclosure - Share-based compensation and stockholders' equity",
     "shortName": "Share-based compensation and stockholders' equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://emergentbiosolutions.com/role/Earningslosspercommonshare",
     "longName": "9952169 - Disclosure - Earnings (loss) per common share",
     "shortName": "Earnings (loss) per common share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://emergentbiosolutions.com/role/Revenuerecognition",
     "longName": "9952170 - Disclosure - Revenue recognition",
     "shortName": "Revenue recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://emergentbiosolutions.com/role/Leases",
     "longName": "9952171 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://emergentbiosolutions.com/role/Incometaxes",
     "longName": "9952172 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://emergentbiosolutions.com/role/Litigation",
     "longName": "9952173 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://emergentbiosolutions.com/role/Segmentinformation",
     "longName": "9952174 - Disclosure - Segment information",
     "shortName": "Segment information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables",
     "longName": "9955512 - Disclosure - Assets and liabilities held for sale (Tables)",
     "shortName": "Assets and liabilities held for sale (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables",
     "longName": "9955513 - Disclosure - Impairment and restructuring charges (Tables)",
     "shortName": "Impairment and restructuring charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://emergentbiosolutions.com/role/InventoriesnetTables",
     "longName": "9955514 - Disclosure - Inventories, net (Tables)",
     "shortName": "Inventories, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables",
     "longName": "9955515 - Disclosure - Property, plant and equipment, net (Tables)",
     "shortName": "Property, plant and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsTables",
     "longName": "9955516 - Disclosure - Intangible assets (Tables)",
     "shortName": "Intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables",
     "longName": "9955517 - Disclosure - Fair value measurements (Tables)",
     "shortName": "Fair value measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://emergentbiosolutions.com/role/DebtTables",
     "longName": "9955518 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables",
     "longName": "9955519 - Disclosure - Share-based compensation and stockholders' equity (Tables)",
     "shortName": "Share-based compensation and stockholders' equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://emergentbiosolutions.com/role/EarningslosspercommonshareTables",
     "longName": "9955520 - Disclosure - Earnings (loss) per common share (Tables)",
     "shortName": "Earnings (loss) per common share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionTables",
     "longName": "9955521 - Disclosure - Revenue recognition (Tables)",
     "shortName": "Revenue recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://emergentbiosolutions.com/role/LeasesTables",
     "longName": "9955522 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://emergentbiosolutions.com/role/SegmentinformationTables",
     "longName": "9955523 - Disclosure - Segment information (Tables)",
     "shortName": "Segment information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails",
     "longName": "9955524 - Disclosure - Nature of the business and organization (Details)",
     "shortName": "Nature of the business and organization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "unitRef": "category",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "unitRef": "category",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
     "longName": "9955525 - Disclosure - Assets and liabilities held for sale - Narrative (Details)",
     "shortName": "Assets and liabilities held for sale - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-91",
      "name": "ebs:DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails",
     "longName": "9955526 - Disclosure - Assets and liabilities held for sale - Schedule of assets and liabilities held for sale (Details)",
     "shortName": "Assets and liabilities held for sale - Schedule of assets and liabilities held for sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://emergentbiosolutions.com/role/DivestituresDetails",
     "longName": "9955527 - Disclosure - Divestitures (Details)",
     "shortName": "Divestitures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
     "longName": "9955528 - Disclosure - Impairment and restructuring charges - Narrative (Details)",
     "shortName": "Impairment and restructuring charges - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
     "longName": "9955529 - Disclosure - Impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)",
     "shortName": "Impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
     "longName": "9955530 - Disclosure - Impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)",
     "shortName": "Impairment and restructuring charges - Schedule Restructuring and Related Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
     "longName": "9955531 - Disclosure - Impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "shortName": "Impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails",
     "longName": "9955532 - Disclosure - Inventories, net - Schedule of Inventory (Details)",
     "shortName": "Inventories, net - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails",
     "longName": "9955533 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "shortName": "Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails",
     "longName": "9955534 - Disclosure - Intangible assets - Schedule of Finite-Lived Intangible Assets (Details)",
     "shortName": "Intangible assets - Schedule of Finite-Lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails",
     "longName": "9955535 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)",
     "shortName": "Intangible assets - Schedule of Finite-lived Intangible Assets Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails",
     "longName": "9955536 - Disclosure - Fair value measurements - Schedule of Fair Value Hierarchy of Assets and Liabilities (Details)",
     "shortName": "Fair value measurements - Schedule of Fair Value Hierarchy of Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
     "longName": "9955537 - Disclosure - Fair value measurements - Narrative (Details)",
     "shortName": "Fair value measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ebs:WarrantLiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-344",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails",
     "longName": "9955538 - Disclosure - Fair value measurements - Level 3 Fair Value Of Common Stock Warrant Liability (Details)",
     "shortName": "Fair value measurements - Level 3 Fair Value Of Common Stock Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-337",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-333",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
     "longName": "9955539 - Disclosure - Fair value measurements - Level 3 Fair Value Inputs In The Black-Scholes Option Pricing Models (Details)",
     "shortName": "Fair value measurements - Level 3 Fair Value Inputs In The Black-Scholes Option Pricing Models (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-340",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "term",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-340",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "term",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
     "longName": "9955540 - Disclosure - Debt - Schedule of Debt (Details)",
     "shortName": "Debt - Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
     "longName": "9955541 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
     "longName": "9955542 - Disclosure - Debt - Senior Unsecured Notes due 2028 (Details)",
     "shortName": "Debt - Senior Unsecured Notes due 2028 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-350",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails",
     "longName": "9955543 - Disclosure - Debt - Term Loan Agreement (Details)",
     "shortName": "Debt - Term Loan Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-355",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-355",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
     "longName": "9955544 - Disclosure - Debt - Revolving Loan Agreement (Details)",
     "shortName": "Debt - Revolving Loan Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-362",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-362",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
     "longName": "9955545 - Disclosure - Share-based compensation and stockholders' equity - Narrative (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9955546 - Disclosure - Share-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails",
     "longName": "9955547 - Disclosure - Share-based compensation and stockholders' equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)",
     "shortName": "Share-based compensation and stockholders' equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails",
     "longName": "9955548 - Disclosure - Earnings (loss) per common share - Schedule of Basic and Diluted Net Loss per Share (Details)",
     "shortName": "Earnings (loss) per common share - Schedule of Basic and Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails",
     "longName": "9955549 - Disclosure - Revenue recognition - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "Revenue recognition - Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-400",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
     "longName": "9955550 - Disclosure - Revenue recognition - Narrative (Details)",
     "shortName": "Revenue recognition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails",
     "longName": "9955551 - Disclosure - Revenue recognition - Schedule of Rollforward of Contract Liabilities (Details)",
     "shortName": "Revenue recognition - Schedule of Rollforward of Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails",
     "longName": "9955552 - Disclosure - Revenue recognition - Schedule of Accounts Receivable, Net (Details)",
     "shortName": "Revenue recognition - Schedule of Accounts Receivable, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails",
     "longName": "9955553 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails",
     "longName": "9955554 - Disclosure - Leases - Schedule of Leases Supplemental Balance Sheets (Details)",
     "shortName": "Leases - Schedule of Leases Supplemental Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://emergentbiosolutions.com/role/IncometaxesDetails",
     "longName": "9955555 - Disclosure - Income taxes (Details)",
     "shortName": "Income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://emergentbiosolutions.com/role/LitigationDetails",
     "longName": "9955556 - Disclosure - Litigation (Details)",
     "shortName": "Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-453",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://emergentbiosolutions.com/role/SegmentinformationNarrativeDetails",
     "longName": "9955557 - Disclosure - Segment information - Narrative (Details)",
     "shortName": "Segment information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
     "longName": "9955558 - Disclosure - Segment information - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "shortName": "Segment information - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955559 - Disclosure - Segment information - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segment information - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ebs_A2024WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "A2024WarrantsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Warrants",
        "verboseLabel": "Warrants issued related to the Term Loan Agreement",
        "label": "2024 Warrants [Member]",
        "documentation": "2024 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_A2025ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "A2025ShareRepurchaseProgramMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Share Repurchase Program",
        "label": "2025 Share Repurchase Program [Member]",
        "documentation": "2025 Share Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r841"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r187",
      "r627"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss, net",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r86",
      "r192",
      "r624",
      "r662",
      "r663",
      "r1106"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r21",
      "r537",
      "r540",
      "r599",
      "r658",
      "r659",
      "r960",
      "r961",
      "r962",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r841",
      "r1170"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1107",
      "r1172"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ebs_AdjustedGrossMargin": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "AdjustedGrossMargin",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment adjusted gross margin reportable segments:",
        "label": "Adjusted Gross Margin",
        "documentation": "Adjusted Gross Margin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_AfterTheSecondAnniversaryOfTheClosingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "AfterTheSecondAnniversaryOfTheClosingDateMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After The Second Anniversary Of The Closing Date",
        "label": "After The Second Anniversary Of The Closing Date [Member]",
        "documentation": "After The Second Anniversary Of The Closing Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r881",
      "r891",
      "r923"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r884",
      "r894",
      "r926"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r919",
      "r927",
      "r931",
      "r939"
     ]
    },
    "ebs_AllOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "AllOtherRevenueMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other revenue",
        "label": "All Other Revenue [Member]",
        "documentation": "All Other Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other segments",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r765",
      "r766"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r494",
      "r495"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for expected credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r299",
      "r303",
      "r304",
      "r305",
      "r1138"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred financing costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r391",
      "r1008",
      "r1122"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsAmortizationExpenseDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r210",
      "r320",
      "r326",
      "r745",
      "r750",
      "r751",
      "r753",
      "r755"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r190",
      "r221",
      "r224",
      "r225",
      "r262",
      "r269",
      "r287",
      "r291",
      "r300",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r526",
      "r529",
      "r575",
      "r614",
      "r615",
      "r620",
      "r697",
      "r765",
      "r766",
      "r777",
      "r841",
      "r849",
      "r850",
      "r862",
      "r1056",
      "r1057",
      "r1125"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Leases Supplemental Balance Sheets",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r195",
      "r221",
      "r224",
      "r225",
      "r300",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r526",
      "r529",
      "r575",
      "r841",
      "r1056",
      "r1057",
      "r1125"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r831"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r110",
      "r181",
      "r182"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale:",
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r107",
      "r110",
      "r181",
      "r182"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ebs_BaltimoreBayviewFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "BaltimoreBayviewFacilityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Baltimore-Bayview Facility",
        "label": "Baltimore-Bayview Facility [Member]",
        "documentation": "Baltimore-Bayview Facility"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_BaltimoreCamdenFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "BaltimoreCamdenFacilityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Baltimore-Camden Facility",
        "label": "Baltimore-Camden Facility [Member]",
        "documentation": "Baltimore-Camden Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BaseRateMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r1055"
     ]
    },
    "us-gaap_BilledContractReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BilledContractReceivables",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Billed",
        "label": "Billed Contracts Receivable",
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_BridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BridgeLoanMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan",
        "label": "Bridge Loan [Member]",
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings, building improvements and leasehold improvements",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent obligations, net",
        "negatedTerseLabel": "Changes in fair value of financial instruments",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r1007"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property, plant and equipment unpaid at period end",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r185",
      "r746"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market accounts",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r574",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "totalLabel": "Total",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r99",
      "r218"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash and cash equivalents and restricted cash:",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r99"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ebs_ChangeinContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ChangeinContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Contract With Customer, Liability [Roll Forward]",
        "label": "Change in Contract With Customer, Liability [Roll Forward]",
        "documentation": "Change in Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share (in dollars per share)",
        "verboseLabel": "Range of Exercise Price per Share (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r227",
      "r421"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ebs_CommercialProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "CommercialProductMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Product sales",
        "label": "Commercial Product [Member]",
        "documentation": "Commercial Product"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_CommercialProductsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "CommercialProductsSegmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Products",
        "label": "Commercial Products Segment [Member]",
        "documentation": "Commercial Products Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_CommitmentContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "CommitmentContingenciesDisclosureTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment Contingencies Disclosure [Table]",
        "label": "Commitment Contingencies Disclosure [Table]",
        "documentation": "Commitment Contingencies Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Line Items]",
        "label": "Commitments and Contingencies Disclosure [Line Items]",
        "documentation": "Commitments and Contingencies Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r854",
      "r856",
      "r857",
      "r858",
      "r859",
      "r1017",
      "r1018",
      "r1020",
      "r1107",
      "r1169",
      "r1172"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r685"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r77",
      "r685",
      "r703",
      "r1172",
      "r1173"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value per share; 200.0 shares authorized, 60.6 and 59.9 shares issued; 52.7 and 54.3 shares outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r400",
      "r406",
      "r623",
      "r841"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss), net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r198",
      "r200",
      "r204",
      "r612",
      "r632",
      "r633"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r824",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1037",
      "r1039",
      "r1040"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r144",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r221",
      "r222",
      "r228",
      "r229",
      "r262",
      "r271",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r617",
      "r765",
      "r766",
      "r953",
      "r954",
      "r1056",
      "r1057"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r144",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r221",
      "r222",
      "r228",
      "r229",
      "r262",
      "r271",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r617",
      "r765",
      "r766",
      "r953",
      "r954",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r757"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction-in-progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Type [Axis]",
        "label": "Business Combination, Contingent Consideration, Type [Axis]",
        "documentation": "Information by type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Type [Domain]",
        "label": "Business Combination, Contingent Consideration, Type [Domain]",
        "documentation": "Type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Rollforward of Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, asset, noncurrent",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r425",
      "r427",
      "r446"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r427",
      "r446"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r427",
      "r446"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofRollforwardofContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized in the period from amounts included in contract liability at the beginning of the period:",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "ebs_ContractsAndGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ContractsAndGrantsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracts and grants",
        "label": "Contracts and Grants [Member]",
        "documentation": "Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r1025"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/LitigationDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of product and services sales, net",
        "terseLabel": "Cost of goods and services sold",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r608",
      "r751",
      "r756",
      "r828",
      "r1001"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSoldAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales reportable segments:",
        "label": "Cost of Product and Service Sold [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products and services sales, net",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r1054"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r1054"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r221",
      "r223",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r356",
      "r357",
      "r369",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r385",
      "r392",
      "r393",
      "r395",
      "r535",
      "r586"
     ]
    },
    "ebs_DebtInstrumentAdditionalDefaultInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentAdditionalDefaultInterestRate",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional default interest rate",
        "label": "Debt Instrument, Additional Default Interest Rate",
        "documentation": "Debt Instrument, Additional Default Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r67",
      "r68",
      "r126",
      "r127",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r839",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1043",
      "r1044",
      "r1045",
      "r1121",
      "r1123",
      "r1135"
     ]
    },
    "ebs_DebtInstrumentBasisSpreadOnMakeWholePremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentBasisSpreadOnMakeWholePremium",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on make-whole premium",
        "label": "Debt Instrument, Basis Spread on Make-Whole Premium",
        "documentation": "Debt Instrument, Basis Spread on Make-Whole Premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantFixedChargeCoverageRatioMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentCovenantFixedChargeCoverageRatioMinimum",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed charge coverage ratio",
        "label": "Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Minimum",
        "documentation": "Debt Instrument, Covenant, Fixed Charge Coverage Ratio, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowers\u2019 total leverage ratio",
        "label": "Debt Instrument, Covenant, Leverage Ratio For Variable Rate Reduction, Maximum",
        "documentation": "Debt Instrument, Covenant, Leverage Ratio For Variable Rate Reduction, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantLeverageRatioMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross leverage ratio",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantLiquidityRequirementMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentCovenantLiquidityRequirementMinimum",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum liquidity requirement",
        "label": "Debt Instrument, Covenant, Liquidity Requirement, Minimum",
        "documentation": "Debt Instrument, Covenant, Liquidity Requirement, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Covenant maturity, number of days prior to the maturity date",
        "label": "Debt Instrument, Covenant Maturity, Number Of Days Prior To The Maturity Date",
        "documentation": "Debt Instrument, Covenant Maturity, Number Of Days Prior To The Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r586",
      "r587",
      "r773",
      "r774",
      "r839"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated interest rate percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r371"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r535",
      "r617",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r839",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1121",
      "r1123"
     ]
    },
    "ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mandatory prepayment, net cash proceeds from disposition of property threshold, annual basis",
        "label": "Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Annual Basis",
        "documentation": "Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Annual Basis"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mandatory prepayment, net cash proceeds from disposition of property threshold, per transaction basis",
        "label": "Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Per Transaction Basis",
        "documentation": "Debt Instrument, Mandatory Prepayment, Net Cash Proceeds From Disposition Of Property Threshold, Per Transaction Basis"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mandatory prepayment, percentage of net cash proceeds from dispositions of property and insurance proceeds",
        "label": "Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Dispositions Of Property And Insurance Proceeds",
        "documentation": "Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Dispositions Of Property And Insurance Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mandatory prepayment, percentage of net cash proceeds from indebtedness incurred",
        "label": "Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Indebtedness Incurred",
        "documentation": "Debt Instrument, Mandatory Prepayment, Percentage Of Net Cash Proceeds From Indebtedness Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount outstanding threshold",
        "label": "Debt Instrument, Maturity Date, Aggregate Principal Amount Outstanding Threshold",
        "documentation": "Debt Instrument, Maturity Date, Aggregate Principal Amount Outstanding Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r839",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1043",
      "r1044",
      "r1045",
      "r1121",
      "r1123",
      "r1135"
     ]
    },
    "ebs_DebtInstrumentOriginalIssueDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentOriginalIssueDiscountPercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issue discount, percentage",
        "label": "Debt Instrument, Original Issue Discount, Percentage",
        "documentation": "Debt Instrument, Original Issue Discount, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentPrepaymentPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentPrepaymentPremium",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment premium",
        "label": "Debt Instrument, Prepayment Premium",
        "documentation": "Debt Instrument, Prepayment Premium"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepayment premium, decrease",
        "label": "Debt Instrument, Prepayment Premium, Scheduled Increase (Decrease)",
        "documentation": "Debt Instrument, Prepayment Premium, Scheduled Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior to August 15, 2023",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upon the occurrence of a change in control",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of long-term debt",
        "label": "Debt Instrument, Repurchase Amount",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DebtInstrumentRepurchaseAmountRemaining": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentRepurchaseAmountRemaining",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase amount remaining",
        "label": "Debt Instrument, Repurchase Amount Remaining",
        "documentation": "Debt Instrument, Repurchase Amount Remaining"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased face amount",
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r46",
      "r47",
      "r53",
      "r120",
      "r121",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r535",
      "r617",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r839",
      "r1011",
      "r1012",
      "r1013",
      "r1016",
      "r1121",
      "r1123"
     ]
    },
    "ebs_DebtInstrumentVariableInterestRateFloor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DebtInstrumentVariableInterestRateFloor",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest rate floor",
        "label": "Debt Instrument, Variable Interest Rate, Floor",
        "documentation": "Debt Instrument, Variable Interest Rate, Floor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, current, net",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1121",
      "r1123"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, net",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1120",
      "r1121",
      "r1123"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1121",
      "r1123"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r621"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r209",
      "r750",
      "r751",
      "r753",
      "r755"
     ]
    },
    "us-gaap_DepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation from reportable segments:",
        "label": "Depreciation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r211",
      "r262",
      "r274",
      "r291",
      "r750",
      "r765",
      "r766"
     ]
    },
    "us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impairment of Long-Lived Assets Held and Used by Asset",
        "label": "Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]",
        "documentation": "Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r112"
     ]
    },
    "ebs_DevelopmentBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DevelopmentBasedMilestonesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development-Based Milestones",
        "label": "Development-Based Milestones [Member]",
        "documentation": "Development-Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails",
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails",
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r16"
     ]
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Held-for-Sale, Not Discontinued Operations",
        "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r16",
      "r181"
     ]
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "negatedTerseLabel": "Valuation allowance",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Valuation Allowance",
        "documentation": "Disposal Group, Including Discontinued Operation, Assets, Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in contingent consideration, asset",
        "label": "Disposal Group, Including Discontinued Operation, Change In Amount Of Contingent Consideration, Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Change In Amount Of Contingent Consideration, Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments receivable",
        "label": "Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable",
        "documentation": "Disposal Group, Including Discontinued Operation, Maximum Contingent Consideration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable",
        "label": "Disposal Group, Including Discontinued Operation, Milestone Payment Receivable",
        "documentation": "Disposal Group, Including Discontinued Operation, Milestone Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r110"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r107",
      "r110"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r110"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets",
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r110"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r110"
     ]
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Disposal Group, Including Discontinued Operation, Transaction Costs",
        "documentation": "Disposal Group, Including Discontinued Operation, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale",
      "http://emergentbiosolutions.com/role/Divestitures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities held for sale",
        "verboseLabel": "Divestitures",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r106"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails",
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r792",
      "r793"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_DonaldDeGolyerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "DonaldDeGolyerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Donald DeGolyer [Member]",
        "documentation": "Donald DeGolyer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in dollars per share)",
        "terseLabel": "Earnings (loss) per common share - basic - basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r205",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248",
      "r250",
      "r255",
      "r256",
      "r257",
      "r261",
      "r398",
      "r493",
      "r519",
      "r525",
      "r548",
      "r549",
      "r613",
      "r634",
      "r758"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in dollars per share)",
        "terseLabel": "Earnings (loss) per common share - basic - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r205",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r250",
      "r255",
      "r256",
      "r257",
      "r261",
      "r398",
      "r493",
      "r519",
      "r525",
      "r548",
      "r549",
      "r613",
      "r634",
      "r758"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per common share",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Earningslosspercommonshare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per common share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r258",
      "r259",
      "r260"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r796"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Line Items]",
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r796"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Table]",
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r796"
     ]
    },
    "ebs_EmployeeBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "EmployeeBenefitsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Employee Benefits [Member]",
        "documentation": "Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance payments",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ebs_EmployeeTransitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "EmployeeTransitionMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee transition",
        "label": "Employee Transition [Member]",
        "documentation": "Employee Transition"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r172",
      "r173",
      "r174",
      "r201",
      "r202",
      "r203",
      "r230",
      "r231",
      "r232",
      "r234",
      "r241",
      "r243",
      "r245",
      "r263",
      "r301",
      "r302",
      "r332",
      "r397",
      "r422",
      "r493",
      "r509",
      "r510",
      "r516",
      "r517",
      "r518",
      "r520",
      "r524",
      "r525",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r590",
      "r599",
      "r631",
      "r658",
      "r659",
      "r660",
      "r673",
      "r722"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r881",
      "r891",
      "r923"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r878",
      "r888",
      "r920"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r565",
      "r831"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r565",
      "r831"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy of Assets and Liabilities",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1108",
      "r1109",
      "r1113"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Level 3 of Significant Unobservable Inputs",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r834"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r564",
      "r565",
      "r567",
      "r572",
      "r600",
      "r601",
      "r602",
      "r743",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r831",
      "r834",
      "r838"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r566"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r555",
      "r831",
      "r1111",
      "r1114"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Fairvaluemeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r560",
      "r562",
      "r563",
      "r564",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r611",
      "r831",
      "r835"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r450",
      "r455",
      "r456",
      "r552",
      "r565",
      "r572",
      "r600",
      "r743",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r831",
      "r838"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r450",
      "r455",
      "r456",
      "r458",
      "r552",
      "r553",
      "r565",
      "r572",
      "r601",
      "r743",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r831",
      "r838"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r552",
      "r553",
      "r554",
      "r555",
      "r565",
      "r572",
      "r602",
      "r743",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r831",
      "r834",
      "r838"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r566"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable Input Reconciliation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r566"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contingent Consideration Roll Forward",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r561",
      "r566"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r555",
      "r831",
      "r1111",
      "r1114"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r566"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of period",
        "periodEndLabel": "Balance, end of period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r566"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r564",
      "r565",
      "r567",
      "r572",
      "r600",
      "r601",
      "r602",
      "r743",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r831",
      "r834",
      "r838"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1114"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Useful Life in Years",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r308",
      "r325",
      "r745"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-lived Intangible Assets Amortization Expense",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r609",
      "r610",
      "r666",
      "r741",
      "r745",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r325",
      "r610",
      "r745"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r325",
      "r327",
      "r328",
      "r330",
      "r609",
      "r741",
      "r745",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r666",
      "r741",
      "r745",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r1037"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r927"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and equipment",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ebs_GainLossOnDispositionOfBusinessIncludingTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "GainLossOnDispositionOfBusinessIncludingTransactionCosts",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) on sale of business and assets held for sale",
        "label": "Gain (Loss) On Disposition of Business, Including Transaction Costs",
        "documentation": "Gain (Loss) On Disposition of Business, Including Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestituresDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale of business and assets held for sale",
        "verboseLabel": "Gain (loss) on sale of business",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r1008"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44",
      "r45"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]",
        "label": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]",
        "documentation": "The name of the impaired assets to be held and used by the entity."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedByTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used by Type [Axis]",
        "label": "Impaired Long-Lived Assets Held and Used by Type [Axis]",
        "documentation": "Information by type of impaired long-lived asset held and used."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "label": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "negatedTerseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37",
      "r109",
      "r206",
      "r751",
      "r832"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r129",
      "r134",
      "r614",
      "r616",
      "r629",
      "r752",
      "r754",
      "r756",
      "r760",
      "r765",
      "r1022",
      "r1024",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails",
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r792",
      "r793"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails",
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails",
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r16",
      "r19",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r62",
      "r63",
      "r64",
      "r111",
      "r335",
      "r336"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r342",
      "r345",
      "r531",
      "r532",
      "r533",
      "r534",
      "r557",
      "r561",
      "r566",
      "r576",
      "r577",
      "r578",
      "r655",
      "r657",
      "r707",
      "r741",
      "r743",
      "r797",
      "r798",
      "r829",
      "r830",
      "r833",
      "r838",
      "r1097",
      "r1098",
      "r1140"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r345",
      "r531",
      "r532",
      "r533",
      "r534",
      "r557",
      "r561",
      "r566",
      "r576",
      "r577",
      "r578",
      "r655",
      "r657",
      "r707",
      "r741",
      "r743",
      "r797",
      "r798",
      "r829",
      "r830",
      "r833",
      "r838",
      "r1097",
      "r1098",
      "r1140"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Incometaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r226",
      "r498",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r513",
      "r514",
      "r515",
      "r619",
      "r665",
      "r672",
      "r796"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r142",
      "r221",
      "r244",
      "r245",
      "r262",
      "r277",
      "r291",
      "r501",
      "r502",
      "r512",
      "r635",
      "r752",
      "r754",
      "r756",
      "r796"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes, net of refunds",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r102",
      "r1009",
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable and payable, net",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ebs_IncreaseDecreaseInLongTermIncentivePlanAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "IncreaseDecreaseInLongTermIncentivePlanAccrual",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term incentive plan accrual",
        "label": "Increase (Decrease) in Long-Term Incentive Plan Accrual",
        "documentation": "Increase (Decrease) in Long-Term Incentive Plan Accrual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive securities - equity awards (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r257",
      "r463"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r919",
      "r927",
      "r931",
      "r939"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r943"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r943"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r943"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Intangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r329",
      "r331",
      "r740",
      "r741"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r752",
      "r756",
      "r963"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r216",
      "r217"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Inventoriesnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories, net",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r748"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories, net",
        "totalLabel": "Total inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r747",
      "r841"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials and supplies",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r957"
     ]
    },
    "ebs_InventoryStepUp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "InventoryStepUp",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory step-up provision",
        "label": "Inventory Step Up",
        "documentation": "Inventory Step Up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r749"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ebs_JansenPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "JansenPharmaceuticalsIncMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jansen Pharmaceuticals, Inc.",
        "label": "Jansen Pharmaceuticals, Inc. [Member]",
        "documentation": "Jansen Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_JanssenPharmaceuticalsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "JanssenPharmaceuticalsInc.Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Pharmaceuticals, Inc.,",
        "label": "Janssen Pharmaceuticals, Inc., [Member]",
        "documentation": "Janssen Pharmaceuticals, Inc.,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandAndLandImprovementsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and improvements",
        "label": "Land and Land Improvements [Member]",
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r840"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails",
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost:",
        "verboseLabel": "Operating leases:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r67",
      "r68",
      "r69",
      "r72",
      "r73",
      "r74",
      "r75",
      "r221",
      "r224",
      "r225",
      "r300",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r527",
      "r529",
      "r530",
      "r575",
      "r684",
      "r759",
      "r777",
      "r862",
      "r1056",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r128",
      "r626",
      "r841",
      "r849",
      "r850",
      "r1011",
      "r1015",
      "r1030",
      "r1119"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r184",
      "r221",
      "r224",
      "r225",
      "r300",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r527",
      "r529",
      "r530",
      "r575",
      "r841",
      "r1056",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, fair value adjustment",
        "label": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r1108"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r110",
      "r181",
      "r182"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities held for sale:",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55",
      "r61",
      "r107",
      "r110",
      "r181",
      "r182"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r71"
     ]
    },
    "ebs_LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity, decrease limit",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Decrease Limit",
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Decrease Limit"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity, increase limit",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Limit",
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Limit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationSettlementGain",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement gain",
        "label": "Litigation Settlement, Gain",
        "documentation": "Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r127",
      "r222",
      "r229",
      "r382",
      "r396",
      "r617",
      "r773",
      "r774",
      "r839",
      "r1136"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, fair value",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r838",
      "r1108",
      "r1110",
      "r1111",
      "r1112",
      "r1115",
      "r1116",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt",
        "terseLabel": "Non-current portion of debt, net",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ebs_LongTermIncentiveAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "LongTermIncentiveAwardMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Incentive Award",
        "label": "Long-Term Incentive Award [Member]",
        "documentation": "Long-Term Incentive Award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r43",
      "r1043",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, accrual, current",
        "label": "Loss Contingency, Accrual, Current",
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual, provision",
        "label": "Loss Contingency Accrual, Provision",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement amount",
        "label": "Loss Contingency, Damages Awarded, Value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages paid",
        "label": "Loss Contingency, Damages Paid, Value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "ebs_LossContingencyDamagesPaidValueFromInsuranceProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "LossContingencyDamagesPaidValueFromInsuranceProceeds",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages paid from insurance proceeds",
        "label": "Loss Contingency, Damages Paid, Value, From Insurance Proceeds",
        "documentation": "Loss Contingency, Damages Paid, Value, From Insurance Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained": {
     "xbrltype": "durationItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of reforms to be maintained",
        "label": "Loss Contingency, Period Of Corporate Governance Reforms To Be Maintained",
        "documentation": "Duration Of Reforms To Be Maintained"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Implementation reforms, period",
        "label": "Loss Contingency, Period Of Implementation Of Corporate Governance Reforms",
        "documentation": "Loss Contingency, Period Of Implementation Of Corporate Governance Reforms"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_LossContingencySettlementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "LossContingencySettlementPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement period",
        "label": "Loss Contingency, Settlement Period",
        "documentation": "Loss Contingency, Settlement Period"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_MCMProductsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "MCMProductsSegmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Products",
        "label": "MCM Products Segment [Member]",
        "documentation": "MCM Products Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r779",
      "r782",
      "r843",
      "r847",
      "r1139",
      "r1141",
      "r1142",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "ebs_MarylandWarehouseSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "MarylandWarehouseSpaceMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofassetsandliabilitiesheldforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maryland Warehouse Space",
        "label": "Maryland Warehouse Space [Member]",
        "documentation": "Maryland Warehouse Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "All other revenues",
        "terseLabel": "Other",
        "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r289",
      "r292",
      "r765",
      "r766"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r157",
      "r158",
      "r170",
      "r171",
      "r264",
      "r352",
      "r353",
      "r354",
      "r355",
      "r459",
      "r487",
      "r488",
      "r489",
      "r496",
      "r555",
      "r605",
      "r654",
      "r656",
      "r664",
      "r676",
      "r677",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r770",
      "r778",
      "r794",
      "r797",
      "r799",
      "r800",
      "r834",
      "r835",
      "r836",
      "r837",
      "r844",
      "r1058",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term (in years)",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r834",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r553",
      "r554",
      "r555",
      "r797",
      "r799",
      "r800",
      "r834"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r797",
      "r799",
      "r800",
      "r834"
     ]
    },
    "ebs_MedicalCountermeasuresMCMProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "MedicalCountermeasuresMCMProductMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Product sales",
        "label": "Medical Countermeasures (MCM) Product [Member]",
        "documentation": "Medical Countermeasures (MCM) Product"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r157",
      "r158",
      "r170",
      "r171",
      "r264",
      "r352",
      "r353",
      "r354",
      "r355",
      "r459",
      "r487",
      "r488",
      "r489",
      "r496",
      "r555",
      "r605",
      "r654",
      "r656",
      "r664",
      "r676",
      "r677",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r770",
      "r778",
      "r794",
      "r797",
      "r799",
      "r800",
      "r834",
      "r835",
      "r836",
      "r844",
      "r1058",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market accounts",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r779",
      "r782",
      "r843",
      "r847",
      "r1139",
      "r1141",
      "r1142",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "netLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r103",
      "r130",
      "r174",
      "r182",
      "r196",
      "r199",
      "r203",
      "r221",
      "r224",
      "r225",
      "r228",
      "r233",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r254",
      "r300",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r398",
      "r401",
      "r403",
      "r407",
      "r493",
      "r519",
      "r525",
      "r549",
      "r575",
      "r630",
      "r704",
      "r720",
      "r721",
      "r752",
      "r754",
      "r756",
      "r860",
      "r1056"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r885",
      "r895",
      "r919",
      "r927"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ebs_NonUnitedStatesGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "NonUnitedStatesGovernmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-USG",
        "label": "Non-United States Government [Member]",
        "documentation": "Non-United States Government"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_NumberOfCategoriesOfPublicHealthThreats": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "NumberOfCategoriesOfPublicHealthThreats",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of categories of public health threats",
        "label": "Number Of Categories Of Public Health Threats",
        "documentation": "Refers to the number of categories of public health threats."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r1023"
     ]
    },
    "ebs_NumberOfProductAndServiceCategories": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "NumberOfProductAndServiceCategories",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product and service categories",
        "label": "Number Of Product And Service Categories",
        "documentation": "Number Of Product And Service Categories"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r769",
      "r1023"
     ]
    },
    "ebs_NumberOfRevenueGeneratingProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "NumberOfRevenueGeneratingProducts",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of revenue generating products",
        "label": "Number Of Revenue Generating Products",
        "documentation": "Refers to the number of revenue generating products."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r752",
      "r756",
      "r760",
      "r1022",
      "r1024",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r840"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r840"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesScheduleofLeasesSupplementalBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r840"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r765",
      "r766"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Natureofthebusinessandorganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of the business and organization",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r175",
      "r176",
      "r178",
      "r667",
      "r668"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments, net",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r124"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss), net of tax",
        "verboseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r124",
      "r197",
      "r200",
      "r241"
     ]
    },
    "ebs_OtherEquityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "OtherEquityAwardsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Equity Awards",
        "label": "Other Equity Awards [Member]",
        "documentation": "Other Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r841"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestituresDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r828"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r883",
      "r893",
      "r925"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r886",
      "r896",
      "r928"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for legal settlements",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ebs_PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Milestone payments from prior asset divestiture",
        "label": "Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities",
        "documentation": "Payments For (Proceeds From) Contingent Consideration Liability (Asset), Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ebs_PaymentsForRepurchaseOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "PaymentsForRepurchaseOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of debt",
        "label": "Payments For Repurchase Of Debt",
        "documentation": "Payments For Repurchase Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for repurchase of debt, excluding gain on extinguishment",
        "label": "Payments For Repurchase Of Debt, Excluding Gain (Loss) On Extinguishment",
        "documentation": "Payments For Repurchase Of Debt, Excluding Gain (Loss) On Extinguishment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r1006"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid for share-based compensation activity",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of convertible note receivable",
        "label": "Payments to Acquire Notes Receivable",
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ebs_PerformanceStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "PerformanceStockOptionMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Option",
        "label": "Performance Stock Option [Member]",
        "documentation": "Performance Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r409"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r685"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r409"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r685",
      "r703",
      "r1172",
      "r1173"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r400",
      "r405",
      "r622",
      "r841"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ebs_ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds allocated to common stock issued in conjunction with debt",
        "label": "Proceeds Allocated To Common Stock Issued In Conjunction With Debt",
        "documentation": "Proceeds Allocated To Common Stock Issued In Conjunction With Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of debt, net of lender fees",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of business",
        "verboseLabel": "Cash purchase price",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from share-based compensation activity",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds allocated to warrants issued in conjunction with debt",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLegalSettlements",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from legal settlements",
        "label": "Proceeds from Legal Settlements",
        "documentation": "Cash received for the settlement of litigation during the current period."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from revolving credit facility",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestiture of facility",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property, plant and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ebs_ProductAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ProductAndServiceMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestituresDetails",
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and services sales, net",
        "label": "Product And Service [Member]",
        "documentation": "Product And Service"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Products",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r756",
      "r779",
      "r780"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestituresDetails",
      "http://emergentbiosolutions.com/role/LitigationDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r168",
      "r294",
      "r608",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r744",
      "r751",
      "r754",
      "r756",
      "r779",
      "r780",
      "r842",
      "r844",
      "r845",
      "r848",
      "r851",
      "r951",
      "r955",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1051",
      "r1052",
      "r1139",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestituresDetails",
      "http://emergentbiosolutions.com/role/LitigationDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r168",
      "r294",
      "r608",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r744",
      "r751",
      "r754",
      "r756",
      "r779",
      "r780",
      "r842",
      "r844",
      "r845",
      "r848",
      "r851",
      "r951",
      "r955",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1051",
      "r1052",
      "r1139",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r598"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r137",
      "r140",
      "r141"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r186",
      "r628"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant and Equipment Income Statement Disclosures [Abstract]",
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r598",
      "r618",
      "r628",
      "r841"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r598"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ebs_RSDLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RSDLMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSDL",
        "label": "RSDL [Member]",
        "documentation": "RSDL"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r157",
      "r158",
      "r170",
      "r171",
      "r264",
      "r352",
      "r353",
      "r354",
      "r355",
      "r449",
      "r459",
      "r487",
      "r488",
      "r489",
      "r492",
      "r496",
      "r555",
      "r603",
      "r604",
      "r605",
      "r654",
      "r656",
      "r664",
      "r676",
      "r677",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r770",
      "r778",
      "r794",
      "r797",
      "r799",
      "r800",
      "r834",
      "r835",
      "r836",
      "r837",
      "r844",
      "r854",
      "r1046",
      "r1058",
      "r1111",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockholdersEquityNoteWarrantsorRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r157",
      "r158",
      "r170",
      "r171",
      "r264",
      "r352",
      "r353",
      "r354",
      "r355",
      "r449",
      "r459",
      "r487",
      "r488",
      "r489",
      "r492",
      "r496",
      "r555",
      "r603",
      "r604",
      "r605",
      "r654",
      "r656",
      "r664",
      "r676",
      "r677",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r770",
      "r778",
      "r794",
      "r797",
      "r799",
      "r800",
      "r834",
      "r835",
      "r836",
      "r837",
      "r844",
      "r854",
      "r1046",
      "r1058",
      "r1111",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r878",
      "r888",
      "r920"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on revolving credit facility",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1011",
      "r1013"
     ]
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfMediumTermNotes",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on term loan facility",
        "label": "Repayments of Medium-Term Note",
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "negatedTerseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r741",
      "r752",
      "r753",
      "r765",
      "r1133"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research &amp; development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r879",
      "r889",
      "r921"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r880",
      "r890",
      "r922"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r887",
      "r897",
      "r929"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1010",
      "r1134",
      "r1137"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1010"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges incurred since inception",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "documentation": "Amount of costs incurred to date for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r346",
      "r348",
      "r350"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workforce reduction",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RestructuringAndRelatedCostNumberOfVacantPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RestructuringAndRelatedCostNumberOfVacantPositionsEliminated",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of currently vacant positions eliminated",
        "label": "Restructuring And Related Cost, Number Of Vacant Positions Eliminated",
        "documentation": "Restructuring And Related Cost, Number Of Vacant Positions Eliminated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs",
        "verboseLabel": "Accruals",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r207",
      "r208",
      "r347",
      "r348",
      "r753",
      "r1047"
     ]
    },
    "ebs_RestructuringChargesAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RestructuringChargesAdjusted",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Restructuring costs",
        "label": "Restructuring Charges, Adjusted",
        "documentation": "Restructuring Charges, Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r343",
      "r344",
      "r348",
      "r349",
      "r753"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Impairmentandrestructuringcharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment and restructuring charges",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RestructuringPlanAugust2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RestructuringPlanAugust2023Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Restructuring Plan",
        "label": "Restructuring Plan August 2023 [Member]",
        "documentation": "Restructuring Plan August 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RestructuringPlanAugust2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RestructuringPlanAugust2024Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2024 Restructuring Plan",
        "label": "Restructuring Plan August 2024 [Member]",
        "documentation": "Restructuring Plan August 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RestructuringPlanJanuary2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RestructuringPlanJanuary2023Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2023 Restructuring Plan",
        "label": "Restructuring Plan January 2023 [Member]",
        "documentation": "Restructuring Plan January 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RestructuringPlanMay2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RestructuringPlanMay2024Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2024 Restructuring Plan",
        "label": "Restructuring Plan May 2024 [Member]",
        "documentation": "Restructuring Plan May 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r349"
     ]
    },
    "us-gaap_RestructuringReservePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReservePeriodIncreaseDecrease",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring reserve",
        "label": "Restructuring Reserve, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in the accrual for restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r122",
      "r625",
      "r661",
      "r663",
      "r671",
      "r686",
      "r841"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r230",
      "r231",
      "r232",
      "r234",
      "r241",
      "r243",
      "r245",
      "r301",
      "r302",
      "r332",
      "r397",
      "r493",
      "r509",
      "r510",
      "r516",
      "r517",
      "r518",
      "r520",
      "r524",
      "r525",
      "r536",
      "r538",
      "r539",
      "r541",
      "r547",
      "r588",
      "r590",
      "r658",
      "r660",
      "r673",
      "r1172"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/DivestituresDetails",
      "http://emergentbiosolutions.com/role/LitigationDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r262",
      "r270",
      "r271",
      "r285",
      "r291",
      "r294",
      "r296",
      "r297",
      "r443",
      "r444",
      "r445",
      "r608",
      "r752",
      "r756"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r742"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Revenuerecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r445",
      "r448"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RevolverLoanDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RevolverLoanDue2025Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolver Loan Due 2025",
        "label": "Revolver Loan Due 2025 [Member]",
        "documentation": "Revolver Loan Due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RevolvingLoansAfterSeptember302025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RevolvingLoansAfterSeptember302025Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Loans, After September 30, 2025",
        "label": "Revolving Loans, After September 30, 2025 [Member]",
        "documentation": "Revolving Loans, After September 30, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RevolvingLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RevolvingLoansMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Loans",
        "label": "Revolving Loans [Member]",
        "documentation": "Revolving Loans"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_RevolvingLoansUntilSeptember302025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "RevolvingLoansUntilSeptember302025Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Loans, Until September 30, 2025",
        "label": "Revolving Loans, Until September 30, 2025 [Member]",
        "documentation": "Revolving Loans, Until September 30, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ebs_SECEnforcementProceedingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SECEnforcementProceedingMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Enforcement Proceeding",
        "label": "SEC Enforcement Proceeding [Member]",
        "documentation": "SEC Enforcement Proceeding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SalesBasedMilestonesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Based Milestones",
        "label": "Sales-Based Milestones [Member]",
        "documentation": "Sales-Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r952"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r177",
      "r179",
      "r246",
      "r460",
      "r949"
     ]
    },
    "ebs_ScheduleOfAccountsReceivableNetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ScheduleOfAccountsReceivableNetTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "label": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "documentation": "Schedule Of Accounts Receivable, Net [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of assets and liabilities held for sale",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r16",
      "r19",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r62",
      "r63",
      "r64",
      "r111",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Earnings per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r325",
      "r327",
      "r328",
      "r330",
      "r609",
      "r741",
      "r745",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r1036"
     ]
    },
    "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofImpairmentofLongLivedAssetsHeldandUsedbyAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "label": "Impaired Long-Lived Asset, Held and Used [Table]",
        "documentation": "Disclosure of information about impairment of long-lived asset held and used. Includes, but is not limited to, description of impaired long-lived asset, facts and circumstances leading to impairment, amount of impairment loss, income statement caption that includes impairment loss, method of fair value determination, and segment in which impaired long-lived asset is reported."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r598"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesNarrativeDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r113",
      "r114"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r116"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ebs_SecuritiesAndShareholderLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SecuritiesAndShareholderLitigationMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities And Shareholder Litigation",
        "label": "Securities And Shareholder Litigation [Member]",
        "documentation": "Securities And Shareholder Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r262",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r297",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r330",
      "r346",
      "r350",
      "r521",
      "r522",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r762",
      "r765",
      "r766",
      "r771",
      "r846",
      "r1139",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Segmentinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r281",
      "r283",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r761",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r769"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "All other revenues less other costs of revenue",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r283",
      "r284",
      "r291",
      "r765"
     ]
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "negatedTerseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r751",
      "r752",
      "r753",
      "r756",
      "r1001"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SeniorUnsecuredNotesDueAugust2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SeniorUnsecuredNotesDueAugust2028Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails",
      "http://emergentbiosolutions.com/role/DebtSeniorUnsecuredNotesdue2028Details",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Unsecured Notes Due August 2028",
        "label": "Senior Unsecured Notes Due August 2028 [Member]",
        "documentation": "Senior Unsecured Notes Due August 2028"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SeriesIIWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SeriesIIWarrantsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series II Warrants",
        "label": "Series II Warrants [Member]",
        "documentation": "Series II Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SeriesIWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SeriesIWarrantsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series I Warrants",
        "label": "Series I Warrants [Member]",
        "documentation": "Series I Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r756",
      "r779",
      "r780"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award performance period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments other than options, forfeited in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments other than options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted long-term incentive award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants in Period, Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants in Period, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492"
     ]
    },
    "ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of vesting increments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Vesting Increments",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Vesting Increments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490"
     ]
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_ShareRepurchaseProgramExciseTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareRepurchaseProgramExciseTaxPayable",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise tax liability accrued for common stock repurchases",
        "label": "Share Repurchase Program, Excise Tax, Payable",
        "documentation": "Amount of excise tax payable on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested options forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentinformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r180",
      "r262",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r297",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r330",
      "r334",
      "r346",
      "r350",
      "r521",
      "r522",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r762",
      "r765",
      "r766",
      "r771",
      "r846",
      "r1139",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r77",
      "r80",
      "r81",
      "r172",
      "r173",
      "r174",
      "r201",
      "r202",
      "r203",
      "r230",
      "r231",
      "r232",
      "r234",
      "r241",
      "r243",
      "r245",
      "r263",
      "r301",
      "r302",
      "r332",
      "r397",
      "r422",
      "r493",
      "r509",
      "r510",
      "r516",
      "r517",
      "r518",
      "r520",
      "r524",
      "r525",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r590",
      "r599",
      "r631",
      "r658",
      "r659",
      "r660",
      "r673",
      "r722"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r263",
      "r399",
      "r400",
      "r402",
      "r404",
      "r590",
      "r608",
      "r669",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r754",
      "r756",
      "r855",
      "r1171"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r177",
      "r179",
      "r246",
      "r460",
      "r949",
      "r950"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r263",
      "r298",
      "r399",
      "r400",
      "r402",
      "r404",
      "r590",
      "r608",
      "r669",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r754",
      "r756",
      "r855",
      "r1171"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r882",
      "r892",
      "r924"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with debt",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r122",
      "r670",
      "r722",
      "r732"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation activity (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r76",
      "r77",
      "r122",
      "r673",
      "r722",
      "r732",
      "r861"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation activity",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r76",
      "r77",
      "r122"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, authorized, amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining authorized amount",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80",
      "r81",
      "r104",
      "r687",
      "r703",
      "r723",
      "r724",
      "r841",
      "r862",
      "r1011",
      "r1014",
      "r1015",
      "r1030",
      "r1119",
      "r1172"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://emergentbiosolutions.com/role/Sharebasedcompensationandstockholdersequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation and stockholders' equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r535",
      "r546",
      "r725",
      "r726",
      "r733"
     ]
    },
    "ebs_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Agreement",
        "label": "Subscription Agreement [Member]",
        "documentation": "Subscription Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_SujataTyagiDayalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "SujataTyagiDayalMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sujata Tyagi Dayal [Member]",
        "documentation": "Sujata Tyagi Dayal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ebs_TermLoanDue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "TermLoanDue2029Member",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan due 2029",
        "label": "Term Loan Due 2029 [Member]",
        "documentation": "Term Loan Due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "TermLoanMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Term Loan [Member]",
        "documentation": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ebs_TravelHealthBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "TravelHealthBusinessMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DivestituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Travel Health Business",
        "label": "Travel Health Business [Member]",
        "documentation": "Travel Health Business"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares average cost price (in dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "negatedPeriodStartLabel": "Beginning balance (in shares)",
        "negatedPeriodEndLabel": "Ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 7.9 and 5.6 common shares, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r80"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchases of common stock (in shares)",
        "terseLabel": "Treasury stock, shares, acquired (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r77",
      "r122"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchases of common stock",
        "terseLabel": "Repurchases of common stock",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r48",
      "r122"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r343",
      "r344",
      "r348",
      "r349",
      "r753"
     ]
    },
    "ebs_UnallocatedResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "UnallocatedResearchAndDevelopmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D",
        "label": "Unallocated Research And Development [Member]",
        "documentation": "Unallocated Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_UnallocatedSellingGeneralAndAdministrativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "UnallocatedSellingGeneralAndAdministrativeMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/ImpairmentandrestructuringchargesScheduleRestructuringandRelatedCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SG&amp;A",
        "label": "Unallocated Selling, General And Administrative [Member]",
        "documentation": "Unallocated Selling, General And Administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled",
        "label": "Unbilled Contracts Receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ebs_UnitedStatesGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "UnitedStatesGovernmentMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USG",
        "label": "United States Government [Member]",
        "documentation": "United States Government [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_UntilTheSecondAnniversaryOfTheClosingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "UntilTheSecondAnniversaryOfTheClosingDateMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Until The Second Anniversary Of The Closing Date",
        "label": "Until The Second Anniversary Of The Closing Date [Member]",
        "documentation": "Until The Second Anniversary Of The Closing Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r797",
      "r800",
      "r834",
      "r1112"
     ]
    },
    "ebs_ValuationTechniqueBlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "ValuationTechniqueBlackScholesModelMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes Method",
        "label": "Valuation Technique, Black-Scholes Model [Member]",
        "documentation": "Valuation Technique, Black-Scholes Model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r797",
      "r800",
      "r834",
      "r1112"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r1055",
      "r1105"
     ]
    },
    "ebs_VariableRateComponentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "VariableRateComponentAxis",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component [Axis]",
        "label": "Variable Rate Component [Axis]",
        "documentation": "Variable Rate Component"
       }
      }
     },
     "auth_ref": []
    },
    "ebs_VariableRateComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "VariableRateComponentDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component [Domain]",
        "label": "Variable Rate Component [Domain]",
        "documentation": "Variable Rate Component [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtRevolvingLoanAgreementDetails",
      "http://emergentbiosolutions.com/role/DebtTermLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r1055",
      "r1105"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ebs_WarrantLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://emergentbiosolutions.com/20250930",
     "localname": "WarrantLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsScheduleofFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/SharebasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrant Liabilities, Fair Value Disclosure",
        "documentation": "Warrant Liabilities, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueOfCommonStockWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r856",
      "r857",
      "r858",
      "r859"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsLevel3FairValueInputsInTheBlackScholesOptionPricingModelsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average number of shares outstanding-diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r257"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Weighted-average number of shares outstanding-basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r257"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001367644-25-000202-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-25-000202-xbrl.zip
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M1_WX=\PMO5+6VLR.'K]QLKDPNA$_VU#I0KRR]N)QYF7C>YZ<+I.TUY\(6L.
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M,ANDJ(GC<.ZYX,1E7G5D9$17%R87",DZSN5&#7Z$+MX:K6+EYMO<:Z6ETVR
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M $;MT05>1FFPZ-CK@K#\83AW\1\.7*)LZG!,6C:_!N\%]//3;E!Q<?@&*.3
MFVN3#;P^\?>\@T]\^9!@*S;0;RA1H/<8ZA/.3U\+<#R.'%1VSGPZ\R;"Y9V#
MR9_92EWY4HF: 44@>+VQ2HZC4H1O.,'G0)K(,P'2 ;,KRC_LN>+Q!EX*!NO?
MU+]_I'CQ#I_L^F" P<^H^HD&+T0%#M2=6[\L^\52F.'\<KP+&D0G!&:&>AV%
M [B";X>)@?(![>;K$85+%"B>$1B5Y8TPQA&SIYQ*ZQ/WQ@N$O/!XB+)TH6B$
MZV*8.>>=C>H'5#:,?X[ZRC0\#6YQ';V300K*/(P87H.O-BPP,G _Y_/NAT#C
M$9RRA61U MNF<[I8RLO$0)1L0 59,24Z[\UQ@2BC,Q<?9?1?<P-K3D&/F>3E
M BVO;O,I<4ZXY!?UK,S0#*PDS'4^XQ][?VIP'Q#+!#J"$+RLH^,B@ XP33,8
M6'UX"LCE5/+O[0 7N= 1Q9KSPWE1A*?H]( ]X-Z S1P/[AX* 4A8T(OV=!.D
M0+\="'4GMH/2 *J0-U8<[D/,NET%89C::%X1S,YE1(IC6+&1M*FW]O.@O)L)
M86[V (B 1TVCXGM@-C !_E;>XH0:,94%6KNUS&6=% >;E%(;E58+Z8!"ZFM!
MSW$":/RL#"K*&)0;L[C0?/!-S\_!=]_N? 1U:WEJ%\4%/LT *"BZ)F<^JAX&
MGC/SI,YWN:9H)P%,@#&,,,&:>/UW@O?_N/JQ?#\\KL^U#9 H5__X=GWW]><@
M:?JU*HUV) INI3-<>W99KE<: *FM+!18("]5]Y]_4MN-STHF7"_U/O0M=\+(
MJ_(WL%-8 =37'9L-@4D?^G_K?[R ?_]S_@QZ@.H?T76ESX8]=T"J/4,&^KC_
MMW:WVH4;K_H_:C#.7)(_(^HK'P93T)$S^U7YX#' (!\#5EQ G/=,@>I7=_]5
MKJHM2=@XA W(J=Q,IW/ ]7?3'L[A1@A$01N!+0<87RA_S.$K<//-]YN_?012
M?^D_Y9+,F:F/+[8+5'6FX -"/&R_ H'_ $<-;(;);4/_XLO%U<77B^N+;Q??
M/Y8_X/X@BW)2&_83:IY<TCLS6.]2UT#0ZR&QQB1GY'SZD1DIP5.;/QM3,BS_
M>_'+_(AQQB=P5YZN?WRY_I]^\G1L'D7&IKA*8-TYY]G'%VJ:^&>HYZ=#(&7:
ML\#SV^'UK2:SY>5+G_XXG_Y-'G1*J>NE6>SIU'"]' Q<_Q=OA[G@217X:>:G
M!T#!@\>R]-F)-<< T4N3KM*TGR7W3L,]BXYM3$U#F*9[O:I!EB 2VPRP& 1B
MIFF_E&UK32@Q.,/706"U#*B\,'\"#A(FE'B>!>["3*,R]"_!F"1[TPRX41 I
MXVL;&[$W2J(QG1%OK8=X:7]#6THH!0^,YV%YJUHON0<,]U.?3K!%^Z[_>-6_
MRZ%]R\Q3 )FR7VWPMOZXNOVHW!$'SP.9,>*Q!#,A9>!;V3=ADL!Q";Q&T>)K
MEB'1?HT90$4O^Z,9\?]]%L2B^*NY7C+==PP"BX&KU#QQ#Q9F/?6&EUQCFA%^
M_,5ROM@UHYHQPARSO_Z#,H #1+_3!&E@!I7.2;KIXE6F>!T\N(3 .32?@2M)
M&?<QI[CR!?^_[F!RC 5+?F/;UM\XF3-\FZ'Y*_%>/0.CXSEPVF;KJSZ2SZ=W
M0G'5#+W-.>-\60\IUD) S\DQP;'Q*Q"]H@HZ,^U%$!=J!!P=[_VX0!1X,6N^
MT28LUE[/:TD,&R;\O,2)I\WHJ^%P??!E[>>E>I-X.1%>D/>XQLJH,1W.F>-%
M*1B.,/*R7#KT&#<C2TCX'%-&%$:Z7/?>8"6PP@9\2%:FJN+9ZB2D&?46^M;6
M PV+%T?Y2C@HE3.8LBR1648QUD;=EV3:B>3/ =8XHX6OA_TSKI:E;^:JNM"A
MKFMZTDG&C 8+\T'UXS9#1]ZJ_OK-FUXB+@P[7IV%8YO/=*FW5U^]D+C(3"^#
M%[98>?E^/@\+FX#CJXI+#80=_NYN%N-\,#YRMF$65S%MF!U89^_=GO4EBH:U
M<&M8NE"\8S;[\S$P*SAWN!'4>^ 8KF!,Q%KP0B;%Q*I6YBM_"#@H]R;PSQEA
M[L(K=L+:3ACN_1]]I3^FEK90;F^OO*I8?6I8!J\NY8?^C/D0/AC^P!E]!DCB
M=/UQ1A[_\LCG]Z?@UWJ!C P=0S<(N*O@ 3'[A2?.XT[P[]0$&_F-L+%] 2&T
MG_OK.XZM&;X@X?*\-TE\ ";JS[1>Z;2;_R=HW_33<K"V&.;A'8>*Y6 PAX[R
M 8?D5U^$WQL49$@1/56V/HB8B ZBARXW5D4RBTLE/]B$YZ/6A)7Q\O5 B'GI
M#9WQ<J^@,'%U[UH5)GZ"(P\4 DS*HDSR^-0\=N:CD:$9O.B2.!-E9-HO*\=W
MM=K"N4H6_"KJ%JS;0W;J= BB/X086;'@29X_MM8J]R5'3\11SR5&XF_L<UCC
M(%HGWZ]>9DZ69<_(1ZI+5RCMN&;EQ7))FG MR3,30PQ69T"!"7$H+I:-&9E*
M;J3*C9 247^5$K0A!"WH>O'=++C<B7$(KZ'W7+6UA""9NQ/;WSC%%S=!Z*:&
MNQZQOOE2X*8%I0G+M=$90Q<(Y/FG97"WS^5#^(9)2L3)5S8?*_TU)Q,"F:!Z
M]=O7_K)ZU5N@XR;9&]R_ W^-K^2!V#LSVXNKUX<&4UT;]'+&]MP%;]+;R+0Q
ML-WP/.M=N/7=NW#EAMHH&VH346[[EL'.4>N]\1I6&XVHO[L' VUJT9'A+K?0
MX+)^H!YY8:NI3. Y</F6;@:\Z@OA^[TLB-H8*+6+K4>YZGKPU>LR[@4E^ 7>
M94QM1LM79 K<Y&^S&5$>P#Q.B4;G?$49-WCB?C;<+>5M]@1MMA[HPG="'[NR
MX<Y;5Z\L-27>%JC*S8$^#K[>RF7UZ'4+CY3P/:7*X!=P\BOE.[= 9WF6Z=;&
M/SYRACY]Q[IHC"/]-$(X!P?7CU^V./C!3^?#A\S%Q3)? +<N#5Z0,%Q'W I8
M7\CBV8#IZHA!/W[1Z)OUG24F8;B#A86U+V^&'.#'__7@U(3TR([633Q&7=\D
MS1&PN:>:0Y-[,-*-3M.-=N::QH/-T;+*TUM 77J=:^ZH]7:U'9=A.=>#HSR"
MO?F2::?*'01;^I'Z1./Y=IZI)Y:!W0?6NR@L(Q4[-%;BX4^P^,-#7,H5-U:%
M0H2$JZZ2K2=B*W%YT8&O&'F\R2NN1P8H4@A1'=NRJ"G9<2IV^.ET<Z%X"QQ>
M\0&S72Q4P)LQS\[]G+F7$@ >P:,,OR,M6!9NQVC.B]+770Z\>\OM6!8^$U"2
MDE>G2J%JBR%H,:]I$4:2&C=D6P4!7BL,OT< -J,(4F(4K1UZ+A?>$A>;S_PN
M/\0P>5,@[LR )$X-9QE5K#?T<!:.2Z>.U];$7MVS#(QQ3=7B:Z^K:C2L4\1]
M$7Z?)(/I_#9T4Q%-,;H]2#@E4$S*URBU935IT$(HI+5+T/7I@L<C%O>'P'LU
M7+X&RMTFO[\,Z 2+ KRPX&QMUXR_#&J-8[3TR*1=!PZ<CFW>+H-Z^WC<"?KM
M"Z]3#[9"(:9Y$:2(=G;PB-R]XVU_&;XZ_%XGE0K$YDO:!EW'/%'WJC'7V][@
M>+$WD==TQVLL@!U;?,F%0;_0M:X\?BLJO&6("B<8K#\U C/0O-9$Z^AY=[C8
M1FM"+84^$W/N5;SP5E[O-"=9K!H":4 10_?4A1-TV<&,R:JQ##&Q&&196.-X
M7K?C)?%-P**?NU@_&_=M:Z<?RZ9@>$%M?W;X.2USWM.)D[4/,%XX!C=VWY:+
M^E=!A1>_YW%5NW>_7'Y<[Q?E?^VO<UQ$=OU*&;C^5[X?T/OWVODP2G]H ^9^
M\!A2P?$'+^-+S?LZZ6WL%UW9 S_H05_87S0-"KWQ#0!Y XFVI.?@^JK"92N
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M;H&Z($B\BX_W=S,\.P'??(/X'8F>R-!O8X^8J@"=;L^D3>57PYR[5#^F,K1
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M-J$H+<!/;>P-ZR:Q!T5,NUI)[& '7.PY/D^)ZS+#"FKI;_U>/#*6C!KA2)Z
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M?_NT+4CY\K[95F0GB)?_*)1$4JHLC%]L?OUOYMA9 F78FN!7*8ERR"%C1RG
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M28.,MO:_RAE/#TL&!P[3M)^!% I_&5=9._:3,6>*!U_.[-7:MM"-H=@+1;=
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MU'3J"YO;I6X]HM$<.]0<TY9VKVK3I'0&W2F.:@7/-^7PF?)*N+!X^)LLH.[
MZ1]PT/IBN^[GP,WPV?JH.V@ANUG@'6 H(.T _NW ^'K>)I\$MW5M5)IK.'S5
MG=DRM!KZ9#60U2#?:LBI/#R9U3!L308-&'5"1@,9#2=$9TZ!XJN:"J/61&N/
MY>;CD;UPC+WP#]]B45R2S 4R%^0+I)S2S9.9"SQE:4#F0DV8B,R%6J SI\3L
M-<V%;J<UZ1T_,YW,!7GF0CJ7Z95L!BHCDD^5,Y%H.=5[I[(WNJK4]NPUJSZ*
MUQH=EKHB)AC>6//].2QPP3?;<A*TQ]\'R2NSI67\Y3/W 1>8SF7!1.AJ<UE>
M,[_T@:=%!92)<E)B>6BK#8MC?F(\E>6_W(SD3IZ!QG/9;-.TG_&N&'$P%L :
M<*$?@P@8;HB14ODN:>HV)9=%&[3[W9&<#!2M/>AG?U7Z5KUV5QW(6E5GO/]6
MQ^;%E-6Y,59*I;+4*FE%",4R]D_C,G8BB:M$(O<@PZ]Q+QZW"A1N%ES&>__
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MCBM*XC_75,/+2";LY4U9C!V!,PZW/3"@M'YG9[O8^E0=4+4/ 48*8/+F(^8
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MUTXGAY^<32[D5(-YY\&.Q)/Z4%;R$5NOTEGD7$T[ZK=2YIRTD159@D*#$]-
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MY_J3?X(VQ:.+,].VG9U6?[#UZO]#E'F,AM2^XGM3UQV]AJGK_IY[!$L;:+I
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MON?YK*$3]PE1I9AX.>Q>"HFH^#-F!HXWJ*,?&400"EB[A'%AL5[YM8^X +6
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MQ0(PH=<]X:S-%BQ<<5R]CSP4+Z.DC90<L>P' 0O?X@"$GX5+DV!O1% *NR8
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M=4NSW!]2_T$R%)Q+CL/F('/I@Z'8SXR'!,V;[*BR6K2H6:%%XN7LY,P*SV>
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M4P& \1<(S@R._:PC<IMG,E(9&!%=<#8N%ON%]79Q^[*77$82:5Q%K(^ +NY
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M;7;6OX%PQM:R>B^?P=[G)'>KEUGNR,HLQ#BL[MI_HFUX+W?J^7AXWJJSF(-
M&BRADNJFFB!8,;6KGE/'JQKNYP7W',N\&-Q'"/?^_A6FJQ48J?J^]'=A(.[4
M7_7LJV/GR'-)O. D?(CQ5(B/ >+EY0/4-=0K@I(<,5@0)?TVH63O6JX5+)1>
M83EX5<0]>?8]J-^5*"0#RGZUG<^V/_%FOIGTTZ9R@@J<D"(NWY^@ZEMC91M1
MN0=6.HW+=HJM='2LE*DWJMTJ",RMXSQTS&C'K$;A\E^O)O;&LV[WHTIE14:9
MNTM:Q.\Z^_AA'_OP]<;[>U5*7*A74MYKSJPY\X!F3V'.[ %G]GLGSYD9:6_1
MLV^GEV;P!]8,,RP/_E.H]D:^M22+,#@L=G"0P906E-2B/3TY[ E^E=5@,/F)
M/\$QW)^*!C\QAR&H"F)8,A&7BL*\8!:.]62)4B28B6/,,%-$) %1T:"E!E?[
MCC)C>.K343#MP/=D49(%?*O-9C!ZND@^'NX#Q=/$*A6F*;_,3J1H*7^$\XJF
M=5V('..E8S_#7$0YFW1R80:0%DZ"%Y.#WWB"W$1S#7X0]84%M3,4K!5CPSQ=
M'XM=</IJ3TSF;X0C=.5!S*;RT[)?8![A54FZ_5F9&L[47[@>G=VDU\X-^-)!
MP$NBX+!P*H[!)!!< U"G.>&36DJ6FAB44ML*26L8$G@!4O ;<,'$J%K*+2XD
MK\(1&1ZN]+/FK#B:<#WE@N$@/85I'*KB=#*F737Q!9J.3+CU4'F=JED &IGQ
M)5^V7B$N-?L5):(QZ:G]21NX<=#5>[H^GF@C;:@RM3/2>H/N9/!_([!XMCE6
M'JN)B=(C7@$S)U^SSL;-S,8=G4LV;DGP.6*2H=IK<:4@^;/8:?IO6 J4W2Y%
M":%O3 ,F3LD5[/=3#L[W^\F#\_P)RF['W>F!IZ@>1"L[&5Q&FT19$I6V)"]\
M2-2A#V<SK#G:5.[_4ULL/W[&S4QF.^.&$Z^%%GX9+P^H,U[=%&XR9J29A$76
M<"0:?R6>W#% <E.]-M@BU@>$A2RB6;NDXEW8LPL?[Z7L2!I4)'&WM4.R:H@Z
M>.NU[6:FIO;/(37UD4I"+):V11LW;/A\+7#GM.#?%^8@<46:J?MA3<T_FU33
MKMH:#(?E9'7V6[U.L4<=(=6THH-2^^E?O?*@>L=/RAV?4W+IX]R!?>6[347&
MOR2+C!\L1?>LJ/@#*[5O2<372A2/^&C:6!M_RY3?BE%ZW[3Q;:CPYBF\6SF8
M&J<U3E\3IV_V),2: 48E?NNC$/7(ZN,C6>EI"W1,_SMHXI+BH*C/EIQWLKV:
MDPD1=V+>XUMN9W]W&2\.&L'/%^Y_28W!#C&+JBHI^/6)DYH)UID@)^F@%"88
M(1,D*Y373% %M-1,D%='JA0>P*,J]='#F@<JRP,YC;_+8()!&\NI584)WLB!
MQ!OJ#(=%:"SA'$CKIE"?4MS9,L"X<RK:551[LMK5U8<33Q4<A33F3'!T:G"<
M(SA*P487L5&5\ZHU-EY%P\H$1Z]*X"C36ZR.JZ!$9>1(V)YFKN?=492EJ-:Z
M\13%VD&*C:&Y\S.JRB/-><B+'"UTLYCHER(FREZ9BCHK:J:LF;(<[7\S4PZ0
M*<<U4]9,63/E\:RNS3PY+*7%0\V3-4_6/%G VMW,E*/&9?<\F/(L3Z^GI1OR
M0U]KG8*CAY5$YP9<<_QSZ=BZC[7R+5A!YCSCX37%!22XT>[:37F;.-4FVSO(
M,T]XM[CBX7>ZY&K]DJ 3!)UP^[.;U1/BP8-_%G*T8HIPP2X'T["+ D7&W$@7
M88.Y_'ADUBFUP?@,3JD]^,NE27343'E*7G&QSX9B6+QK",H..N?,NS>+DXW(
MX\_\O"(>- S/L9W?";9>MS4<%#LTE7D$:M@:5^^P6$4[.'0&ASTL5H).(_:L
M@@GS6S@Q^:!@2[:Y7/L TV .7B4/69=QY./5*+!M;VA3<]V@#$C=?:+NVG$X
MNM5=.[92'K=(O7]3](F][\)ETPOCU\7<T$&G^X!:XK"]Q34JT)E:I*T1-/Y/
MW>J];O5>DKV_SV&*-!? L-.X'):6(',.=2-K]CEC]MGG&$8J^V!95G7_0Q<'
MYQ^A!LD12 +VN3%?8IWP^O[B]Y]J,_L=-=%(8G1SO9-P&3I3Q<F1JU3VMKBF
M+Q7/E-Z\KZN%GO=F>7Y;8B&-,MF@.F5/'. 9K*P>U">85ULC_KP07T@)W KQ
ME-Q0EA)8D63AJ@)X@S:QTU9W6K//50Q&6UPSELI#N4K#-NKQV;41.OQ6^\.V
MIMFR9]1N7 Y*R^&H0&Y4#97=]Z@<J*B-RW%E"D2<W;G@(D=:]MVT2BI85;M)
M:S=I>1M5JLRA^,+>N?AU?*$R.*H9I_1M.Y5Q,++0V;^F61U9..+]$2JO-^XZ
MI:&=33PB725;;Z.Q5P77UZXY6KG[S]S]] ?]@8GW,"!L6N8P[# 7JO;8V$5Y
MMV*:XR::^)Z2+-NP'E7<GM-/"G0W[\!R,:_X6M[+I:0O'V$AU8;"<^G_NV'
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M(> VIJ"$<0P@ '^XK(B3T%D\Z@2,[]M&>UECD'1S+1Y\[6%1E:7M&E2 @DK
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M CW?Y:ASF7@1=AF1,6_/%DT\@S='L-D,"8EQ$-^9"M_MPH;=!DOK^?J36,!
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MW.CP2<7:UV7M+7(6H^T9U\%M\U>IC;?(5]A%6A7'G'.'GK/P72 '+M//):/
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ME(Z)/!@GG(<BN//DL_LT9.[;_%JXJ-<NPS6?1&G=@'SED7ER\18J'!K >N,
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M"N,++6M8:5C1.YPJ,ZT9#/)J19TU0(DU*J-MM)-4O*_<5@HB@,LVMYO88%4
ME4U&!&K)Y1W677CMH/B@JBA8XSCY)A4%&ZRXWE,+!"D3XZQK!N@)% /-(''1
MX2QBQPT@^GMT;F"C/Z+I1<E^T@?O8%-%T$VQ>]UDPOSF :;]+1Z*O,J[-&4P
MPS^PU@=H+)8-F@[2<4##T*'"[6_:LZ!P/M:N"/6&)1$-T3*)M^_S_!E3E$#Y
MP$H4/"/ 9WFT :NZ^@W^Q!,PL@< >E;*X2,T7O\U\<V)CV.9 W8OC*\=M]4B
MK%\N[\6([5:$#IB\P14BCES6%+1<AUFC$]/V661A2DT>X@#6*.UBH@\X9VZG
M71[QKWS=5F;=V+O0R:S83"_BD88O>%%M#8BG;P>D-[H&I&S6N*;H^'EL D0K
MVNPB0P+/^J]HC*<FFEI2IE("IH ,F9KN$Q4="*61'I=>C(4.V-E&WLYN%;A-
MDKY1Z)&=F_:83P;;B'P6^L)")QCDX8D=^-8D<L?IIH+%ZGC:^D$5W!\+TRMU
M^NQLXB_A6VA)H:^!VRL!:NS8]RDT?Q:H[7PX5I]LR=:6(G<SFVAR#P8;2TV1
MA;&8UIZJ$/Y,96Z(F#I(]/<UC( 5W4.)S"!6&1UK9W0,ZI[1T8!0F;R$L!@9
M_UUX51H@^F],WYH*A_FH2.5/_ _I_%/DYHOGLK(37)PQ@/G+KR[RH5P&NKQ<
M(YXFF;D7(0O_,_XEAS(^;1++#*:8D<Y]L:!%6'0Q4>)=MY_STTA_F!VD\P5X
M_S44IZS$F?@FJZ$6A"(I[7LJ^UV>2+(JTV)I!?RP3+P(P84=9AN(3I9!X%G<
M"\@$'8L8+9QDDC!QC9>]>2O!U%4ZGZ)%Q1,3$D]!@ IK_MSC!D<L!\*<P\R8
MML$E= P4Y-^3B#61>_*]%W:Y$%OS 7K.;"MI."HL-&'_%EP+%"=1K73J"<IG
M;& 8]_P]K:A_XG;L 5RD[M$4]D5BW3=EFWQ%K<AQ@RF0(\/E[Y[WETGNS5<L
M_F!S37OF24Q>="U\9KX>8 S<") *3OPS8%J<[!10^H,7^RZV$$#?#NUYJJ%+
M2@$4%0K9_3[!4^:1R&U.FYSP/UOT W;,ER!"%LSW <N'[6MLE_"'GK3NE49)
M O-L)]^"%](WB(%)?*83T.8PU9C,$(5X%V]>Q(^IK:C.P[)!#<^'O3)&1CJ[
MH+>@E#NLL3$W6\[CD-V$4MF3ENNZ?(YT7"2U[@OV--G?-YX#F!%JFT,X_5'V
M>JJ]<Q#)D ["B5E=JY A+#[X]LZ=/OIZ3I\C.9N2E(Q^5N]8;;HN.3U&1IA=
M/DOEYR]88-1^%K)Y 7&0BA(_"#>P\0( 2U%$>RJ3).<+U'2QQMD,]CH-A-63
MS-'M%.E3L1V(6399I42R F;%26I:7"A&<+*IJ#NQ\4J$?!H<B^$B$MDNWN>0
M>B4@'&#DK"D",W.Q=ZF+G_%_INA[*)L  S['+AM,@TN5>F5J:')<\&HT1P1^
MURMRMA0ZZ[P9D!%W)V:8[4J Q$S88VW%'ND$KYRD]BC<8OTV^;P;\HU"T)=Q
MR^^&[5%V9S@A"K=A]F=VT3]>N-;6%D?I[6[V1R;W@[Q'QPR9VQ3]0T\I6^?=
MH#T<\*\/VIT.5DKD$[1XO&7,8\$R)488)#\M&P6Y^3/_'=9[&J9]ZR00!=YU
MC;:>V\^S:3O,?Y7=.-]2*H%F)6 ;S&'NJ6L#KO[A<FMMS(VDY C*7$"I))=!
MF<M9!DN=S'()B3V '*A("C:QZ)/-(D_AF3'[CR6<\"!A[ 8(L-(YZLIH^[OT
MR9-7/I);OP&R"W;Q[@7(8%ON "B,3N%W_?:(R TD,0V6W1.O;1D#7+)%5$K?
M+? 4-+W-8)JN]#;AJ3GN>$';D(D?!#WSR"D!0V!$9 =3*=IS[I(\DRK%$O3N
M HM;PA*D7P.-^L+=%W !>_Q_?[$?@9(?.X!]_>[8&(]'C^;0'&A4TX>FT>\^
M]O]_K=/]I9KWSGZ_OKVXO;R^^$J^?;^ZNWBX_G9[3[[]>77WY_75/YO+].[$
M[=:Z\[9_RLXB(2WH$AY?XHU+<*1]IG&K8MD2C+$IV#BLD*A>NMNTDT^<N5AH
M),DMP<HG^::VIO">.F3."Z?(^/[8?D),E\.QNN<CG L-LC?!.&#GT]? AD^X
MYSR.R;M;H..;<6/N"L!^M)9OST6>7,&'6QCCQ0I38XI%R&:\?F=R;XVZ+".3
MNU#P!@H;@RN,7#M\/1>)=JE<4I8W*3WPYB,*61[.X9ODE\TGHNY5,F5JBS7.
MFSF6+Z,8&44" B#A(^493"%]\LU0YD!@+\%,1IE+0TS";0ENP,VM&H+A6&4^
M2)H]I_HM)'PYSA*03!EAP-7'I"OCF[T:N5^))?^EFIQ(K^L?]U]2SD&>1L$R
MC!,-U9>?_I(,/T_WE91+D.(AI3Y&?O*2=%DF]]AO93"-U>.:VZR,(HE#;%AG
M > JDFQG>+N-<3S&&F?41(=ND-(JL3 &>X45GK0QCP68A2CNCYQHBN$A\7R,
M.ELKJ4PJ]%'.<N*9Y$>#"&]%Q8=Y_^7M[7+C$0MCG.-R6UA@9 ;_^4G'Y]P<
M%D#CR36>J)<1.\2<N&ZF&[%D]=+>K*HJ)2RW/D9]V92483N>8%Q=159$D6(,
M'WZRO3A&B%4X)AYH[2DV%B=SX\N Q:#)@^F ">FI6S,\5S,==[3=B6_*='3
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M VJ3NF/Y/2#.+W=T#OR 50&[IT\SY )W-(B<,/B%X1BL"'9L,L0"\6A% 39
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M,3$#XM-GZD;P)8?"6WBC%6NI!";\DYCNF-BK"GZVLY//J6]1>/^)+GXGX_H
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MH:0*S/(4F\F.$BN?1Z^',K\TE2NS3:J:@UZ";-PZW0$6_>[V3^0#D@,R!W[
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M.FQ'(5@-$*S\A8GJ(%ASY5J9"Q,-D&9OV)VR9X_KN70YZJBWJO.6 FC#WE(
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M4BW/L0_Q8*),L_VY*6, G +!;+$U8=6@9S:%60COC4=QI'/U&2-9REC5R*I
M6C?<!+&GN-RF,)$8P>?7YW:HF#>Y@/-KPQ]HVS:Q63,IU:)7,1;\CGB=SIJI
M3J=J75;A[2+,EDX@FFD3S*7>B7X^MPW+(\[2:OYEY[>O3@803A/-=QS\T3-3
M'9R*8>L*^ZF9OLZB(2KB0BL3./ ''X+FDH&V@,%^376GB@$3CH6U4O(]:(Q&
M8@R1TK0\#P0?JI9KBOC]'MPNAXU3WV P(#W:K"R)4*_Q2!&;SB"W6HQ-1]A4
M/=7K5._(V'2EM4SYMI <TAF&LL(]+GTD16#Z577Q0IG;4UPZU*-!F!7A_LUU
MY"(N7<2EB[ATBNAM)"T$[O:2HA=LRO+9:XA>8?=3$%7>SO"R140O$#4/6X@G
M<FSI'C0I!_<2392'\K ,MI +- L7.EW><!?0,24*9",:]YK" $<K\@**O( ]
MY@5$'4D)*4!2HEH54N*L)9'A]R0D%L(B@OGG,QQR**4WKLYR64JW=S,Y4&0(
M9"5#(&?^JR+"'(LPMZJ)Y*FXJEUMM)=YY=?GHNL$EW<-[94D7YCZGFX_6;*"
M$0]5!44&1\#9@T)R[]@C8Z(Z>L$VUB6E4VG[\#A!Q%-YSLR)X<^4J^[W;W>!
MD:[.,3X ZIE0%8LMWUQ0@A8N;D2Z')3:1W[=F0=/E.8LY5T$7:N-AFSN'M.6
MVX%3I=;<35_>,/):38^\-MM_V?"]?4M!?4.6%>.#T:D(8U88B M2Q161470"
M&2ZHGC@Y=00F)C<^8Q: "0MBH>1".Q0N93Q=Y-$V?3Q6"@RJ()\>00G!F*T4
MP3/CI\*/$]XTLQVF3)GZB (Q-"GDSLDYQG)A4)P!"89QWSD6;-N^"T,$P>8P
M8DLU^>[!8].URD(JV_+@= 17 %^T!K8 O:.R0.++HMSMQ&3>792[>WVMW-Y_
MZPV40>^/WLU#;YCW%66\OCSCGJ,A<QX-C>7>9R37$3HQ(T(P62C"16!@ZNPC
M_VB%UTCU/,<8^03C@&],%/8*9D_,R$L-?5VH,]C9B,D#8^,4N=!#\2/U;?D3
M_.X<3GN5)V6=]P)7Y"SRGX9E&7,VD6\P)(!*;,UCWR'77?@JT%)=>3*F*,07
MY\,=$A&3-,G%HX*!Y!),SV12L*AB/#PL-?8>Z4>2)J-81F3[4O;$ @J,31#E
MF0W2QI/L@MPE8LCD=CP7A13K%E*TCZ^0(N,L_D+&7(2G"ZY#[ME]?$T36E-P
M<Z/)7.6F$F7ZS4:0QK6O$HIU2YV#B!6P/@;6@^K&)$&$V3W9S@^1W8$3ZHU
M*59S9>???S^4C0]2#:AAEGL]/8/9J!EG<^]"DZUWTF*?+>G,Z2S8MWN+?2:U
M6!ST0W.!BZK.R/#XX2B@6GD<!8X3Z#]4RW79@EXW#'_6G0#OQ;\294#A#L2U
M5J[>Q;3CM$6DZ'L4&4B,AXAWI-HF%.*_OJ0*!TEK>U)1CSE5X3UK(^GI;;*J
MLY;TU.YZ>0N58I\J1;K=B+OY!,1W2L%'3#Q"'$NR@E'A@]W7@0Y,>\[A6BU8
M.:TY+?I@Z'\_,49P*4<5F$FKKC=TO3-2S]1VE55K9VJC51^U_E.MUD[RJ]=<
M]6^Z-Q?][K5R<7MSV;_OW]Z4E.O^[P]]^(]_*]V;2^6B>]>_AQ\,>L/;A\'%
M1A[*3+*'6R")T'FMV9:(6ABNXOHSE*]_<A!;GJCF?MEIP8@F3T(Z<"40B#QB
MNJISEWV1?WS5#7=NJL]?#(NF3 ]]C;\AY4;2"_G7H<%=KG"C6T"RBC>+K\OP
MU>?%SQOM<J?63OVJ4JZF?KYLJ&JSW&RU-AIJ^>?U9G-?DVILN+XWF52SG?Z5
M'&KC?G."76S='R/Q? IFK_!>;=!%1/3<V.PZ=\KUM7A83/ANU5+DW6W9)=/$
MCE4SL6,O]&'8:>LW;>JZU<:'HH<&^V)X\")M#6'T44?^S]&WA9[I?MK'D62?
M"$%-;F:!^'*Q4XUBI];9J0O*6%!V;-FZ:5OAP_>07J+=!UHN98-$--E7[RJ_
MR<B[/G\4,]M37V'>]:Z3!9I<XIS!3"-J6H)_L/_YQJ-JLJC7:<TV>$?:S3UM
M=9GMX%=K-,M;=C%\J\[L*]H%%A26?0KK='),8,'S:[0US5?OTFJC?8!3.7"'
MTFWUR+R)Z %FZQH:%9J D%ZJ-*ZBZI2E9Y^JZ^5-J7K%";\&K]F36KK"?,G4
M>;3*U5TLEJU9<BZ)]V.]L^ X>E6ZS1LW3I= :S/A2-PG%LJK5PX1Q+JW$78!
MV7-IP9(B\\I9PL3#KGV;M1I?X0$Y/MUXS75G]J;4&AU91?8Z2\^HQ5;0:S[I
MM5IIRF2;HZ+7(S8 ZUN>UQ&H'(E:DFJ#%( #Z?#%\_MUH!]>)J3'<LYMQ[&?
M8*);1G'6X5+O\?D7R$9F95FVQ9:_+B^_>B\>K$LV\DJ*Q0AFP+=$%3QE?XX\
MQ7!='UN9\T+T]^/>:K7JLO(VSPZNHSR7(W \'MVY4.5U[>L!3B8;>NY><A'J
MF="I5CG11H%F]4IF=^%NR!BU;R,(\^!N*.CU>.EURWA[INGU>-UCVZD.A8LL
MVRZFO#]_Y"ZR?]K.#\*74^=8?U'XR=[03W8TKJ,+ ;?(,^9WL?J.2(]*6UUF
M!5+[+&C F$-W2D%AV:>P9N>L<-AE\%SJA_!N9T/A/OZZ(2&738/W(#+8=I&;
M7)J3U7JK*(/(XKFT:N5&<2Z9.Y>/U=;ZN=#'XW79BW&6_8#-4]S.WU3:OSLO
M^&;KSBS)MYJ5C9GMII7\6;3X"GK-)[TV0&FK'R&]'J_]V#B$VRC;JL/A<Q;?
M,/_Q\!/<^V(_$XY@AOI%TF#KXF.M0JZ]<PQ+,^:@#PYMW]%X&](+KA(J ^;R
M#_,.5OE/IDS51_@?P_5L![F'^2S0*YG.T4WG##='-%\6.K'"?LX9 EOZ#G6)
M JXUF88]H+5E("RBF)!:38N!;0L^C:*F!DVC0WC=6/_G,)]*0-P^J@[VQ5(T
MA\&,%%6B2L.X<(2F3T_B4NZ9,U.N;=C@ 'F:1N0 KK@Y=,ABG">Q-<Q%&C?<
M*6P([Y$->R_ _EE9@1U43==6; V6!JOAB+$C3S4L"0,*KP^::\O^+3@?S9[-
M$#C;L[4?BC^WK5BS;?ZQ:+%=5KHTM_3>!,T2GZT..Y(HS$P]!MZJ*P17B;;'
M$GVX89;!1N.IJYKHR^W/14>%!3#P$'!XP!YM\Q&?O.![&>SWPCJ4< D1#&YE
MQ$P#:$*T]#:P+W1X"TT#EJ)3<Y?P@"GU.ECL&)%58W2&U!- ?I<4U8%STV%/
M5(\.$RF,WA.2)4?R]@C6FR.$6W!?%>^)F8\!0'-PL$'6-V_.XS*"?F662_TT
M+=*Q")\YQ(8%PO(XI18-9=8-C9P=7T.9;,M!O)O*<(KW9<#F< >G"#A^QU&R
M\R[^;BWL JU-!3>MIK$BU;) )T=Q&/"B<UMU=+SHEX;#-!"<+C%?U?>F-H=W
MQ@&<<+M"OKG80T$T\TJVXXH)AX_X"_RJ5OFZ\D#H-]6OGQ0<V $V.L;6DY$U
MUMJTQE8Y\K ;8=TK1U=F*K)F^$=GB[(0WXE#  >UL,GD#ZR/<7C3,Y \'O;4
MM-C$]GB;+1#REJMJ0KPAG+WHGD-2: 9[3N4U> 0NSL>-;"@VBC!-G(K.X$+"
M8_"1P&=/;B30![ #$O8C>A2QN.$0&;::##I7BOD&<-UN1#,8JW3&46F#+Q*/
MP.("KK_T%&D!)7A$<VRX9I8],S2%68^&8UL)/03[4[H>?6C/Y[;C^9:062A&
M0,,*.FRDO=" G]!9.BI-= YR1Q-M,M8Z6]=WY[SK )P=-DN%2V18/D*6>W08
M7.W!\?K6V.0;. @Z;W<U3S23KT6[T#-+)94$?^%/X/XKU59)_,J8@93"\;%5
MJ,Y'0OVC^A=L1(K:D*?^E,2%15=!CU -+%[4L_@E<2($311*O%^)@A'3&\M*
M+QQ6U30'%Z?SWJ%A2R@\D#4Z,31I>1\JVS4-S213O-QV*^)\T_<,DWCAAS.9
M+Q/5,S]4FXGF-LA'(CPSV;*>GJHENS?*FP7_,V>HWP&7*7%2!5465#GL.RQO
MZ(=V^:S-W]XN5RK8[I8/4!(M;TG9A2L+RES  T(:3+YG76469<.'>B/9>#G4
MM.,+%]QN39Z\4_>8;*L>0V9AY\L'T*$U'QM?W=A>= OR?M%(^WCF1-&.$DZ*
M?I'0+21IQ2E'Z!AUT#&4@,HF8'M-T,J9!QZ-4+JFB9"TQBM+PYIOL$VI9."F
MS?(-)L,EG]Q^E)DN8S^H3[@4UJXG_"@^LHVI$1R>ESPO5$/25X=:4U2/"B1;
MZ65E"@4WJ1)/P+> 1Z$"Y8,<CLI'4I]TAI*>>QZPNSBP(V2 "ZI0B;P5@=4-
M \%?CO2Q2'^-#X0EG0_\*74^!Q; NY/@XGCW+%-]6M2MRLH.4N>)Q53##ZUR
M9P?R7W(@Z SXL""RX)@X2%:H&HX9^1<((TNS)Q9O]Z),4%$A%P_Z(GS#G7(5
M;XS;Y-@_C1D_U ])N;=*R@BOSX=:?4%8+A$N* $\<E,M6>@&\N3M^PD1NO,5
M^G;RSON1B_ &0$3U=%+4AUZGRP_4-N.J-5*O$[@PH\ZM]=N%-;GN5*DUUFTV
MU.(%-7GH+-1J@%)7RUYGH4:GL;])G;UJ$Y^,A_;3HZ;!0CO'U&'BA;:NNZ5E
MY;Z;S;ZZV&S5>B-CE+)K?YM7:&MQ7+O;V$L.9(ZZO*1?NANT!5#M$.H).5H_
M^JAI&]:GHN?+/BLDVMDE@]N4,&K14V7IZC*;GM6I;5R]F)V2@H+ LD]@U?K9
MMF"[NU+8/NL4,LR*^Q0A7,V*CS>+MEW?-NVY2&Y^3;G2VOC6[^E8WHD"=A4D
M$^YXZ_-9<E>KE=MO6W175$&^5 79J92;;WXF[T3(]\9CQG-IV$^-MYUU,(S%
M_W8QE+1%>Y:CUPXJ!01Q!D_E<%"W^VY]6\\NQR!''><4QB[,X:5]$;XQ$=J#
M#5%TV\= (?G'WETYZ3YW);,7N-JH[]A!9Z>-R:B[J;@)[^\F-!H[8N6^^44X
M\D+-,##1#>SB==-<,IL>E!IT2ZMDVRP-"';083Q)KM&4=!RDC%&YPEQUJ+Q"
MU!>L,6R#YT3*L5'YL-:>/F;/SQT#C@7V3]$=XY%9^&/?&JN/<-IX/Z3) P,G
ML%FB>7<NG* QAAM@>3"2:3]A<G=8-$C3H5Q%8^2+^CZL8)D[;*X:>K3>@V-S
MEK V !,%L?!$8Z!!X5SP5UBA86&Y+'/+RC<X-282L^;J,R5%*E2@AVF9-F5M
MR2(#JIIU>2G'#/_D*5Y\3/A(9)GS@M)@KGP<+[+%M.&PTXG=D!M%PX^H)H;.
MT60N+#;83LNV3GEIJ(X$+](X[?$85DVOF?(EX2&*:<'.(_T<<:YYZ%-?Q46R
MP0>,%/__UGR@5D^65+PV'TB=?IP/J!XG?9G 2I73X?WF8QH63X3DQ-F(7CHJ
M0AY>7N\[2;Q5;JYQ;"F%NBC63^OEE#Q(K$GC) BGT&Y\34V_?XN$U#"#G!A2
MM%B=:A)4TS-FML-.+]092$;,W$:@Q.<2L#U8$:][YTQ$L M9D9=2]&A$,[/A
M0R (&P@LPD"1XU**"3)"B_&)!>08G5DR@=MSU$=F*E,&,YXJ(]_%PGX7R>)<
M1:P V-8;4+8,#7/I;8TQW5VLSX=O0%S1ZDQ5U.>A'4T8!<E*P&A1?[A/Y^KS
MHP'G(C<*9S!\!@9M,9X?KL(R9=T<6>PIV K!3114#7<$+OHS4YVRLI0;%T7C
M"3S=HFC\;:5I&*LZ1IU<Y+Y%X#WV((>KK7:RN.0U!/'*N2]3QJ.B-WS0]KV8
M (YRQ;#8!M5KP=1%"6^27V.M TS>"4!#2/P@5HN)6"V"?>+\B&FZKJWQHJ>4
M;HM\Y0FV"LL.YDI+3,HK6")I$%*C2&@246@/%;;R*9Q="09T$*)&E/S$JO;Q
MN>4BC&9/KEB8*Q4_E95N4)V#5:Q$(JG[C=O,]%A%5U@NFMS?U67?..OT0LO(
MZ+*4>V'G\'THC$YM4&M.\:_02,ER(1%V\,P[/WH!$2A>@>PJ'UJ=A2HQ>'YL
M_,3Z-* "THU0X:8X(Y$G$2M\_LSK CU1PU>&MS).)%5XGP"FP#T5^!-(\_A^
M7CH'U^@BP,*YB&+A7 58.,, "P>?O0,Z4_HEI0^?*=42U_0,5[D"5@&O//V=
MV.S8=\A>1Y0"GRJVC]A ?; $VD' ">\=X/^NTJ5 ,1[0E4#)&D3J,_-.Y/]D
MI ]K'E*1Q*(( )M0X7:GMN.=$D?&73%M.%/Q7V!G@0PBW(G ]Q3QP:3HVR5.
M]S#91\0,B%>ZXDV:VXB_@10K^'?(@4DZP4_&/@Z5@']9P/L*+(ZP"E!XJ]95
ME!I)(JZW7C[%T\THG6/?*4.P#5%BP#'"7Z<+9UE=.PI<:WT]B(&;N.Z-<HM*
M'%^&K/M:G,:;G89%<#K+3'*\0O MJG;\LIT;MKBHQ2F]X2FM"=;X=;E_HCB3
M?9])_-:$0HI"&72#W*]X1-OJ1\61;'PDJQ!'0X!,_'(3S(5L:FE@=".>)OR_
MY8,MCVBLCN'^X%S!CVNNH?U.UH7@Z)Q&Z?<1"SED--*X1GQ46/V? 7!;1"J
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M4RTI<ANL@8Z\0.QP_#UEI:M,G^>(.DP6=7BM4/(@'B9S4-_'TYO;AN7)2[+
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M#-\#\<MLR/@EEYIP*3V0E83&"6!O%DB+Z1Q&*#+1@ 7Q;A28<Q')AQ&H8V%
M3:0(""PZN(86@L0A"I'(-/(MB304::25'"7H@ %2E1;CP+7#]C?"@S4VO$4\
M=3Y0;.(A99./@KR5\&\T#>[),3QVBG.)][:DJQD>W<2V=0+0"\, (,M!L!K"
M44:7)XI6)E+N C$LHY!,L.D5D4?N45_$.,K#U=E0H JP>O1#B11$P=?GY+E1
MA.?6#;(G(RU1-FAW&GWTE=OC;K0!.S7,?3UM>,-#I/ZNO<%Y:>&(=,</@3N#
M=K# .1::ZN*IV8Y:6FC!F]Y:E@86[%*CQ H?=5CN-DSI.YN'J[,ZUFLIW^&B
M5)MD?-0%*J%J!4DI=[+G%O4UQ,V+PBA&=1C>39<]8J86ZHV69:-YPG68E.NS
M^K[%-)  6/ /]:<VA?/,81_J QF9=&Y_&(\V$%RQ:^ON6DRN)^"=@8UAMI4V
M-7[XUL2WGE7E4=4T;",;8%LJ%]_ZO_VA_'%]QY6J.".![:!$WW/F6)3?Y?W)
M'%,51H.PZ-- Q2.H_O"#(6S)I<$FE#1F&F!G6(9*_@U5-(F7=W?N&#PF^J'6
MKI1KL9Z5&+:GR"AE<(IW:\"@8 ,=N,8Z,BN>JZ_TP\J4(%56=!9/:SH.+_3G
M..R'LX6&Y0E?1725\%BP?<*FA5?,Z8L I9F'JQ^%1JOZH%HY$NA9>!@>RL,R
M?8N)=7/1(YRTXE.>*KYRRO6%*8]DT#;LM&X%>C8\6#"G@CF]R:Y1$V8PZ765
M=ZY'T=TZ!E7D'S[<Q5I%EL]=J*1D*2/#OINJSDQ5KJ\OE(\BZ"2^%1&G3R4L
M1 +-S= -Y%OQBA+EHV=/&-E79-2)9[EF*<8; KM'9ZP<C@(.Y*_$;!A+Z9*Y
M&NA#(3XMC<BU3.Y9Y?8:3Q'#,;G!B.;&^HKK2C:>2"ZO-Q.L2B3 A<FZBLA9
M@K^Z_@2./-CE_%=Q$-W -H1EER"98H=')T%-8I'?K#Y'-#@43FT:\^GVNZ4
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M+.)\$5Y@W7-L9?D<&V7E>_^FIPR[5[W[?RN7_>'%]>WP8? .SB^NM14 1 *
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M=9*\30YB8((Q7XPV[>/P-U]^/%8R;"GU#M;H#5[3&4V/A# 1\RJMG]5[0T/
ME/5 U,0L?*2#K[5CLA',XV9%&QWTJ(FYE/6:T!<738&BE0?EZ:O DP!CF<:D
MR)=.K3OZ[#F)>)<DN+^L.YB=JV6>'53/3^=D#K_!^61V?N&_SGJLE\HG->=]
M521Q%"TZEX,G:SO1XH.WX!QGX"5M99%AD<USS.\!\W&3J+?>.A0J;(#\SW!\
MBAL0NYRX54R"XR07%7T$SRS6T3E&>?K28^OJE?$HOTNBM=):AZ*)2X?LV0OQ
M))%,YF2+,RE0F\C H2!;W)$UYKTBD(&;K)'PEM9;URUP'C=S6NFA0Q7%)6@K
M*J^1U8XWO^'RPXS67H=YT8$,CBD#2CHZF4WQ$(NDG91KSECKS6<(KN^(-"TT
MTR%M^M:S]W?\<_6K:M)KK9#7R7"NIDAF!!^4AJ!H;_2L2"9:Y[0.0_:X&=1!
M.]<YY'L:0]] %I:U(UA05&:T.>9<BTP1&$I/IIPJQN[2_OF^&;2%;FX(ZVT=
M[MUTD56]2G(Q7Y<_PN<WM?TCJ66YG$_BZ;(FX/TQ>T,OPG1Y5+@AY9<Z2Z(0
M_GHO&F3*Y!)DP1BS2H?6=XY;0G[<K-NE/F_@8\M4I\OA;YL5>D(C8JY>9W00
MG*W[+A/D@W+E8VN>#;I^:!))MT&$X+($I54!96KJ6HH6N+(&T9$62OMQ=;='
MTIM&AJW*RH<$,7M7;\-K2I4CBJ$*PDM'X+JZ2]<CPUU*1LZZG89I/IZ$.#FF
MS\7%!SS.939?A&/\/<S/NBD_KS?'Q_<96CGV"0T+0[9:7*-:D+.=[.OU[--P
M7,<)O_N N%RUK%XG\3R?+&H"_RFI^^D7^N;CC"#^;3X[_;B@CSB;D%'_YJQS
M"^9OC5N^W?CRF+GGTD$I-9+."D+ HB#;I'D.'%WNT_%D)\MKTR>F)]2S-'^I
MI%?,T';H ^WZ6M.NSXV&:%A@**2,L?7.L:.E[:K>YE#?F9O;XAP6HPZE0NC2
M,I\=A\5B4B9GP]!7^>X,$:/C'HPT=+X*].!3R&"84C(YM$ZV3N*Y ]*^JH0.
MDD6S?MKLD.AQ"[SSK+DA #L5(]T);C^%24U5.IPN6^AC+\1),4>!28#-KM34
M%4M^+3D#T?)@M++>Z=:AS#T1YH[RI?WR98P:>O/D[Q=<B-GRYBWW/+,V^L*+
M(^M"NEP[0PM>$1?@,802BC?<M.Y2=D^HNX\P-5;Z;93JI+$.F:S]C8'5RZI#
M3K8F0"2)M66G0/ \\SK=1-7AZEJ%A^<I_C#B;C?B#I!;'9(]1P'^/9S@^68S
M!/8N+,3AD/=C-QXBBV[;^SM3H+>Q,0*^3*SDPB,X49L@U2B&4V2&N9Q*D*J6
M@[9.9CXHYMYAP#YBXH[1?$/"UIGOOX7Y%Q)D_E>8XX?9Z0+??0QI75(HA1(N
MY=HAE%M0C-<[.;1T6@51DG:9A2NAT&O7!W<]8\]V:R\ES3I(N*&Y6G%=DL/M
M8CB[B*E9!&??'A_/_JPOWY%(,I*R!7#""RJZ %XE"[(4QP73D3,S@" -H.SE
MAOV@H]S[T/%&BN[C\O-=^H#Y]!AG=#+>^H?=+D='(]C=Y>EVPGF(EZO!650N
M@>.TR2J#";RUM--*YI X[GQIW;OHQ^7J-?_7>8TNH@,;T(!2DD%$9<!$KCTO
MY *S]D/N?ERN[N"=V=?EZAA&/93+566Y24(+R+Z.+ ZJ@$-9P"@M%6.^5J/\
MN%S=&XM&7JZ.T>9>[LB& /QQN7IOE8Z^++N//O9SN:J8UIDI,%(04&<3A-J[
M.S@15$[*1=FZ&\/#O%SMRY<Q:CB@RU63%"=+(H+QSI-U(>H<$O(NK73(A0]2
MVM9MAA_3Y>H8I3>Z7!VCL8=[N<I)CB%K#K98#0I#!N_IW>622Q501^_9@_-1
M?AAQMQMQ!\BM [I<'0+[Q^7J8;*HT1W5?2AP0)>KW D;I/"062Z@O+ 0$V=@
M50DV<9V];]V'\J"8>QB7JWLA[@C-[_)R-:,5B@N$9.F@4I%'B'7LE9%2VT N
M@HI7G*='?+DZ2DE#+U?'2+B#N7IV U,G40V_A%L/Q&)81 Y*0C"HZY J#W78
M/)A,5K^/*CC6NKQB"[B/_/)UBRCXKCC0@;XC(+^9X\<PR23Y52GXV:*/;'09
M7>' 8E:@+.WX+@@)D3Q684S*H;2^Z]D6\^Z)O#."W'::]M9N;SOP+OPS^G+Y
MY0WM$75WJ*7G'^NN<:1L5HF1["*K'0P-<^",XJ"+3=JXD@KO6L1V3]P_6-I-
MR[U][MO7</']RI*C0F,@"RY);)R#RUZ -\X4J3QGIG6*__V0_F!C0TTV;)#;
M*O\K!^.]4@Y,-7I43@:"0@;2V.2\RMRE-,!/>9 Y?KMFVCYTUJ$U[SW$=N2%
M8IXC!VN0K&Q+@O/:1,A:%1<]%NE;E]K= ^;CI^"N=-BA3>^K;PF,]Y.7]2BR
MR!R281R4MPY\B0XXO4Y&%$PAMJ[ V!;S#]=[$X%WRH;]>CAG#=A.Y_/5 )FO
MRSZ2J$-TQ0.9&^2C,19(<D4":L]"8(J[TC6/[%ZH=\_HW3)E2Z-R2S4? %$O
M0><%&28)+!E;2\0)ND@,F'#):87HL6O-VSBX/ZC91;$=G.[[RNW(6&:X9AIB
MJ7-\N6(0LXB0?-"9TS_0M.[^=5^LWQD;=Z+2C?YWEP*FYY-/N%A.EM5&NG\1
MTDV?TK"0Z$Z0#[ 8B#P?2?L342)5'J(2];K10RE.1QVXD_CP>OR]>FC%0,D%
M;U+DH&.-4A3O(9J$$'Q64O/$,V]MGOXH!MK).[.O8J QC'HHQ4!%1U5,<9"5
MJ5VH5YW^DP$M7.&)%<SN1Z?%_;%H9#'0&&WNI:9C", ?Q4#W5NGHXH[[Z&,_
M5608E,TY0,F9S&Q<-90G,QN#%:X&AC&V;BB_)\)L60S4ER]CU-";)V??T 9;
MGGYY-Z"^1 ?$;!(#$E$ E:T"[U(!J3%'2S+#TK4B:"3>0RP+&J7^V\C54W</
MMS9(!Z-=B :\R@:440FB,Q&LM,@B^JCQX761^&'3W6[3'2"W#J@V: CL'[5!
MA\FB9HT7QU/@@&J#5(R%L6PAU6Y_2F*!X$QM_H>*##(;H^S:(WS?S#V,VJ!]
M$'>,YAO7!OTQ#Y_P^.\8CI<?GIXN)E-<K$VI%)FP)4EPENPIY9,'YZ6$)"0)
MR0AA_5UW K<_X>'4!8U2T*RY=!NW7'S[[OFK<Q3,*E8T"D##R4Y7-:F%N0B:
MJ2"#UIJ)(=5?WS[Q\>OTGM)K_-[2]K><G,SF^"R<9)R^"*E>2GXY!Q:<2Y9%
M!@D=;6+>"/*"9  ;N:"?($]2#E#KK0]Y_)IN)^.&=O(E8$_#ET\3_/,*,J&)
M>[EV#"Z\'F&6CK#H#1AK1,H\(;LZ;.1V[=_XE.](_=M+N6$^_5H:SU9KKO?E
M]-5BDL\7_O3+'_0!*TLF(S,R!P7()*U6* 7.&0M,\!S08$JJ=5+3G:!^^/>;
M_?NV&MT=Y2J\\U=M",!.3OB=X/;C;C=6ZC#*;*F1#C[QW4#IS(PLZ01D^9(]
M;.DD==EH\!E],B4*>;7)^T.ES!U^[KX9,T81C8W:YTC>TNSCV0Z]P/S;Y!@7
MRQEY36N;2Q4;JL$=O"!LJ?9G4*4Z337!.&.(5P<.W5P$=L=S=F_;-%;+K)-,
M&SNB]4)G<3,JSLE^*NC!>D:H1# 0>4WX"9G5+ZR-;("F-S_A,>FXD1P;OLV+
M^?+HS7R63]/R]?P=SC]-TMG>Y9TM(3D-)M _5"YD-7-/!I(5LF@;6+*#ZHGI
M 1>V>/KNV_:^Z=D_;,_KMF<3/34LW;R 9T'".4>T.'\_AH :8UX.(]%U(+LU
M)=OHZ+K"&PFXSZYQ [B,W)H8&?A8'>Y</'B,"KC60CG#,=M!&8B'I?4-UN .
ME3Y&KHT-OG-0WS"M;1*IH@X$Q(I"6QE9(>#H8 3%D'O!67!9##C]-WS\[H[^
MAH*?M95:A]P7@I40\^(%+?]"M<;KLK[Y0&*OC8(.(PDYA=5X7R*N4A9"Y,DC
MF9U>M_;R!L!ZW-7+VV3,M];I_H:'_18^3TY.3S88X6\QX>33RHSB#H70F5Y#
MK!VEA"!Q.;+)I58>!4>/>8CGT0':#YK>Z.#NF0.M8R##E_/L0Z!5O)P^.9F=
M3I>ORX9UK5IH'#DE32FID(?/:$D^('B9ZR2U8JU$6X0;%#KI ^\'M;>D=C<N
M-+ZZ'/.VKF,9;\*7JJ(+[R>+&EE%[+)R-;U80BPJDQ',9=3:BFR&I"TT ?.#
MNMONRFWTW.'"ZV^DC5>SQ>+UM$;8OAD]9+D3%J\S'0@UO;T4"=XI>I6B*$H*
MKS1O72&P"<L/^FVR79MHKV%L:^1K\<<\3!<AK3;WV6*Y.#(L*UU3$1EQ Y0F
M600E BA7BD!K'98A8Y"W@/"#:UMN=5OIM$.KLK?X"0E@]>ZJP5";8_QKLOSP
M[)3VXQ.<__KY?#'5;*#_Y3_"YZ,DK.'2,W J95"*L;H=)] A>L:98EFW+@2^
M!\P?5-VT+?;6^76:FFUINFKK\_ML.CL3Q?3]F:Q__?P1IPL\BD('Z[2O(=%0
M.YO6X>B)@XTY!.LS_:IUXOSMB'Z0;Q/Y&FKR.L]LRPCFF<UP'FJ=?,+S+KJ:
M.689*^!S3=NN_0"C+ 5*9%%PDW.0K:=RW8WJ!]^&Q"\;:/0ZYUS'ODPO3SZ&
MR;S*-TPS27 Y)^"G<Q)9^A#HOUO\'N956I^V&!T__AD->SIMN<!&'9_>7GQP
M-<N(P?0SG'_";R1,.H:8F05O=*TK#@XB:@07BD'.7-$)FUL]=^/:=L=[ESY@
M/JWOQ:6GK9YT3"]W7IFI9_D%01?C&3E+S 4DM\E9<"XCH,I,1Z9Y\:W'K(Z
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M[44/:714;WHTDGR'V.AZ#!$!6W]YH8'!*LEOW3Q+IX2>T_G*:U]<$139^#J
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M&]9HGDSS6:/@UZ?+Q3),\RI><CDUIXX_TTQD#73R>3KU!)+I3"<PSU(GS7A
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MWQ-T@/62S**V%OJ@K4Y7^*/+/](D3=T5 GT5KU'BL_EBHO 2Z\JJ$^&2.Q:
M68,NLK1E6L-5.8I6CDL?-*G>'+ /P)=D//UII@?._&6$GN+F 'X)=B033X8%
MAPZ14! D:G <_:-625$O/0VL=DU9-V3#&\XII>X]:&_KGG9BQ[?+GRVZ7?YJ
MYFEUK=$LKS6.<8[;&=1)'.@^3X253G8W7EK=?14J8^)/HRM5&1'=H@S@M31
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M6"09_8$,Z&B$!4<X!Y^U#M9YHQ-]0F#[O_70EL7%F[:\91$2*TH0/PF@3/"
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M(:D,9.#,&\K7,J2.KC0RSY*\!>@ #9 \V3>-L>%"N<.C"=Z%; M=HS(=\Y3
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MM5<H30!F.31(#5=?8M4(@ +Q#TL92P""DBC9,6$39F77+VZC5BXN$8#D0T'
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M@&5@K=.MMQ*)]&5'#J<+YY/HJ>YP7.K;%6H>F(R&)T7+/LIJ>?@I[+V=Z8O
MNM/TU*JSO74"^<CI8?O-[MW6NBKV0O2IC(K"NUM.;1(-H\/6TJXLP5+D54%/
M57K"Q#PLLN D52Q.5_:D'W9N6)3CBR2R;SWZ XP$'D.%&JY)&"#++ E :J=6
M\)HTZ1?PU8LHU,4ZWT%LCD!QH+EDU/DNFF_$VG2)D0"P,Y?@?&X2@ ]/RF,@
MGC^'/)88"[SB1\/-;>*2I41ZH9YO*OYCFG<C^<Y=;]+2N$)D<4!$E<L3F(JJ
MH0.MS815P8M$Y +\O%]U%>==/^U]GP (H%_R*%N)R-<6.#2&Y&K7C&T0 '\#
M48RGSIZF,WO(SA5[RFM,+$A':I:SEZ&M:TJ^[EU!IV54D":!^\#B61FXGKNM
M&;O"98I.FY=PYGW*$IE8,)KS@4=/:CO]H'++CLBIRDFF:<=Q!'=AHN>'EW5U
M"(9*A;$%U.+*08X2&Z7!VZJU:DVOZUY1/76\>7W0GZ3)\Y,GO+RC>%#PX)7&
MC+D/E"\^,9!::X55AK[6[EYM<88I4B8?VP#M7+W\4U1S#]P3)P!-G'OXJEX"
M<"9-#-+97?/M&K^K$D$VI1#9LPR*?U2GZK6SJ0)UQ$B@Y3$Z8V:[3PA ?<$X
M7OG6VYP<#SQRYB%JTX>5#3?6V%[:9SIXKK;&F-5;A&**QH7&U4>+S>Q?C(&!
MWWMPNITN667V,A[D3+;>-U"WTM'*E6JSN>GPALKX,0T,-'_,KR';YL3T9%%7
MV_24P_R[1HY=4!_(DQP  &[0 @Q4/777!U]Z#3E;*-]>D>7[7;JXF>XI$^GB
MT(6O/$( E-LO-[BMRWO_\1G+'1D7Q(;$6^$<K'#T)\"(TW>^-QZ,UZ,+L4Y)
M $I6<(6I-3OZX3^ZA@"U%!UH/O$0YNT$=%_T@W=6+XZ$'9^*K9E[,$T ].-@
M=O>$PW8^F3%LJGOC!6<3A7BM*OM&2F"F"5Z5NZ<%*;D*L)$LG6,F<6':S_\8
MXYRVN4^?8"E7ERJL)-*V2$OG4B@,0&UMY&$(I]8MKZZ-%Q\'2&]IE&J&26WS
M%T0$3Y+=?E*ZXU8TV\H>NJ\4)N@4VU#>^#!U_=35V,<*+?7439JXIE@*:LEA
M[QE,7*(YU;39=\V O\-&6IJ%1#G3Q,+%Q*M78D/04HK*R;5UW,LOPEV#R-W9
MQD8'6%2V!IWB!85=W'.'Y9$Y+X-Y78NN"D%HA:72K>$)G9L5S![#5F+]D^5>
MY;*6"2P5>NY31HF7/(V&]MT\]4-L. X+0ZR)JQ. :_P$8$,ODV'2CN(GN+D?
M#D8V]4-PUJ5$\#?Q0CEJ?Z\7^%U,)]'X44/N;L)VQ?57\U''" !TOKVP!>&#
M0!. I7Q9A\JNV?>OP885J\,=E066.9+&LJD/AYE=?79\O%-I#EA<3,U4BX<:
MUNZ(QKRFN'ECKD??SEUSN?J%"^J*D^[;F$3>5^LO0ILU2?3TL)WY,,P:BT/I
M4<DI$@K8V7,Y%KR-2B77J\><4># -^V4 E<6CJPVW^V=W<OKF.=-&O_Q)X93
M8HALR6X_LQ<SNGN!7J6=_4N]ZGY_[Q2R,2:%:!"-$8 .EGB&C??"WPC*88_.
MZC7A062?N"".NR+SAM//V:CDH_[54_Q$_]+0@0#L2IUDV+728OW[/*&Q'@BG
M+34WIYNU+4<43BQPLR[=N^4SVQK(T:A]\O5^DKCW5CZ(?<E=_!-H\KRCD6OV
M!Z^>&:,O"5Z+I)=U;A-J04['1P1+62;16%07"6YQIM@_)P#&.]4WR^)'W^V9
M#.//A[#@JHTM*U[-W/O48!/U\>&#%J**B2, &>IX=>0V\Q&PU1E<BMU@OZ_^
MTX17%(TL=\X)T-\?;HP]Y+?)D^L><@3\0=9RS%UT IZ0L\_YD]!6;*"WO%$9
MW&A[W&TZ-L*GS+I/#+1673=*-X(50H/GRA-OO7*N:G>E1? (R>B,N_@4LI4(
MG F/"IZFN$JU5T2CI,S:0X%]D?E3D ROQSU!3AUR)Y+2@F@K78X'S\[?^%9<
M/QDR(*8N=2.' @C .:/4&NQN*G$MM=QH,6EA@G72]0GN@PQ#ZTMW%Y%K(*ZP
MS2N-,<G)*&W-WX* WV]LJT30[K'>13/=>:$V:V]I))W36*-#G"3;1-Y[TRK<
MI 9888E5)] G5H)6IKHW(:-\Z7X,_<>@%4PWHHKI[)A56X7Y5$5$R;U^R(PC
MVCH-R"(D-L 2L5"+W'#;Y#-M%_L90.CT.$C4._U$ENDU(4+"90W1#?'OVHUK
M)4NB!$ (M>=!  :EST.C,_\(@?ZB-U80T"I)0XQU6DR1 ;[&Z'14^00MOE68
MY0YT6:H)(+4'FY.[AZ18Z.CCL@S-/Z2]K?29MI/;RZ;.JL-$$Z%2FZ+KQY^K
M5=89;:JZ*F_AABO4:#S<*;0#O26S=IQY:SQ5EN;)Q3%/S&@#C*8XC%&MXE+L
MW7WWF8NNJ!SJFFH6&,+M[$?<4!PC%7WP(T8X^4H 5BW327_*P%SS=5$E^8!M
M**BMGV::V3V.!LH.(?="&3A!)A-1$\PQ^A_?2V-689*OHDL;/MX\?QY9P<;;
M>/ PF_F0<F77[S\31GFR'1L215RH_4C<81XEI^&?<4BWU#U'U\05B'I$ +%Q
M)<ETN$?Q.]^$/H&+(9LNC^)?*^-#8BKY3!NJZW8+%]?"QMJQR+V[ZLQY8KM"
M20?DN'3+.Y8OKS6_LVU DC/W!"CIS"K@*,AS#]H-/&*.%\H^1S\VUZW[$"O;
M:^)^?6STV "F !I+>[T!X4KNS%SRW&/C-BHKJKCB\.ZQ4]'& VKVNWF"31@^
M VHG58L7$JNM&^ZHF?*U)=Z<=<7_*/\  ZE;1;ZI1Q><:GS/O+08>Y";(^PX
M_X<=YX62EN S57U,]ID,VYL:8>]1S,BFMUD$H$]IFXADMS/!\U9@[(G5JL(D
MO5&#*RME9:^4(Q5L[%(KJ*_>>4?C3N*W]1SR'G%05MAJ#.<PJ5;H$$E1?^])
MD\"S,[I]]:#(LK&Q@Q6J4Q\8-@47]]Q/S?CK2ZD:%U?&'UWOI[)^[[54I=OX
M,9[V$Z+HGG=,R59\O3S8F;%.0*:2T4%XVVR(RR B5$Y)=+B* 1/#K%ZG[[:M
MJ51((9L./>[/"3&3$.*2,CIZ-[&LW07 ;J6R_D&^_!?!?1^E9D0MD_=)\!+*
M!TD'"4HZ!B?Z#VC1$O6(OG7[@Z%7N7*:("LRI;BQ]A7QEW(3<3^/\\8+^N_S
M A:GNZV&SEK=JW@:-D6O[&#"IJW,5P_ZZ(F 8Y&3V=7,\_S.\%NOPG@MR3WT
M4KBJ)47@H.B*<. -CQ>[I#XI'6@1]1_E%_Q=P"S&PECNP,DJ]BX\O.?7M+[4
MA^(Q9DG!7*-:##_0FF";%NV%<G$ZW7 ,&<*G0P NW@VKX+C@Q2$XS*%Q44[;
MBZ<N6LY&43K^1Q[+_],GWI/QK@%ZST+49"K(M"]U%S(!D,PD:!2<W<TQ9K'J
MR;B_F=&TP3;9;8_&Q;%UH@7;I4@:X/U,UCC5]#WU$OL1VRMQD:I2'(FJ'&NJ
M<A=(&'_\*4NP4IAV]W&1F&//]Y;$C.2Y1*^&HLI-$-(@ L"7X"DD+F)[E&'+
M/^3%%8NM3/?T<[&'UZ#1'=O+.=+9T D=4("-%OO%_W5H3^(IH&?8_OQBK$YH
MQWN&EO($VH5%!28:6XHFUJ",YMK,L_TIW&].W9SK5GV[_'@3X85UA03=6N,<
M/("]]2E,\B @Y538)AUS\9QKJ,7L25UM7=X/%NG(4WCE-Y-"E]_ S4:T$MMW
MW-)VX>G)NN93/[84H%7U1L$=QCS$T"LB6)ME*3DS?T$E\ *J/QLO6PS;78'@
M/3<ZVI^;/_B&R(5;(00@(G007YN/G+LPK ;^-A;Q@XTX]A317[(0W-TK(1I1
MS?+M72[)?YLF7;$L+M*];'BJ.=B^K2[8=5<#4E\-;"'?:+/@JTU*^WM7+!GF
M\&W+E1Z2F:?A,UFT.X63>3M'BPWW*$8^1]BC6:WTW<ZC3<*,Z*-?=\=LV22%
MPC:<R&FH25INC#BM5):\!DOACISI<7/.?&)Q\UZ>Z3!'Y 5.:G*)9O:R9C"[
MY%#CLTQ).M!VNY?;B2/>=@_L,OI4%F+CY2G6.3VN>\K1W3@>6D%_?_UV/.T4
MK"@449#C[O%Q=)<[4TBVNG;4"M_LT[3N5CUB.5AAM3LG&NPZ@TZ]+"O@_:/Z
M^*MF[] 642N'7]C&N>?A \^905,ROU6ND,=NMXDKHGR) -C"<-S^4>#U^<\@
M!+K3LN4N[K2\=#TY$0)ES*SCY6YBW8/5;,AJ0$8-J>#':R=;H2/T89=? =?>
M2+8;B=VJM!JR#UE+]PY>A%[\@[&&?[#7@;?U.A%BZP5OZ<Y='V[2UKX48\(%
M %(<JT1@9D,;3EQ+E*S<.Y5\^\.2WLY))Y%JUK;)7)6F$/6AB[6/B<Q(3_+C
M+C>1&=NWPHC464K'.0GBPQ+3@G<^>?W$K%T$WQCN,(J-[BZ.[O*<(_?P[_FN
MAZ^#>X[\=(@ 6(WNF:IZK16S_N'UE!XEPS1LUQ[SOG-8F7?;Q#?RH-E>RJW2
M^1#O2R^ME13(/7PPIO4Q'KPO'VIVC;I=#M6:=+L'W["%CMO+*2M2&)^XHIK,
MV/U[S\,@_:G">+Q"HOL4M\Y^IP ^9X[$H"R1*WVK64E1&^\!-V$T;")M.S1-
M2/G)=1'Q=PYC:U-VD;:2CLL9<!4,<+BU*'@MB_0/T?"?*NSLWU68P#]5V*AM
MS&6JO<;:*M$NK.5MP:*9:>M"Q=$%-EO1XD9KY[[):6MJZM,@1>F6_W7@O@](
M')E0DSKLQ) 2(TX5FDZ5(T5*V]%U(=T^Y<PY'O,WJF(]\:YB[E)C@@]L,($Z
M#9@'*]W63EH)U M]JJ%7(!"RJ."LO6[A?>EE<EP8! 9N:(,^.@2ND]")*:H^
MNH,0:)_:J[Z<)[_ZYC\H<.-IQU ]?@W3KS.V&-2RI<)Q4W*-8_C(X]#2M=2#
MH:+!-U--1VN\1:3(,Y0_M8=63]WL02ZRNQ* -!$MK\WB/%_-!A0T9V,1*GNE
MD;^01;PMR.%^.&!]_NY%>5TN!I*X]C"Q"P8K;_13=5=-9)YPVVI,WR^*CN1:
M!N?.#KD<Y ;MRB0MZ.#97OIH%LHDE0=+[P:O-HTNL9,$RXA$:+%/&PY(&*B]
M4.Q2?N"S=3+>W-I%%3Z<->)W2WYRX-+E!M?&.G6JNC2,A7I)N3]G7.VG,J?N
MEZ(5ZL6!#"V!)!&#1Y?.0]OUO\=0O^^#+:KWE^ 5)$8WMZIW3W GP4-_@;\L
MQN@H_%EF95P3<N/Y,>)(6?)_^3^C!S/ZP(Q?WD3WQG:_&$06UZM9IS2)B6BD
MDMXF%2(%(Q3=Z"<9$8SFS1G]3U]LF_J&&S#([T2\5K9S V85:J0N*4K/_\2,
MB4L94B6&O8P?BL8B4E7Q/OMO?M*2O::2OLS-;!02H'&N94RH)2LF B6CP?H'
M1(_(QZ(X(I=.R9@3 (/]1#]P)O,6W/FG]O8>KL;BE=Y+X"LD\$%$;S*Y^+NR
M'EUMCMKQ)0"#V_C^#S?<7JC\A"TCISZN6\\@>R 3),7_?#A:[='4XF)A$G[#
M><<3)FWLXLM#M;?&??GV%?8;LV,B!>':CX*]4ZT5F+PEV2.TV#9^4Y\&3@C2
MZF'T&RZH70X_2WIZOJU1YE:(K81*WX[N_#MM[3C C7)R!3;JM+8Q="V*/N?,
M0]<;MA'<RR[WHDM'V1@0]HI)V@=%??XX_2!GQY%THQC%S5,'Q$\S/:Q+;H_E
M,>64TJ(M@WY*ITK3(P?:J[ ')I_ F/4>MHI.OXN[^M"!M5) ^727K3AEJ#QP
M@X)5R%B'O?@W[ C0:E@C:H>1BP#D'B8B!9]6,+K\CRF>OW;S0WXA3-S-C&@J
MI%7C7,)PC/Q.>NTAR(!-T_YI6"T*0P"V^A)E#,PWC/[Z=7#G@#BU;S8W*8VU
M C,%>[CRS9-]%SASMN#A&"2:S5ZC_%Y.K0!&+TV6;]B[Q#BV8Y5C5JCOP-(X
M6G:T(A-MYXYS(P"(ZWA1YMARB1<!NOYK87H[N6CL:_$MGDWHT_\<,(^#PS'D
M:DFRZC>>Q(O1CCSSOGH3S81A5H0.-[FRAN077_-M,'<[ALDF3[$Z$K 92.H8
M[L5<E&M=V""ITLI"V@37;I/MV1_<_/0-24/Q'GS 0M^O[=GVNE)O[*%K=#3)
M^TPB4GDHK54N]T&8)AZ"ECR8.F/KRBU?Q3(^UOEPXH$,D.8=FDKEA3K?13N5
MR(^A3\>@-)]HJSWF&Y@*B!0+N7(^KJ[TQ"/OF4]&PP_%G=.,HM_VA-6$<%JH
M"E[5B!][?'>)F:34=E\A<\ZYFG=T^3)*VEOW'(Z'>*X2@  /NDK,T[RJM,SE
MR(]2'IW.O.# HT];[[VN<B/CH:!]0RWD0.*Y]RI#>=I2Y:>LY"VNQ4$"P/ID
M97?/$'?P40=,^1<)(E 13#,!.!Z:@I]"[&H>X(3,]/S=X)2Q F%&5FKB@T:O
MFJ@84MJ )*^DM*DLT_?F6 5G-DGI&-\PG84'O!AP"FKA5U:WX:]<*%.9A]H;
M8072>5J<26FUV'5^(M!DAAE$*R]2X!D[IPB BLVKM=N(^4>;7A0$("84\3%B
MFV9Q;W&0ICV"^^_&\W\RXA,],\@8)#0TY>X(XVNW]R852VHL^E383M,ROP<\
M4O"K-X!\37EW]E^D@GVA\D7U/O*+[9>RW[]#*KZU4-:'EP>D3&XJ9H5>>0".
MDH>A" !-)=)Q<G#=1OQFT4->2ZN$G#LNA;?\HU?WEW0J#&1?%O7\/I'(*J[N
M?]+U:H";$QZ1(H5]=(S<[B56#LV!Z4\;7>^R+\I B&M/CJ8!^@3 SW@B;)?\
M.@$8+92G_X1QG-"#;\6ZV> &S0WS]H)&<7> 3P)%>T\.O?K$< ,>R<ZV.5OC
M\,F31X/UNT_T?#4V:*62,8,S+?T5@\<5=H2M63-92KBC3B,DZR5UJA"Y%RH)
M?Q!]/3;8;G93!KQ6W<IANO*6%2BR6BX[*L>@8E1+KRC]ZS4X4%\/V<\;+PB<
M]>>0 =%4#.GX[D1^QVZYC3E Q-;;L,TWDP3@;#RY^[#6][K9*9Q4QOKQ$X"%
M;N1LO\6;!C<++"(;WGX23T4 &@G JWKTP+IZRC^^KV'3-!9$2K15ZPA H(?)
M>\$K;A+#0=.#*RX<]=N+!8?6K6&HN+VC;A>[YZM5$4391HVX)<H(%B^,QSQI
MH;2<@0DLI%\0,U@P*%NK_4^(XI ![">MM3U9@VF<25F20L<Z(*TC" SY/0[W
MTV^F:<KX/EY4%%!MWY4-F+Z4&-&DK?LTE_Q@M+\S'H46;$!"5?*[(Z9")/6*
M*1+"@<;E3V0<QH 1TFD6V%'B!@W4[:DU99 .7*[8YG:XA"03;U/&;9@/*8MF
M8EW0 F7XP#0%^A35FC5VYQFIR7V&MC-#9TM9%,C#&YUNC56]GEA +4$/RKZR
M;AI,->][/555"^,4<;GWA,SIN 33I1OP\HXB7L$#_8WIYOD/^">83LZK$JVN
M& ?90A;U#I 6NX$G@O>._%< -H:Q&!.$SB<ROJRH?/DJT?GFB2FG6A/XK>"H
MH3'0>=/[!&!?ZQL"L$%51 "J%;T@6%Y!(M!UB'3A<?L Q/@5)T.\5PQJ>U8#
M]/4W/:$8'8,C!"#).!VW2P<@WQ2L5N/ _(B5CB0PGC[6CP#,,A!1T\,/@*WF
M5 H2 /E6];V-SU4K?L;CR%UR?>1HLOS_OM&H Y16\4_'9P>8!49X5:8LE_,%
M.MX'W]X;NQG'^$M#]5?"7W\+[;2_R0L4P1S>;B[CV[W>!9*V=7LN2>+4N]<B
MQ*$A>IS*MB6.W'W&\C[]E*K-O5:.RUGET@G9O%39X"$:6Q[?"W]0K4^,'JGB
MXO+A1Q9N;!W(&LH<#(85*CFMZR'=-OQ4:EDKW++H.V!4S>SG&I1//&TVN6FK
MRL41Z<R1J"IW@97A'UKLS]C,ACI@#HSC9.JEHX>DGU;JVC3>S7W(X[]OY$YP
MV&F?(')WY:\7(\[G/YB=_HS1R%XC:@Q@']+5*F3VFW$]F.90J3&69&?=DN30
M!.=^5QE.6PV8XHT06SBBIK"+@_%>_LI?'!N),'V!B62\H$A7YO4L(6Z*\5%T
M<+3D)B1"OCV_^I\#:]+\V]!-%S6N[G=/TEU\R"8LR@VY"Q:$X\Q>,N6FK^Y_
ML]TO/F=SLV^R^7&<:7=@_9!I!JD+U:4;LH[UHX5M+YYG7TAYSY)R;'U::,UT
MV4/C2HH;LO?,32<ML1S1FA6^F:[GKA89(Y3/9 RDZ%(RF1_KD4"[-8X7?\7S
MC"RPCS.K(\E66?I,:A;'F\BMCU(S4"/\N@LD]OC,&'8OI<R_M(C1N",>8"=Q
M*2?#U;-.4G*VQ39'1HB]6".$YU=4&*A )9_;D>V2@HD)*P T<R0"X$AUHFR]
M@1W&GU"=O#J:WY]_G:>S_1&Y\E/6EL=#[I2TX&V-J#J9?1&)<M_95%RJ%%Y=
MOXZV.?!\H,PW@3$0X0ALXB9OP$5;&IBK^Y-,JS'(+:N2!Y2G6ANC*][>2::!
MJ8O+OZN;HS,=>>KK>CABM;%.FN5 +NK>.V#GDZ9U/W-M0C-QF2I*!L%!?! ;
M.M5]#R8U'E22:0#@#E -EMMS]_/(Y)46/(^L&?1N>(-(76B<CGM*7K\U'N9O
M_]*C*WTPF\;#Z<CB2M10W'G7!POKRT15S*T'94)#%T?!/IQ^3ITE9KD-TPC5
M9QHMD.2@TRMG/7?6ZT=(/F)91]%BQ4X3;:2M@6Q2L[+=+=ZNO/3(+7.JR=E?
M9OVP^*U.-I:P@+O]WBR[<K>D#;%C.EB8%5B=\Z<*#@5/AX?G7@ C%.X*CG4O
M3586V<=3=LC>>\V@=YMVR-4;!&'U5*!7_-5ZR=_)]78_063 7=T'S[HO9EH<
MZ/=;\C71/O!2".4@)UI\?X..#76: /R3JY^S_EOBR[_1:*"4-">NTQTS1US<
MHU\7S>\+9)?/ 5,)08:LS;VZOZOV?B _?K+X$TKI*X89)/K9$Y<*^M,6J/6I
M#S,,YESW5G&)(P#E,R>D85%D<N?A7#'=\Y:=6VL>AK'/1X5#6W=6#*E>+TW3
M][;!W7L-XE<V)-G\E5G7*/+N[ASP^Y\.J#"-Y(_A&.L/[7]ZL6U_603IG;4D
M$XK]0AKN8%$FERAY!L,OUH'[WX<]G-0;491S+"Q=EIP?EEB+(M4B<SM9+[<<
MO^7M+OH>#+_V9=*)'..XP&.+'*?G+2V['*4EL4N,D^'&5RUSELM8WF75#1%=
M7O6O.A?Z=Q$)2C:,S7BV^6&SH@6M2''J''8&'<UH]B$:BN<0BZ_8E=3V351R
MJ+:NTE@VT*)<*@5!)U%QKOK[-_*GZT6Z1%F $+L"GJ?N%@U>/W7N2AU]08+Q
MS1!V"+,(#:C1ZAQ0]A=F_R:-'[3+O!J+/RLG@2^%X1A.B$&>_5RIS[[O)_%_
M\?GND;'JMX*+E+H*/:D-*%%:TERG5Q&A#E$##$?7!Z2HU_U,61FV+#5^J91^
MO9%=GT"$+562I3\>O!M;Z/WJY:%M5$4ITX.4)CZG(6M/[WX*:#M.7;/LX[VT
MJM<1STM+;==D[#EVJ3VI@Y+(M$%: )!*]L7\_YQM6] &\G-PC,UB97?#$'>L
MB UE]-W]V!_V]W\KWO.C,:I]P!C69G5%#=W-*'BHI5SA06X*^'U8!TOB;>>I
MAD:FR#2]Y53(&P_!57<"X)WW1+U;%[)REF>F];%H73*K.X/ZNW1O:>-O4^;=
MO?:D,4G#?4-FHN(&[RLQ("[X^?2#)YFC3\A4%6K*NY_XM? 1W!"SCC[4='K<
M70KO"(Q*H\H#HDN:EB>A@GN,FD_;2&[!+_PBFXRZY(T'I*?2'!&1]N:ZEA='
M>[0_'U$XS],FV-*>EF(82"?W0EUU$ATS"!D?*SD6=RQMK!8W,3$,9>*08ENU
ME3BGQT)Q1E;S99CE&;WNXT!6$@#4 -8 V!.8Y?:<_V:2H7J1=F9IVG;6VM&>
MQC><6'W"%9:AY)ZRC W5(+'W=T^U^>N>+Y>"&U 6WU_VX8=^%-( U9])^/ 2
MQH%Y6'<LUD_@0F(V^&ISC^HTA^&*TB3/PG+JV&J-$"M;'-VWG ">)0!>,)JV
M6&M9B0S$+G^724\<FF[I(]^6:M@P0TUL$FZ2YC<XZ'>*!* Y").P3>GTO2U4
MRT0\PR:]\(]Y@M]W#W]&3Q)=V%%/.#O<5_=B=Z KRP-LK(\<)/OL_&M=*0/R
MKMF.>E>$+1(R43WF[-[8/OERW^L%C0_IV@6Q.VKM>08S'SK>13UK/011!D4_
M\LY)O4VC3$K;=/QU=Y?N51A=UT.;R$)]L>WSD7&_!1I0;P\I9-.P,WZZ!!]U
M]K)HTY?F'^P:_KTA>IKX/+U.B W(<W]WT?,_$+F%M"&*8K'>=Y$+2]4;:D2A
M=/Q2*#<-O9%KDG,$8&N3 *0ZTH&VES3^"*4]=+H]O[H/<#M!-"#5+Q" 7 @!
M4%*] )I]]),!KWW NF P:NWD/&*9:%>F"7VXX>%^^:O/=T?'8M\*ON+S.-8S
MA5L#7FE*P2HUA/B'4).7ZI4QO5-[M8Y%HG/E-W]T3&J+MU4\!:L.3SG3/?K.
M3(C!/*Y0G&!7=VCD>I;!-P26AR56\:#/KCS<I#PEIU#($4#A^31"B7*0Z4:4
MWS7<E4"35F%.I?N/OF3J'PR G@1/(@80^-.O4)MCU;MPEQC1F?@O,X,["4"A
M%=8OKWJA$[EQI\/?/>#[W?Q@\UOY-3^L6C[32Z:1A:H(W1"_Z]ZQG[5U\'U8
M/(/\>$ 6JN+XAC%7"MD-T,YH]IRN-//4@/V\L^/AMEL1[A3+4'LC?QTFD? Z
M;Q[YMB][W!#T<]E9G0GDRU4=I"O8;UY@+5M& !QCMI1XN9YK:(AN*/Y*? :*
MAC9<<H*IQ&K</57G,3\@BKTO)&.+*/410:A'.W@SQ(3#GI8XVHY>./&^KJCP
M_!)':"-?VU2AL%PS1Y3*OF]VA4$;ZG567ET+WG+J]:"EG"<'F%^VO!>:W[_M
MSTDTCG++V%O)KOG *[OL!J\?'^9;O*GF=/RHRJ1&%J3#GBM;N%6X^:8J9\;9
M@>^3_VUOI9S1A(5.?O>XV@/#0NACJ&E( P.3@S'K)'LRJZ?;531L;'/;9__H
ME7N5']910M 1>:B"2-@X,VD6"6J"0H7<@6'RZTH*&4$*)Z@N.F=$YS&E,#>)
M6J!(N'+7"ISZ*D2&1LS7]@B#&-4>M 8%L0N#D)8E[,<I6+OM:-T-J9[S5683
M[A^T>\Q E;24;L12\:L:D!:S_IF'"<#FFU$B$P=%)$I\Z8_OUFV9$0#-+&2U
M.3:7.QEUZ5^J5(%)8<U+'AD.7K.T.CFX"/4I<8KHRW6Y-Z#0>.V^ 8LPW*DJ
MX57UT_XMJ3.QA0D"965Y]UX5Z&Z43?1\@IW[5@G,>9!BO"3\K^E?7XZO;>?M
M2>;*;L2W.X0ESY?>75Y.?F!GR%<<,/VIN@EM4WIT0K<HW:S'T*X2A3+=GBOI
MUHFU'GT3>[BMX"WK4&@Z:]BM7=IN&H5:^I6WF2=.5J3GKWX(SFQ^8Y[)?\SU
MV=M+_W/[!]]M=AJW(C_G*H;AW$OP@2[GH:%S7SI\V:OJ>&5F!'ZD>B-TPA..
MR_I#1ES+0/A7]QTKOM5KW'/5FS5$-Z.9.TGNX$_GI_]:9LW?/H:&*@7Z)/.T
MG.;E9O6F5B"UI9#UEB+WA$]A3J.E9&]9X)YFE%[7Z7=N@PS<@JWUR#>VO3XA
M+\?L=#.C@Z7W-S8 OVA$-Z]?'CQ3%(/?J1??FC=0ON=I!SCRU?MI,Q72)!V4
M3X*VMS](E"M'?WIV[_8[A_"8JWJB]6;J?#76QE% T] &!76W?D0"V5<)<?_A
M($_LZ2KNF2P+ QN:OV#\T8O7'R$:R.X6:QFF^G<7+]Z\5)-:LZ/T92I^4K04
M$]'T\42<E^7*)@YOMJ4?:MLKWBF#VC73</99#1?"\GC.FGW773DR"0D)"S[U
M7,UAV,BHG-$:VC(%&WD?BJHT\I.;5,% 3K'+)GZ5=PJ>#$F[\6"_*$U6%N7G
M0TN8(M4!:M4DZ$LXG1O#!5;E'(R_T':E[.$7WN&.NH]LC]V;+QL\<ID*-3_L
M[P[[+?NI]VS$.4FJ' K68&\H*8T3:RB%G!EX"O401D9<IOKXT8!;G*"8TD)Y
MU0>.,:!FX6VG1F'<U#MGVJ;VQW]W/4"V=>IE/5Q7KYY,G'"F/BC977AH$> :
M2O2T=4HR[8:3X5#>=U^C3Y/+"A4$EK)TM:2:#A^7G-OKBBQ:9)]KE3DI-GOY
MXP<Q;PK_[M!3%$'28SR>$(ZH>56NJ//[Q7X=0'\GA&>T)X;,[$&,%N%UZ3K:
M,S)_!&Y^K=EW+#'6,N?JZ[0)2J-PV_3\Q1:7;.ID?PHYGA-DIUI/V%E<3,UH
MUGJ^=*)WP[TW8@T5(@N]/RY50O7>F TWU#>'KX\;O^8@RQNJ"^&IEM/W>;;W
M=I$ *,_LH)Q]&Y2/,+J=.HQ>F8$)OK6?'=U_+2#K6V0=<>)ME(#3/6FU[-(K
M>Q<^$\T%JPR3A1R=LLZ5E)0T7DBYWNDP(J<[7TD 1%L:;J0\#.E)N60I@+^\
MAM4=PV=WV?.Z&PP++ ZI4?GPU&V2VNM _#6;9(_M'FV^P'UV6'1L7C.:0=J>
M/K7$L/?BN]<ZMW_5Q*Y%,%5/W2,.8TOTIE6?93),?>79Y")-\C!KW<B%2M@N
MN.LT_/'S'Y!K\ QL0 VO(([8W!K=/3$G!)=)_=)3R:M%[##9$8 ]%Z)6D0D"
M]K8R_LCR?;NOBCA=];G2,OUSI268 *1P//?<.'?C9_TOY]@&]1TZ>]@V&W%R
M<>9""/@WY9@@U_/=N786&2LYJ6;W6&^@RQ-HE&<5F$02_"]K>5/24>$ C!6:
M9+ QWBG.,F@+.#P/>"PX1(@V!YT_^-HA(9DC5XWV1]P*]ABM$J48';W)$#51
MX7U962+OWED#P$%5R<]9'_NP5S%Q^%,5>_0/1>9T7NSE=[6'WW9>E)2<>O!H
MX[*>YSO%IE^<= (I<"/_+%S0W7$;HG"]!\.7?^J$GL^N='\)7K%W='.V>O>4
MV6EXW??[^5&KZ3=*HWZTF.LOS5$#KDYV-$NT?5H+Z(A&N8 +[Z1P-99$/E>N
M-R'T)'A=7&6 4[ATH.E<N(LW-07V@ K5ET3?RQ[C?&95R<^DC+^VS.7I3GDH
MK+6]L8NN@Z7S.]IY#1&,%X+3=23R.@PZ9T1943)?HL!M^(2-GWY)HZ ;<=1.
MS!/#^4V-%\P(RX#1$/,-JY=^AYS+E="OF<0ITM;GIN.O"G'=06VJ>2.=D X=
M[2ESOX=KT,@J42SG80/3!QMG<,TG5OC#D=GS^A-"B.G'LBT^N"LRO=NNOF:F
M[[0^4PN2CSDTUO!B8JE$5WYNP-7V1 32F75A+RZ0U"<B$';GQK1CN(X7RLA)
MO?:8NO?8FEBIHBB5JNAX>FQU.R>HP9DB68-%,2B9V?(W5]*-'3V#5VHF  M^
MU?B'].RR][X,U6T&+';BT[4(@$?7SC7-T_!G/P(BO]&\<#:E3MX_>.U9*U66
M=J>_ F2'MIO6FX*41OZ42%"D362Y^W[?Z8OGK"U599Z7PP2<5FH..1F][\DU
M[AJNTIGOB.KDV&JGP.V*,S)6>50Q=[IU?H3%1A&!=ME:;W9"MS Q^O)@:F4O
MRG[;O.2)+NW2MP]KCZ=%^XWZYDK4[;4Z4ZPG<4W;X*;QBYYV1ALWE.D[SQ5E
M5+PHSR4 JV[M,O2^_@+B,5&&5.5Y7,/.[HT?CPF4F$_LUZ[,=T>7D+(P'+57
M-APWFNL(ICD7KM[YQB:3Q<QRQUET+/M2(LN]I]HF59\JTGN05^-[DMO^:Z/_
MJS;Z9W)U.NG6;U=!N]F[-[;J(U:;[A?H-3,^"R<1"?%:/LHKP*  M'=44SIE
MM3=(V[D\]=HQG(X4W9X(!Y5+;%];=?F+Y^]K5_2[H ;#6F#2<1DKX\,LZAMZ
M?2^&FI"]THE&BHCI2!K'Q#/!0O"S[R)%/PU\F\G\9Y6O[B+^4A%6O(US$<2'
MZ-.TOYS_#>C\_4A<RVA1._8-<FF/ -PE*G2=+Q6Z*U>-U0XC*P'(/0+;Y>L0
M79Y/_DW:)(P>$EM9S#LTKX/9!^]>RV ""B?L 1NO5PJ>DN!T>G;).U^Z%A]'
M"R]TNEXX-RBK?*K2T[4I,G-IM(5YSXYY #S7\DLU#ZE!,;AIN:E/,,1P#END
M?_K(Q)1Y4CU^DHEY[1XH8.3L1:=,ANFOX\/P!QCFU2&+J#":.^;E+3UH*T9J
MSJ?(8)^/)R]"4YJ](FF['YCV:_]^Q0:I,?6^EZ2TWE!6GV[:H6, QG025F>%
M.9U'GI*>B6^MO%]$';.6D.^+6A8B2Y9S\#\=^23>@6$F\<CJO>Q)QK#".0VQ
M4H1L^K0_JVLSVXYNJ&)P!7)?/E' :E8%:^5XWU0(;%+=D5CP9NC=IA6:V;[$
MDLH2J5JZNB_'5&R1?> 7%7__?UK7GYM0L\OCQ[BUI"5Y6FKHC=G_ZHB(Q5^X
MLB@VI/_H>GS/J7+3=W@XQG:7TO+TA0,G J>[LA6B=HH,0IH-PG"38[UUY0;8
M4P'3! #<OK*,[P6':2\I%4=?##-&K,7&&CP-X\R3W?U%6"^L#LY5L5K<458D
MI5D?(2S#8:@H0XOED]*<IX3<L3^A=*US)S=XHMXH.2C@Q(5=U7NH'<?KZCE8
MJ0DUQ"']A]GB4S=4&?;0PC#[@)GB@)::VRQ)[LS2$=DL9MA>+3=J=J@L'^[I
MV=E=54?#K&'&S?RF[TOG(70K7FFA?9N_>B.>)R)1^2O1G-FZ0P#"^)7Q%;4$
M($E.3'0N_D?"O' ;7&KUU*%;!,"0*-K/#*+ D^5?P!LD"TMTF",:U8F65!Z.
MO30)6GW'\P\L&GCM5>I7]QLRXX+8(!<KG#5B5^2<&?3,3Q9[_E[RW3^@;Q0K
M@U[J]2RFO<]RNR@N:U@>>I!55L2G)D8VBM&F.UGF>@;#+B3M3LS <*KNE@!G
M2:D&NGR#=55AF4&%I\59ATSE<\ZZXN_0$-.#5MMCD5C="N/:O9W],#-\G42(
M .CXLG#:;(=A"T\WMM4\8T /L_UR>O\'D'D_UKUH3R(H-8K4_?G B$%<&UU=
MQ (^F^'H%&WWP=NF05\F4L/C</'+^T;O"-T>'_-##TY%]'(-.2?8=)1<7 )M
M]@A]2_X)C^.8*#SM!9(5#:5!H;!6G]ZVV*G@L,N^.[Y(^P.L""E*CJFU"ZP'
MO^1 HIWAQX5.?$$=3:Y]6^9Y.-6.1IX(XKG\N *K:$&N<Y+I[,<GSP=GM_+U
M^I."]MOI32IT\ 1#,^6NA/'5YW-$WO&]_B/<3S5LJ%S4^X*C:_-HC*NY)Y3Q
M(*B62DC+__)1$@855D\%.A#GD^?ZLUMSID9T#AUGA/(;DK5<Q_X:,)\.Y!+[
MSDLD?FGT_'92.OPE+A[1/8]:&4#R!IF9=FO5_PL<\=<F.+E6!Q3M14H;KC#F
M+>,S=*DJV'Q0NVR]I![J__Y6M=8'FB*FHE?S(C>7#82D&[L+-L,R6DQ- Q_4
MV8ZDR97GCEBTKFT,+JQ*!<AEW&1.*[J-[XU:7]S=79F(GD:=_U8TBI,M>CV8
MRJ^V<O75^6MN<UR;2@F=1PHY7Z8@+_:=5EU76-C9$8TO_N=Q994$X+G[K7'U
MPP-.N8-MGCOWN7;[*,DZ=K>& C#7J%@"J"A@I\\56?"^@&D/XB&/5R43^%8C
MIQ/SD53EB#7WWEE[[0_6_XUF_ G1C+_AA. ;1&#>6';URU%1\6B[4<F%*16G
M0ZSXN9J#&5,95"#C?37MY<^BN<[&<%*'@GFYJ7)R1!A4FEB]*=B]I>@58;\Z
M"]#DZ&$/SL:QA^H%5^C==>;4'U7"V* LKGEYV#6=HR:DX=H,Y\#C4L]= X^9
MZU5&"IN:2)F82/&I?CY)6.X"Z_'O4.U/JQ=RA_WEQ$S]/?QK(E KO: P[;/_
MJ;+<O_/);^;R1HU)8$/"D;W[PW"'S1BV[7\S P?ZD "8C:74'TZ%Q<VAO>7\
MWK9!)U2Q67HP> ?H#S[!CO)6!!HD<L7,)LKO@./)=M)\LV2L%F687!S108J9
M^VJ]W.N(EN:MN@')'H$C1^+C#MI*J7GD<Y4\QA>_/JU$T:(I[QKR"V#_%YK_
MEZA(<MN48>I^*$:J<<9GYQCPM_HA6?8):)W\X.8%!B$E?0MC9M=87VK<@'!O
MUOTU%(S6?R3MQ *L!QD[Y*X#$2K.N&GXR&3766T#B;Q?\Z 1XLW;!,\Y1_[U
M4&9S^B_: FUC8R[>C(?[VK%N?H[,#K$@F(Z5-M=F*O2G'"M*UA=X>M:I>GZA
M$)Z[:AKRHO(*.3E;9:!"#!.><;*=GP$1=*BXVN_)K%FO=JPY?^]\937[6+Z3
MU/B)D2<>B]7*_7C7W$R'GH_.7O^U._\,N_,OEL\YMT.8-%S<W/C[F^?UFQP&
MSL\\N);(9HN<?A*U=M"&T2U]ZFZ2Z,*OFD_62)I*9XLQ?LEAM4"!M)9!A00&
M6)GDE-)CLL'0%NI/^O(>[@O'7G]\[2B0C&2+GQA_6 '3[ !U:BO1:QEIRVL
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MUQI]%-G<]8CK9'M_VA0>>)JY/2#"1?=BY8PB7Y"T!E;;?&O*OLOGX]?J>]X
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MP01Y>P#&Z.*@@YH(F9\/UKAZ@<J2S9B%QZ..7LQ6 A"CJ77& Z@G'H2[RGR
MB\/1$X<I$6\>H9*Q($/,.!X8B](!X0[Q$3#[% -XDG 5X\,JZ)?7[SB,E4?@
M6R2O-PD$77<B'XSA,B## ZTBD&95G/@Y;_B(.EH5YY/O98]8:N39&;L3^P:Q
M2N&W$HD'0B\:0M"7*@A2*.4F-"$98W\/^(O?7K]CYSSE7X:N-]:>L#XJF19^
M/DY=EI[>7H):G$;G0-_W$Z9^,19/O%XYF_93?&?M9,X.9[KPU2("X*C(_L0;
MRJH$2,*Q2.4V4)/V6/(]';2L[N1+Y*=C_)10&DK9U\-!,NR_2!9NJM7PP [T
MBMIR\U0.;_V-)]Y3DF<#,^*.\\-?E"7X>>>0;V^]>3.D7!+:W"P<0$K#9I?Y
M)BO4&Z%NK]C %G%![9XC@8Z:*O_I:2(8M[#/C=L_K-6 >VQ5)?ETQ?%.Z^$N
M0^7,T6+M<YY5W*Y!+QF4DFX'D7B*?_GN-/+]_F*T\1>_/=-[_]M']%XY.]\Y
MZKN7[,A)VRP)H@A5YD_W#T_]NSQVH(>H2O\\C(%;O%<<?83<Q(=Q>6H3$%NN
M7Q&)5XYM%OT=8OJ-/&\/D/$P-Y753>)8 6_KDZ352M7YN+D;S34M3"HZ$3JA
M"]_G*49H#59HYB-MIU5L9K&E]YK(7 D <9@P=&\'K3S^(F<>/%2Y=VUQOF5_
M/XGDHV>#EAPET4CN(>R9<^A/\: N2^\_S!@@V?#/J7Q>=(\!OKEXRP;:*I69
MG@0!&),@3)GT6Y;?<7G_:@<'T6'X;2$DS;E,D=R;L68D)52Q/"*!!ZUKN_7+
MM)^ZJ05X@O['%+^/*3"4[#F6Y#)L=EP/3TQEI>P%?0#V\K/_VXRI$Z!&#W?4
MC+2',"[A,/>P0%.;>=64.T^B'XHA;=UT)7LD6M4K*6*F# ^\QL4M&A8L0JYK
M/IUV]#3"W2B=[BC<C'=A*PI/C;LL3AEM:GB&DTD6'';CC64N<PC4BIZ3_<3S
MCB[APJ/I:E^2=$'J;*P7\TZ;M=YC*-D)/=5+3F-<"'Y;67*B(Z?M'V^FS.$!
M^'$'K33RLTP26;-+JJ6>T-556 $J]MZ\E*[-)]GMEV.@YMO)<60+\%>WL=W0
MTT2C%4$A%MW:EX5+<:70O4%O6LA.ZMZ@13413H=CD,G4,<GEAWN[0-XB_-K0
M4;""AUEOGYS@99/9J_QT?'T_W.#^TM$J>TB+@GFMZ.'ERPJM*B$T!07R\GMU
M=57V/4N@E!WV%: X2MGZ-_"(0E.'R!#C&AV(61\\T!:A(>/&_B\WN_I-+M$?
MR HT7AD*)8<UMHQ:'84[3CK-G8"-,9?L Z,*"!KYU'+)HCCYA%K+?<M?J,R0
ML"%%JZ_47@YV,_7>3/X4<6;C6#!5A3SL7A)8ZQJ-_3D"W)?B&\F&DTXO6;JY
MS0<=C3'>2 _SJ="6'JQOF",Y)*,)J(7^N)F)H3X#K$HL#CNT7))>ZY&L\+E^
MWV53R5]W0"&Q#Q#CO)X$'KQ'X$&MVX)S$K_8G_+7J.47\S5VX_#.&(;>WLH(
M&31GZ9WNW7QJHK'B;7N6U-;TIN]^$[D7XE95G"2>)2,(LNF* X6'):[J7[;5
M:WG/]I1$M!'-<'\+..1V+&OI$FOZS[T@UGB:%R&I422*--F<4YH!I+ :1C7P
M)^;"QPUI!E<MEU'KA0W[/8WM7VXQFC"/Q8?'?1[8A*0BS),/4HAJ/9"[/RHM
M)]TV^1P58"C.RC J8/Z$Y\Z),[#W7SDCB,81ARN@^FC<QVX&>D.?7)/P#^^N
M[F&Z1%%&M4DW*98.#L0#U:*SE2L;1@2K514/U'+J$/Y%/O04#[0,!F+7X'B
M;D?ROM]:Q& _((8T\,!2T(XH_P^[!'P7C3R+H)@1G+9O8%R^7!FS>'C>WWNO
M[Z*F351$!A?,T"[<5^;4Y[$SYE34#15<^Y)I4'(92%'2W?6B) ?N[ <X](U/
M<LIW.D7_J?,#?VU\@TUO)>Y,"6)M>&@+MH^RI9#K*ZO(=3)4"F0S>O]]#8-1
MI>QR S)&!DQV$L[NI>MFGV9EVU.=5;'JF.R%4\6T&(-#8@XM*RVG;^AI)R T
M"Y?=DGF&/J@^5EDOL6A]3U_-2DZ%)64-DY.E8PG7)WXXO&F2TW-FP4BL*RA1
M)$'_/<W,A=-?L @%A>"EEVU/J9??O].0LR==G,F1$$@*SO"5Z*I5H5 Z^9ZN
M,^-(F^,,]]M5K+9Y;[*6"U_=X8_<@4;]%'/& F>24A",KN.I+:PQ9U[75XNV
M7GR:S6W%7HK5CAWW8.8#2['EE8L^W^F?!\DP'>@QFOC!<P$.]KB(5K894WB/
M2Z(>TI+=*&6O!^T1MVNK MA>U&\CH_LN$J&P6/_:6,D^?;E6U?V'7 :,H@.O
MP=7DB0U]9=^SP)YBXRO'FBX2Y"$*,06Y0+YE]HN#$O_QSA,0EGR;Q!_P0$\_
M8BHVO0J]\/G@BYE*8H)]8M>!!^9G\8#"P@G08E_*;U%#F-PG7_R./;"3<7XL
MZ0&!!B&XX(AX4!NG][]*8I\,Z.'C%SL1 P01HF247H79^MROK7H#5PK?Z-D,
M.@-7G_G1FT(1(1RM)$8>O.]9/C&E'"D+2I9Q9P(Y[#"Z'/7^%>VM]>V]'$JE
M#H5/MJ4".1JNN?:YGCK%%KU7)^;J\SG!VA,_8RKLQ?*=?]EM_;#@6<CC%R]L
MPQ^NL6VO DYF;%R9/#7 !<#+QT,<=:C$^_G(S?L1RYYY3B*P;9\W? @NJ3#O
MM29QH(!H#ISR4YK#YJWU6#R@\0@/5-["Y$Z?2N9H_YSA_W9-HGYM<=(_@E(I
M&)V6*N?J4XP5LU3HW>>V&)WO/9:8$@M_D[XDTY(E=1 %46G;-S@;7!K2OGP,
MN'<)OA!VQ'B1Y=(DR3$9H3G6H?!O>^,]!F7^ E6B#<::_;&1HUJELG>*Z"+L
M?+R9Y*,)IH1+%+4HUO$)_>CG*F]_J76J2*03Q5KAS?B^LS$BJR:&U:CZ\5L$
MI3DM'^ T):7Z^,I,\=#,0AI%B?@'+%OP=EK :??P\-=9(.?= EMHS9%W,.:.
MI\*2R#7G<*G;Y@Q!R&AP63&5YP>":O:<'R_UKRFY1:Y_XRZS+MV:N3-/W=*U
M"PJ'+#['$M'8!X[)HFH5G?6C'XE]%'&K+:_&!GC$.)XR,)&E$JU]IX:2"(6L
M2]YD( ":IX?QP!;/I>"ETJ]Z<,EO)6I@MU4G[ @")6@W N7GS_Q7YBB+S@WM
MJ(O*+90-%KJ7U+PW^AL%-B9E-%QF<%@VL$;4#CFH F;%!BZT1?9G)6G3'WUY
MXV*(:9^R^1:<KWXU__[+$?;'^0@:A&8OSAW.%^44<F16]N4-R<Y3C0E;!*NG
M?I!>]9KTZ]?$D,0$]@O+#;K)[DHYW*\OI2_2;F3T/@UNRA3]\N:\NA\O9+PK
M$6EN4Z9O+$V@1&R-^4I0A=E3J%N?7'*V:+8-47AQ@8.VU+S3:^\2!L81?'G0
M*@ +YD[@J3J@#_>:AU[L-'4H&4J]H^G9:PEOZ5@S:$??M";1T6[97ZJ:I[.I
MO.KI>6LU:$'*\(=[+K?<-2#GP=RR-D-:563LHR)'5]F*4UWPB3E3KS61QO9L
MW%I.QJZ22.A*"X3BBFHGJ\5)EA<^N@S8NFI.1@'^ZIWR+EDPS='DT_^#-U_
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MTVX_])P61R\_C"W]B^M7 ^?PP)A=AEYEX,E^RH]0@0^1;P:(5N3GCE^LV[8
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MZP.H8P)NX;RC72ADT*[^=6->BU;*5,72U$\#U/UJZP[G8/ONN6RLZ!L$80S
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MD8/MK]QFFH7.E77ON;KJJW+(')1?>_BJO1K)>&V*'VQ^IQDK,568/(M?J]_
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M@_S;\JF&=Q@_+F^JDG+.ZH]5^? ^?^9UDS=/%;\6[Y[JO.!US>LE]?T8^5Q
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M5;!+ULQB6""K9T"FQ<O,GG2\P)89L.4&=.PL@#&4Q@;&'@U']L:"@5G-CSU
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M6=9-O0Q]P1#Q,XC]@$/DB0CB4"009R23WE#"2("6N^<4)VW .6QHZ?OHL<R
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MI*VD@ANYOKJ$)[:9/1N@DGO079&;3X#6!E#/OYP"%C.CN4:D'1Z_Y@%\DTR
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M*(PA8IZTYI0)&+!84")-5A1HQ0D&-"<.!G:OLF[H6O5%T<%/3W,=HV*FRE:
MV,],&1?1]1B4 8IO,]ED'(*3PTHT'K4S!M?-/:]4H4[%[WE1Y\^\RU=\*NOZ
M,V^NQ2W^WC5?D3^O) _\/>_^W/1%38C'A$<(%*FZ?^<G/B2I:I"-, W#Q(MX
MA$ULQ?DL36Q*6@;;.KL-A^M<83=Z=9,L;/!WS9F/#M^'GNV9%V4ST]0!O,<<
MZ'.4/W[J /[< 2R9G*3/K3MT'%DU!PS-:O3< ?C:)CI<V;R228;>N?SD;865
MH]_>J,AYK4Y9/N4%OVKX@\ZP5HU5IDSVM\1!3QVLR;?'_NUY$9/[3 W^4+R
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M;"SC,&8!4PX1SPA$S$]A*CTDZ(6!GS$2I2PR&GIZFM3$ZM6=#-G7!IR&R."
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MAWC8M?HY!Q>CMC^:D@XT_QE;8;860)JB[#8"TGUDBJJ-]^4#SHNEEY  >8A
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M+T2^@269@,5YK,ZON30R35EP\-BS#]2WH;\2T):' I:WS T>F4S^PL;#S;?
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M),%Y<@<W55[0_!&OM@W(I$=<\>=R]=R>.7?'>:(__#&]#W *3#WE/@\;RWL
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M,.[!D%(2!2'G//4,6N:,T=-2T[,[YNS76+2WS_6=G4&XQIV\LZ5W4%72DUV
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M5]+3'[>=8T2:JT)5A2G-?X?KO/[Z6'',KHO?<96KM/@7:1;\981"ZB$?02]
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M\,(C:U'%3V5*BX*K1]U?4QDURM)1%KARD)J>[6IO7C+V\O32),5\$ LA9ZM
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M 7+1@/1'WOAK;H)?UOS\:D:0=ECZ7T'#E%-XV!5U.S4Q(I8PW3$"C XC@9S
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M(8HCG,LP(YAQJ]K;L[@869^LR0?/ILG=LZB"6H^)"WZ9+0*^G,])56__ZZ]
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M8[W.:OU#D[I]2D$(XF&2(9S0$%'U[RBC5,8EY:DD5D%%2WJC:ZFZ-G5Z+?F
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M!)<D(7;9J;8$QSZ2*Y/P1*K*1&DAPXFM(;,TO3T" ;2^#65D2 =;VFW3NXO
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M:;D(:LT7S#6P@K,HRRSGF40R"1,%8D$1+850.C#")4MQSA-05-,;CNXZ<%H
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M7+#EKFU8%'AM(_(NB'I2O]/P/*DZG_0S[!\/TQ*']U&Z,E>N_%:(RI0!?UZ
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MJ"R%1)@4"2KR)$8QSXH2L[1,L-4L7PM:(V^QU@/;#F=9TW8Z'?LPL]M_GI
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M]+Q_??U_\>/3?[W7-X>Z4$UO0QX ,-M>!@R G@-PK9*B#CQ8#+G314A_(_"
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MT1L88D;6]ZUN0TXU]]FG@KX W.4^JMA_G^;4#+&O]MP:9HMJ0JQG;MT#9V9
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M(1@R'N=RXY)>:1$G'(9,]0W(TR#1Z]5L2MCW=M:QH;SZ/2.&]0^Z$.KYI#Z
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M]GG!7GO6%YXR]Z)5#L<UW3WC]?KE#I?L'_6^A.:00*KI5^NLY5F-CE.=.EZ
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M+4@0YA1&** 0$93*<V.(H1 1*_(D)C'5VBT-:/I6O(8+L&>C28"I@60$M)P
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M;6S/0#OI6=G9LJ.N=)M)EIHR-_6'-=](+('@II?S&KCJ&5&W:)F9Q6.@WC?
M='W->PZ:1%*'K<WUQ75DM30(+FJ'] %X;5D,WK3,[-SL2E:NF_D1WU0&?'/1
MWMYE<J;(JCNNY]Y^]>/L[GC55.6VW9E6"+%"!"&%E!!I3DB Y;E,!-*PI$S@
MO*!9;C3?P0E7OG,W)8^P9Q+4>R[M)SNX^19Z)FAQA,VLU) ]<. /] RVUFO
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M-8,[9U_VK)@#:@8S7R^+.AW3F2VEZ0:*F]X#PXD+VD(;A71&!;.*ZIQ?<;'
MSJA P]C.^(.^VRBM,IY&.97[(Z(QE;^0!&(AL4QY$(H\3(JB0*O==H?7>CNE
M/FDCY=PSH/VS^[GO:_?<M@$"8M\%R+JGG0&N>CNL'[3,E-QQXZ2WZ);D>(\V
M(/P7[8YT:>^V6,'. KWG@E<59^W*;5+I9REE.X9,LK'"A3QG$Q9#AB(U7;J(
M(.&9ZDF<2'\]"3,>HOX8?J_OJ4\2MCB4W]M<R^/';;4K_RU50^6)'Q+'Z6@:
MM"68>M;&#39VDPT5!L>IX%?@0+O)%G=G.;0%=60PINDM:B>TQ7]M'O1?-/?N
M;S>U-#F5='?NMNN22A.CTM"OV?9):EAS&:/IZ4\NY-GK[^B#WCGNN>CJO[:4
MLV>52-=QI'\HF$9H^H#@%!PS%3?$!?RAV'%T(ZPMMM518GKUQ8X5VH(.CQCZ
M+YFK=9<6<OVSK'45>/"*9U7M*&EZ^:_%F=8V2TG,]*HC OY09!SIRQG&K31C
MN,YB.G"&^>%/^[E_MIE%U*?X7V]8<Q_U?;MFJ@_%KGQH#CI]7[TXIB'A D81
MRR$*8@QS'B209$6&"I('C.H/L=4DZONJ^% :(_D  T; @1.303N:4$XHG">
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MG" 4K.1*9.NZEV!#WT0EAEQH:T9#Q;[+JAF818"Q0#R%-%4Q^!B':O!2!GG
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MDHP:!E##P:*[;FNX:!X(F-L"0AVJ/8@3S7D[@$#$<-+D S38=Z5H*XA]W#=
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M!8YH3FU!,U7:HBWN]<SF91^DV?"2:7=JB\I=3QH;!ER<! /K>-AFAZC^?WB
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M^,.[&:[+8GD&\&^;7WNY^/QM.?WX:?V#8$)?_MCE=Y?_S()0UB,'BX*#*L@
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M1ZV3$,@$NE3: >36NW>#1\<'GHW$.C(XJM5[L<RXH5L9EZ)WA6+O)$$9(6H
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M2884==%Y9Y(41BVR!E-\(9O!*?K5"B&BCB5STIIL?7KP%#WC5LUVA^AFJNL
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MUCFWS]$T[OWAV)[E,0KJQ^+M+L5)1%?K* 3H4LO(!<LD.)*>12]1Z1*D;XW
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M&+63?@]0BO'\['Q3)/UV_2DOJZ"6^1/%O],O>9L->,$88Z5D42*XFKVBD'%
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M'3/:8.)^(Y9&&NC?W7JW7)!S273.<..NY/\\GWZN%O8P(_/DXYJ:G-T);V2
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MC[=RVZ^3)7AREM5[2EX$;4JD=U^'D\ID@O'2!FV':/NY,X''>RP?<?877%?
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M@2JA3D/GACQ5#%%EK[B8-"'EF+YIDR&J T_L, UUA[JK_*PSAB)DY35P6</
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M]P2!0W6V:BG F1%P=3_^<[FY\NZW%R4Q\^;RT^7F@EAR^^IIDS43P8(5MHX
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MVAP7C26C#!Q*S(1",KP!M<L@@ZL80A_=%&D@I\EQB3(C]YQ!<I*8\S*"QYS
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M<7FKVM+[P"0O'$@8EC:V<$ &2P$9A(TRR<*Q=>>R*?B8%]Q'P.K^63FWCCO
M^2]D.ZZ^Y[R]DMY_W3ZM[RH;HD068KU[MO-L-1T"125@WG$;1/'!M$[0?)*8
MF8_3V7&RFD)I':#O0R:39Q$O<MJR\L_EXF+SX>,_=\PH'KUEB9'A@]L'*0V>
M%0TR6I]XP>)YZP2\9PF:-QNJ.Q2V4UX'2/PSK\MJ_:4V%-\*<5_.;$K)P7E)
M$E'UQ8&L<A=-!LNT"\9%S+&UD_,$*?.F1W6'OA8*FSM5;[7\]%=>?_EM62.+
MBV]Y*ZI];Z\43>!*0D&KZL.:@R!E)CN';!SE2XAIR%"AY]:8-^NI&T0U5<7,
MD+J]*QX:!UPKXL.""9&$(S4">K200O2\N,+,H/EXSZTQ;S)45Y!JIHJ9(?7^
MXG->7[U2;:6T/V@C"SSR.K9-9@Y*:#(Z*S-.J)0M&D%\#$#3$Q\_;Z)35T!J
MH8 .+*R/EV&S2 M<?_^(VZ>INBFV/KP3+AN#=*"R6I*?(H,0700LF$S2FL?<
MVLY_DIB9;?PN'N[::*H'R-V07_?A^W)KSL2^'80Q6NJ,$%W-'V2B[A\R%UV1
MR3J>+5WOK;'W(E4S/W>T4?]]4+75Q<R78I517"^V5_KU+(S]W6Z]"-(EJ&7;
MH$Q1@")X0$F68PJ<8QK21?"9)6;&1V--KMJ+M8.SY^TY;C;OR[]J#'MY\7[]
MH59?;W>1K7UABM& R,A#]4S60UI""-P7XL:5TCJD_"0Q,S\J=''=M=%4KY#;
M[4CM@@Z)C,7D(PD(>2(N:$>*PB*)#-$9<PK0]7#!-5+X$!@=(/VY;[:\7N3-
M;SLV]KZ&]$$0Z1RRD4C[R]/A&VR$A-E;9F/4]VOA'[_3'OOP#L%PB-I6+678
M!PCN<X!H8BS6@XU"@[*< [K @/&@E;<AHQV2__CXI\\\K&$Z&!PCQ1EQL%E?
M7+V#?,A?+]?Q,UV\?ZY7G];X97M42F.5L%)#2/6=744/H00)MOABB0Z=V* +
MA9:Y=9G0=S<7R?,4S/QZ/:OITE W72)LO_$D#SD64Y]%R=^L@RK)!PA ;$3E
M'*; !C6>.PAC<UHJ+?7[(F0.$/;,U].;JK['F;EN$NV*KRF4Z+$ZBP[!>^,@
MHBDN:Q[*_>251V^J%Q?J#1Z'Z'(UE6 [<(E>/)R?.IO?75<X./2)D8$&N7H"
M-:T!G+5U1$+)K.8U>-D\S?EHJF>.PW7AUY]8]Z\9[5>QR<T_MF;J;\L_R7!=
MI3-AHB@)$4(F&U4YP6C7TU?.N"@4!BU4ZS>#MAQTGC;8&'^MX'\\&%[S5K@*
MM-Z4IFVVX=>_/N/R<;GX;-%Y5&"R(ULLUL:9)OC:%H!C4%&6^V'P^3;)2-XZ
MSW?L=/M,":"YGX4.E<GVCUL),3O6BV$Z:ZS&*9)^0IU?Z80'H60HECO/W9!&
M38W)ZCS1<AK8SZW>UXKLD;M]^UUMX?$K+M;_@^>7^4Q*A\XZ"=J6[<5:P*E@
MH1B23U0QX/TARVTWP=$<=)Y&VN%^.2UH7K,UMOWC?_+F8K'\="4,?I:$2I@,
M@YB(8^6U@,!3 "FB*ZED;4SK<10MZ>\\1;93J^I8(+S6^V7?#&K'^K8M\?;(
M. M61!%$ANQ4!*62 6^]J]F@S')AM9W6>'J2LLY3=SN\#]HHN9=S/KPL@?#$
MF\,?J^4WDD'>?__K:EWR@K[?2^BJU.>,A^)")I_)ZAJ1]4I#4-J#T:Y(7HS1
MHO68AQ.Q-F]CQ1YNA\[@T\NNFL3.O!;0]6M$*=9QYK9M1PPHFVOR$TF*JQSJ
M4"NN[_=.[O@YZP%[\[:1[&%W=0BCN3,0:B+SPSC[Y<7GU7KQ?W-Z\V5UN;S@
M9TYZE:P*P&J["86"KF)5)"2+= NGQ)UODHPPC)QYFU7.A.2IU-7+&?^ K5_^
MCHM-_@O_)AENXZ':8XQ!><#ZAY),@(^I=B*FW:7I9R[C%,?SBY3-W/6RAZ.U
MK?8ZP.1?=2C)Y?K[=LMMWYW>Q&W76!+RYN+W3%LNG:G(C#7(@.G:K,R7 CYY
M"P(M+X4;H5-K4WP(73.WRYP9C\TUUQL:KPSY/5-GNBBA#&TGZ369&SXH\,AJ
M%U(KC0U""SLI".^2,PQ[/VK@M)6>>H/<GHDW5WUIZT8B8W?+X%F).B3#&6"2
M=+"SX@!Y-'6THL9 %H?!."7^GJ%M&!A_M'#FI!KL )F/6\$?<LW^7"P_W9C#
M-[^S-XQ345:I^OC!3,TW$ F"2P(X.J441Z7:OYT=3.TP]/YHP<43:[D'/-^J
M*;[S5O?;9G-9WQ5NU1B?26>X95Q!B217%3/M6H4<K/ B&V=,*<WS$D?0-PRS
M/VR$;RI-]H72MZOE9D&:W KW0XYY\2VG]W>8"R798&HG,IT0%$H$A[4(7A3C
M2(@RWJ^6:PG3EPD<AM,?+5 WO2[[ NJ?Z\4V(>O*S-%."B9E L$-F3F.!4!A
M"F!MWV%R#8!,>'3>H648_'[84%<+#76 M'<+#'6V[2)OKK.3WJ3_?;FYJ ([
M*[4[L\T9]#:E%4E8P44)AO%:UZ&D2;PQWIZG:!CJ?M004$-M=8"]1VNVKXV.
M'.N\-.+T+9Z?Y_33]WT9]NX7:QDE5TYY#2QJ#LHR!2&) CE&@9X+++SUD( C
M21Z&WA\M[#.'OF?.%]O1_MA^_7FQB>>KS27=%1B]"+8$X-6U4XQ+P.09""-*
ML-89SX>D#@]:;%@QR(\6X)E&%S_0:*I]J>?JRI9YD+SSR]_UR],,KAI)RUQC
MK8X1V6F&7M%-SZP3"!IE[4X;:N&&-"""9C*PB":4*9X(3S#TZGIT0EY_6^Q:
MAS\\5LZW'TE?O2_D#ZX^+>LCVU5J2WTUWEP5)Q>C?,RHP65!6][YV@DQ14C"
M:*VRU\B;!^.G8*3K85ACL/CT,*RYU-Z!E?S;DDZDJR'6]5)\MV-QVT@D%.^U
MX!9L++;6'M9Z7E9(N"4))ZV1HG4IQ3/D]#(T:S:PK*;17+\@W+4K86B\L4Q#
M]F0Q*4[6.0E*@G=1:!2<Q^;3VIXE:%X@-E/[,#@=H(,. %6W&#E]>'X]^",Q
MH[UV&GRRM-,"&?IHN0&G"H\&H^6Z]6W\@(@N@7.(@N][WD=)NP.X?"!-$ &?
MWRS3S_E;/E]]K1+:6=H[ECP3D3NG(!E>0"DK(=1@%)-9&Q>M$++UV_@ LN9M
MPC =I%IKI .0?<SG]*-/_\C+O,9S8NQ-^K)8+JHA6T?*['C;[Z#,I)8H(@CO
MZ"BO=;R^&K;!T?Z1.D3+FE=:C"%PWC8(TP%O.BUU ,$VINO-FYDNV22A$UAE
M#"CA$W@I"FCNK3?"NG"_[V^[(9!M6.AEH$<O3L6<".E@@^PXR^EQQG>[_TQG
MF9V(2)8-XZ!8LH"2#!UKLN%!!QY%ZX3.893-:V'."I[[XZ7;:_+'?9=_\+ZV
M#XZM=L&Q.1[H!Q/5R4O]84(\S9-]YM$)QY$N@I@)ZX5!T,Z -(45&UD16;>V
M)B=]LG\TV'MU_=F2<G%(O')';H$U"9SACLX/HM$X65QJ'9YXFIJN'\_'H&)0
MM'V\ CJX\Y^>]V$2SSHR <G7C( <)& D/R)88YSEV2 V?S,Z:A3/:<=@'*#M
MP;-UQHB^5PSMO%%4M7@ID".:=0!5LB(?$3/8C,$(984IK3WY5SA;9Y3"1\S6
M&2/]#OK6JWO30"P*9"HSVE.5?$%>G2_&DAT<8S)*>SUH6MPC']TA$ Y1V:J=
M_ Y6_[>\#JL&O28^U&RE[6X0 ;5QW@!WU?/1!2$@N3_*6D>>"@;G!A4'O-!-
MXGK!#J?K''Z['"[*F7N-;(G> =<Y@YZY[5 &(MN1;>:D\*"(@UA4U$HV0\#<
MPRH.5-9]=1\@N9D5_OMBN?ARN1^>X83EZ!P#;UFJ%?<1@B )2,\X!AFPW!_
M?I#*[RPZL](/4=FJA?SF5CS^?8MPP>E<H[N-'"].[$NZI(+<MD-RV2&CXV]8
MIMA+BK^]Z#PG?C/%'RR_7IV%FU=/4[3*/&&M'JLGGR886^V HS?1)1.4.,D
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MM \SSQ8Y;^UY/$?/O"] 4V#E_BG93!NSIP7^[]5Z+YG--B.V9)$$BQ82QYK
M+@I@<0Z8\J%DIHWV@TJ-7\P-O+_RO*AII]%5,_'.#(X_\$M^7^[PL"N8T);;
MS(VKSK D>3 -@<6ZDV2Q3!7)S* &62]@Y$D"YDLB/E:CJ];BG;F$Z)_+.F=U
MVQ=E\X_5M[Q>UJ>^79JLRB[4?HA0(BJR FN:+)(I**/2Q1"+O@SI!_S<&O,A
MH9'Z5A/(<F9,_+%:/LM*<CFG0/+ASM4N"\("YAH T9P.4VXX$V4 +%Y89KY\
M\_;(:"G1F<'Q_^)R0YKXDYS%+Q@S^1T1SS>_+>/_L^.EN"A,)N?5<&Y!:5:E
M%3.$6CLN4"KAPP!TO+3./(^1T\"CJ4QG-CK^7*_29;QXO][U=-E>L2YKRVQM
M89Y5+;21%D)2Q$0VR@IO2?LM"I4>6WO>N-\D5NG1(NX#(ILWR[3C8+/;0%;S
M*'+AP*VO'79BV#: !*V).=I Q,B@%^MA.'E(P'S6R/$Z?0B0(P4\\T53@]0U
M]1S/=^SLFSAZGX4T"FRHAI2BX]89NYUO9"P3K+#[S7T?O5^>^/C9$7"LTE9M
M)3@S"'[/J=Z%;^NC=%Y_V0Y?S9O?W_Y^EZ-LA%""67",15#DR(%/+D'(R06G
M>%)AB,TQ;+7Y#-/V$)E OG/WQ#@_?W_Q.:]W-^W>P,[%>O+ P,=JF>E:Z8M6
M@L&Z&4JN!58# /+HA\]GB;;'P_'2ZR"FN9/%=6?I:)CR'APJ6X/YLHZE5\"3
MU,8+I6)L71U[AX!Y8M_MX7&\=#N QA/V^+OK^CDA##,R$LIESC6;4P"ZY$"$
MR!G]/5/#6BH<'XEYUT<U=7,/9A)5= "M%\)65Q'X.F6;7'WZ+_V%?Y\Y5ESP
MM5Q#:F*Q,$7[J%91DDTFHRW9B]8%6@>0V65@YT"</.@:/ZW2^B]X?9@H\$<M
M\:WI(RVS(!Y\Z,39#L\S<>*LAIB3-UE+*%F3PY5Y'4MN#1@5,9;@";ZMY]'T
MD-7@E5+!2 F1/ 2Z';0%3S8!9.Z<==Q'DUHG<[S^K(8Q6!F5U3!&&_U<IQ]R
M-5CI!/XSK\MJ_067,;\/YXM/UTVYXP4=RXLO]"MUHLS%8E.N9JQ_O,#UQ<]X
M<?641EZJ3!83R)HGHI@4X+GT4)S'PDI00DV46-2(@RXOX0.0]?@%/(>:.P#Y
MB[:-]&1,2(=D42=RKVI3RY 40C'"FD _C;'U0+TF[L@\ 95C@-A4%1U :]#&
M.@NI<%1,5+<-0?DZ<2M;<N6\55SIE$OSTI)!A'5YVAV(A4-.O%&*>2UH>^X8
MOQKGP<\<[=&<B@ 9A*U=_0)@,06XRC[9D!A+K5_K6M'>Y<%X0LRV5F\'L'[4
M4M]L\L4?]-]J&2_7535G/MHH$D9 S!J4, I<,1'H%G(VN!0-:UT0/8RR+I\.
MVT!R M5T"KAW"PR+\\7%][<[GHA^:8H*D#&1F:.%@,!$ ,8]9TE;4_0IX':?
MKGF+_$X.MJ/4\IIKICZLSL_I]/\/KM.J["6SE\8B'S'ZJ<6J)ZNB.D@,IRZG
M2H);61 BJMKEME@@%SA"M%FXE)3.\<3QA6,?'K=Y+9]K2XK%\ME=6=7SZY5Z
MSIS$PLD!!)=JN-,%7P<8.=!9AE*<\[FP%Z!YR+JOX\%Q#$;N9!=-J87>K^(S
M)HL(/@4(.?(:^>2 0C)@,MA"?R=S:=YS^SF"YL':]#@8<Q&/4LK!"/NZ=66V
MSXXGP)D)1+JR F*N$79GR9*-@D,6R1OAM/2A_13Z8W'6W,GM#&=CE'(DSGY9
MINE1=NW>[X>KGA6)G"=6^:IMI'-VX)F6$(-3QF.F:['UO-IQ%,[CV?:%P^/4
M]II=D#<QUHS5#;&>%]_JVS]Y_=/X'<\N=3)G8SC#)_8P3&3D-^L"V;*: L-U
M';W&@//,0HF<0->ZR_:)4AM^6IR?UQ'05RO<"+[VV&>L=O.!H"WQ'$0&YY4%
M'6P4QF5=FM_)3Q+S.GR,,2BY?P2VT4,'#L4_E^$.*[<V\YD4/DHG:M:'K#EE
ML@ZSU(9\LJ2]DX'+U/J^?8:<>2,9IP!5*UUT *LZM_X_-1)#]L;/J\MP42[/
M'UX79PR#X99),"++W=QZ;S1P)[R5TM%F:IU),(RR>6,4IP#;!!HZHG?[)ZPQ
MNG;P>\PRV3^)9\($XX(!<JU!:1Y(:D5 3A9K]T^?4NM(Q7/TS!NA. G46FFC
M63/4B;R#=QDW>7-C(->F=JME[5*\*MN?U6CT<G-$#O/8%9KZ D>QU\@%N*+A
M&I;.RJ(2G4<Q,$77HJ_%R.1@<E-XJ2\BMGEES%T*CCVIMI_V=K6YN&:);O+,
M%-F.)LK:W17)7:XG;C'"$5LF/.AOTX:EVT3,:\ ?H>/[1\]QXNW D'K_-=>2
M@>6G+2=7,_C*/S=YFU7PYLMJ?;'XO]>)+K3WSC@KF.HCLXVV@'+2U2HX#]:7
MPF,T-D;=&#YC:>P 78=#8G5"_72'ORJV,RW(%!1UDCTF6?L":>( $Q!GM;8N
M:,-;#^%\2,6\WN"4&!HMXPY0<D-X+L9H920XERTH7K\*Z$&3!6-C5H['22[D
MP9B8S&EKBXG#)/K:#.3=]Y=?R?*]F@+R$YY7I_3CYYPOCDC:.7"A2<WE0YB=
MQFJ.15N3- .34K6H"@,OT!#"2LA<1Z%DZ\Z^;:WFNR?FK?RFW8"8S<^7-XW+
M-3)OG3'DNO)2B]<LN"0-1*TMCRYPW;R/\1CZ.K"&#D/&\]=80Z5T<,$]:^:=
MQ1PT2S:"<+4U/O<&0DGUA5;9.CLFA=+ZTGN6H'DA-1T.QMC>HY32'<(>Y/%J
M3VZ#BQZDKP/=0@I 6U)!-CSDRA"SK<-[SU,TKP$^$\:.4DN_(+M5FB"5-<$)
M3S8KDK7)(H+C*D&DK2,+HG6N]="4%XF:UZZ?&VH'*J=?M)UYIK70W ,WS "Y
M-J[&,BWPP$(L 5&)UFFJ3Y R;^QE;F2-4D0'@^B>O>^W3:RKU-Z77Q=+<JMJ
MA\G59G'U]D9>U&81SHGWZE&K9'T@9UJ0)TZ'-O&.L5;',!-39$4YU;H H1'I
M\XZ&ZL.PFTC1_9Z7.UMC!-^B2.+ !F#9;MNU! A29B ?KO9N=U&9$QVPHVD?
MA'#S@R'\1*KN%^(W-LX(UF7V,M;!ORG5*MJ8R,$SRH%-DB7NBBEY6J_[*/('
M =W^J$"?7.$=8/UA0,#Y0#<2V>\<:R9\L!)\YAR8<XSY2/NV><NUPT+[TP;.
MVCPW'B?>ACT06YV&]\9(7_>UV/[PK[S^PL]LMAE)*K7[&NT 9@LXVII@"THM
M=2KM&Y&,I;&#Y^S#0?'LX=58/QV<4,_R5R>EU[2]#W0^_YG7L3Y \*13\*:
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ME%D,JR$:1& )CR)LO?ON$5W<-"%YZTG8!A$^.-3N^+D0HEJP'%8Z3],Y&/=
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M/QANTO-;6:]5M;/?W_TKGFS_C^2Y!;_S1_3U#\P_.)NK__RW_P502P,$%
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M.3,P,C4N:'1M4$L! A0#%     @ THQ=6U]4:+?) P  QPP  !H
M     ( !OQ$  &$S,C(M;&EN9&%H;&-E<G0P.3,P,C4N:'1M4$L! A0#%
M  @ THQ=6WAU9,/6]P$ :K<? !               ( !P!4  &5B<RTR,#(U
M,#DS,"YH=&U02P$"% ,4    " #2C%U;Y1]T.\H5  !L]   $
M    @ '$#0( 96)S+3(P,C4P.3,P+GAS9%!+ 0(4 Q0    ( -*,75LAPS^Z
MS"(  (]/ 0 4              "  ;PC @!E8G,M,C R-3 Y,S!?8V%L+GAM
M;%!+ 0(4 Q0    ( -*,75OTHT_F1G$  (L@!0 4              "  ;I&
M @!E8G,M,C R-3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( -*,75M/HRIG8HH
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;,"YH=&U02P4&      T #0!Q P  *C0%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>ebs-20250930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ebs="http://emergentbiosolutions.com/20250930"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ebs-20250930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2025-10-22</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:MarylandWarehouseSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-14</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:DevelopmentBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:RSDLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-20</startDate>
            <endDate>2024-08-20</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreCamdenFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreBayviewFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-19</startDate>
            <endDate>2025-03-19</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:BaltimoreBayviewFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ImpairedLongLivedAssetsHeldAndUsedByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:MCMProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedSellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlanAugust2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:SeriesIWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:SeriesIIWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ebs:ValuationTechniqueBlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ebs:ValuationTechniqueBlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ebs:ValuationTechniqueBlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolverLoanDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-07</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:VariableRateComponentAxis">ebs:UntilTheSecondAnniversaryOfTheClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ebs:VariableRateComponentAxis">ebs:AfterTheSecondAnniversaryOfTheClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansUntilSeptember302025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansUntilSeptember302025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansAfterSeptember302025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansAfterSeptember302025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:RevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:LongTermIncentiveAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:PerformanceStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:LongTermIncentiveAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ebs:OtherEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">ebs:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ebs:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-17</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ebs:A2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:CommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:MedicalCountermeasuresMCMProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:AllOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JanssenPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SecuritiesAndShareholderLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-18</startDate>
            <endDate>2025-04-18</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ebs:SECEnforcementProceedingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ProductAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:CommercialProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:DonaldDeGolyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:DonaldDeGolyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:SujataTyagiDayalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ebs:SujataTyagiDayalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="category">
        <measure>ebs:category</measure>
    </unit>
    <unit id="product">
        <measure>ebs:product</measure>
    </unit>
    <unit id="category2">
        <measure>ebs:Category</measure>
    </unit>
    <unit id="segment">
        <measure>ebs:segment</measure>
    </unit>
    <unit id="employee">
        <measure>ebs:employee</measure>
    </unit>
    <unit id="positions">
        <measure>ebs:positions</measure>
    </unit>
    <unit id="term">
        <measure>ebs:Term</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="increment">
        <measure>ebs:increment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001367644</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1070">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-1071">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1074">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-1075">http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1078">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-1079">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <ecd:TrdArrDuration contextRef="c-467" id="f-1251">P445D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-469" id="f-1252">P292D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33137</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">EMERGENT BIOSOLUTIONS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">300 Professional Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">631-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">52519964</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-30" unitRef="usd">245500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-31" unitRef="usd">99500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-5" id="f-32" unitRef="usd">3700000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-5" id="f-33" unitRef="usd">6100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-5" id="f-34" unitRef="usd">149500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-35" unitRef="usd">154500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-5" id="f-36" unitRef="usd">356300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-37" unitRef="usd">311700000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-5" id="f-38" unitRef="usd">25600000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-5" id="f-39" unitRef="usd">26900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-3" decimals="-5" id="f-40" unitRef="usd">6300000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-4" decimals="-5" id="f-41" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-5" id="f-42" unitRef="usd">786900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-5" id="f-43" unitRef="usd">598700000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-5" id="f-44" unitRef="usd">209800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-45" unitRef="usd">270600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-5" id="f-46" unitRef="usd">452700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-5" id="f-47" unitRef="usd">501500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-5" id="f-48" unitRef="usd">11600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-5" id="f-49" unitRef="usd">18900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-5" id="f-50" unitRef="usd">1461000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-5" id="f-51" unitRef="usd">1389700000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-5" id="f-52" unitRef="usd">57400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-5" id="f-53" unitRef="usd">60900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-54" unitRef="usd">13900000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-55" unitRef="usd">17700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-56" unitRef="usd">36600000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-57" unitRef="usd">56100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-58" unitRef="usd">24100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-59" unitRef="usd">27700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-3" decimals="-5" id="f-60" unitRef="usd">4500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-4" decimals="-5" id="f-61" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-62" unitRef="usd">136500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-63" unitRef="usd">162400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-5" id="f-64" unitRef="usd">663100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-5" id="f-65" unitRef="usd">663700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-3" decimals="-5" id="f-66" unitRef="usd">36300000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-5" id="f-67" unitRef="usd">41700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-5" id="f-68" unitRef="usd">42600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-5" id="f-69" unitRef="usd">39100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-5" id="f-70" unitRef="usd">878500000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-5" id="f-71" unitRef="usd">906900000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-72"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="-5" id="f-74" unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-5" id="f-75" unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-77" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-78" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-79" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-5" id="f-80" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-5" id="f-81" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-83"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-5" id="f-84" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-5" id="f-85" unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-5" id="f-86" unitRef="shares">60600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-5" id="f-87" unitRef="shares">59900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-5" id="f-88" unitRef="shares">52700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-5" id="f-89" unitRef="shares">54300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-5" id="f-90" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-5" id="f-91" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="-5" id="f-92" unitRef="shares">7900000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="-5" id="f-93" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-3" decimals="-5" id="f-94" unitRef="usd">243500000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-5" id="f-95" unitRef="usd">227700000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-5" id="f-96" unitRef="usd">938600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-5" id="f-97" unitRef="usd">928000000.0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-5" id="f-98" unitRef="usd">-7500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-5" id="f-99" unitRef="usd">-5200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-100" unitRef="usd">-105200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-101" unitRef="usd">-212400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-5" id="f-102" unitRef="usd">582500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-103" unitRef="usd">482800000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-5" id="f-104" unitRef="usd">1461000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-5" id="f-105" unitRef="usd">1389700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-5" id="f-106" unitRef="usd">222000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-5" id="f-107" unitRef="usd">283800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-5" id="f-108" unitRef="usd">561400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-5" id="f-109" unitRef="usd">824300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-5" id="f-110" unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-5" id="f-111" unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-5" id="f-112" unitRef="usd">32800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-5" id="f-113" unitRef="usd">24600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-5" id="f-114" unitRef="usd">231100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-5" id="f-115" unitRef="usd">293800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-116" unitRef="usd">594200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-5" id="f-117" unitRef="usd">848900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-5" id="f-118" unitRef="usd">85900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-14" decimals="-5" id="f-119" unitRef="usd">122600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-120" unitRef="usd">241300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-15" decimals="-5" id="f-121" unitRef="usd">563300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-5" id="f-122" unitRef="usd">13500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-5" id="f-123" unitRef="usd">13800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-124" unitRef="usd">41100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-5" id="f-125" unitRef="usd">61600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-5" id="f-126" unitRef="usd">38900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-5" id="f-127" unitRef="usd">76600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-128" unitRef="usd">135000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-5" id="f-129" unitRef="usd">247200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-5" id="f-130" unitRef="usd">16300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-131" unitRef="usd">16300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-132" unitRef="usd">48800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-133" unitRef="usd">48800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-13" decimals="-5" id="f-134" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-14" decimals="-5" id="f-135" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-136" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-15" decimals="-5" id="f-137" unitRef="usd">27200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-13" decimals="-5" id="f-138" unitRef="usd">154600000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-14" decimals="-5" id="f-139" unitRef="usd">229300000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-1" decimals="-5" id="f-140" unitRef="usd">466200000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-15" decimals="-5" id="f-141" unitRef="usd">948100000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-5" id="f-142" unitRef="usd">76500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-5" id="f-143" unitRef="usd">64500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-5" id="f-144" unitRef="usd">128000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-5" id="f-145" unitRef="usd">-99200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-5" id="f-146" unitRef="usd">15200000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-5" id="f-147" unitRef="usd">8300000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-5" id="f-148" unitRef="usd">44600000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-15" decimals="-5" id="f-149" unitRef="usd">56200000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-13" decimals="-5" id="f-150" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-14" decimals="-5" id="f-151" unitRef="usd">64300000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-5" id="f-152" unitRef="usd">-12200000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-15" decimals="-5" id="f-153" unitRef="usd">24300000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-5" id="f-154" unitRef="usd">-3700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-5" id="f-155" unitRef="usd">21900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-156" unitRef="usd">62300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-5" id="f-157" unitRef="usd">15800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-5" id="f-158" unitRef="usd">-18900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-14" decimals="-5" id="f-159" unitRef="usd">77900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-160" unitRef="usd">5500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-15" decimals="-5" id="f-161" unitRef="usd">-16100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-5" id="f-162" unitRef="usd">57600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-5" id="f-163" unitRef="usd">142400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-164" unitRef="usd">133500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-165" unitRef="usd">-115300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-5" id="f-166" unitRef="usd">6400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-5" id="f-167" unitRef="usd">27600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-168" unitRef="usd">26300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-5" id="f-169" unitRef="usd">44000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-5" id="f-170" unitRef="usd">51200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-5" id="f-171" unitRef="usd">114800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-172" unitRef="usd">107200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-173" unitRef="usd">-159300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">2.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-177"
      unitRef="usdPerShare">-3.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-178"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-179"
      unitRef="usdPerShare">2.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-180"
      unitRef="usdPerShare">1.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-181"
      unitRef="usdPerShare">-3.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-5" id="f-182" unitRef="shares">53200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-5" id="f-183" unitRef="shares">53100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-184" unitRef="shares">53900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-5" id="f-185" unitRef="shares">52600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-5" id="f-186" unitRef="shares">56500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-5" id="f-187" unitRef="shares">55600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-188" unitRef="shares">56700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-5" id="f-189" unitRef="shares">52600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-5" id="f-190" unitRef="usd">51200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-5" id="f-191" unitRef="usd">114800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-192" unitRef="usd">107200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-193" unitRef="usd">-159300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-5" id="f-194" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-5" id="f-195" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-196" unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-5" id="f-197" unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-5" id="f-198" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-5" id="f-199" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-200" unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-5" id="f-201" unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-5" id="f-202" unitRef="usd">51800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-5" id="f-203" unitRef="usd">113000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-204" unitRef="usd">104900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-5" id="f-205" unitRef="usd">-160900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-206" unitRef="usd">107200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-207" unitRef="usd">-159300000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-208" unitRef="usd">10900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-5" id="f-209" unitRef="usd">13700000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-210" unitRef="usd">72300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-15" decimals="-5" id="f-211" unitRef="usd">82800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-212" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-5" id="f-213" unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-5" id="f-214" unitRef="usd">7200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-15" decimals="-5" id="f-215" unitRef="usd">5200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-5" id="f-216" unitRef="usd">-5500000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-15" decimals="-5" id="f-217" unitRef="usd">-5100000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <ebs:GainLossOnDispositionOfBusinessIncludingTransactionCosts contextRef="c-1" decimals="-5" id="f-218" unitRef="usd">-12200000</ebs:GainLossOnDispositionOfBusinessIncludingTransactionCosts>
    <ebs:GainLossOnDispositionOfBusinessIncludingTransactionCosts contextRef="c-15" decimals="-5" id="f-219" unitRef="usd">32200000</ebs:GainLossOnDispositionOfBusinessIncludingTransactionCosts>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-5" id="f-220" unitRef="usd">-1800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-15" decimals="-5" id="f-221" unitRef="usd">-1100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-222" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-15" decimals="-5" id="f-223" unitRef="usd">27200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-5" id="f-224" unitRef="usd">-3500000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-15" decimals="-5" id="f-225" unitRef="usd">-28900000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-226" unitRef="usd">8700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-15" decimals="-5" id="f-227" unitRef="usd">-3900000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-5" id="f-228" unitRef="usd">26400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-5" id="f-229" unitRef="usd">-52700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-230" unitRef="usd">44500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-15" decimals="-5" id="f-231" unitRef="usd">35500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-5" id="f-232" unitRef="usd">-27100000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-15" decimals="-5" id="f-233" unitRef="usd">-146300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-5" id="f-234" unitRef="usd">-19800000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-15" decimals="-5" id="f-235" unitRef="usd">-22800000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-5" id="f-236" unitRef="usd">-27000000.0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-15" decimals="-5" id="f-237" unitRef="usd">32900000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual contextRef="c-1" decimals="-5" id="f-238" unitRef="usd">2300000</ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual>
    <ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual contextRef="c-15" decimals="-5" id="f-239" unitRef="usd">2500000</ebs:IncreaseDecreaseInLongTermIncentivePlanAccrual>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-5" id="f-240" unitRef="usd">-21800000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-15" decimals="-5" id="f-241" unitRef="usd">-9900000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable contextRef="c-1" decimals="-5" id="f-242" unitRef="usd">4600000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable contextRef="c-15" decimals="-5" id="f-243" unitRef="usd">26600000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-5" id="f-244" unitRef="usd">1100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-15" decimals="-5" id="f-245" unitRef="usd">-18800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-246" unitRef="usd">92900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-5" id="f-247" unitRef="usd">138600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-248" unitRef="usd">9900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-5" id="f-249" unitRef="usd">21200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-250" unitRef="usd">38200000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-15" decimals="-5" id="f-251" unitRef="usd">7600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <ebs:PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities contextRef="c-1" decimals="-5" id="f-252" unitRef="usd">-50000000.0</ebs:PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities>
    <ebs:PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities contextRef="c-15" decimals="-5" id="f-253" unitRef="usd">0</ebs:PaymentsForProceedsFromContingentConsiderationLiabilityAssetInvestingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-1" decimals="-5" id="f-254" unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-15" decimals="-5" id="f-255" unitRef="usd">110200000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-1" decimals="-5" id="f-256" unitRef="usd">5000000.0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-15" decimals="-5" id="f-257" unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-258" unitRef="usd">73300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-5" id="f-259" unitRef="usd">96600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-1" decimals="-5" id="f-260" unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-15" decimals="-5" id="f-261" unitRef="usd">219000000.0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-5" id="f-262" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-15" decimals="-5" id="f-263" unitRef="usd">13400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <ebs:ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt contextRef="c-1" decimals="-5" id="f-264" unitRef="usd">0</ebs:ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt>
    <ebs:ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt contextRef="c-15" decimals="-5" id="f-265" unitRef="usd">9300000</ebs:ProceedsAllocatedToCommonStockIssuedInConjunctionWithDebt>
    <us-gaap:RepaymentsOfMediumTermNotes contextRef="c-1" decimals="-5" id="f-266" unitRef="usd">0</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes contextRef="c-15" decimals="-5" id="f-267" unitRef="usd">198200000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-5" id="f-268" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-15" decimals="-5" id="f-269" unitRef="usd">65000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-1" decimals="-5" id="f-270" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-15" decimals="-5" id="f-271" unitRef="usd">284200000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-5" id="f-272" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-15" decimals="-5" id="f-273" unitRef="usd">14600000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-5" id="f-274" unitRef="usd">1000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-15" decimals="-5" id="f-275" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ebs:PaymentsForRepurchaseOfDebt contextRef="c-1" decimals="-5" id="f-276" unitRef="usd">6900000</ebs:PaymentsForRepurchaseOfDebt>
    <ebs:PaymentsForRepurchaseOfDebt contextRef="c-15" decimals="-5" id="f-277" unitRef="usd">0</ebs:PaymentsForRepurchaseOfDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-5" id="f-278" unitRef="usd">15800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-15" decimals="-5" id="f-279" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-5" id="f-280" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-15" decimals="-5" id="f-281" unitRef="usd">700000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-282" unitRef="usd">1000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-15" decimals="-5" id="f-283" unitRef="usd">900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-284" unitRef="usd">-22700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-5" id="f-285" unitRef="usd">-190500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-286" unitRef="usd">100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-15" decimals="-5" id="f-287" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-288" unitRef="usd">143600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-15" decimals="-5" id="f-289" unitRef="usd">44700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-5" id="f-290" unitRef="usd">105600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-16" decimals="-5" id="f-291" unitRef="usd">111700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-292" unitRef="usd">249200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-5" id="f-293" unitRef="usd">156400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-5" id="f-294" unitRef="usd">41700000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-15" decimals="-5" id="f-295" unitRef="usd">55800000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-5" id="f-296" unitRef="usd">27500000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-15" decimals="-5" id="f-297" unitRef="usd">35500000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-5" id="f-298" unitRef="usd">1800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-15" decimals="-5" id="f-299" unitRef="usd">1600000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-5" id="f-300" unitRef="usd">1100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-15" decimals="-5" id="f-301" unitRef="usd">600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-5" id="f-302" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-15" decimals="-5" id="f-303" unitRef="usd">7700000</us-gaap:StockIssued1>
    <us-gaap:ShareRepurchaseProgramExciseTaxPayable contextRef="c-3" decimals="-5" id="f-304" unitRef="usd">200000</us-gaap:ShareRepurchaseProgramExciseTaxPayable>
    <us-gaap:ShareRepurchaseProgramExciseTaxPayable contextRef="c-17" decimals="-5" id="f-305" unitRef="usd">0</us-gaap:ShareRepurchaseProgramExciseTaxPayable>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-306" unitRef="usd">245500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-17" decimals="-5" id="f-307" unitRef="usd">149900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-5" id="f-308" unitRef="usd">3700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-17" decimals="-5" id="f-309" unitRef="usd">6500000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-310" unitRef="usd">249200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-5" id="f-311" unitRef="usd">156400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="INF"
      id="f-312"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-313"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-314"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-20"
      decimals="INF"
      id="f-315"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-21"
      decimals="INF"
      id="f-316"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-16"
      decimals="INF"
      id="f-317"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-318"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-17"
      decimals="INF"
      id="f-319"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-22" decimals="-5" id="f-320" unitRef="shares">59900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-5" id="f-321" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-23" decimals="-5" id="f-322" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-5" id="f-323" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-5" id="f-324" unitRef="usd">928000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-5" id="f-325" unitRef="usd">-5200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-5" id="f-326" unitRef="usd">-212400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-327" unitRef="usd">482800000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-328" unitRef="usd">68000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-5" id="f-329" unitRef="usd">68000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-29" decimals="-5" id="f-330" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="-5" id="f-331" unitRef="usd">2800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-28" decimals="-5" id="f-332" unitRef="usd">2800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-31" decimals="-5" id="f-333" unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-5" id="f-334" unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued contextRef="c-32" decimals="-5" id="f-335" unitRef="shares">60100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-5" id="f-336" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-33" decimals="-5" id="f-337" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-5" id="f-338" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-5" id="f-339" unitRef="usd">930800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-5" id="f-340" unitRef="usd">-6100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-5" id="f-341" unitRef="usd">-144400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-5" id="f-342" unitRef="usd">552700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-5" id="f-343" unitRef="usd">-12000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-38" decimals="-5" id="f-344" unitRef="usd">-12000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-39" decimals="-5" id="f-345" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-40" decimals="-5" id="f-346" unitRef="usd">4400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-38" decimals="-5" id="f-347" unitRef="usd">4400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-41" decimals="-5" id="f-348" unitRef="shares">1100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-41" decimals="-5" id="f-349" unitRef="usd">6900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-38" decimals="-5" id="f-350" unitRef="usd">6900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-42" decimals="-5" id="f-351" unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-38" decimals="-5" id="f-352" unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued contextRef="c-43" decimals="-5" id="f-353" unitRef="shares">60400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-5" id="f-354" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-44" decimals="-5" id="f-355" unitRef="shares">6700000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-5" id="f-356" unitRef="usd">-234600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-5" id="f-357" unitRef="usd">935200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-5" id="f-358" unitRef="usd">-8100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-5" id="f-359" unitRef="usd">-156400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-5" id="f-360" unitRef="usd">536200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-48" decimals="-5" id="f-361" unitRef="usd">51200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-5" id="f-362" unitRef="usd">51200000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-49" decimals="-5" id="f-363" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-50" decimals="-5" id="f-364" unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-5" id="f-365" unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-51" decimals="-5" id="f-366" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-51" decimals="-5" id="f-367" unitRef="usd">8900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-13" decimals="-5" id="f-368" unitRef="usd">8900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-52" decimals="-5" id="f-369" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-5" id="f-370" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued contextRef="c-53" decimals="-5" id="f-371" unitRef="shares">60600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-5" id="f-372" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-54" decimals="-5" id="f-373" unitRef="shares">7900000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-5" id="f-374" unitRef="usd">-243500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-5" id="f-375" unitRef="usd">938600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-5" id="f-376" unitRef="usd">-7500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-5" id="f-377" unitRef="usd">-105200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-5" id="f-378" unitRef="usd">582500000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="INF"
      id="f-379"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-380"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-381"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-20"
      decimals="INF"
      id="f-382"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-21"
      decimals="INF"
      id="f-383"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-16"
      decimals="INF"
      id="f-384"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-385"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-17"
      decimals="INF"
      id="f-386"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-58" decimals="-5" id="f-387" unitRef="shares">57800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-5" id="f-388" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-59" decimals="-5" id="f-389" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-59" decimals="-5" id="f-390" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-5" id="f-391" unitRef="usd">904400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-5" id="f-392" unitRef="usd">-5700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-5" id="f-393" unitRef="usd">-21800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-5" id="f-394" unitRef="usd">649300000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-63" decimals="-5" id="f-395" unitRef="usd">9000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-64" decimals="-5" id="f-396" unitRef="usd">9000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-65" decimals="-5" id="f-397" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-66" decimals="-5" id="f-398" unitRef="usd">5400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-64" decimals="-5" id="f-399" unitRef="usd">5400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-67" decimals="-5" id="f-400" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-64" decimals="-5" id="f-401" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued contextRef="c-68" decimals="-5" id="f-402" unitRef="shares">58000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-5" id="f-403" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-69" decimals="-5" id="f-404" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-5" id="f-405" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-70" decimals="-5" id="f-406" unitRef="usd">909800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-71" decimals="-5" id="f-407" unitRef="usd">-5500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-5" id="f-408" unitRef="usd">-12800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-5" id="f-409" unitRef="usd">663900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-73" decimals="-5" id="f-410" unitRef="usd">-283100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-74" decimals="-5" id="f-411" unitRef="usd">-283100000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-75" decimals="-5" id="f-412" unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-76" decimals="-5" id="f-413" unitRef="usd">5500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-74" decimals="-5" id="f-414" unitRef="usd">5500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:CommonStockSharesIssued contextRef="c-77" decimals="-5" id="f-415" unitRef="shares">58500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-77" decimals="-5" id="f-416" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-78" decimals="-5" id="f-417" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-78" decimals="-5" id="f-418" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-79" decimals="-5" id="f-419" unitRef="usd">915300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-80" decimals="-5" id="f-420" unitRef="usd">-5500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-81" decimals="-5" id="f-421" unitRef="usd">-295900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-5" id="f-422" unitRef="usd">386300000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-82" decimals="-5" id="f-423" unitRef="usd">114800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-5" id="f-424" unitRef="usd">114800000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-83" decimals="-5" id="f-425" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-84" decimals="-5" id="f-426" unitRef="usd">1400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-14" decimals="-5" id="f-427" unitRef="usd">1400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-83" decimals="-5" id="f-428" unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-84" decimals="-5" id="f-429" unitRef="usd">7700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-5" id="f-430" unitRef="usd">7700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-85" decimals="-5" id="f-431" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-5" id="f-432" unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued contextRef="c-86" decimals="-5" id="f-433" unitRef="shares">59700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-86" decimals="-5" id="f-434" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-87" decimals="-5" id="f-435" unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-87" decimals="-5" id="f-436" unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-88" decimals="-5" id="f-437" unitRef="usd">924400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-89" decimals="-5" id="f-438" unitRef="usd">-7300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-90" decimals="-5" id="f-439" unitRef="usd">-181100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-5" id="f-440" unitRef="usd">508400000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-441">Nature of the business and organization&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent BioSolutions Inc. (&#x201c;Emergent,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (&#x201c;PHTs&#x201d;). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (&#x201c;CDMO&#x201d;) services portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on the following four PHT categories: chemical, biological, radiological, nuclear and explosives (&#x201c;CBRNE&#x201d;); emerging infectious diseases (&#x201c;EID&#x201d;); emerging health crises; and acute, emergency and community care. As of September 30, 2025, the Company has a portfolio of 11 products consisting of vaccines, therapeutics, and drug-device combination products, including KLOXXADO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nasal Spray for which the Company obtained certain exclusive commercial rights for product sales and marketing in the United States and Canada. The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures (&#x201c;MCM&#x201d;) products, Naloxone commercial products, Smallpox - MCM products and Emergent Bioservices (CDMO) (&#x201c;Bioservices&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages the business with a focus on three operating segments: (1) a Commercial Products segment consisting of NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nasal Spray and &lt;/span&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;KL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OXXADO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nasal Spray, described below; (2) a MCM Products segment consisting of our Anthrax - MCM, Smallpox - MCM and Other Products, described below and (3) a Services segment consisting of our Bioservices offerings. Commercial Products and MCM Products are our two reportable segments (see Note 17, &#x201c;Segment information&#x201d; for more information on our reportable segments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Company's products and services include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial Products Segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Naloxone Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (naloxone HCl) Nasal Spray is an intranasal formulation of naloxone approved by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) (including in over-the-counter (&#x201c;OTC&#x201d;) form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;KLOXXADO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(naloxone HCl) Nasal Spray. On January 14, 2025, the Company announced an agreement with Hikma Pharmaceuticals Inc. (&#x201c;Hikma&#x201d;) in which the Company obtained exclusive commercial rights for product sales and marketing in the United States and Canada to Hikma&#x2019;s KLOXXADO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (naloxone HCl) Nasal Spray, an 8 mg naloxone agent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MCM Products Segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Anthrax - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Anthrasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;BioThrax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;CYFENDUS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is procured by certain authorized government buyers for their use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Smallpox - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;ACAM2000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;CNJ-016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;TEMBEXA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;BAT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Ebanga&#x2122; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics (&#x201c;Ridgeback&#x201d;), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#x2122; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#x2122;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Trobigard Revocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 2, 2024, the Belgium Federal Agency for Medicines and Health Products acknowledged and confirmed Emergent&#x2019;s request to revoke the Market Authorization for the Trobigard Auto-Injector.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sale of RSDL&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2024, the Company entered into the Stock and Asset Purchase Agreement (the &#x201c;RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Agreement&#x201d;) with SERB Pharmaceuticals, through its wholly owned subsidiary BTG International Inc. (collectively, &#x201c;SERB&#x201d;), pursuant to which, among other things, the Company sold its worldwide rights to RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to SERB (the &#x201c;RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Transaction&#x201d;). See Note 4, &#x201c;Divestitures&#x201d; for more information on the RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Services Segment:&lt;/span&gt;&lt;/div&gt;As of the first quarter of 2025, the Company&#x2019;s Services operating segment no longer met the quantitative thresholds of a reportable segment and did not meet the aggregation criteria set forth in Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, Segment Reporting, and as such is categorized within &#x201c;All other revenues&#x201d; along with &#x201c;Contracts and Grants&#x201d; within Note 17 &#x201c;Segment information&#x201d;. See Note 17, &#x201c;Segment information&#x201d; for more information about the Company&#x2019;s reportable segments.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ebs:NumberOfCategoriesOfPublicHealthThreats
      contextRef="c-1"
      decimals="INF"
      id="f-442"
      unitRef="category">4</ebs:NumberOfCategoriesOfPublicHealthThreats>
    <ebs:NumberOfRevenueGeneratingProducts
      contextRef="c-1"
      decimals="INF"
      id="f-443"
      unitRef="product">11</ebs:NumberOfRevenueGeneratingProducts>
    <ebs:NumberOfProductAndServiceCategories
      contextRef="c-1"
      decimals="INF"
      id="f-444"
      unitRef="category2">4</ebs:NumberOfProductAndServiceCategories>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-445"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-446"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-447">Summary of significant accounting policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC on March 3, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2025. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement&#x2019;s specified effective date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company does not expect a material impact from this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a public business entity to disclose additional information about specific expense categories in the notes to financial statements on an annual and interim basis. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. A public entity should apply the amendments either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-448">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, as filed with the SEC on March 3, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2025. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-449">&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement&#x2019;s specified effective date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The amendments in the ASU are effective for public business entities for annual periods beginning after December 15, 2024, although early adoption is permitted. The Company does not expect a material impact from this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a public business entity to disclose additional information about specific expense categories in the notes to financial statements on an annual and interim basis. The amendments are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. A public entity should apply the amendments either prospectively to financial statements issued for reporting periods after the effective date of the ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-450">Assets and liabilities held for sale&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 10, 2025, the Company classified the assets and related liabilities associated with warehouse space in Maryland as held for sale. In the accompanying Condensed Consolidated Balance Sheet as of September 30, 2025, the assets and liabilities that are expected to be conveyed are classified as held for sale and are measured at the lower of (i) the carrying value of the disposal group and (ii) the fair value of the disposal group, less estimated costs to sell. An orderly liquidation value was applied to estimate the fair value of the assets held for sale, representing Level 3 non-recurring fair value measurement. Effective with the designation of the assets as held for sale on March 10, 2025, the Company suspended recording depreciation of property, plant and equipment and right-of-use assets while these assets are classified as held for sale. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. The Company recognized a loss on assets held for sale of $12.2&#160;million during the nine months ended September 30, 2025 in &#x201c;Gain (loss) on sale of business and assets held for sale&#x201d; within non-operating activities on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheet as of September 30, 2025 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Divestitures&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sale of Travel Health Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2023, pursuant to the Purchase and Sale Agreement (the &#x201c;Purchase and Sale Agreement&#x201d;), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic (&#x201c;Bavarian Nordic&#x201d;), the Company completed the previously announced sale of the Company&#x2019;s travel health business, including rights to Vivotif&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the licensed typhoid vaccine; Vaxchora&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company&#x2019;s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, Bavarian Nordic paid a cash purchase price of $270.2&#160;million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic was required to pay milestone payments totaling $80.0&#160;million, which the Company records within &#x201c;Other, net&#x201d; in the Condensed Consolidated Statement of Operations, upon satisfaction of the following milestones:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;On July 18, 2024, Bavarian Nordic announced that the European Medicines Agency had validated the marketing authorization application for CHIKV VLP, which triggered a development milestone payment receivable in the amount of $10.0&#160;million. The Company received this milestone payment in the fourth quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;On August 13, 2024, Bavarian Nordic announced that the FDA has accepted and granted Priority Review for the Biologics License Application for CHIKV VLP, which triggered a milestone payment receivable in the amount of $20.0&#160;million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received this milestone payment in the fourth quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;On February 14, 2025, Bavarian Nordic announced that the FDA approved CHIKV VLP under the Priority Review, which triggered a milestone payment in the amount of $30.0&#160;million which was recorded in &#x201c;Other, net&#x201d; during the nine months ended September 30, 2025. The Company received this milestone payment during the first quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;On February 28, 2025, Bavarian Nordic announced that the European Commission approved CHIKV VLP, which triggered a milestone payment receivable in the amount of $20.0&#160;million which was recorded in &#x201c;Other, net&#x201d; during the nine months ended September 30, 2025. The Company received this milestone payment in the second quarter of 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Purchase and Sale Agreement, the Company may receive up to $30.0&#160;million of earn-out payments from Bavarian Nordic based on aggregate net sales of Vaxchora&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Vivotif&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in calendar year 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sale of RSDL&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2024, the Company, through its wholly owned subsidiary Emergent BioSolutions Canada Inc., entered into the RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement with SERB pursuant to which, among other things, the Company sold its worldwide rights to RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to SERB. The RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Transaction also included the sale to SERB of all the outstanding capital stock of Emergent Protective Products USA Inc. (&#x201c;EPPU&#x201d;), a wholly owned subsidiary of the Company, which leases a manufacturing facility in Hattiesburg, Mississippi, as well as certain assets related to RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including intellectual property rights, contract rights, inventory and marketing authorizations. In addition, the employees of EPPU joined SERB in connection with the RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, SERB paid a cash purchase price of $75.0&#160;million, exclusive of customary closing adjustments related to inventory. In addition, SERB will owe the Company a $5.0&#160;million payment upon achievement of a milestone relating to sourcing of a certain component of RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; decontamination lotion. In connection with the RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction, the Company recognized a pre-tax gain of $60.8&#160;million, net of transaction costs of $4.1&#160;million, recorded within &#x201c;Gain (loss) on sale of business&#x201d; on the Consolidated Statements of Operations during the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and SERB entered into a transition services agreement (the &#x201c;SERB TSA&#x201d;) to ensure the orderly transition of RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; decontamination lotion and the related assets to SERB, and a supply agreement (the &#x201c;SERB Supply Agreement&#x201d;) pursuant to which SERB has a suite reservation at the Company&#x2019;s Winnipeg facility where the Company will perform Bioservices activities to manufacture and supply bulk lotion to SERB. The Company and SERB also entered into a reverse supply agreement (together with the SERB TSA and the SERB Supply Agreement, the &#x201c;SERB Agreements&#x201d;) pursuant to which SERB supplies to the Company finished RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the purposes of the Company&#x2019;s performance of certain transitional distribution services under customer contracts that have not yet transferred to SERB. Under the SERB Agreements, the Company will retain a portion of net sales received upon delivery of RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the delayed transfer customers. Income from performing services under the SERB TSA is recorded within &#x201c;Product and services sales, net&#x201d; on the Condensed Consolidated Statements of Operations and was $0.1&#160;million and $1.7&#160;million for the three and nine months ended September 30, 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sale of Baltimore-Camden Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 20, 2024, pursuant to the Asset Purchase Agreement, the Company completed the sale of its Drug Product facility in Baltimore-Camden to an affiliate of Bora. The Baltimore-Camden facility, which was part of the Company&#x2019;s Services operating segment, had clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. At closing, Bora paid a cash purchase price of approximately $35.0&#160;million, which included customary closing adjustments to date for working capital and transaction expenses of the business at closing. As a result of the divestiture, the Company recognized a pre-tax loss of $36.5&#160;million, net of transaction costs of $3.8&#160;million, during the year ended December 31, 2024 recorded within &#x201c;Gain (loss) on sale of business and assets held for sale&#x201d; on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the divestiture, the Company entered into a Transition Services Agreement (the &#x201c;Bora TSA&#x201d;) with Bora to help support its ongoing operations. Under the Bora TSA, the Company is providing certain transition services to Bora, including information technology, finance and enterprise resource planning, human resources, employee benefits and other limited services. Income from performing services under the Bora TSA is recorded within &#x201c;Other, net&#x201d; on the Condensed Consolidated Statements of Operations and was zero and $0.4&#160;million for the three and nine months ended September 30, 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Sale of Baltimore-Bayview Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 19, 2025, the Company completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International (&#x201c;Syngene&#x201d;). At closing, Syngene paid a cash purchase price of $36.5&#160;million. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the divestiture, the Company recognized a pre-tax gain of $7.9&#160;million, net of transaction costs of $1.2&#160;million, during the nine months ended September 30, 2025 recorded within &#x201c;Other, net&#x201d; on the Condensed Consolidated Statements of Operations. The Company determined that the disposal of the Baltimore-Bayview facility does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on the Company&#x2019;s operations and financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <ebs:DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance contextRef="c-91" decimals="-5" id="f-451" unitRef="usd">12200000</ebs:DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-452">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheet as of September 30, 2025 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets contextRef="c-91" decimals="-5" id="f-453" unitRef="usd">400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="c-91" decimals="-5" id="f-454" unitRef="usd">13600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="c-91" decimals="-5" id="f-455" unitRef="usd">4500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <ebs:DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance contextRef="c-91" decimals="-5" id="f-456" unitRef="usd">12200000</ebs:DisposalGroupIncludingDiscontinuedOperationAssetsValuationAllowance>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-91" decimals="-5" id="f-457" unitRef="usd">6300000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities contextRef="c-91" decimals="-5" id="f-458" unitRef="usd">700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities contextRef="c-91" decimals="-5" id="f-459" unitRef="usd">3800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-91" decimals="-5" id="f-460" unitRef="usd">4500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-92" decimals="-5" id="f-461" unitRef="usd">270200000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable contextRef="c-93" decimals="-5" id="f-462" unitRef="usd">80000000</ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable>
    <ebs:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset contextRef="c-94" decimals="-5" id="f-463" unitRef="usd">10000000</ebs:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset>
    <ebs:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset contextRef="c-95" decimals="-5" id="f-464" unitRef="usd">20000000</ebs:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsiderationAsset>
    <ebs:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable contextRef="c-96" decimals="-5" id="f-465" unitRef="usd">30000000</ebs:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable>
    <ebs:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable contextRef="c-97" decimals="-5" id="f-466" unitRef="usd">20000000</ebs:DisposalGroupIncludingDiscontinuedOperationMilestonePaymentReceivable>
    <ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable contextRef="c-98" decimals="-5" id="f-467" unitRef="usd">30000000</ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-99" decimals="-5" id="f-468" unitRef="usd">75000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable contextRef="c-100" decimals="-5" id="f-469" unitRef="usd">5000000</ebs:DisposalGroupIncludingDiscontinuedOperationMaximumContingentConsiderationReceivable>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-101" decimals="-5" id="f-470" unitRef="usd">60800000</us-gaap:GainLossOnSaleOfBusiness>
    <ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts contextRef="c-101" decimals="-5" id="f-471" unitRef="usd">4100000</ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-5" id="f-472" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-5" id="f-473" unitRef="usd">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-104" decimals="-5" id="f-474" unitRef="usd">35000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-105" decimals="-5" id="f-475" unitRef="usd">-36500000</us-gaap:GainLossOnSaleOfBusiness>
    <ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts contextRef="c-105" decimals="-5" id="f-476" unitRef="usd">3800000</ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-106" decimals="INF" id="f-477" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-107" decimals="-5" id="f-478" unitRef="usd">400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-108" decimals="-5" id="f-479" unitRef="usd">36500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-109" decimals="-5" id="f-480" unitRef="usd">7900000</us-gaap:GainLossOnSaleOfBusiness>
    <ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts contextRef="c-109" decimals="-5" id="f-481" unitRef="usd">1200000</ebs:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock contextRef="c-1" id="f-482">Impairment and restructuring charges&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. There were no impairment charges recorded on long-lived assets during the three and nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2024 Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the preparation of the Company&#x2019;s financial statements for the three months ended June&#160;30, 2024, due to the decision to close the Company&#x2019;s Baltimore-Bayview Drug Substance manufacturing facility and the Rockville, Maryland Drug Product facility, the Company determined there were sufficient indicators of impairment for the Bayview and Rockville asset groups within the Bioservices reporting unit. As a result, the Company performed recoverability tests on those asset groups and concluded that the Bayview and Rockville asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values. The Company allocated and recognized a non-cash impairment charge of $27.2 million during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the total impairment charge by asset class for the nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;January 2023 Organizational Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company initiated an organizational restructuring plan (the &#x201c;January 2023 Plan&#x201d;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#x2019;s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees. The charges related to the January 2023 Plan consisted primarily of charges related to employee transition, severance payments and employee benefits. The cumulative amount of restructuring charge related to the January 2023 Plan since inception was $9.3&#160;million. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#x2019;s classification policy for each category of operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;August 2023 Organizational Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company initiated the August 2023 Plan, which was intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees. The charges related to the August 2023 Plan consisted primarily of employee transition, severance payment and employee benefit charges. The cumulative amount of restructuring charge related to the August 2023 Plan since inception is $19.4&#160;million. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#x2019;s classification policy for each category of operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;May 2024 Organizational Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company initiated the May 2024 Plan. These strategic actions led to a reduction of the Company&#x2019;s workforce by approximately 300 employees across all areas of the Company and the elimination of approximately 85 positions that were vacant, as well as the closure of the Company&#x2019;s Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. Decisions regarding the elimination of positions and the closure of manufacturing facilities were subject to local law and consultation requirements in certain countries, as well as the Company&#x2019;s business needs. The cumulative amount of restructuring charge related to the May 2024 Plan since inception is $18.5&#160;million. All activities related to the May 2024 Plan were substantially completed during the third quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;August 2024 Organizational Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024, the Company initiated the August 2024 Plan at the Company&#x2019;s Lansing facility, which reduced the Company&#x2019;s workforce by approximately 70 employees, as well as eliminated several open positions. The Company also implemented non-labor optimization efforts, such as reducing the Company&#x2019;s external and vendor spend. The cumulative amount of restructuring charges related to the August 2024 Plan since inception is $2.5&#160;million. All activities related to the August 2024 Plan were substantially completed during the fourth quarter of 2024. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company&#x2019;s classification policy for each category of operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by reportable segment as well as amounts included within non-reportable segments, unallocated corporate selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expense and research and development (&#x201c;R&amp;amp;D&#x201d;) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment restructuring costs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs included in Cost of product and services sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate restructuring costs: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by function:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt; Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee transition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All financial impacts of the January 2023 Plan were reflected in the Company&#x2019;s consolidated financial statements by the second quarter of 2024. As a result, there was no activity related to the January 2023 Plan for the three and nine months ended September 30, 2025. The following table provides the components of and changes in the Company&#x2019;s restructuring accrual for the January 2023 Plan during the three and nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All financial impacts of the August 2023 Plan were reflected in the Company&#x2019;s consolidated financial statements by the fourth quarter of 2024. As a result, there was no activity related to the August 2023 Plan for three and nine months ended September 30, 2025. The following table provides the components of and changes in the Company&#x2019;s restructuring accrual for the August 2023 Plan during the three and nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide the components of and changes in the Company&#x2019;s restructuring accrual for the May 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide the components of and changes in the Company&#x2019;s restructuring accrual for the August 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-13" decimals="-5" id="f-483" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-5" id="f-484" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-74" decimals="-5" id="f-485" unitRef="usd">27200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock contextRef="c-1" id="f-486">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the total impairment charge by asset class for the nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-110" decimals="-5" id="f-487" unitRef="usd">7800000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-111" decimals="-5" id="f-488" unitRef="usd">14100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-112" decimals="-5" id="f-489" unitRef="usd">200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-113" decimals="-5" id="f-490" unitRef="usd">5100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-15" decimals="-5" id="f-491" unitRef="usd">27200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-114"
      decimals="0"
      id="f-492"
      unitRef="employee">125</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c-115" decimals="-5" id="f-493" unitRef="usd">9300000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-116"
      decimals="-2"
      id="f-494"
      unitRef="employee">400</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c-117" decimals="-5" id="f-495" unitRef="usd">19400000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-118"
      decimals="-2"
      id="f-496"
      unitRef="employee">300</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <ebs:RestructuringAndRelatedCostNumberOfVacantPositionsEliminated
      contextRef="c-118"
      decimals="INF"
      id="f-497"
      unitRef="positions">85</ebs:RestructuringAndRelatedCostNumberOfVacantPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c-119" decimals="-5" id="f-498" unitRef="usd">18500000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-120"
      decimals="-1"
      id="f-499"
      unitRef="employee">70</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 contextRef="c-121" decimals="-5" id="f-500" unitRef="usd">2500000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by reportable segment as well as amounts included within non-reportable segments, unallocated corporate selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expense and research and development (&#x201c;R&amp;amp;D&#x201d;) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment restructuring costs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs included in Cost of product and services sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate restructuring costs: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs related to the January 2023 Plan, August 2023 Plan, May 2024 Plan and August 2024 Plan by function:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt; Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee transition&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-122" decimals="-5" id="f-502" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-123" decimals="-5" id="f-503" unitRef="usd">4900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-124" decimals="-5" id="f-504" unitRef="usd">-1000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-125" decimals="-5" id="f-505" unitRef="usd">7500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-126" decimals="-5" id="f-506" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-127" decimals="-5" id="f-507" unitRef="usd">100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-128" decimals="-5" id="f-508" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-129" decimals="-5" id="f-509" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-130" decimals="-5" id="f-510" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-131" decimals="-5" id="f-511" unitRef="usd">5000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-132" decimals="-5" id="f-512" unitRef="usd">-1000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-133" decimals="-5" id="f-513" unitRef="usd">7800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-134" decimals="-5" id="f-514" unitRef="usd">100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-135" decimals="-5" id="f-515" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-136" decimals="-5" id="f-516" unitRef="usd">-500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-137" decimals="-5" id="f-517" unitRef="usd">9200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-138" decimals="-5" id="f-518" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-139" decimals="-5" id="f-519" unitRef="usd">600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-140" decimals="-5" id="f-520" unitRef="usd">-600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-141" decimals="-5" id="f-521" unitRef="usd">5900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-13" decimals="-5" id="f-522" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-14" decimals="-5" id="f-523" unitRef="usd">6300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-524" unitRef="usd">-2100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-15" decimals="-5" id="f-525" unitRef="usd">22900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-142" decimals="-5" id="f-526" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-143" decimals="-5" id="f-527" unitRef="usd">100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-144" decimals="-5" id="f-528" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-145" decimals="-5" id="f-529" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-146" decimals="-5" id="f-530" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-147" decimals="-5" id="f-531" unitRef="usd">5000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-148" decimals="-5" id="f-532" unitRef="usd">-1300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-149" decimals="-5" id="f-533" unitRef="usd">19300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-150" decimals="-5" id="f-534" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-151" decimals="-5" id="f-535" unitRef="usd">1200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-152" decimals="-5" id="f-536" unitRef="usd">-800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-153" decimals="-5" id="f-537" unitRef="usd">3300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-13" decimals="-5" id="f-538" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-14" decimals="-5" id="f-539" unitRef="usd">6300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-540" unitRef="usd">-2100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-15" decimals="-5" id="f-541" unitRef="usd">22900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease contextRef="c-154" decimals="INF" id="f-542" unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease contextRef="c-155" decimals="INF" id="f-543" unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-544">The following table provides the components of and changes in the Company&#x2019;s restructuring accrual for the January 2023 Plan during the three and nine months ended September 30, 2024:&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table provides the components of and changes in the Company&#x2019;s restructuring accrual for the August 2023 Plan during the three and nine months ended September 30, 2024:&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide the components of and changes in the Company&#x2019;s restructuring accrual for the May 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide the components of and changes in the Company&#x2019;s restructuring accrual for the August 2024 Plan during the three and nine months ended September 30, 2025, and the three and nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-156" decimals="-5" id="f-545" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-157" decimals="-5" id="f-546" unitRef="usd">1400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-158" decimals="-5" id="f-547" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-159" decimals="-5" id="f-548" unitRef="usd">1400000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring contextRef="c-160" decimals="-5" id="f-549" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-161" decimals="-5" id="f-550" unitRef="usd">1300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-162" decimals="-5" id="f-551" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-163" decimals="-5" id="f-552" unitRef="usd">1300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-164" decimals="-5" id="f-553" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-165" decimals="-5" id="f-554" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-166" decimals="-5" id="f-555" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-167" decimals="-5" id="f-556" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring contextRef="c-168" decimals="-5" id="f-557" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-169" decimals="-5" id="f-558" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-170" decimals="-5" id="f-559" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-171" decimals="-5" id="f-560" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-172" decimals="-5" id="f-561" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-173" decimals="-5" id="f-562" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-174" decimals="-5" id="f-563" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-175" decimals="-5" id="f-564" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-176" decimals="-5" id="f-565" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-177" decimals="-5" id="f-566" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-178" decimals="-5" id="f-567" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-179" decimals="-5" id="f-568" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease contextRef="c-180" decimals="INF" id="f-569" unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease contextRef="c-181" decimals="INF" id="f-570" unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReserve contextRef="c-182" decimals="-5" id="f-571" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-183" decimals="-5" id="f-572" unitRef="usd">5300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-184" decimals="-5" id="f-573" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-185" decimals="-5" id="f-574" unitRef="usd">5400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-186" decimals="-5" id="f-575" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-187" decimals="-5" id="f-576" unitRef="usd">-500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-188" decimals="-5" id="f-577" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-189" decimals="-5" id="f-578" unitRef="usd">-500000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-186" decimals="-5" id="f-579" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-187" decimals="-5" id="f-580" unitRef="usd">3600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-188" decimals="-5" id="f-581" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-189" decimals="-5" id="f-582" unitRef="usd">3600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-190" decimals="-5" id="f-583" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-191" decimals="-5" id="f-584" unitRef="usd">1200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-192" decimals="-5" id="f-585" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-193" decimals="-5" id="f-586" unitRef="usd">1300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-194" decimals="-5" id="f-587" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-195" decimals="-5" id="f-588" unitRef="usd">-100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-196" decimals="-5" id="f-589" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-197" decimals="-5" id="f-590" unitRef="usd">-100000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-194" decimals="-5" id="f-591" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-195" decimals="-5" id="f-592" unitRef="usd">500000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-196" decimals="-5" id="f-593" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-197" decimals="-5" id="f-594" unitRef="usd">600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-198" decimals="-5" id="f-595" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-199" decimals="-5" id="f-596" unitRef="usd">600000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-200" decimals="-5" id="f-597" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-201" decimals="-5" id="f-598" unitRef="usd">600000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring contextRef="c-202" decimals="-5" id="f-599" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-203" decimals="-5" id="f-600" unitRef="usd">300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-204" decimals="-5" id="f-601" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-205" decimals="-5" id="f-602" unitRef="usd">300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-206" decimals="-5" id="f-603" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-207" decimals="-5" id="f-604" unitRef="usd">300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-208" decimals="-5" id="f-605" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-209" decimals="-5" id="f-606" unitRef="usd">300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-210" decimals="-5" id="f-607" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-211" decimals="-5" id="f-608" unitRef="usd">4500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-212" decimals="-5" id="f-609" unitRef="usd">800000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-213" decimals="-5" id="f-610" unitRef="usd">5300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-214" decimals="-5" id="f-611" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-215" decimals="-5" id="f-612" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-216" decimals="-5" id="f-613" unitRef="usd">-700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-217" decimals="-5" id="f-614" unitRef="usd">-700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-214" decimals="-5" id="f-615" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-215" decimals="-5" id="f-616" unitRef="usd">2700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-216" decimals="-5" id="f-617" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-217" decimals="-5" id="f-618" unitRef="usd">2800000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-218" decimals="-5" id="f-619" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-219" decimals="-5" id="f-620" unitRef="usd">1800000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-220" decimals="-5" id="f-621" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-221" decimals="-5" id="f-622" unitRef="usd">1800000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-222" decimals="-5" id="f-623" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-223" decimals="-5" id="f-624" unitRef="usd">-900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-224" decimals="-5" id="f-625" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-225" decimals="-5" id="f-626" unitRef="usd">-900000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-222" decimals="-5" id="f-627" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-223" decimals="-5" id="f-628" unitRef="usd">800000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-224" decimals="-5" id="f-629" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-225" decimals="-5" id="f-630" unitRef="usd">800000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-226" decimals="-5" id="f-631" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-227" decimals="-5" id="f-632" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-228" decimals="-5" id="f-633" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-229" decimals="-5" id="f-634" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-230" decimals="-5" id="f-635" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-231" decimals="-5" id="f-636" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-232" decimals="-5" id="f-637" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-233" decimals="-5" id="f-638" unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-230" decimals="-5" id="f-639" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-231" decimals="-5" id="f-640" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-232" decimals="-5" id="f-641" unitRef="usd">300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-233" decimals="-5" id="f-642" unitRef="usd">400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-234" decimals="-5" id="f-643" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-235" decimals="-5" id="f-644" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-236" decimals="-5" id="f-645" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-119" decimals="-5" id="f-646" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-237" decimals="-5" id="f-647" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-238" decimals="-5" id="f-648" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-239" decimals="-5" id="f-649" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-240" decimals="-5" id="f-650" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-241" decimals="-5" id="f-651" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-242" decimals="-5" id="f-652" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-243" decimals="-5" id="f-653" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-244" decimals="-5" id="f-654" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-245" decimals="-5" id="f-655" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-246" decimals="-5" id="f-656" unitRef="usd">14800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-247" decimals="-5" id="f-657" unitRef="usd">2200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-248" decimals="-5" id="f-658" unitRef="usd">17200000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-245" decimals="-5" id="f-659" unitRef="usd">200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-246" decimals="-5" id="f-660" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-247" decimals="-5" id="f-661" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-248" decimals="-5" id="f-662" unitRef="usd">200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-249" decimals="-5" id="f-663" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-250" decimals="-5" id="f-664" unitRef="usd">14800000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-251" decimals="-5" id="f-665" unitRef="usd">2200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-252" decimals="-5" id="f-666" unitRef="usd">17000000.0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-253" decimals="-5" id="f-667" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-254" decimals="-5" id="f-668" unitRef="usd">2300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-255" decimals="-5" id="f-669" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-256" decimals="-5" id="f-670" unitRef="usd">2800000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-253" decimals="-5" id="f-671" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-254" decimals="-5" id="f-672" unitRef="usd">6300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-255" decimals="-5" id="f-673" unitRef="usd">700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-256" decimals="-5" id="f-674" unitRef="usd">7000000.0</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-257" decimals="-5" id="f-675" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-258" decimals="-5" id="f-676" unitRef="usd">10800000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-259" decimals="-5" id="f-677" unitRef="usd">2000000.0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-260" decimals="-5" id="f-678" unitRef="usd">12800000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-261" decimals="-5" id="f-679" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-262" decimals="-5" id="f-680" unitRef="usd">1900000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-263" decimals="-5" id="f-681" unitRef="usd">500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-264" decimals="-5" id="f-682" unitRef="usd">2400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-265" decimals="-5" id="f-683" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-266" decimals="-5" id="f-684" unitRef="usd">-200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-267" decimals="-5" id="f-685" unitRef="usd">-400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-268" decimals="-5" id="f-686" unitRef="usd">-600000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-265" decimals="-5" id="f-687" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-266" decimals="-5" id="f-688" unitRef="usd">1100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-267" decimals="-5" id="f-689" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-268" decimals="-5" id="f-690" unitRef="usd">1200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-269" decimals="-5" id="f-691" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-270" decimals="-5" id="f-692" unitRef="usd">600000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-271" decimals="-5" id="f-693" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-272" decimals="-5" id="f-694" unitRef="usd">600000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-273" decimals="-5" id="f-695" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-274" decimals="-5" id="f-696" unitRef="usd">-200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-275" decimals="-5" id="f-697" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-276" decimals="-5" id="f-698" unitRef="usd">-200000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-273" decimals="-5" id="f-699" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-274" decimals="-5" id="f-700" unitRef="usd">400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-275" decimals="-5" id="f-701" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-276" decimals="-5" id="f-702" unitRef="usd">400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-277" decimals="-5" id="f-703" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-278" decimals="-5" id="f-704" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-279" decimals="-5" id="f-705" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-280" decimals="-5" id="f-706" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-281" decimals="-5" id="f-707" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-282" decimals="-5" id="f-708" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-283" decimals="-5" id="f-709" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-121" decimals="-5" id="f-710" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-284" decimals="-5" id="f-711" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-285" decimals="-5" id="f-712" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-286" decimals="-5" id="f-713" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-287" decimals="-5" id="f-714" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-288" decimals="-5" id="f-715" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-289" decimals="-5" id="f-716" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-290" decimals="-5" id="f-717" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-291" decimals="-5" id="f-718" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-292" decimals="-5" id="f-719" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-293" decimals="-5" id="f-720" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-294" decimals="-5" id="f-721" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-295" decimals="-5" id="f-722" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-296" decimals="-5" id="f-723" unitRef="usd">100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-297" decimals="-5" id="f-724" unitRef="usd">2700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-298" decimals="-5" id="f-725" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-299" decimals="-5" id="f-726" unitRef="usd">3500000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-296" decimals="-5" id="f-727" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-297" decimals="-5" id="f-728" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-298" decimals="-5" id="f-729" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-299" decimals="-5" id="f-730" unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-300" decimals="-5" id="f-731" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-301" decimals="-5" id="f-732" unitRef="usd">2700000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-302" decimals="-5" id="f-733" unitRef="usd">700000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-303" decimals="-5" id="f-734" unitRef="usd">3400000</us-gaap:RestructuringReserve>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-735">Inventories, net &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;356.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;311.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is stated at the lower of cost or net realizable value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-736">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;356.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;311.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-3" decimals="-5" id="f-737" unitRef="usd">126500000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-4" decimals="-5" id="f-738" unitRef="usd">95900000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-3" decimals="-5" id="f-739" unitRef="usd">115800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-5" id="f-740" unitRef="usd">86300000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-3" decimals="-5" id="f-741" unitRef="usd">114000000.0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-5" id="f-742" unitRef="usd">129500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-5" id="f-743" unitRef="usd">356300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-744" unitRef="usd">311700000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-745">Property, plant and equipment, net&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024 &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;667.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(290.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(397.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During 2024, the Company recorded non-cash impairment charges of $27.2 million related to certain Bioservices long-lived assets. See Note 5, &#x201c;Impairment and restructuring charges&#x201d; for more details regarding the impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025 and December&#160;31, 2024, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;construction-in-progress primarily included costs incurred to advance the Company&#x2019;s MCM Products capabilities. Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-746">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024 &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;667.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(290.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(397.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During 2024, the Company recorded non-cash impairment charges of $27.2 million related to certain Bioservices long-lived assets. See Note 5, &#x201c;Impairment and restructuring charges&#x201d; for more details regarding the impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-304" decimals="-5" id="f-747" unitRef="usd">20700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-305" decimals="-5" id="f-748" unitRef="usd">25800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-306" decimals="-5" id="f-749" unitRef="usd">159400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-307" decimals="-5" id="f-750" unitRef="usd">196100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-308" decimals="-5" id="f-751" unitRef="usd">252900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-309" decimals="-5" id="f-752" unitRef="usd">368300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-310" decimals="-5" id="f-753" unitRef="usd">62200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-311" decimals="-5" id="f-754" unitRef="usd">67200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-312" decimals="-5" id="f-755" unitRef="usd">5300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-313" decimals="-5" id="f-756" unitRef="usd">10300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-5" id="f-757" unitRef="usd">500500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-5" id="f-758" unitRef="usd">667700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-5" id="f-759" unitRef="usd">290700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-760" unitRef="usd">397100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-5" id="f-761" unitRef="usd">209800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-762" unitRef="usd">270600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-314" decimals="-5" id="f-763" unitRef="usd">27200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-764">Intangible assets&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s finite-lived intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company&#x2019;s finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;353.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;501.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;353.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;501.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company&#x2019;s finite-lived intangible assets was recorded as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-765">The following table summarizes the Company&#x2019;s finite-lived intangible assets:&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;353.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;501.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;452.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;353.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;501.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-315" id="f-766">P13Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-315" decimals="-5" id="f-767" unitRef="usd">855400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-315" decimals="-5" id="f-768" unitRef="usd">402700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-315" decimals="-5" id="f-769" unitRef="usd">452700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-316" decimals="-5" id="f-770" unitRef="usd">855400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-316" decimals="-5" id="f-771" unitRef="usd">353900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-316" decimals="-5" id="f-772" unitRef="usd">501500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-3" decimals="-5" id="f-773" unitRef="usd">855400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-5" id="f-774" unitRef="usd">402700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-5" id="f-775" unitRef="usd">452700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-5" id="f-776" unitRef="usd">855400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-5" id="f-777" unitRef="usd">353900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-5" id="f-778" unitRef="usd">501500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c-1" id="f-779">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company&#x2019;s finite-lived intangible assets was recorded as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-5" id="f-780" unitRef="usd">16300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-781" unitRef="usd">16300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-782" unitRef="usd">48800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-783" unitRef="usd">48800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-784">Fair value measurements&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company&#x2019;s assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2024 Warrant liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s Credit Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto (the &#x201c;Term Loan Agreement&#x201d;), the Company issued to the lenders warrants to purchase 1.0&#160;million shares of the Company&#x2019;s common stock at an exercise price of $9.8802 per share (the &#x201c;Series I Warrants&#x201d;) and warrants to purchase 1.5&#160;million shares at an exercise price of $15.7185 per share (the &#x201c;Series II Warrants&#x201d; and, together with the Series I Warrants, the &#x201c;Warrants&#x201d;). The Warrants are currently exercisable and will expire on August 30, 2029. Because the Warrants could be cash settled based on events that are outside the control of the Company, it precludes the Warrants from applying the equity contract scope exception, and so are classified as a liability. As a result, the fair value of the Warrants will be remeasured each period with the gain or loss on the warrant liability included in &#x201c;Other, net&#x201d; on the Condensed Consolidated Statement of Operations. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025 and December&#160;31, 2024, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he fair value of the warrant liability was $14.4 million and $16.2&#160;million, respectively, and was included within &#x201c;Other Liabilities&#x201d; on the Condensed Consolidated Balance Sheets, as determined using the Black-Scholes method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to calculate the fair value of the Warrants at each reporting period. Assumptions used in the Black-Scholes option pricing model take into account the agreement terms as well as the quoted price of the Company&#x2019;s common stock in an active market. The volatility is based on the average historical volatility of the common stock. The expected life is based on the remaining contractual term of the Warrants, and the risk free interest rate is based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the Warrants&#x2019; expected life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a reconciliation of the beginning and ending balance of the Company&#x2019;s Level 3 warrant liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurement for the Company's warrant liability used the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Black-Scholes Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-variable rate debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2024, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he fair value of the Company&#x2019;s 3.875% Senior Unsecured Notes due 2028 (the &#x201c;Senior Unsecured Notes&#x201d;) was $368.6&#160;million and $369.1&#160;million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#x2019;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, &#x201c;Debt&#x201d;, for more information regarding the Company&#x2019;s repurchase of a portion of the Senior Unsecured Notes during the third quarter of 2025).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-785">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company&#x2019;s assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-317" decimals="-5" id="f-786" unitRef="usd">105800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-318" decimals="-5" id="f-787" unitRef="usd">105800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-319" decimals="-5" id="f-788" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-320" decimals="-5" id="f-789" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-321" decimals="-5" id="f-790" unitRef="usd">45700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-322" decimals="-5" id="f-791" unitRef="usd">45700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-323" decimals="-5" id="f-792" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-324" decimals="-5" id="f-793" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-5" id="f-794" unitRef="usd">105800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-325" decimals="-5" id="f-795" unitRef="usd">105800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-326" decimals="-5" id="f-796" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-327" decimals="-5" id="f-797" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-5" id="f-798" unitRef="usd">45700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-328" decimals="-5" id="f-799" unitRef="usd">45700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-329" decimals="-5" id="f-800" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-330" decimals="-5" id="f-801" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-5" id="f-802" unitRef="usd">14400000</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-325" decimals="-5" id="f-803" unitRef="usd">0</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-326" decimals="-5" id="f-804" unitRef="usd">0</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-327" decimals="-5" id="f-805" unitRef="usd">14400000</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-5" id="f-806" unitRef="usd">16200000</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-328" decimals="-5" id="f-807" unitRef="usd">0</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-329" decimals="-5" id="f-808" unitRef="usd">0</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-330" decimals="-5" id="f-809" unitRef="usd">16200000</ebs:WarrantLiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-3" decimals="-5" id="f-810" unitRef="usd">14400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-325" decimals="-5" id="f-811" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-326" decimals="-5" id="f-812" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-327" decimals="-5" id="f-813" unitRef="usd">14400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-5" id="f-814" unitRef="usd">16200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-328" decimals="-5" id="f-815" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-329" decimals="-5" id="f-816" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-330" decimals="-5" id="f-817" unitRef="usd">16200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-331"
      decimals="-5"
      id="f-818"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-331"
      decimals="4"
      id="f-819"
      unitRef="usdPerShare">9.8802</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-332"
      decimals="-5"
      id="f-820"
      unitRef="shares">1500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-332"
      decimals="4"
      id="f-821"
      unitRef="usdPerShare">15.7185</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-5" id="f-822" unitRef="usd">14400000</ebs:WarrantLiabilitiesFairValueDisclosure>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-4" decimals="-5" id="f-823" unitRef="usd">16200000</ebs:WarrantLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-824">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a reconciliation of the beginning and ending balance of the Company&#x2019;s Level 3 warrant liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-333" decimals="-5" id="f-825" unitRef="usd">16200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-334" decimals="-5" id="f-826" unitRef="usd">-9500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-335" decimals="-5" id="f-827" unitRef="usd">6700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-336" decimals="-5" id="f-828" unitRef="usd">2900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-337" decimals="-5" id="f-829" unitRef="usd">9600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-338" decimals="-5" id="f-830" unitRef="usd">4800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-339" decimals="-5" id="f-831" unitRef="usd">14400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-832">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurement for the Company's warrant liability used the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024 Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Black-Scholes Method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-340" decimals="INF" id="f-833" unitRef="term">3.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-341" decimals="3" id="f-834" unitRef="number">0.037</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-342" decimals="2" id="f-835" unitRef="number">1.03</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-343"
      decimals="INF"
      id="f-836"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-344"
      decimals="INF"
      id="f-837"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue contextRef="c-344" decimals="-5" id="f-838" unitRef="usd">368600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-343" decimals="-5" id="f-839" unitRef="usd">369100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-840">Debt&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the components of the Company&#x2019;s debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Term loan due 2029&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;700.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;663.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;663.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were $35.0&#160;million of unamortized debt issuance costs recorded in connection with the execution of the Term Loan Agreement within a contra account to directly offset the Term Loan balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs associated with the Company&#x2019;s Revolving Loans, as described in further detail below, were recorded as an asset within &#x201c;Other long-term assets&#x201d; on the Company&#x2019;s Condensed Consolidated Balance Sheets. As of September 30, 2025, the Company has $3.0&#160;million in debt issuance costs associated with the Revolving Loans. If the Company draws on the capacity available under the Revolving Loans, the debt issuance costs would be reclassified to a contra account to directly offset the Revolving Loans balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, the Company issued $450.0&#160;million aggregate principal amount of its Senior Unsecured Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Interest on the Senior Unsecured Notes is payable on February 15 and August 15 of each year until maturity, beginning on February 15, 2021. The Senior Unsecured Notes will mature on August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of August 15, 2023, the Company may redeem all or a portion of the Senior Unsecured Notes at a redemption price equal to 100% of the principal amount of the Senior Unsecured Notes plus a &#x201c;make-whole&#x201d; premium and accrued and unpaid interest as set forth in the related indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the Senior Unsecured Notes at a purchase price of 101% of the principal amount of such notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Negative covenants in the indenture governing the Senior Unsecured Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;restricted payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;7, 2025, the Board of Directors authorized the Company to repurchase up to $30.0 million in aggregate principal amount of the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company may seek to opportunistically use this authority to repurchase its Senior Unsecured Notes in open market purchases, privately negotiated transactions or otherwise. Any such repurchases will depend upon prevailing market conditions, our liquidity requirements, contractual restrictions, applicable securities law and other factors. During the three and nine months ended September 30, 2025, the Company repurchased $6.9 million principal amount of its outstanding Senior Unsecured Notes. The Company paid $5.8&#160;million in cash, including fees and accrued interest, in connection with the repurchases and recognized a gain on extinguishment of approximately $1.1&#160;million, which was included in &#x201c;Other, net&#x201d; on the Consolidated Statement of Operations. As of September 30, 2025, the Company had $23.1&#160;million available to repurchase additional Senior Unsecured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Term Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2024, the Company entered into the Term Loan Agreement with OHA Agency LLC, as administrative agent, and the lenders from time to time party thereto. The Term Loan Agreement provides for a term loan (the &#x201c;Term Loan&#x201d;) of $250.0&#160;million, which was drawn in full on the date of entry into the Term Loan Agreement (the &#x201c;Closing Date&#x201d;). The Term Loan was issued with an original issue discount of 3.00%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan will accrue interest at the Company&#x2019;s option at (i) the Base Rate (as defined in the Term Loan Agreement) (subject to a floor of 1.00%) plus 7.25% per annum, referred to as &#x201c;Term Base Rate Loans&#x201d; or (ii) Adjusted Term SOFR (as defined in the Term Loan Agreement) (subject to a floor of 2.00% until the second anniversary of the Closing Date, and thereafter, 3.00%) plus 8.25% per annum, referred to as &#x201c;Term SOFR Loans&#x201d;). A default interest rate of an additional 2.00% per annum would apply on all outstanding obligations that are not paid when due. If any defaulted obligations are Term SOFR Loans, then such loans would, at the end of the applicable interest period, automatically be converted to Term Base Rate Loans that would continue to be subject to the default interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan will mature on the first to occur (such date, the &#x201c;Term Loan Maturity Date&#x201d;) of (i) August 30, 2029, (ii) the date of acceleration of the Term Loan upon the occurrence and during the continuance of an event of default and (iii) solely to the extent the aggregate principal amount of Senior Unsecured Notes outstanding exceeds $25.0 million, May 15, 2028, which is three months prior to the August 15, 2028 maturity date of the Senior Unsecured Notes. The Term Loan Agreement contains certain customary default and cross-default provisions, representations and warranties and affirmative and negative covenants, including (a) restrictions on prepayments and repurchases of indebtedness, including the Senior Unsecured Notes, subject to further customary permitted debt payments, (b) a minimum liquidity requirement of $75.0&#160;million commencing on September 30, 2024 and tested every two weeks, and (c) a consolidated gross leverage ratio tested every fiscal quarter commencing with the fiscal quarter ending December 31, 2025, initially at 5.10:1.00 with step-downs as set forth in the Term Loan Agreement. As of September 30, 2025, the Company was in compliance with all covenants under the Term Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All indebtedness outstanding under the Term Loan Agreement is guaranteed by certain of the Company&#x2019;s direct and indirect subsidiaries, other than certain subsidiaries that are not material, are excluded pursuant to the terms of the Term Loan Agreement, or will become guarantors on a post-closing basis (the Company and the guarantors, collectively, the &#x201c;Credit Parties&#x201d;). The indebtedness under the Term Loan Agreement is secured by a first-priority security interest in and lien on substantially all assets of the Company and the other Credit Parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may elect to prepay the Term Loan, in whole or in part, subject to (i) through and including the first anniversary of the Closing Date, a make-whole premium plus 4.00% of the aggregate principal amount of the Term Loan subject to prepayment and (ii) after the first anniversary of the Closing Date, a 4.00% prepayment premium, which percentage shall be reduced by 0.25% as set forth on a schedule attached to the Term Loan Agreement. The Term Loan Agreement requires mandatory prepayments of the Term Loan in an amount equal to (a) 100% of the aggregate net cash proceeds from the incurrence of certain indebtedness by the Term Loan Credit Parties and (b) (subject to certain reinvestment rights) 100% of the aggregate net cash proceeds from (1) subject to certain specified exceptions, dispositions of property by the Credit Parties (provided that with respect to any dispositions occurring on or after the Closing Date, prepayment will not be required unless the net cash proceeds exceed $10.0 million in the aggregate per fiscal year or $5.0 million on a per-transaction basis) and (2) insurance proceeds received by any Credit Party or their subsidiaries resulting from theft, loss, physical destruction or damage of property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Closing Date, the Company used a portion of the proceeds of the Term Loan to repay all amounts outstanding and terminate commitments under the senior term loan facility under its Amended and Restated Credit Agreement, dated October 15, 2028, by and among the Company, the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the Administrative Agent (the &#x201c;Prior Credit Agreement&#x201d;), plus accrued interest and fees. The Company previously repaid all amounts outstanding under the revolving credit facility under the Prior Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revolving Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2024, the Company entered into a credit agreement for asset-based revolving loans (the &#x201c;Revolving Credit Agreement&#x201d;) with certain subsidiary borrowers (together with the Company, the &#x201c;Borrowers&#x201d;), the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as agent (the &#x201c;Agent&#x201d;). The Credit Agreement provides for commitments with respect to the revolving loans (the &#x201c;Revolving Loans&#x201d;) of up to the lesser of (x) $100.0 million, which may be increased (but not above $125.0 million, or the &#x201c;Maximum Revolver Amount&#x201d;) or decreased (but not below $50.0 million) by the Borrowers in accordance with the terms of the Revolving Credit Agreement and (y) the Borrowing Base (as defined in the Revolving Credit Agreement). Once reduced, the facility may not be increased. Up to $5.0 million of capacity under the Revolving Loans may be used for swing loans and up to $10.0 million may be used for the issuance of letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Loans accrue interest at the Base Rate (as defined in the Revolving Credit Agreement) plus a margin of 1.25% (such loans, &#x201c;Revolving Base Rate Loans&#x201d;) or, at the Company&#x2019;s election, at a rate equal to Adjusted Term SOFR (as defined in the Revolving Credit Agreement and subject to a floor of 0.00%) plus a margin of 2.25% (such loans, &#x201c;Revolving SOFR Loans&#x201d;), in each case until September 30, 2025. After September 30, 2025, the applicable margin may be reduced to 0.75% in the case of Revolving Base Rate Loans, or 1.75% in the case of Revolving SOFR Loans, provided the Borrowers&#x2019; total leverage ratio is less than 4.00 to 1.00 for the most recently completed fiscal quarter and an event of default is not continuing. A default interest rate of an additional 2.00% per annum would apply on all outstanding obligations that are not paid when due.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Loans will mature on the first to occur of (i) September 30, 2029; (ii) to the extent there remain outstanding any portion of the term loans extended under the Term Loan Agreement, the date that is 90 days prior to the maturity date under the Term Loan Agreement; and (iii) to the extent any of the Senior Unsecured Notes remain outstanding, May 17, 2028, which is 90 days prior to the August 15, 2028 maturity date of the Senior Unsecured Notes. The Revolving Credit Agreement contains certain customary default and cross-default provisions (including with respect to defaults under the Term Loan Agreement), representations and warranties and affirmative and negative covenants, including (a) restrictions on prepayments and repurchases of indebtedness, including the Senior Unsecured Notes, (b) restrictions on dispositions of material intellectual property, (c) a minimum liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requirement of $50.0&#160;million through the day prior to the first date following September 30, 2025 on which the Company&#x2019;s total leverage ratio measured as of the preceding 12-month period is less than 5.25 to 1.00 (the &#x201c;Covenant Conversion Date&#x201d;) and (d) from the Covenant Conversion Date, a fixed charge coverage ratio requirement of at least 1.00 to 1.00. As of September 30, 2025, the Company was in compliance with all covenants under the Revolving Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All indebtedness outstanding under the Revolving Credit Agreement is guaranteed by certain of the Borrowers&#x2019; material direct and indirect subsidiaries, subject to customary exclusions. The indebtedness under the Credit Agreement is secured by a first-priority security interest in and lien on the ABL Priority Collateral and a second-priority security interest and lien on the Term Loan Priority Collateral (in each case as defined in the Revolving Credit Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Borrowers may elect to prepay any Revolving Loans, in whole or in part, without premium or penalty. If at any time outstanding Revolving Loans and letters of credit exceed the lesser of (i) the Borrowing Base, as adjusted for reserves established by the Agent, and (ii) the Maximum Revolver Amount, the Borrowers will be required to prepay outstanding obligations in the amount of such excess. The Agent may establish, increase or decrease reserves at its discretion.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-841">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the components of the Company&#x2019;s debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Term loan due 2029&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;700.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;663.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;663.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt contextRef="c-345" decimals="-5" id="f-842" unitRef="usd">250000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-346" decimals="-5" id="f-843" unitRef="usd">250000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-344"
      decimals="INF"
      id="f-844"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-343"
      decimals="INF"
      id="f-845"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-344" decimals="-5" id="f-846" unitRef="usd">443100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-343" decimals="-5" id="f-847" unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-5" id="f-848" unitRef="usd">693100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-5" id="f-849" unitRef="usd">700000000.0</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-3" decimals="-5" id="f-850" unitRef="usd">30000000.0</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-4" decimals="-5" id="f-851" unitRef="usd">36300000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-5" id="f-852" unitRef="usd">663100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-5" id="f-853" unitRef="usd">663700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-347" decimals="-5" id="f-854" unitRef="usd">35000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-348" decimals="-5" id="f-855" unitRef="usd">3000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-349"
      decimals="INF"
      id="f-856"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-349" decimals="-5" id="f-857" unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-350"
      decimals="INF"
      id="f-858"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-351"
      decimals="INF"
      id="f-859"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-352" decimals="-5" id="f-860" unitRef="usd">30000000.0</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-344" decimals="-5" id="f-861" unitRef="usd">6900000</us-gaap:DebtInstrumentRepurchaseAmount>
    <ebs:PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment contextRef="c-353" decimals="-5" id="f-862" unitRef="usd">5800000</ebs:PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment>
    <ebs:PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment contextRef="c-354" decimals="-5" id="f-863" unitRef="usd">5800000</ebs:PaymentsForRepurchaseOfDebtExcludingGainLossOnExtinguishment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-354" decimals="-5" id="f-864" unitRef="usd">1100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-353" decimals="-5" id="f-865" unitRef="usd">1100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <ebs:DebtInstrumentRepurchaseAmountRemaining contextRef="c-344" decimals="-5" id="f-866" unitRef="usd">23100000</ebs:DebtInstrumentRepurchaseAmountRemaining>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-355" decimals="INF" id="f-867" unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <ebs:DebtInstrumentOriginalIssueDiscountPercentage
      contextRef="c-355"
      decimals="INF"
      id="f-868"
      unitRef="number">0.0300</ebs:DebtInstrumentOriginalIssueDiscountPercentage>
    <ebs:DebtInstrumentVariableInterestRateFloor
      contextRef="c-356"
      decimals="INF"
      id="f-869"
      unitRef="number">0.0100</ebs:DebtInstrumentVariableInterestRateFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-356"
      decimals="INF"
      id="f-870"
      unitRef="number">0.0725</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ebs:DebtInstrumentVariableInterestRateFloor
      contextRef="c-357"
      decimals="INF"
      id="f-871"
      unitRef="number">0.0200</ebs:DebtInstrumentVariableInterestRateFloor>
    <ebs:DebtInstrumentVariableInterestRateFloor
      contextRef="c-358"
      decimals="INF"
      id="f-872"
      unitRef="number">0.0300</ebs:DebtInstrumentVariableInterestRateFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-359"
      decimals="INF"
      id="f-873"
      unitRef="number">0.0825</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ebs:DebtInstrumentAdditionalDefaultInterestRate
      contextRef="c-360"
      decimals="INF"
      id="f-874"
      unitRef="number">0.0200</ebs:DebtInstrumentAdditionalDefaultInterestRate>
    <ebs:DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold contextRef="c-355" decimals="INF" id="f-875" unitRef="usd">25000000.0</ebs:DebtInstrumentMaturityDateAggregatePrincipalAmountOutstandingThreshold>
    <ebs:DebtInstrumentCovenantLiquidityRequirementMinimum contextRef="c-361" decimals="INF" id="f-876" unitRef="usd">75000000</ebs:DebtInstrumentCovenantLiquidityRequirementMinimum>
    <ebs:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="c-355"
      decimals="INF"
      id="f-877"
      unitRef="number">5.10</ebs:DebtInstrumentCovenantLeverageRatioMaximum>
    <ebs:DebtInstrumentBasisSpreadOnMakeWholePremium
      contextRef="c-355"
      decimals="INF"
      id="f-878"
      unitRef="number">0.0400</ebs:DebtInstrumentBasisSpreadOnMakeWholePremium>
    <ebs:DebtInstrumentPrepaymentPremium
      contextRef="c-355"
      decimals="INF"
      id="f-879"
      unitRef="number">0.0400</ebs:DebtInstrumentPrepaymentPremium>
    <ebs:DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease
      contextRef="c-355"
      decimals="INF"
      id="f-880"
      unitRef="number">-0.0025</ebs:DebtInstrumentPrepaymentPremiumScheduledIncreaseDecrease>
    <ebs:DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred
      contextRef="c-360"
      decimals="INF"
      id="f-881"
      unitRef="number">1</ebs:DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromIndebtednessIncurred>
    <ebs:DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds
      contextRef="c-360"
      decimals="INF"
      id="f-882"
      unitRef="number">1</ebs:DebtInstrumentMandatoryPrepaymentPercentageOfNetCashProceedsFromDispositionsOfPropertyAndInsuranceProceeds>
    <ebs:DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis contextRef="c-360" decimals="INF" id="f-883" unitRef="usd">10000000.0</ebs:DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdAnnualBasis>
    <ebs:DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis contextRef="c-360" decimals="INF" id="f-884" unitRef="usd">5000000.0</ebs:DebtInstrumentMandatoryPrepaymentNetCashProceedsFromDispositionOfPropertyThresholdPerTransactionBasis>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-362" decimals="INF" id="f-885" unitRef="usd">100000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ebs:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit contextRef="c-362" decimals="INF" id="f-886" unitRef="usd">125000000.0</ebs:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseLimit>
    <ebs:LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit contextRef="c-362" decimals="INF" id="f-887" unitRef="usd">50000000.0</ebs:LineOfCreditFacilityMaximumBorrowingCapacityDecreaseLimit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-363" decimals="INF" id="f-888" unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-364" decimals="INF" id="f-889" unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-365"
      decimals="INF"
      id="f-890"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ebs:DebtInstrumentVariableInterestRateFloor
      contextRef="c-366"
      decimals="INF"
      id="f-891"
      unitRef="number">0.0000</ebs:DebtInstrumentVariableInterestRateFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-366"
      decimals="INF"
      id="f-892"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-367"
      decimals="INF"
      id="f-893"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-368"
      decimals="INF"
      id="f-894"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ebs:DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum
      contextRef="c-362"
      decimals="INF"
      id="f-895"
      unitRef="number">4.00</ebs:DebtInstrumentCovenantLeverageRatioForVariableRateReductionMaximum>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-362"
      decimals="INF"
      id="f-896"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ebs:DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate contextRef="c-369" id="f-897">P90D</ebs:DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate>
    <ebs:DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate contextRef="c-369" id="f-898">P90D</ebs:DebtInstrumentCovenantMaturityNumberOfDaysPriorToTheMaturityDate>
    <ebs:DebtInstrumentCovenantLiquidityRequirementMinimum contextRef="c-362" decimals="INF" id="f-899" unitRef="usd">50000000</ebs:DebtInstrumentCovenantLiquidityRequirementMinimum>
    <ebs:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="c-362"
      decimals="INF"
      id="f-900"
      unitRef="number">5.25</ebs:DebtInstrumentCovenantLeverageRatioMaximum>
    <ebs:DebtInstrumentCovenantFixedChargeCoverageRatioMinimum
      contextRef="c-362"
      decimals="INF"
      id="f-901"
      unitRef="number">1.00</ebs:DebtInstrumentCovenantFixedChargeCoverageRatioMinimum>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-902">Share-based compensation and stockholders' equity&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share-based compensation expense relates to stock options, performance stock options, restricted stock units, performance stock units and liability classified long-term incentive awards. During the nine months ended September 30, 2025, the Company granted stock options to purchase 1.6&#160;million shares of common stock, 2.7&#160;million restricted stock units and 0.3&#160;million performance stock units. The grants were made under the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan and the Emergent BioSolutions Inc. Inducement Plan. The performance stock units settle in stock at the end of a one-year performance period based on the Company's results compared to the performance criteria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2024, the Company granted an $8.0&#160;million long-term incentive award, subject to market conditions, with the option to settle in any combination of cash or shares, which is accounted for as a liability classified award. The Company&#x2019;s performance stock options and the long-term incentive award are valued using Monte Carlo valuation models, and each have a performance period of five years to vest based on the Company&#x2019;s stock price performance. The long-term incentive award is revalued at each reporting period until the award is earned or expires. The Company&#x2019;s other equity awards typically vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the nine months ended September 30, 2025, 0.4&#160;million stock options, 0.3&#160;million of restricted stock units and an immaterial number of performance stock units were forfeited prior to the completion of the applicable vesting requirements or expiration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.459%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products and services sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research &amp;amp; development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2025 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;31, 2025, the Company announced that its Board of Directors had authorized the repurchase of up to $50.0&#160;million of the Company&#x2019;s common stock (the &#x201c;2025 Share Repurchase Program&#x201d;) on or before March 27, 2026. Repurchases under the 2025 Share Repurchase Program may be made from time to time on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the Company&#x2019;s management based on its evaluation of market conditions and other factors, including the market price of the Company&#x2019;s common shares, macroeconomic environment and other investment opportunities, consistent with the Company&#x2019;s insider trading policy. The 2025 Share Repurchase Program may be suspended or discontinued at any time. The Inflation Reduction Act of 2022, which was enacted on August 16, 2022, imposed a nondeductible 1% &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;excise tax on the net value of certain stock repurchases made after December 31, 2022. Excise tax accrued during the three and nine months ended September 30, 2025 was $0.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2025, the Company utilized $8.9&#160;million and $15.8&#160;million to repurchase 1.1&#160;million and 2.3&#160;million shares, respectively, at an average price of $7.87 and $7.00 per share, excluding commissions and excise taxes, respectively. As of September 30, 2025, the Company had $34.2&#160;million available to repurchase shares under the 2025 Share Repurchase Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2024 Issuance of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Term Loan Agreement, the Company entered into a Subscription Agreement, dated as of August 30, 2024 (the &#x201c;Subscription Agreement&#x201d;) with the lenders under the Term Loan Agreement, under which on September 17, 2024, the Company issued to the lenders 1.1&#160;million shares of common stock with an aggregate value of $10.0&#160;million, at a price per share of $8.98, which was based on the volume weighted average price per share of common stock for the 30 consecutive trading days ending on, but excluding, the tenth business day of the Term Loan Agreement. At inception, the Subscription Agreement represented a forward sale of the Company&#x2019;s common stock (the &#x201c;Forward&#x201d;). The Forward was initially classified and recorded as a liability and was remeasured to its fair value, resulting in a $1.6&#160;million gain on settlement on September&#160;17, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2024 Warrant Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Term Loan Agreement, the Company issued to the lenders Series I Warrants to purchase 1.0&#160;million shares of common stock and Series II Warrants to purchase 1.5&#160;million shares of common stock. The Warrants are currently exercisable and will expire on August 30, 2029. Because the Warrants could be cash settled based on events that are outside the control of the Company, it precludes the Warrants from applying the equity contract scope exception, and so are classified as a liability. As of September 30, 2025, the fair value of the Warrants was $14.4 million. See Note 9, &#x201c;Fair value measurements,&#x201d; for more information on the accounting treatment and valuation of the Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025, the Company had the following Warrants outstanding to acquire shares of its common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Range of Exercise&lt;br/&gt;&#160;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued related to the Term Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.88 - $15.72&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2025, no Warrants expired or were exercised.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-370"
      decimals="-5"
      id="f-903"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-371"
      decimals="-5"
      id="f-904"
      unitRef="shares">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-372"
      decimals="-5"
      id="f-905"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod contextRef="c-372" id="f-906">P1Y</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod>
    <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue contextRef="c-373" decimals="-5" id="f-907" unitRef="usd">8000000</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-374" id="f-908">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-375" id="f-909">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements
      contextRef="c-376"
      decimals="INF"
      id="f-910"
      unitRef="increment">3</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingIncrements>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-372" id="f-911">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="c-1" decimals="-5" id="f-912" unitRef="shares">400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-371"
      decimals="-5"
      id="f-913"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-372"
      decimals="-5"
      id="f-914"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-915">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.459%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products and services sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research &amp;amp; development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-377" decimals="-5" id="f-916" unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-378" decimals="-5" id="f-917" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-379" decimals="-5" id="f-918" unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-380" decimals="-5" id="f-919" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-381" decimals="-5" id="f-920" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-382" decimals="-5" id="f-921" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-383" decimals="-5" id="f-922" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-384" decimals="-5" id="f-923" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-385" decimals="-5" id="f-924" unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-386" decimals="-5" id="f-925" unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-387" decimals="-5" id="f-926" unitRef="usd">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-388" decimals="-5" id="f-927" unitRef="usd">10900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-5" id="f-928" unitRef="usd">4800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-5" id="f-929" unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-930" unitRef="usd">10900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-5" id="f-931" unitRef="usd">13700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-389" decimals="INF" id="f-932" unitRef="usd">50000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ShareRepurchaseProgramExciseTaxPayable contextRef="c-3" decimals="-5" id="f-933" unitRef="usd">200000</us-gaap:ShareRepurchaseProgramExciseTaxPayable>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-390" decimals="-5" id="f-934" unitRef="usd">8900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-391" decimals="-5" id="f-935" unitRef="usd">15800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-390"
      decimals="-5"
      id="f-936"
      unitRef="shares">1100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-391"
      decimals="-5"
      id="f-937"
      unitRef="shares">2300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-390"
      decimals="2"
      id="f-938"
      unitRef="usdPerShare">7.87</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-391"
      decimals="2"
      id="f-939"
      unitRef="usdPerShare">7.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-392" decimals="-5" id="f-940" unitRef="usd">34200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-393"
      decimals="-5"
      id="f-941"
      unitRef="shares">1100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-393" decimals="-5" id="f-942" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-394"
      decimals="2"
      id="f-943"
      unitRef="usdPerShare">8.98</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c-393" decimals="-5" id="f-944" unitRef="usd">1600000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-331"
      decimals="-5"
      id="f-945"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-332"
      decimals="-5"
      id="f-946"
      unitRef="shares">1500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ebs:WarrantLiabilitiesFairValueDisclosure contextRef="c-3" decimals="-5" id="f-947" unitRef="usd">14400000</ebs:WarrantLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-948">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025, the Company had the following Warrants outstanding to acquire shares of its common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Range of Exercise&lt;br/&gt;&#160;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued related to the Term Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.88 - $15.72&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-395"
      decimals="-5"
      id="f-949"
      unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-396"
      decimals="2"
      id="f-950"
      unitRef="usdPerShare">9.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-397"
      decimals="2"
      id="f-951"
      unitRef="usdPerShare">15.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-3" decimals="-5" id="f-952" unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-953">Earnings (loss) per common share&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per common share is calculated using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per common share adjusts basic earnings (loss) per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units and performance stock units, as well as shares issuable upon exercises of the Warrants. Diluted earnings (loss) per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plans and pursuant to exercises of the Warrants that were excluded from diluted earnings (loss) per common share because their effect would have been antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted earnings (loss) per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities - equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings (loss) per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings (loss) per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-954">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted earnings (loss) per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities - equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings (loss) per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings (loss) per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-5" id="f-955" unitRef="usd">51200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-5" id="f-956" unitRef="usd">114800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-957" unitRef="usd">107200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-958" unitRef="usd">-159300000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-5" id="f-959" unitRef="shares">53200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-5" id="f-960" unitRef="shares">53100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-961" unitRef="shares">53900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-5" id="f-962" unitRef="shares">52600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-13" decimals="-5" id="f-963" unitRef="shares">3300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-14" decimals="-5" id="f-964" unitRef="shares">2500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-5" id="f-965" unitRef="shares">2800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-15" decimals="-5" id="f-966" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-5" id="f-967" unitRef="shares">56500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-5" id="f-968" unitRef="shares">55600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-969" unitRef="shares">56700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-5" id="f-970" unitRef="shares">52600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-971"
      unitRef="usdPerShare">0.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-972"
      unitRef="usdPerShare">2.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-973"
      unitRef="usdPerShare">1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-974"
      unitRef="usdPerShare">-3.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-975"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-976"
      unitRef="usdPerShare">2.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-977"
      unitRef="usdPerShare">1.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-978"
      unitRef="usdPerShare">-3.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="-5" id="f-979" unitRef="shares">5000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-14" decimals="-5" id="f-980" unitRef="shares">2600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-981" unitRef="shares">4700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-15" decimals="-5" id="f-982" unitRef="shares">4400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-983">Revenue recognition&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates the majority of its revenues through product sales to customers. The Company also generates revenues through its Bioservices offerings and suite reservations for and to third parties and Contracts and grants revenue. The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with (a) customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Nasal Naloxone Products are sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration include allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; may also be sold on consignment through third-party online retailers where revenues are recognized at the point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as SG&amp;amp;A expenses and Cost of Commercial Product sales, respectively, in the Condensed Consolidated Statement of Operations. Revenues from OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including inventory levels within the distribution channel, product shelf life and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's revenues disaggregated by major sources for the three and nine months ended September 30, 2025 and 2024 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;161.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;293.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; includes Services and Contracts and grants revenue.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="36" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;235.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;357.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;319.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;324.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;594.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;343.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; includes Services and Contracts and grants revenue.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; for the nine months ended September 30, 2024 includes $50.0 million attributable to the confidential arbitration settlement (the &#x201c;Settlement Agreement&#x201d;) with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;) related to the 2022 termination of the manufacturing services agreement with Janssen (the &#x201c;Janssen Agreement&#x201d;).  The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, &#x201c;Litigation&#x201d; for additional information related to the accounting treatment and settlement of the arbitration with Janssen.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction price allocated to remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025, the Company has future contract value on unsatisfied performance obligations of approximately $322.5&#160;million associated with all arrangements entered into by the Company. The Company expects to recognize $259.2&#160;million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associated with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#x2019;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and that the Company does not currently have a contractual right to bill, to be contract assets. As of September 30, 2025 and December&#160;31, 2024, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Company had $2.3 million an&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.7 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, of contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded within &#x201c;Accounts receivable, net&#x201d; on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Condensed Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.6pt;font-weight:400;line-height:120%"&gt;Revenue recognized in the period from amounts included in contract liability at the beginning of the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025 and December&#160;31, 2024, the current portion of contract liabilities was $6.1&#160;million and $4.8&#160;million, respectively, and was included in &#x201c;Other current liabilities&#x201d; on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable and allowance for expected credit losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-984">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration include allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; may also be sold on consignment through third-party online retailers where revenues are recognized at the point in time when sold to the end customer. The Company pays these third-party online retailers selling commissions and fulfillment fees which are recorded as SG&amp;amp;A expenses and Cost of Commercial Product sales, respectively, in the Condensed Consolidated Statement of Operations. Revenues from OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of OTC NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including inventory levels within the distribution channel, product shelf life and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-985">The Company's revenues disaggregated by major sources for the three and nine months ended September 30, 2025 and 2024 were as follows: &lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;161.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;293.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; includes Services and Contracts and grants revenue.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="36" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;235.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;357.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;319.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;324.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;594.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;343.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; includes Services and Contracts and grants revenue.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; for the nine months ended September 30, 2024 includes $50.0 million attributable to the confidential arbitration settlement (the &#x201c;Settlement Agreement&#x201d;) with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;) related to the 2022 termination of the manufacturing services agreement with Janssen (the &#x201c;Janssen Agreement&#x201d;).  The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, &#x201c;Litigation&#x201d; for additional information related to the accounting treatment and settlement of the arbitration with Janssen.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-398" decimals="-5" id="f-986" unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-399" decimals="-5" id="f-987" unitRef="usd">74200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-400" decimals="-5" id="f-988" unitRef="usd">74900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-401" decimals="-5" id="f-989" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-402" decimals="-5" id="f-990" unitRef="usd">95300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-403" decimals="-5" id="f-991" unitRef="usd">95300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-404" decimals="-5" id="f-992" unitRef="usd">123200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-405" decimals="-5" id="f-993" unitRef="usd">19300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-406" decimals="-5" id="f-994" unitRef="usd">142500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-407" decimals="-5" id="f-995" unitRef="usd">161800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-408" decimals="-5" id="f-996" unitRef="usd">12400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-409" decimals="-5" id="f-997" unitRef="usd">174200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-410" decimals="-5" id="f-998" unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-411" decimals="-5" id="f-999" unitRef="usd">4600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-412" decimals="-5" id="f-1000" unitRef="usd">13700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-413" decimals="-5" id="f-1001" unitRef="usd">9700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-414" decimals="-5" id="f-1002" unitRef="usd">14600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-415" decimals="-5" id="f-1003" unitRef="usd">24300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-416" decimals="-5" id="f-1004" unitRef="usd">133000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-417" decimals="-5" id="f-1005" unitRef="usd">98100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-5" id="f-1006" unitRef="usd">231100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-418" decimals="-5" id="f-1007" unitRef="usd">171500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-419" decimals="-5" id="f-1008" unitRef="usd">122300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-5" id="f-1009" unitRef="usd">293800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-420" decimals="-5" id="f-1010" unitRef="usd">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-421" decimals="-5" id="f-1011" unitRef="usd">185700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-422" decimals="-5" id="f-1012" unitRef="usd">187700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-423" decimals="-5" id="f-1013" unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-424" decimals="-5" id="f-1014" unitRef="usd">333400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-425" decimals="-5" id="f-1015" unitRef="usd">333800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-426" decimals="-5" id="f-1016" unitRef="usd">235800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-427" decimals="-5" id="f-1017" unitRef="usd">121700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-428" decimals="-5" id="f-1018" unitRef="usd">357500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-429" decimals="-5" id="f-1019" unitRef="usd">319700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-430" decimals="-5" id="f-1020" unitRef="usd">73300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-431" decimals="-5" id="f-1021" unitRef="usd">393000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-432" decimals="-5" id="f-1022" unitRef="usd">31800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-433" decimals="-5" id="f-1023" unitRef="usd">17200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-434" decimals="-5" id="f-1024" unitRef="usd">49000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-435" decimals="-5" id="f-1025" unitRef="usd">23700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-436" decimals="-5" id="f-1026" unitRef="usd">98400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-437" decimals="-5" id="f-1027" unitRef="usd">122100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-438" decimals="-5" id="f-1028" unitRef="usd">269600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-439" decimals="-5" id="f-1029" unitRef="usd">324600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-1030" unitRef="usd">594200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-440" decimals="-5" id="f-1031" unitRef="usd">343800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-441" decimals="-5" id="f-1032" unitRef="usd">505100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-5" id="f-1033" unitRef="usd">848900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-442" decimals="-5" id="f-1034" unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-3" decimals="-5" id="f-1035" unitRef="usd">322500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-443" decimals="-5" id="f-1036" unitRef="usd">259200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-443" id="f-1037">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-3" decimals="-5" id="f-1038" unitRef="usd">2300000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-4" decimals="-5" id="f-1039" unitRef="usd">9700000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-1040">The following table presents the roll forward of the contract liability balances:&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.6pt;font-weight:400;line-height:120%"&gt;Revenue recognized in the period from amounts included in contract liability at the beginning of the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-5" id="f-1041" unitRef="usd">9300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-5" id="f-1042" unitRef="usd">10300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-1043" unitRef="usd">2100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-5" id="f-1044" unitRef="usd">6100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-5" id="f-1045" unitRef="usd">4800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ebs:ScheduleOfAccountsReceivableNetTableTextBlock contextRef="c-1" id="f-1046">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:ScheduleOfAccountsReceivableNetTableTextBlock>
    <us-gaap:BilledContractReceivables contextRef="c-3" decimals="-5" id="f-1047" unitRef="usd">131500000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables contextRef="c-4" decimals="-5" id="f-1048" unitRef="usd">135400000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable contextRef="c-3" decimals="-5" id="f-1049" unitRef="usd">19300000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable contextRef="c-4" decimals="-5" id="f-1050" unitRef="usd">19600000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-3" decimals="-5" id="f-1051" unitRef="usd">1300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-4" decimals="-5" id="f-1052" unitRef="usd">500000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-5" id="f-1053" unitRef="usd">149500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-1054" unitRef="usd">154500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1055">Leases &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is the lessee for operating leases for offices, R&amp;amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are reflected as components of &#x201c;Cost of product and services sales, net&#x201d;, &#x201c;R&amp;amp;D&#x201d; expense and &#x201c;SG&amp;amp;A&#x201d; expense on the Company's Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1070"&gt;&lt;span style="-sec-ix-hidden:f-1071"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1074"&gt;&lt;span style="-sec-ix-hidden:f-1075"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1078"&gt;&lt;span style="-sec-ix-hidden:f-1079"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1056">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="-5" id="f-1057" unitRef="usd">400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-14" decimals="-5" id="f-1058" unitRef="usd">700000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-5" id="f-1059" unitRef="usd">1500000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-15" decimals="-5" id="f-1060" unitRef="usd">2500000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-5" id="f-1061" unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-5" id="f-1062" unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-1063" unitRef="usd">600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-15" decimals="-5" id="f-1064" unitRef="usd">600000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost contextRef="c-13" decimals="-5" id="f-1065" unitRef="usd">600000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-14" decimals="-5" id="f-1066" unitRef="usd">900000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-5" id="f-1067" unitRef="usd">2100000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-15" decimals="-5" id="f-1068" unitRef="usd">3100000</us-gaap:LeaseCost>
    <ebs:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-1069">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1070"&gt;&lt;span style="-sec-ix-hidden:f-1071"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1074"&gt;&lt;span style="-sec-ix-hidden:f-1075"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1078"&gt;&lt;span style="-sec-ix-hidden:f-1079"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-5" id="f-1072" unitRef="usd">7200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-5" id="f-1073" unitRef="usd">11700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-5" id="f-1076" unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-5" id="f-1077" unitRef="usd">2700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-5" id="f-1080" unitRef="usd">6100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-5" id="f-1081" unitRef="usd">9700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-5" id="f-1082" unitRef="usd">7900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-5" id="f-1083" unitRef="usd">12400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-1084">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1085">P5Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-1086" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1087" unitRef="number">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1088">Income taxes &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated effective annual tax rate as of September 30, 2025 and 2024 for the years ended December&#160;31, 2025 and 2024, excluding the impact of discrete adjustments, was 22% and 20%, respectively. The effective tax rate for the nine months ended September 30, 2025 and 2024 was 20% and (38)%, respectively. The increase in the estimated effective annual tax rate and the effective quarterly tax rate is primarily due to an increase in estimated profit combined with a change in jurisdictional mix of income and losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted into law in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. These impacts did not have a material effect on the tax rate for the three and nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c-444"
      decimals="2"
      id="f-1089"
      unitRef="number">0.22</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c-314"
      decimals="2"
      id="f-1090"
      unitRef="number">0.20</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="2" id="f-1091" unitRef="number">0.20</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="2" id="f-1092" unitRef="number">-0.38</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1093">Litigation &lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Securities and shareholder litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#x2019;s common stock, seeking to pursue remedies under the Exchange Act. These complaints were filed by Palm Tran, Inc. &#x2013; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth, and Stephen M. Weiss, respectively. The complaints alleged, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The lead plaintiffs in the consolidated matter (the "Lead Plaintiffs") are Nova Scotia Health Employees&#x2019; Pension Plan and The City of Fort Lauderdale Police &amp;amp; Firefighters&#x2019; Retirement System. An order granting the Lead Plaintiffs&#x2019; motion for class certification and appointment of class representatives was entered on June 18, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 12, 2024, the Company and the Lead Plaintiffs entered into an agreement in principle to settle the claims against the Company and each of the Company&#x2019;s current and former officers and directors. On October 4, 2024, the Court granted preliminary approval of the proposed settlement, ordered notice to the settlement class and scheduled a fairness hearing for February 27, 2025. On February 6, 2025, the Lead Plaintiffs filed a Motion for Final Approval of Class Action Settlement, Certification of the Settlement Class and Approval of Plan of Allocation and Motion for Award of Attorneys' Fees, Reimbursement of Expenses and Compensatory Awards for Lead Plaintiffs. Under the settlement, the claims against the Company and its officers and directors were dismissed with prejudice and released in exchange for a payment from the Company of $40.0&#160;million, $30.0&#160;million of which was paid from insurance proceeds, and had previously been funded in the fourth quarter of 2024. The Company recorded the settlement and insurance recoverable amounts as pre-tax operating expense and income, respectively, within &#x201c;Selling, general and administrative&#x201d; expenses on the Consolidated Statement of Operations for the year ended December&#160;31, 2024. At the scheduled fairness hearing on February 27, 2025, the Court granted final approval of the settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2021, Lincolnshire Police Pension Fund (&#x201c;Lincolnshire&#x201d;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints sought the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-DLB. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022, the Court approved the parties' joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp;amp; Police Officers Pension Fund, respectively, in the Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints sought the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#x2019; filed a motion to dismiss the complaint. On March 29, 2022, an order was granted staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds, respectively, in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#x2019; motion to dismiss, and on November 2, 2023, the Court approved the parties' joint stipulation to extend the stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 7, 2025, plaintiffs Lincolnshire and Pooja Sayal filed a motion in the United States District Court for the District of Maryland seeking preliminary approval of a stipulation of settlement with regard to the above referenced derivative matters (&#x201c;Proposed Settlement&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, the Proposed Settlement intends to resolve all matters among and between the following parties: (i) Lincolnshire and Pooja Sayal, plaintiffs in the stockholder derivative action captioned In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-DLB, pending in the U.S. District Court for the District of Maryland; (ii) North Collier Fire Control and Rescue District Firefighter Pension Plan, Chang Kyum Kim and Mark Nevins, plaintiffs in the stockholder derivative action captioned In re Emergent BioSolutions Inc. Derivative Litigation, Case No. 2021-0974-MTZ, pending in the Delaware Court of Chancery; (iii) Zachary Elton, Jeffery Reynolds and Eric White, plaintiffs in the stockholder derivative action captioned Elton v. Kramer, et al, Case No. C-15-CV-21-000496, pending in the Circuit Court of Maryland for Montgomery County; (iv) Richard J. Levine and Christopher Seaver, plaintiffs in the stockholder derivative action captioned In Re Emergent BioSolutions Inc. Demand Refused Stockholder Derivative Litigation, Master File No. 8:23-cv-02969-DLB, pending in the U.S. District Court for the District of Maryland; (v) Christopher Andrews, plaintiff in the stockholder derivative action captioned Andrews v. Kramer, C.A. No. 2024-0925-MTZ, pending in the Delaware Court of Chancery; (vi) individual defendants Robert G. Kramer Sr., Fuad El-Hibri, Richard S. Lindahl, Ronald B. Richard, Zsolt Harsanyi, Louis W. Sullivan, George A. Joulwan, Jerome M. Hauer, Kathryn C. Zoon, Marvin White, Syed T. Husain, Seamus Mulligan, Adam Havey, Sean Kirk, Atul Saran and Sue Bailey and (vii) the Company, as nominal defendant (collectively with the individual defendants, the &#x201c;Defendants&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Proposed Settlement provided that no later than 20 business days following the satisfaction of all conditions precedent set forth in the Proposed Settlement, Defendants must cause their insurers to pay to the Company a settlement amount of $15.0&#160;million, less a court-approved fee and expense amount (the &#x201c;Settlement Amount&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, no later than 60 days following the satisfaction of all conditions precedent set forth in the Proposed Settlement, the Company must effectuate a series of corporate governance reforms and maintain such reforms for a period of not less than four years, subject to the terms and conditions set forth in the Proposed Settlement. On May 9, 2025, the United States District Court for the District of Maryland (the &#x201c;Court&#x201d;) issued an order granting preliminary approval of the Proposed Settlement. The Proposed Settlement included no admission of fault, liability or wrongdoing by any of the Defendants. On August 6, 2025, the Court granted final approval of the Proposed Settlement without modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received the Settlement Amount in September 2025. Accordingly, during the three and nine months ended September 30, 2025, the Company recorded $10.5&#160;million with respect to the Settlement Amount as a reduction of &#x201c;Selling, general and administrative&#x201d; expenses on the Condensed Consolidated Statement of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Government investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the actions described above under &#x201c;Securities and shareholder litigation,&#x201d; the Company received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC (as discussed further below) and the Maryland Attorney General&#x2019;s Office. The Company produced documents in response and will continue to cooperate with these government inquiries should further requests be made.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2021, the Company also received inquiries and subpoenas from the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries and the Select Subcommittee released its final report related to the coronavirus crisis on December 9, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in the second quarter of 2021, the Company also received subpoenas from the SEC related to certain disclosures regarding the incidents described above under the heading &#x201c;Securities and shareholder litigation.&#x201d; The Company has been cooperating with the SEC&#x2019;s investigation. During the first quarter of 2025, the Company determined that a loss resulting from the investigation was probable and that the amount of loss could be reasonably estimated. As a result, the Company recorded an accrual within &#x201c;Selling, general and administrative&#x201d; expenses on the Consolidated Statement of Operations for the year ended December&#160;31, 2024 of $1.5&#160;million, and the related liability was included in &#x201c;Other current liabilities&#x201d; on the Company&#x2019;s Consolidated Balance Sheet as of December&#160;31, 2024. On April 7, 2025, the Company consented to the SEC&#x2019;s entry of an administrative order under which the Company agreed to cease and desist from committing or causing a violation of Section 17(a)(2) of the Securities Act of 1933 and to pay a fine of $1.5&#160;million. The Company paid the fine on April 18, 2025 and no liability balance remains on the Company&#x2019;s Consolidated Balance Sheet as of September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2025, the Company received an additional inquiry from the New York Attorney General&#x2019;s Office related to certain past trading activity by the Company&#x2019;s former Chief Executive Officer. The Company has produced documents and is cooperating with the New York Attorney General&#x2019;s office on this matter.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2025, the Company met with representatives of the Department of Justice regarding the Company&#x2019;s 2017 and 2019 contracts with the Department of State to provide medical countermeasures for exposure to nerve toxins. The Company has provided documents and is continuing discussions with the Department of Justice on this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen, for large-scale drug substance manufacturing of Johnson &amp;amp; Johnson&#x2019;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#x201c;Product&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2022, the parties exchanged notices alleging material breaches of the Janssen Agreement, with each asserting the other had failed to meet key contractual obligations. Janssen subsequently initiated arbitration proceedings, and the Company responded with counterclaims. On July 3, 2024, the Company and Janssen entered into the Settlement Agreement to resolve all claims among the parties arising from the Janssen Agreement and the activities referenced above. Pursuant to the terms of the Settlement Agreement, Janssen paid the Company $50.0&#160;million on July 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the fourth quarter of 2022, because the arbitration process with Janssen was expected to extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from &#x201c;Inventories, net&#x201d; and from &#x201c;Prepaid expenses and other current assets&#x201d; to &#x201c;Other assets&#x201d;, resulting in $152.7&#160;million in long-term assets related to the Janssen Agreement on the Condensed Consolidated Balance Sheet as of December 31, 2022. The long-term asset balance within &#x201c;Other Assets&#x201d; prior to announcing the Settlement Agreement was $158.7&#160;million. The Company recorded $50.0&#160;million in &#x201c;Product and services sales, net&#x201d; and &#x201c;Cost product and services sales, net&#x201d; on the Condensed Consolidated Statement of Operations during the second quarter of 2024 to reflect the settlement receivable as a change in the transaction price for the Janssen Agreement. Additionally, the Company recorded $110.2&#160;million in the second quarter of 2024 within &#x201c;Cost product and services sales, net&#x201d; on the Condensed Consolidated Statement of Operations to write down the remaining inventory to its net realizable value and for estimated disposal costs. The receivable for the settlement amount was collected during the third quarter of 2024 and there was no long-term asset balance remaining within &#x201c;Other Assets&#x201d; related to the Janssen Agreement as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="c-445" decimals="-5" id="f-1094" unitRef="usd">40000000</us-gaap:LossContingencyDamagesPaidValue>
    <ebs:LossContingencyDamagesPaidValueFromInsuranceProceeds contextRef="c-445" decimals="-5" id="f-1095" unitRef="usd">30000000</ebs:LossContingencyDamagesPaidValueFromInsuranceProceeds>
    <ebs:LossContingencySettlementPeriod contextRef="c-446" id="f-1096">P20D</ebs:LossContingencySettlementPeriod>
    <us-gaap:LossContingencyDamagesAwardedValue contextRef="c-446" decimals="-5" id="f-1097" unitRef="usd">15000000</us-gaap:LossContingencyDamagesAwardedValue>
    <ebs:LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms contextRef="c-446" id="f-1098">P60D</ebs:LossContingencyPeriodOfImplementationOfCorporateGovernanceReforms>
    <ebs:LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained contextRef="c-446" id="f-1099">P4Y</ebs:LossContingencyPeriodOfCorporateGovernanceReformsToBeMaintained>
    <us-gaap:LitigationSettlementGain contextRef="c-447" decimals="-5" id="f-1100" unitRef="usd">10500000</us-gaap:LitigationSettlementGain>
    <us-gaap:LitigationSettlementGain contextRef="c-448" decimals="-5" id="f-1101" unitRef="usd">10500000</us-gaap:LitigationSettlementGain>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-449" decimals="-5" id="f-1102" unitRef="usd">1500000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent contextRef="c-450" decimals="-5" id="f-1103" unitRef="usd">1500000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-451" decimals="-5" id="f-1104" unitRef="usd">1500000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent contextRef="c-452" decimals="INF" id="f-1105" unitRef="usd">0</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:ProceedsFromLegalSettlements contextRef="c-453" decimals="-5" id="f-1106" unitRef="usd">50000000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-454" decimals="-5" id="f-1107" unitRef="usd">152700000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-455" decimals="-5" id="f-1108" unitRef="usd">158700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-456" decimals="-5" id="f-1109" unitRef="usd">50000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-457" decimals="-5" id="f-1110" unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryWriteDown contextRef="c-456" decimals="-5" id="f-1111" unitRef="usd">110200000</us-gaap:InventoryWriteDown>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-458" decimals="INF" id="f-1112" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1113">Segment information&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2025, using the guidance provided in ASC 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 280&#x201d;), along with the adoption of ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company reevaluated its reportable and operating segments. Based on updates to the Company&#x2019;s internal operating and reporting structure and quantitative tests outlined in ASC 280, the Company manages its business with a focus on two reportable segments; the Commercial Products segment, which includes Naloxone products and the MCM Products segment, which includes the Anthrax - MCM products, Smallpox - MCM products and Other Products. The Company&#x2019;s Services operating segment no longer meets the quantitative threshold for determining reportable segments and is now included within &#x201c;All other revenues&#x201d; along with the Company&#x2019;s Contracts and grants business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its President and Chief Executive Officer. The CODM evaluates the performance of the Company's reportable segments based on segment adjusted gross margin. The Company defines segment adjusted gross margin as sales less cost of sales excluding restructuring costs, changes in fair value of financial instruments, settlement charges, net and inventory step-up provision for each reportable segment. The Company does not allocate amortization of intangible assets, research and development expenses, selling, general and administrative costs, interest and other income (expense) or taxes to each reportable segment in the operating results that are regularly reviewed by the CODM. The CODM uses these reported measures to assess segment performance, allocate resources and monitor budget and guidance versus actual results. These metrics are used by the CODM to make key operating decisions, such as decisions about allocating capital and other resources to each segment. The accounting policies for segment reporting are the same as those described in Note 2, "Summary of significant accounting policies" in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2024. Intersegment revenue, cost of sales, and profit are eliminated in the segment measures regularly reviewed by the CODM as these activities are eliminated in consolidation and thus are not included in management&#x2019;s evaluation of performance for each segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its assets on a total company basis, not by segment, as the Company's operating assets are shared or commingled. Therefore, the Company&#x2019;s CODM does not regularly review any asset information by segment and, accordingly, the Company does not report asset information by segment. The measure of segment assets is reported on the Condensed Consolidated Balance Sheet as "Total assets".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment information provided to the CODM, along with a reconciliation of segment adjusted gross margin to income before income taxes as reported in the Condensed Consolidated Statement of Operation for the three and nine months ended September 30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;357.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;545.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;726.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;293.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;594.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of sales reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total of reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment adjusted gross margin reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;181.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;244.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total of reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation to income (loss) before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues less other costs of revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(141.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory step-up provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(76.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(135.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(247.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on sale of business and assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(115.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; and &#x201c;All other revenues less other cost of revenue&#x201d; includes Services and Contracts and grants revenue, and Services and Contracts and grants revenue less Cost of services, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Excludes $&#x2014; million and $0.2 million of restructuring costs for the three and nine months ended September 30, 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For 2025, excludes $1.8 million of inventory step-up provision for the nine months ended September 30, 2025 and $0.2 million and $(0.8) million of restructuring costs for the three and nine months ended September 30, 2025, respectively. For 2024, excludes $0.6 million of changes in fair value of financial instruments for the nine months ended September 30, 2024; it also excludes $4.9 million and $7.5 million of restructuring costs, and $1.2 million of inventory step up for each of the three and nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation from reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Items not included in depreciation from reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other segment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1114"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-1115">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment information provided to the CODM, along with a reconciliation of segment adjusted gross margin to income before income taxes as reported in the Condensed Consolidated Statement of Operation for the three and nine months ended September 30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;357.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;393.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;545.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;726.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;293.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;594.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;848.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of sales reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total of reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;290.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment adjusted gross margin reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;181.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;244.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total of reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation to income (loss) before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other revenues less other costs of revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(141.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory step-up provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(76.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(135.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(247.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on sale of business and assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(115.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;All other revenues&#x201d; and &#x201c;All other revenues less other cost of revenue&#x201d; includes Services and Contracts and grants revenue, and Services and Contracts and grants revenue less Cost of services, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Excludes $&#x2014; million and $0.2 million of restructuring costs for the three and nine months ended September 30, 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For 2025, excludes $1.8 million of inventory step-up provision for the nine months ended September 30, 2025 and $0.2 million and $(0.8) million of restructuring costs for the three and nine months ended September 30, 2025, respectively. For 2024, excludes $0.6 million of changes in fair value of financial instruments for the nine months ended September 30, 2024; it also excludes $4.9 million and $7.5 million of restructuring costs, and $1.2 million of inventory step up for each of the three and nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-459" decimals="-5" id="f-1116" unitRef="usd">74900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-460" decimals="-5" id="f-1117" unitRef="usd">95300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-461" decimals="-5" id="f-1118" unitRef="usd">187700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-462" decimals="-5" id="f-1119" unitRef="usd">333800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-122" decimals="-5" id="f-1120" unitRef="usd">142500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-123" decimals="-5" id="f-1121" unitRef="usd">174200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-124" decimals="-5" id="f-1122" unitRef="usd">357500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-125" decimals="-5" id="f-1123" unitRef="usd">393000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-130" decimals="-5" id="f-1124" unitRef="usd">217400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-131" decimals="-5" id="f-1125" unitRef="usd">269500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-132" decimals="-5" id="f-1126" unitRef="usd">545200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-133" decimals="-5" id="f-1127" unitRef="usd">726800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-463" decimals="-5" id="f-1128" unitRef="usd">13700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-464" decimals="-5" id="f-1129" unitRef="usd">24300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-465" decimals="-5" id="f-1130" unitRef="usd">49000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-466" decimals="-5" id="f-1131" unitRef="usd">122100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-5" id="f-1132" unitRef="usd">231100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-5" id="f-1133" unitRef="usd">293800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-1134" unitRef="usd">594200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-5" id="f-1135" unitRef="usd">848900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-459" decimals="-5" id="f-1136" unitRef="usd">42600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-460" decimals="-5" id="f-1137" unitRef="usd">47200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-461" decimals="-5" id="f-1138" unitRef="usd">103300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-462" decimals="-5" id="f-1139" unitRef="usd">152700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-122" decimals="-5" id="f-1140" unitRef="usd">37900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-123" decimals="-5" id="f-1141" unitRef="usd">47900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-124" decimals="-5" id="f-1142" unitRef="usd">113300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-125" decimals="-5" id="f-1143" unitRef="usd">138000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-130" decimals="-5" id="f-1144" unitRef="usd">80500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-131" decimals="-5" id="f-1145" unitRef="usd">95100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-132" decimals="-5" id="f-1146" unitRef="usd">216600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-133" decimals="-5" id="f-1147" unitRef="usd">290700000</us-gaap:CostOfGoodsAndServicesSold>
    <ebs:AdjustedGrossMargin contextRef="c-459" decimals="-5" id="f-1148" unitRef="usd">32300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-460" decimals="-5" id="f-1149" unitRef="usd">48100000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-461" decimals="-5" id="f-1150" unitRef="usd">84400000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-462" decimals="-5" id="f-1151" unitRef="usd">181100000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-122" decimals="-5" id="f-1152" unitRef="usd">104600000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-123" decimals="-5" id="f-1153" unitRef="usd">126300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-124" decimals="-5" id="f-1154" unitRef="usd">244200000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-125" decimals="-5" id="f-1155" unitRef="usd">255000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-130" decimals="-5" id="f-1156" unitRef="usd">136900000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-131" decimals="-5" id="f-1157" unitRef="usd">174400000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-132" decimals="-5" id="f-1158" unitRef="usd">328600000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin contextRef="c-133" decimals="-5" id="f-1159" unitRef="usd">436100000</ebs:AdjustedGrossMargin>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-130" decimals="-5" id="f-1160" unitRef="usd">-8500000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-131" decimals="-5" id="f-1161" unitRef="usd">-2900000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-132" decimals="-5" id="f-1162" unitRef="usd">-25300000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-133" decimals="-5" id="f-1163" unitRef="usd">141200000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-130" decimals="-5" id="f-1164" unitRef="usd">16300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-131" decimals="-5" id="f-1165" unitRef="usd">16300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-132" decimals="-5" id="f-1166" unitRef="usd">48800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-133" decimals="-5" id="f-1167" unitRef="usd">48800000</us-gaap:AmortizationOfIntangibleAssets>
    <ebs:RestructuringChargesAdjusted contextRef="c-130" decimals="-5" id="f-1168" unitRef="usd">200000</ebs:RestructuringChargesAdjusted>
    <ebs:RestructuringChargesAdjusted contextRef="c-131" decimals="-5" id="f-1169" unitRef="usd">4900000</ebs:RestructuringChargesAdjusted>
    <ebs:RestructuringChargesAdjusted contextRef="c-132" decimals="-5" id="f-1170" unitRef="usd">-800000</ebs:RestructuringChargesAdjusted>
    <ebs:RestructuringChargesAdjusted contextRef="c-133" decimals="-5" id="f-1171" unitRef="usd">7500000</ebs:RestructuringChargesAdjusted>
    <ebs:InventoryStepUp contextRef="c-130" decimals="-5" id="f-1172" unitRef="usd">0</ebs:InventoryStepUp>
    <ebs:InventoryStepUp contextRef="c-131" decimals="-5" id="f-1173" unitRef="usd">1200000</ebs:InventoryStepUp>
    <ebs:InventoryStepUp contextRef="c-132" decimals="-5" id="f-1174" unitRef="usd">1800000</ebs:InventoryStepUp>
    <ebs:InventoryStepUp contextRef="c-133" decimals="-5" id="f-1175" unitRef="usd">1200000</ebs:InventoryStepUp>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-130" decimals="-5" id="f-1176" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-131" decimals="-5" id="f-1177" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-132" decimals="-5" id="f-1178" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-133" decimals="-5" id="f-1179" unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-130" decimals="-5" id="f-1180" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-131" decimals="-5" id="f-1181" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-132" decimals="-5" id="f-1182" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-133" decimals="-5" id="f-1183" unitRef="usd">27200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-130" decimals="-5" id="f-1184" unitRef="usd">13500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-131" decimals="-5" id="f-1185" unitRef="usd">13800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-132" decimals="-5" id="f-1186" unitRef="usd">41100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-133" decimals="-5" id="f-1187" unitRef="usd">61600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-130" decimals="-5" id="f-1188" unitRef="usd">38900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-131" decimals="-5" id="f-1189" unitRef="usd">76600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-132" decimals="-5" id="f-1190" unitRef="usd">135000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-133" decimals="-5" id="f-1191" unitRef="usd">247200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:InterestExpenseNonoperating contextRef="c-130" decimals="-5" id="f-1192" unitRef="usd">15200000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-131" decimals="-5" id="f-1193" unitRef="usd">8300000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-132" decimals="-5" id="f-1194" unitRef="usd">44600000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-133" decimals="-5" id="f-1195" unitRef="usd">56200000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-130" decimals="-5" id="f-1196" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-131" decimals="-5" id="f-1197" unitRef="usd">64300000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-132" decimals="-5" id="f-1198" unitRef="usd">-12200000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-133" decimals="-5" id="f-1199" unitRef="usd">24300000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-130" decimals="-5" id="f-1200" unitRef="usd">-3700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-131" decimals="-5" id="f-1201" unitRef="usd">21900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-132" decimals="-5" id="f-1202" unitRef="usd">62300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-133" decimals="-5" id="f-1203" unitRef="usd">15800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-130" decimals="-5" id="f-1204" unitRef="usd">57600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-131" decimals="-5" id="f-1205" unitRef="usd">142400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-132" decimals="-5" id="f-1206" unitRef="usd">133500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-133" decimals="-5" id="f-1207" unitRef="usd">-115300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RestructuringCharges contextRef="c-459" decimals="-5" id="f-1208" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-461" decimals="-5" id="f-1209" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <ebs:InventoryStepUp contextRef="c-124" decimals="-5" id="f-1210" unitRef="usd">1800000</ebs:InventoryStepUp>
    <ebs:RestructuringChargesAdjusted contextRef="c-122" decimals="-5" id="f-1211" unitRef="usd">200000</ebs:RestructuringChargesAdjusted>
    <ebs:RestructuringChargesAdjusted contextRef="c-124" decimals="-5" id="f-1212" unitRef="usd">-800000</ebs:RestructuringChargesAdjusted>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-125" decimals="-5" id="f-1213" unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <ebs:RestructuringChargesAdjusted contextRef="c-123" decimals="-5" id="f-1214" unitRef="usd">4900000</ebs:RestructuringChargesAdjusted>
    <ebs:RestructuringChargesAdjusted contextRef="c-125" decimals="-5" id="f-1215" unitRef="usd">7500000</ebs:RestructuringChargesAdjusted>
    <ebs:InventoryStepUp contextRef="c-123" decimals="-5" id="f-1216" unitRef="usd">1200000</ebs:InventoryStepUp>
    <ebs:InventoryStepUp contextRef="c-125" decimals="-5" id="f-1217" unitRef="usd">1200000</ebs:InventoryStepUp>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1218">&lt;div style="margin-bottom:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation from reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MCM Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Items not included in depreciation from reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other segment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Depreciation contextRef="c-122" decimals="-5" id="f-1219" unitRef="usd">4700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-123" decimals="-5" id="f-1220" unitRef="usd">4700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-124" decimals="-5" id="f-1221" unitRef="usd">13800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-125" decimals="-5" id="f-1222" unitRef="usd">16000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-126" decimals="-5" id="f-1223" unitRef="usd">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-127" decimals="-5" id="f-1224" unitRef="usd">2300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-128" decimals="-5" id="f-1225" unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-129" decimals="-5" id="f-1226" unitRef="usd">7400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-463" decimals="-5" id="f-1227" unitRef="usd">2100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-464" decimals="-5" id="f-1228" unitRef="usd">3100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-465" decimals="-5" id="f-1229" unitRef="usd">6800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-466" decimals="-5" id="f-1230" unitRef="usd">10600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-1231" unitRef="usd">7100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-1232" unitRef="usd">10100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1233" unitRef="usd">23500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-1234" unitRef="usd">34000000.0</us-gaap:Depreciation>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-13" id="f-1235">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2025, directors and officers (as defined in Exchange Act Rule 16a-1(f)) of the Company adopted written plans for the sale of the Company&#x2019;s common stock intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (&#x201c;Rule 10b5-1 trading arrangements&#x201d;) as set forth in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Action&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adoption date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rule 10b5-1 Trading Plan Provides for Purchase/Sale &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Shares of Common Stock to be Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration Date &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Donald DeGolyer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Director&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 11, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,081&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;October 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sujata Tyagi Dayal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Director&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 8, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 27, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales may begin on the 91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day following the adoption of the Rule 10b5-1 trading arrangement.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Subject to early termination in accordance with the terms of the Rule 10b5-1 trading arrangement.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-13" id="f-1236">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:TrdArrIndName contextRef="c-467" id="f-1237">Donald DeGolyer</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-467" id="f-1238">Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-467" id="f-1239">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-467" id="f-1240">August 11, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-468"
      decimals="INF"
      id="f-1241"
      unitRef="shares">51081</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-467" id="f-1242">October 30, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName contextRef="c-469" id="f-1243">Sujata Tyagi Dayal</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-469" id="f-1244">Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-469" id="f-1245">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-469" id="f-1246">August 8, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-470"
      decimals="INF"
      id="f-1247"
      unitRef="shares">22313</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-469" id="f-1248">May 27, 2026</ecd:TrdArrExpirationDate>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-13" id="f-1249">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-13" id="f-1250">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-121"
          xlink:label="f-121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-119"
          xlink:label="f-119"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-118"
          xlink:label="f-118"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-120"
          xlink:label="f-120"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="padding-left:6pt"><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Exclusive of intangible asset amortization</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-121"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-119"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-118"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-120"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
